FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Goldstein, G AF Goldstein, Gerald BE Thomas, JC Hersen, M TI Correlational Methods SO UNDERSTANDING RESEARCH IN CLINICAL AND COUNSELING PSYCHOLOGY, SECOND EDITION LA English DT Article; Book Chapter ID SCHIZOPHRENIA; COEFFICIENT; BATTERY; MODEL C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. NR 23 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-83170-0 PY 2011 BP 181 EP 199 PG 19 WC Psychology, Clinical SC Psychology GA BUP10 UT WOS:000289949300008 ER PT B AU McNeil, M Hula, W Sung, JE AF McNeil, Malcolm Hula, William Sung, Jee Eun BE Guendouzi, J Loncke, F Williams, MJ TI The Role of Memory and Attention in Aphasic Language Performance SO HANDBOOK OF PSYCHOLINGUISTIC AND COGNITIVE PROCESSES: PERSPECTIVES IN COMMUNICATION DISORDERS LA English DT Article; Book Chapter ID SHORT-TERM-MEMORY; VERBAL WORKING-MEMORY; BRAIN-DAMAGED ADULTS; LATENT-VARIABLE ANALYSIS; DUAL-TASK CONDITIONS; SENTENCE COMPREHENSION; AUDITORY COMPREHENSION; STROOP TASK; SYNTACTIC COMPREHENSION; INDIVIDUAL-DIFFERENCES C1 [McNeil, Malcolm] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [McNeil, Malcolm; Hula, William] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP McNeil, M (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. NR 171 TC 5 Z9 5 U1 1 U2 3 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-84800-5; 978-1-84872-910-0 PY 2011 BP 551 EP 577 PG 27 WC Linguistics; Psychology, Experimental SC Linguistics; Psychology GA BUI08 UT WOS:000289414500028 ER PT S AU Kakar, S AF Kakar, Sanjay BE Monga, SPS TI Fibrolamellar Hepatocellular Carcinoma SO MOLECULAR PATHOLOGY OF LIVER DISEASES SE Molecular Pathology Library LA English DT Article; Book Chapter ID COMPARATIVE GENOMIC HYBRIDIZATION; FOCAL NODULAR HYPERPLASIA; CLINICOPATHOLOGICAL FEATURES; LIVER-TRANSPLANTATION; PROGNOSTIC-FACTORS; VARIANT; EXPRESSION; TUMOR; HEPATOMA; CHILDHOOD C1 [Kakar, Sanjay] Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kakar, S (reprint author), Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA. EM sanjay.kakar@ucsf.edu NR 88 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1935-987X BN 978-1-4419-7106-7 J9 MOL PATHOL LIB PY 2011 VL 5 BP 849 EP 857 DI 10.1007/978-1-4419-7107-4_57 D2 10.1007/978-1-4419-7107-4 PG 9 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Pathology SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Pathology GA BSW52 UT WOS:000285958200057 ER PT B AU Baldwin, ML Marcus, SC AF Baldwin, Marjorie L. Marcus, Steven C. BE Schultz, IZ Rogers, ES TI Stigma, Discrimination, and Employment Outcomes among Persons with Mental Health Disabilities SO WORK ACCOMMODATION AND RETENTION IN MENTAL HEALTH LA English DT Article; Book Chapter ID ATTRIBUTIONAL ANALYSIS; PSYCHIATRIC-DISORDERS; AFRICAN-AMERICAN; SOCIAL DISTANCE; ILLNESS; ATTITUDES; SCHIZOPHRENIA; DANGEROUSNESS; COMMUNITY; PEOPLE C1 [Baldwin, Marjorie L.] Arizona State Univ, Dept Econ, WP Carey Sch Business, Tempe, AZ 85287 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Baldwin, ML (reprint author), Arizona State Univ, Dept Econ, WP Carey Sch Business, POB 873806, Tempe, AZ 85287 USA. EM Marjorie.Baldwin@asu.edu; marcuss@sp2.upenn.edu NR 59 TC 2 Z9 2 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0427-0 PY 2011 BP 53 EP 69 DI 10.1007/978-1-4419-0428-7_3 D2 10.1007/978-1-4419-0428-7 PG 17 WC Public, Environmental & Occupational Health; Psychology; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA BSO47 UT WOS:000285117700003 ER PT B AU Adams, SG Anzueto, A AF Adams, Sandra G. Anzueto, Antonio BE Hanania, NA Sharafkhaneh, A TI Exacerbations of COPD SO COPD: A GUIDE TO DIAGNOSIS AND CLINICAL MANAGEMENT SE Respiratory Medicine Series LA English DT Article; Book Chapter DE COPD exacerbation; pneumonia; dyspnoea; nosocomial infection ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; REQUIRING MECHANICAL VENTILATION; PROTECTED SPECIMEN BRUSH; PLACEBO-CONTROLLED TRIAL; CHRONIC-BRONCHITIS; ANTIBIOTIC-TREATMENT; LUNG-DISEASE; DOUBLE-BLIND; INFECTIVE EXACERBATIONS C1 [Adams, Sandra G.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Adams, Sandra G.; Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Adams, SG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. NR 79 TC 0 Z9 0 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-949-9 J9 RESPIR MED SER PY 2011 BP 191 EP 209 DI 10.1007/978-1-59745-357-8_11 D2 10.1007/978-1-59745-357-8 PG 19 WC Respiratory System SC Respiratory System GA BSZ62 UT WOS:000286167300011 ER PT B AU Bourbeau, J Sharafkhaneh, A Adams, SG AF Bourbeau, Jean Sharafkhaneh, Amir Adams, Sandra G. BE Hanania, NA Sharafkhaneh, A TI Disease Management Programs for COPD SO COPD: A GUIDE TO DIAGNOSIS AND CLINICAL MANAGEMENT SE Respiratory Medicine Series LA English DT Article; Book Chapter DE COPD; chronic care; patient education; self-management ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC CARE MODEL; SELF-MANAGEMENT; CHRONIC ILLNESS; INTERVENTIONS; METAANALYSIS; DEPRESSION; SEVERITY; OUTCOMES; TRIAL C1 [Bourbeau, Jean] McGill Univ, Royal Victoria Hosp, Resp Epidemiol & Clin Res Unit, Montreal Chest Inst,Hlth Ctr, Montreal, PQ H3A 1A1, Canada. [Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Adams, Sandra G.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sharafkhaneh, Amir] Baylor Coll Med, Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. RP Bourbeau, J (reprint author), McGill Univ, Royal Victoria Hosp, Resp Epidemiol & Clin Res Unit, Montreal Chest Inst,Hlth Ctr, Montreal, PQ H3A 1A1, Canada. NR 35 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-949-9 J9 RESPIR MED SER PY 2011 BP 283 EP 297 DI 10.1007/978-1-59745-357-8_16 D2 10.1007/978-1-59745-357-8 PG 15 WC Respiratory System SC Respiratory System GA BSZ62 UT WOS:000286167300016 ER PT B AU Sharafkhaneh, A Jamshidi, M Sharafkhaneh, H Hirshkowitz, M AF Sharafkhaneh, Amir Jamshidi, Mohammed Sharafkhaneh, Hossein Hirshkowitz, Max BE Hanania, NA Sharafkhaneh, A TI General Management Issues in COPD: Sleep, Travel and Preoperative Management SO COPD: A GUIDE TO DIAGNOSIS AND CLINICAL MANAGEMENT SE Respiratory Medicine Series LA English DT Article; Book Chapter DE Air travel; insomnia; perioperative management; sleep apnea ID OBSTRUCTIVE PULMONARY-DISEASE; OXYGEN DESATURATION; AIRWAY-RESISTANCE; RESPIRATION; SATURATION; RAMELTEON; INSOMNIA; SURGERY; COMPLICATIONS; HYPOXEMIA C1 [Sharafkhaneh, Amir; Sharafkhaneh, Hossein; Hirshkowitz, Max] Baylor Coll Med, Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. [Jamshidi, Mohammed] TriCity Med Ctr, Cardiovasc Inst, Oceanside, CA USA. RP Sharafkhaneh, A (reprint author), Baylor Coll Med, Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. NR 59 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-949-9 J9 RESPIR MED SER PY 2011 BP 299 EP 312 DI 10.1007/978-1-59745-357-8_17 D2 10.1007/978-1-59745-357-8 PG 14 WC Respiratory System SC Respiratory System GA BSZ62 UT WOS:000286167300017 ER PT B AU Machicado, GA Jensen, DM AF Machicado, Gustavo A. Jensen, Dennis M. BE Wu, GY Wu, GY Sridhar, S TI Acute Colonic Bleeding SO DIAGNOSTIC AND THERAPEUTIC PROCEDURES IN GASTROENTEROLOGY: AN ILLUSTRATED GUIDE SE Clinical Gastroenterology LA English DT Article; Book Chapter DE Acute; Colonic; Bleeding; Bowel preparation; Lesions ID SOLITARY RECTAL ULCER; LOWER GASTROINTESTINAL HEMORRHAGE; SEVERE HEMATOCHEZIA; INTERNAL HEMORRHOIDS; URGENT COLONOSCOPY; DIVERTICULAR HEMORRHAGE; DIAGNOSIS; OUTCOMES; MANAGEMENT; THERAPY C1 [Machicado, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Jensen, Dennis M.] Univ Calif Los Angeles, Ctr Hlth Sci, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Machicado, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 56 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-478-4 J9 CLIN GASTROENT-SER PY 2011 BP 307 EP 326 DI 10.1007/978-1-59745-044-7_19 D2 10.1007/978-1-59745-044-7 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BTL68 UT WOS:000287221400019 ER PT B AU Kakar, S AF Kakar, Sanjay BE Ferrell, LD Kakar, S TI Acute Hepatitis SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID ONSET AUTOIMMUNE HEPATITIS; CELIAC-DISEASE; SPECIAL STAINS; LIVER-INJURY; DIAGNOSIS; AUTOANTIBODIES; NECROSIS C1 [Kakar, Sanjay] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kakar, S (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 1 EP 14 PG 14 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800001 ER PT B AU Ramachandran, R Kakar, S AF Ramachandran, Rageshree Kakar, Sanjay BE Ferrell, LD Kakar, S TI Acute Liver Failure SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID FULMINANT HEPATIC-FAILURE; VIRUS HEPATITIS; TRANSPLANTATION; ETIOLOGY; ADULTS; THERAPY; INJURY C1 [Ramachandran, Rageshree] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Ramachandran, R (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. NR 34 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 15 EP 19 PG 5 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800002 ER PT B AU Kakar, S AF Kakar, Sanjay BE Ferrell, LD Kakar, S TI Sinusoidal Dilatation and Congestion SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID BUDD-CHIARI-SYNDROME; SICKLE-CELL HEPATOPATHY; FULMINANT HEPATIC-FAILURE; VENOUS OUTFLOW IMPAIRMENT; VENOOCCLUSIVE DISEASE; LIVER METASTASES; LIGHT-CHAIN; PRIMARY AL; OBSTRUCTION SYNDROME; DEPOSITION DISEASE C1 [Kakar, Sanjay] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Kakar, S (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 175 EP 186 PG 12 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800011 ER PT B AU Gill, RM Kakar, S Ferrell, LD AF Gill, Ryan M. Kakar, Sanjay Ferrell, Linda D. BE Ferrell, LD Kakar, S TI Macrophage Infiltrate SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID NIEMANN-PICK-DISEASE; NONCIRRHOTIC PORTAL-HYPERTENSION; HERMANSKY-PUDLAK-SYNDROME; GAUCHERS-DISEASE; TANGIER-DISEASE; KUPFFER CELLS; MASSIVE LYMPHADENOPATHY; HEMOPHAGOCYTIC SYNDROME; VISCERAL LEISHMANIASIS; SINUS HISTIOCYTOSIS C1 [Gill, Ryan M.; Ferrell, Linda D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Gill, RM (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 265 EP 274 PG 10 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800018 ER PT B AU Jain, D Kakar, S AF Jain, Dhanpat Kakar, Sanjay BE Ferrell, LD Kakar, S TI Approach to Liver Biopsy With Minimal or Nonspecific Histologic Findings SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID VITAMIN-A; LIPOCYTES; RELEASE; CELLS C1 [Jain, Dhanpat] Yale Univ, Sch Med, Dept Anat Pathol, New Haven, CT 06520 USA. [Kakar, Sanjay] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Jain, D (reprint author), Yale Univ, Sch Med, Dept Anat Pathol, New Haven, CT 06520 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 275 EP 280 PG 6 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800019 ER PT B AU Ramachandran, R Kakar, S AF Ramachandran, Rageshree Kakar, Sanjay BE Ferrell, LD Kakar, S TI Metastatic Tumors: Illustration of Immunohistochemical Workup SO LIVER PATHOLOGY SE Consultant Pathology LA English DT Article; Book Chapter ID RENAL-CELL CARCINOMA; TRANSCRIPTION FACTOR-I; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL-DIAGNOSIS; GLYPICAN-3 EXPRESSION; MONOCLONAL-ANTIBODY; LUNG ADENOCARCINOMA; HEP PAR-1; LIVER; NEOPLASMS C1 [Ramachandran, Rageshree] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Kakar, Sanjay] San Francisco VA Med Ctr, San Francisco, CA USA. RP Ramachandran, R (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. NR 49 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-93-8 J9 CONSULT PATHOL PY 2011 VL 4 BP 431 EP 439 PG 9 WC Gastroenterology & Hepatology; Pathology SC Gastroenterology & Hepatology; Pathology GA BUO60 UT WOS:000289931800027 ER PT B AU Morshed, SA Latif, R Davies, TF AF Morshed, Syed A. Latif, Rauf Davies, Terry F. BE Eisenbarth, GS TI Immunopathogenesis of Graves' Disease SO IMMUNOENDOCRINOLOGY: SCIENTIFIC AND CLINICAL ASPECTS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Graves' disease; autoimmune thyroid disease; TSH receptor antibodies; Thyroid-specific T cells; Genetic susceptibility; Environmental influences ID AUTOIMMUNE THYROID-DISEASE; HUMAN THYROTROPIN RECEPTOR; REGULATORY T-CELLS; STIMULATING HORMONE-RECEPTOR; OPPOSITE PHENOTYPIC MANIFESTATIONS; FAS-MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODIES; TSH-RECEPTOR; DENDRITIC CELLS; MURINE MODEL C1 [Morshed, Syed A.] James J Peters VA Med Ctr, Dept Endocrinol, Bronx, NY 10468 USA. [Morshed, Syed A.; Latif, Rauf] Mt Sinai Sch Med, Bronx, NY USA. [Davies, Terry F.] James J Peters VA Med Ctr, New York, NY USA. [Davies, Terry F.] Mt Sinai Med Ctr, New York, NY 10029 USA. RP Morshed, SA (reprint author), James J Peters VA Med Ctr, Dept Endocrinol, Bronx, NY 10468 USA. OI latif, rauf/0000-0002-4226-3728 NR 126 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-477-7 J9 CONTEMP ENDOCRINOL S PY 2011 BP 457 EP 481 DI 10.1007/978-1-60327-478-4_28 D2 10.1007/978-1-60327-478-4 PG 25 WC Endocrinology & Metabolism; Immunology SC Endocrinology & Metabolism; Immunology GA BSY64 UT WOS:000286133200028 ER PT S AU Chaney, E Bonner, L Vivell, S Cohen, AN Young, AS Rubenstein, L AF Chaney, Edmund Bonner, Laura Vivell, Susan Cohen, Amy N. Young, Alexander S. Rubenstein, Lisa BE Dewan, NA Luo, JS Lorenzi, NM TI How Behavioral Healthcare Informatics Systems Interface with Medical Informatics Systems: A Work in Progress SO INFORMATION TECHNOLOGY ESSENTIALS FOR BEHAVIORAL HEALTH CLINICIANS SE Health Informatics Series LA English DT Article; Book Chapter ID QUALITY IMPROVEMENT; CHRONIC ILLNESS; COLLABORATIVE MANAGEMENT; DEPRESSION CARE; SELF-ASSESSMENT; MENTAL-HEALTH; SCHIZOPHRENIA; INTERVENTIONS; OUTCOMES; CLINICS C1 [Chaney, Edmund; Bonner, Laura] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Vivell, Susan; Cohen, Amy N.; Young, Alexander S.; Rubenstein, Lisa] VA Ctr Study Healthcare Provider Behav, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cohen, Amy N.; Young, Alexander S.; Rubenstein, Lisa] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rubenstein, Lisa] RAND Hlth Program, Santa Monica, CA USA. RP Chaney, E (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 NR 32 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1431-1917 BN 978-1-84996-343-5 J9 HEALTH INFORM SER PY 2011 BP 195 EP 204 DI 10.1007/978-1-84996-344-2_12 D2 10.1007/978-1-84996-344-2 PG 10 WC Behavioral Sciences; Medical Informatics SC Behavioral Sciences; Medical Informatics GA BSE55 UT WOS:000284286700012 ER PT S AU Garnovskaya, MN Raymond, JR AF Garnovskaya, Maria N. Raymond, John R. BE DiGiovanni, G Esposito, E DiMatteo, V TI Serotonin 5-HT(2C) Receptor Signal Transduction SO 5-HT2C RECEPTORS IN THE PATHOPHYSIOLOGY OF CNS DISEASE SE Receptors Series LA English DT Article; Book Chapter ID PROTEIN-KINASE-C; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; AGONIST-DIRECTED TRAFFICKING; PLEXUS EPITHELIAL-CELLS; PDZ DOMAIN PROTEIN; CHOROID-PLEXUS; MESSENGER-RNA; XENOPUS OOCYTES; 5-HYDROXYTRYPTAMINE(2C) RECEPTORS; PREFRONTAL CORTEX C1 [Garnovskaya, Maria N.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA. [Garnovskaya, Maria N.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA. [Garnovskaya, Maria N.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Med Serv, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA. EM garnovsk@musc.cdu NR 110 TC 0 Z9 0 U1 0 U2 6 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1048-6909 BN 978-1-60761-940-6 J9 RECEPT SER JI Recept. Ser. PY 2011 BP 75 EP 96 DI 10.1007/978-1-60761-941-3_5 PG 22 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BSR21 UT WOS:000285532800005 ER PT S AU Schang, AY Fisher, BE Sashkin, NR Moore, C Dirling, LB Petzinger, GM Jakowec, MW Meshul, CK AF Schang, Alexandra Y. Fisher, Beth E. Sashkin, Natalie R. Moore, Cindy Dirling, Lisa B. Petzinger, Giselle M. Jakowec, Michael W. Meshul, Charles K. BE Raber, J TI Correlates and Analysis of Motor Function in Humans and Animal Models of Parkinson's Disease SO ANIMAL MODELS OF BEHAVIORAL ANALYSIS SE Neuromethods LA English DT Article; Book Chapter ID BERG BALANCE SCALE; VESICULAR GLUTAMATE TRANSPORTERS; DWELLING ELDERLY-PEOPLE; TEST-RETEST RELIABILITY; RATING-SCALE; BASAL GANGLIA; POSTURAL INSTABILITY; IN-VIVO; GO TEST; STROKE REHABILITATION AB The purpose of this chapter is to first describe common clinical and laboratory tests and measures used to capture alterations in motor control in individuals with Parkinson's disease (PD) and secondly, to detail both morphological and motor tests that arc used in two rodent models of PD. For the description in humans, it is organized within the body structure and function and activity categories of the International Classification of Functioning, Disability, and Health (ICF). Specific tests discussed include the retropulsion test, turning test, Unified Parkinson's Disease Rating Scale, Timed Up-and-Go, Berg Balance Scale, electromyography, quantitative digitography, motion analysis, and force plate perturbation. Testing procedure, set-up, and interpretation are described and examples of application in the PD population are provided. We hope that clinicians and researchers develop a beginning understanding of the different methods available for examining alterations in motor control in individuals with PD. Using the rat model of PD, we first describe in detail a new ultrastructural processing method that is used not only to process tissue but also to localize specific proteins that can then be used to correlate synaptic changes with motor alterations that are observed following depletion of dopamine. Finally, using a mouse model of PD, we describe three locomotor tests that can be quantified and correlated with the loss of dopamine-labeled neurons in the substantia nigra. C1 [Schang, Alexandra Y.; Fisher, Beth E.] Univ So Calif, Dept Phys Therapy, Los Angeles, CA 90089 USA. [Sashkin, Natalie R.; Moore, Cindy; Dirling, Lisa B.] Portland VA Med Ctr, Portland, OR USA. [Petzinger, Giselle M.] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Elect Microscopy Facil, Portland, OR 97201 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. [Jakowec, Michael W.] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Jakowec, Michael W.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA USA. RP Schang, AY (reprint author), Univ So Calif, Dept Phys Therapy, Los Angeles, CA 90089 USA. NR 116 TC 1 Z9 1 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 0893-2336 BN 978-1-60761-882-9 J9 NEUROMETHODS JI Neuromethods PY 2011 VL 50 BP 55 EP 90 DI 10.1007/978-1-60761-883-6_3 D2 10.1007/978-1-60761-883-6 PG 36 WC Behavioral Sciences; Cell Biology; Neurosciences SC Behavioral Sciences; Cell Biology; Neurosciences & Neurology GA BRN68 UT WOS:000283191100003 ER PT S AU Phillips, TJ Pastor, R Scibelli, AC Reed, C Tarragon, E AF Phillips, Tamara J. Pastor, Raul Scibelli, Angela C. Reed, Cheryl Tarragon, Ernesto BE Raber, J TI Behavioral Sensitization to Addictive Drugs: Clinical Relevance and Methodological Aspects SO ANIMAL MODELS OF BEHAVIORAL ANALYSIS SE Neuromethods LA English DT Article; Book Chapter ID POSITRON-EMISSION-TOMOGRAPHY; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS DOPAMINE; RECOMBINANT INBRED MICE; REPEATED D-AMPHETAMINE; INDUCED LOCOMOTOR SENSITIZATION; CONDITIONED-PLACE PREFERENCE; REPEATED ETHANOL WITHDRAWAL; COCAINE-SEEKING BEHAVIOR; RECEPTOR KNOCKOUT MICE AB Sensitization to the locomotor stimulant effects of abused drugs provides 3 behavioral measure thought to reflect underlying neural adaptations to repeated drug exposure. Neurochemical measures have provided information about the specific neural systems impacted and altered by repeated drug exposure. In pre-clinical studies, sensitized animals exhibit facilitated acquisition of drug self-administration and preference for cues associated with past drug experiences. This has suggested a role for sensitization in the development of drug abuse and in relapse. In humans, self-reports of sensitized vigor and energy levels have been described that may relate to the more direct measurements of locomotor sensitization in animals. Described in this chapter are methods used to measure psychomotor sensitization in mice, which are partially dependent upon the drug under investigation. The advantages to the use of mice in pre-clinical research are (1) that they readily sensitize to all drugs of abuse, (2) many methods have been developed for studying other aspects of their behavior that may be related to sensitization, and (3) they are an excellent species for genetic investigations aimed at determining susceptibility to behavioral sensitization and thus neuroadaptations related to drug abuse. Factors to consider when designing a study of drug-induced psychomotor sensitization include dose, number or treatments, frequency or interval between treatments and challenge, and duration of testing. First, a measure of baseline level of activity should be obtained, followed by measurement of the initial drug effect, measures of the change in initial effect with repeated administration, and a subsequent measure of baseline to see how it may have changed after repeated drug testing. Depending upon the goal of the research, a drug withdrawal period may be desirable, followed by another drug challenge to determine whether sensitization is still present. Such a withdrawal or "incubation" period has been instated to allow for the establishment of long-term central nervous system changes that may accompany sensitization in studies of mechanism. The recommended frequency of dosing is dependent upon characteristics of the drug, particularly its clearance rate. More intermittent schedules of administration are particularly important for inducing robust sensitization to classical psychostimulant drugs like cocaine and methamphetamine. The recommended duration of:testing is influenced by the duration of drug effect, but data should be collected in isolated time units so that the time response curve can be examined. Finally, associative conditioning and stress-related factors can have large impacts on sensitization and should be carefully considered in all aspects of the research design, including whether drug treatment is linked to the test environment or not, density of housing, and specifics of handling. C1 [Phillips, Tamara J.; Pastor, Raul; Scibelli, Angela C.; Reed, Cheryl] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. [Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR USA. [Pastor, Raul; Tarragon, Ernesto] Univ Jaume 1, Area Psicobiol, Castellon de La Plana, Spain. RP Phillips, TJ (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. RI Tarragon Cros, Ernesto/P-5224-2016 OI Tarragon Cros, Ernesto/0000-0001-9575-5585 NR 212 TC 2 Z9 2 U1 2 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 0893-2336 BN 978-1-60761-882-9 J9 NEUROMETHODS JI Neuromethods PY 2011 VL 50 BP 267 EP 305 DI 10.1007/978-1-60761-883-6_11 D2 10.1007/978-1-60761-883-6 PG 39 WC Behavioral Sciences; Cell Biology; Neurosciences SC Behavioral Sciences; Cell Biology; Neurosciences & Neurology GA BRN68 UT WOS:000283191100011 ER PT B AU Singh, N Alexander, BD AF Singh, Nina Alexander, Barbara D. BE Heitman, J Kozel, TR KwonChung, KJ Perfect, JR Casadevall, A TI Cryptococcosis in Transplant Recipients SO CRYPTOCOCCUS: FROM HUMAN PATHOGEN TO MODEL YEAST LA English DT Article; Book Chapter ID RECONSTITUTION INFLAMMATORY SYNDROME; CALCINEURIN-INHIBITOR AGENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; SOLID-ORGAN; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; STEM-CELL; CORNEAL TRANSPLANTATION; LIVER-TRANSPLANTATION; PRACTICE GUIDELINES C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. NR 77 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-501-1 PY 2011 BP 507 EP 514 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA BSJ71 UT WOS:000284727500037 ER PT S AU Yang, YF Keung, EC Scheinman, MM AF Yang, Yanfei Keung, Edmund C. Scheinman, Melvin M. BE Yan, GX Kowey, PR TI History of Supraventricular Tachycardia SO MANAGEMENT OF CARDIAC ARRHYTHMIAS, SECOND EDITION SE Contemporary Cardiology LA English DT Editorial Material; Book Chapter DE Supraventricular tachycardia; atrioventricular (AV) nodal reentry; AV node; pre-excitation; accessory pathways; Wolf-Parkinson-White syndrome; atrial flutter; cavotricuspid isthmus-dependent atrial flutter; atypical atrial flutter; atrial fibrillation; catheter ablation; cardiac electrosurgery ID PARKINSON-WHITE-SYNDROME; NODAL REENTRANT TACHYCARDIA; RADIOFREQUENCY CATHETER ABLATION; RIGHT ATRIAL-FLUTTER; BUNDLE-BRANCH BLOCK; P-R INTERVAL; ACCESSORY ATRIOVENTRICULAR PATHWAYS; ISTHMUS DEPENDENT CIRCUIT; PROLONGED QRS COMPLEX; LOWER LOOP REENTRY AB In this chapter, we will discuss the history of supraventricular tachycardia (SVT) that includes four sections atrioventricular (AV) nodal reentry. AV reentry, atrial flutter (AFL), and atrial fibrillation (AF). We will focus on the historical evolution of the electrophysiologic study of the mechanism and the development of surgical and catheter ablation of these SVTs We will also discuss potentially newer therapeutic approaches for these arrhythmias C1 [Yang, Yanfei; Scheinman, Melvin M.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Keung, Edmund C.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, VA Med Ctr, San Francisco, CA 94143 USA. RP Yang, YF (reprint author), Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. NR 180 TC 2 Z9 2 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1191-7601 BN 978-1-60761-160-8 J9 CONTEMP CARDIOL JI Contemp. Cardiol. PY 2011 BP 17 EP 38 DI 10.1007/978-1-60761-161-5_2 D2 10.1007/978-1-60761-161-5 PG 22 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BRD19 UT WOS:000282391900002 ER PT S AU Bekris, LM Yu, CE Bird, TD Tsuang, D AF Bekris, Lynn M. Yu, Chang-En Bird, Thomas D. Tsuang, Debby BE Blass, JP TI The Genetics of Alzheimer's Disease and Parkinson's Disease SO NEUROCHEMICAL MECHANISMS IN DISEASE SE Advances in Neurobiology LA English DT Article; Book Chapter DE Alzheimer's disease; Parkinson's disease; Presenilin; Amyloid precursor protein; Apolipoprotein E; Synuclein; Parkin; LRRK2; PINK1; neurodegeneration ID AMYLOID-PRECURSOR-PROTEIN; EARLY-ONSET PARKINSONISM; APOLIPOPROTEIN-E GENOTYPE; TERMINAL HYDROLASE L1; GAMMA-SECRETASE ACTIVITY; ACID BETA-GLUCOSIDASE; AUTOSOMAL RECESSIVE PARKINSONISM; PALLIDO-PYRAMIDAL DEGENERATION; SUPRANUCLEAR UPGAZE PARESIS; PATHOGENIC DJ-1 MUTATIONS AB Alzheimer's disease (AD) is the most common neurodegenerative disorder. It is characterized by progressive loss of memory and other cognitive domains along with functional decline that can occur in the third to eighth decades. The early onset (<60 years old) familial forms of AD have an autosomal dominant inheritance linked to three causative genes: APP, PSEN1, and PSEN2. The most common sporadic form of AD occurs after the age of 60 and is associated with the APOE gene. The mechanistic contribution of these genes in AD pathogenesis has been studied extensively but is still unclear, suggesting that other AD associated genes remain to be elucidated. Parkinson's disease (PD) is the second most common neurodegenerative disorder. Idiopathic PD is the most frequent form of Parkinsonism, although rare forms of PD in which genetic factors dominate exist. Family studies have identified 13 causative genetic loci linked to PD of which 8 genes have been described: four autosomal dominant (SNCA, LRRK2, UCHL1, and HTRA2) and four autosomal recessive (PRKN, DJ1, PINK1, and ATP13A2). In addition, another gene has recently been described as a possible risk factor for PD (GBA). The function of these genes and their contribution to PD pathogenesis remains to be fully elucidated. Like AD, other genes that contribute to PD risk likely exist. The prevalence, incidence, clinical manifestations, and genetic components of these two neurodegenerative disorders, AD and PD, are discussed in this chapter. C1 [Tsuang, Debby] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bekris, Lynn M.; Yu, Chang-En] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Yu, Chang-En; Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Bird, Thomas D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Tsuang, Debby] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Tsuang, D (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM lbekris@u.washington.edu; changeyu@u.washington.edu; tomnroz@u.washington.edu; dwt1@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 NR 413 TC 0 Z9 0 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 2190-5215 BN 978-1-4419-7103-6 J9 ADV NEUROBIOL JI Adv. Neurobiol. PY 2011 VL 1 BP 695 EP 755 DI 10.1007/978-1-4419-7104-3_21 D2 10.1007/978-1-4419-7104-3 PG 61 WC Biology; Clinical Neurology; Neurosciences SC Life Sciences & Biomedicine - Other Topics; Neurosciences & Neurology GA BSV43 UT WOS:000285936400021 ER PT J AU Siochi, RA Balter, P Bloch, CD Santanam, L Blodgett, K Curran, BH Engelsman, M Feng, WZ Mechalakos, J Pavord, D Simon, T Sutlief, S Zhu, XR AF Siochi, R. Alfredo Balter, Peter Bloch, Charles D. Santanam, Lakshmi Blodgett, Kurt Curran, Bruce H. Engelsman, Martijn Feng, Wenzheng Mechalakos, Jim Pavord, Dan Simon, Tom Sutlief, Steven Zhu, X. Ronald TI A rapid communication from the AAPM Task Group 201: Recommendations for the QA of external beam radiotherapy data transfer. AAPM TG 201: Quality assurance of external beam radiotherapy data transfer SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE quality assurance; record & verify; treatment planning; DICOM; datatransfer ID VERIFICATION; DICOM AB The transfer of radiation therapy data among the various subsystems required for external beam treatments is subject to error. Hence, the establishment and management of a data transfer quality assurance program is strongly recommended. It should cover the QA of data transfers of patient specific treatments, imaging data, manually handled data and historical treatment records. QA of the database state (logical consistency and information integrity) is also addressed to ensure that accurate data are transferred. C1 [Siochi, R. Alfredo] Univ Iowa Hosp & Clin, Dept Radiat Oncol, Iowa City, IA 52242 USA. [Zhu, X. Ronald] UT MD Anderson Canc Ctr, Dept Radiat Phys, Unit 1150, Houston, TX USA. [Bloch, Charles D.; Santanam, Lakshmi] Washington Univ, Dept Radiat Oncol, St Louis, MO USA. [Blodgett, Kurt] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA. [Curran, Bruce H.] Rhode Isl Hosp, Dept Radiat Oncol, Providence, RI USA. [Engelsman, Martijn] Paul Scherrer Inst, Ctr Proton Therapy, Villigen, Switzerland. [Feng, Wenzheng] New York Presbyterian Hosp, New York, NY USA. [Mechalakos, Jim] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA. [Pavord, Dan] Vassar Bros Hosp, Poughkeepsie, NY USA. [Simon, Tom] Sun Nucl Corp, Melbourne, FL USA. [Sutlief, Steven] VA Puget Sound Hlth Care Syst, VA Med Ctr, Seattle, WA USA. RP Siochi, RA (reprint author), Univ Iowa Hosp & Clin, Dept Radiat Oncol, 200 Hawkins Dr, Iowa City, IA 52242 USA. EM ralfredo-siochi@uiowa.edu OI Mechalakos, James/0000-0001-9373-836X; Siochi, Ramon Alfredo/0000-0002-7313-577X NR 16 TC 4 Z9 4 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2011 VL 12 IS 1 BP 170 EP 181 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 750MO UT WOS:000289551600018 ER PT J AU Olfson, M Marcus, SC Doshi, JA AF Olfson, Mark Marcus, Steven C. Doshi, Jalpa A. TI Schizophrenia-Related Outpatient Treatment of Medicaid-Financed Patients After Hospital Discharge Reply SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter C1 [Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Doshi, Jalpa A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Doshi, Jalpa A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA. EM mo49@columbia.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2011 VL 72 IS 1 BP 113 EP 114 DI 10.4088/JCP.10lr06511ayel PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 719BT UT WOS:000287175100016 ER PT J AU Dao, TK Teten, AL Nguyen, Q AF Dao, Tam K. Teten, Andra L. Nguyen, Quang TI Linear and orthogonal models of acculturation and its relations to cultural variables: An examination of the Suinn-Lew Asian Self-Identity Acculturation Scale (SL-ASIA) SO INTERNATIONAL JOURNAL OF INTERCULTURAL RELATIONS LA English DT Article DE Acculturation; Linear; Orthogonal models ID VALIDATION; ETHNICITY AB The Suinn-Lew Asian Self-Identity Acculturation Scale (SL-ASIA) is the most widely used measure of acculturation for Asians. The purpose of the current study was twofold: First, the study explored the consistency of the SL-ASIA in characterizing Asian American men's level of acculturation - Asian-Identified, Western-Identified. Bicultural - using the items of the scale in orthogonal versus linear approaches. Second, the study examined the association between the two scoring methods and characteristics indicative of Asian culture-family allocentrism, loss of face, and affect intensity. An orthogonal approach suggests individuals may identify both with Asian and Western cultures, whereas a linear approach indicates an individual identifies with one culture at the expense of the other (e.g., high Asian, low Western identified). We examined the classification rates of these two methods using a large sample of Asian-American collegiate men (n = 521) and then within each ethnic subgroup of Asian men (e.g., Chinese, Japanese. Korean). Results suggested the two methods of characterizing men consistently diverged. Across the Asian subgroups, the overall agreement rates using linear and orthogonal methods were approximately at chance. Furthermore, significant correlations were observed among acculturation scoring methods and variables indicative of social integrity and family attitude. The implications for these findings and potential future directions for the study of acculturation are discussed. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Dao, Tam K.] Univ Houston, Baylor Coll Med, Dept Educ Psychol, Dept Psychiat & Behav Sci, Houston, TX 77204 USA. [Nguyen, Quang] Baylor Coll Med, Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affair Med Ctr, Houston, TX 77030 USA. RP Dao, TK (reprint author), Univ Houston, Baylor Coll Med, Dept Psychiat & Behav Med, 491 Farish Hall, Houston, TX 77204 USA. EM tkdao@uh.edu NR 28 TC 6 Z9 6 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0147-1767 J9 INT J INTERCULT REL JI Int. J. Intercult. Relat. PD JAN PY 2011 VL 35 IS 1 BP 61 EP 68 DI 10.1016/j.ijintrel.2010.10.001 PG 8 WC Psychology, Social; Social Sciences, Interdisciplinary; Sociology SC Psychology; Social Sciences - Other Topics; Sociology GA 714YI UT WOS:000286847200007 ER PT J AU Childers, JW Gordon, A McNeil, M Conigliaro, J Broyles, L Spagnoletti, C Kraemer, KL AF Childers, J. W. Gordon, A. McNeil, M. Conigliaro, J. Broyles, L. Spagnoletti, C. Kraemer, K. L. TI Infusing SBIRT into Faculty Teaching-A Model Faculty Training to Acquire SBIRT Awareness, Knowledge, and Skills SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Childers, J. W.; Gordon, A.; McNeil, M.; Spagnoletti, C.; Kraemer, K. L.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Gordon, A.; McNeil, M.; Broyles, L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Conigliaro, J.] Univ Kentucky, Lexington, KY 40506 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 1 BP 48 EP 49 PG 2 WC Substance Abuse SC Substance Abuse GA 717GE UT WOS:000287030800012 ER PT J AU Smith, M AF Smith, M. TI Characteristics of Community-Dwelling Older Adults Associated with the Concurrent Use of Alcohol with Alcohol-Interactive Medications SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Smith, M.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN4, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 1 BP 50 EP 51 PG 2 WC Substance Abuse SC Substance Abuse GA 717GE UT WOS:000287030800016 ER PT J AU Broyles, LM Kraemer, KL Hanusa, BH Luther, JL Gordon, J AF Broyles, L. M. Kraemer, K. L. Hanusa, B. H. Luther, J. L. Gordon, J. TI Factors Associated with Nurses' Readiness to Provide Alcohol-Related Care for Inpatients SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Broyles, L. M.; Kraemer, K. L.; Hanusa, B. H.; Luther, J. L.; Gordon, J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Broyles, L. M.; Kraemer, K. L.; Hanusa, B. H.; Luther, J. L.; Gordon, J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 1 BP 52 EP 52 PG 1 WC Substance Abuse SC Substance Abuse GA 717GE UT WOS:000287030800019 ER PT J AU Khodneva, Y Pletcher, M Safford, M Schumacher, J Tucker, J Kertesz, S AF Khodneva, Y. Pletcher, M. Safford, M. Schumacher, J. Tucker, J. Kertesz, S. TI Do Race and Sex Alter the Association between Non-Marijuana Drug Use Trajectories and Depressive Symptoms in a Community-Based Adult Cohort? (the CARDIA study) SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Khodneva, Y.; Safford, M.; Schumacher, J.; Tucker, J.; Kertesz, S.] Univ Alabama, Birmingham, AL USA. [Kertesz, S.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 1 BP 55 EP 56 PG 2 WC Substance Abuse SC Substance Abuse GA 717GE UT WOS:000287030800027 ER PT J AU Smith, M AF Smith, M. TI Trajectories of Concurrent Alcohol and Medication Use among Older Adults SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Smith, M.] VA Pittsburgh Healthcare Syst, VISN4 Mental Illness Res, Educ & Clin Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 1 BP 67 EP 68 PG 2 WC Substance Abuse SC Substance Abuse GA 717GE UT WOS:000287030800054 ER PT J AU Dickey, MW Bunger, AC AF Dickey, Michael Walsh Bunger, Ann C. TI Comprehension of elided structure: Evidence from sluicing SO LANGUAGE AND COGNITIVE PROCESSES LA English DT Article DE Sentence processing; Ellipsis; Sluicing; Lexical information ID SENTENCE COMPREHENSION; ARGUMENT STRUCTURE; VP-ELLIPSIS; PARALLELISM; ANAPHORA; DEEP; RESOLUTION AB In sluiced sentences like oNolan colored, but he wouldn't tell me whato, the elided clause (owhat [Nolan colored _]o) contains a gap not present in the antecedent clause (oNolan coloredo). Previous work has shown that interpreting such nonparallel sluiced sentences creates measurable processing difficulty, and these processing costs have been interpreted as evidence for an ellipsis-specific osproutingo operation. The current study compared sluiced sentences and their nonelided counterparts in a self-paced reading task. Results show that nonparallelism was equally costly for both sluiced and nonelided sentences. This finding suggests that these processing costs are as likely to be due to a violation of parallelism expectations for coordinated structures as to be due to ellipsis-specific operations. For nonelided sentences, moreover, the transitivity biases of individual verbs affected the magnitude of these parallelism costs: verb-specific transitivity biases were a reliable predictor of reading times for the nonelided sentences, though not for the sluiced sentences. Implications for the representation and processing of elided structure and the role of verb-specific transitivity biases are discussed. C1 [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dickey, Michael Walsh] Ctr Geriatr Res Educ & Clin, VA Pittsburgh Healthcare Syst, Washington, DC USA. [Bunger, Ann C.] Univ Delaware, Dept Psychol, Newark, DE USA. RP Dickey, MW (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4032 Forbes Tower, Pittsburgh, PA 15260 USA. EM mdickey@pitt.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 NR 46 TC 3 Z9 3 U1 0 U2 0 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0169-0965 J9 LANG COGNITIVE PROC JI Lang. Cogn. Process. PY 2011 VL 26 IS 1 BP 63 EP 78 AR PII 921647873 DI 10.1080/01690961003691074 PG 16 WC Linguistics; Psychology, Experimental SC Linguistics; Psychology GA 712BG UT WOS:000286636400004 ER PT J AU Starks, H Farber, S Vig, E VandeKieft, G AF Starks, Helene Farber, Stuart Vig, Elizabeth VandeKieft, Gregg TI Words That Work: Patient-Centered Strategies for Difficult Conversations SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Farber, Stuart] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Vig, Elizabeth] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [VandeKieft, Gregg] Providence St Peter Hosp, Olympia, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 176 EP 177 DI 10.1016/j.jpainsymman.2010.10.023 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400036 ER PT J AU Goldstein, N Cohen, L Arnold, R Arons, S Goy, E Ganzini, L AF Goldstein, Nathan Cohen, Lewis Arnold, Robert Arons, Stephen Goy, Elizabeth Ganzini, Linda TI Results of a National Study of Hospice and Palliative Medicine Physicians About Accusations of Hastening a Patient's Death SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Goldstein, Nathan] Mt Sinai Sch Med, New York, NY USA. [Cohen, Lewis] Baystate Hlth, Springfield, MA USA. [Arnold, Robert] Univ Pittsburgh, Pittsburgh, PA USA. [Arons, Stephen] Univ Massachusetts Amherst, N Hatfield, MA USA. [Goy, Elizabeth; Ganzini, Linda] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 190 EP 191 DI 10.1016/j.jpainsymman.2010.10.047 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400060 ER PT J AU Ahluwalia, S Leos, R Lorenz, KA Goebel, J AF Ahluwalia, Sangeeta Leos, Rosana Lorenz, Karl A. Goebel, Joy TI A User-Centered Design Approach to the Development of an EMR-Based Symptom Assessment Tool SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Ahluwalia, Sangeeta; Leos, Rosana; Lorenz, Karl A.] VA Greater Los Angeles, Los Angeles, CA USA. [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 195 EP 196 DI 10.1016/j.jpainsymman.2010.10.054 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400067 ER PT J AU Sudore, R Castillo, L Williams, B Hooper, S Sabatino, C AF Sudore, Rebecca Castillo, Lesley Williams, Brie Hooper, Sarah Sabatino, Charles TI The Clash Between Advance Directive Law and Clinical Care: Ramifications for Vulnerable Populations SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Hooper, Sarah] Univ Calif San Francisco, UC Hastings Consortium Law Sci & Hlth Policy, San Francisco, CA 94143 USA. [Sabatino, Charles] Amer Bar Assoc, Washington, DC 20013 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 235 EP 236 DI 10.1016/j.jpainsymman.2010.10.119 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400132 ER PT J AU Mohanty, S Kubicek, K Shoenberger, J Grudzen, C Lorenz, KA Stone, S AF Mohanty, Sarita Kubicek, Katrina Shoenberger, Jan Grudzen, Corita Lorenz, Karl A. Stone, Susan TI Emergency Medicine Physician Perspectives on Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Mohanty, Sarita] Univ So Calif, Los Angeles, CA USA. [Kubicek, Katrina] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Grudzen, Corita] Mt Sinai Sch Med, New York, NY USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Stone, Susan] Cedars Sinai Univ Calif Los Angeles, Venice, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 240 EP 240 DI 10.1016/j.jpainsymman.2010.10.126 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400138 ER PT J AU Villars, P Widera, E Blacker, S AF Villars, Patrice Widera, Eric Blacker, Susan TI Conscious Conversations: Managing Conflict and Collaboration in Interprofessional Palliative Care Teams SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Villars, Patrice; Widera, Eric] San Francisco VA Med Ctr, San Francisco, CA USA. [Blacker, Susan] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 256 EP 256 DI 10.1016/j.jpainsymman.2010.10.152 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400164 ER PT J AU Sullivan, M Childers, J Buckholz, G Yang, H Nisco, M Nowak, J King, L Merlin, J Lorenz, K AF Sullivan, Malgorzata Childers, Julie Buckholz, Gary Yang, Holly Nisco, Michael Nowak, JoAnne King, Linda Merlin, Jessica Lorenz, Karl TI Career Speed Dating Professionals in Training SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Sullivan, Malgorzata] Capital Hosp, Washington, DC USA. [Childers, Julie; King, Linda] Univ Pittsburgh, Pittsburgh, PA USA. [Buckholz, Gary; Yang, Holly] San Diego Hosp, San Diego, CA USA. [Buckholz, Gary; Yang, Holly] Inst Palliat Med, San Diego, CA USA. [Nisco, Michael] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Nowak, JoAnne] Partners Hosp, Andover, MA USA. [Merlin, Jessica] Mt Sinai Sch Med, New York, NY USA. [Lorenz, Karl] VA Greater Los Angeles Healthcare, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 264 EP 264 DI 10.1016/j.jpainsymman.2010.10.167 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400178 ER PT J AU Kehrle, B Steckart, J Moran, D AF Kehrle, Bettina Steckart, Jillisa Moran, Deborah TI Palliative Care for Veterans with PTSD SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Kehrle, Bettina; Steckart, Jillisa; Moran, Deborah] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 267 EP 267 DI 10.1016/j.jpainsymman.2010.10.172 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400183 ER PT J AU Alshehabi, M Schillerstrom, J O'Donnell, L Ross, J Sanchez-Reilly, S AF Alshehabi, Muna Schillerstrom, Jason O'Donnell, Louise Ross, Jeanette Sanchez-Reilly, Sandra TI Interviewing Those Who Just Lost Their Loved Ones: An Innovative Method to Introduce Palliative Medicine to Medical Students SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Alshehabi, Muna; Schillerstrom, Jason; O'Donnell, Louise; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 273 EP 274 DI 10.1016/j.jpainsymman.2010.10.183 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400194 ER PT J AU Bael, N Gonzalez, M Chang, V Yan, HL Paulino, R AF Bael, Nancy Gonzalez, Melanie Chang, Victor Yan, Houling Paulino, Robert TI Comparison of Hospice Eligible (HE) Versus Hospice Ineligible (HI) Patients Admitted to a Medical Service: A Retrospective Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Bael, Nancy] VA Lyons, E Orange, NJ USA. [Gonzalez, Melanie; Chang, Victor; Yan, Houling] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. [Paulino, Robert] James J Peters Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 275 EP 275 DI 10.1016/j.jpainsymman.2010.10.185 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400196 ER PT J AU Bailey, FA Ritchie, C Jackson, JR AF Bailey, F. Amos Ritchie, Christine Jackson, James R. TI Self-Assessment of Clinical Competency: We and They Don't Know What They Don't Know SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Jackson, James R.] Univ Alabama, Sch Med, Birmingham, AL USA. [Bailey, F. Amos] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 275 EP 276 DI 10.1016/j.jpainsymman.2010.10.186 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400197 ER PT J AU Barnett, M Tucker, R Williams, B AF Barnett, Michael Tucker, Rodney Williams, Beverly TI Sudden Advanced Illness: An Emerging Concept Among Palliative Care and Surgical Critical Care Physicians SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Barnett, Michael] Univ Alabama, Birmingham, AL USA. [Tucker, Rodney] Univ Alabama Palliti Care, Birmingham, AL USA. [Williams, Beverly] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 276 EP 277 DI 10.1016/j.jpainsymman.2010.10.188 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400199 ER PT J AU Grudzen, C Stone, S Mohanty, S Lorenz, KA Torres, J Ortiz, J Timmermans, S AF Grudzen, Corita Stone, Susan Mohanty, Sarita Lorenz, Karl A. Torres, Jacqueline Ortiz, Joanna Timmermans, Stefan TI "I Want to Be Taking My Own Last Breath'': Patients' Reflections on Illness When Presenting to an Emergency Department at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Grudzen, Corita; Torres, Jacqueline; Ortiz, Joanna] Mt Sinai Sch Med, New York, NY USA. [Stone, Susan] Cedars Sinai & UCLA, Venice, CA USA. [Mohanty, Sarita] Univ So Calif, Los Angeles, CA 90089 USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Timmermans, Stefan] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 285 EP 286 DI 10.1016/j.jpainsymman.2010.10.202 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400213 ER PT J AU Leigh, A Bailey, FA Burgio, K Williams, B AF Leigh, Alexandra Bailey, F. Amos Burgio, Kathryn Williams, Beverly TI A Hospice Emergency Kit (HEK): Evaluation of Effectiveness by Retrospective Chart Review and Hospice Nurse Questionnaires SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hosp & Palliat, Hosp & Palliat Nurses Assoc C1 [Leigh, Alexandra] Univ Alabama Birmingham, Birmingham, AL USA. [Bailey, F. Amos; Burgio, Kathryn] Univ Alabama Birmingham, Birmingham, AL USA. [Bailey, F. Amos; Williams, Beverly] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 295 EP 295 DI 10.1016/j.jpainsymman.2010.10.217 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400228 ER PT J AU Madhusudanannair, V Lee, S Ross, J Hartronft, S Sanchez-Reilly, S AF Madhusudanannair, Vinu Lee, Shuko Ross, Jeanette Hartronft, Scotte Sanchez-Reilly, Sandra TI A Comparison Among Cancer and Non-Cancer Terminally Ill Subjects: Who Is Suffering More? SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Madhusudanannair, Vinu] Univ Texas San Antonio, San Antonio, TX USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ross, Jeanette; Hartronft, Scotte; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 297 EP 298 DI 10.1016/j.jpainsymman.2010.10.221 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400232 ER PT J AU Stanley, N Hadid, T Lee, S Ross, J Sanchez-Reilly, S AF Stanley, Noelle Hadid, Tarik Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Relationship Between Comorbidity Index and Symptom Burden in Chronically Ill Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Stanley, Noelle; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hadid, Tarik] Temple Univ, Pittsburgh, PA USA. [Hadid, Tarik] W Penn Allegheny Hlth Syst, Pittsburgh, PA USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 307 EP 308 DI 10.1016/j.jpainsymman.2010.10.237 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400248 ER PT J AU Steil, N Bailey, FA Carr, J AF Steil, Neal Bailey, F. Amos Carr, James TI Parenteral Diuretic Rescue for Hospice Patients with CHF Refractory to Oral Diuretics SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Steil, Neal] Hosp Bluegrass, Lexington, KY USA. [Bailey, F. Amos] Birmingham VAMC, Birmingham, AL USA. [Bailey, F. Amos] Univ Alabama, Birmingham, AL USA. [Carr, James] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 308 EP 309 DI 10.1016/j.jpainsymman.2010.10.238 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400249 ER PT J AU Williams, B Tucker, R Barnett, M Ritchie, C AF Williams, Beverly Tucker, Rodney Barnett, Michael Ritchie, Christine TI "Keeping It Congruent with Reality'': Palliative Care and Surgical Physicians' Perspectives on Family Members in the SICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of American-Academy-of-Hospice-and-Palliative-Medicine and Hospice-and-Palliative-Nurses-Associations CY FEB 16-19, 2011 CL Vancouver, CANADA SP Amer Acad Hospice & Palliative, Hospice & Palliative Nurses Assoc C1 [Williams, Beverly] Birmingham VAMC, Birmingham, AL USA. [Tucker, Rodney] Univ Alabama, Ctr Palliat Care, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2011 VL 41 IS 1 BP 314 EP 315 DI 10.1016/j.jpainsymman.2010.10.248 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 704LB UT WOS:000286053400259 ER PT J AU Sung, JE McNeil, MR Pratt, SR Dickey, MW Fassbinder, W Szuminsky, NJ Kim, A Doyle, PJ AF Sung, Jee Eun McNeil, Malcolm R. Pratt, Sheila R. Dickey, Michael Walsh Fassbinder, Wiltrud Szuminsky, Neil J. Kim, Aelee Doyle, Patrick J. TI Real-time processing in reading sentence comprehension for normal adult individuals and persons with aphasia SO APHASIOLOGY LA English DT Article DE Online processing in reading sentence comprehension; Linguistic integration; Adjective padding ID WORKING-MEMORY; COMPLEXITY; CAPACITY; DISSOCIATION; PERFORMANCE; LOAD AB Background: Persons with aphasia (PWA) have shown difficulties in integrating linguistic materials over time and distance in sentence processing. However, few studies have investigated sentence-processing difficulties among PWA as reflected in online processing measures. Furthermore, relatively few studies have examined the online processing of syntactically simple but computationally demanding sentences among PWA. Such sentences are important from the perspective of resource-related theories of aphasic language deficits, which predict that such sentences should be challenging for PWA even if the syntactic structures involved are not. Aims: The purpose of the study was to investigate the sentence-level online reading times of normal adult individuals (NAI) and PWA by word category and as a function of adjective padding. It was assumed that head nouns entail greater processing costs than determiners because they represent the point at which integration of material within a noun phrase must take place. It was also assumed that increasing adjectival padding within a noun phrase requires more integration and creates greater processing costs. Methods Procedures: A total of 30 NAI and 30 PWA participated in the current study. Sentence stimuli were obtained from the Computerised Revised Token Test (CRTT) (McNeil et al., 2008). Sentences were presented using a non-cumulative (Word Fade = WF) self-paced word-by-word reading method (CRTT-R-WF). Reading times for the determiners and the correct nouns were analysed. Outcomes Results: Both groups showed significantly longer reading times for the nouns than for determiners and in two-adjective than in one-adjective conditions. Furthermore, the reading times for the two-adjective condition were significantly longer than the one-adjective condition for nouns but not determiners across the groups. The PWA exhibited significantly longer overall reading times, as well as significantly longer reading times on the nouns than the NAI. Conclusions: Increased linguistic integration costsimposed by greater amounts of material to be integrated, and appearing at the point where integration must take placedifferentiated reading-time performance between the NAI and PWA participant groups. The PWA showed differentially longer online processing times for elements that imposed high integration costs. This difference appeared most dramatically when two adjectives intervened between the determiner and the head noun. The current results are consistent with resource-related hypotheses regarding aphasic language deficits, which suggest that PWA with limited control of processing resources should show differentially greater impairments in sentence processing as compared to NAI. C1 [Sung, Jee Eun] Ewha Womans Univ, Dept Commun Disorders, Seoul 120750, South Korea. [Sung, Jee Eun; McNeil, Malcolm R.; Pratt, Sheila R.; Dickey, Michael Walsh; Fassbinder, Wiltrud; Szuminsky, Neil J.; Kim, Aelee; Doyle, Patrick J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sung, Jee Eun; McNeil, Malcolm R.; Pratt, Sheila R.; Dickey, Michael Walsh; Fassbinder, Wiltrud; Szuminsky, Neil J.; Kim, Aelee; Doyle, Patrick J.] Univ Pittsburgh, Pittsburgh, PA USA. RP Sung, JE (reprint author), Ewha Womans Univ, Dept Commun Disorders, Case Hall,Grad Sch Bldg,Room 121, Seoul 120750, South Korea. EM jeesung@ewha.ac.kr RI Pratt, Sheila/H-7139-2013 OI Dickey, Michael Walsh/0000-0002-9068-3313 FU VAPHS; University of Pittsburgh; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service [C47074X, C3118R] FX The current academic affiliation of the first author is Ewha Womans University, but the work was accomplished with support of the VAPHS and the University of Pittsburgh.; This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service (award #C47074X to Malcolm R. McNeil and award #C3118R to Patrick J. Doyle and Sheila R. Pratt), and resources and facilities provided by the Geriatric Research Education and Clinical Center in the VA Pittsburgh Healthcare System. NR 32 TC 3 Z9 3 U1 2 U2 6 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2011 VL 25 IS 1 BP 57 EP 70 AR PII 926132018 DI 10.1080/02687031003714434 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA 714TK UT WOS:000286831700004 ER PT J AU Shalygin, N Sanders, N AF Shalygin, N. Sanders, N. TI INHIBITION OF ASTROCYTE GLT-1 IN THE VENTROMEDIAL HYPOTHALAMUS ENHANCES THE EPINEPHRINE RESPONSE IN HYPOGLYCEMIA COUNTERREGULATORY FAILURE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Shalygin, N.] Univ Washington, Sch Med, Seattle, WA USA. [Shalygin, N.; Sanders, N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2011 VL 59 IS 1 MA 147 BP 129 EP 130 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 697TZ UT WOS:000285542500162 ER PT J AU Heinze, E Chan, G Mory, R Khavari, R Nishimura, R Weisbart, R AF Heinze, E. Chan, G. Mory, R. Khavari, R. Nishimura, R. Weisbart, R. TI T-REGULATORY AND TUMOR SUPPRESSOR FUNCTIONS OF FOXP3 ARE MEDIATED THROUGH SEPARATE SIGNALING PATHWAYS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Heinze, E.; Mory, R.; Khavari, R.] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. [Chan, G.; Weisbart, R.] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. [Nishimura, R.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2011 VL 59 IS 1 MA 257 BP 160 EP 160 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 697TZ UT WOS:000285542500272 ER PT J AU Delaney, KE Lapham, GT Rubinsky, AD Johnson, ML Bradley, KA AF Delaney, K. E. Lapham, G. T. Rubinsky, A. D. Johnson, M. L. Bradley, K. A. TI ALCOHOL USE DISORDERS IDENTIFICATION TEST - CONSUMPTION QUESTIONNAIRE (AUDIT-C): HOW OFTEN DO SCREENING RESULTS CONTRADICT REPORTED DRINKING LEVELS? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Delaney, K. E.; Bradley, K. A.] Univ Washington, Seattle, WA 98195 USA. [Lapham, G. T.; Rubinsky, A. D.; Johnson, M. L.; Bradley, K. A.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2011 VL 59 IS 1 MA 337 BP 182 EP 182 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 697TZ UT WOS:000285542500352 ER PT J AU Izadi, N Graber, CJ Goetz, MB AF Izadi, N. Graber, C. J. Goetz, M. B. TI INVERSE CORRELATION OF INITIAL CD8 LYMPHOCYTE COUNT AND CD4 LYMPHOCYTE RESPONSE TO COMBINATION ANTIRETROVIRAL THERAPY IN TREATMENT-NAIVE VETERANS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Izadi, N.] Univ Calif Los Angeles, Los Angeles, CA USA. [Graber, C. J.; Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2011 VL 59 IS 1 MA 447 BP 213 EP 213 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 697TZ UT WOS:000285542500462 ER PT J AU Sevilla, C Scott, V Wang, MM Yano, E Anger, J AF Sevilla, Claudia Scott, Victoria Wang, Mingming Yano, Elizabeth Anger, Jennifer TI PATTERNS OF MANAGEMENT OF URETHRAL STRICTURE DISEASES IN THE VA SYSTEM SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 8th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology CY MAR 01-06, 2011 CL Phoenix, AZ SP Soc Urodynam Female Urol C1 [Sevilla, Claudia; Scott, Victoria; Anger, Jennifer] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Wang, Mingming; Yano, Elizabeth] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Anger, Jennifer] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2011 VL 30 IS 2 BP 221 EP 221 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 716UB UT WOS:000286997900041 ER PT J AU Roodman, G AF Roodman, G. TI New anabolic approaches to treating myeloma bone disease SO BONE LA English DT Meeting Abstract CT 10th International Conference on Cancer - Induced Bone Disease CY SEP 22-25, 2010 CL Sheffield, ENGLAND SP Canc & Bone Soc (CABS), Int Bone & Mineral Soc (IBMS), Bone & Canc Fdn (BCF), European Calcified Tissue Soc (ECTS) C1 [Roodman, G.] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA. [Roodman, G.] Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN 1 PY 2011 VL 48 IS 1 SI SI BP S9 EP S9 DI 10.1016/j.bone.2010.10.025 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 705IL UT WOS:000286122000038 ER PT J AU Garcia, HA Finley, EP Lorber, W Jakupcak, M AF Garcia, Hector A. Finley, Erin P. Lorber, William Jakupcak, Matthew TI A Preliminary Study of the Association Between Traditional Masculine Behavioral Norms and PTSD Symptoms in Iraq and Afghanistan Veterans SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE masculinity; PTSD; Veterans; Iraq/Afghanistan War ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; VIETNAM VETERANS; HELP-SEEKING; EXPOSURE; GENDER; SERVICE; TRAUMA; CARE AB Studies identifying a high prevalence of posttraumatic stress disorder (PTSD) and low treatment utilization among Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) Veterans reinforce the need for a greater understanding of the disorder in this population. Although traditional masculine norms have been found to relate to both help seeking and PTSD among civilians, little is known about their impact on war Veterans. The current study examined relationships between masculine behaviors, using the Masculine Behavior Scale (MBS), and PTSD symptoms in OEF/OIF Veterans, drawing on archival clinical data from 69 patients at an outpatient PTSD clinic. Despite a positive trend, total MBS scores were not correlated with overall PTSD severity. However, the MBS subscale Exaggerated Self-Reliance and Control positively predicted hyperarousal symptoms in a hierarchical regression model. Unexpectedly, the MBS subscale Success Dedication negatively predicted avoidance, suggesting that this masculine norm may serve a protective function against avoidance symptoms. Results suggest that elements of masculinity are related to specific PTSD symptom clusters in ways that may be both adaptive and maladaptive. Implications for PTSD treatment are discussed. C1 [Garcia, Hector A.] S Texas Vet Hlth Care Syst, Frank Tejeda Outpatient Clin, Dept Vet Affairs, San Antonio, TX 78240 USA. [Garcia, Hector A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Lorber, William] Clement J Zablocki VA Med Ctr, Dept Psychiat & Behav Med, Milwaukee, WI USA. [Lorber, William] Med Coll Wisconsin, Milwaukee, WI USA. [Jakupcak, Matthew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Jakupcak, Matthew] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Garcia, HA (reprint author), S Texas Vet Hlth Care Syst, Frank Tejeda Outpatient Clin, Dept Vet Affairs, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Hector.Garcia2@va.gov OI Finley, Erin/0000-0003-4497-7721 NR 39 TC 10 Z9 10 U1 1 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD JAN PY 2011 VL 12 IS 1 BP 55 EP 63 DI 10.1037/a0020577 PG 9 WC Psychology, Social SC Psychology GA 710ZH UT WOS:000286555000005 ER PT J AU Isaac, C Chertoff, J Lee, B Carnes, M AF Isaac, Carol Chertoff, Jocelyn Lee, Barbara Carnes, Molly TI Do Students' and Authors' Genders Affect Evaluations? A Linguistic Analysis of Medical Student Performance Evaluations SO ACADEMIC MEDICINE LA English DT Article ID PROGRAM DIRECTORS; ACADEMIC MEDICINE; SELECTION PROCESS; DEANS LETTER; RECOMMENDATION; WOMEN; RESIDENTS; ADVANCEMENT; LEADERSHIP; LANGUAGE AB Purpose Recent guidelines for the Medical Student Performance Evaluation (MSPE) have standardized the "dean's letter." The authors examined MSPEs for linguistic differences according to student or author gender. Method This 2009 study analyzed 297 MSPEs for 227 male and 70 female medical students applying to a diagnostic radiology residency program. Text analysis software identified word counts, categories, frequencies, and contexts; factor analysis detected patterns of word categories in student-author gender pairings. Results Analyses showed a main effect for student gender (P=.046) and a group difference for the author-student gender combinations (P=.048). Female authors of male student MSPEs used the fewest "positive emotion" words (P=.006). MSPEs by male authors were shorter than those by females (P=.014). MSPEs for students ranked in the National Resident Matching Program contained more "standout" (P=.002) and "positive emotion" (P=.001) words. There were no differences in the author-gender pairs in the proportion of students ranked, although predominant word categories differed by author and student gender. Factor analysis revealed differences among the author-student groups in patterns of correlations among word categories. Conclusions MSPEs differed slightly but significantly by student and author gender. These differences may derive from societal norms for male and female behaviors and the subsequent linguistic interpretation of these behaviors, which itself may be colored by the observer's gender. Although the differences in MSPEs did not seem to influence students' rankings, this work underscores the need for awareness of the complex effects of gender in evaluating students and guiding their specialty choices. C1 [Isaac, Carol; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Molly] Meriter Hosp, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Med & Psychiat, Sch Med & Publ Hlth, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Coll Engn, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Women Vet Hlth Program, Madison, WI USA. [Chertoff, Jocelyn] Dartmouth Hitchcock Med Ctr, Dept Diagnost Radiol, Lebanon, NH 03766 USA. [Chertoff, Jocelyn] Dartmouth Hitchcock Med Ctr, Sect Gastrointestinal Radiol, Lebanon, NH 03766 USA. [Chertoff, Jocelyn] Dartmouth Med Sch, Lebanon, NH USA. [Lee, Barbara] Univ S Florida, Louis de la Parte Florida Mental Hlth Inst, Tampa, FL USA. [Lee, Barbara] Hillsborough Cty Publ Sch, Tampa, FL USA. RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU National Institute on Aging [T32 AG00265]; NSF [SBE-0619979]; NIH [RO1 GM088477-01] FX Dr. Isaac was funded by the National Institute on Aging, grant no. T32 AG00265. Dr. Carnes' research on gender and the advancement of women in academic science and engineering is funded by NSF SBE-0619979 and NIH RO1 GM088477-01. Dr. Carnes is employed part-time by the William S. Middleton Veterans Hospital. This is GRECC manuscript number 2010-10. NR 46 TC 16 Z9 16 U1 4 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JAN PY 2011 VL 86 IS 1 BP 59 EP 66 DI 10.1097/ACM.0b013e318200561d PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 700GL UT WOS:000285725900021 PM 21099389 ER PT J AU Iwashyna, TJ Fuld, A Asch, DA Bellini, LM AF Iwashyna, Theodore J. Fuld, Alexander Asch, David A. Bellini, Lisa M. TI The Impact of Residents, Interns, and Attendings on Inpatient Laboratory Ordering Patterns: A Report From One University's Hospitalist Service SO ACADEMIC MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; DIAGNOSTIC-TESTS; PHYSICIAN AWARENESS; QUALITY IMPROVEMENT; BRITISH-COLUMBIA; MEDICAL-CARE; FEEDBACK; COST; INTERVENTION; EDUCATION AB Purpose To examine the laboratory test ordering patterns of interns to determine the effects of more senior residents' and attendings' supervision on trainees' patterns and residents' perceptions of control in test ordering. Method In a 2007 cohort study of 2,066 patients cared for by 85 interns, 56 residents, and 27 attendings on the University of Pennsylvania general medical hospitalist service, the authors studied variation in laboratory test utilization and costs in 10,908 patient-days. Ordinary least squares regression was used to partition variance among supervised and supervising physicians. Interns and residents were surveyed about their perceived control over lab test ordering. Results Forty-five percent (95% confidence interval [CI]: 39-53) of the variation in laboratory test utilization was attributable to interns' ordering, 26% (95% CI: 21-34) to residents, and 9% (95% CI: 7-16) to attendings; 20% (95% CI: 6-25) could not be uniquely attributed to a particular level of the care team. Similar results were obtained for variation in laboratory costs. Interns underestimated their control over laboratory test utilization, residents overestimated their control, and both groups had inaccurate assessments of their utilization relative to peers. Conclusions Attending faculty had relatively little impact on laboratory ordering patterns. This may reflect a consistent baseline impact of attending physicians on laboratory use, but it may also represent a missed opportunity to reduce practice variation and improve patient care. Observing variation in trainee practice patterns in the face of different supervisors represents a new approach to measuring the supervision in clinical settings. C1 [Iwashyna, Theodore J.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Iwashyna, Theodore J.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Fuld, Alexander] Dartmouth Hitchcock Med Ctr, Div Hematol Oncol, Lebanon, NH 03766 USA. [Bellini, Lisa M.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Asch, DA (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk, Philadelphia, PA 19104 USA. EM asch@wharton.upenn.edu RI Kim, Hyung Woo /G-7525-2011 OI Asch, David/0000-0002-7970-286X; Iwashyna, Theodore/0000-0002-4226-9310 FU Leonard Davis Institute of Health Economics of the University of Pennsylvania FX This work was supported by a Pilot Grant from the Leonard Davis Institute of Health Economics of the University of Pennsylvania. NR 46 TC 15 Z9 15 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JAN PY 2011 VL 86 IS 1 BP 139 EP 145 DI 10.1097/ACM.0b013e3181fd85c3 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 700GL UT WOS:000285725900035 PM 20938318 ER PT J AU Back, SE Book, SW Santos, AB Brady, KT AF Back, Sudie E. Book, Sarah W. Santos, Alberto B. Brady, Kathleen T. TI Training Physician-Scientists: A Model for Integrating Research Into Psychiatric Residency SO ACADEMIC PSYCHIATRY LA English DT Article ID INSTITUTE; PROGRAM AB Objective: The number of physicians engaged in research careers has declined significantly over the past two decades. Physicians with in-depth experience and formal training in research design, development, implementation, statistical analysis, and interpretation of scientific information are rare. Methods: In response to this shortage, the Medical University of South Carolina (MUSC) launched an NIH-funded research track in 2006 to address the institutional, financial, and regulatory barriers to research training during residency. The primary aim was to incorporate a research track within a 4-year psychiatric residency program for physicians. A secondary goal was to extend recruitment into earlier phases of medical training by offering summer research fellowships to medical and undergraduate students. Results: This article describes the program including core mechanisms of training, recruitment, and outcomes to date. Conclusions: The program provides a model to effectively integrate research training during residency without increasing the number of years of residency training. The training components described herein should be exportable to other psychiatric residency training programs and potentially other specialties of medicine. C1 [Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA. RP Back, SE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,POB 250861, Charleston, SC 29425 USA. EM backs@musc.edu FU NIDA NIH HHS [R25 DA020537, R25 DA020537-04, K23 DA021228, R25 DA020357, K23 DA021228-03] NR 18 TC 19 Z9 19 U1 5 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1042-9670 J9 ACAD PSYCHIATR JI Acad. Psych. PD JAN-FEB PY 2011 VL 35 IS 1 BP 40 EP 45 DI 10.1176/appi.ap.35.1.40 PG 6 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA 702TK UT WOS:000285918600009 PM 21209406 ER PT J AU Akiba, Y Kaunitz, JD AF Akiba, Y. Kaunitz, J. D. TI Luminal chemosensing in the duodenal mucosa SO ACTA PHYSIOLOGICA LA English DT Review DE acid sensor; calcium-sensing receptor; carbonic anhydrase; glutamate receptor; taste receptor; vanilloid receptor ID CALCIUM-SENSING RECEPTOR; GASTRIC-ACID-SECRETION; GLUCAGON-LIKE PEPTIDE-2; BITTER TASTE RECEPTORS; RAT SMALL-INTESTINE; GASTROINTESTINAL-TRACT; BICARBONATE SECRETION; CARBONIC-ANHYDRASES; HCO3-TRANSPORT; PH REGULATION AB The upper gastrointestinal (GI) mucosa is exposed to endogenous and exogenous chemicals, including gastric acid, CO(2) and nutrients. Mucosal chemical sensors are necessary to exert physiological responses such as secretion, digestion, absorption and motility. We propose the mucosal chemosensing system by which luminal chemicals are sensed to trigger mucosal defence mechanisms via mucosal acid sensors and taste receptors. Luminal acid/CO(2) is sensed via ecto- and cytosolic carbonic anhydrases and ion transporters in the epithelial cells and via acid sensors on the afferent nerves in the duodenum and the oesophagus. Gastric acid sensing is differentially mediated via endocrine cell acid sensors and afferent nerves. Furthermore, a luminal l-glutamate signal is mediated via epithelial l-glutamate receptors, including metabotropic glutamate receptors and taste receptor 1 family heterodimers, with activation of afferent nerves and cyclooxygenase, whereas luminal Ca2+ is differently sensed via the calcium-sensing receptor in the duodenum. These luminal chemosensors help to activate mucosal defence mechanisms in order to maintain the mucosal integrity and physiological responses of the upper GI tract. Stimulation of luminal chemosensing in the upper GI mucosa may prevent mucosal injury, affect nutrient metabolism and modulate sensory nerve activity. C1 Brentwood Biomed Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Vet Affairs Greater Los Angles Healthcare Syst, Los Angeles, CA 90073 USA. RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yakiba@verizon.net FU Ajinomoto Inc., Japan; AstraZeneca [IRUSESOM0424]; Department of Veterans Affairs; NIH-NIDDK [R01 DK54221] FX We thank Drs Misa Mizumori, Maggie Ham, Chikako Watanabe, Takanari Nakano and Joonho Wang for their research contributions. This study was supported by a research grant from Ajinomoto Inc., Japan (Y. Akiba), Investigator-Sponsored Study Program of AstraZeneca IRUSESOM0424 (Y. Akiba), Department of Veterans Affairs Merit Review Award (J. Kaunitz) and NIH-NIDDK R01 DK54221 (J. Kaunitz). NR 75 TC 20 Z9 20 U1 0 U2 11 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1748-1708 J9 ACTA PHYSIOL JI Acta Physiol. PD JAN PY 2011 VL 201 IS 1 BP 77 EP 84 DI 10.1111/j.1748-1716.2010.02149.x PG 8 WC Physiology SC Physiology GA 692LA UT WOS:000285153100008 PM 20518751 ER PT J AU Kaunitz, JD Akiba, Y AF Kaunitz, J. D. Akiba, Y. TI Purinergic regulation of duodenal surface pH and ATP concentration: implications for mucosal defence, lipid uptake and cystic fibrosis SO ACTA PHYSIOLOGICA LA English DT Review DE alkaline phosphatase; ecto-ATPase; extracellular purines; HCO(3)- secretion; mucosal defence; P2Y receptors ID INTESTINAL ALKALINE-PHOSPHATASE; MALE REPRODUCTIVE-TRACT; BICARBONATE SECRETION; EPITHELIAL-CELLS; HCO3-SECRETION; MUCOCILIARY CLEARANCE; RAT DUODENUM; PSEUDOMONAS-AERUGINOSA; RECEPTOR AGONISTS; AIRWAY EPITHELIA AB The duodenum secretes HCO(3)- as part of a multi-layered series of defence mechanisms against damage from luminal acid. In the 1980s, an alkaline surface layer was measured over the mucosa which correlated with the rate of HCO(3)- secretion. As all biological processes are regulated, we investigated how the alkaline pH of the surface layer was maintained. As the ecto-phosphorylase alkaline phosphatase (AP) is highly expressed in the duodenal brush border, we hypothesized that its extreme alkaline pH optimum (similar to pH 8-9) combined with its ability to hydrolyse regulatory purines such as ATP was part of an ecto-purinergic signalling system, consisting also of brush border P2Y receptors and cystic fibrosis transmembrane regulator-mediated HCO(3)- secretion. Extracellular ATP increases the rate of HCO(3)- secretion through this purinergic system. At high surface pH (pH(s)), AP activity is increased, which then increases the rate of ATP hydrolysis, decreasing surface ATP concentration ([ATP](s)), with a resultant decrease in the rate of HCO(3)- secretion, which subsequently decreases pH(s). This feedback loop is thus hypothesized to regulate pH(s) over the duodenal mucosa, and in several other HCO(3)- secretory organs. As AP activity is directly related to pH(s), and as AP hydrolyses ATP, [ATP](s) and pH(s) are co-regulated. As many essential tissue functions such as ciliary motility and lipid uptake are dependent on [ATP](s), dysregulation of pH(s) and [ATP](s) may help explain the tissue dysfunction characteristic of diseases such as cystic fibrosis. C1 [Kaunitz, J. D.; Akiba, Y.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaunitz, J. D.; Akiba, Y.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, J. D.; Akiba, Y.] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Department of Veterans Affairs; NIH-NIDDK [R01 DK54221, R21 DK081199] FX We thank Coleen Palileo for her assistance with manuscript preparation. This study was supported by a Department of Veterans Affairs Merit Review Award, NIH-NIDDK R01 DK54221 and R21 DK081199 (J. Kaunitz). NR 56 TC 11 Z9 12 U1 0 U2 10 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1748-1708 J9 ACTA PHYSIOL JI Acta Physiol. PD JAN PY 2011 VL 201 IS 1 BP 109 EP 116 DI 10.1111/j.1748-1716.2010.02156.x PG 8 WC Physiology SC Physiology GA 692LA UT WOS:000285153100011 PM 20560899 ER PT J AU Moore, AA Blow, FC Hoffing, M Welgreen, S Davis, JW Lin, JC Ramirez, KD Liao, DH Tang, LQ Gould, R Gill, M Chen, O Barry, KL AF Moore, Alison A. Blow, Fred C. Hoffing, Marc Welgreen, Sandra Davis, James W. Lin, James C. Ramirez, Karina D. Liao, Diana H. Tang, Lingqi Gould, Robert Gill, Monica Chen, Oriana Barry, Kristen L. TI Primary care-based intervention to reduce at-risk drinking in older adults: a randomized controlled trial SO ADDICTION LA English DT Article DE Aged; alcohol; comorbidity; intervention; primary care; screening ID BRIEF PHYSICIAN ADVICE; PROBLEMS SURVEY ARPS; ALCOHOL-USE; EPIDEMIOLOGIC SURVEY; HAZARDOUS DRINKING; DRINKERS; CONSUMPTION; PREVALENCE; HARMFUL AB Aims To examine whether a multi-faceted intervention among older at-risk drinking primary care patients reduced at-risk drinking and alcohol consumption at 3 and 12 months. Design Randomized controlled trial. Setting Three primary care sites in southern California. Participants Six hundred and thirty-one adults aged >= 55 years who were at-risk drinkers identified by the Comorbidity Alcohol Risk Evaluation Tool (CARET) were assigned randomly between October 2004 and April 2007 during an office visit to receive a booklet on healthy behaviors or an intervention including a personalized report, booklet on alcohol and aging, drinking diary, advice from the primary care provider and telephone counseling from a health educator at 2, 4 and 8 weeks. Measurements The primary outcome was the proportion of participants meeting at-risk criteria, and secondary outcomes were number of drinks in past 7 days, heavy drinking (four or more drinks in a day) in the past 7 days and risk score. Findings At 3 months, relative to controls, fewer intervention group participants were at-risk drinkers [odds ratio (OR) 0.41; 95% confidence interval (CI) 0.22-0.75]; they reported drinking fewer drinks in the past 7 days [rate ratio (RR) 0.79; 95% CI 0.70-0.90], less heavy drinking (OR 0.46; 95% CI 0.22-0.99) and had lower risk scores (RR 0.77 95% CI 0.63-0.94). At 12 months, only the difference in number of drinks remained statistically significant (RR 0.87; 95% CI 0.76-0.99). Conclusions A multi-faceted intervention among older at-risk drinkers in primary care does not reduce the proportions of at-risk or heavy drinkers, but does reduce amount of drinking at 12 months. C1 [Moore, Alison A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Dept Psychiat & Biobehav Sci,Dept Med, Los Angeles, CA 90095 USA. [Hoffing, Marc] Desert Oasis Healthcare, Palm Springs, CA USA. [Blow, Fred C.; Barry, Kristen L.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Blow, Fred C.; Barry, Kristen L.] Vet Affairs Natl Serious Mental Illness Treatment, Ann Arbor, MI USA. [Welgreen, Sandra] Kaiser Permanente, Panorama City, CA USA. [Lin, James C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lin, James C.] Cheng Ching Hosp, Dept Med, Taichung, Taiwan. [Tang, Lingqi] Univ Calif Los Angeles, Hlth Serv Res Ctr, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Gould, Robert] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA. [Gill, Monica] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Chen, Oriana] Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Rootstown, OH 44272 USA. [Chen, Oriana] Northeastern Ohio Univ Coll Med & Pharm, Coll Pharm, Rootstown, OH USA. RP Moore, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Dept Psychiat & Biobehav Sci,Dept Med, 10945 Le Conte Blvd,Suite 2339, Los Angeles, CA 90095 USA. EM aamoore@mednet.ucla.edu FU National Institute of Alcohol Abuse and Alcoholism [R01 AA013937, K23 AA00270, K24 AA15957]; National Institute on Aging [P30AG021684, T35 AG026736, P30AG028748]; National Institute of Mental Health [P30MH082760]; John A. Hartford Foundation FX This study was supported by R01 AA013937, K23 AA00270, and K24 AA15957 (awarded to Dr Moore) from the National Institute of Alcohol Abuse and Alcoholism, P30AG021684 from the National Institute on Aging (Dr Moore), P30MH082760 from the National Institute of Mental Health (Dr Tang), the Medical Student Training in Aging Program, funded by the National Institute on Aging (T35 AG026736), and the John A. Hartford Foundation (Ms Gill and Ms Chen), Special Fellowship in Advanced Geriatrics, Veterans Affairs Greater Los Angeles Healthcare System (Dr Lin). Data management activities were supported by the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute on Aging (P30AG028748). The sponsor provided financial support for the study only and had no role in the design and conduct of the study; the collection, management, analysis and interpretation of the study; or in the preparation, review or approval of the manuscript. We gratefully acknowledge the patients and clinicians at Desert Oasis Healthcare (DOHC), Kaiser Permanente Southern California (KPSC)-Panorama City and Woodland Hills and UCLA Healthcare, without whom this study could not have been completed. We also thank Michael Mason MD for his leadership of this project at SCKP-Woodland Hills, James Miller for his recruiting efforts at DOHC and Eric Zamora BA, who both recruited subjects and conducted countless interviews. We also would like to acknowledge the assistance provided by the UCLA Academic Technology Services Statistical Consulting Group. NR 36 TC 38 Z9 38 U1 4 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2011 VL 106 IS 1 BP 111 EP 120 DI 10.1111/j.1360-0443.2010.03229.x PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 693DO UT WOS:000285205000018 PM 21143686 ER PT J AU Anacker, AMJ Loftis, JM Kaur, S Ryabinin, AE AF Anacker, Allison M. J. Loftis, Jennifer M. Kaur, Simranjit Ryabinin, Andrey E. TI Prairie voles as a novel model of socially facilitated excessive drinking SO ADDICTION BIOLOGY LA English DT Article DE Alcoholism; c-Fos; circadian activity; ethanol self-administration; Microtus ochrogaster; peer-pressure ID CORTICOTROPIN-RELEASING-FACTOR; INCENTIVE-SENSITIZATION THEORY; VOLUNTARY ETHANOL-CONSUMPTION; NUCLEUS-ACCUMBENS DOPAMINE; EDINGER-WESTPHAL NUCLEUS; ALCOHOL-PREFERRING RATS; INBRED MOUSE STRAINS; C-FOS EXPRESSION; MICROTUS-OCHROGASTER; PARTNER PREFERENCES AB Social relationships strongly affect alcohol drinking in humans. Traditional laboratory rodents do not exhibit social affiliations with specific peers, and cannot adequately model how such relationships impact drinking. The prairie vole is a socially monogamous rodent used to study social bonds. The present study tested the prairie vole as a potential model for the effects of social affiliations on alcohol drinking. Same-sex adult sibling prairie voles were paired for five days, and then either separated into individual cages, or housed in pairs. Starting at the time of separation, the voles received unlimited access to alcohol in a two-bottle choice test versus water. Pair-housed siblings exhibited higher preference for alcohol, but not saccharin, than singly housed voles. There was a significant correlation between the amount of alcohol consumed by each member of a pair when they were housed together (r = 0.79), but not when housed apart (r = 0.20). Following automated analysis of circadian patterns of fluid consumption indicating peak fluid intake before and after the dark phase, a limited access two-hour two-bottle choice procedure was established. Drinking in this procedure resulted in physiologically relevant blood ethanol concentrations and increased Fos immunoreactivity in perioculomotor urocortin containing neurons (but not in nucleus accumbens or central nucleus of the amygdala). The high ethanol preference and sensitivity to social manipulation indicate that prairie voles can serve to model social influences on excessive drinking. C1 [Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Res & Dev Serv, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Res & Dev Serv, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Ryabinin, AE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Res & Dev Serv, Portland Vet Affairs Med Ctr, 3181 SW Sam Jackson Pk Rd,L470, Portland, OR 97239 USA. EM ryabinin@ohsu.edu FU National Institute of Health [AA016886, AA016647]; [AA007468-22] FX This work was supported by National Institute of Health grants AA016886 and AA016647 to AER, and training grant AA007468-22. We would like to thank Erika Spangler and Zuzzie Kapasova for technical assistance, Drs. Deborah Finn, Matthew Ford, Sue Carter and Larry Young for valuable consultations, Drs. Joseph Lonstein, Phillip Smith and Karen Bales for donating prairie voles for our colony, and the Veterinary Medical Unit at the Portland VA Medical Center for the care and maintenance of our vole colony. NR 76 TC 31 Z9 31 U1 2 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1355-6215 J9 ADDICT BIOL JI Addict. Biol. PD JAN PY 2011 VL 16 IS 1 BP 92 EP 107 DI 10.1111/j.1369-1600.2010.00234.x PG 16 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA 686LU UT WOS:000284698600009 PM 20579002 ER PT J AU Gray, KM LaRowe, SD Watson, NL Carpenter, MJ AF Gray, Kevin M. LaRowe, Steven D. Watson, Noreen L. Carpenter, Matthew J. TI Reactivity to in vivo marijuana cues among cannabis-dependent adolescents SO ADDICTIVE BEHAVIORS LA English DT Article DE Marijuana; Cannabis; Cue reactivity; Craving; Youth; Adolescent ID SMOKERS; RELIABILITY; RESPONSES; VALIDITY; USERS AB Introduction Cannabis dependence is a common but poorly understood condition in adolescents Marijuana craving has been posited as a potential contributing factor to continued use and relapse but relatively few studies have focused on the measurement of craving and reactivity to marijuana cues The present work sought to explore reactivity to marijuana cues within this age group Methods Thirty treatment-seeking cannabis dependent adolescents (age 13-20) completed a cue reactivity session consisting of exposure to and manipulation of in vivo marijuana cues ( joint and lighter) and matching neutral cues (pencil and eraser) in counterbalanced order Subjective craving and physiological reactivity were assessed Results Participants demonstrated increased craving and skin conductance reactivity in response to marijuana cues relative to neutral cues Conclusion In vivo marijuana cues appear to elicit significant subjective and physiological reactivity among treatment seeking cannabis dependent adolescents Further work is needed with a larger sample and with a wider variety of cues (C) 2010 Elsevier Ltd All rights reserved C1 [Gray, Kevin M.; LaRowe, Steven D.; Watson, Noreen L.; Carpenter, Matthew J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Watson, Noreen L.] Texas Tech Univ, Dept Psychol, Lubbock, TX 79409 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RP Gray, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. OI LaRowe, Steven/0000-0002-7664-2451 FU NIDA [K12DA000357, R01DA026777, K23DA020482]; USPHS [M01RR01070]; Pfizer Inc FX Funding was provided through NIDA grants K12DA000357 (KMG) R01DA026777 (KMG) and K23DA020482 (MJC) and by USPHS grant M01RR01070 The funding agencies had no role in the study design collection analysis or interpretation of the data writing the manuscript or the decision to submit the paper for publication; No conflicts are declared for Dr LaRowe Dr Carpenter or Ms Watson Dr Gray receives research support (medication and placebo supply for NIH funded research) from Pfizer Inc NR 18 TC 16 Z9 16 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD JAN-FEB PY 2011 VL 36 IS 1-2 BP 140 EP 143 DI 10.1016/j.addbeh.2010.08.021 PG 4 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 694VK UT WOS:000285326900022 PM 20851531 ER PT J AU Robinson, CM Paukert, A Kraus-Schuman, CA Snow, AL Kunik, ME Wilson, NL Teri, L Stanley, MA AF Robinson, Christina M. Paukert, Amber Kraus-Schuman, Cynthia A. Snow, A. Lynn Kunik, Mark E. Wilson, Nancy L. Teri, Linda Stanley, Melinda A. TI The involvement of multiple caregivers in cognitive-behavior therapy for anxiety in persons with dementia SO AGING & MENTAL HEALTH LA English DT Article DE cognitive-behavioral therapy; anxiety; dementia ID RANDOMIZED CONTROLLED-TRIAL; ALZHEIMERS-DISEASE; GROUP INTERVENTION; CLINICAL-TRIAL; NURSING-HOME; PEOPLE; CARE; SCALE; PREVALENCE; DEPRESSION AB Objectives: Peaceful Mind, a cognitive-behavioral therapy for treating anxiety in persons with dementia, is a promising new treatment currently under investigation. This article reports results of our examination of a modification of the treatment protocol in two cases that included multiple caregivers in treating two persons with dementia. Method: Two case presentations of the benefits and challenges of including multiple caregivers in treatment are discussed. Treatment outcome data for these cases were collected as part of a larger investigation of Peaceful Mind. Results: The involvement of multiple collaterals resulted in several benefits, including increased family communication, as well as increased opportunities for the practice of new skills. These cases have also presented unique challenges requiring alterations in therapy structure and attention to issues of family conflict. Conclusions: Including multiple collaterals in cognitive-behavioral therapy for treating anxiety in persons with dementia is feasible and may be beneficial in maximizing treatment gains and increasing the family's investment in therapy. C1 [Kunik, Mark E.; Wilson, Nancy L.; Stanley, Melinda A.] VA HSR&D Houston Ctr Excellence, Houston, TX USA. [Robinson, Christina M.] Univ Houston, Dept Psychol, Houston, TX USA. [Paukert, Amber] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kraus-Schuman, Cynthia A.; Kunik, Mark E.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Snow, A. Lynn] Univ Alabama, Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Snow, A. Lynn; Kunik, Mark E.; Stanley, Melinda A.] VA S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Kunik, Mark E.; Wilson, Nancy L.; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA. [Teri, Linda] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. RP Stanley, MA (reprint author), VA HSR&D Houston Ctr Excellence, Houston, TX USA. EM mstanley@bcm.tmc.edu FU National Institute of Mental Health [R34-MH078925]; VA HSR&D Houston Center of Excellence [HFP90-020] FX This study was supported by Grant R34-MH078925 from the National Institute of Mental Health awarded to the last author. It is also based upon work supported in part by the VA HSR&D Houston Center of Excellence (HFP90-020). NR 37 TC 3 Z9 4 U1 3 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 EI 1364-6915 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2011 VL 15 IS 3 BP 291 EP 298 DI 10.1080/13607860903493374 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 748QC UT WOS:000289404500002 PM 21491216 ER PT J AU O'Rourke, N Claxton, A Chou, PHB Smith, JZ Hadjistavropoulos, T AF O'Rourke, Norm Claxton, Amy Chou, Pak Hei Benedito Smith, JuliAnna Z. Hadjistavropoulos, Thomas TI Personality trait levels within older couples and between-spouse trait differences as predictors of marital satisfaction SO AGING & MENTAL HEALTH LA English DT Article DE discrepancy analyses; long-term marriage; marital satisfaction; older adults; personality ID LONG-TERM MARRIAGES; ENDURING MARRIAGES; 5-FACTOR MODEL; LIFE-COURSE; WOMEN WANT; QUALITY; DISSOLUTION; ADJUSTMENT; STABILITY; MIDDLE AB In this study of 125 older couples married for an average of 34 years, multilevel models were computed to simultaneously examine intra-couple personality trait averages and between-spouse trait similarity as predictors of marital satisfaction. Our findings suggest that higher intra-couple levels of extraversion predict marital satisfaction, both husbands and wives. In addition, between-spouse similarity in openness to experience appears associated with higher levels of marital satisfaction as reported by husbands; concomitantly, between-spouse similarity in agreeableness predicts wives' marital satisfaction. With respect to openness (husbands) and agreeableness (wives), it did not matter which spouse within couples reported higher or lower trait levels. The most notable finding to emerge from this study is that neuroticism is not associated with marital satisfaction, neither husbands nor wives. This result stands in contrast to previously reported findings - the vast majority of prior research conducted with dating and newlywed couples. Conflicting results may reflect the degree to which neuroticism determines divorce within the first years of married life, adaptation to the foibles of one's spouse over time, overreliance on younger samples in marriage and family research, or some combination of these alternate explanations. C1 [O'Rourke, Norm] Simon Fraser Univ, Dept Gerontol, Vancouver, BC, Canada. [Claxton, Amy] Univ Washington, Sch Med, VA Puget Sound Healthcare Syst, Seattle, WA USA. [Chou, Pak Hei Benedito] Univ Victoria, Ctr Aging, Victoria, BC, Canada. [Smith, JuliAnna Z.] Univ Massachusetts Amherst, Ctr Res Families, Amherst, MA USA. [Hadjistavropoulos, Thomas] Univ Regina, Dept Psychol, Regina, SK S4S 0A2, Canada. RP O'Rourke, N (reprint author), Simon Fraser Univ, Dept Gerontol, Vancouver Campus, Vancouver, BC, Canada. EM ORourke@sfu.ca RI Hadjistavropoulos, Thomas /D-5976-2011 OI O'Rourke, Norm/0000-0001-5100-427X; Hadjistavropoulos, Thomas /0000-0002-8586-0450 FU Social Sciences and Humanities Research Council of Canada (SSHRC) [410-2005-2328]; Canadian Institutes of Health Research (CIHR) [127915, 136727] FX Support for this study was provided by the Social Sciences and Humanities Research Council of Canada (SSHRC #410-2005-2328) and from the Canadian Institutes of Health Research (CIHR #127915 & 136727), each awarded to Dr O'Rourke. NR 57 TC 3 Z9 3 U1 1 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 EI 1364-6915 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2011 VL 15 IS 3 BP 344 EP 353 DI 10.1080/13607863.2010.519324 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 748QC UT WOS:000289404500008 PM 21491219 ER PT J AU Feil, DG Lukman, R Simon, B Walston, A Vickrey, B AF Feil, Denise G. Lukman, Revana Simon, Barbara Walston, Amy Vickrey, Barbara TI Impact of dementia on caring for patients' diabetes SO AGING & MENTAL HEALTH LA English DT Article DE cognitive impairment; comorbidity; caregivers; quality of care ID RANDOMIZED CONTROLLED-TRIAL; BLOOD-GLUCOSE CONTROL; COGNITIVE IMPAIRMENT; ALZHEIMER-DISEASE; OLDER-ADULTS; CAREGIVER SUPPORT; GLYCEMIC CONTROL; CHRONIC ILLNESS; PRIMARY-CARE; MANAGEMENT AB Objective: To explore caregivers' challenges and quality-of-life issues managing diabetes in patients with dementia. Method: We conducted six focus groups with 21 caregivers of patients with dementia and type 2 diabetes. Focus groups were digitally recorded, transcribed, and translated using a software coding system. Emergent themes were identified and confirmed. Results: Three themes emerged. (1) Memory loss was the first identified cause of self-care neglect leading to caregiver intervention. (2) Behavioral and psychological symptoms of dementia (BPSD) disrupted the daily diabetes care routine, with 'denial' of having diabetes or memory loss (anosognosia) being the most disruptive. (3) Caregivers reported that caring for both diabetes and dementia was highly burdensome, felt overwhelmed with BPSD, and wanted more support from family and patients' healthcare providers. Conclusion: Caregivers of patients with dementia and diabetes face extraordinary challenges managing both conditions and the accompanying BPSD. Their identified need for a greater response from the healthcare system should be tested in quality improvement programs for this overlooked yet rapidly growing population. C1 [Feil, Denise G.; Simon, Barbara; Vickrey, Barbara] Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Sepulveda, CA USA. [Feil, Denise G.; Vickrey, Barbara] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Feil, Denise G.; Lukman, Revana; Walston, Amy; Vickrey, Barbara] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Feil, DG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Sepulveda, CA USA. EM denise.feil@va.gov FU Veterans' Administration Health Services; West Los Angeles Veterans' Administration Department of Research and Development FX This study was supported by funding from a Veterans' Administration Health Services Research Career Development Award and from the West Los Angeles Veterans' Administration Department of Research and Development. NR 44 TC 6 Z9 6 U1 1 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2011 VL 15 IS 7 BP 894 EP 903 DI 10.1080/13607863.2011.569485 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 881KI UT WOS:000299482500011 PM 21547750 ER PT J AU Curran, GM Pyne, J Fortney, JC Gifford, A Asch, SM Rimland, D Rodriguez-Barradas, M Monson, TP Kilbourne, AM Hagedorn, H Atkinson, JH AF Curran, Geoffrey M. Pyne, Jeffrey Fortney, John C. Gifford, Allen Asch, Stephen M. Rimland, David Rodriguez-Barradas, Maria Monson, Thomas P. Kilbourne, Amy M. Hagedorn, Hilde Atkinson, Joseph H. TI Development and implementation of collaborative care for depression in HIV clinics SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE depression; health services; HIV ID QUALITY-IMPROVEMENT; COST-EFFECTIVENESS; ANTIRETROVIRAL THERAPY; QUERI SERIES; INFECTION; MANAGEMENT; MORTALITY; RISK; AIDS; DISSEMINATION AB We sought to develop and implement collaborative depression care in human immunodeficiency virus (HIV) clinics in a project called HIV Translating Initiatives for Depression into Effective Solutions (HITIDES). Here we describe: (i) the formative evaluation (FE) conducted prior to implementation; (ii) the process used to adapt the primary care collaborative care model for depression to specialty HIV clinics; and (iii) the intervention itself. The overall design of HITIDES was a multi-site randomized trial in United States Department of Veterans Affairs (VA) HIV clinics comparing the depression collaborative care intervention to usual depression care. Qualitative methods were used for the FEs and informed the evidence-based quality improvement (EBQI) methods that were used for adapting and implementing the intervention. Baseline assessments were completed by 249 depressed HIV participants. Summaries of respective key informant interviews with eight HIV patients who were receiving depression treatment and 25 HIV or mental health (MH) providers were presented to each site. EBQI methods were used to tailor the HITIDES intervention to each site while maintaining true to the evidence base for depression collaborative care. EBQI methods provided a useful framework for intervention adaptation and implementation. The HITIDES study provides the opportunity to evaluate collaborative depression care in a specialty physical health clinic setting with a population that has a high prevalence of depression and MH comorbidity. C1 [Curran, Geoffrey M.; Pyne, Jeffrey; Fortney, John C.; Monson, Thomas P.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72114 USA. [Gifford, Allen; Atkinson, Joseph H.] Bedford Vet Affairs Med Ctr, Bedford, MA USA. [Asch, Stephen M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, Maria] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Kilbourne, Amy M.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Hagedorn, Hilde] Minneapolis Vet Affairs Healthcare Ctr, Minneapolis, MN USA. RP Curran, GM (reprint author), Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72114 USA. EM currangeoffreym@uams.edu NR 51 TC 9 Z9 9 U1 4 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 12 BP 1626 EP 1636 DI 10.1080/09540121.2011.579943 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 881KA UT WOS:000299481400013 PM 21714689 ER PT J AU Oursler, KK Goulet, JL Crystal, S Justice, AC Crothers, K Butt, AA Rodriguez-Barradas, MC Favors, K Leaf, D Katzel, LI Sorkin, JD AF Oursler, Krisann K. Goulet, Joseph L. Crystal, Stephen Justice, Amy C. Crothers, Kristina Butt, Adeel A. Rodriguez-Barradas, Maria C. Favors, Knachelle Leaf, David Katzel, Leslie I. Sorkin, John D. TI Association of Age and Comorbidity with Physical Function in HIV-Infected and Uninfected Patients: Results from the Veterans Aging Cohort Study SO AIDS PATIENT CARE AND STDS LA English DT Article ID MYOCARDIAL-INFARCTION; MEDICAL CONDITIONS; NEGATIVE VETERANS; CIGARETTE-SMOKING; MEN; DISEASE; RISK; HEALTH; IMPACT; DISABILITY AB HIV clinical care now involves prevention and treatment of age-associated comorbidity. Although physical function is an established correlate to comorbidity in older adults without HIV infection, its role in aging of HIV-infected adults is not well understood. To investigate this question we conducted cross-sectional analyses including linear regression models of physical function in 3227 HIV-infected and 3240 uninfected patients enrolled 2002-2006 in the Veterans Aging Cohort Study-8-site (VACS-8). Baseline self-reported physical function correlated with the Short Form-12 physical subscale (rho = 0.74, p < 0.001), and predicted survival. Across the age groups decline in physical function per year was greater in HIV-infected patients (beta(coef) -0.25, p < 0.001) compared to uninfected patients (beta(coef) -0.08, p = 0.03). This difference, although statistically significant (p < 0.01), was small. Function in the average 50-year old HIV-infected subject was equivalent to the average 51.5-year-old uninfected subject. History of cardiovascular disease was a significant predictor of poor function, but the effect was similar across groups. Chronic pulmonary disease had a differential effect on function by HIV status (Delta beta(coef) -3.5, p = 0.03). A 50-year-old HIV-infected subject with chronic pulmonary disease had the equivalent level of function as a 68.1-year-old uninfected subject with chronic pulmonary disease. We conclude that age-associated comorbidity affects physical function in HIV-infected patients, and may modify the effect of aging. Longitudinal research with markers of disease severity is needed to investigate loss of physical function with aging, and to develop age-specific HIV care guidelines. C1 [Oursler, Krisann K.; Favors, Knachelle; Katzel, Leslie I.; Sorkin, John D.] Univ Maryland, Sch Med, Dept Med, Vet Affairs Maryland Healthcare Syst, Baltimore, MD 21201 USA. [Goulet, Joseph L.; Justice, Amy C.] Yale Univ, Sch Med & Publ Hlth, Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, Inst Hlth, New Brunswick, NJ 08903 USA. [Crothers, Kristina] Univ Washington, Seattle, WA 98195 USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Leaf, David] Univ Calif Los Angeles, Sch Med, Greater Los Angeles Vet Affairs Healthcare Syst L, Los Angeles, CA 90024 USA. [Katzel, Leslie I.; Sorkin, John D.] Baltimore Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA. RP Oursler, KK (reprint author), Univ Maryland, Sch Med, Dept Med, Vet Affairs Maryland Healthcare Syst, 10 N Greene St BVAMC, Baltimore, MD 21201 USA. EM koursler@grecc.umaryland.edu OI Goulet, Joseph/0000-0002-0842-804X; Crothers, Kristina/0000-0001-9702-0371 FU National Institutes of Health (NIH) [K23AG024896, U01AA13566, R01HL090342, R01MH058984]; University of Maryland Claude D. Pepper Older Americans Independence Center [P60AG 028747]; Department of Veterans Affairs Baltimore Geriatric Research, Clinical and Education Center FX Supported by the National Institutes of Health (NIH) K23AG024896 (K.K.O.); U01AA13566 (A.C.J.); R01HL090342 (K.C.); R01MH058984 (S.C.); University of Maryland Claude D. Pepper Older Americans Independence Center P60AG 028747 (K.K.O., L.I.K., J.D.S., K.F.), and Department of Veterans Affairs Baltimore Geriatric Research, Clinical and Education Center (L.I.K., J.D.S.). NR 36 TC 45 Z9 45 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD JAN PY 2011 VL 25 IS 1 BP 13 EP 20 DI 10.1089/apc.2010.0242 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 704PW UT WOS:000286065900003 PM 21214375 ER PT J AU Evans, DA Grodstein, F Loewenstein, D Kaye, J Weintraub, S AF Evans, Denis A. Grodstein, Francine Loewenstein, David Kaye, Jeffrey Weintraub, Sandra TI Reducing case ascertainment costs in US population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2 SO ALZHEIMERS & DEMENTIA LA English DT Article; Proceedings Paper CT Conference on Prevalence and Trends of Alzheimers Disease and Other Age-Related Cognitive Impairment CY MAR 19-20, 2009 CL Washington, DC DE Alzheimer's disease; Dementia; Cognitive impairment; Cognitive function; Cognitive assessment; Technology; Monitoring system ID MINI-MENTAL STATE; SEMANTIC INTERFERENCE; OLDER-ADULTS; MEMORY IMPAIRMENT; APOLIPOPROTEIN-E; DECLINE; VARIABILITY; EDUCATION; ELDERS; INDIVIDUALS AB Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically "normal" at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask "Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?" Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic "Smart Home," outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms. (C) 2011 The Alzheimer's Association. All rights reserved. C1 [Evans, Denis A.] Rush Univ, Med Ctr, Rush Inst Healthy Aging, Chicago, IL 60612 USA. [Evans, Denis A.] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA. [Grodstein, Francine] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Grodstein, Francine] Brigham & Womens Hosp, Boston, MA 02115 USA. [Loewenstein, David] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA. [Loewenstein, David] Mt Sinai Med Ctr, Wien Ctr Alzheimers Dis & Memory Disorders, Miami, FL USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. [Kaye, Jeffrey] Portland VA Med Ctr, Portland, OR USA. [Weintraub, Sandra] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Weintraub, Sandra] Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL 60611 USA. RP Evans, DA (reprint author), Rush Univ, Med Ctr, Rush Inst Healthy Aging, Chicago, IL 60612 USA. EM Denis_Evans@rush.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [P30 AG008017-15, P30 AG013854, P30 AG013854-10, P30 AG024978, P30 AG024978-08, P30 AG008017, P30AG008017, P30AG013854, P30AG024978, R01 AG011101, R01 AG011101-17, R01 AG024059, R01 AG024059-05, R01 AG024215, R01 AG024215-05, R01AG011101, R01AG024059, R01AG024215] NR 88 TC 17 Z9 17 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JAN PY 2011 VL 7 IS 1 BP 110 EP 123 DI 10.1016/j.jalz.2010.11.008 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA 716XJ UT WOS:000287006500011 PM 21255748 ER PT J AU Barnes, DE Lee, SJ AF Barnes, Deborah E. Lee, Sei J. TI Predicting Alzheimer's risk: Why and how? SO ALZHEIMERS RESEARCH & THERAPY LA English DT Editorial Material AB Because the pathologic processes that underlie Alzheimer's disease (AD) appear to start 10 to 20 years before symptoms develop, there is currently intense interest in developing techniques to accurately predict which individuals are most likely to become symptomatic. Several AD risk prediction strategies - including identification of biomarkers and neuroimaging techniques and development of risk indices that combine traditional and non-traditional risk factors - are being explored. Most AD risk prediction strategies developed to date have had moderate prognostic accuracy but are limited by two key issues. First, they do not explicitly model mortality along with AD risk and, therefore, do not differentiate individuals who are likely to develop symptomatic AD prior to death from those who are likely to die of other causes. This is critically important so that any preventive treatments can be targeted to maximize the potential benefit and minimize the potential harm. Second, AD risk prediction strategies developed to date have not explored the full range of predictive variables (biomarkers, imaging, and traditional and non-traditional risk factors) over the full preclinical period (10 to 20 years). Sophisticated modeling techniques such as hidden Markov models may enable the development of a more comprehensive AD risk prediction algorithm by combining data from multiple cohorts. As the field moves forward, it will be critically important to develop techniques that simultaneously model the risk of mortality as well as the risk of AD over the full preclinical spectrum and to consider the potential harm as well as the benefit of identifying and treating high-risk older patients. C1 [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94118 USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, Div Geriatr, Program Aging Century, San Francisco, CA 94118 USA. [Lee, Sei J.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA 94121 USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94118 USA. EM deborah.barnes@ucsf.edu FU NIA NIH HHS [K23 AG040779] NR 10 TC 4 Z9 4 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PY 2011 VL 3 IS 6 AR 33 DI 10.1186/alzrt95 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V27JB UT WOS:000208608400003 PM 22126363 ER PT J AU Wang, TY Peterson, ED Ou, FS Nallamothu, BK Rumsfeld, JS Roe, MT AF Wang, Tracy Y. Peterson, Eric D. Ou, Fang-Shu Nallamothu, Brahmajee K. Rumsfeld, John S. Roe, Matthew T. CA Natl Cardiovasc Data Registry TI Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: A report from the National Cardiovascular Data Registry SO AMERICAN HEART JOURNAL LA English DT Article ID ASSOCIATION TASK-FORCE; PRIMARY ANGIOPLASTY; IMMEDIATE THROMBOLYSIS; HEART-ASSOCIATION; AMERICAN-COLLEGE; REPERFUSION; CARE; THERAPY; SYSTEMS; TIMELINESS AB Background National initiatives have reduced door-to-balloon (DTB) times for direct-arrival ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). However, STEMI patients requiring interhospital transfer for primary PCI are often excluded from public performance assessments of this quality metric. Methods We compared DTB time improvements between 2005 and 2007 for 29,248 transfer (25%) and 86,382 direct-arrival STEMI patients treated with primary PCI at 790 hospitals in the National Cardiovascular Data Catheterization PCI Registry. Among the 165 hospitals that submitted data for >= 10 patients per year, we examined the correlation between hospital-level changes in transfer and direct-arrival DTB times. Results Although DTB times decreased significantly over time for both groups, transfer STEMI patients had longer DTB times (median 149 vs 79 minutes, P < .0001), few received PCI <= 90 minutes (10% vs 63%, P < .0001), and the adjusted rate of DTB time improvement was slower (5% vs 9% relative decrease per year, P < .001) compared with direct-arrival patients. Larger annual transfer volume (not necessarily for primary PCI) was associated with greater improvement in transfer DTB times. However, there was no correlation between hospitals that improved direct-arrival DTB times and those that improved transfer DTB times (r = 0.094, P = .23). Conclusions Although there has been modest temporal improvement in DTB times, transfer patients still rarely achieve benchmark standards. Hospitals that had greater improvements in direct-arrival DTB times were not necessarily those with greater improvements in transfer DTB times. These results highlight the need for targeted system and policy approaches to improve DTB time for transferred primary PCI patients. (Am Heart J 2011;161:76-83.e1.) C1 [Wang, Tracy Y.; Peterson, Eric D.; Ou, Fang-Shu; Roe, Matthew T.] Duke Clin Res Inst, Durham, NC 27705 USA. [Nallamothu, Brahmajee K.] Univ Michigan, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. [Rumsfeld, John S.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. RP Wang, TY (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM tracy.wang@duke.edu FU Medicines Company, Parsippany, NJ; Sanofi; Schering-Plough (Merck), Whitehouse Station, NJ; Heartscape, Bothell, WA; Eli Lilly; Indianapolis; IN/Daiichi Sankyo Alliance, Parsippany, NJ; Bristol-Myers Squibb, New York, NY; Bristol-Myers Squibb/Sanofi, Bridgewater, NJ; Daiichi-Sankyo, Parsippany, NJ; Indianapolis, IN; Portola Pharmaceuticals, San Francisco, CA; KAI Pharmaceuticals, San Francisco, CA; Schering-Plough (Merck) Whitehouse Station, NJ; Sanofi-Aventis, Bridgewater, NJ; Bridgewater, NJ/BMS, New York, NY FX TY Wang: research grants from the Medicines Company, Parsippany, NJ, Sanofi, Bridgewater, NJ/BMS Partnership, New York, NY, Schering-Plough (Merck), Whitehouse Station, NJ, Heartscape, Bothell, WA, and Eli Lilly, Indianapolis, IN/Daiichi Sankyo Alliance, Parsippany, NJ.; ED Peterson: research grants from Bristol-Myers Squibb, New York, NY, Bristol-Myers Squibb/Sanofi, Bridgewater, NJ.; MT Roe: research grants from Daiichi-Sankyo, Parsippany, NJ, Eli Lilly, Indianapolis, IN, Portola Pharmaceuticals, San Francisco, CA, KAI Pharmaceuticals, San Francisco, CA, Schering-Plough (Merck) Whitehouse Station, NJ, Sanofi-Aventis, Bridgewater, NJ; consultant for KAI Pharmaceuticals, San Francisco, CA, Schering-Plough; Clinical Events Committees for Genentech, San Francisco, CA, Novartis, Basel, Switzerland; speakers bureau for Schering-Plough. NR 32 TC 37 Z9 38 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JAN PY 2011 VL 161 IS 1 DI 10.1016/j.ahj.2010.10.001 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 695MZ UT WOS:000285376200007 PM 21167337 ER PT J AU Huddle, TS AF Huddle, Thomas S. TI Clarifying the Dispute over Academic-Industry Relationships SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID CONFLICTS-OF-INTEREST C1 [Huddle, Thomas S.] UAB Sch Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Huddle, TS (reprint author), UAB Sch Med, 1530 3rd Ave S, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 8 TC 3 Z9 3 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 J9 AM J BIOETHICS JI Am. J. Bioeth. PD JAN PY 2011 VL 11 IS 1 BP 47 EP 49 DI 10.1080/15265161.2010.534540 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 717LV UT WOS:000287047300018 PM 21240812 ER PT J AU Ahmadi, N Nabavi, V Hajsadeghi, F Flores, F French, WJ Mao, SS Shavelle, D Ebrahimi, R Budoff, M AF Ahmadi, Naser Nabavi, Vahid Hajsadeghi, Fereshteh Flores, Ferdinand French, William J. Mao, Song S. Shavelle, David Ebrahimi, Ramin Budoff, Matthew TI Mortality Incidence of Patients With Non-Obstructive Coronary Artery Disease Diagnosed by Computed Tomography Angiography SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID HISTOLOGY INTRAVASCULAR ULTRASOUND; ACUTE MYOCARDIAL-INFARCTION; CLINICAL PRESENTATION; PLAQUE COMPOSITION; VULNERABLE PLAQUE; PROGNOSTIC VALUE; ATHEROSCLEROSIS; SEVERITY; LESIONS; QUANTIFICATION AB It was previously reported that event-free survival rates of symptomatic patients with coronary artery disease (CAD) diagnosed by computed tomographic angiography decreased incrementally from normal coronary arteries to obstructive CAD. The aim of this study was to investigate the clinical outcomes of symptomatic patients with nonobstructive CAD with luminal stenoses of 1% to 49% on the basis of coronary plaque morphology in an outpatient setting. Among 3,499 consecutive symptomatic subjects who underwent computed tomographic angiography, 1,102 subjects with nonobstructive CAD (mean age 59 +/- 14 years, 69.9% men) were prospectively followed for a mean of 78 +/- 12 months. Coronary plaques were defined as noncalcified, mixed, and calcified per patient. Multivariate Cox proportional-hazards models were developed to predict all-cause mortality. The death rate of patients with nonobstructive CAD was 3.1% (34 deaths). The death rate increased incrementally from calcified plaque (1.4%) to mixed plaque (3.3%) to noncalcified plaque (9.6%), as well as from single- to triple-vessel disease (p < 0.001). In subjects with mixed or calcified plaques, the death rate increased with the severity of coronary artery calcium from 1 to 9 to >= 400. The risk-adjusted hazard ratios of all-cause mortality in patients with nonobstructive CAD were 3.2 (95% confidence interval 1.3 to 8.0, p = 0.001) for mixed plaques and 7.4 (95% confidence interval 2.7 to 20.1, p = 0.0001) for noncalcified plaques compared with calcified plaques. The areas under the receiver-operating characteristic curve to predict all-cause mortality were 0.75 for mixed and 0.86 for noncalcified coronary lesions. In conclusion, this study demonstrates that the presence of noncalcified and mixed coronary plaques provided incremental value in predicting all-cause mortality in symptomatic subjects with nonobstructive CAD independent of age, gender, and conventional risk factors. (c) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:10-16) C1 [Ahmadi, Naser; Nabavi, Vahid; Hajsadeghi, Fereshteh; Flores, Ferdinand; French, William J.; Mao, Song S.; Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Ahmadi, Naser; Shavelle, David] Univ So Calif, Los Angeles, CA USA. RP Budoff, M (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. EM mbudoff@labiomed.org NR 27 TC 43 Z9 43 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 1 PY 2011 VL 107 IS 1 BP 10 EP 16 DI 10.1016/j.amjcard.2010.08.034 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 705KI UT WOS:000286126900003 PM 21146679 ER PT J AU Sonnenberg, A Faigel, DO AF Sonnenberg, Amnon Faigel, Douglas O. TI The Endoscopist's Influence on Endoscopic Test Characteristics SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. [Faigel, Douglas O.] Mayo Clin, Scottsdale, AZ USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 1 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2011 VL 106 IS 1 BP 10 EP 13 DI 10.1038/ajg.2010.297 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 717CS UT WOS:000287021200004 PM 21212751 ER PT J AU Njoroge, JN El Khoudary, SR Fried, LF Barinas-Mitchell, E Sutton-Tyrrell, K AF Njoroge, Jennifer N. El Khoudary, Samar R. Fried, Linda F. Barinas-Mitchell, Emma Sutton-Tyrrell, Kim TI High Urinary Sodium Is Associated With Increased Carotid Intima-Media Thickness in Normotensive Overweight and Obese Adults SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; carotid IMT; hypertension; obesity; sodium; vascular remodeling ID DENSITY-LIPOPROTEIN CHOLESTEROL; LARGE ARTERY STRUCTURE; HIGH-SALT DIET; BLOOD-PRESSURE; HYPERTENSION; WOMEN; SERUM; MEN; DISTENSIBILITY; INTERSALT AB BACKGROUND Increased dietary sodium has been reported to increase cardiovascular disease (CVD) risk, perhaps through blood pressure (BP)-independent vascular remodeling. Carotid intima-media thickness (IMT) is an accepted measure of structural vascular remodeling and a strong predictor of CVD. This study aimed to determine whether urinary sodium is positively associated with carotid IMT in normotensive overweight and obese adults. METHODS We evaluated baseline data from 258 participants in the Slow Adverse Vascular Effects (SAVE) clinical trial. Urinary sodium was measured from one 24-h urine collection from each individual. Carotid IMT was measured using high-resolution B-mode ultrasonography. Participants were categorized into quartiles of urinary sodium. RESULTS There was a significant positive trend with greater IMT associated with increasing urinary sodium quartile in univariate linear regression (P = 0.047). This trend was significant when adjusting for age, sex, race, and systolic BP (SBP) (P = 0.03) as well as in a fully adjusted model (P = 0.04). In pairwise comparisons, the highest urinary sodium quartile had a significantly greater mean IMT (0.62 mm) than the lowest urinary sodium quartile (0.59 mm) after adjustment for age, sex, race, and SBP (P = 0.04). This comparison lost significance after the addition of BMI. CONCLUSIONS In our community-based sample of normotensive overweight and obese adults, we observed a significant positive trend in carotid IMT with increasing quartile of urinary sodium. If the ongoing clinical trial confirms this relationship between sodium and carotid IMT, it would lend support to efforts to decrease sodium intake in overweight and obese individuals. C1 [Njoroge, Jennifer N.; El Khoudary, Samar R.; Fried, Linda F.; Barinas-Mitchell, Emma; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA. RP Sutton-Tyrrell, K (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. EM Tyrrell@edc.pitt.edu OI El Khoudary Abushaban, Samar/0000-0003-2913-0821; Barinas-Mitchell, Emma/0000-0002-7280-7781 FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01 HL077525-01A2, T32 HL083825-01] FX This independent investigator-promoted research was supported by grants R01 HL077525-01A2 and T32 HL083825-01 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. We acknowledge Janice Sabatine, Avanti Strategies, Cranberry Township, Pennsylvania, for writing and editing assistance. NR 36 TC 18 Z9 20 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD JAN PY 2011 VL 24 IS 1 BP 70 EP 76 DI 10.1038/ajh.2010.113 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 697GS UT WOS:000285501800012 PM 20508622 ER PT J AU Peralta, CA Katz, R Shlipak, M Dubin, R DeBoer, I Jenny, N Fitzpatrick, A Koro, C Kestenbaum, B Ix, J Sarnak, M Cushman, M AF Peralta, Carmen A. Katz, Ronit Shlipak, Michael Dubin, Ruth DeBoer, Ian Jenny, Nancy Fitzpatrick, Annette Koro, Carol Kestenbaum, Bryan Ix, Joachim Sarnak, Mark Cushman, Mary TI Kidney Function Decline in the Elderly: Impact of Lipoprotein-Associated Phospholipase A(2) SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Chronic kidney disease; Elderly; Estimated GFR; Kidney decline; Lipoprotein-associated phospholipase A(2) ID GLOMERULAR-FILTRATION-RATE; ACTIVATING-FACTOR ACETYLHYDROLASE; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; SERUM CYSTATIN-C; RENAL-FUNCTION; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; OLDER-ADULTS; DYSFUNCTION AB Background: Whether lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels are associated with kidney function decline has not been well studied. Methods: We investigated associations of Lp-PLA(2) antigen and activity with kidney function decline and rapid decline over 5.7 years in the Cardiovascular Health Study (n = 4,359). We estimated kidney function by cystatin C (eGFRcys) in repeated measures, and defined rapid decline as >= 3 ml/min/1.73 m(2) per year. We stratified by baseline preserved GFR (>= 60 ml/min/1.73 m(2)). Results: Mean age was 72 +/- 5 years. Average eGFRcys decline was -1.79 ml/min/1.73 m(2) (SD = 2.60) per year. Among persons with preserved GFR, compared to the lowest quartile of Lp-PLA(2) antigen, eGFRcys decline was faster among persons in the second, beta-0.31 (95% CI -0.52, -0.10), third -0.19 (-0.41, 0.02) and fourth quartiles -0.26 (-0.48, -0.04) after full adjustment. Persons in the highest quartile of Lp-PLA(2) antigen had increased odds of rapid decline 1.34 (1.03, 1.75), compared to the lowest. There was no significant association between levels of Lp-PLA(2) activity and eGFRcys decline or rapid decline. Associations were not statistically significant among persons with low eGFR (<60 ml/min/1.73 m(2)) at baseline. Conclusion: Higher levels of Lp-PLA(2) antigen but not activity were significantly associated with faster rates of kidney function decline. These findings may suggest a novel vascular pathway for kidney disease progression. Copyright (C) 2011 S. Karger AG, Basel C1 [Peralta, Carmen A.; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael; Dubin, Ruth] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Katz, Ronit; DeBoer, Ian; Fitzpatrick, Annette; Kestenbaum, Bryan] Univ Washington, Seattle, WA 98195 USA. [Jenny, Nancy; Cushman, Mary] Univ Vermont, Coll Med, Burlington, VT USA. [Koro, Carol] GlaxoSmithKline Inc, Collegeville, PA USA. [Ix, Joachim] Univ Calif San Diego, La Jolla, CA 92093 USA. [Sarnak, Mark] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Heart, Lung, and Blood Institute [U01 HL080295]; National Institute of Neurological Disorders and Stroke; GlaxoSmithKline (GSK); [N01-HC-85079]; [N01-HC-85086]; [N01-HC-35129]; [N01 HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133]; [RO1 AG 027002]; [K23SK082793] FX CHS is supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. This project is also supported by RO1 AG 027002 (Sarnak) and K23SK082793 (Peralta). A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm.; This study is supported by a grant from GlaxoSmithKline (GSK). Dr. Koro is an employee at GSK. Drs. Peralta, Cushman, and Fitzpatrick have funding from GSK. The funding sources did not have a role in the design, analysis or approval of the manuscript. NR 35 TC 5 Z9 5 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2011 VL 34 IS 6 BP 512 EP 518 DI 10.1159/000333045 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 867XA UT WOS:000298486900004 PM 22056971 ER PT J AU Jotwani, V Scherzer, R Choi, A Szczech, L Polak, JF Kronmal, RA Grunfeld, C Shlipak, M AF Jotwani, Vasantha Scherzer, Rebecca Choi, Andy Szczech, Lynda Polak, Joseph F. Kronmal, Richard A. Grunfeld, Carl Shlipak, Michael TI Reduced Kidney Function and Preclinical Atherosclerosis in HIV-Infected Individuals: The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Cystatin C; Intima-medial thickness; HIV; Atherosclerosis; Cardiovascular disease; Kidney ID ALL-CAUSE MORTALITY; CYSTATIN-C; CARDIOVASCULAR EVENTS; SERUM CREATININE; MEDIA THICKNESS; DISEASE; ASSOCIATION; INTIMA; ALBUMINURIA; OUTCOMES AB Background/Aims: Reduced kidney function and albuminuria are associated with higher risk for cardiovascular disease (CVD) and mortality in HIV-infected individuals. We investigated whether reduced estimated glomerular filtration rate (eGFR) and albuminuria are associated with subclinical vascular disease, as assessed by carotid intima-medial thickness (cIMT). Methods: Cross-sectional analysis of 476 HIV-infected individuals without clinical evidence of CVD enrolled in the Fat Redistribution and Metabolic Change in HIV infection (FRAM) study, using multivariable linear regression. eGFR(Cys) and eGFR(Cr) were calculated from cystatin C and creatinine levels. Albuminuria was defined as a positive urine dipstick (>= 1+) or urine albumin-to-creatinine ratio >= 30 mg/g. Common and internal cIMT were measured by high-resolution B-mode ultrasound. Results: In unadjusted analyses, eGFR(Cys) and eGFR(Cr) were strongly associated with common and internal cIMT. Each 10 ml/min/1.73 m(2) decrease in eGFR(Cys) and eGFR(cr), was associated with a 0.008 mm higher common cIMT (p = 0.003, p = 0.01) and a 0.024 and 0.029 mm higher internal cIMT (p = 0.003), respectively. These associations were eliminated after adjustment for age, gender, and race. Albuminuria showed little association with common or internal cIMT in all models. Conclusions: In HIV-infected individuals without prior CVD, reduced kidney function and albuminuria were not independently associated with subclinical vascular disease, as assessed by cIMT. These results suggest that research should focus on searching for novel mechanisms by which kidney disease confers cardiovascular risk in HIV-infected individuals. copyright (C) 2011 S. Karger AG, Basel C1 [Jotwani, Vasantha; Scherzer, Rebecca; Choi, Andy; Grunfeld, Carl; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Jotwani, Vasantha; Scherzer, Rebecca; Choi, Andy; Grunfeld, Carl; Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Szczech, Lynda] Duke Univ, Med Ctr, Durham, NC USA. [Polak, Joseph F.] Tufts Med Ctr, Boston, MA USA. [Kronmal, Richard A.] Univ Washington, Seattle, WA 98195 USA. RP Shlipak, M (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU NIH [RO1-DK57508, HL74814, HL53359]; NIH GCRC [M01-RR00036, RR00051, RR00052, RR00054, RR00083, RR0636, RR00865, UL1 RR024131, P30 DK 026687-269012]; Veterans Affairs Medical Centers of Atlanta, District of Columbia, New York, and San Francisco FX Supported by NIH grants RO1-DK57508, HL74814, and HL53359, and NIH GCRC grants M01-RR00036, RR00051, RR00052, RR00054, RR00083, RR0636, RR00865, UL1 RR024131, and P30 DK 026687-269012, the Albert L. and Janet A. Schultz Supporting Foundation, and with resources and the use of facilities of the Veterans Affairs Medical Centers of Atlanta, District of Columbia, New York, and San Francisco. NR 25 TC 5 Z9 5 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2011 VL 33 IS 5 BP 453 EP 460 DI 10.1159/000327606 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 767FQ UT WOS:000290841100009 PM 21508633 ER PT J AU Jhamb, M Pike, F Ramer, S Argyropoulos, C Steel, J Dew, MA Weisbord, SD Weissfeld, L Unruh, M AF Jhamb, Manisha Pike, Francis Ramer, Sarah Argyropoulos, Christos Steel, Jennifer Dew, Mary Amanda Weisbord, Steven D. Weissfeld, Lisa Unruh, Mark TI Impact of Fatigue on Outcomes in the Hemodialysis (HEMO) Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE End-stage renal disease; Fatigue; Vitality; Health-related quality of life ID QUALITY-OF-LIFE; DIALYSIS PATIENTS; MAINTENANCE HEMODIALYSIS; HEALTH-STATUS; INTERLEUKIN-6; METAANALYSIS; MORTALITY; SYMPTOMS; TRIAL; SERUM AB Background: Fatigue is a common debilitating symptom in chronic kidney disease patients on maintenance hemodialysis. However, little is known about its pathogenesis and association with survival. Methods: This study examines the correlates and outcomes of fatigue among 1,798 hemodialysis patients enrolled in the HEMO study. Fatigue was assessed using the SF-36 vitality scale. Multivariable analysis was used to assess independent associations of demographic and clinical characteristics with baseline fatigue and longitudinal changes in fatigue. The association of fatigue with all-cause and cause-specific mortality and cardiac hospitalizations was also assessed. Results: Higher index of coexistent diseases (ICED) score, diabetes, non-African-American race, lower serum albumin, use of medications for sleep and poor sleep quality were found to be significantly associated with more fatigue at baseline. In longitudinal analyses, patients who were older, had been on dialysis longer, had higher ICED score, and reported using medications for sleep were more likely to experience worsening fatigue, whereas higher serum albumin was strongly associated with an improvement in level of fatigue. A 10-point increase in vitality score was associated with 10% increase in mean survival (p < 0.0001). Conclusions: Demographic and clinical factors have significant associations with fatigue, which itself predicts mortality. Improving fatigue in the end-stage renal disease population may positively impact patient well-being and survival. Copyright (C) 2011 S. Karger AG, Basel C1 [Unruh, Mark] Univ Pittsburgh, Sch Med, Med Ctr, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Pike, Francis; Dew, Mary Amanda; Weissfeld, Lisa] Univ Pittsburgh, Med Ctr, Dept Biostat, Pittsburgh, PA 15213 USA. [Steel, Jennifer; Dew, Mary Amanda] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. [Steel, Jennifer] Univ Pittsburgh, Sch Med, Liver Canc Ctr, Dept Surg,Starzl Transplantat Inst, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Unruh, M (reprint author), Univ Pittsburgh, Sch Med, Med Ctr, Renal Electrolyte Div, 200 Lothrop St,PUH C-1111, Pittsburgh, PA 15213 USA. EM unruh@pitt.edu RI Jhamb, Manisha/E-4169-2013 OI Argyropoulos, Christos/0000-0002-9679-7805 FU NIDDK NIH HHS [R01 DK077785] NR 32 TC 25 Z9 28 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2011 VL 33 IS 6 BP 515 EP 523 DI 10.1159/000328004 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 780BG UT WOS:000291825500007 PM 21555875 ER PT J AU Yang, N Mosher, R Seo, S Beebe, D Friedl, A AF Yang, Ning Mosher, Rachel Seo, Songwon Beebe, David Friedl, Andreas TI Syndecan-1 in Breast Cancer Stroma Fibroblasts Regulates Extracellular Matrix Fiber Organization and Carcinoma Cell Motility SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID HEPARAN-SULFATE CHAINS; FIBRONECTIN MATRIX; ESTROGEN-RECEPTOR; INTEGRIN ACTIVATION; IN-VIVO; MIGRATION; EXPRESSION; BINDING; ALPHA(V)BETA(3); POLYMERIZATION AB Stromal fibroblasts of breast carcinomas frequently express the cell surface proteoglycan syndecan-1 (Sdc1). In human breast carcinoma samples, stromal Sdc1 expression correlates with an organized, parallel, extracellular matrix (ECM) fiber architecture. To examine a possible link between stromal Sdc1 and the fiber architecture, we generated bioactive cell-free three-dimensional ECMs from cultures of Sdc1-positive and Sdc1-negative murine and human mammary fibroblasts (termed ECM-Sdc1 and ECM-mock, respectively). Indeed, ECM-Sdc1 showed a parallel fiber architecture that contrasted markedly with the random fiber arrangement of ECM-mock. When breast carcinoma cells were seeded into the fibroblast-free ECMs, ECM-Sdc1, but not ECM-mock, promoted their attachment, invasion, and directional movement. We further evaluated the contribution of the structural/compositional modifications in ECM-Sdc1 on carcinoma cell behavior. By microcontact printing of culture surfaces, we forced the Sdc1-negative fibroblasts to produce ECM with parallel fiber organization, mimicking the architecture observed in ECM-Sdc1. We found that the fiber topography governs carcinoma cell migration directionality. Conversely, an elevated fibronectin level in ECM-Sdc1 was responsible for the enhanced attachment of the breast carcinoma cells. These observations suggest that Sdc1 expression in breast carcinoma stromal fibroblasts promotes the assembly of an architecturally abnormal ECM that is permissive to breast carcinoma directional migration and invasion. (An: J Pathol 2011, 178:325-335; DOI: 10.1016/j.ajpath.2010.11.039) C1 [Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Wisconsin Inst Med Res WIMR 6051, Madison, WI 53705 USA. [Mosher, Rachel; Beebe, David] Univ Wisconsin, Dept Biomed Engn, Coll Engn, Madison, WI 53705 USA. [Seo, Songwon] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Lab Med Serv, Madison, WI USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Wisconsin Inst Med Res WIMR 6051, 1111 Highland Ave, Madison, WI 53705 USA. EM afriedl@wisc.edu FU National Institutes of Health [RO1 CA107012] FX Supported by the National Institutes of Health (grant RO1 CA107012). NR 61 TC 47 Z9 48 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 2011 VL 178 IS 1 BP 325 EP 335 DI 10.1016/j.ajpath.2010.11.039 PG 11 WC Pathology SC Pathology GA 710EM UT WOS:000286493700035 PM 21224069 ER PT J AU Thrower, EC Yuan, JZ Usmani, A Liu, YN Jones, C Minervini, SN Alexandre, M Pandol, SJ Guha, S AF Thrower, Edwin C. Yuan, Jingzhen Usmani, Ashar Liu, Yannan Jones, Courtney Minervini, Samantha N. Alexandre, Martine Pandol, Stephen J. Guha, Sushovan TI A novel protein kinase D inhibitor attenuates early events of experimental pancreatitis in isolated rat acini SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE PKD/PKD1 inhibitor CRT0066101; zymogen activation; amylase secretion; cell injury ID ACTIVATION LOOP SER(744); KAPPA-B ACTIVATION; ZYMOGEN ACTIVATION; IN-VIVO; C-EPSILON; MEDIATED PHOSPHORYLATION; POTENT INHIBITOR; PHORBOL ESTERS; PKC-DELTA; GO 6976 AB Novel protein kinase C isoforms (PKC delta and epsilon) mediate early events in acute pancreatitis. Protein kinase D (PKD/PKD1) is a convergent point of PKC delta and epsilon in the signaling pathways triggered through CCK or cholinergic receptors and has been shown to activate the transcription factor NF-kappa B in acute pancreatitis. For the present study we hypothesized that a newly developed PKD/PKD1 inhibitor, CRT0066101, would prevent the initial events leading to pancreatitis. We pretreated isolated rat pancreatic acinar cells with CRT0066101 and a commercially available inhibitor Go6976 (10 mu M). This was followed by stimulation for 60 min with high concentrations of cholecystokinin (CCK, 0.1 mu M), carbachol (CCh, 1 mM), or bombesin (10 mu M) to induce initial events of pancreatitis. PKD/PKD1 phosphorylation and activity were measured as well as zymogen activation, amylase secretion, cell injury and NF-kappa B activation. CRT0066101 dose dependently inhibited secretagogue-induced PKD/PKD1 activation and autophosphorylation at Ser-916 with an IC(50) similar to 3.75-5 mu M but had no effect on PKC-dependent phosphorylation of the PKD/PKD1 activation loop (Ser-744/748). Furthermore, CRT0066101 reduced secretagogue-induced zymogen activation and amylase secretion. Go6976 reduced zymogen activation but not amylase secretion. Neither inhibitor affected basal zymogen activation or secretion. CRT0066101 did not affect secretagogue-induced cell injury or changes in cell morphology, but it reduced NF-kappa B activation by 75% of maximal for CCK- and CCh-stimulated acinar cells. In conclusion, CRT0066101 is a potent and specific PKD family inhibitor. Furthermore, PKD/PKD1 is a potential mediator of zymogen activation, amylase secretion, and NF-kappa B activation induced by a range of secretagogues in pancreatic acinar cells. C1 [Thrower, Edwin C.; Usmani, Ashar; Jones, Courtney; Minervini, Samantha N.; Alexandre, Martine] Dept Internal Med, Sect Digest Dis, West Haven, CT USA. [Thrower, Edwin C.; Usmani, Ashar; Jones, Courtney; Minervini, Samantha N.; Alexandre, Martine] Vet Adm Connecticut Healthcare, West Haven, CT USA. [Thrower, Edwin C.; Usmani, Ashar; Jones, Courtney; Minervini, Samantha N.; Alexandre, Martine] Yale Univ, Sch Med, New Haven, CT USA. [Yuan, Jingzhen; Liu, Yannan; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Hlth Care Syst, So Calif Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. [Yuan, Jingzhen; Liu, Yannan; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Guha, Sushovan] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX USA. RP Thrower, EC (reprint author), Vet Adm Med Ctr, 950 Campbell Ave,Bldg 4, West Haven, CT 06516 USA. EM edwin.thrower@yale.edu FU National Institutes of Health (NIH) [DK69702, 5P30CA16672]; National Institute on Alcohol Abuse and Alcoholism [5 P60 AA11999]; MD Anderson Cancer Center; McNair Foundation; Tsukamoto FX This work was supported by a National Institutes of Health (NIH) Grant R21 (DK69702 to E. C. Thrower) USC-UCLA Research Center for Alcoholic Liver and Pancreatic Injury Grant (5 P60 AA11999 from the National Institute on Alcohol Abuse and Alcoholism; Tsukamoto; to S. J. Pandol), MD Anderson Cancer Center Physician Scientist Program Award (to S. Guha), McNair Foundation Scholar Award (to S. Guha), and NIH 5P30CA16672 (Career Development Award to S. Guha). NR 43 TC 14 Z9 14 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 2011 VL 300 IS 1 BP G120 EP G129 DI 10.1152/ajpgi.00300.2010 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 700LV UT WOS:000285744300012 PM 20947701 ER PT J AU Mariappan, MM D'Silva, K Lee, MJ Sataranatarajan, K Barnes, JL Choudhury, GG Kasinath, BS AF Mariappan, Meenalakshmi M. D'Silva, Kristin Lee, Myung Ja Sataranatarajan, Kavithalakshmi Barnes, Jeffrey L. Choudhury, Goutam Ghosh Kasinath, Balakuntalam S. TI Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ribosomal deoxyribonucleic acid transcription; diabetic kidney disease; hypertrophy; mammalian target of rapamycin; ribonucleic acid; polymerase I ID MESSENGER-RNA TRANSLATION; POLYMERASE-I; DIABETIC-NEPHROPATHY; PROTEIN-SYNTHESIS; GENE-TRANSCRIPTION; RENAL HYPERTROPHY; CARDIAC MYOCYTES; HIGH INSULIN; GROWTH; PHOSPHORYLATION AB Mariappan MM, D'Silva K, Lee MJ, Sataranatarajan K, Barnes JL, Choudhury GG, Kasinath BS. Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells. Am J Physiol Renal Physiol 300: F219-F230, 2011. First published October 13, 2010; doi:10.1152/ajprenal.00207.2010.-Diabetes promotes protein synthesis to induce kidney hypertrophy and increase renal matrix proteins. Increased capacity for mRNA translation by way of ribosomal biogenesis facilitates sustained stimulation of protein synthesis. We tested the hypothesis that high glucose induces ribosomal biogenesis as indicated by an increase in rRNA synthesis in the setting of augmented protein synthesis. High glucose (30 mM) increased global protein synthesis, expression of matrix proteins, laminin gamma 1 and fibronectin, and rDNA transcription in glomerular epithelial cells (GECs) compared with 5 mM glucose. High glucose induced Ser(388) phosphorylation of upstream binding factor (UBF), an rDNA transcription factor, along with increased phosphorylation of Erk and p70S6 kinase. Inactivation of Erk and p70S6 kinase either by their respective chemical inhibitors or by expression of their inactive mutant constructs blocked high-glucose-induced UBF phosphorylation. High glucose reduced nuclear content of p19ARF and promoted dissolution of inactive UBF-p19ARF complex. High glucose also promoted association of UBF with RPA194, a subunit of RNA polymerase I. Inhibition of Erk, p70S6 kinase, and UBF1 by transfecting GECs with their respective inactive mutants abolished laminin gamma 1 synthesis, protein synthesis, and rDNA transcription. Renal cortex from type 1 diabetic rats and type 2 diabetic db/db mice showed increased phosphorylation of UBF, Erk, and p70S6 kinase coinciding with renal hypertrophy and onset of matrix accumulation. Our data suggest that augmented ribosome biogenesis occurs in an UBF-dependent manner during increased protein synthesis induced by high glucose in the GECs that correlates with UBF activation and renal hypertrophy in rodents with type 1 and type 2 diabetes. C1 [Mariappan, Meenalakshmi M.; D'Silva, Kristin; Lee, Myung Ja; Sataranatarajan, Kavithalakshmi; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] S Texas Vet Healthcare Syst, Vet Affairs Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. RP Mariappan, MM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM malini@uthscsa.edu FU National Institutes of Health [DK-077295, RC2AG-036613, DK-050190, DK-080106]; National Institute of Diabetes and Digestive and Kidney Diseases O'Brien Kidney Center; Veterans Affairs (VA) Medical Research Service; Juvenile Diabetes Research Foundation [3-2007-245, 1-2008-185]; VA Research Career Scientist Award FX This study was supported by the National Institutes of Health Grants DK-077295 and RC2AG-036613 to B. S. Kasinath, DK-050190 to G. G. Choudhury, and DK-080106 to J. L. Barnes; a National Institute of Diabetes and Digestive and Kidney Diseases O'Brien Kidney Center Grant (B. S. Kasinath); the Veterans Affairs (VA) Medical Research Service (B. S. Kasinath, G. G. Choudhury, and J. L. Barnes); and Juvenile Diabetes Research Foundation Grants 3-2007-245 to M. M. Mariappan/B. S. Kasinath and 1-2008-185 to G. G. Choudhury. G. G. Choudhury is a recipient of VA Research Career Scientist Award. NR 46 TC 11 Z9 11 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2011 VL 300 IS 1 BP F219 EP F230 DI 10.1152/ajprenal.00207.2010 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 703FP UT WOS:000285964000025 PM 20943765 ER PT J AU Medverd, JR Pugsley, JM Harley, JD Bhargava, P AF Medverd, Jonathan R. Pugsley, Jeffrey M. Harley, John D. Bhargava, Puneet TI Lateral Approach for Radiocarpal Wrist Arthrography SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE arthrography; arthrography technique; CT arthrography; MR arthrography; wrist; wrist injuries; wrist joint AB OBJECTIVE. We describe a technique of radiocarpal arthrography using the lateral approach. This technique may be used as an alternative to conventional dorsal techniques. CONCLUSION. Radiocarpal injection using the lateral approach can be considered as an alternative to conventional dorsal approaches in the evaluation of wrist pain and instability. C1 [Medverd, Jonathan R.; Harley, John D.; Bhargava, Puneet] Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. [Pugsley, Jeffrey M.] Univ Washington, Dept Radiol, Diagnost Radiol Residency Program, Seattle, WA 98108 USA. RP Medverd, JR (reprint author), Univ Washington, Dept Radiol, VA Puget Sound Hlth Care Syst, Seattle Div, 1660 South Columbian Way S 114 RAD, Seattle, WA 98108 USA. EM jmed@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 8 TC 2 Z9 2 U1 1 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JAN PY 2011 VL 196 IS 1 BP W58 EP W60 DI 10.2214/AJR.10.4900 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V32SY UT WOS:000208972100009 PM 21178032 ER PT J AU Dailey, NJM Young, EJ AF Dailey, Natalie J. M. Young, Edward J. TI Candida glabrata Spinal Osteomyelitis SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Candida glabrata; Torulopsis glabrata; Osteomyelitis; Disseminated infection ID TORULOPSIS-GLABRATA; VERTEBRAL OSTEOMYELITIS; INVASIVE CANDIDIASIS; CASPOFUNGIN; ALBICANS AB Invasive disease caused by Candida spp. is being appreciated with increased frequency especially associated with widespread use of immunosuppressive drug therapy. We report a case of spinal osteomyelitis and epidural abscess caused by Candida glabrata occurring in a patient who had been diagnosed with candidemia 3 months before that patient was treated with fluconazole. The infection was successfully treated with amphotericin B, but the patient eventually required surgical intervention for spondylolisthesis with impingement on the cauda equina. C1 Baylor Coll Med, Med Serv, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Dailey, NJM (reprint author), N Carolina Div Publ Hlth, 1902 Mail Serv Ctr, Raleigh, NC 27669 USA. EM janine.dailey@dhhs.nc.gov NR 18 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2011 VL 341 IS 1 BP 78 EP 82 DI 10.1097/MAJ.0b013e3181f6c6ea PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 716MQ UT WOS:000286973800016 PM 21030857 ER PT J AU Lee, G Gardner, BK Elashoff, DA Purcell, CM Sandha, HS Mao, JT Krysan, K Lee, JM Dubinett, SM AF Lee, Gina Gardner, Brian K. Elashoff, David A. Purcell, Colleen M. Sandha, Harpavan S. Mao, Jenny T. Krysan, Kostyantyn Lee, Jay M. Dubinett, Steven M. TI Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH LA English DT Article DE Lung cancer; connective tissue activating peptide (CTAP)-III; neutrophil activating peptide (NAP)-2; CXC chemokines AB Despite advances in treatments, lung cancer has been the leading cause of cancer-related deaths in the United States for the past several decades. Recent findings from the National Lung Screening Trial reveal that low-dose helical computed tomography (CT) scan screening of high-risk individuals reduces lung cancer mortality. This suggests that early detection is of key importance to improving patient outcome. However, of those screened with CT scans, 25% had positive scans that require further follow-up studies which often involve more radiation exposure and invasive tests to reduce false positive results. The purpose of this study was to identify candidate plasma biomarkers to aid in diagnosis of lung cancer in at-risk individuals. We found increased expression of the CXC chemokine connective tissue-activating peptide (CTAP)-III from plasma specimens of lung cancer patients compared to at-risk control subjects. Identification of the peptide was confirmed by the addition of an anti-NAP-2 antibody that recognizes CTAP-III and NAP-2. We also quantified and verified the increased levels of plasma CTAP-III with ELISA in patients with lung cancer (mean +/- SD, 1859 +/- 1219 ng/mL) compared to controls (698 +/- 434 ng/mL; P<0.001). Our findings demonstrate elevated plasma levels of CTAP-III occur in lung cancer patients. Further studies are required to determine if this chemokine could be utilized in a blood-based biomarker panel for the diagnosis of lung cancer. C1 [Lee, Gina; Gardner, Brian K.; Elashoff, David A.; Purcell, Colleen M.; Sandha, Harpavan S.; Krysan, Kostyantyn; Lee, Jay M.; Dubinett, Steven M.] Univ Calif Los Angeles, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Lee, Gina; Gardner, Brian K.; Elashoff, David A.; Purcell, Colleen M.; Sandha, Harpavan S.; Krysan, Kostyantyn; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lee, Jay M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lee, Gina; Gardner, Brian K.; Dubinett, Steven M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Mao, Jenny T.] New Mexico Vet Affairs Healthcare Syst, Dept Med, Albuquerque, NM USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. EM bgardner@mednet.ucla.edu; SDubinett@mednet.ucla.edu FU National Institutes of Health [U01 CA152751, 1 P50 CA90388]; LUNGevity Foundation; Medical Research Funds from the Department of Veterans Affairs FX This work was supported by the National Institutes of Health U01 CA152751 and 1 P50 CA90388, the LUNGevity Foundation, and Medical Research Funds from the Department of Veterans Affairs. NR 31 TC 3 Z9 3 U1 0 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1943-8141 J9 AM J TRANSL RES JI Am. J. Transl. Res. PY 2011 VL 3 IS 3 BP 226 EP 233 PG 8 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA V28QG UT WOS:000208694700001 PM 21654877 ER PT J AU Orloff, SL Hwee, YK Kreklywich, C Andoh, TF Hart, E Smith, PA Messaoudi, I Streblow, DN AF Orloff, S. L. Hwee, Y. -K. Kreklywich, C. Andoh, T. F. Hart, E. Smith, P. A. Messaoudi, I. Streblow, D. N. TI Cytomegalovirus Latency Promotes Cardiac Lymphoid Neogenesis and Accelerated Allograft Rejection in CMV Naive Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Chronic rejection; cytomegalovirus; latency; transplant vascular sclerosis ID TRANSPLANT VASCULAR SCLEROSIS; APOE KNOCKOUT MICE; RAT SMALL-BOWEL; T-CELLS; MEMORY INFLATION; RENAL-ALLOGRAFT; HEART-TRANSPLANTS; RISK-FACTORS; INFECTION; DISEASE AB Human cytomegalovirus (HCMV) infection is associated with the acceleration of transplant vascular sclerosis (TVS) and chronic allograft rejection (CR). HCMV-negative recipients of latently HCMV infected donor grafts are at highest risk for developing CMV disease. Using a rat heart transplant CR model, we have previously shown that acute rat CMV (RCMV) infection following transplantation significantly accelerates both TVS and CR. Here, we report that RCMV-naive recipients of heart allografts from latently RCMV-infected donors undergo acceleration of CR with similar kinetics as acutely infected recipients. In contrast to acutely infected recipients, treatment of recipients of latently infected donor hearts with ganciclovir did not prevent CR or TVS. We observed the formation of tertiary lymphoid structures (TLOs) containing macrophages and T cells in latently infected hearts prior to transplantation but not in uninfected rats. Moreover, pathway analysis of gene expression data from allografts from latently infected donors indicated an early and sustained production of TLO-associated genes compared to allografts from uninfected donors. We conclude that RCMV-induced TLO formation and alteration of donor tissue T cell profiles prior to transplantation in part mediate the ganciclovir-insensitive rejection of latently infected donor allografts transplanted into naive recipients by providing a scaffold for immune activation. C1 [Orloff, S. L.; Hwee, Y. -K.; Kreklywich, C.; Andoh, T. F.; Streblow, D. N.] Portland VA Med Ctr, Portland, OR USA. [Orloff, S. L.; Hwee, Y. -K.; Kreklywich, C.; Andoh, T. F.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. [Orloff, S. L.; Kreklywich, C.; Smith, P. A.; Messaoudi, I.; Streblow, D. N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR USA. [Orloff, S. L.; Kreklywich, C.; Hart, E.; Smith, P. A.; Messaoudi, I.; Streblow, D. N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR USA. RP Streblow, DN (reprint author), Portland VA Med Ctr, Portland, OR USA. EM streblow@ohsu.edu FU Department of Veterans Affairs; National Institutes of Health [HL 66238-01, HL083194, HL 088603]; AHA FX This work was supported by research grants to S.L. Orloff from the Department of Veterans Affairs and from the National Institutes of Health (HL 66238-01) and grants from the National Institutes of Health to D.N. Streblow (HL083194) and J.A. Nelson (HL 088603). D.N. Streblow and I. Messaoudi are supported by AHA Scientist Development Grants. NR 50 TC 15 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2011 VL 11 IS 1 BP 45 EP 55 DI 10.1111/j.1600-6143.2010.03365.x PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 700ZG UT WOS:000285783500010 PM 21199347 ER PT J AU Ballenger, JF Best, SR Metzler, TJ Wasserman, DA Mohr, DC Liberman, A Delucchi, K Weiss, DS Fagan, JA Waldrop, AE Marmar, CR AF Ballenger, James F. Best, Suzanne R. Metzler, Thomas J. Wasserman, David A. Mohr, David C. Liberman, Akiva Delucchi, Kevin Weiss, Daniel S. Fagan, Jeffrey A. Waldrop, Angela E. Marmar, Charles R. TI Patterns and Predictors of Alcohol Use in Male and Female Urban Police Officers SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CRITICAL INCIDENT EXPOSURE; PERITRAUMATIC DISSOCIATION; SOCIAL DESIRABILITY; OCCUPATIONAL STRESS; SCREENING-TEST; RISK-FACTORS; SCALE; PERSONNEL; CONSUMPTION AB In a large sample of urban police officers, 18.1% of males and 15.9% of females reported experiencing adverse consequences from alcohol use and 7.8% of the sample met criteria for lifetime alcohol abuse or dependence. Female officers had patterns of alcohol use similar to male officers and substantially more than females in the general population. Critical incident exposure and posttraumatic stress disorder (PTSD) symptoms were not associated with level of alcohol use. Greater psychiatric symptoms were related to adverse consequences from alcohol use. There was a noteworthy gender by work stress interaction: greater routine work stress related to lower current alcohol use in female officers. (Am J Addict 2010;00:1-9). C1 [Ballenger, James F.; Best, Suzanne R.; Metzler, Thomas J.; Wasserman, David A.; Mohr, David C.; Waldrop, Angela E.; Marmar, Charles R.] Dept Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Metzler, Thomas J.; Delucchi, Kevin; Weiss, Daniel S.; Waldrop, Angela E.; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Liberman, Akiva] Natl Inst Justice, Washington, DC USA. [Fagan, Jeffrey A.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. RP Waldrop, AE (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116P, San Francisco, CA 94121 USA. EM angela.waldrop@ucsf.edu FU NCRR NIH HHS [UL1 RR025741]; NICHD NIH HHS [RL1 HD058295]; NIMH NIH HHS [R01 MH056350, R01 MH056350-03S1] NR 38 TC 13 Z9 14 U1 2 U2 16 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD JAN-FEB PY 2011 VL 20 IS 1 BP 21 EP 29 DI 10.1111/j.1521-0391.2010.00092.x PG 9 WC Substance Abuse SC Substance Abuse GA 700NM UT WOS:000285750600004 PM 21175917 ER PT J AU Simpson, TL Galloway, C Rosenthal, CF Bush, KR McBride, B Kivlahan, DR AF Simpson, Tracy L. Galloway, Christopher Rosenthal, Christina F. Bush, Kristen R. McBride, Brittney Kivlahan, Daniel R. TI Daily Telephone Monitoring Compared with Retrospective Recall of Alcohol Use among Patients in Early Recovery SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID ECOLOGICAL MOMENTARY ASSESSMENT; TIMELINE FOLLOW-BACK; DRINKING PATTERNS; REACTIVITY; CONSUMPTION; RELIABILITY; VARIABLES; VALIDITY; DRUG AB Most studies comparing frequent self-monitoring protocols and retrospective assessments of alcohol use find good correspondence, but have excluded participants with significant comorbidity and/or social instability, and some have included abstainers. We evaluated the correspondence between measures of alcohol use based on daily interactive voice response (IVR) telephone monitoring and a 28-day modification of the Form-90 (Form-28). Participants were 25 outpatients with alcohol use disorder and significant PTSD symptomatology. Overall correlations between the IVR and Form-28 on days drinking and total standard drink units (SDUs) were strong for the entire sample and the subsample of drinkers (n = 7). Day-to-day correspondence between IVR and Form-28 was modest, but much stronger for the most recent week assessed than for the prior 3 weeks. Finally, the drinkers reported significantly greater total SDUs and heavy drinking days on the Form-28 than via IVR. The results indicate a need for further refinement of IVR methodology for treatment seeking populations as well as caution when retrospectively assessing drinking over time periods longer than a week among these individuals. (Am J Addict 2010;00:1-6). C1 [Simpson, Tracy L.; Bush, Kristen R.; McBride, Brittney; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Simpson, Tracy L.; Kivlahan, Daniel R.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Simpson, Tracy L.; Bush, Kristen R.; McBride, Brittney; Kivlahan, Daniel R.] Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Simpson, Tracy L.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Simpson, Tracy L.; Rosenthal, Christina F.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Galloway, Christopher] San Francisco VA Med Ctr, San Francisco, CA USA. RP Simpson, TL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,ATC-116-S, Seattle, WA 98108 USA. EM Tracy.Simpson@va.gov NR 31 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD JAN-FEB PY 2011 VL 20 IS 1 BP 63 EP 68 DI 10.1111/j.1521-0391.2010.00094.x PG 6 WC Substance Abuse SC Substance Abuse GA 700NM UT WOS:000285750600009 PM 21175922 ER PT J AU Gandy, S Wustman, B AF Gandy, Sam Wustman, Brandon TI New Pathway Links gamma-Secretase to Inflammation and Memory While Sparing Notch SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; MUTATIONS; RECEPTOR; NSAIDS C1 [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Gandy, Sam] James J Peters VA Med Ctr, Alzheimers Dis Res Ctr, New York, NY USA. [Wustman, Brandon] Amicus Therapeut, La Jolla, CA USA. RP Gandy, S (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. FU NIA NIH HHS [P01 AG010491-14, P01 AG10491, P01 AG010491]; NINDS NIH HHS [R01 NS075685] NR 22 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 2011 VL 69 IS 1 BP 5 EP 7 DI 10.1002/ana.22310 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714ZS UT WOS:000286850800005 PM 21280069 ER PT J AU Whitmer, RA Quesenberry, CP Zhou, JF Yaffe, K AF Whitmer, Rachel A. Quesenberry, Charles P., Jr. Zhou, Jufen Yaffe, Kristine TI Timing of Hormone Therapy and Dementia: The Critical Window Theory Revisited SO ANNALS OF NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; POPULATION; BRAIN; RISK; STEROIDS; NEURONS AB Objective: Although previous research has shown that initiation of postmenopausal estrogen hormone therapy (HT) in late life increases risk of dementia, animal studies and some observational studies have suggested that midlife use of HT may be beneficial; however, this has not been rigorously investigated in large population-based studies. Our objective was to compare HT use in midlife with that in late life on risk of dementia among 5,504 postmenopausal female members of an integrated healthcare delivery system. Methods: HT use was determined at midlife (mean age, 48.7 years) from a survey in 1964 and in late life (mean age, 76 years) using pharmacy databases from 1994 to 1998. Risk of dementia diagnosis was evaluated with inpatient and outpatient diagnoses made in Neurology, Neuropsychology, and Internal Medicine from 1999 to 2008. Cox proportional hazard models were used to examine effects of HT use at different times on dementia risk with adjustment for age, education, race, body mass index, number of children, and comorbidities. Results: A total of 1,524 women (27%) were diagnosed with dementia during the follow-up period. Compared to women never on HT, those taking HT only at midlife had a 26% decreased risk (multivariate adjusted hazards ratio [aHR], 0.74; 95% confidence interval [CI], 0.58-0.94), whereas those taking HT only in late life had a 48% increased risk (aHR, 1.48; 95% CI, 1.10-1.98), and women taking HT at both mid and late life had a similar risk of dementia (aHR, 1.02; 95% CI, 0.78-1.34). Interpretation: These findings suggest that use of HT in midlife only may protect against cognitive impairment, whereas HT initiation in late life could have deleterious effects. ANN NEUROL 2011;69:163-169 C1 [Whitmer, Rachel A.; Quesenberry, Charles P., Jr.; Zhou, Jufen] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Whitmer, RA (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM raw@dor.kaiser.org FU Kaiser Permanente Community Benefits; National Institutes of Health [NIA AG021918, NIA AG 031155]; NIA; Orgnanon FX This study was supported by Kaiser Permanente Community Benefits (R.A.W.) and National Institutes of Health (NIA AG021918, K.Y.; NIA AG 031155, K.Y.).; K.Y. has held board membership for Pfizer and Medivation, has grants pending from NIA and Orgnanon, and has received honoraria from Novartis. NR 23 TC 84 Z9 88 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 2011 VL 69 IS 1 BP 163 EP 169 DI 10.1002/ana.22239 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 714ZS UT WOS:000286850800022 PM 21280086 ER PT J AU Zhang, ZH Tendulkar, A Sun, K Saloner, DA Wallace, AW Ge, LA Guccione, JM Ratcliffe, MB AF Zhang, Zhihong Tendulkar, Amod Sun, Kay Saloner, David A. Wallace, Arthur W. Ge, Liang Guccione, Julius M. Ratcliffe, Mark B. TI Comparison of the Young-Laplace Law and Finite Element Based Calculation of Ventricular Wall Stress: Implications for Postinfarct and Surgical Ventricular Remodeling SO ANNALS OF THORACIC SURGERY LA English DT Article ID ENDOVENTRICULAR PATCH PLASTY; CANINE LEFT-VENTRICLE; MYOCARDIAL-INFARCTION; ACTIVE CONTRACTION; CARDIAC-MUSCLE; ANEURYSM; HEART; MECHANICS; DEVICE; MODEL AB Background. Both the Young-Laplace law and finite element (FE) based methods have been used to calculate left ventricular wall stress. We tested the hypothesis that the Young-Laplace law is able to reproduce results obtained with the FE method. Methods. Magnetic resonance imaging scans with non-invasive tags were used to calculate three-dimensional myocardial strain in 5 sheep 16 weeks after anteroapical myocardial infarction, and in 1 of those sheep 6 weeks after a Dor procedure. Animal-specific FE models were created from the remaining 5 animals using magnetic resonance images obtained at early diastolic filling. The FE-based stress in the fiber, cross-fiber, and circumferential directions was calculated and compared to stress calculated with the assumption that wall thickness is very much less than the radius of curvature (Young-Laplace law), and without that assumption (modified Laplace). Results. First, circumferential stress calculated with the modified Laplace law is closer to results obtained with the FE method than stress calculated with the YoungLaplace law. However, there are pronounced regional differences, with the largest difference between modified Laplace and FE occurring in the inner and outer layers of the infarct borderzone. Also, stress calculated with the modified Laplace is very different than stress in the fiber and cross-fiber direction calculated with FE. As a consequence, the modified Laplace law is inaccurate when used to calculate the effect of the Dor procedure on regional ventricular stress. Conclusions. The FE method is necessary to determine stress in the left ventricle with postinfarct and surgical ventricular remodeling (Ann Thorac Surg 2011; 91: 150-6) (C) 2011 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@med.va.gov FU National Institutes of Health [R01-HL-77921, R01-HL-63348] FX This study was supported by National Institutes of Health grant R01-HL-77921 (Dr. Guccione), and R01-HL-63348 (Dr. Ratcliffe). This support is gratefully acknowledged. NR 34 TC 23 Z9 23 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JAN PY 2011 VL 91 IS 1 BP 150 EP 156 DI 10.1016/j.athoracsur.2010.06.132 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 695ZM UT WOS:000285411700029 PM 21172505 ER PT S AU Dixon, JA Spinale, FG AF Dixon, Jennifer A. Spinale, Francis G. BE Julius, D Clapham, DE TI Myocardial Remodeling: Cellular and Extracellular Events and Targets SO ANNUAL REVIEW OF PHYSIOLOGY, VOL 73 SE Annual Review of Physiology LA English DT Review; Book Chapter DE matrix metalloproteinases; large-animal models; myocardial infarction ID COLONY-STIMULATING FACTOR; MESENCHYMAL STEM-CELLS; MATRIX-METALLOPROTEINASE INHIBITION; LEFT-VENTRICULAR FUNCTION; ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW-CELLS; ENHANCES COLLATERAL PERFUSION; CARDIOVASCULAR RISK-FACTORS; CARDIAC FIBROBLAST FUNCTION; RANDOMIZED CONTROLLED-TRIAL AB The focus of this review is on translational studies utilizing large-animal models and clinical studies that provide fundamental insight into cellular and extracellular pathways contributing to post myocardial infarction (MI) left ventricle (LV) remodeling. Specifically, both large-animal and clinical studies have examined the potential role of endogenous and exogenous stem cells to alter the course of LV remodeling. Interestingly, there have been alterations in LV remodeling with stem cell treatment despite a lack of long-term cell engraftment. The translation of the full potential of stem cell treatments to clinical studies has yet to be realized. The modulation of proteolytic pathways that contribute to the post-MI remodeling process has also been examined. On the basis of recent large-animal studies, there appears to be a relationship between stem cell treatment post-MI and the modification of proteolytic pathways, generating the hypothesis that stem cells leave an echo effect that moderates LV remodeling. C1 [Dixon, Jennifer A.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Dixon, Jennifer A.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Dixon, JA (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU NHLBI NIH HHS [R01 HL059165-12, R01 HL057952-12, HL059165, R01 HL057952, HL057952, R01 HL059165] NR 136 TC 24 Z9 24 U1 0 U2 8 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4278 BN 978-0-8243-0373-0 J9 ANNU REV PHYSIOL JI Annu. Rev. Physiol. PY 2011 VL 73 BP 47 EP 68 DI 10.1146/annurev-physiol-012110-142230 PG 22 WC Physiology SC Physiology GA BUD92 UT WOS:000288968800003 PM 21314431 ER PT J AU Anderson, RM Colman, RJ AF Anderson, Rozalyn M. Colman, Ricki J. TI Prospects and Perspectives in Primate Aging Research SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Editorial Material AB As improvements in standard of living and advances in medicine have resulted in greater life expectancy, the relative proportion of elderly has continued to increase in human populations across the globe. The primary goal of aging research is to gain a better understanding of the series of events that lead to increased frailty and disease vulnerability with age. The direct study of human aging is an active area of research; however, the opportunity to conduct mechanistic studies and gain insights into the underlying biology is limited. In this special forum issue of Antioxidant & Redox Signaling, we present a selection of articles and reviews that illustrate some of the recent advances in primate aging research. The overarching goal of this work is to underscore the potential for mechanistic discovery that is presented by nonhuman primate models, and to promote studies that validate novel approaches and techniques in nonhuman primates before their adaptation for human health care. Antioxid. Redox Signal. 14, 203-205. C1 [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Anderson, Rozalyn M.; Colman, Ricki J.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI USA. RP Anderson, RM (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM rmanderson5@wisc.edu FU NIA NIH HHS [R01 AG040178, R01 AG037000] NR 8 TC 3 Z9 3 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JAN PY 2011 VL 14 IS 2 BP 203 EP 205 DI 10.1089/ars.2010.3227 PG 3 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 695RR UT WOS:000285390800003 PM 20712396 ER PT J AU Jensen, JD Fujita, M Dellavalle, RP AF Jensen, J. Daniel Fujita, Mayumi Dellavalle, Robert P. TI Validation of Psoriasis Clinical Severity and Outcome Measures Searching for a Gold Standard SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID PHYSICIANS GLOBAL ASSESSMENT; SELF-ADMINISTERED PSORIASIS; INVOLVED SURFACE-AREA; MINOLTA CHROMA METER; MACHINE VISION; INDEX; ERYTHEMA; DISEASE; EYE C1 [Jensen, J. Daniel; Fujita, Mayumi; Dellavalle, Robert P.] Univ Colorado Denver, Sch Med, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Dellavalle, Robert P.] Colorado Sch Publ Hlth, Aurora, CO USA. RP Dellavalle, RP (reprint author), Dept Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X NR 22 TC 6 Z9 6 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD JAN PY 2011 VL 147 IS 1 BP 95 EP 98 DI 10.1001/archdermatol.2010.242 PG 4 WC Dermatology SC Dermatology GA 706OZ UT WOS:000286229000023 PM 20855674 ER PT J AU Baker, LD Cross, DJ Minoshima, S Belongia, D Watson, S Craft, S AF Baker, Laura D. Cross, Donna J. Minoshima, Satoshi Belongia, Dana Watson, Stennis Craft, Suzanne TI Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes SO ARCHIVES OF NEUROLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; BRAIN ACTIVATION; BLOOD-FLOW; DISEASE; RISK; HYPERINSULINEMIA; INFORMATION; IMPAIRMENT; MELLITUS; IMAGES AB Background: Insulin resistance is a causal factor in prediabetes (PD) and type 2 diabetes (T2D) and increases the risk of developing Alzheimer disease (AD). Reductions in cerebral glucose metabolic rate (CMRglu) as measured by fludeoxyglucose F 18-positron emission tomography (FDG-PET) in parietotemporal, frontal, and cingulate cortices are associated with increased AD risk and can be observed years before dementia onset. Objectives: To examine whether greater homeostasis model assessment insulin resistance (HOMA-IR) is associated with reduced resting CMRglu in areas vulnerable in AD in cognitively normal adults with newly diagnosed PD or T2D(PD/T2D), and to determine whether adults with PD/T2D have abnormal patterns of CMRglu during a memory encoding task. Design: Randomized crossover design of resting and activation FDG-PET. Setting: University imaging center and Veterans Affairs clinical research unit. Participants: Twenty-three older adults (mean [SEM] age, 74.4 [1.4] years) with no prior diagnosis of diabetes but who met American Diabetes Association glycemic criteria for PD (n=11) or diabetes (n=12) based on fasting or 2-hour oral glucose tolerance test (OGTT) glucose values and 6 adults (mean [SEM] age, 74.3 [2.8] years) with normal fasting glucose values and glucose tolerance. No participant met Petersen criteria for mild cognitive impairment. Interventions: Fasting participants underwent resting and cognitive activation FDG-PET imaging on separate days. Following a 30-minute transmission scan, subjects received an intravenous injection of 5 mCi of FDG, and the emission scan commenced 40 minutes after injection. In the activation condition, a 35-minute memory encoding task was initiated at the time of tracer injection. Subjects were instructed to remember a repeating list of 20 words randomly presented in series through earphones. Delayed free recall was assessed once the emission scan was complete. Main Outcome Measures: The HOMA-IR value was calculated using fasting glucose and insulin values obtained during OGTT screening and then correlated with CMRglu values obtained during the resting scan. Resting CMRglu values were also subtracted from CMRglu values obtained during the memory encoding activation scan to examine task-related patterns of CMRglu. Results: Greater insulin resistance was associated with an AD-like pattern of reduced CMRglu in frontal, parietotemporal, and cingulate regions in adults with PD/T2D. The relationship between CMRglu and HOMA-IR was independen to fage, 2-hour OGTT glucose concentration, or apolipoprotein E epsilon 4 allele carriage. During the memory encoding task, healthy adults showed activation in right anterior and inferior prefrontal cortices, right inferior temporal cortex, and medial and posterior cingulate regions. Adults with PD/T2D showed a qualitatively different pattern during the memory encoding task, characterized by more diffuse and extensive activation, and recalled fewer items on the delayed memory test. Conclusions: Insulin resistance may be a marker of AD risk that is associated with reduced CMRglu and subtle cognitive impairments at the earliest stage of disease, even before the onset of mild cognitive impairment. C1 [Baker, Laura D.; Belongia, Dana; Watson, Stennis; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Baker, Laura D.; Belongia, Dana; Watson, Stennis; Craft, Suzanne] Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cross, Donna J.; Minoshima, Satoshi] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. RP Baker, LD (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,VAPSHCS A-182-GRECC, Seattle, WA 98195 USA. EM ldbaker@uw.edu FU National Institute of Diabetes [RO1 DK061606]; Digestive and Kidney Diseases; Department of Veterans Affairs FX This study was supported by grant RO1 DK061606 from the National Institute of Diabetes and Digestive and Kidney Diseases (Dr Craft) and by the Department of Veterans Affairs. NR 34 TC 189 Z9 194 U1 1 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JAN PY 2011 VL 68 IS 1 BP 51 EP 57 DI 10.1001/archneurol.2010.225 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 704MO UT WOS:000286057300007 PM 20837822 ER PT J AU Schneider, LS Insel, PS Weiner, MW AF Schneider, Lon S. Insel, Philip S. Weiner, Michael W. CA Alzheimers Dis Neuroimaging TI Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative SO ARCHIVES OF NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; MODERATE; DIAGNOSIS; DONEPEZIL; EFFICACY; SCALE AB Objectives: To assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride. Design: Cohort study. Setting: The 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants: Outpatients with MCI and AD in ADNI. Main Outcome Measures: The AD Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, and Functional Activities Questionnaire (FAQ). Results: A total of 177 (44.0%) of 402 MCI patients and 159 (84.6%) of 188 mild-AD patients were treated with ChEIs and 11.4% of MCI patients and 45.7% of AD patients with memantine at entry. Mild-cognitive-impairment patients who received ChEIs with or without memantine were more impaired, showed greater decline in scores, and progressed to dementia sooner than patients who did not receive ChEIs. Alzheimer-disease patients who received ChEIs and memantine took them longer, were more functionally impaired, and showed greater decline on the MMSE and CDR (but not on the ADAS-cog or FAQ) than those who received ChEIs only. Conclusions: Academic physicians frequently prescribe ChEIs and memantine earlier than indicated in the US Food and Drug Administration-approved labeling to patients who are relatively more severely impaired or who are rapidly progressing toward cognitive impairment. The use of these medications in ADNI is associated with clinical decline and may affect the interpretation of clinical trial outcomes. C1 [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Behav Sci & Neurol, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Leonard Davis Sch Gerontol, Los Angeles, CA USA. [Insel, Philip S.; Weiner, Michael W.] Univ Calif San Francisco, Sch Med, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Schneider, LS (reprint author), Univ So Calif, Keck Sch Med, Dept Psychiat, 1510 San Pablo St,HCC 600, Los Angeles, CA 90033 USA. EM lschneid@usc.edu RI Scharre, Douglas/E-4030-2011 FU Alzheimer's Association; AstraZeneca Pharmaceuticals; Baxter International Inc; Elan Pharmaceuticals; Forest Laboratories Inc; Johnson & Johnson Consumer Companies Inc; Eli Lilly and Company; Myriad Pharmaceuticals Inc; Novartis Pharmaceuticals Corporation; Pfizer Incorporated; Takeda Pharmaceutical Company Ltd; Wyeth Pharmaceuticals; Abbott Laboratories; AC Immune SA; Allergan Inc; Allon Therapeutics; Alzheimer's Drug Discovery Foundation; Bristol-Myers Squibb; ExonHit Therapeutics; GlaxoSmithKline plc; Ipsen Group; H. Lundbeck A/S, Myriad Pharmaceuticals Inc; MedAvante Inc; Medivation Inc; Merck Co Inc; Merz Pharmaceuticals GmbH; F. Hoffman-La Roche Ltd; Sanofi-aventis LLC; Servier Laboratories; Schering-Plough Corporation; Schwabe Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Toyama Pharmaceutical Co Ltd; Transition Therapeutics Inc; Voyager Pharmaceuticals Corp; l'Alliance Medicale et Scientifique; Alzheimer's Disease Neuroimaging Initiative; Avid Pharmaceuticals Inc; Banner Pharmacaps Inc Alzheimer's Institute; Bayer Health-Care; Elan Corporation plc/Wyeth Pharmaceuticals Alzheimer's Immunotherapy North American Advisory Board; Beijing Institute of Geriatrics; Centre Hospitalier Regional Universitaire-Hopital Roger Salengro; Clinical Trials on Alzheimer's Disease; Colloquium Paris; Foundation for the National Institutes of Health; GE Healthcare Japan; Geneva University Hospitals; Innogenetics NV; Institut Catala de Neurociencias Aplicades; Ipsen; Johns Hopkins University; Korean Neurological Association; Michael J. Fox Foundation for Parkinson's Research; Montreal Neurological Institute and Hospital at McGill University; Mount Sinai Medical Center; National Multiple Sclerosis Society; Neuroscience Early Stage Research Training; NeuroVigil Inc; New York University; Pfizer Inc Global Research and Development; Research Association for Biotechnology; Rotman Research Institute of Baycrest; Siemens AG; Society of Photo-Optical Instrumentation Engineers; Tel-Aviv University Medical School; Telemedicine & Advanced Technology Research Center; University of Pittsburgh; Wien Center for Alzheimer's Disease and Memory Disorders; University of Califonia Davis; United States Social Security Administration; Wenner-Grem Foundation; Washington University in St Louis; United States Department of Veterans Affairs Central Office; University of New Mexico School of Medicine; University of Paris; Avid Radiopharmaceuticals Inc; National Institutes of Health [U01AG024904, P41 RR023953, R01AG10897, P01AG19724, P50AG23501, R24 RR021992, R01 NS031966, P01AG012435, P50AG05142]; United States Department of Defense [DAMD17-01-0764]; Veterans Administration [MIRECC VISN 21]; University of Southern California Alzheimer's Disease Research Center FX Dr Schneider is an editor for the Cochrane Dementia and Cognitive Improvement Group, which oversees systematic reviews of medications for cognitive impairment and dementia; has received a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials and grant or research support from AstraZeneca Pharmaceuticals, Baxter International Inc, Elan Pharmaceuticals, Forest Laboratories Inc, Johnson & Johnson Consumer Companies Inc, Eli Lilly and Company, Myriad Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Incorporated, Takeda Pharmaceutical Company Ltd, and Wyeth Pharmaceuticals; has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune SA, Allergan Inc, Allon Therapeutics, Alzheimer's Drug Discovery Foundation, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Elan Pharmaceuticals, Eli Lilly and Company, ExonHit Therapeutics, Forest Laboratories Inc, GlaxoSmithKline plc, Ipsen Group, Johnson & Johnson Consumer Companies Inc, H. Lundbeck A/S, Myriad Pharmaceuticals Inc, MedAvante Inc, Medivation Inc, Merck & Co Inc, Merz Pharmaceuticals GmbH, Novartis Pharmaceuticals Corporation, F. Hoffman-La Roche Ltd, Sanofi-aventis LLC, Servier Laboratories, Schering-Plough Corporation, Schwabe Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Toyama Pharmaceutical Co Ltd, Transition Therapeutics Inc, Voyager Pharmaceuticals Corp, and Wyeth Pharmaceuticals. Dr Weiner serves on scientific advisory boards for Aegis Therapies, Allergan Inc, Araclon Biotech, Avid Radiopharmaceuticals Inc, the Banner Pharmacaps Inc Alzheimer's Institute Alzheimer's Prevention Initiative; Bayer Schering Pharma AG, Biogen Idec, Bristol-Myers Squibb, CoMentis Inc, the Elan Corporation plc/Wyeth Pharmaceuticals Alzheimer's Immunotherapy Program, Eli Lilly and Company, Eisai Inc, Forest Laboratories Inc, Genentech Inc, Institut Catala de Neurociencias Aplicades, Neurochem Inc, Lippincott Williams & Wilkins, McKinsey & Company, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, and the United States Department of Veterans Affairs Central Office Gulf War Veterans' Illnesses Advisory Committee; has received funding for traval from l'Alliance Medicale et Scientifique, Alzheimer's Association, Alzheimer's Disease Neuroimaging Initiative, AstraZeneca Pharmaceuticals, Avid Pharmaceuticals Inc, the Banner Pharmacaps Inc Alzheimer's Institute, Bayer Health-Care, Elan Corporation plc/Wyeth Pharmaceuticals Alzheimer's Immunotherapy Program North American Advisory Board, Beijing Institute of Geriatrics, Centre Hospitalier Regional Universitaire-Hopital Roger Salengro, Clinical Trials on Alzheimer's Disease, Colloquium Paris, Eli Lilly and Company, Forest Laboratories Inc, Foundation for the National Institutes of Health, GE Healthcare Japan, Geneva University Hospitals, Innogenetics NV, Institut Catala de Neurociencias Aplicades, Ipsen, The Johns Hopkins University, Korean Neurological Association, The Michael J.; Fox Foundation for Parkinson's Research, Montreal Neurological Institute and Hospital at McGill University, Mount Sinai Medical Center, National Multiple Sclerosis Society, Neuroscience Early Stage Research Training, NeuroVigil Inc, New York University, Pfizer Inc Global Research and Development, Research Association for Biotechnology, Rotman Research Institute of Baycrest, Siemens AG, Society of Photo-Optical Instrumentation Engineers, Tel-Aviv University Medical School, Telemedicine & Advanced Technology Research Center, University of Pittsburgh, Wen Center for Alzheimer's Disease and Memory Disorders, University of Califonia Davis, United States Social Security Administration, Wenner-Grem Foundation, Washington University in St Louis, United States Department of Veterans Affairs Central Office, University of New Mexico School of Medicine, and University of Paris and from Kenes International and Nestle SA to attend conferences not funded by industry; serves on the editorial board of Alzheimer's & Dementia: The Journal of the Alzheimer's Association; has received honoraria from American Academy of Neurology, BOLT International, GE Healthcare Japan, Institut Catala de Neurociencias Aplicades, Ipsen, The Johns Hopkins University, NeuroVigil Inc, the Rotman Research Institute, and the Research Institute for Biotechnology; serves as a consultant for Araclon Biotech, AstraZeneca Pharmaceuticals, Bayer Healthcare, Bayer Schering Pharma AG, Biogen Idec, CoMentis Inc, Daiichi Sankyo Co Ltd, Elan Corporation plc, Eli Lilly and Company, ExonHit Therapeutics SA, Forest Laboratories Inc, Medivation Inc/Pfizer Inc, Ipsen, Neurochem International Limited (now Bellus Health International Limited), Novartis Pharmaceuticals Corporation, Pfizer Inc Global Research and Development, Servier Laboratories, Synarc Inc, and TauRx Therapeutics LTD; receives research support from Merck & Co Inc, Avid Radiopharmaceuticals Inc, the National Institutes of Health (as a private investigator: U01AG024904, P41 RR023953, and R01AG10897; and as a coinvestigator: P01AG19724, P50AG23501, R24 RR021992, R01 NS031966, and P01AG012435), the United States Department of Defense (as a private investigator: DAMD17-01-0764), and the Veterans Administration (as a core private investigator: MIRECC VISN 21); and holds stock in Synarc Inc and Elan Corporation plc.; The Foundation for the National Institutes of Health (http://www.fnih.org) coordinates the private sector participation of the $60 million ADNI public/private partnership begun by the National Institute on Aging and supported by the National Institutes of Health. To date, more than $27 million has been provided to the FNIH by Abbott Laboratotries, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation plc, Genentech Inc, GE HealthCare, GlaxoSmithKline plc, Innogenetics, Johnson & Johnson Consumer Companies Inc, Eli Lilly and Company, Merck & Co Inc, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd, Schering-Plough Corporation, Synarc Inc, and Wyeth Pharmaceuticals, as well as nonprofit partners the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation. This research was also supported by National Institutes of Health grant P50AG05142 in conjunction with the University of Southern California Alzheimer's Disease Research Center. Additional Information: The Alzheimer's Disease Neuroimaging Initiative: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI, NIA U01 AG024904) database (www.loni.ucla.edu/ADNI). As such, the investigators within ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete list of investigators in ADNI is listed at: http://adni.loni.ucla.edu/about/who-we-are/principal-investigators/. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as to lessen the time and cost of clinical trials. NR 24 TC 60 Z9 64 U1 2 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JAN PY 2011 VL 68 IS 1 BP 58 EP 66 DI 10.1001/archneurol.2010.343 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 704MO UT WOS:000286057300008 PM 21220675 ER PT J AU Morita, Y Ismail, DM Elkon, KB Chu, CQ AF Morita, Yoshiaki Ismail, Doaa M. Elkon, Keith B. Chu, Cong-Qiu TI Dichotomous Response to Transforming Growth Factor beta After T Cell Receptor Activation by Naive CD4+ T Cells From DBA/1 Mice Enhanced Retinoic Acid Receptor-Related Orphan Nuclear Receptor gamma t Expression yet Reduced FoxP3 Expression SO ARTHRITIS AND RHEUMATISM LA English DT Article ID COLLAGEN-INDUCED ARTHRITIS; IFN-GAMMA; TGF-BETA; DEFICIENT MICE; CYTOKINE MILIEU; DIFFERENTIATION; T(H)17; INTERLEUKIN-17; SUSCEPTIBILITY; INFLAMMATION AB Objective. To investigate the molecular mechanism for biased interleukin-17 (IL-17) production by DBA/1 CD4+ T cells upon T cell receptor (TCR) and transforming growth factor beta (TGF beta) stimulation. Methods. Purified naive CD4+ T cells were stimulated with anti-CD3/CD28 under Th1, Th2, Th17, and induced T regulatory (iTreg) cell conditions. Cytokine production was assayed by intracellular staining and enzyme-linked immunosorbent assay. Expression of transcription factors was determined by reverse transcription-polymerase chain reaction, flow cytometry, and immunoblotting techniques. Results. Naive CD4+ T cells from DBA/1 mice produced more IL-17 under Th17 cell polarizing conditions as compared with those from C57BL/6 or BALB/c mice. Further investigation revealed no difference among the strains in terms of CD4+ T cell survival, upstream TCR signaling, or CD69 expression or in the phosphorylation of STAT-3 and expression of suppressor of cytokine signaling 3 that positively or negatively regulate IL-17 cell production. However, DBA/1 CD4+ T cells expressed increased levels of retinoic acid-related orphan receptor gamma t (ROR gamma t). Furthermore, under iTreg cell polarizing conditions, DBA/1 CD4+ T cells showed a strikingly reduced level of FoxP3 expression. When interferon-gamma and IL-4 were blocked, FoxP3 expression increased but remained lower in DBA/1 CD4+ T cells following exposure to TGF beta as compared with C57BL/6 CD4+ T cells. Moreover, DBA/1 CD4+ T cells showed reduced phosphorylation of Smad2 and Smad3 under both Th17 and iTreg cell polarizing conditions. Conclusion. These results indicate that naive CD4+ T cells from DBA/1 mice have a dichotomous response to TGF beta: enhanced ROR gamma t, yet reduced FoxP3, up-regulation. This observation may help to elucidate the branch point of TGF beta signaling that leads to skewed Th17, but reduced iTreg, cell differentiation. C1 [Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97239 USA. [Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA. [Morita, Yoshiaki; Ismail, Doaa M.; Elkon, Keith B.; Chu, Cong-Qiu] Univ Washington, Seattle, WA 98195 USA. RP Chu, CQ (reprint author), Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, 3181 SW Sam Jackson Pk Rd,OP09, Portland, OR 97239 USA. EM chuc@ohsu.edu FU NIH [AR-055254]; Herndon and Esther Maury Fund; Bristol-Myers Squibb FX Supported by the NIH (grant AR-055254 to Dr. Chu) and the Herndon and Esther Maury Fund. Dr. Chu has received speaking fees or honoraria from Bristol-Myers Squibb (less than $10,000). NR 29 TC 5 Z9 5 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD JAN PY 2011 VL 63 IS 1 BP 118 EP 126 DI 10.1002/art.27759 PG 9 WC Rheumatology SC Rheumatology GA 702ZJ UT WOS:000285934100014 PM 20862680 ER PT J AU Saag, KG Yazdany, J Alexander, C Caplan, L Coblyn, J Desai, SP Harrington, T Liu, JN McNiff, K Newman, E Olson, R AF Saag, Kenneth G. Yazdany, Jinoos Alexander, Christopher Caplan, Liron Coblyn, Jonathan Desai, Sonali Parekh Harrington, Timothy, Jr. Liu, Jigna McNiff, Kristen Newman, Eric Olson, Richard CA Amer Coll Rheumatology Quality Mea TI Defining Quality of Care in Rheumatology: The American College of Rheumatology White Paper on Quality Measurement SO ARTHRITIS CARE & RESEARCH LA English DT Article ID ELECTRONIC MEDICAL-RECORD; CONTROLLED-TRIAL; SYSTEM LEVELS; ARTHRITIS; IMPROVEMENT; DISEASES; PERSPECTIVE; MANAGEMENT; VACCINATION; POPULATION C1 [Saag, Kenneth G.] Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35233 USA. [Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Coblyn, Jonathan; Desai, Sonali Parekh] Brigham & Womens Hosp, Boston, MA 02115 USA. [Harrington, Timothy, Jr.] Univ Wisconsin, Madison, WI 53706 USA. [McNiff, Kristen] Amer Coll Rheumatol, Atlanta, GA 30329 USA. [Newman, Eric] Geisinger Med Ctr, Danville, PA 17822 USA. [Olson, Richard] Rockford Orthoped Associates, Rockford, IL USA. RP Saag, KG (reprint author), Univ Alabama, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 820, Birmingham, AL 35233 USA. EM ksaag@uab.edu FU Lilly; Merck; Aventis; NicOx; Genentech; Pfizer; Amgen; Novartis; Corrona; Takeda; BMS; Abbott FX Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Lilly, Merck, Aventis, NicOx, Genentech, and Pfizer, and (more than $10,000 each) from Amgen and Novartis. Dr. Harrington has received consultant fees, speaking fees, and/or honoraria (more than $10,000) from Corrona, and owns stock and/or holds stock options in Murray Electronics. Dr. Olson has received speaking fees (less than $10,000 each) from Lilly, Novartis, Takeda, BMS, and Abbott. NR 42 TC 18 Z9 18 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2011 VL 63 IS 1 BP 2 EP 9 DI 10.1002/acr.20369 PG 8 WC Rheumatology SC Rheumatology GA 703AA UT WOS:000285935800002 PM 20945349 ER PT J AU Katiyar, SK Raman, C AF Katiyar, Santosh K. Raman, Chander TI Green tea: a new option for the prevention or control of osteoarthritis SO ARTHRITIS RESEARCH & THERAPY LA English DT Editorial Material ID NITRIC-OXIDE SYNTHASE; HUMAN CHONDROCYTES; POLYPHENOLS; EXPRESSION; REPAIR; MICE AB IL-1 beta is a major cytokine driving the inflammatory processes leading to the pathophysiology of osteoarthritis and other inflammatory diseases. Blockade of IL-1 beta activity using substances such as the naturally occurring IL-1 receptor antagonist or anti-IL-1 beta monoclonal antibody are currently being used or tested as therapy. However, such treatments are ineffective in osteoarthritis. In a recent study, epigallocatechin-3-gallate, a green tea polyphenol, was found to be effective in reducing IL-1 beta-induced inflammatory cytokines, TNF alpha, IL-6, granulocyte-macrophage colony-stimulating factor and several chemokines from human chondrocytes. The use of green tea polyphenols may be beneficial as a therapeutic addition to biologics that control IL-1 beta activity by increasing effectiveness and/or reducing dosage. C1 [Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Raman, Chander] Univ Alabama, Div Clin Immunol & Rheumatol, Dept Med, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [5R01AT2536, R01 AT002536]; NCI NIH HHS [1R01CA140197, CA140832, R01 CA140197, R21 CA140832]; NIAID NIH HHS [1R01AI1076562, R01 AI076562] NR 10 TC 7 Z9 7 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2011 VL 13 IS 4 AR 121 DI 10.1186/ar3428 PG 2 WC Rheumatology SC Rheumatology GA 849UG UT WOS:000297150200035 PM 21861859 ER PT J AU Hong, EK Pearlman, J Salatin, B Wang, HW Liu, HY Cooper, RA Hargroder, T AF Hong, Eun-Kyoung Pearlman, Jon Salatin, Benjamin Wang, Hongwu Liu, Hsin-Yi Cooper, Rory A. Hargroder, Todd TI Design and Development of a Lightweight, Durable, Adjustable Composite Backrest Mounting SO ASSISTIVE TECHNOLOGY LA English DT Article DE adjustment; ANSI/RESNA wheelchair testing; backrest; design; focus group; wheelchair ID SPINAL-CORD-INJURY; WHEELCHAIR PROPULSION; SHOULDER PAIN; USERS AB Rigid backrest systems for wheelchairs provide a stable and comfortable base of support to help users maintain good posture while propelling and sitting static. Unfortunately, these backrest systems lack the adjustability necessary to allow users to comfortably perform some tasks, such as dressing; consequently, many users retain their sling-style backrests. We developed a lightweight, durable, adjustable composite (LWDAC) backrest mounting system to address these shortcomings and performed engineering and human subjects testing to evaluate the feasibility of the device. The LWDAC prototype passed the static engineering evaluation, as well as nearly all of the fatigue testing prior to failure of the device. Clinicians (n = 9) and users (n = 8) who evaluated the device in a focus group forum had an overall positive response. The participants agreed the backrest mounting can be operated with one hand and felt comfortable when participants were seated. Wheelchair users were interested in purchasing the backrest, and clinicians indicated they would recommend the LDWAC. C1 [Hong, Eun-Kyoung; Pearlman, Jon; Salatin, Benjamin; Wang, Hongwu; Liu, Hsin-Yi; Cooper, Rory A.] Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA. [Hong, Eun-Kyoung; Pearlman, Jon; Salatin, Benjamin; Wang, Hongwu; Liu, Hsin-Yi; Cooper, Rory A.] Univ Pittsburgh, CAF Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Hargroder, Todd] Accessible Designs Inc, San Antonio, TX USA. RP Cooper, RA (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs 151R1 H, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144; Pearlman, Jon/0000-0003-0830-9136 NR 24 TC 1 Z9 1 U1 0 U2 4 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 EI 1949-3614 J9 ASSIST TECHNOL JI Assist. Technol. PY 2011 VL 23 IS 1 BP 24 EP 35 DI 10.1080/10400435.2010.541405 PG 12 WC Rehabilitation SC Rehabilitation GA 880SP UT WOS:000299427800003 ER PT J AU Cooper, RA Teodorski, EE Sporner, ML Collins, DM AF Cooper, Rory A. Teodorski, Emily E. Sporner, Michelle L. Collins, Diane M. TI Manual Wheelchair Propulsion Over Cross-Sloped Surfaces: A Literature Review SO ASSISTIVE TECHNOLOGY LA English DT Review DE accessibility; manual wheelchair; manual wheelchair propulsion ID USERS; REHABILITATION; BIOMECHANICS; DESIGN AB Manual wheelchair propulsion may be facilitated or impeded depending upon the surface and the environment. One barrier may be the cross-slope of pathways. The purpose of this systematic literature review was to determine the quality of the evidence on the effects of cross-slopes on manual wheelchair propulsion. The goal was to identify and to understand the optimal design for cross-slopes that have the least negative impact for wheelchair users. Fifty-two articles were reviewed by 15 expert reviewers. Six were identified to be relevant to propulsion over cross-slopes. Most studies agree that traversing a cross-slope in a manual wheelchair is more difficult than propelling on a level surface. However, agreement has not been reached as to the percentage increase in effort or the optimal degree of cross-slopes that should be used as an acceptable standard. There is a paucity of research investigating the impact of cross-slopes on wheelchair mobility and community participation. C1 [Cooper, Rory A.; Teodorski, Emily E.; Sporner, Michelle L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [Cooper, Rory A.; Teodorski, Emily E.; Sporner, Michelle L.; Collins, Diane M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 7180 Highland Dr,Bldg 4,2nd Floor,151R1-H, Pittsburgh, PA 15206 USA. EM Rory.Cooper@va.gov NR 17 TC 5 Z9 5 U1 0 U2 4 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2011 VL 23 IS 1 BP 42 EP 51 DI 10.1080/10400435.2010.541408 PG 10 WC Rehabilitation SC Rehabilitation GA 880SP UT WOS:000299427800005 ER PT J AU Grindle, GG Wang, HW Salatin, BA Vazquez, JJ Cooper, RA AF Grindle, Garrett G. Wang, Hongwu Salatin, Benjamin A. Vazquez, Juan J. Cooper, Rory A. TI Design and Development of the Personal Mobility and Manipulation Appliance SO ASSISTIVE TECHNOLOGY LA English DT Article DE control; manipulation; power wheelchair; robots ID WHEELCHAIR; PEOPLE AB For people with significant mobility impairments who also have both lower and upper limb disability, there are few technology solutions. The aim of this article is to describe the design and development of the Personal Mobility and Manipulation Appliance, a device that provides coordinated mobility and bimanual manipulation for people with both lower and upper limb impairment. The Personal Mobility and Manipulation Appliance is integrated from several commercial products and custom technologies, including two robotic arms mounted on a mobile robotic base. It has three primary operating modes: local user, remote user, and autonomous. It also has a cooperative control mode where two or more of the primary modes can be used simultaneously. The device was evaluated in a kitchen and was able to perform several complex tasks. Future work should focus on interface improvements and evaluations by end users. C1 Univ Pittsburgh, Dept Vet Affairs, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Qual Technol Engn Res Ctr, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R1-H, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144 NR 46 TC 8 Z9 10 U1 1 U2 2 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2011 VL 23 IS 2 BP 81 EP 92 DI 10.1080/10400435.2011.567374 PG 12 WC Rehabilitation SC Rehabilitation GA 880SR UT WOS:000299428000004 ER PT J AU Cooper, RA Ferretti, E Oyster, M Kelleher, A Cooper, R AF Cooper, Rory A. Ferretti, Eliana Oyster, Michelle Kelleher, Annmarie Cooper, Rosemarie TI The Relationship Between Wheelchair Mobility Patterns and Community Participation Among Individuals With Spinal Cord Injury SO ASSISTIVE TECHNOLOGY LA English DT Article DE activity; community participation; manual wheelchair; powered wheelchair; wheelchair ID POWER-ASSISTED WHEELCHAIR; LIFE SATISFACTION; HEALTH-STATUS; PUSHRIM; TETRAPLEGIA; IMPACT; USERS AB Participation is considered the most meaningful outcome of rehabilitation. The purpose of this study was to investigate whether there were correlations between wheelchair activity recorded with a data logger and community participation as measured by the Participation Survey/Mobility. Data from 16 participants were included in this study. Data collected during a two week period using a data logging device were analyzed to determine the mobility characteristics of participants. Among manual wheelchair users, significant positive correlations were found between average speed traveled and the community participation content areas of transportation (r(s) = .837, p = .019) and socialization (r(s) = .772, p = .042). In addition, for manual wheelchair users there was a trend toward a significant correlation between average speed traveled and total community participation score (r(s) = .714, p = .071). Among power wheelchair users, there was a trend toward a significant negative correlation between average speed traveled and the community participation content area of leisure activity (r(s) = -.635, p = .066). Understanding the relationship between wheelchair speed and community participation can be useful information to enable clinicians to recommend the most appropriate mobility devices designed to enhance community participation. C1 [Cooper, Rory A.; Kelleher, Annmarie; Cooper, Rosemarie] Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, Dept Rehabil Sci & Technol,Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA. [Ferretti, Eliana] Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Pittsburgh, PA USA. [Oyster, Michelle] Univ Pittsburgh, Human Engn Res Labs, Rehabil Res & Dev Serv, Dept Vet Affairs, Pittsburgh, PA 15206 USA. [Oyster, Michelle] Univ Pittsburgh, Human Engn Res Labs, Rehabil Res & Dev Serv, Dept Phys Med & Rehabil, Pittsburgh, PA 15206 USA. RP Cooper, RA (reprint author), Univ Pittsburgh, VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, Dept Rehabil Sci & Technol,Rehabil Res & Dev Serv, 7180 Highland Dr,151R1-B, Pittsburgh, PA 15206 USA. EM Rory.Cooper@va.gov NR 28 TC 4 Z9 4 U1 0 U2 8 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2011 VL 23 IS 3 BP 177 EP 183 DI 10.1080/10400435.2011.588991 PG 7 WC Rehabilitation SC Rehabilitation GA 880SU UT WOS:000299428300005 ER PT J AU Jefferds, AN Pearlman, JL Wee, J Cooper, RA AF Jefferds, Alexandra N. Pearlman, Jon L. Wee, Joy Cooper, Rory A. TI International Mobility Technology Research: A Delphi Study to Identify Challenges and Compensatory Strategies SO ASSISTIVE TECHNOLOGY LA English DT Article DE cross-cultural; Delphi technique; evidence-based practice; international; translations; wheelchairs ID INFORMED-CONSENT; REHABILITATION RESEARCH; COLLABORATIVE RESEARCH; HEALTH; ISSUES; INDIA; IDENTIFICATION; TRANSLATION; RECRUITMENT; DISABILITY AB We sought to identify logistical and ethical challenges to performing wheelchair-related research in low-and middle-income countries and to generate a list of compensatory strategies to address these challenges. Thirteen individuals with experience in the field participated in an online Delphi study. The surveys asked participants to identify research challenges, suggest strategies to address the selected challenges, and critique each other's strategies. Participants identified challenges in the use of research techniques, compensation for participation that does not result coercion, oral and written translation materials, funding for research, collaboration with local professionals, and "respect for persons." Effective international mobility research requires time, cultural sensitivity, collaboration, and careful planning. An understanding of these requirements can allow researchers to anticipate and compensate for common pitfalls of their work, thus making the research more productive and beneficial to subjects. Future research is required to verify the general effectiveness of compensatory strategies. C1 [Jefferds, Alexandra N.; Pearlman, Jon L.; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Pearlman, Jon L.; Cooper, Rory A.] Univ Pittsburgh, Dept Vet Affairs, Pittsburgh, PA USA. [Wee, Joy] Queens Univ, Kingston, ON, Canada. RP Pearlman, JL (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor,151R1-H, Pittsburgh, PA 15206 USA. EM jlp46@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 NR 54 TC 1 Z9 1 U1 3 U2 5 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2011 VL 23 IS 4 BP 232 EP 242 DI 10.1080/10400435.2011.614677 PG 11 WC Rehabilitation SC Rehabilitation GA 882PK UT WOS:000299576000006 PM 22256672 ER PT J AU Mendez, MF Fras, IA Kremen, SA Tsai, PH AF Mendez, Mario F. Fras, Ivan Andrew Kremen, Sarah A. Tsai, Po-Heng TI False reports from patients with frontotemporal dementia: Delusions or confabulations? SO BEHAVIOURAL NEUROLOGY LA English DT Article ID SCHIZOPHRENIA-LIKE PSYCHOSIS; STRATEGIC RETRIEVAL; LOBAR DEGENERATION; DISEASE; DYSFUNCTION; MEMORY; RECOGNITION; PREVALENCE; MECHANISMS; SYMPTOMS AB Patients with behavioral variant frontotemporal dementia (bvFTD) can make false statements consistent with delusions or confabulations. It is unclear whether bvFTD is primarily associated with either delusions or with confabulations and whether they can be explained by the pathophysiology of this disease. In order to clarify this, we retrospectively surveyed the records of 48 patients with bvFTD for the presence of any false reports and identified four patients. Their false reports included continued interaction with a favorite but dead relation, fictitious marriages with movie stars, and two who claimed that their partner was having an affair. When confronted with the falsity of their statements, the patients conveyed a lack of certainty regarding their external or internal source but persisted in the constancy of their reports. On functional neuroimaging, the patients had predominant frontal involvement. This report found that patients with bvFTD can have both fantastic, wish fulfilling confabulations and typical content-specific delusions. We propose that both phenomena result from known disturbances of ventromedial prefrontal cortex in bvFTD, including deficits in source monitoring and in activating an automatic "doubt tag" for false reports. C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF,Dept Neurol & Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Biobehav Sci, Los Angeles, CA 90073 USA. RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF,Dept Neurol & Psychiat, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu NR 59 TC 6 Z9 6 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0953-4180 J9 BEHAV NEUROL JI Behav. Neurol. PY 2011 VL 24 IS 3 BP 237 EP 244 DI 10.3233/BEN-2011-0335 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 834NC UT WOS:000295967200006 PM 21876263 ER PT J AU Tregellas, JR Tanabe, J Rojas, DC Shatti, S Olincy, A Johnson, L Martin, LF Soti, F Kem, WR Leonard, S Freedman, R AF Tregellas, Jason R. Tanabe, Jody Rojas, Donald C. Shatti, Shireen Olincy, Ann Johnson, Lynn Martin, Laura F. Soti, Ferenc Kem, William R. Leonard, Sherry Freedman, Robert TI Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE CHRNA7; default network; functional magnetic resonance imaging; nicotinic receptors; schizophrenia ID TASK-INDUCED DEACTIVATION; RECEPTOR SUBUNIT GENE; NICOTINIC RECEPTORS; RESTING-STATE; GTS-21; FMRI; PHARMACOKINETICS; ASSOCIATION; SMOKING; HEALTHY AB Background: 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at alpha 7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of schizophrenia. This study examined the effects of DMXB-A on default network activity as a biomarker for drug effects on pathologic brain function associated with schizophrenia. Methods: Placebo and two doses of DMXB-A were administered in a random, double-blind crossover design during a Phase 2 study of DMXB-A. Functional magnetic resonance imaging was performed on 16 nonsmoking patients with schizophrenia while they performed a simple eye movement task. Independent component analysis was used to identify the default network component. Default network changes were evaluated in the context of a polymorphism in CHRNA7, the alpha 7-nicotinic acetylcholine receptor subunit gene, which was previously found to be associated with schizophrenia. Results: Compared with placebo, both 150 and 75 mg twice daily DMXB-A altered default network activity, including a reduction in posterior cingulate, inferior parietal cortex, and medial frontal gyrus activity and an increase in precuneus activity. The most robust difference, posterior cingulate activity reduction, was affected by CHRNA7 genotype. Conclusions: The observed DMXB-A-related changes are consistent with improved default network function in schizophrenia. Pharmacogenetic analysis indicates mediation of the effect through the alpha 7-nicotinic receptor. These results further implicate nicotinic cholinergic dysfunction in the disease and suggest that default network activity may be a useful indicator of biological effects of novel therapeutic agents. C1 [Tregellas, Jason R.; Tanabe, Jody; Rojas, Donald C.; Shatti, Shireen; Olincy, Ann; Johnson, Lynn; Martin, Laura F.; Leonard, Sherry; Freedman, Robert] Denver VA Med Ctr, Dept Psychiat, Aurora, CO USA. [Tregellas, Jason R.; Tanabe, Jody; Rojas, Donald C.; Shatti, Shireen; Olincy, Ann; Johnson, Lynn; Martin, Laura F.; Leonard, Sherry; Freedman, Robert] Univ Colorado Denver, Aurora, CO USA. [Tanabe, Jody] Univ Colorado Denver, Dept Radiol, Aurora, CO USA. [Soti, Ferenc; Kem, William R.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA. RP Tregellas, JR (reprint author), Univ Colorado, Sch Med, 13001 E 17th Pl,MS F546, Aurora, CO 80045 USA. EM Jason.tregellas@ucdenver.edu RI Rojas, Don/F-4296-2012; Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU VA Biomedical Laboratory and Clinical Science Research and Development Service; Mental Illness Research, Education and Clinical Centers of Veterans Integrated Service Networks [19]; National Institute of Mental Health [MH-061412, MH-086383]; National Association for Research in Schizophrenia and Affective Disorders; Dana Foundation; National Institute on Drug Abuse [DA-024104, DA-027748]; Institute for Children's Mental Disorders; Lundbeck FX Supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service; the Mental Illness Research, Education and Clinical Centers of Veterans Integrated Service Networks 5 and 19; National Institute of Mental Health Grant Nos. MH-061412 and MH-086383; the National Association for Research in Schizophrenia and Affective Disorders; the Dana Foundation and National Institute on Drug Abuse Grant Nos. DA-024104 and DA-027748; and the Institute for Children's Mental Disorders. We thank Dietmar Cordes, Ph.D., for critical comments during manuscript preparation.; Drs. Leonard and Freedman have patents through the Department of Veterans Affairs on the CHRNA7 gene sequence. Drs. Kem and Soti have patents through the University of Florida on the manufacture and use of DMXB-A. Drs. Olincy and Johnson receive research support from Lundbeck. All other authors report no biomedical financial interests or potential conflicts of interest. NR 26 TC 59 Z9 59 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 1 PY 2011 VL 69 IS 1 BP 7 EP 11 DI 10.1016/j.biopsych.2010.07.004 PG 5 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 702RH UT WOS:000285911300003 PM 20728875 ER PT J AU Jani, A AF Jani, Alkesh BE Edelstein, CL TI Biomarkers in Kidney Transplantation SO BIOMARKERS OF KIDNEY DISEASE LA English DT Article; Book Chapter ID RENAL-ALLOGRAFT REJECTION; POLYOMAVIRUS-ASSOCIATED NEPHROPATHY; PRETRANSPLANT SOLUBLE CD30; MOLECULE GENE-EXPRESSION; ACUTE CELLULAR REJECTION; DELAYED GRAFT FUNCTION; ACUTE TUBULAR-NECROSIS; GROWTH-FACTOR BETA(1); URINE FLOW-CYTOMETRY; MESSENGER-RNA C1 Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO 80220 USA. RP Jani, A (reprint author), Denver Vet Affairs Med Ctr, Renal Sect, Denver, CO 80220 USA. NR 117 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-375673-2 PY 2011 BP 233 EP 290 DI 10.1016/B978-0-12-375672-5.10006-4 PG 58 WC Pharmacology & Pharmacy; Urology & Nephrology SC Pharmacology & Pharmacy; Urology & Nephrology GA BEU29 UT WOS:000318163200008 ER PT J AU Arthur, JM Budisavljevic, MN Janech, MG AF Arthur, John M. Budisavljevic, Milos N. Janech, Michael G. BE Edelstein, CL TI Biomarkers in Glomerular Disease SO BIOMARKERS OF KIDNEY DISEASE LA English DT Article; Book Chapter ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GELATINASE-ASSOCIATED LIPOCALIN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; FIBROBLAST-SPECIFIC PROTEIN-1; ACETYL-BETA-GLUCOSAMINIDASE; SERUM IGA/C3 RATIO; NEPHROTIC SYNDROME; URINARY INTERLEUKIN-6; PROGNOSTIC MARKER; GROWTH-FACTOR C1 [Arthur, John M.; Budisavljevic, Milos N.; Janech, Michael G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Arthur, John M.; Budisavljevic, Milos N.; Janech, Michael G.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Arthur, JM (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. OI Janech, Michael/0000-0002-3202-4811 NR 53 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-375673-2 PY 2011 BP 367 EP 383 DI 10.1016/B978-0-12-375672-5.10010-6 PG 17 WC Pharmacology & Pharmacy; Urology & Nephrology SC Pharmacology & Pharmacy; Urology & Nephrology GA BEU29 UT WOS:000318163200012 ER PT J AU Buracchio, TJ Mattek, NC Dodge, HH Hayes, TL Pavel, M Howieson, DB Kaye, JA AF Buracchio, Teresa J. Mattek, Nora C. Dodge, Hiroko H. Hayes, Tamara L. Pavel, Misha Howieson, Diane B. Kaye, Jeffrey A. TI Executive function predicts risk of falls in older adults without balance impairment SO BMC GERIATRICS LA English DT Article AB Background: Executive dysfunction has previously been found to be a risk factor for falls. The aim of this study is to investigate the association between executive dysfunction and risk of falling and to determine if this association is independent of balance. Methods: Participants were 188 community-dwelling individuals aged 65 and older. All participants underwent baseline and annual evaluations with review of health history, standardized neurologic examination, neuropsychological testing, and qualitative and quantitative assessment of motor function. Falls were recorded prospectively using weekly online health forms. Results: During 13 months of follow-up, there were 65 of 188 participants (34.6%) who reported at least one fall. Univariate analysis showed that fallers were more likely to have lower baseline scores in executive function than non-fallers (p = 0.03). Among participants without balance impairment we found that higher executive function z-scores were associated with lower fall counts (p = 0.03) after adjustment for age, sex, health status and prior history of falls using negative binomial regression models. This relationship was not present among participants with poor balance. Conclusions: Lower scores on executive function tests are a risk factor for falls in participants with minimal balance impairment. However, this effect is attenuated in individuals with poor balance where physical or more direct motor systems factors may play a greater role in fall risk. C1 [Buracchio, Teresa J.; Mattek, Nora C.; Dodge, Hiroko H.; Howieson, Diane B.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Buracchio, Teresa J.; Kaye, Jeffrey A.] Portland VA Med Ctr, Neurol Serv, Portland, OR 97239 USA. [Mattek, Nora C.; Dodge, Hiroko H.; Hayes, Tamara L.; Pavel, Misha; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97239 USA. [Hayes, Tamara L.; Pavel, Misha] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. RP Buracchio, TJ (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,CR 131, Portland, OR 97239 USA. EM buracchi@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU National Institutes of Health [P30AG024978, R01AG024059, P30 AG008017, K01 AG23014]; Intel Corporation FX The authors thank the research volunteers for their invaluable donation to research, and the research staff of the Living Laboratory and ISAAC studies for their assistance. The study was funded by grants from the National Institutes of Health: P30AG024978, R01AG024059, P30 AG008017, K01 AG23014 and the Intel Corporation. NR 48 TC 18 Z9 18 U1 3 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PY 2011 VL 11 AR 74 DI 10.1186/1471-2318-11-74 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA V29EM UT WOS:000208731700074 PM 22070602 ER PT J AU Hung, WW Ross, JS Boockvar, KS Siu, AL AF Hung, William W. Ross, Joseph S. Boockvar, Kenneth S. Siu, Albert L. TI Recent trends in chronic disease, impairment and disability among older adults in the United States SO BMC GERIATRICS LA English DT Article DE chronic disease; impairment; disability; prevalence trends AB Background: To examine concurrent prevalence trends of chronic disease, impairment and disability among older adults. Methods: We analyzed the 1998, 2004 and 2008 waves of the Health and Retirement Study, a nationally representative survey of older adults in the United States, and included 31,568 community dwelling adults aged 65 and over. Measurements include: prevalence of chronic diseases including hypertension, heart disease, stroke, diabetes, cancer, chronic lung disease and arthritis; prevalence of impairments, including impairments of cognition, vision, hearing, mobility, and urinary incontinence; prevalence of disability, including activities of daily living (ADLs) and instrumental activities of daily living (IADLs). Results: The proportion of older adults reporting no chronic disease decreased from 13.1% (95% Confidence Interval [CI], 12.4%-13.8%) in 1998 to 7.8% (95% CI, 7.2%-8.4%) in 2008, whereas the proportion reporting 1 or more chronic diseases increased from 86.9% (95% CI, 86.2%-89.6%) in 1998 to 92.2% (95% CI, 91.6%-92.8%) in 2008. In addition, the proportion reporting 4 or more diseases increased from 11.7% (95% CI, 11.0%-12.4%) in 1998 to 17.4% (95% CI, 16.6%-18.2%) in 2008. The proportion of older adults reporting no impairments was 47.3% (95% CI, 46.3%48.4%) in 1998 and 44.4% (95% CI, 43.3%-45.5%) in 2008, whereas the proportion of respondents reporting 3 or more was 7.2% (95% CI, 6.7%-7.7%) in 1998 and 7.3% (95% CI, 6.8%-7.9%) in 2008. The proportion of older adults reporting any ADL or IADL disability was 26.3% (95% CI, 25.4%-27.2%) in 1998 and 25.4% (95% CI, 24.5%-26.3%) in 2008. Conclusions: Multiple chronic disease is increasingly prevalent among older U.S. adults, whereas the prevalence of impairment and disability, while substantial, remain stable. C1 [Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, Bronx, NY USA. [Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ross, Joseph S.] Yale Univ, Sch Med, Div Gen Internal Med, New Haven, CT USA. [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Hung, WW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. EM william.hung@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU National Institute on Aging [K08 AG032886, U01AG009740]; American Federation of Aging Research through the Paul B. Beeson Career Development Award Program FX WH is a John A Hartford Foundation Center of Excellence Scholar and a New York Academy of Medicine Hoar Fellow. JR is currently supported by the National Institute on Aging (K08 AG032886) and by the American Federation of Aging Research through the Paul B. Beeson Career Development Award Program. The Health and Retirement Study is sponsored by the National Institute on Aging (grant number U01AG009740) and conducted by the Institute for Social Research at the University of Michigan. NR 45 TC 73 Z9 78 U1 1 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PY 2011 VL 11 AR 47 DI 10.1186/1471-2318-11-47 PG 12 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA V29EM UT WOS:000208731700047 PM 21851629 ER PT J AU Roodman, GD AF Roodman, G. David TI Osteoblast function in myeloma SO BONE LA English DT Review DE Multiple myeloma; Bone disease; Osteoclast; Osteoblast; Cancer ID NF-KAPPA-B; MULTIPLE-MYELOMA; BONE-DISEASE; IN-VIVO; PROTEASOME INHIBITOR; SERUM CONCENTRATIONS; BORTEZOMIB; DIFFERENTIATION; CELLS; ACTIVATION AB Multiple myeloma (MM) is the most frequent cancer to involve the skeleton and results in purely osteolytic lesions that rarely heal. MM bone disease is responsible for some of the most devastating complications of MM. The marrow microenvironment plays a key role in MM bone disease as well as in the initiation, expansion and chemoresistance of MM cells. How this microenvironment becomes so supportive of MM, and the contribution and interaction of the various components of the microenvironment to enhancing MM growth are only beginning to be understood. However, it is clear that suppression of osteoblast activity plays a key role in the bone destructive process as well as progression of the tumor burden in myeloma. The impairment of osteoblast activity in MM results primarily from blockade of osteogenic differentiation of mesenchymal progenitors to mature osteoblasts. MM patients have low to normal levels of bone formation markers, such as alkaline phosphatase and osteocalcin in the setting of increased bone resorption. In contrast, MM patients without bone lesions display balanced bone remodeling with increased osteoclastogenesis and normal or increased bone formation rates. Both soluble factors and cell-to-cell contact between MM cells and osteoblast progenitors are responsible for the suppression of osteoblast differentiation in MM. In this article, the mechanism responsible for osteoblast suppression will be reviewed, and the effects of novel bone anabolic agents on myeloma bone disease will be discussed. (C) 2010 Elsevier Inc. All rights reserved. C1 [Roodman, G. David] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Roodman, G. David] Univ Pittsburgh, Dept Med Hematol Oncol, Pittsburgh, PA USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Res & Dev, R&D 151U,Room 2E113,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 65 TC 26 Z9 28 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN 1 PY 2011 VL 48 IS 1 SI SI BP 135 EP 140 DI 10.1016/j.bone.2010.06.016 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 705IL UT WOS:000286122000019 PM 20601285 ER PT J AU McFadden, JL Borckardt, JJ George, MS Beam, W AF McFadden, James L. Borckardt, Jeff J. George, Mark S. Beam, William TI Reducing procedural pain and discomfort associated with transcranial direct current stimulation SO BRAIN STIMULATION LA English DT Article DE anode; cathode; EMLA; pain reduction; transcranial direct current stimulation; tDCS ID HIERARCHICAL LINEAR-MODELS; HUMAN MOTOR CORTEX; DC STIMULATION; PERCEPTION AB Background Transcranial direct current stimulation (tDCS) appears to have modulatory effects on the excitability of cortical brain tissue. Though tDCS as presently applied causes no apparent harm to brain structure or function, a number of uncomfortable sensations can occur beneath the electrodes during stimulation, including tingling, pain, itching, and burning sensations. Therefore, we investigated the effect of topically applied Eutectic mixture of local anesthetics (EMLA) on tDCS-related discomfort. Methods Nine healthy adults received both anodal and cathodal 2.0 mA tDCS for 5 minutes over the prefrontal cortex with the skin pretreated for 20 minutes with either EMLA or placebo cream. Participants rated procedural discomfort six times across eight dimensions of sensation. Results On average, the mean sensation ratings for EMLA-associated tDCS stimulation were significantly lower than placebo-associated stimulation for every cutaneous sensation evaluated. Cathodal stimulation was associated with higher ratings of "sharpness" and intolerability than anodal stimulation. Conclusions Topical EMLA may reduce tDCS-related discomfort. (C) 2011 Elsevier Inc. All rights reserved. C1 [McFadden, James L.; Borckardt, Jeff J.; George, Mark S.; Beam, William] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Borckardt, JJ (reprint author), MUSC Inst Psychiat, 67 President St,PH 518, Charleston, SC 29425 USA. EM borckard@musc.edu RI Westwood, Sam/P-7000-2015 FU Medical University of South Carolina College of Graduate Studies; National Institutes of Health (National Institute of Mental Health, National Institute on Drug Abuse, National Institutes), the Department of Defense and Veterans Administration; National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research); Robert Wood Johnson Foundation FX Mr McFadden was funded through a grant from the Medical University of South Carolina College of Graduate Studies Summer Health Professionals Research Program.; Dr George was funded through grants from the National Institutes of Health (National Institute of Mental Health, National Institute on Drug Abuse, National Institutes), the Department of Defense and Veterans Administration.; Dr Borckardt was funded through grants from the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research) and the Robert Wood Johnson Foundation. NR 16 TC 17 Z9 18 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD JAN PY 2011 VL 4 IS 1 BP 38 EP 42 DI 10.1016/j.brs.2010.05.002 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 719AZ UT WOS:000287172900005 PM 21255753 ER PT J AU Celli, A Mackenzie, DS Crumrine, DS Tu, CL Hupe, M Bikle, DD Elias, PM Mauro, TM AF Celli, A. Mackenzie, D. S. Crumrine, D. S. Tu, C. L. Hupe, M. Bikle, D. D. Elias, P. M. Mauro, T. M. TI Endoplasmic reticulum Ca2+ depletion activates XBP1 and controls terminal differentiation in keratinocytes and epidermis SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID CALCIUM GRADIENT; PERMEABILITY BARRIER; MESSENGER-RNA; ER STRESS; SARCO/ENDOPLASMIC RETICULUM; INVOLUCRIN EXPRESSION; TRANSCRIPTION FACTOR; DARIER-DISEASE; MICE; SKIN AB P>Background Endoplasmic reticulum (ER) Ca2+ depletion, previously shown to signal pathological stress responses, has more recently been found also to trigger homeostatic physiological processes such as differentiation. In keratinocytes and epidermis, terminal differentiation and barrier repair require physiological apoptosis and differentiation, as evidenced by protein synthesis, caspase 14 expression, lipid secretion and stratum corneum (SC) formation. Objectives To investigate the role of Ca2+ depletion-induced ER stress in keratinocyte differentiation and barrier repair in vivo and in cell culture. Methods The SERCA2 Ca2+ pump inhibitor thapsigargin (TG) was used to deplete ER calcium both in cultured keratinocytes and in mice. Levels of the ER stress factor XBP1, loricrin, caspase 14, lipid synthesis and intracellular Ca2+ were compared after both TG treatment and barrier abrogation. Results We showed that these components of terminal differentiation and barrier repair were signalled by physiological ER stress, via release of stratum granulosum (SG) ER Ca2+ stores. We first found that keratinocyte and epidermal ER Ca2+ depletion activated the ER-stress-induced transcription factor XBP1. Next, we demonstrated that external barrier perturbation resulted in both intracellular Ca2+ emptying and XBP1 activation. Finally, we showed that TG treatment of intact skin did not perturb the permeability barrier, yet stimulated and mimicked the physiological processes of barrier recovery. Conclusions This report is the first to quantify and localize ER Ca2+ loss after barrier perturbation and show that homeostatic processes that restore barrier function in vivo can be reproduced solely by releasing ER Ca2+, via induction of physiological ER stress. C1 [Celli, A.; Mackenzie, D. S.; Tu, C. L.; Hupe, M.; Bikle, D. D.; Mauro, T. M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94121 USA. [Crumrine, D. S.; Hupe, M.; Elias, P. M.; Mauro, T. M.] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA. RP Celli, A (reprint author), Univ Calif San Francisco, Dept Dermatol, 4150 Clement St, San Francisco, CA 94121 USA. EM celli.anna@gmail.com FU National Institutes of Health [AR051930, AR19098]; San Francisco Veterans' Affairs Medical Center FX This work was supported by National Institutes of Health grants AR051930 (T.M.) and AR19098 (P.E.) and the San Francisco Veterans' Affairs Medical Center. The authors wish to thank Debra Crumrine for expert technical assistance. NR 39 TC 21 Z9 21 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JAN PY 2011 VL 164 IS 1 BP 16 EP 25 DI 10.1111/j.1365-2133.2010.10046.x PG 10 WC Dermatology SC Dermatology GA 700NY UT WOS:000285752000005 PM 20846312 ER PT J AU Komers, R Oyama, TT Beard, DR Anderson, S AF Komers, R. Oyama, T. T. Beard, D. R. Anderson, S. TI Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article DE diabetic nephropathy; RhoA GTPase; Rho associated kinase; Y27632; fasudil; effective renal plasma flow; myosin light chain; ruboxistaurin ID RENIN-ANGIOTENSIN SYSTEM; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; PKC-BETA INHIBITOR; PROTEIN-KINASE; SIGNALING PATHWAYS; MICROVASCULAR TONE; MYOSIN PHOSPHATASE; HYPERTENSIVE-RATS; RHOA/RHO-KINASE AB BACKGROUND AND PURPOSE The RhoA/Rho associated kinases (ROCK) pathway has been implicated in the pathophysiology of diabetic nephropathy (DN). Early stages of diabetes are associated with renal haemodynamic changes, contributing to later development of DN. However, the role of RhoA/ROCK, known regulators of vascular tone, in this process has not been studied. EXPERIMENTAL APPROACH Blood pressure (BP), glomerular filtration (GFR), effective renal plasma flow and filtration fraction (FF) in response to the ROCK inhibitors Y27632 (0.1 and 0.5 mg center dot kg-1) and fasudil (0.3 and 1.5 mg center dot kg-1) were examined in streptozotocin-diabetic rats and non-diabetic controls. KEY RESULTS Diabetic rats demonstrated baseline increases in GFR and FF. In contrast to similar decreases in BP in diabetic and control rats, renal vasodilator effects and a decrease in FF, following ROCK inhibition were observed only in diabetic rats. The vasodilator effects of Y27632 and a further decrease in FF, were also detected in diabetic rats pretreated with the angiotensin antagonist losartan. The effects of ROCK inhibitors in diabetic rats were modulated by prior protein kinase C (PKC)beta inhibition with ruboxistaurin, which abolished their effects on FF. Consistent with the renal vasodilator effects, the ROCK inhibitors reduced phosphorylation of myosin light chain in diabetic kidneys. CONCLUSIONS AND IMPLICATIONS The results indicate greater dependence of renal haemodynamics on RhoA/ROCK and beneficial haemodynamic effects of ROCK inhibitors in diabetes, which were additive to the effects of losartan. In this process, the RhoA/ROCK pathway operated downstream of or interacted with, PKC beta in some segments of the renal vascular tree. C1 [Komers, R.; Oyama, T. T.; Anderson, S.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Beard, D. R.; Anderson, S.] Portland VA Med Ctr, Portland, OR USA. RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU Juvenile Diabetes Research Foundation [1-2008-314] FX Ruboxistaurin was a generous gift from Eli Lilly and Co. Parts of these studies have been previously presented at the meetings of the European Diabetic Nephropathy Study Group, Hannover, Germany, 2008; and the American Society of Nephrology, San Diego, CA, USA, 2009. These studies were supported by the Juvenile Diabetes Research Foundation (R.K. 1-2008-314). NR 52 TC 16 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD JAN PY 2011 VL 162 IS 1 BP 163 EP 174 DI 10.1111/j.1476-5381.2010.01031.x PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 690LN UT WOS:000285006400013 PM 20840471 ER PT J AU Chan, JM Weinberg, V Magbanua, MJ Sosa, E Simko, J Shinohara, K Federman, S Mattie, M Hughes-Fulford, M Haqq, C Carroll, PR AF Chan, June M. Weinberg, Vivian Magbanua, Mark J. Sosa, Eduardo Simko, Jeffry Shinohara, Katsuto Federman, Scot Mattie, Mike Hughes-Fulford, Millie Haqq, Christopher Carroll, Peter R. TI Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer SO CANCER CAUSES & CONTROL LA English DT Article DE Prostate cancer; Active surveillance; Fish oil; Lycopene; Randomized clinical trial ID FOOD FREQUENCY QUESTIONNAIRE; GROWTH-FACTOR SYSTEM; MARINE FATTY-ACIDS; LIFE-STYLE CHANGES; GENE-EXPRESSION; LYCOPENE SUPPLEMENTATION; ARACHIDONIC-ACID; DOUBLE-BLIND; FACTOR-I; RISK AB Nutritional factors are associated with reduced risk of prostate cancer progression, yet mechanisms remain unclear. We examined the effects of lycopene and fish oil supplements versus placebo on the normal prostate microenvironment, among men pursuing active surveillance for low-burden prostate cancer. We hypothesized that lycopene or fish oil supplements would down-regulate insulin-like growth factor-1 (IGF-1) and cyclooxygenase 2 (COX-2) gene expression, respectively, reflecting putative proliferation (IGF-1) and inflammatory (COX-2) pathways relevant to carcinogenesis. We conducted a 3-month randomized, double-blinded, clinical trial comparing prostate tissue gene expression profiles (assessed by qRT-PCR) among men with favorable-risk prostate cancer receiving either 30 mg/day lycopene, 3 g/day fish oil (including 1,098 mg eicosapentaenoic and 549 mg docosahexaenoic fatty acids) or placebo. Among 69 men (22 assigned to lycopene, 21 to fish, and 26 to placebo), there was no difference in the change from baseline to the 3 months in IGF-1 expression level between the placebo and lycopene arms (p = 0.93) nor in COX-2 expression between the placebo and fish arms (p = 0.99). Compared to placebo, 3-month intervention with lycopene or fish oil did not significantly change IGF-1 and COX-2 gene expression in the normal prostate microenvironment in men with low-burden prostate cancer. Further analysis of global gene expression profiles may shed light on the bioactivity and relevance of these nutrients in prostate cancer. C1 [Chan, June M.; Simko, Jeffry; Shinohara, Katsuto; Hughes-Fulford, Millie; Haqq, Christopher; Carroll, Peter R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94158 USA. [Chan, June M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA. [Chan, June M.; Magbanua, Mark J.; Sosa, Eduardo; Simko, Jeffry; Federman, Scot; Mattie, Mike; Carroll, Peter R.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA. [Weinberg, Vivian] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr Biostat C, San Francisco, CA 94158 USA. [Simko, Jeffry] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA. [Hughes-Fulford, Millie] San Francisco VA Med Ctr, San Francisco, CA USA. RP Chan, JM (reprint author), Univ Calif San Francisco, Dept Urol, MC 3110,1450 3rd St,POB 589001, San Francisco, CA 94158 USA. EM june.chan@ucsf.edu FU NCI NIH HHS [R01 CA101042, R01CA101042] NR 46 TC 22 Z9 23 U1 1 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD JAN PY 2011 VL 22 IS 1 BP 141 EP 150 DI 10.1007/s10552-010-9684-5 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 695HH UT WOS:000285360700016 PM 21103921 ER PT J AU Singh, T Vaid, M Katiyar, N Sharma, S Katiyar, SK AF Singh, Tripti Vaid, Mudit Katiyar, Nandan Sharma, Samriti Katiyar, Santosh K. TI Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E-2 and prostaglandin E-2 receptors SO CARCINOGENESIS LA English DT Article ID GRAPE SEED PROANTHOCYANIDINS; MOUSE SKIN; INFLAMMATORY RESPONSES; CUTANEOUS MELANOMA; GUANYLATE-CYCLASE; CARCINOMA-CELLS; NITRIC-OXIDE; LUNG-CANCER; APOPTOSIS; ARREST AB Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize. We have examined the effect of berberine, an isoquinoline alkaloid, on human melanoma cancer cell migration and the molecular mechanisms underlying these effects using melanoma cell lines, A375 and Hs294. Using an in vitro cell migration assay, we show that over expression of cyclooxygenase (COX)-2, its metabolite prostaglandin E-2 (PGE(2)) and PGE(2) receptors promote the migration of cells. We found that treatment of A375 and Hs294 cells with berberine resulted in concentration-dependent inhibition of migration of these cells, which was associated with a reduction in the levels of COX-2, PGE(2) and PGE(2) receptors (EP2 and EP4). Treatment of cells with celecoxib, a COX-2 inhibitor, or transient transfection of cells with COX-2 small interfering RNA, also inhibited cell migration. Treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), an inducer of COX-2 or PGE(2), enhanced cell migration, whereas berberine inhibited TPA- or PGE(2)-promoted cell migration. Berberine reduced the basal levels as well as PGE(2)-stimulated expression levels of EP2 and EP4. Treatment of the cells with the EP4 agonist stimulated cell migration and berberine blocked EP4 agonist-induced cell migration activity. Moreover, berberine inhibited the activation of nuclear factor-kappa B (NE-kappa B), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NE-kappa B, inhibited cell migration. Together, these results indicate for the first time that berberine inhibits melanoma cell migration, an essential step in invasion and metastasis, by inhibition of COX-2, PGE(2) and PGE(2) receptors. C1 [Singh, Tripti; Vaid, Mudit; Katiyar, Nandan; Sharma, Samriti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration FX Veterans Administration Merit Review Award to S.K.K. NR 29 TC 73 Z9 77 U1 1 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 2011 VL 32 IS 1 BP 86 EP 92 DI 10.1093/carcin/bgq215 PG 7 WC Oncology SC Oncology GA 707RF UT WOS:000286303000014 PM 20974686 ER PT J AU Milo-Cotter, O Cotter-Davison, B Lombardi, C Sun, HR Bettari, L Bugatti, S Rund, M Metra, M Kaluski, E Kobrin, I Frey, A Rainisio, M McMurray, JJV Teerlink, JR Cotter-Davison, G AF Milo-Cotter, Olga Cotter-Davison, Beth Lombardi, Carlo Sun, Hengrui Bettari, Luca Bugatti, Silvia Rund, Michele Metra, Marco Kaluski, Edo Kobrin, Isaac Frey, Aline Rainisio, Maurizio McMurray, John J. V. Teerlink, John R. Cotter-Davison, Gad TI Neurohormonal Activation in Acute Heart Failure: Results from VERITAS SO CARDIOLOGY LA English DT Article DE Heart failure; Inflammation; Prognosis ID TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; NATRIURETIC PEPTIDE; MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; CYTOKINES; TROPONIN; TRIAL; INTERLEUKIN-6; ENDOTHELIN-1 AB Objectives: Recent heart failure studies have suggested that inflammatory and immune system activation are associated with increased levels of cytokines, chemokines and inflammatory proteins during acutely decompensated heart failure. The objectives of this substudy were to evaluate the role of neurohormonal and inflammatory activation in the pathogenesis and outcome of acute heart failure (AHF) and the correlation between biomarker levels and clinical outcomes. Methods: Serum levels of B-type natriuretic peptide-32 (BNP-32), endothelin-1 (ET-1), norepinephrine, troponins I and T, C-reactive protein (CRP), von Willebrand factor, plasminogen activator inhibitor-1, interleukin-6 (IL-6) and tissue plasminogen activator (TPA) were measured at baseline, 24 and 48 h and 7 and 30 days in 112 patients with AHF recruited to the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Study neurohormonal substudy. Results: On univariable analysis, CRP, BNP and ET-1 were predictive of worsening heart failure by day 30; when considered together, only CRP and BNP were significantly associated with this outcome. On adjustment for age, baseline blood pressure, serum sodium and serum creatinine, only age and BNP remained significant. CRP, IL-6 and TPA levels were significantly correlated with 180-day mortality on univariable analysis. Conclusion: Circulating markers of inflammation may be useful in gauging prognosis in patients with AHF. Copyright (C) 2011 S. Karger AG, Basel C1 [Milo-Cotter, Olga; Cotter-Davison, Beth; Sun, Hengrui; Rund, Michele; Cotter-Davison, Gad] Momentum Res Inc, Durham, NC 27707 USA. [Kaluski, Edo] Univ Med & Dent New Jersey, Cardiac Catheterizat Labs, Dept Cardiol, Newark, NJ 07103 USA. [Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Lombardi, Carlo; Bettari, Luca; Bugatti, Silvia; Metra, Marco] Univ Brescia, Brescia, Italy. [Rainisio, Maurizio] AbaNovus Srl, San Remo, Italy. [Kobrin, Isaac; Frey, Aline] Actel Pharmaceut, Allschwil, Switzerland. [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland. RP Milo-Cotter, O (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM olgacotter@momentum-research.com RI Teerlink, John/D-2986-2012; lombardi, carlo /O-2130-2013 OI lombardi, carlo /0000-0002-7120-5877; Davison, Beth/0000-0003-2374-6449; Metra, Marco/0000-0001-6691-8568; Kaluski, Edo/0000-0002-1400-3988; mcmurray, john/0000-0002-6317-3975 FU Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; Momentum Research Inc., Durham, N.C., USA; Actelion FX The conduct of this substudy was supported by Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. Analysis and manuscript preparation were supported by Momentum Research Inc., Durham, N.C., USA.; Drs. Milo-Cotter, Cotter-Davison and Sun are employees of Momentum Research Inc., which has provided consulting and trial management services to Novacardia, Merck, Nile Therapeutics, Bioheart, Celladon, Corthera and Novartis. Drs. Kobrin and Frey are employees of Actelion. Dr. Rainisio was an employee of Actelion at the time the study was conducted. Drs. McMurray and Teerlink received research grants from Actelion, the sponsor of the study. NR 33 TC 21 Z9 21 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2011 VL 119 IS 2 BP 96 EP 105 DI 10.1159/000330409 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 824KR UT WOS:000295201300006 PM 21912122 ER PT J AU Basile, JN AF Basile, Jan N. TI The role of vasodilating beta-blockers in controlling arterial hypertension as a means of reducing cardiovascular and stroke risk SO CARDIOVASCULAR THERAPY AND PREVENTION LA Russian DT Review DE beta-blockers; efficacy; hypertension; nebivolol; tolerability; vasodilating beta-blockers ID RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE; 1ST-LINE THERAPY; HEART-FAILURE; NITRIC-OXIDE; NEBIVOLOL; METOPROLOL; ATENOLOL; CARVEDILOL; PREVENTION AB beta-blockers have played a key role in the management of hypertension-related cardiovascular disease for decades, and continue to be recommended as a mainstay of therapy in national guidelines statements. Recent data have shown less optimal reductions in total mortality, CVD mortality, and CVD events with beta-blockers compared with renin-angiotensin system-blocking agents or calcium channel blockers. The beta-blocker class, however, spans a wide range of agents, and the growing concern about the risk-benefit profile of beta-blockers should not be generalized to later-generation vasodilating beta-blockers such as carvedilol and nebivolol. A growing database from hypertension studies confirms the clinical efficacy and safety of vasodilating beta-blockers, and outcome studies indicate that these agents can play an important role in global CVD reduction in patients with hypertensive or ischemic heart failure. C1 [Basile, Jan N.] Med Univ S Carolina, Coll Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Basile, JN (reprint author), Med Univ S Carolina, Coll Med, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU SILICEA-POLIGRAF PI MOSCOW PA KASHIRSKOJE SH 24 A/JA 509, MOSCOW, 115478, RUSSIA SN 1728-8800 J9 CARDIOVASC THER PREV JI Cardiovasc. Ther. Prevent. PY 2011 VL 10 IS 3 BP 97 EP 102 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 751EP UT WOS:000289600600017 ER PT J AU Bakris, GL Basile, JN Giles, TD Taylor, AA AF Bakris, G. L. Basile, J. N. Giles, T. D. Taylor, A. A. TI The role of nitric oxide in improving endothelial function andcardiovascular health: focus on nebivolor SO CARDIOVASCULAR THERAPY AND PREVENTION LA Russian DT Review DE beta-blockers; endothelial function; hypertension; nebivolol; nitric oxide; vasodilating beta-blockers ID DEPENDENT VASCULAR RELAXATION; VASODILATING BETA-BLOCKERS; CENTRAL AORTIC PRESSURE; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; ERECTILE DYSFUNCTION; INSULIN-RESISTANCE; RANDOMIZED-TRIAL; HEART-FAILURE AB Although beta-blockers have been endorsed by guidelines committees for the treatment of patients with hypertension, particularly those with significant CVD and high CVD risk, there are concerns about conventional beta-blockers related to poorer clinical outcomes compared with other classes of antihypertensive agents, as well as deleterious effects on quality of life and lipid and carbohydrate metabolism. beta-blockers comprise a heterogeneous group of antihypertensive agents, including nonselective agents, cardioselective, nonvasodilating agents, and vasodilating agents that either combine beta-nonselectivity with beta-blockade or possess cardioselectivity without beta-blockade. The pharmacologic, mechanistic, and hemodynamic differences between conventional, nonvasodilating beta-blockers and vasodilating beta-blockers are discussed in this review, with a focus on the cardioselective vasodilating beta-blocker nebivolol. These differences may have important clinical implications, particularly in the treatment of complicated hypertension, such as that associated with patients with diabetes or cardiometabolic syndrome, elderly patients, and African American patients, suggesting that mechanism of action may be an important consideration when choosing a beta-blocker. C1 [Bakris, G. L.] Univ Chicago, Med Ctr, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA. [Basile, J. N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Coll Med, Charleston, SC USA. [Giles, T. D.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA. [Taylor, A. A.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Taylor, A. A.] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. [Taylor, A. A.] Baylor Coll Med, Dept Mol Physiol, Houston, TX 77030 USA. RP Bakris, GL (reprint author), Univ Chicago, Med Ctr, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA. NR 41 TC 0 Z9 0 U1 1 U2 2 PU SILICEA-POLIGRAF PI MOSCOW PA KASHIRSKOJE SH 24 A/JA 509, MOSCOW, 115478, RUSSIA SN 1728-8800 J9 CARDIOVASC THER PREV JI Cardiovasc. Ther. Prevent. PY 2011 VL 10 IS 2 BP 116 EP 121 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 770HL UT WOS:000291077500020 ER PT J AU Garcia, S Rider, JE Moritz, TE Pierpont, G Goldman, S Larsen, GC Shunk, K Littooy, F Santilli, S Rapp, J Reda, DJ Ward, HB McFalls, EO AF Garcia, Santiago Rider, James E. Moritz, Thomas E. Pierpont, Gordon Goldman, Steven Larsen, Greg C. Shunk, Kendrick Littooy, Fred Santilli, Steven Rapp, Joseph Reda, Domenic J. Ward, Herbert B. McFalls, Edward O. TI Preoperative Coronary Artery Revascularization and Long-Term Outcomes Following Abdominal Aortic Vascular Surgery in Patients with Abnormal Myocardial Perfusion Scans: A Subgroup Analysis of the Coronary Artery Revascularization Prophylaxis Trial SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE percutaneous coronary intervention; peripheral vascular disease; diagnostic cardiac catheterization ID PERIOPERATIVE CARDIOVASCULAR EVALUATION; HIGH-RISK PATIENTS; CARDIAC RISK; NONCARDIAC SURGERY; CARP TRIAL; INFARCTION; INDEX; DISEASE AB Background: Abdominal aortic operations have the highest perioperative cardiac risk. To test the impact of preoperative coronary artery revascularization (PR) in this high-risk subset, a post hoc analysis was performed in patients undergoing aortic surgery within the Coronary Artery Revascularization Prophylaxis (CARP) trial. Methods: The study cohort was a subset of 109 CARP patients with myocardial ischemia on nuclear imaging randomized to a strategy of PR (N = 52) or no PR (N = 57) before their scheduled abdominal aortic vascular operation. The clinical indications for vascular surgery were an expanding aneurysm (N = 62) or severe claudication (N = 47). The composite end-point of death and nonfatal myocardial infarction (MI) was determined by an intention-to-treat analysis following randomization. Results: The median time (Interquartiles) from randomization to vascular surgery was 56 (40, 81) days in patients assigned to PR and 19 (10, 43) days in patients assigned to no PR (P < 0.001). At 2.7 years following randomization, the probability of remaining free of death and nonfatal MI was 0.65 with PR and 0.55 with no PR [unadjusted P = 0.08, odds ratio 5 1.67, 95% confidence interval (0.93, 2.99)]. Using a Cox proportional hazard model, predictors of the composite of death and nonfatal MI (odds ratio; 95% confidence interval) were no PR (1.90; 1.06-3.43; P = 0.03) and anterior ischemia on preoperative imaging (1.79; 0.99-3.23; P = 0.07). Conclusions: In patients with an abnormal cardiac imaging before abdominal aortic vascular surgery, PR was associated with a reduced risk of death and nonfatal MI while anterior ischemia was an identifier of poor outcome independent of the revascularization status. (C) 2010 Wiley-Liss, Inc. C1 [Garcia, Santiago; Rider, James E.; Pierpont, Gordon; Santilli, Steven; Ward, Herbert B.; McFalls, Edward O.] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Garcia, Santiago; Rider, James E.; Pierpont, Gordon; McFalls, Edward O.] Univ Minnesota, Dept Med, Div Cardiol, Minneapolis, MN 55455 USA. [Moritz, Thomas E.; Reda, Domenic J.] VA Cooperat Studies Program, Hines, IL USA. [Goldman, Steven] So Arizona VA Hlth Care Syst, Tucson, AZ USA. [Goldman, Steven] Univ Arizona, Sarver Heart Ctr, Tucson, AZ USA. [Larsen, Greg C.] Portland VA Med Ctr, Div Cardiol, Portland, OR USA. [Santilli, Steven] Univ Minnesota, Dept Surg, Div Vasc Surg, Minneapolis, MN 55455 USA. [Ward, Herbert B.] Univ Minnesota, Dept Surg, Div Cardiovasc & Thorac Surg, Minneapolis, MN 55455 USA. [Shunk, Kendrick; Rapp, Joseph] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shunk, Kendrick; Rapp, Joseph] San Francisco VA Med Ctr, San Francisco, CA USA. [Littooy, Fred] Edward Hines VA Med Ctr, Div Peripheral Vasc Surg, Hines, IL USA. RP McFalls, EO (reprint author), VA Med Ctr, Div Cardiol, 111C,1 Vet Dr, Minneapolis, MN 55417 USA. EM mcfal00l@umn.edu FU Department of Veterans Affairs Office of Research and Development FX Grant sponsor: Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development NR 19 TC 9 Z9 12 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD JAN 1 PY 2011 VL 77 IS 1 BP 134 EP 141 DI 10.1002/ccd.22699 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 700UO UT WOS:000285770000032 PM 20602474 ER PT J AU Saless, N Litscher, SJ Houlihan, MJ Han, IK Wilson, D Demant, P Blank, RD AF Saless, Neema Litscher, Suzanne J. Houlihan, Meghan J. Han, In Kyu Wilson, Derek Demant, Peter Blank, Robert D. TI Comprehensive Skeletal Phenotyping and Linkage Mapping in an Intercross of Recombinant Congenic Mouse Strains HcB-8 and HcB-23 SO CELLS TISSUES ORGANS LA English DT Article DE Biomechanics; Bone modeling; Quantitative trait loci; Linkage; Pleiotropy; Principal components ID TRAITS; BONE; STRENGTH; POWER; GENE; MICE AB Bone biomechanical performance is a complex trait or, more properly, an ensemble of complex traits. Biomechanical performance incorporates flexibility under loading, yield and failure load, and energy to failure; all are important measures of bone function. To date, the vast majority of work has focused on yield and failure load and its surrogate, bone mineral density. We performed a reciprocal intercross of the mouse strains HcB-8 and HcB-23 to map and ultimately identify genes that contribute to differences in biomechanical performance. Mechanical testing was performed by 3-point bending of the femora. We measured femoral diaphysis cross-sectional anatomy from photographs of the fracture surfaces. We used beam equations to calculate material level mechanical properties. We performed a principal component (PC) analysis of normalized whole bone phenotypes (17 input traits). We measured distances separating mandibular landmarks from calibrated digital photographs and performed linkage analysis. Experiment-wide alpha = 0.05 significance thresholds were established by permutation testing. Three quantitative trait loci (QTLs) identified in these studies illustrate the advantages of with LOD scores as large as 17.5, encompassing size, cross-sectional ellipticity, stiffness, yield and failure load, and bone mineral density. This locus was linked to 3 of the PCs but unlinked to any of the tissue level phenotypes. From this pattern, we infer that the QTL operates by modulating the proliferative response to mechanical loading. On this basis, we successfully predicted that this locus also affects the length of a specific region of the mandible. A pleiotropic locus on chromosome 10 with LOD scores displays opposite effects on failure load and toughness with LOD scores of 4.5 and 5.5, respectively, so that the allele that increases failure load decreases toughness. A chromosome 19 QTL for PC2 with an LOD score of 4.8 was not detected with either the whole bone or tissue level phenotypes. We conclude that first, comprehensive, system-oriented phenotyping provides much information that could not be obtained by focusing on bone mineral density alone. Second, mechanical performance includes inherent trade-offs between strength and brittleness. Third, considering the aggregate phenotypic data allows prediction of novel QTLs. Copyright (C) 2011 S. Karger AG, Basel C1 [Saless, Neema; Litscher, Suzanne J.; Houlihan, Meghan J.; Han, In Kyu; Wilson, Derek; Blank, Robert D.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Saless, Neema; Litscher, Suzanne J.; Houlihan, Meghan J.; Han, In Kyu; Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Wilson, Derek] Ft Valley State Univ, Ft Valley, GA USA. [Demant, Peter] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. RP Blank, RD (reprint author), Univ Wisconsin, Dept Med, 4142 MFCB 5148,1685 Highland Ave, Madison, WI 53705 USA. EM rdb@medicine.wisc.edu OI Blank, Robert Daniel/0000-0003-2950-1944 FU Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs; NIH [R01 AR054753] FX This material is based on work supported by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs (R.D.B.), and this work was performed in part at the Geriatrics Research, Education, and Clinical Center of the William S. Middleton Memorial Veterans Hospital. This is Madison GRECC manuscript 10-23. This study was also supported by NIH R01 AR054753 (R.D.B.). NR 14 TC 9 Z9 9 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1422-6405 J9 CELLS TISSUES ORGANS JI Cells Tissues Organs PY 2011 VL 194 IS 2-4 BP 244 EP 248 DI 10.1159/000324774 PG 5 WC Anatomy & Morphology; Cell Biology; Developmental Biology SC Anatomy & Morphology; Cell Biology; Developmental Biology GA 806VH UT WOS:000293842500029 PM 21625064 ER PT J AU Ahmad, A Khundmiri, SJ Pribble, F Merchant, ML Ameen, M Klein, JB Levi, M Lederer, ED AF Ahmad, Aamir Khundmiri, Syed J. Pribble, Francesca Merchant, Michael L. Ameen, Mohammed Klein, Jon B. Levi, Moshe Lederer, Eleanor D. TI Role of Vacuolar ATPase in the Trafficking of Renal Type IIa Sodium-phosphate Cotransporter SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY LA English DT Article DE NpT2a; Opossum Kidney (OK) cells; Lysosomal degradation; PTH; Low Pi medium; Brefeldin A ID NA/P-I COTRANSPORTER; PARATHYROID-HORMONE; H+-ATPASE; PROXIMAL TUBULES; EPITHELIAL-CELLS; KIDNEY-CELLS; K ATPASE; V-ATPASE; EXPRESSION; PROTEIN AB Background/Aims: Total body phosphate homeostasis is regulated by expression of type IIa sodium phosphate cotransporter (NpT2a) in the apical membrane (BBM) of renal proximal tubule cells. NpT2a expression is regulated by dietary phosphate and PTH but the mechanisms for trafficking of the protein are unknown. Based on 2D gel electrophoresis and mass spectroscopy data that changes in dietary phosphate stimulated changes in BBM expression of vacuolar H(+)-ATPase, we hypothesized that vacuolar H(+)-ATPase plays a significant role in regulation of NpT2a in opossum kidney (OK) cells, a model for renal proximal tubule transport. Methods: Role of vacuolar H(+)-ATPase was studied in opossum kidney (OK) cells by examining the effect of inhibition of vacuolar H(+)-ATPase on Pi uptake and NpT2a expression. Results: Pretreatment of OK cells with bafilomycin A 1 and concanamycin A, inhibitors of vacuolar H(+)-ATPases, blocked high phosphate-and PTH-induced degradation of NpT2a, but had no effect on high phosphate or PTH induced inhibition of sodium-dependent phosphate transport. Exposure of the cells to bafilomycin A 1 significantly decreased phosphate transport and apical membrane expression of NpT2a. Treatment with brefeldin A, an inhibitor of Golgi transport, decreased phosphate transport and apical membrane expression of NpT2a while treatment of cells with both brefeldin A and bafilomycin A 1 had no additive effect. Conclusion: We conclude that vacuolar H(+)-ATPase plays a significant role in exocytosis of NpT2a into the apical membrane and in degradation of NpT2a but has no role in endocytosis. Copyright (C) 2011 S. Karger AG, Basel C1 [Lederer, Eleanor D.] Univ Louisville, Kidney Dis Program, Dept Med, Louisville, KY 40202 USA. [Khundmiri, Syed J.; Lederer, Eleanor D.] Univ Louisville, Dept Physiol, Louisville, KY 40202 USA. [Klein, Jon B.; Lederer, Eleanor D.] Louisville Vet Affairs Hosp, Louisville, KY USA. [Levi, Moshe] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Levi, Moshe] Univ Colorado, Hlth Sci Ctr, Dept Physiol, Denver, CO 80262 USA. [Levi, Moshe] Denver Vet Affairs Hosp, Denver, CO USA. [Levi, Moshe] Univ Colorado, Hlth Sci Ctr, Dept Biophys, Denver, CO USA. RP Lederer, ED (reprint author), Univ Louisville, Kidney Dis Program, Dept Med, Baxter Res Bldg,102 570 S Preston St, Louisville, KY 40202 USA. EM e.lederer@louisville.edu RI Klein, Jon/B-9833-2013; Merchant, Michael/F-7109-2013 OI Levi, Moshe/0000-0002-6225-946X; Ahmad, Aamir/0000-0003-1784-5723 FU Veteran Affairs; NIH [1 R01 DK066029]; American Heart Association [0435153N, 0120318B] FX "The opinions expressed in this manuscript do not reflect the opinions of the Department of Veteran Affairs". The authors thank Nina Lesousky for expert technical assistance. The work was supported by Veteran Affairs Merit Review grant (EDL and JBK), NIH 1 R01 DK066029 to ML, and Scientist Development Grant from American Heart Association (National, 0435153N) and American Heart Association, Ohio Valley Affiliate, postdoctoral fellowship grant (0120318B) to SJK. NR 29 TC 6 Z9 6 U1 0 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-8987 J9 CELL PHYSIOL BIOCHEM JI Cell. Physiol. Biochem. PY 2011 VL 27 IS 6 BP 703 EP 714 DI 10.1159/000330079 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 779CX UT WOS:000291756800009 PM 21691088 ER PT J AU Funkhouser, E Houston, TK Levine, DA Richman, J Allison, JJ Kiefe, CI AF Funkhouser, Ellen Houston, Thomas K. Levine, Deborah A. Richman, Joshua Allison, Jeroan J. Kiefe, Catarina I. TI Physician and Patient Influences on Provider Performance beta-Blockers in Postmyocardial Infarction Management in the MI-Plus Study SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE myocardial infarction; beta-blockers; provider performance ID ACUTE MYOCARDIAL-INFARCTION; TRANSIENT ISCHEMIC ATTACK; HEALTH-CARE; SECONDARY PREVENTION; CLINICAL-EXPERIENCE; RANDOMIZED TRIAL; ELDERLY-PATIENTS; KIDNEY-DISEASE; QUALITY; GUIDELINES AB Background-Efforts to improve the quality of care for patients with cardiovascular disease frequently target the decrease of physician-level performance variability. We assessed how variability in providing beta-blockers to ambulatory postmyocardial infarction (MI) patients was influenced by physician and patient level characteristics. Methods and Results-beta-Blocker prescription and patient characteristics were abstracted from charts of post-MI patients treated by 133 primary care physicians between 2003 and 2007 and linked to physician and practice characteristics. Associations of beta-blocker prescription with physician-and patient-level characteristics were examined using mixed-effects models, with physician-level effects as random. Mean physician-specific predicted probabilities and the intraclass correlations, which assessed the proportion of variance explainable at the physician level, were estimated. Of 1901 patients without major contraindication, 69.1% (range across physicians, 20% to 100%) were prescribed beta-blockers. Prescription varied with comorbidity from 78.3% in patients with chronic kidney disease to 54.7% for patients with stroke. Although physician characteristics such as older physician age, group practice, and rural location were each positively associated with beta-blocker prescription, physician factors accounted for only 5% to 8% of the variance in beta-blocker prescription; the preponderance of the variance, 92% to 95%, was at the patient level. The mean physician-specific probability of beta-blocker prescription (95% confidence interval) in the fully adjusted model was 63% (61% to 65%). Conclusions-beta-Blocker prescription rates were surprisingly low. The contribution of physician factors to overall variability in beta-blocker prescription, however, was limited. Increasing evidence-based use of beta-blockers may not be accomplished by focusing mostly on differential performance across physicians. (Circ Cardiovasc Qual Outcomes. 2011;4:99-106.) C1 [Funkhouser, Ellen; Richman, Joshua] Birmingham VA Med Ctr, VA Res Enhancement Award Program, Birmingham, AL USA. [Funkhouser, Ellen; Levine, Deborah A.; Richman, Joshua] Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA. [Funkhouser, Ellen; Richman, Joshua] Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. [Houston, Thomas K.; Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Levine, Deborah A.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Levine, Deborah A.] Univ Michigan, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. RP Funkhouser, E (reprint author), UAB, SOM, Div Prevent Med, 1717 11th Ave S,611 MT, Birmingham, AL 35205 USA. EM emfunk@uab.edu RI Houston, Thomas/F-2469-2013 FU Centers for Medicare and Medicaid Services, Department of Health Human Services [500-02-AL02]; National Heart, Lung, and Blood Institute [R01 HL70786]; VA Health Services Research and Development [SDR 03-090-1] FX We greatly appreciate the contributions of the Division of Continuing Medical Education at the University of Alabama at Birmingham and Periyakaruppan Krishnamoorthy, whose expertise in computer programming and website development facilitated the completion of this project. The analyses on which this publication is based were performed under Contract No. 500-02-AL02, entitled "Utilization and Quality Control Peer Review Organization for the State (Commonwealth) of Alabama," sponsored by the Centers for Medicare and Medicaid Services, Department of Health & Human Services.; This project was funded in part by grant NR 39 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2011 VL 4 IS 1 BP 99 EP 106 DI 10.1161/CIRCOUTCOMES.110.942318 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 707TS UT WOS:000286311700017 PM 21139090 ER PT J AU Alexander, KP Wang, TY Li, SA Lytle, BL Slattery, LE Calhoun, S Poteat, J Roe, MT Rumsfeld, JS Cannon, CP Peterson, ED AF Alexander, Karen P. Wang, Tracy Y. Li, Shuang Lytle, Barbara L. Slattery, Lara E. Calhoun, Sarah Poteat, Jennifer Roe, Matthew T. Rumsfeld, John S. Cannon, Christopher P. Peterson, Eric D. TI Randomized Trial of Targeted Performance Feedback to Facilitate Quality Improvement in Acute Myocardial Infarction Care SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE randomized controlled trials; quality improvement; acute myocardial infarction ID ACUTE CORONARY SYNDROMES; OF-CARE; OUTCOMES; INTERVENTION; ASSOCIATION; GUIDELINES; LESSONS; SURGERY AB Background-Efforts to improve quality of care for patients with acute myocardial infarction (AMI) are a national priority. To date, there have been few studies that have prospectively evaluated hospital quality improvement (QI) interventions. Methods and Results-Using hospitals in the National Cardiovascular Data Registry (NCDR) ACTION Registry-GWTG, a cluster randomized trial of the effectiveness of targeted performance feedback to facilitate process improvement for AMI care will be conducted. ACTION Registry-GWTG hospitals with a minimum of 50 AMI patients per 2 quarters are eligible for randomization. The control arm receives standard performance feedback reports, and the intervention arm receives standard performance feedback reports in addition to a supplemental report on the "top 3" centrally identified, hospital-specific performance gaps. The primary outcome will be improvement in a composite of all metrics, and the secondary outcome will be improvement in the targeted metrics. At study inception in January 2009, 149 sites were randomized: 76 to the intervention arm, and 73 to the control arm. Intervention and control sites were well balanced in terms of baseline performance, center characteristics, and AMI volume (approximate to 70 patients per quarter). The intervention phase will continue for 5 feedback cycles, each containing 2 quarters of data feedback over 18 months. A final trial outcome report will follow. Conclusions-This randomized trial will evaluate a novel hospital-level QI intervention of targeted performance feedback for AMI, thereby demonstrating the effective use of national registries for QI and furthering our understanding of effective QI methods. C1 [Alexander, Karen P.; Wang, Tracy Y.; Li, Shuang; Lytle, Barbara L.; Calhoun, Sarah; Poteat, Jennifer; Roe, Matthew T.; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA. [Alexander, Karen P.; Wang, Tracy Y.; Roe, Matthew T.; Peterson, Eric D.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Slattery, Lara E.] Amer Coll Cardiol, Washington, DC USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Cannon, Christopher P.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Alexander, KP (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Box 3411, Durham, NC 27710 USA. EM karen.alexander@duke.edu FU Agency for Healthcare Research and Quality [U18HS010548]; Society of Chest Pain Centers; Society of Hospital Medicine; American College of Emergency Physicians; Bristol-Myers Squibb/Sanofi Pharmaceuticals; Bristol Myers Squibb; Daiichi Pharmaceuticals; Heartscape Technologies; Johnson Johnson; Lilly; Sanofi-Aventis; Schering Plough Corporation; Medicines Company; Eli Lilly Co; Acumetrics; AstraZeneca; GlaxoSmithKline; Intekrin Therapeutis; Merck; Takeda; Bristol-Myers Squibb/Sanofi; Novartis; Alnylam; American College of Cardiology; Society of Thoracic Surgeons; American Heart Association FX This project was supported by grant number U18HS010548 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors, and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from Society of Chest Pain Centers, The Society of Hospital Medicine, and The American College of Emergency Physicians. The registry is sponsored by Bristol-Myers Squibb/Sanofi Pharmaceuticals.; Dr Wang received research grants from Bristol Myers Squibb, Daiichi Pharmaceuticals, Heartscape Technologies, Johnson & Johnson, Lilly, Sanofi-Aventis, Schering Plough Corporation, and The Medicines Company; education activities or lectures include Heartscape Technologies. Dr Roe received research grants from Bristol Myers Squibb, Eli Lilly & Co, Sanofi-Aventis, and Schering-Plough Corporation; consulting includes AstraZeneca, Bristol Myers Squibb, Eli Lilly & Company, Glaxo SmithKline, Merck & Co, Novartis Pharmaceutical Company, Sanofi-Aventis, and Schering-Plough Corporation. Dr Rumsfeld is Chief Science Officer for the National Cardiovascular Data Registry (NCDR). Dr Cannon received research grants from Acumetrics, AstraZeneca, GlaxoSmithKline, Intekrin Therapeutis, Merck, and Takeda; advisory board (but funds donated to charity) includes Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; honorarium for development of independent educational symposia includes Pfizer and AstraZeneca; clinical advisor and equity in Automedics Medical Systems. Dr Peterson received research grants from the American College of Cardiology, Bristol Myers Squibb, Eli Lilly & Company, Johnson & Johnson, Merck & Co, Sanofi-Aventis, Schering-Plough Corporation, the Society of Thoracic Surgeons, and the American Heart Association; consulting includes Bristol Myers Squibb, Merck & Co, and Tethysbio, Astra Zeneca. NR 23 TC 4 Z9 4 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2011 VL 4 IS 1 BP 129 EP 135 DI 10.1161/CIRCOUTCOMES.110.958470 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 707TS UT WOS:000286311700021 PM 21245461 ER PT J AU Komajda, M Carson, PE Hetzel, S McKelvie, R McMurray, J Ptaszynska, A Zile, MR DeMets, D Massie, BM AF Komajda, Michel Carson, Peter E. Hetzel, Scott McKelvie, Robert McMurray, John Ptaszynska, Agata Zile, Michael R. DeMets, David Massie, Barry M. TI Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; preserved ejection fraction; outcome; prognosis evaluation ID OBSTRUCTIVE PULMONARY-DISEASE; CONVERTING ENZYME-INHIBITORS; SYSTOLIC FUNCTION; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; RISK-FACTOR; MORTALITY; DYSFUNCTION; PREDICTION; HOSPITALIZATIONS AB Background-The determinants of prognosis in patients with heart failure and preserved ejection fraction (HF-PEF) are poorly documented. Methods and Results-We evaluated data from 4128 patients in the I-PRESERVE trial (Irbesartan in Heart Failure with Preserved Ejection Fraction Study). Multivariable Cox regression models were developed using 58 baseline demographic, clinical, and biological variables to model the primary outcome of all-cause mortality or cardiovascular hospitalization (1505 events), all-cause mortality (881 events), and HF death or hospitalization (716 events). Log N-terminal pro-B-type natriuretic peptide, age, diabetes mellitus, and previous hospitalization for HF were the most powerful factors associated with the primary outcome and with the HF composite. For all-cause mortality, log N-terminal pro-B-type natriuretic peptide, age, diabetes mellitus, and left ventricular EF were the strongest independent factors. Other independent factors associated with poor outcome included quality of life, a history of chronic obstructive lung disease, log neutrophil count, heart rate, and estimated glomerular filtration rate. The models accurately stratified the actual 3-year rate of outcomes from 8.1% to 59.9% (primary outcome) 2.7% to 36.5% (all-cause mortality), and 2.1% to 38.9% (HF composite) for the lowest to highest septiles of predicted risks. Conclusions-In a large sample of elderly patients with HF and preserved EF enrolled in I-Preserve, simple clinical, demographic, and biological variables were associated with outcome and identified subgroups at very high and very low risk of events. C1 [Komajda, Michel] Univ Paris 06, Pitie Salpetriere Hosp, Paris, France. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Hetzel, Scott; DeMets, David] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada. [McMurray, John] Univ Glasgow, British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Ptaszynska, Agata] Bristol Myers Squibb Co, Princeton, NJ USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael R.] Vet Affairs Med Ctr, RHJ Dept, Charleston, SC 29403 USA. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Komajda, M (reprint author), CHU Pitie Salpetriere, Inst Cardiol, 47-83 Blvd Hop, F-75013 Paris, France. EM michel.komajda@psl.aphp.fr FU Bristol-Myers-Squibb; SanofiAventis FX Drs Komajda, Carson, McKelvie, Zile, and Massie received consulting fees from Bristol-Myers-Squibb as Executive Committee Members of the I-PRESERVE trial. Dr McMurray received support from Bristol-Myers-Squibb to Glasgow University. Scott Hetzel and Dr DeMets are employed by the Statistical Data Analysis Center at the University of Wisconsin-Madison, which conducted statistical analysis for the study supported by Bristol-Myers-Squibb and SanofiAventis. Dr Ptaszynska is an employee of and has an equity interest in Bristol-Myers-Squibb. NR 40 TC 95 Z9 97 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2011 VL 4 IS 1 BP 27 EP U73 DI 10.1161/CIRCHEARTFAILURE.109.932996 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 707UC UT WOS:000286312900009 PM 21068341 ER PT J AU Mallone, R Mannering, SI Brooks-Worrell, BM Durinovic-Bello, I Cilio, CM Wong, FS Schloot, NC AF Mallone, R. Mannering, S. I. Brooks-Worrell, B. M. Durinovic-Bello, I. Cilio, C. M. Wong, F. S. Schloot, N. C. CA Immunology Diabet Soc T Cell Works TI Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Review DE ELISPOT; freezing; shipping; T cell; tetramer ID LEPTIN RECEPTOR MUTATION; WHOLE-BLOOD; AUTOIMMUNE ENCEPHALOMYELITIS; LYMPHOCYTE IMMUNOPHENOTYPE; ACETYLCHOLINE-RECEPTOR; CYTOKINE PRODUCTION; ELISPOT DETECTION; OXIDATIVE STRESS; CLINICAL-TRIALS; FLOW-CYTOMETRY AB P>Autoimmune T cell responses directed against insulin-producing beta cells are central to the pathogenesis of type 1 diabetes (T1D). Detection of such responses is therefore critical to provide novel biomarkers for T1D 'immune staging' and to understand the mechanisms underlying the disease. While different T cell assays are being developed for these purposes, it is important to optimize and standardize methods for processing human blood samples for these assays. To this end, we review data relevant to critical parameters in peripheral blood mononuclear cell (PBMC) isolation, (cryo)preservation, distribution and usage for detecting antigen-specific T cell responses. Based on these data, we propose recommendations on processing blood samples for T cell assays and identify gaps in knowledge that need to be addressed. These recommendations may be relevant not only for the analysis of T cell responses in autoimmune disease, but also in cancer and infectious disease, particularly in the context of clinical trials. C1 [Mallone, R.] Hop St Vincent de Paul, DeAR Lab Avenir, INSERM, U986, F-75674 Paris 14, France. [Mannering, S. I.] Univ Melbourne, St Vincents Inst Med Res, Dept Med, St Vincents Hosp, Fitzroy, Vic 3065, Australia. [Brooks-Worrell, B. M.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Washington, DC USA. [Durinovic-Bello, I.] Benaroya Res Inst, Seattle, WA USA. [Cilio, C. M.] Lund Univ, Dept Clin Sci, Cellular Autoimmun Unit, Malmo, Sweden. [Wong, F. S.] Cardiff Univ, Ctr Endocrine & Diabet Sci, Cardiff, S Glam, Wales. [Schloot, N. C.] Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Inst Diabet Res,Dept Metab Dis,Univ Hosp, Dusseldorf, Germany. RP Mallone, R (reprint author), Hop St Vincent de Paul, DeAR Lab Avenir, INSERM, U986, 82 Ave Denfert Rochereau, F-75674 Paris 14, France. EM roberto.mallone@inserm.fr RI Mallone, Roberto/H-4430-2013 FU Juvenile Diabetes Research Foundation (JDRF) [5-2009-413] FX The T-Cell Workshop Committee of the Immunology of Diabetes Society is supported generously by the Juvenile Diabetes Research Foundation (JDRF grant no. 5-2009-413). We wish to thank L. C. Harrison, T. Delovitch, G. T. Nepom and B. O. Roep for critical review of the manuscript. NR 72 TC 82 Z9 84 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9104 EI 1365-2249 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD JAN PY 2011 VL 163 IS 1 BP 33 EP 49 DI 10.1111/j.1365-2249.2010.04272.x PG 17 WC Immunology SC Immunology GA 688LW UT WOS:000284851800005 PM 20939860 ER PT J AU Gordon, SN Fitzpatrick, PJ Hilsabeck, RC AF Gordon, Shalanda N. Fitzpatrick, Pamela J. Hilsabeck, Robin C. TI No Effect of PTSD and Other Psychiatric Disorders on Cognitive Functioning in Veterans With Mild TBI SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Mild traumatic brain injury; mTBI; Post-traumatic stress disorder; PTSD; Cognitive functioning ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; VIETNAM VETERANS; PROCESSING SPEED; TEST-PERFORMANCE; IRAQ-WAR; ATTENTION; SEQUELAE AB There has been speculation that post-traumatic stress disorder (PTSD) superimposed on mild traumatic brain injury (mTBI) may have synergistic, negative effects on cognitive functioning. The purpose of this study was to investigate differences in processing speed, executive functioning, and memory of 82 veterans with mTBI and PTSD, mTBI, and another psychiatric condition, or mTBI alone. It was hypothesized that there would be no group differences in cognitive performances. Participants completed the Trail Making Test, Stroop, Rey Complex Figure, and California Verbal Learning Test-2. There were no significant group differences on any cognitive measure. Findings suggest that PTSD and other psychiatric disorders do not necessarily have a negative exacerbating effect on processing speed, executive functioning, or memory in veterans with mTBI. C1 [Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Calif San Diego, San Diego, CA 92103 USA. [Gordon, Shalanda N.] Cent Texas Vet Hlth Care Syst, Temple, TX USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Hilsabeck@uthscsa.edu RI Schueter, nicos/A-3625-2014 NR 52 TC 16 Z9 16 U1 1 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2011 VL 25 IS 3 BP 337 EP 347 AR PII 934025482 DI 10.1080/13854046.2010.550634 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 751RU UT WOS:000289636100001 PM 21360415 ER PT J AU Pella, RD Fallows, RR Hilsabeck, RC AF Pella, Russell D. Fallows, Robert R. Hilsabeck, Robin C. TI Casebook of clinical neuropsychology. SO CLINICAL NEUROPSYCHOLOGIST LA English DT Book Review C1 [Pella, Russell D.; Fallows, Robert R.; Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Pella, RD (reprint author), S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM rpella1@lsu.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2011 VL 25 IS 5 BP 843 EP 845 DI 10.1080/13854046.2011.586597 PG 3 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 882JE UT WOS:000299559000010 ER PT J AU Hilsabeck, RC Gordon, SN Hietpas-Wilson, T Zartman, AL AF Hilsabeck, Robin C. Gordon, Shalanda N. Hietpas-Wilson, Tammy Zartman, Andrea L. TI Use of Trial 1 of the Test of Memory Malingering (TOMM) as a Screening Measure of Effort: Suggested Discontinuation Rules SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Malingering; Effort; Discontinuation rules; Test of Memory Malingering; TOMM; Cognitive disorders ID BASE RATES; CLINICAL NEUROPSYCHOLOGY; INSUFFICIENT EFFORT; RESPONSE BIAS; UNITED-STATES; PERFORMANCE; NAN AB Trial 1 of the Test of Memory Malingering (TOMM) has been suggested as a screening tool, with several possible cut-off scores proposed. The purpose of the present study was to replicate the utility of previously suggested cut-off scores and to characterize neuropsychological profiles of persons who "pass'' the TOMM but obtain Trial 1 scores <45 and of persons with cognitive disorders. A total of 229 veterans were administered the TOMM as part of a neuropsychological evaluation. Trial 1 scores >= 41 and <= 25 showed good utility as discontinuation scores for adequate and poor effort, respectively, beyond which administration of additional trials were unnecessary. Findings suggest better Trial 1 performance is significantly related to better speeded mental flexibility and memory. C1 [Hilsabeck, Robin C.; Gordon, Shalanda N.; Hietpas-Wilson, Tammy; Zartman, Andrea L.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Gordon, Shalanda N.] Cent Texas Vet Hlth Care Syst, Psychol Serv, Austin, TX USA. [Zartman, Andrea L.] Vet Affairs N Texas Hlth Care Syst, Psychol Serv, Dallas, TX USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Hilsabeck@uthscsa.edu NR 26 TC 10 Z9 10 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2011 VL 25 IS 7 BP 1228 EP 1238 DI 10.1080/13854046.2011.589409 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 882JJ UT WOS:000299559600009 PM 21846261 ER PT J AU Goudreau, KA AF Goudreau, Kelly A. TI LACE, APRN Consensus ... and WIIFM (What's in It for Me)? SO CLINICAL NURSE SPECIALIST LA English DT Editorial Material C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Goudreau, KA (reprint author), Portland VA Med Ctr, P2EDUC,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kagoudreau@hotmail.com NR 1 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD JAN-FEB PY 2011 VL 25 IS 1 BP 5 EP 7 DI 10.1097/NUR.0b013e3182036221 PG 3 WC Nursing SC Nursing GA 691NF UT WOS:000285087300002 PM 21139459 ER PT J AU Nakano, V Silva, ADE Merino, VRC Wexler, HM Avila-Campos, MJ AF Nakano, Viviane do Nascimento e Silva, Amanda Castillo Merino, Victor Rafael Wexler, Hannah M. Avila-Campos, Mario Julio TI Antimicrobial resistance and prevalence of resistance genes in intestinal Bacteroidales strains SO CLINICS LA English DT Article DE Bacteroides spp.; Parabacteroides distasonis; beta-lactamase activity; Antimicrobial resistance; Resistance genes ID IN-VITRO ACTIVITY; ANAEROBIC-BACTERIA; CARBAPENEM RESISTANCE; INSERTION-SEQUENCE; MULTICENTER SURVEY; CLINICAL ISOLATE; FRAGILIS GROUP; SUSCEPTIBILITY; DETERMINANTS; INFECTIONS AB OBJECTIVE: This study examined the antimicrobial resistance profile and the prevalence of resistance genes in Bacteroides spp. and Parabacteroides distasonis strains isolated from children's intestinal microbiota. METHODS: The susceptibility of these bacteria to 10 antimicrobials was determined using an agar dilution method. beta-lactamase activity was assessed by hydrolysis of the chromogenic cephalosporin of 114 Bacteriodales strains isolated from the fecal samples of 39 children, and the presence of resistance genes was tested using a PCR assay. RESULTS: All strains were susceptible to imipenem and metronidazole. The following resistance rates were observed: amoxicillin (93%), amoxicillin/clavulanic acid (47.3%), ampicillin (96.4%), cephalexin (99%), cefoxitin (23%), penicillin (99%), clindamycin (34.2%) and tetracycline (53.5%). beta-lactamase production was verified in 92% of the evaluated strains. The presence of the cfiA, cepA, ermF, tetQ and nim genes was observed in 62.3%, 76.3%, 27%, 79.8% and 7.8% of the strains, respectively. CONCLUSIONS: Our results indicate an increase in the resistance to several antibiotics in intestinal Bacteroides spp. and Parabacteroides distasonis and demonstrate that these microorganisms harbor antimicrobial resistance genes that may be transferred to other susceptible intestinal strains. C1 [Nakano, Viviane; do Nascimento e Silva, Amanda; Castillo Merino, Victor Rafael; Avila-Campos, Mario Julio] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Anaerobe Lab, Sao Paulo, Brazil. [Wexler, Hannah M.] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. [Wexler, Hannah M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Nakano, V (reprint author), Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Anaerobe Lab, Sao Paulo, Brazil. EM vivinkn@usp.br RI Nakano, Viviane/D-7955-2012; Avila-Campos, Mario/D-7727-2012 OI Avila-Campos, Mario/0000-0002-2378-7251 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [08/57330-4, 09/03792-0] FX The authors thank Mrs. Zulmira Alves de Souza for her technical support. This study was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP Grant 08/57330-4 and 09/03792-0). NR 31 TC 17 Z9 17 U1 3 U2 11 PU HOSPITAL CLINICAS, UNIV SAO PAULO PI SAO PAULO PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL SN 1807-5932 J9 CLINICS JI Clinics PY 2011 VL 66 IS 4 BP 543 EP 547 DI 10.1590/S1807-59322011000400004 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 773MT UT WOS:000291312100004 PM 21655744 ER PT J AU Kasckow, J Felmet, K Zisook, S AF Kasckow, John Felmet, Kandi Zisook, Sidney TI Managing Suicide Risk in Patients with Schizophrenia SO CNS DRUGS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-INPATIENTS; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; DEPRESSIVE SYMPTOMS; CLOZAPINE TREATMENT; ANTIPSYCHOTIC MEDICATION; RESISTANT SCHIZOPHRENIA; PSYCHOLOGICAL AUTOPSY; COMPLETED SUICIDE AB The management of suicide risk in patients with schizophrenia poses many challenges for clinicians. Compared with the general population, these patients have an 8.5-fold greater risk of suicide. This article reviews the literature dealing with the treatment of at-risk patients with schizophrenia. An integrated psychosocial and pharmacological approach to managing this population of patients is recommended. Although there is at least modest evidence suggesting that antipsychotic medications protect against suicidal risk, the evidence appears to be most favourable for second-generation anti-psychotics, particularly clozapine, which is the only medication approved by the US FDA for preventing suicide in patients with schizophrenia. In addition, treating depressive symptoms in patients with schizophrenia is an important component of suicide risk reduction. While selective serotonin receptor inhibitors (SSRIs) ameliorate depressive symptoms in patients with schizophrenia, they also appear to attenuate suicidal thoughts. Further research is needed to more effectively personalize the treatment of suicidal thoughts and behaviours and the prevention of suicide in patients with schizophrenia. C1 [Kasckow, John; Felmet, Kandi] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA 15206 USA. [Kasckow, John; Felmet, Kandi] VA Pittsburgh Hlth Care Syst, Behav Hlth Serv, Pittsburgh, PA 15206 USA. [Kasckow, John] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. [Zisook, Sidney] VA San Diego Hlth Care Syst, San Diego, CA USA. [Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, MIRECC, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu FU VISN 4 CPPF; American Foundation for Suicide Prevention; VISN 4 and VISN 22 MIRECC; University of California, San Diego Center for Community; Aspect Medical and PamLab; Forest; AstraZeneca; Bristol Meyers Squibb; Pfizer; Johnson Johnson; Solvay; Eli Lilly; [MH6398] FX Supported by MH6398 (SZ, JK), a VISN 4 CPPF grant (JK) and a grant from the American Foundation for Suicide Prevention (JK), the VISN 4 and VISN 22 MIRECC and the University of California, San Diego Center for Community-Based Research in Older People with Psychoses. The contents do not represent the views of the Department of Veterans Affairs of the US government.; Sidney Zisook, MD, has received research support from Aspect Medical and PamLab and speaker's honoraria from Forest Pharmaceuticals, Inc. and GlaxoSmithKline. John Kasckow, MD, PhD, has received grant support as well as honoraria for speaking and consultation from Forest, AstraZeneca, Bristol Meyers Squibb, Pfizer, Johnson & Johnson, Solvay and Eli Lilly. Ms Felmet has no conflicts of interest to declare. NR 134 TC 31 Z9 33 U1 4 U2 13 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PY 2011 VL 25 IS 2 BP 129 EP 143 DI 10.2165/11586450-000000000-00000 PG 15 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 724DS UT WOS:000287556900003 PM 21254789 ER PT J AU Matthews, AM Wilson, VB Mitchell, SH AF Matthews, Annette M. Wilson, Vanessa B. Mitchell, Suzanne H. TI The Role of Antipsychotics in Smoking and Smoking Cessation SO CNS DRUGS LA English DT Review ID NICOTINE REPLACEMENT THERAPY; PLACEBO-CONTROLLED TRIAL; CHRONIC-SCHIZOPHRENIA; CIGARETTE-SMOKING; SUBSTANCE-ABUSE; DOUBLE-BLIND; COCAINE DEPENDENCE; REDUCES SMOKING; CLOZAPINE; SMOKERS AB Persons with severe and persistent mental illnesses, e.g. schizophrenia spectrum disorders and bipolar disorder, smoke at a much higher rate than the general population. Treatment options for schizophrenia spectrum disorders and bipolar disorder often include the first-generation (typical) and second-generation (atypical) antipsychotics, which have been shown to be effective in treating both psychotic and mood symptoms. This article reviews studies examining the relationship between antipsychotic medication and cigarette smoking. These studies suggest that in persons with schizophrenia and schizoaffective disorder, typical antipsychotics may increase basal smoking and decrease people's ability to stop smoking, whereas atypical antipsychotics decrease basal smoking and promote smoking cessation. However, we found that the data available were generally of moderate quality and from small studies, and that there were conflicting findings. The review also critically assesses a number of potential mechanisms for this effect: the use of smoking as a form of self-medication for the side effects of antipsychotics, the effect of antipsychotics on smoking-related cues and the effect of antipsychotics on the appreciation of the economic cost of smoking behaviour. Gaps in the research are noted and recommendations for further study are included. More study of this important issue is needed to clarify the effect of antipsychotics on smoking behaviours. C1 [Matthews, Annette M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Matthews, Annette M.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Matthews, Annette M.; Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Wilson, Vanessa B.; Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Matthews, AM (reprint author), Portland VA Med Ctr P3 MHDC, 3710 SW US Vet Hosp Rd,POB 1035, Portland, OR 97207 USA. EM Annette.Matthews@va.gov OI Mitchell, Suzanne/0000-0002-0225-7200 FU Veterans Affairs Career Developmant Award; National Institutes of Health [DA0145543, DA024195] FX This work was done as part of a Veterans Affairs Career Developmant Award (A.M. Matthews) and National Institutes of Health grants DA0145543 and DA024195 (S.H. Mitchell). The funding sources did not influence the content of the text. The authors report no conflicts of interest. The authors would like to thank Andrew Hamilton and Sharon Medley for help obtaining the reviewed material. NR 69 TC 15 Z9 15 U1 1 U2 14 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1172-7047 EI 1179-1934 J9 CNS DRUGS JI CNS Drugs PY 2011 VL 25 IS 4 BP 299 EP 315 PG 17 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 750GT UT WOS:000289535300003 PM 21425883 ER PT J AU Singh, JA Wells, GA Christensen, R Ghogomu, ET Maxwell, L MacDonald, JK Filippini, G Skoetz, N Francis, D Lopes, LC Guyatt, GH Schmitt, J La Mantia, L Weberschock, T Roos, JF Siebert, H Hershan, S Lunn, MPT Tugwell, P Buchbinder, R AF Singh, J. A. Wells, G. A. Christensen, R. Ghogomu, Tanjong E. Maxwell, L. MacDonald, J. K. Filippini, G. Skoetz, N. Francis, D. Lopes, L. C. Guyatt, G. H. Schmitt, J. La Mantia, L. Weberschock, T. Roos, J. F. Siebert, H. Hershan, S. Lunn, M. P. T. Tugwell, P. Buchbinder, R. TI Adverse effects of biologics: a network meta-analysis and Cochrane overview SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID ACTIVE RHEUMATOID-ARTHRITIS; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; INTERLEUKIN-1 RECEPTOR ANTAGONIST; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; PATIENT-REPORTED OUTCOMES; RECEIVING CONCOMITANT METHOTREXATE AB Background Biologics are used for the treatment of rheumatoid arthritis and many other conditions. While the efficacy of biologics has been established, there is uncertainty regarding the adverse effects of this treatment. Since serious risks such as tuberculosis (TB) reactivation, serious infections, and lymphomas may be common to the biologics but occur in small numbers across the various indications, we planned to combine the results from biologics used in many conditions to obtain the much needed risk estimates. Objectives To compare the adverse effects of tumor necrosis factor blocker (etanercept, adalimumab, infliximab, golimumab, certolizumab), interleukin (IL)-1 antagonist (anakinra), IL-6 antagonist (tocilizumab), anti-CD28 (abatacept), and anti-B cell (rituximab) therapy in patients with any disease condition except human immunodeficiency disease (HIV/AIDS). Methods Randomized controlled trials (RCTs), controlled clinical trials (CCTs) and open-label extension (OLE) studies that studied one of the nine biologics for use in any indication (with the exception of HIV/AIDS) and that reported our pre-specified adverse outcomes were considered for inclusion. We searched The Cochrane Library, MEDLINE, and EMBASE (to January 2010). Identifying search results and data extraction were performed independently and in duplicate. For the network meta-analysis, we performed mixed-effects logistic regression using an arm-based, random-effects model within an empirical Bayes framework. Main results We included 163 RCTs with 50,010 participants and 46 extension studies with 11,954 participants. The median duration of RCTs was six months and 13 months for OLEs. Data were limited for tuberculosis (TB) reactivation, lymphoma, and congestive heart failure. Adjusted for dose, biologics as a group were associated with a statistically significant higher rate of total adverse events (odds ratio (OR) 1.19, 95% CI 1.09 to 1.30; number needed to treat to harm (NNTH) = 30, 95% CI 21 to 60) and withdrawals due to adverse events (OR 1.32, 95% CI 1.06 to 1.64; NNTH = 37, 95% CI 19 to 190) and an increased risk of TB reactivation (OR 4.68, 95% CI 1.18 to 18.60; NNTH = 681, 95% CI 143 to 14706) compared to control. The rate of serious adverse events, serious infections, lymphoma, and congestive heart failure were not statistically significantly different between biologics and control treatment. Certolizumab pegol was associated with significantly higher risk of serious infections compared to control treatment (OR 3.51, 95% CI 1.59 to 7.79; NNTH = 17, 95% CI 7 to 68). Infliximab was associated with significantly higher risk of withdrawals due to adverse events compared to control (OR 2.04, 95% CI 1.43 to 2.91; NNTH = 12, 95% CI 8 to 28). Indirect comparisons revealed that abatacept and anakinra were associated with a significantly lower risk of serious adverse events compared to most other biologics. Although the overall numbers are relatively small, certolizumab pegol was associated with significantly higher odds of serious infections compared to etanercept, adalimumab, abatacept, anakinra, golimumab, infliximab, and rituximab; abatacept was significantly less likely than infliximab and tocilizumab to be associated with serious infections. Abatacept, adalimumab, etanercept and golimumab were significantly less likely than infliximab to result in withdrawals due to adverse events. Authors' conclusions Overall, in the short term biologics were associated with significantly higher rates of total adverse events, withdrawals due to adverse events and TB reactivation. Some biologics had a statistically higher association with certain adverse outcomes compared to control, but there was no consistency across the outcomes so caution is needed in interpreting these results. There is an urgent need for more research regarding the long-term safety of biologics and the comparative safety of different biologics. National and international registries and other types of large databases are relevant sources for providing complementary evidence regarding the short-and longer-term safety of biologics. C1 [Singh, J. A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA. [Wells, G. A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [Christensen, R.] Copenhagen Univ Hosp, Parker Inst, Musculoskeletal Stat Unit MSU, Copenhagen, Denmark. [Christensen, R.] Univ So Denmark, Inst Sports Sci & Clin Biomech, Fac Hlth Sci, Odense, Denmark. [Ghogomu, Tanjong E.; Maxwell, L.] Univ Ottawa, Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON, Canada. [MacDonald, J. K.] Robarts Res Inst, London, ON N6A 5C1, Canada. [Filippini, G.] Fdn IRCCS, Neuroepidemiol Unit, Ist Neurol Carlo Besta, Milan, Italy. [Skoetz, N.] Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Dept Internal Med 1, Cologne, Germany. [Lopes, L. C.] Univ Sorocaba, Sci Pharmaceut Program, Sao Paulo, Sorocaba, Brazil. [Francis, D.] Univ W Indies, Epidemiol Res Unit, Kingston 7, Jamaica. [Guyatt, G. H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Schmitt, J.] Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany. [La Mantia, L.] IRCCS Santa Maria Nascente Fdn Don Gnocchi, Unit Neurol, Multiple Sclerosis Ctr, Milan, Italy. [Weberschock, T.] JW Goethe Univ Hosp, Ctr Dermatol, Frankfurt, Germany. [Weberschock, T.] Goethe Univ Frankfurt, Inst Gen Practice, Frankfurt, Germany. [Roos, J. F.; Hershan, S.; Buchbinder, R.] Monash Univ, Monash Dept Clin Epidemiol, Cabrini Hosp, Dept Epidemiol & Prevent Med, Malvern, Australia. [Siebert, H.] Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Cologne, Germany. [Lunn, M. P. T.] Natl Hosp Neurol & Neurosurg, Dept Neurol, London WC1N 3BG, England. [Tugwell, P.] Univ Ottawa, Fac Med, Ctr Global Hlth, Inst Populat Hlth, Ottawa, ON, Canada. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com RI Buchbinder, Rachelle/G-2952-2011; Fittipaldo, Andrea/A-5991-2013 FU AMGEN; Allergan; Takeda; Savient; URL Pharma; Novartis; Bristol-Myers Squibb; Abbott; UCB; Astellas Pharma; Axellus; Cambridge Nutritional Foods; Centocor; DSM Nutritional Products; Hypo-Safe; MSD; MundiPharma; NorPharma; Pharmavie; Pfizer; Roche; Sanofi-Aventis; Scandinavian Clinical Nutrition; Lotte and John Hecht Foundation; Astra Zeneca; Up-To-Date; Eli Lilly Canada; Bristol Myers; Chiltern International; Wyeth; Institute of Population Health, University of Ottawa, Canada; Oak Foundations; Canadian Institutes of Health Research, Canada; National Institutes of Health Research, UK FX JS: speaker honoraria from Abbott; research grants from AMGEN, Allergan, Takeda, Savient; consultant fee from Savient, URL Pharma, Novartis; GW: research grant and consultant fee from Bristol-Myers Squibb; consultant fees from Abbott, Amgen, UCB; Data Safety Monitoring for Novartis.; RC: has received consulting fees, honoraria, research or institutional support, educational grants, equipment, services or expenses from: Abbott, Astellas Pharma, Axellus, Bristol-Myers Squibb, Cambridge Nutritional Foods, Centocor, DSM Nutritional Products, Hypo-Safe, MSD, MundiPharma, NorPharma, Pharmavie, Pfizer, Roche, Sanofi-Aventis, Scandinavian Clinical Nutrition.; Guyatt: in the last 5 years, Dr Guyatt has received grant funding from Pfizer, Lotte and John Hecht Foundation, Bristol-Myers-Squibb, and Astra Zeneca. Dr Guyatt has also received consultation fee from Up-To-Date and Eli Lilly Canada. To our knowledge, none of these are conflicted with the subject matter of this submission.; PT: grants/honoraria from Bristol Myers, Chiltern International, and UCB; Schmitt: research grant from Wyeth.; Institute of Population Health, University of Ottawa, Canada.; Logistic support; The Parker Institute: Musculoskeletal Statistics Unit, Copenhagen University Hospital, Denmark.; The Oak Foundations provide support to the Parker Institute; Canadian Institutes of Health Research, Knowledge Synthesis Grant, Canada.; Funding for logistics, organization and administrative support; National Institutes of Health Research, Cochrane Review Incentive Scheme 2009, UK.; Funding for administrative support NR 281 TC 164 Z9 166 U1 2 U2 26 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 2 AR CD008794 DI 10.1002/14651858.CD008794.pub2 PG 60 WC Medicine, General & Internal SC General & Internal Medicine GA 738CJ UT WOS:000288616600032 ER PT J AU Rapuano, BE MacDonald, DE AF Rapuano, Bruce E. MacDonald, Daniel E. TI Surface oxide net charge of a titanium alloy Modulation of fibronectin-activated attachment and spreading of osteogenic cells SO COLLOIDS AND SURFACES B-BIOINTERFACES LA English DT Article DE Cell attachment; Coatings; Fibronnectin; Metal oxides; Surface charge ID HUMAN-PLASMA FIBRONECTIN; ATOMIC-FORCE MICROSCOPY; CONFORMATIONAL-CHANGES; IN-VITRO; PROTEIN ADSORPTION; BONE SIALOPROTEIN; THIN-FILMS; ADHESION; DIFFERENTIATION; FLUORESCENCE AB In the current study we have altered the surface oxide properties of a Ti6A14V alloy using heat treatment or radiofrequency glow discharge (RFGD) in order to evaluate the relationship between the physico chemical and biological properties of the alloys surface oxide The effects of surface pretreatments on the attachment of cells from two osteogenic cell lines (MG63 and MC3T3) and a mesenchymal stem cell line (C3H10T1/2) to fibronectin adsorbed to the alloy were measured Both heat and RFGD pretreatments produced a several fold increase in the number of cells that attached to fibronectin adsorbed to the alloy at a range of coating concentrations (0001-10 nM FN) for each cell line tested An antibody (HFN7 1) directed against the central integrin binding domain of fibronectin produced a 65-70% inhibition of cell attachment to fibronectin-coated disks indicating that cell attachment to the metal discs was dependent on fibronectin binding to cell integrin receptors Both treatments also accelerated the cell spreading response manifested by extensive flattening and an increase in mean cellular area The treatment induced increases in the cell attachment activity of adsorbed fibronectin were correlated with previously demonstrated increases in Ti6A14V oxide negative net surface charge at physiological pH produced by both heat and RFGD pretreatments Since neither treatment increased the adsorption mass of fibronectin these findings suggest that negatively charged surface oxide functional groups in Ti6A14V can modulate fibronectin's integrin receptor activity by altering the adsorbed protein's conformation Our results further suggest that negatively charged functional groups in the surface oxide can play a prominent role in the osseointegration of metallic implant materials Published by Elsevier B V C1 [Rapuano, Bruce E.; MacDonald, Daniel E.] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA. [MacDonald, Daniel E.] Gen Med Res James J Peters VA Med Ctr, Bronx, NY 10468 USA. [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA. RP MacDonald, DE (reprint author), Cornell Univ, Weill Med Coll, Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. FU NIH [RO1 DE017695]; National Center for Research Resources NIH [C06-RR12538-01] FX The project described was supported by Grant Number NIH RO1 DE017695 (Awarded to DEM) The sponsor did not have any role in the study design the collection analysis and interpretation of data the writing of the report or the decision to submit the paper for publication This material is also the result of work supported with resources and the use of facilities at the James J Peters VA Medical Center Bronx New York This investigation was also conducted at the HSS research facility constructed with support of Grant C06-RR12538-01 from the National Center for Research Resources NIH We would like to acknowledge Dr Stephen Doty and Tony Labisserie for help with scanning electron microscopy Special thanks goes to Christine Marsh and Kyle Hackshaw for their assistance with the cell culture experiments NR 74 TC 27 Z9 27 U1 1 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0927-7765 J9 COLLOID SURFACE B JI Colloid Surf. B-Biointerfaces PD JAN 1 PY 2011 VL 82 IS 1 BP 95 EP 103 DI 10.1016/j.colsurfb.2010.08.023 PG 9 WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials SC Biophysics; Chemistry; Materials Science GA 673YH UT WOS:000283699600014 PM 20884181 ER PT J AU MacDonald, DE Rapuano, BE Schniepp, HC AF MacDonald, Daniel E. Rapuano, Bruce E. Schniepp, Hannes C. TI Surface oxide net charge of a titanium alloy Comparison between effects of treatment with heat or radiofrequency plasma glow discharge SO COLLOIDS AND SURFACES B-BIOINTERFACES LA English DT Article DE Titanium alloy; Oxides; Surface treatments; Net surface charge; Wettability ID ATOMIC-FORCE MICROSCOPY; OSTEOBLAST-LIKE CELLS; PHOTOELECTRON-SPECTROSCOPY; PHYSIOLOGICAL SOLUTION; THIN-FILMS; ADSORPTION; BEHAVIOR; BIOMATERIAL; FIBRONECTIN; ROUGHNESS AB In the current study we have compared the effects of heat and radiofrequency plasma glow discharge (RFGD) treatment of a Ti6Al4V alloy on the physico chemical properties of the alloys surface oxide Titanium alloy (Ti6Al4V) disks were passivated alone heated to 600 C or RFGD plasma treated in pure oxygen RFGD treatment did not alter the roughness topography elemental composition or thickness of the alloys surface oxide layer In contrast heat treatment altered oxide topography by creating a pattern of oxide elevations approximately 50-100 nm in diameter These nanostructures exhibited a three fold increase in roughness compared to untreated surfaces when RMS roughness was calculated after applying a spatial high-pass filter with a 200 nm cutoff wavelength Heat treatment also produced a surface enrichment in aluminum and vanadium oxides Both RFGD and heat treatment produced similar increases in oxide wettability Atomic force microscopy (AFM) measurements of metal surface oxide net charge signified by a long-range force of attraction to or repulsion from a (negatively charged) silicon nitride AFM probe were also obtained for all three experimental groups Force measurements showed that the RFGD treated Ti6Al4V samples demonstrated a higher net positive surface charge at pH values below 6 and a higher net negative surface charge at physiological pH (pH values between 7 and 8) compared to control and heat treated samples These findings suggest that RFGD treatment of metallic implant materials can be used to study the role of negatively charged surface oxide functional groups in protein bioactivity osteogenic cell behavior and osseointegration independently of oxide topography Published by Elsevier B V C1 [MacDonald, Daniel E.; Rapuano, Bruce E.] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA. [MacDonald, Daniel E.] Gen Med Res James Peters VA Med Ctr, Bronx, NY 10468 USA. [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA. [Schniepp, Hannes C.] Coll William & Mary, Dept Appl Sci, Williamsburg, VA 23185 USA. RP MacDonald, DE (reprint author), Cornell Univ, Weill Med Coll, Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. RI Schniepp, Hannes/B-8368-2008 OI Schniepp, Hannes/0000-0003-4645-9469 FU NIH [RO1 DE017695]; National Center for Research Resources NIH [C06-RR12538-01] FX The project described was supported by Grant number NIH RO1 DE017695 (Awarded to DEM) The sponsor did not have any role in the study design the collection analysis and interpretation of data the writing of the report or the decision to submit the paper for publication This material is also the result of work supported with resources and the use of facilities at the James J Peters VA Medical Center Bronx New York This investigation was also conducted at the HSS research facility constructed with support of Grant C06-RR12538-01 from the National Center for Research Resources NIH We would like to acknowledge Michael Stranick of Colgate Palmolive Inc for assistance with the ESCA measurements Special thanks goes to Ryan Jeong and Dana McCloskey for their help in preparing and treating the alloy disks NR 62 TC 18 Z9 19 U1 0 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0927-7765 J9 COLLOID SURFACE B JI Colloid Surf. B-Biointerfaces PD JAN 1 PY 2011 VL 82 IS 1 BP 173 EP 181 DI 10.1016/j.colsurfb.2010.08.031 PG 9 WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials SC Biophysics; Chemistry; Materials Science GA 673YH UT WOS:000283699600025 PM 20880672 ER PT J AU Gros, DF Strachan, M Ruggiero, KJ Knapp, RG Frueh, BC Egede, LE Lejuez, CW Tuerk, PW Acierno, R AF Gros, Daniel F. Strachan, Martha Ruggiero, Kenneth J. Knapp, Rebecca G. Frueh, B. Christopher Egede, Leonard E. Lejuez, C. W. Tuerk, Peter W. Acierno, Ron TI Innovative service delivery for secondary prevention of PTSD in at-risk OIF-OEF service men and women SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE PTSD; Depression; Exposure therapy; Telehealth; OEF/OIF ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY PERSONNEL; EXPOSURE THERAPY; COMBAT VETERANS; HEALTH PROBLEMS; PRIMARY-CARE; US VETERANS; TELEPSYCHIATRY; AFGHANISTAN; SYMPTOMS AB Service personnel involved in Operation Enduring Freedom/Operation Iraqi Freedom are at high risk for trauma-related physical injury and emotional problems, including posttraumatic stress disorder (PTSD) and major depression. Although evidence-based psychotherapies are increasingly available and effective in treating symptoms of PTSD, a large number of service personnel are reluctant to seek mental health treatments due to both perceived stigma associated with these treatments and geographically-based barriers to care at specialized treatment facilities. The present investigation evaluates an innovation in service delivery designed to address these concerns. Specifically, we are comparing exposure-based therapy for PTSD delivered via traditional, in-person settings to the same exposure-based treatment delivered via telehealth technology. The proposed project is a prospective, randomized repeated measures design with two treatment groups (telehealth and in-person) assessed at pre-treatment, mid-treatment, post-treatment and 3- and 12-month follow-up points. Outcome measures ascertain longer-term effects of the treatments on three domains: clinical, process, and economic. Non-inferiority and superiority analyses will be conducted to determine symptom changes between pre-treatment, post-treatment, and follow-up time points between the two treatment conditions. The study will determine whether an exposure therapy for PTSD delivered via telehealth is at least as successful as the same exposure-based therapy delivered in-person in treating the symptoms of PTSD in both subthreshold and fully diagnosed cases. Published by Elsevier Inc. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Strachan, Martha; Ruggiero, Kenneth J.; Knapp, Rebecca G.; Egede, Leonard E.; Tuerk, Peter W.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Lejuez, C. W.] Univ Maryland, Ctr Addict Personal & Emot Res, College Pk, MD 20742 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Defense [W81XWH-07-FTSD-IIRA]; Ralph H. Johnson VAMC Research Enhancement Award [REA08-261]; Center for Disease Prevention and Health Interventions for Diverse Populations FX This research is supported by the Department of Defense Grant W81XWH-07-FTSD-IIRA (PI: Acierno). Several authors are also core and affiliate members of the Ralph H. Johnson VAMC Research Enhancement Award Program (REA08-261; PI: Egede), the Center for Disease Prevention and Health Interventions for Diverse Populations. NR 44 TC 21 Z9 21 U1 5 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JAN PY 2011 VL 32 IS 1 BP 122 EP 128 DI 10.1016/j.cct.2010.10.003 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 710YI UT WOS:000286552500017 PM 20951235 ER PT B AU Shemansky, WJ Goldstein, G AF Shemansky, Wendy J. Goldstein, Gerald BE Goldstein, G Incagnoli, TM Puente, AE TI Behavioral toxicological disorders SO CONTEMPORARY NEUROBEHAVIORAL SYNDROMES LA English DT Article; Book Chapter ID SICK-BUILDING SYNDROME; MULTIPLE CHEMICAL-SENSITIVITY; PRENATAL METHYLMERCURY EXPOSURE; DEPLETED URANIUM EXPOSURE; RISK-ASSESSMENT; GENERAL-POPULATION; MERCURY EXPOSURE; FISH CONSUMPTION; METHYL MERCURY; PCB EXPOSURE C1 [Shemansky, Wendy J.] VA Med Ctr, Pittsburgh, PA USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Shemansky, WJ (reprint author), VA Med Ctr, Pittsburgh, PA USA. NR 102 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-20382-965-3 PY 2011 BP 195 EP 218 PG 24 WC Psychology, Biological; Psychiatry SC Psychology; Psychiatry GA BUM37 UT WOS:000289774000010 ER PT J AU Ehlenbach, WJ Curtis, JR AF Ehlenbach, William J. Curtis, J. Randall TI The meaning of do-not-resuscitation orders: A need for clarity SO CRITICAL CARE MEDICINE LA English DT Editorial Material DE cardiopulmonary resuscitation; do-not-resuscitate; advance care planning; end-of-life; ethics ID DECISION-MAKING; IMPACT C1 [Ehlenbach, William J.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Ehlenbach, William J.; Curtis, J. Randall] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Ehlenbach, WJ (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 14 TC 3 Z9 3 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2011 VL 39 IS 1 BP 193 EP 194 DI 10.1097/CCM.0b013e318202e7d4 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 698FQ UT WOS:000285579600032 PM 21178531 ER PT B AU McIntyre, LK Langdale, LA AF McIntyre, Lisa K. Langdale, Lorrie A. BE Bland, KI Sarr, MG Buchler, MW Csendes, A Garden, OJ Wong, J TI Pulmonary Embolism SO CRITICAL CARE SURGERY: HANDBOOKS IN GENERAL SURGERY LA English DT Article; Book Chapter ID D-DIMER; VENOUS THROMBOEMBOLISM; CLINICAL-MODEL; PROBABILITY; CT C1 [McIntyre, Lisa K.] Univ Washington, Harborview Med Ctr, Dept Gen Surg, Seattle, WA 98104 USA. [Langdale, Lorrie A.] Univ Washington, Dept Surg, Seattle, WA 98104 USA. [Langdale, Lorrie A.] VA Puget Sound Hlth Care, Seattle, WA USA. RP McIntyre, LK (reprint author), Univ Washington, Harborview Med Ctr, Dept Gen Surg, 325 9th Ave, Seattle, WA 98104 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG LONDON LTD PI GODALMING PA SWEETAPPLE HOUSE CATTESHALL RD FARNCOMBE, GODALMING GU7 1NH, SURREY, ENGLAND BN 978-1-84996-377-0 PY 2011 BP 157 EP 171 DI 10.1007/978-1-84996-378-7_10 D2 10.1007/978-1-84996-378-7 PG 15 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA BRS18 UT WOS:000283523400010 ER PT J AU Fett, N Liu, RH AF Fett, Nicole Liu, Rosemarie H. TI Multicentric Reticulohistiocytosis with Dermatomyositis-Like Features: A More Common Disease Presentation than Previously Thought SO DERMATOLOGY LA English DT Review DE Multicentric reticulohistiocytosis; Dermatomyositis ID INTERSTITIAL LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; THERAPY; METHOTREXATE; CYCLOPHOSPHAMIDE; COMBINATION; INFLIXIMAB; INHIBITOR; LESIONS AB Multicentric reticulohistiocytosis (MRH) is a rare form of non-Langerhans histiocytosis that presents with erosive arthritis and skin nodules. Approximately 25% of patients with MRH have an associated malignancy. Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy. To date, 7 cases of MRH have been reported to present with cutaneous features of dermatomyositis. We describe an eighth patient with MRH who presented with dermatomyositis-like features (V-neck erythema, shawl sign, Gottron's papules and periungual erythema), who developed metastatic breast cancer 1 year after diagnosis. We hypothesized that clinical overlap between MRH and dermatomyositis was not as uncommon as review of the literature suggested. Careful review of the physical exam findings and photographs of the 234 papers reporting MRH revealed 27 cases of MRH with dermatomyositis-like features. Of these 27 cases, 7 (26%) were associated with a malignancy. Skin biopsies of the cutaneous features mimicking dermatomyositis revealed pathologic features of MRH. This is a descriptive analysis of published case reports. Based on a review of published case reports, MRH presenting with dermatomyositis-like features is likely fairly common. Histological examination of skin biopsies allows for disease differentiation. Differentiating MRH from dermatomyositis is important for management decisions and comorbidity screening. Copyright (C) 2011 S. Karger AG, Basel C1 [Fett, Nicole] Univ Penn, Sch Med, Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Fett, Nicole] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Liu, Rosemarie H.] Univ Wisconsin, Madison Hosp & Clin, Madison, WI USA. RP Fett, N (reprint author), Univ Penn, Sch Med, Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM nicole.fett@uphs.upenn.edu NR 42 TC 7 Z9 8 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-8665 J9 DERMATOLOGY JI Dermatology PY 2011 VL 222 IS 2 BP 102 EP 108 DI 10.1159/000323254 PG 7 WC Dermatology SC Dermatology GA 757NM UT WOS:000290094200002 PM 21252485 ER PT J AU Wade, AN Fedyna, S Mehta, NN St Clair, C Ginwala, N Krishna, RK Qasim, AN Braunstein, S Iqbal, N Schutta, MH Reilly, MP AF Wade, Alisha N. Fedyna, Sean Mehta, Nehal N. St Clair, Caitlin Ginwala, Naeema Krishna, Rama K. Qasim, Atif N. Braunstein, Seth Iqbal, Nayyar Schutta, Mark H. Reilly, Muredach P. TI Type 2 diabetes does not attenuate racial differences in coronary calcification SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Race; Coronary artery calcification; Atherosclerosis; Type 2 diabetes ID CARDIOVASCULAR RISK-FACTORS; ELECTRON-BEAM TOMOGRAPHY; ARTERY CALCIFICATION; COMPUTED-TOMOGRAPHY; ATHEROSCLEROSIS MESA; ETHNIC-DIFFERENCES; ASYMPTOMATIC SUBJECTS; HEART-DISEASE; CALCIUM; PREVALENCE AB Aims: Coronary artery calcification (CAC) is a strong predictor of atherosclerotic cardiovascular disease (CVD). Whites appear to have a higher prevalence of CAC than African-Americans (AAs), but it is unknown if type 2 diabetes, a major cardiovascular risk factor, attenuates this difference. We investigated the relationship of race and CAC in a sample of patients with type 2 diabetes without clinical CVD. Methods: Multivariable analyses of self-reported ethnicity and CAC scores, stratified by gender, in 861 subjects [32% AA, 66.9% male] with type 2 diabetes. Results: AA race was associated with lower CAC scores in age-adjusted models in males [Tobit ratio for AAs vs. Whites 0.14 (95% CI 0.08-0.24, p < 0.001)] and females [Tobit ratio 0.26 (95% CI 0.09-0.77, p = 0.015)]. This persisted in men after adjustment for traditional, metabolic and inflammatory risk factors, but adjustment for plasma triglycerides [0.48 (95% CI 0.15-1.49, p = 0.201)] and HOMA-IR [0.28 (95% CI 0.08-1.03, p = 0.055)] partially attenuated the association in women. Conclusions: Relative to African-Americans, White race is a strong predictor of CAC, even in the presence of type 2 diabetes. The relationship in women appears less robust possibly due to gender differences in metabolic risk factors. (C) 2010 Published by Elsevier Ireland Ltd. C1 [Reilly, Muredach P.] Univ Penn, Med Ctr, Cardiovasc Inst, Sch Med, Philadelphia, PA 19104 USA. [Wade, Alisha N.; Fedyna, Sean; Braunstein, Seth; Schutta, Mark H.; Reilly, Muredach P.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA. [Reilly, Muredach P.] Univ Penn, Sch Med, Dept Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Reilly, Muredach P.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA. [Ginwala, Naeema] SUNY Upstate Med Univ, Syracuse, NY USA. [Krishna, Rama K.] Penn Hosp, Philadelphia, PA 19104 USA. [Iqbal, Nayyar] Philadelphia Vet Affairs Med Ctr, Dept Med, Div Endocrinol, Philadelphia, PA 19104 USA. [Wade, Alisha N.] Univ Witwatersrand, Fac Hlth Sci, Div Endocrinol & Metab, Johannesburg, South Africa. RP Reilly, MP (reprint author), Univ Penn, Med Ctr, Cardiovasc Inst, Sch Med, 609 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA. EM muredach@mail.med.upenn.edu FU National Center for Research Resources (NCRR) [UL1RR024134]; Diabetes and Endocrine Research Center [P20-DK 019525]; National Institutes of Health [RO1-DK071224, P50 HL-083799-SCCOR] FX This work was supported by a Clinical and Translational Science Award (UL1RR024134) from the National Center for Research Resources (NCRR) and a Diabetes and Endocrine Research Center (P20-DK 019525) award, both to the University of Pennsylvania. M. P. R. is also supported by RO1-DK071224 and P50 HL-083799-SCCOR from the National Institutes of Health. NR 28 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD JAN PY 2011 VL 91 IS 1 BP 101 EP 107 DI 10.1016/j.diabres.2010.07.004 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 698XS UT WOS:000285629100024 PM 21067835 ER PT J AU Prisciandaro, JJ Gebregziabher, M Grubaugh, AL Gilbert, GE Echols, C Egede, LE AF Prisciandaro, James J. Gebregziabher, Mulugeta Grubaugh, Anouk L. Gilbert, Gregory E. Echols, Carrae Egede, Leonard E. TI Impact of Psychiatric Comorbidity on Mortality in Veterans with Type 2 Diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID COMMON MENTAL-DISORDERS; GLYCEMIC CONTROL; ALL-CAUSE; DEPRESSION; PREVALENCE; MORBIDITY; MELLITUS; ILLNESS; ADULTS AB Background: Particular psychiatric disorders, such as depression, have a significant and negative effect on diabetes outcomes. However, we know very little about the impact of other psychiatric disorders, and of the effect of multiple psychiatric comorbidities, on the clinical course of diabetes. As such, the present study examined the impact of a wide range of psychiatric comorbidities on all-cause mortality in individuals with type 2 diabetes. Methods: Retrospective follow-up was conducted of 15,065 veterans with type 2 diabetes enrolled in hospital care between 1997 and 2006. Clinical diagnoses from patient records were used to construct four psychiatric disorder scales: internalizing (i.e., depression and anxiety); externalizing (i.e., alcohol and drug abuse); psychotic; and bipolar. Longitudinal relationships were examined between these scales and mortality using Cox regression. Results: Only externalizing disorders were significantly associated with mortality: hazard ratio = 1.22 (95% confidence interval = 1.02-1.47). In other words, each additional diagnosed externalizing disorder increased an individual's chance of dying over the follow-up period by 22%. This association remained significant when demographics and medical comorbidities were statistically controlled, but was rendered nonsignificant when medication adherence was introduced to the regression model. Conclusions: The results provide evidence that among individuals with diabetes, alcohol and drug abuse/dependence have a significant impact on mortality. This increased risk of mortality may have been due to the association between psychiatric disorders and adherence to antidiabetes medications observed in the present study. Individuals with co-occurring diabetes and alcohol or drug abuse should be targeted for intensive interventions given their acute increased risk of mortality. C1 [Prisciandaro, James J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Grubaugh, Anouk L.; Gilbert, Gregory E.; Echols, Carrae; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Prisciandaro, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,POB 250861, Charleston, SC 29425 USA. EM priscian@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU VA Health Services Research and Development Program [REA 08-261, IIR-04-421-3, IIR 07-139-3, IIR-06-219-2, MHI 08-105-2]; National Institutes of Health [RO1DK081121-01A1, T35DK007431]; Centers for Disease Control and Prevention [U58DP001015]; Department of Defense [PT073980] FX L.E.E. is funded on multiple grants from the VA Health Services Research and Development Program (REA 08-261, IIR-04-421-3, IIR 07-139-3, IIR-06-219-2, and MHI 08-105-2), the National Institutes of Health (RO1DK081121-01A1 and T35DK007431), the Centers for Disease Control and Prevention (U58DP001015), and the Department of Defense (PT073980). NR 26 TC 9 Z9 9 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD JAN PY 2011 VL 13 IS 1 BP 73 EP 78 DI 10.1089/dia.2010.0092 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 697WH UT WOS:000285550000011 PM 21175275 ER PT J AU Akiba, Y Kaunitz, JD AF Akiba, Yasutada Kaunitz, Jonathan D. TI Duodenal Chemosensing and Mucosal Defenses SO DIGESTION LA English DT Article; Proceedings Paper CT 2010 IUPHAR Gastrointestinal Pharmacology Section Workshop on Gastrointestinal Nutrient Chemosensing and the Gut Brain Axis CY JUL 17-24, 2010 CL Copenhagen, DENMARK DE Acid sensor; Vanilloid receptor; Carbonic anhydrase; Luminal nutrient; G-protein-coupled receptors ID CALCIUM-SENSING RECEPTOR; GLUCAGON-LIKE PEPTIDE-2; PROTEIN-COUPLED RECEPTORS; BITTER TASTE RECEPTORS; GASTRIC-ACID-SECRETION; RAT SMALL-INTESTINE; GASTROINTESTINAL-TRACT; BICARBONATE SECRETION; ENTEROENDOCRINE CELLS; CARBONIC-ANHYDRASES AB The duodenal mucosa is exposed to endogenous and exogenous chemicals, including acid, CO2, bile acids and nutrients. Mucosal chemical sensors are necessary to exert physiological responses such as secretion, digestion, absorption, and motility. We propose a mucosal chemosensing system by which luminal chemicals are sensed via mucosal acid sensors and G-protein-coupled receptors. Luminal acid/CO2 sensing consists of ecto- and cytosolic carbonic anhydrases, epithelial ion transporters, and acid sensors expressed on the afferent nerves in the duodenum. Furthermore, a luminal L-glutamate signal is mediated via mucosal L-glutamate receptors, including metabotropic glutamate receptors and taste receptor 1 family heterodimers, with activation of afferent nerves and cyclooxygenase, whereas luminal Ca2+ is differently sensed via the calcium-sensing receptor in the duodenum. Recent studies also show the involvement of enteroendocrine G-protein-coupled receptors in bile acid and fatty acid sensing in the duodenum. These luminal chemosensors help activate mucosal defense mechanisms in order to maintain the mucosal integrity and physiological responses. Stimulation of luminal chemosensing in the duodenal mucosa may prevent mucosal injury, affect nutrient metabolism, and modulate sensory nerve activity. Copyright (C) 2011 S. Karger AG, Basel C1 Univ Calif Los Angeles, Sch Med, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yakiba@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK054221, R01 DK54221] NR 71 TC 16 Z9 16 U1 0 U2 7 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0012-2823 J9 DIGESTION JI Digestion PY 2011 VL 83 SU 1 BP 25 EP 31 DI 10.1159/000323401 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 734DD UT WOS:000288312500006 PM 21389725 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Effects of Environment and Lifestyle on Gastroesophageal Reflux Disease SO DIGESTIVE DISEASES LA English DT Article DE Barrett's esophagus; Erosive esophagitis; Esophageal adenocarcinoma; Geographic variation; Gastroesophageal reflux disease; Helicobacter pylori; Natural history; Obesity; Peptic stricture; Time trends ID LOWER ESOPHAGEAL SPHINCTER; BARRETTS-ESOPHAGUS; RISK-FACTORS; ACID REFLUX; UNITED-STATES; PEPTIC-ULCER; EPIDEMIOLOGIC TRENDS; HELICOBACTER-PYLORI; SYSTEMIC-SCLEROSIS; HIATAL-HERNIA AB Background: Gastroesophageal reflux disease (GERD) is comprised of a spectrum of related disorders, including hiatal hernia, reflux disease with its associated symptoms, erosive esophagitis, peptic stricture, Barrett's esophagus, and esophageal adenocarcinoma. Besides multiple pathophysiological associations among these disorders, they are also characterized by their comorbid occurrence in identical patients and by their similar epidemiologic behavior. The occurrence of GERD is shaped by marked temporal and geographic variations, suggesting the influence of environmental risk factors in the etiology of these diseases. Variations by Time, Geography, and Race: Between 1975 and 2005, the incidence of GERD and esophageal adenocarcinoma increased fivefold in most Western countries. The incidence of GERD also appears to be rising in the most developed countries of Asia. All severe forms of GERD, such as erosive esophagitis, peptic stricture, Barrett's metaplasia, and esophageal adenocarcinoma, are more common among whites than other ethnic groups. Affluence and Obesity as Risk Factors: Barrett's esophagus and esophageal adenocarcinoma tend to occur slightly more often in subjects with higher income. Overweight and obesity contribute to the development of hiatal hernia, increase intra-abdominal pressure, and promote gastroesophageal reflux. Weight gain increases reflux symptoms, whereas weight loss decreases such symptoms. Other risk factors, such as smoking, alcohol, dietary fat, or drugs, play only a minor role in shaping the epidemiologic patterns of GERD. Protection through Helicobacter pylori : On a population level, a high prevalence of H. pylori infection is likely to reduce levels of acid secretion and protect some carriers of the infection against reflux disease and its associated complications. Several studies have confirmed a lesser prevalence of H. pylori among subjects with than without GERD. Until recently, populations in Africa and Asia may have been protected against the development of GERD and esophageal adenocarcinoma by their higher prevalence of H. pylori infection. Conclusion: The study of environmental risk factors may provide an opportunity to better understand GERD and develop a means of its prevention. Copyright (C) 2011 S. Karger AG, Basel C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 58 TC 19 Z9 19 U1 1 U2 7 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 J9 DIGEST DIS JI Dig. Dis. PY 2011 VL 29 IS 2 BP 229 EP 234 DI 10.1159/000323927 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 789FI UT WOS:000292499500015 PM 21734389 ER PT J AU Bambara, JK Turner, AP Williams, RM Haselkorn, JK AF Bambara, Jennifer K. Turner, Aaron P. Williams, Rhonda M. Haselkorn, Jodie K. TI Perceived social support and depression among Veterans with multiple sclerosis SO DISABILITY AND REHABILITATION LA English DT Article DE Social support; depression; Veterans; multiple sclerosis ID QUALITY-OF-LIFE; MAJOR DEPRESSION; DISABILITY; ADJUSTMENT; COMORBIDITY; IMPAIRMENT; PREVALENCE; SEVERITY; SYMPTOMS; ILLNESS AB Purpose. To examine the association between perceived social support and self-reported depression among Veterans of the US Armed Forces ('Veterans') with multiple sclerosis (MS), and differences in this relationship between specific support subtypes (tangible, positive social interaction, emotional/informational and affective). Method. Participants were Veterans with MS (N = 451) receiving medical services through the Veterans Health Administration who completed mailed surveys. Hierarchical regression examined the extent to which global perceived social support concurrently predicted depression among a predominantly male sample of individuals with MS. Exploratory correlational analyses examined the relationship between specific subtypes of perceived social support and depression. Results. Greater global perceived social support was associated with less depression after controlling for sociodemographic and disease-related variables. In follow-up analyses examining specific subtypes of support, greater positive social interaction, greater emotional/informational support, and greater affective support were related to less depression. There was no relationship between perceived tangible support and depression. Conclusions. Interventions aimed at increasing positive social interactions, expressed affection and emotional/information support may be particularly helpful for individuals with MS and their caregivers. C1 [Bambara, Jennifer K.; Turner, Aaron P.; Williams, Rhonda M.; Haselkorn, Jodie K.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Bambara, Jennifer K.; Turner, Aaron P.; Williams, Rhonda M.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Heath Care Syst, Dept Rehabil Med, S-117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI Turner, Aaron/0000-0001-6897-8003 FU VA Rehabilitation Research and Development Service [B4972W] FX This material is based on work supported by a grant for the Department of Veterans Affairs VHA VISN 20 and by VA Rehabilitation Research and Development Service Career Development grant (B4972W). NR 54 TC 7 Z9 7 U1 3 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2011 VL 33 IS 1 BP 1 EP 8 DI 10.3109/09638288.2010.481026 PG 8 WC Rehabilitation SC Rehabilitation GA 686KL UT WOS:000284695100001 PM 20812812 ER PT J AU Lehman, LA Woodbury, M Shechtman, O Wang, YC Pomeranz, J Gray, DB Velozo, CA AF Lehman, Leigh A. Woodbury, Michelle Shechtman, Orit Wang, Ying-Chih Pomeranz, Jamie Gray, David B. Velozo, Craig A. TI Development of an item bank for a computerised adaptive test of upper-extremity function SO DISABILITY AND REHABILITATION LA English DT Article DE ICF; ICF activity measure; upper-extremity; computer adaptive testing ID INFORMATION-SYSTEM PROMIS; OUTCOMES MEASUREMENT; MANUAL ABILITY; SHOULDER AB Purpose. The purpose of this study was to determine the psychometric characteristics of an upper-extremity item bank as a precursor to developing a computer adaptive patient reported outcome instrument. The Activity dimension of the World Health Organization's International Classification of Functioning, Disability and Health (ICF) provided the conceptual framework for the items. Method. Factor and Rasch analyses were used to evaluate the psychometric properties of the item bank, including: monotonicity, local independence, dimensionality, item difficulty hierarchy and match between sample ability and item difficulty. Results. Monotonicity of the rating scale was supported. Nine item pairs were locally dependent, and thus one item from each pair was removed from subsequent analyses. There was evidence for two unidimensional constructs; gross upper-extremity and fine hand. Both constructs showed good internal consistency and person separation. In general, the order of item difficulty within each construct replicated the hypothesised item difficulty order. The fine hand construct had a ceiling effect. Conclusions. The above study of our newly developed upper-extremity item bank empirically verified the intended item difficulty order, identified separate constructs (i.e. gross upper-extremity and fine hand) and provided insights into eliminating the ceiling effect of one of the constructs. These findings are critical precursors to the development of upper-extremity components of the ICF Activity Measure, an ICF-based, CAT located on the web at: www.icfmeasure.phhp.ufl.edu. C1 [Lehman, Leigh A.] Univ S Carolina Upstate, Dept Psychol, Spartanburg, SC 29303 USA. [Woodbury, Michelle] Ralph H Johnson Vet Affairs Med Ctr, Dept Occupat Therapy, Charleston, SC 29401 USA. [Woodbury, Michelle] Med Univ S Carolina, Dept Occupat Therapy, Charleston, SC 29403 USA. [Shechtman, Orit; Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, Gainesville, FL 32601 USA. [Wang, Ying-Chih] Univ Wisconsin, Dept Occupat Sci & Technol, Milwaukee, WI 53201 USA. [Wang, Ying-Chih] Focus Therapeut Outcomes Inc, Knoxville, TN 37939 USA. [Pomeranz, Jamie] Univ Florida, Dept Behav Sci & Community Hlth, Gainesville, FL 32610 USA. [Gray, David B.] Washington Univ, Sch Med, Dept Neurol & Occupat Therapy, St Louis, MO 63108 USA. [Velozo, Craig A.] N Florida S Georgia Vet Affairs Syst Rehabil Outc, Lake City, FL 32025 USA. RP Lehman, LA (reprint author), Univ S Carolina Upstate, Dept Psychol, 800 Univ Way, Spartanburg, SC 29303 USA. EM llehman@uscupstate.edu FU Department of Education, National Institute of Disability Rehabilitation Research (NIDRR) [H133G000227] FX This study was funded by the Department of Education, National Institute of Disability Rehabilitation Research (NIDRR), project number H133G000227. NR 39 TC 5 Z9 5 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2011 VL 33 IS 21-22 BP 2092 EP 2104 DI 10.3109/09638288.2011.560336 PG 13 WC Rehabilitation SC Rehabilitation GA 826GJ UT WOS:000295340600019 PM 21401332 ER PT J AU Bikle, DD Oda, Y Teichert, A AF Bikle, Daniel David Oda, Yuko Teichert, Arnaud TI The Vitamin D Receptor: A Tumor Suppressor in Skin SO DISCOVERY MEDICINE LA English DT Article AB Epidemiologic evidence supporting a major chemopreventive role for vitamin D in various malignancies is strong. Likewise the use of the active metabolite of vitamin D, 1,25(OH)(2)D-3, and its analogs to prevent and/or treat a wide variety of malignancies in animals is well established. The evidence has been less compelling for epidermal carcinogenesis perhaps because the same agent that produces vitamin D in the skin, UVB radiation (UVR), is also the same agent that results in most epidermal malignancies. However, recent studies indicate that the role of vitamin D and its receptor (VDR) in protecting against the development of epidermal tumors deserves a closer look. One such study found mice lacking the VDR were quite sensitive to epidermal tumor formation following the administration of the carcinogen DMBA. A more recent study showed that these mice were similarly more sensitive to tumor formation following UVR, results we have confirmed. The epidermis of the VDR null mouse is hyperproliferative with gross distortion of hair follicles, structures that may provide the origin for the tumors found in the skin following such treatment. Two interacting pathways critical for epidermal and hair follicle function, beta-catenin and hedgehog (Hh), result in epidermal tumors when they are activated abnormally. Thus, we considered the possibility that loss of VDR predisposes to epidermal tumor formation by activation of either or both beta-catenin and Hh signaling. We determined that all elements of the Hh signaling pathway are upregulated in the epidermis and utricles of the VDR null mouse, and that 1,25(OH)(2)D-3 suppresses the expression of these elements in normal mouse skin. In addition we observed that the transcriptional activity of beta-catenin was increased in keratinocytes lacking the VDR. These results lead us to the hypothesis that the VDR with its ligand 1,25(OH)(2)D-3 functions as a tumor suppressor with respect to epidermal tumor formation in response to UVR by regulating Hh and beta-catenin signaling. [Discovery Medicine 11(56):7-17, January 2011] C1 [Bikle, Daniel David] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Bikle, DD (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.bikle@ucsf.edu FU BLRD VA [I01 BX001066]; NIAMS NIH HHS [R01 AR050023] NR 61 TC 24 Z9 25 U1 1 U2 1 PU DISCOVERY MEDICINE PI TIMONIUM PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA SN 1539-6509 EI 1944-7930 J9 DISCOV MED JI Discov. Med. PD JAN PY 2011 VL 11 IS 56 BP 7 EP 17 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA V27UW UT WOS:000208639100001 PM 21276406 ER PT J AU Yehuda, R AF Yehuda, Rachel TI Disease Markers: Molecular Biology of PTSD Introduction SO DISEASE MARKERS LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; HOLOCAUST SURVIVORS C1 James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM Rachel.Yehuda@va.gov NR 4 TC 2 Z9 2 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 2-3 BP 61 EP 65 DI 10.3233/DMA-2011-0785 PG 5 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 773YN UT WOS:000291348100001 PM 21508510 ER PT J AU Yehuda, R Koenen, KC Galea, S Flory, JD AF Yehuda, Rachel Koenen, Karestan C. Galea, Sandro Flory, Janine D. TI The role of genes in defining a molecular biology of PTSD SO DISEASE MARKERS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN TRANSPORTER GENOTYPE; GLUCOCORTICOID-RECEPTOR NUMBER; HURRICANE-EXPOSED ADULTS; DNA METHYLATION; MATERNAL-CARE; CHILDHOOD ABUSE; ENVIRONMENTAL-INFLUENCES; INDIVIDUAL-DIFFERENCES; TRAUMATIC EVENTS AB Because environmental exposure to trauma is the sine qua non for the development of Post Traumatic Stress Disorder (PTSD), the recent focus on genetic studies has been noteworthy. The main catalyst for such studies is the observation from epidemiological studies that not all trauma survivors develop this disorder. Furthermore, neuroendocrine findings suggest pre-existing hormonal alterations that confer risk for PTSD. This paper presents the rationale for examining genetic factors in PTSD and trauma exposure, but suggests that studies of genotype may only present a limited picture of the molecular biology of this disorder. We describe the type of information that can be obtained from candidate gene and genomic studies that incorporate environmental factors in the design (i.e., gene - environment interaction and gene-environment correlation studies) and studies that capitalize on the idea that environment modifies gene expression, via epigenetic or other molecular mechanisms. The examination of epigenetic mechanisms in tandem with gene expression will help refine models that explain how PTSD risk, pathophysiology, and recovery is mediated by the environment. Since inherited genetic variation may also influence the extent of epigenetic or gene expression changes resulting from the environment, such studies should optimally be followed up by studies of genotype. C1 [Yehuda, Rachel; Flory, Janine D.] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel; Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Koenen, Karestan C.] Harvard Ctr Developing Child, Cambridge, MA USA. [Galea, Sandro] Columbia Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. EM Rachel.Yehuda@va.gov NR 79 TC 22 Z9 24 U1 5 U2 18 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 2-3 BP 67 EP 76 DI 10.3233/DMA-2011-0794 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 773YN UT WOS:000291348100002 PM 21508511 ER PT J AU Sarapas, C Cai, GQ Bierer, LM Golier, JA Galea, S Ising, M Rein, T Schmeidler, J Muller-Myhsok, B Uhr, M Holsboer, F Buxbaum, JD Yehuda, R AF Sarapas, Casey Cai, Guiqing Bierer, Linda M. Golier, Julia A. Galea, Sandro Ising, Marcus Rein, Theo Schmeidler, James Mueller-Myhsok, Bertram Uhr, Manfred Holsboer, Florian Buxbaum, Joseph D. Yehuda, Rachel TI Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks SO DISEASE MARKERS LA English DT Article DE Stress disorders; post-traumatic; gene expression; genotype; FKBP5 protein; human; cortisol; September 11 terrorist attacks; childhood trauma ID POSTTRAUMATIC-STRESS-DISORDER; SEPTEMBER-11 TERRORIST ATTACKS; NEW-YORK-CITY; PERIPHERAL-BLOOD; GLUCOCORTICOID-RECEPTOR; EXPRESSION PROFILES; TRAUMA EXPOSURE; IN-VIVO; FKBP5; POLYMORPHISMS AB We have previously reported the differential expression of 17 probe sets in survivors of the 9/11 attacks with current posttraumatic stress disorder (PTSD) compared to similarly exposed survivors with no lifetime PTSD. The current study presents an expanded analysis of these subjects, including genotype at FKBP5, a modulator of glucocorticoid receptor (GR) sensitivity. It includes data from additional subjects who developed PTSD following 9/11 but then recovered, distinguishing expression profiles associated with risk for developing PTSD, resilience, and symptom recovery. 40 Caucasians (20 with and 20 without PTSD, matched for exposure, age, and gender) were selected from a population-representative sample of persons exposed to the 9/11 attacks from which longitudinal data had been collected in four previous waves. Whole blood gene expression and cortisol levels were obtained and genome-wide gene expression was analyzed. 25 probe sets were differentially expressed in PTSD. Identified genes were generally involved in hypothalamic-pituitary-adrenal axis, signal transduction, or in brain and immune cell function. STAT5B, a direct inhibitor of GR, and nuclear factor I/A, both showed reduced expression in PTSD. Comparison of lifetime versus current PTSD identified overlapping genes with altered expression suggesting enduring markers, while some markers present only in current PTSD may reflect state measures. As a follow-up, direct comparisons of expression in current PTSD, lifetime-only PTSD, and control groups identified FKBP5 and MHC Class II as state markers, and also identified several trait markers. An analysis of indirect effects revealed that homozygosity for any of 4 PTSD risk-related polymorphisms at FKBP5 predicted FKBP5 expression, which mediated indirect effects of genotype on plasma cortisol and PTSD severity. C1 [Bierer, Linda M.; Golier, Julia A.; Schmeidler, James; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10458 USA. [Sarapas, Casey] Univ Illinois, Dept Psychol, Chicago, IL 60680 USA. [Cai, Guiqing; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY USA. [Bierer, Linda M.; Golier, Julia A.; Schmeidler, James; Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY USA. [Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Ising, Marcus; Rein, Theo; Mueller-Myhsok, Bertram; Uhr, Manfred; Holsboer, Florian] Max Planck Inst Psychiat, D-80804 Munich, Germany. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH PTSD 116-A,130 W Kingsbridge Rd, Bronx, NY 10458 USA. EM rachel.yehuda@va.gov RI Muller-Myhsok, Bertram/A-3289-2013 OI Buxbaum, Joseph/0000-0001-8898-8313 NR 41 TC 52 Z9 52 U1 12 U2 22 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 2-3 BP 101 EP 110 DI 10.3233/DMA-2011-0764 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 773YN UT WOS:000291348100005 PM 21508514 ER PT J AU O'Donovan, A Sun, B Cole, S Rempel, H Lenoci, M Pulliam, L Neylan, T AF O'Donovan, Aoife Sun, Bing Cole, Steve Rempel, Hans Lenoci, Maryann Pulliam, Lynn Neylan, Thomas TI Transcriptional control of monocyte gene expression in post-traumatic stress disorder SO DISEASE MARKERS LA English DT Article ID NF-KAPPA-B; URINARY CORTISOL EXCRETION; PITUITARY-ADRENAL AXIS; LONG-TERM STRESS; HOLOCAUST SURVIVORS; DISEASE MORTALITY; SEX-DIFFERENCES; ACTH RESPONSE; PTSD SYMPTOMS; CATECHOLAMINES AB Post-traumatic stress disorder (PTSD) confers an increased risk for disorders with an inflammatory etiology. PTSD-related dysregulation of the sympathetic nervous system (SNS) and hypothalamic-pituitary adrenal (HPA) axis and associated alterations in inflammatory activity may contribute to this increased risk. However, little is known about convergent SNS, HPA and inflammatory signaling at the level of the immune cell transcriptome in PTSD. To explore such signaling, we examined the prevalence of specific transcription factor binding motifs in the promoter regions of differentially expressed genes in monocytes from individuals with PTSD and matched controls. Participants included 49 men (24 PTSD+ and 25 trauma-exposed controls) and 18 women (10 PTSD+ and 8 controls). Men with PTSD showed up-regulation of target genes for the NF-kappa B/Rel family of transcription factors, which convey inflammatory signals, up-regulation of target genes for CREB/ATF transcription factors, which convey adrenergic signals from the SNS, and down-regulation of target genes for the glucocorticoid receptor, which conveys glucocorticoid signals from the HPA axis. Women with PTSD also showed significant up-regulation of target genes for NF-kappa B and non-significant down-regulation of target genes for GR, but significant down-regulation of target genes for CREB/ATF. Altered transcriptional control of monocyte gene expression could contribute to exaggerated inflammatory activity in PTSD. C1 [O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [O'Donovan, Aoife; Sun, Bing; Rempel, Hans; Lenoci, Maryann; Pulliam, Lynn; Neylan, Thomas] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [O'Donovan, Aoife; Sun, Bing; Rempel, Hans; Lenoci, Maryann; Pulliam, Lynn; Neylan, Thomas] No Calif Inst Res & Educ, San Francisco, CA USA. [Sun, Bing; Pulliam, Lynn] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94121 USA. [Cole, Steve] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. RP O'Donovan, A (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. EM aoife.odonovan@ucsf.edu FU Department of Defense [W81XWH-05-2-0094]; Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration; National Institute for Mental Health (TCN) [R01 MH73978] FX We thank Cyrus Calosing for excellent technical assistance and Joshua D. Woolley, MD/PhD for comments on an earlier draft of this manuscript. This research was supported in part by grants from the Department of Defense (W81XWH-05-2-0094), the Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration, and the National Institute for Mental Health (TCN: R01 MH73978). This material is the result of work supported with resources and the use of facilities at the Veterans Administration Medical Center, San Francisco California. NR 68 TC 48 Z9 48 U1 3 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 2-3 BP 123 EP 132 DI 10.3233/DMA-2011-0768 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 773YN UT WOS:000291348100007 PM 21508516 ER PT J AU Flory, JD Bierer, LM Yehuda, R AF Flory, Janine D. Bierer, Linda M. Yehuda, Rachel TI Maternal exposure to the holocaust and health complaints in offspring SO DISEASE MARKERS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; ADULT LIFE; DEVELOPMENTAL ORIGINS; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASES; METABOLIC SYNDROME; LOW CORTISOL; RISK; PTSD AB Although the link between chronic stress and the development of cardiovascular and metabolic diseases of adulthood has been known for some time, there is growing recognition that early environmental influences may result in developmental programming via epigenetic mechanisms, thereby affecting the developmental trajectory of disease progression. Previous studies support the idea that offspring of Holocaust survivors may have been subjected to early developmental programming. We evaluated the relationship between parental exposure to the Holocaust and self-reported health ratings and disorders made by their adult offspring (i.e., second generation Holocaust survivors). A total of 137 subjects were evaluated. Regression analyses demonstrated that maternal but not paternal exposure to the Holocaust was related to poorer subjective impressions of emotional and physical health. This relationship was diminished when the offspring's own level of trait anxiety was considered. Offspring with maternal, but not paternal, Holocaust exposure also reported greater use of psychotropic and other medications, including medications for the treatment of hypertension and lipid disorders. The mechanism linking these health outcomes and maternal exposure deserves further investigation, including the possibility that fetal or early developmental programming is involved. C1 [Flory, Janine D.] CUNY, Queens Coll, Dept Psychol, Flushing, NY 11367 USA. [Flory, Janine D.] CUNY, Grad Ctr, Flushing, NY 11367 USA. [Flory, Janine D.; Bierer, Linda M.; Yehuda, Rachel] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Flory, JD (reprint author), CUNY, Queens Coll, Dept Psychol, NSB E-318,65-30 Kissena Blvd, Flushing, NY 11367 USA. EM janine.flory@qc.cuny.edu FU NIMH [R01-MH-64675-01] FX This work was supported by NIMH grant R01-MH-64675-01 ("Biology of Risk and PTSD in Holocaust Survivor Offspring") to Rachel Yehuda. NR 47 TC 15 Z9 15 U1 0 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 2-3 BP 133 EP 139 DI 10.3233/DMA-2011-0748 PG 7 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 773YN UT WOS:000291348100008 PM 21508517 ER PT J AU Connolly, KR Thase, ME AF Connolly, K. Ryan Thase, Michael E. TI If at First You Don't Succeed A Review of the Evidence for Antidepressant Augmentation, Combination and Switching Strategies SO DRUGS LA English DT Review ID MAJOR DEPRESSIVE DISORDER; TREATMENT-RESISTANT-DEPRESSION; SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED TRIAL; ASTERISK-D REPORT; TREATMENT-REFRACTORY DEPRESSION; MONOAMINE-OXIDASE INHIBITORS; VENLAFAXINE EXTENDED-RELEASE; FAILED MEDICATION TREATMENTS; DOUBLE-BLIND AB Major depressive disorder is a common and disabling illness that leads to significant reductions in quality of life and considerable cost to society. Despite numerous advances in the pharmacological treatment of depression, many patients remain ill despite initial treatment. Beyond first-line treatment, current guidelines recommend either augmentation or switching of the initial antidepressant. In this narrative review, we summarize the data from randomized controlled trials and meta-analyses in order to concisely discuss how the impact of current research can be translated into clinical practice and, ultimately, into lasting improvements in patient outcomes. The augmentation strategies reviewed are lithium, thyroid hormone, pindolol, psychostimulants and second-generation antipsychotics. The data on switching from first-line antidepressants to other antidepressants are also reviewed, and include switching within the same class, switching to other first-line antidepressant classes and switching to less commonly prescribed antidepressants. Finally, the strategy of antidepressant combinations is examined. Overall, the strength of evidence supporting a trial of augmentation or a switch to a new agent is very similar, with remission rates between 25% and 50% in both cases. Our review of the evidence suggests several conclusions. First, although it is true that adjunctive lithium and thyroid hormone have established efficacy, we can only be confident that this is true for use in combination with tricyclic antidepressants (TCAs), and the trials were done in less treatment-resistant patients than those who typically receive TCAs today. Of these two options, triiodothyronine augmentation seems to offer the best benefit/risk ratio for augmentation of modern antidepressants. After failure of a first-line selective serotonin reuptake inhibitor (SSRI), neither a switch within class nor a switch to a different class of antidepressant is unequivocally supported by the data, although switching from an SSRI to venlafaxine or mirtazapine may potentially offer greater benefits. Interestingly, switching from a newer antidepressant to a TCA after a poor response to the former is not supported by strong evidence. Of all strategies to augment response to new-generation antidepressants, quetiapine and aripiprazole are best supported by the evidence, although neither the cost effectiveness nor the longer-term benefit of these strategies has been established. The data to guide later steps in the treatment of resistant depression are sparse. Given the wide variety of options for the treatment of major depressive disorder, and the demonstrated importance of truly adequate treatment to the long-term outcomes of patients facing this illness, it is clear that further well conducted studies are needed. C1 [Connolly, K. Ryan; Thase, Michael E.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Connolly, KR (reprint author), Univ Penn, Sch Med, Philadelphia VA Med Ctr, MIRECC Rm 228B, Philadelphia, PA 19104 USA. EM Kevin.connolly2@va.gov FU Eli Lilly Company; GlaxoSmithKline; National Institute of Mental Health; Sepracor, Inc.; American Psychiatric Publishing, Inc.; Guilford Publications; Herald House; Oxford University Press; W.W. Norton Company; Philadelphia Veterans Affairs Medical Center's Mental Illness Research Education and Clinical Center (MIRECC) FX No sources of funding were used in the preparation of this article. Dr Thase has provided scientific consultation to Astra-Zeneca, Bristol-Myers Squibb Company, Eli Lilly & Company, Forest Pharmaceuticals, Inc., GlaxoSmithKline, MedAvante, Inc., Neuronetics, Inc., Novartis, Pfizer (formerly Wyeth-Ayerst Laboratories), Schering-Plough, Shire US Inc., Supernus Pharmaceuticals, Takeda and Transcept Pharmaceuticals. Dr Thase has been a member of the speakers' bureaus for AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly & Company and Pfizer (formerly Wyeth-Ayerst Laboratories). He receives grant funding from Eli Lilly & Company, GlaxoSmithKline, National Institute of Mental Health and Sepracor, Inc. Dr Thase has equity holdings in MedAvante, Inc. and receives royalty income from American Psychiatric Publishing, Inc., Guilford Publications, Herald House, Oxford University Press and W.W. Norton & Company. His wife is employed as the senior medical director for Advogent.; Dr Connolly would like to thank the Philadelphia Veterans Affairs Medical Center's Mental Illness Research Education and Clinical Center (MIRECC) for their support. Dr Connolly has no competing interests. NR 84 TC 104 Z9 108 U1 3 U2 20 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2011 VL 71 IS 1 BP 43 EP 64 DI 10.2165/11587620-000000000-00000 PG 22 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 710HU UT WOS:000286502700003 PM 21175239 ER PT J AU Muscogiuri, G Kamat, A Balas, B Giaccari, A DeFronzo, RA Musi, N Katz, MS AF Muscogiuri, Giovanna Kamat, Amrita Balas, Bogdan Giaccari, Andrea DeFronzo, Ralph A. Musi, Nicolas Katz, Michael S. TI beta-Adrenergic Responsive Induction of Insulin Resistance in Liver of Aging Rats SO ENDOCRINE RESEARCH LA English DT Article DE Glucose production; Catecholamines; beta-Adrenergic receptor ID ADENYLATE-CYCLASE; GLUCOSE-PRODUCTION; DIABETIC RATS; HUMAN TISSUES; AGE; GLYCOGENOLYSIS; EPINEPHRINE; EXPRESSION; RECEPTORS; STRESS AB Introduction. We previously demonstrated increases in beta-adrenergic receptor (beta-AR) density in rat liver, in association with increased beta-AR-mediated stimulation of glucose output in rat hepatocytes, during senescent aging. We therefore hypothesized that pharmacologic beta-adrenergic stimulation might induce insulin resistance and glucose output in liver of aging rats in vivo. Methods. In this study, pancreatic clamps were performed on young adult (4-month-old) and senescent (24-month-old) Fischer 344 male rats by infusing somatostatin (3 mu g/kg/min) at time 0 to inhibit insulin secretion, and then infusing insulin (1 mU/kg/min) to replace basal insulin concentrations. At time 0 rats also received either the beta-AR agonist isoproterenol (100 ng/kg/min) or saline (control). After 120 min the insulin infusion rate was increased to 4 mU/kg/min for an additional 120 min. Tritiated glucose was infused throughout the study to measure glucose turnover rates. Results and Conclusion. The results of the pancreatic clamp studies demonstrated that under saline control conditions hepatic glucose production (HGP) was suppressed during hyper-insulinemia in both young and old rats, with a trend toward reduced insulin sensitivity in the older animals. Isoproterenol infusion impaired insulin-induced suppression of HGP in both age groups. The results suggest that beta-AR stimulation by isoproterenol increases HGP and acutely induces hepatic insulin resistance in both young and old rats. A similar role for beta-adrenergic-mediated hepatic insulin resistance in aging humans would suggest a novel therapeutic target for the treatment or prevention of glucose dysregulation and diabetes developing with advancing age. C1 [Kamat, Amrita; Katz, Michael S.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Muscogiuri, Giovanna; Kamat, Amrita; Balas, Bogdan; DeFronzo, Ralph A.; Musi, Nicolas; Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Kamat, Amrita; DeFronzo, Ralph A.; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Giaccari, Andrea] Catholic Univ, Rome & Don Gnocchi Fdn, Dept Endocrinol, Milan, Italy. [Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. RP Kamat, A (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM kamat@uthscsa.edu RI Giaccari, Andrea/J-1889-2012 OI Giaccari, Andrea/0000-0002-7462-7792 FU Department of Veterans Affairs; American Heart Association; Kronos Longevity Research Institute FX This work was supported by a VISN 17 Award from the Department of Veterans Affairs (AK), a Grant-in-Aid American Heart Association Award (AK), and a research grant from the Kronos Longevity Research Institute (MSK). NR 35 TC 6 Z9 6 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0743-5800 J9 ENDOCR RES JI Endocr. Res. PY 2011 VL 36 IS 2 BP 74 EP 82 DI 10.3109/07435800.2010.539993 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 758KK UT WOS:000290163400004 PM 21438725 ER PT J AU Wu, SV Yuan, PQ Lai, J Wong, K Chen, MC Ohning, GV Tache, Y AF Wu, S. Vincent Yuan, Pu-Qing Lai, Jim Wong, Kelvin Chen, Monica C. Ohning, Gordon V. Tache, Yvette TI Activation of Type 1 CRH Receptor Isoforms Induces Serotonin Release from Human Carcinoid BON-1N Cells: An Enterochromaffin Cell Model SO ENDOCRINOLOGY LA English DT Article ID 7TH TRANSMEMBRANE DOMAIN; IRRITABLE-BOWEL-SYNDROME; FUNCTIONAL-CHARACTERIZATION; CRF1 RECEPTOR; IN-VITRO; VISCERAL HYPERSENSITIVITY; HORMONE-RECEPTOR; COLONIC FUNCTION; 5-HT3 RECEPTORS; CONSCIOUS RATS AB CRH and 5-hydroxytryptamine (5-HT) are expressed in human colonic enterochromaffin (EC) cells, but their interactions at the cellular level remain largely unknown. The mechanistic and functional relationship between CRH and 5-HT systems in EC cells was investigated in a human carcinoid cloned BON cell line (BON-1N), widely used as an in vitro model of EC cell function. First, we identified multiple CRH(1) splice variants, including CRH(1a), CRH(1c), CRH(1f), and a novel form lacking exon 4, designated here as CRH(1i), in the BON-1N cells. The expression of CRH(1i) was also confirmed inhumanbrain cortex, pituitary gland, and ileum. Immunocytochemistry and immunoblot analysis confirmed that BON-1N cells were CRH(1) and 5-HT positive. CRH, urocortin (Ucn)-1, and cortagine, a selective CRH(1) agonist, all increased intracellular cAMP, and this concentration-dependent response was inhibited by CRH(1)-selective antagonist NBI-35965. CRH and Ucn-1, but not Ucn-2, stimulated significant ERK1/2 phosphorylation. In transfected human embryonic kidney-293 cells, CRH1i isoforms produced a significant increase in pERK1/2 in response to CRH(1) agonists that was sensitive to NBI-35965. CRH and Ucn-1 stimulated 5-HT release that reached a maximal increase of 3.3- and 4-fold at 10(-8) M over the basal level, respectively. In addition, exposure to CRH for 24-h up-regulated tryptophan hydroxylase-1 mRNA levels in the BON-1N cells. These findings define the expression of EC cell-specific CRH(1) isoforms and activation of CRH(1)-dependent pathways leading to 5-HT release and synthesis; thus, providing functional evidence of a link exists between CRH and 5-HT systems, which have implications in stress-induced CRH(1) and 5-HT-mediated stimulation of lower intestinal function. (Endocrinology 152: 126-137, 2011) C1 [Wu, S. Vincent] Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90073 USA. RP Wu, SV (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Bldg 115,Room 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM vwu@ucla.edu FU National Institutes of Health (NIH) [DK 57238]; NIH Center [DK 41301]; Hirshberg Foundation FX This work was supported by the National Institutes of Health (NIH) R01 Grant DK 57238; a Veterans Affairs (VA) Merit Review award and a VA Research Career Scientist award (Y.T.); the Peptidomics and Antibody Core from NIH Center Grant DK 41301 CURE: Digestive Diseases Research Center (to G.V.O.); and a Seed grant from Hirshberg Foundation (S.V.W.). NR 57 TC 17 Z9 17 U1 1 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2011 VL 152 IS 1 BP 126 EP 137 DI 10.1210/en.2010-0997 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 698DT UT WOS:000285573000014 PM 21123435 ER PT J AU Sonnenberg, A AF Sonnenberg, A. TI When to stop the search for an elusive source of gastrointestinal bleeding SO ENDOSCOPY LA English DT Article ID EPIDEMIOLOGY; DIAGNOSIS AB Background and study aims: This analysis investigates the clinical parameters that should drive decisions about when to continue or stop the search for an elusive source of gastrointestinal bleeding. Patients and methods: The number of endoscopies necessary to find a source of bleeding was estimated using the geometric distribution. A threshold analysis was used to develop a stop rule for the search for a site of bleeding. Bayes' formula served to estimate changes in the probability of achieving a diagnosis associated with a series of consecutive endoscopic tests. Results: With decreasing probability of diagnostic success associated with an individual endoscopic procedure, such as p = 50%, 33%, or 25%, the mean (standard deviation [SD]) number of procedures needed to find the source of bleeding increases to 2 (1.41), 3 (2.45), or 4 (3.46), respectively. The threshold analysis suggests that workup should be discontinued if the expected rise in diagnostic probability does not exceed the ratio of work-up cost to bleeding cost, that is, Delta p < work-up cost/bleeding cost. For instance, a 10-fold higher cost of bleeding than endoscopy would justify continued work-up if it can improve diagnostic probability by 10%. Bayesian analysis shows that after three negative tests the diagnostic probability drops below such a threshold. Conclusions: The analysis suggests the following basic rules. The search for a site of gastrointestinal bleeding will take on average 2 procedures with a range of 1-4. The search should be continued as long as the diagnostic probability is expected to rise by more than 10%, which is unlikely after three consecutive negative tests. C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 3 Z9 3 U1 0 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X J9 ENDOSCOPY JI Endoscopy PD JAN PY 2011 VL 43 IS 1 BP 4 EP 7 DI 10.1055/s-0030-1255847 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 706AY UT WOS:000286186700001 PM 21038292 ER PT J AU Larson, PS Martin, AJ AF Larson, Paul S. Martin, Alastair J. BE Arle, JE Shils, JL TI Safety Concerns and Limitations SO ESSENTIAL NEUROMODULATION LA English DT Article; Book Chapter ID DEEP BRAIN-STIMULATION; SPINAL-CORD STIMULATION; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; INITIAL-EXPERIENCE; PARKINSONS-DISEASE; CARDIAC-PACEMAKERS; PATIENT; MRI; ELECTRODES; DEVICES C1 [Larson, Paul S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Larson, Paul S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Martin, Alastair J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Larson, PS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. NR 39 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-381410-4 PY 2011 BP 397 EP 410 DI 10.1016/B978-0-12-381409-8.00018-8 PG 14 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA BGM07 UT WOS:000323483300035 ER PT J AU Novakovic, V Sher, L Lapidus, KAB Mindes, J Golier, JA Yehuda, R AF Novakovic, Vladan Sher, Leo Lapidus, Kyle A. B. Mindes, Janet Golier, Julia A. Yehuda, Rachel TI Brain stimulation in posttraumatic stress disorder SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Review DE Brain stimulation; PTSD; ECT; TMS; depression; anxiety AB Posttraumatic stress disorder (PTSD) is a complex, heterogeneous disorder that develops following trauma and often includes perceptual, cognitive, affective, physiological, and psychological features. PTSD is characterized by hyperarousal, intrusive thoughts, exaggerated startle response, flashbacks, nightmares, sleep disturbances, emotional numbness, and persistent avoidance of trauma-associated stimuli. The efficacy of available treatments for PTSD may result in part from relief of associated depressive and anxiety-related symptoms in addition to treatment of core symptoms that derive from reexperiencing, numbing, and hyperarousal. Diverse, heterogeneous mechanisms of action and the ability to act broadly or very locally may enable brain stimulation devices to address PTSD core symptoms in more targeted ways. To achieve this goal, specific theoretical bases derived from novel, well-designed research protocols will be necessary. Brain stimulation devices include both long-used and new electrical and magnetic devices. Electroconvulsive therapy (ECT) and Cranial electrotherapy stimulation (CES) have both been in use for decades; transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), deep brain stimulation (DBS), transcranial Direct Current Stimulation (tDCS), and vagus nerve stimulation (VNS) have been developed recently, over approximately the past twenty years. The efficacy of brain stimulation has been demonstrated as a treatment for psychiatric and neurological disorders such as anxiety (CES), depression (ECT, CES, rTMS, VNS, DBS), obsessive-compulsive disorder (OCD) (DBS), essential tremor, dystonia (DBS), epilepsy (DBS, VNS), Parkinson Disease (DBS), pain (CES), and insomnia (CES). To date, limited data on brain stimulation for PTSD offer only modest guidance. ECT has shown some efficacy in reducing comorbid depression in PTSD patients but has not been demonstrated to improve most core PTSD symptoms. CES and VNS have shown some efficacy in reducing anxiety, findings that may suggest possible utility in relieving PTSD-associated anxiety. Treatment of animal models of PTSD with DBS suggests potential human benefit. Additional research and novel treatment options for PTSD are urgently needed. The potential usefulness of brain stimulation in treating PTSD deserves further exploration. C1 [Novakovic, Vladan; Sher, Leo; Lapidus, Kyle A. B.; Mindes, Janet; Golier, Julia A.; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Novakovic, Vladan; Sher, Leo; Lapidus, Kyle A. B.; Mindes, Janet; Golier, Julia A.; Yehuda, Rachel] James J Peters VA Med Ctr, Dept Psychiat, New York, NY 10468 USA. RP Novakovic, V (reprint author), James J Peters VA Med Ctr, Dept Psychiat, New York, NY 10468 USA. EM Vladan.Novakovic@va.gov NR 126 TC 7 Z9 7 U1 8 U2 23 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2011 VL 2 AR 5609 DI 10.3402/ejpt.v2i0.5609 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EX UT WOS:000208868000002 ER PT J AU Ruzek, JI Weingardt, K Kuhn, E Hoffman, JE AF Ruzek, Josef I. Weingardt, Ken Kuhn, Eric Hoffman, Julia E. TI Caring for Trauma Survivors in Large Health Care Systems: Towards Internet-Facilitated Treatment SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract C1 [Ruzek, Josef I.; Kuhn, Eric] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. [Weingardt, Ken] US Dept Vet Affairs, Vet Hlth Adm, Washington, DC USA. [Hoffman, Julia E.] Natl Ctr Telehlth & Technol, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2011 VL 2 SU 1 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EZ UT WOS:000208868200011 ER PT J AU Al Jurdi, RK Gyulai, L Sajatovic, M Nguyen, CX AF Al Jurdi, R. K. Gyulai, L. Sajatovic, M. Nguyen, C. X. TI BIPOLAR DEPRESSION SYMPTOMS ACROSS THE LIFESPAN SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Al Jurdi, R. K.; Nguyen, C. X.] Michael E De Bakey VA Med Ctr, Houston, TX USA. [Al Jurdi, R. K.] Baylor Coll Med, Houston, TX 77030 USA. [Gyulai, L.] Univ Penn, Philadelphia, PA 19104 USA. [Sajatovic, M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. RI Sajatovic, Martha/I-8001-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2011 VL 26 SU 1 MA P01-189 PG 2 WC Psychiatry SC Psychiatry GA V27VS UT WOS:000208641300190 ER PT J AU Tapp, A Wood, AE Kennedy, A Sylvers, P AF Tapp, A. Wood, A. E. Kennedy, A. Sylvers, P. TI QUETIAPINE FOR THE TREATMENT OF COCAINE DEPENDENCE SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Tapp, A.; Wood, A. E.; Kennedy, A.; Sylvers, P.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Tapp, A.; Wood, A. E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2011 VL 26 SU 1 MA P01-113 PG 1 WC Psychiatry SC Psychiatry GA V27VS UT WOS:000208641300114 ER PT S AU Cooper, RA Cooper, R Srinivasa, S Xu, JJ Wang, HW Grindle, G Salatin, B Chung, CS Kelleher, A Vazquez, J AF Cooper, Rory A. Cooper, Rosemarie Srinivasa, Siddhartha Xu, Jijie Wang, Hongwu Grindle, Garrett Salatin, Ben Chung, Chengshiu Kelleher, Annmarie Vazquez, Juan BE Gelderblom, GJ Soede, M Adriaens, L Miesenberger, K TI Quality of Life Technology Robots (QoLTbots): Towards Providing Assistance in the Home and Community for People with Disabilities and Older Adults SO EVERYDAY TECHNOLOGY FOR INDEPENDENCE AND CARE SE Assistive Technology Research Series LA English DT Proceedings Paper CT 11th Bi-Annual AAATE Conference CY AUG 31-SEP 02, 2011 CL Maastricht, NETHERLANDS SP Assoc Advancement Assist Technol Europe DE Assistive robots; QolTbots; robot; rehabilitation; acceptance; design ID ASSISTIVE TECHNOLOGY; WHEELCHAIR; USERS AB There is increasing progress towards robotic devices that will provide beneficial assistance to people with disabilities and older adults in the home. In recent years, there has been a break from the traditional robotics approach of creating autonomous robotic systems and tele-operated robots, towards symbiotic robotic systems that work in partnership with and incorporate the strengths and capabilities of humans and robots working collaboratively, and in many cases intimately together. This has resulted in a new class of assistive robots termed Quality of Life Technology Robots or QoLTbots. This paper describes work on two QoLTbots with different structures, yet they share many core technologies. The ultimate goal of these QoLTbots is to create a framework and actual demonstration units (i.e., testbeds) to demonstrate the ability to assist people with disabilities and older adults in meaningful ways, and to study their acceptance of QoLTbots. C1 [Cooper, Rory A.; Cooper, Rosemarie; Xu, Jijie; Wang, Hongwu; Grindle, Garrett; Salatin, Ben; Chung, Chengshiu; Kelleher, Annmarie; Vazquez, Juan] US Dept Vet Affairs, Human Engn Res Labs, Rehabil Res & Dev Serv, Washington, DC USA. [Cooper, Rory A.; Cooper, Rosemarie; Xu, Jijie; Wang, Hongwu; Grindle, Garrett; Salatin, Ben; Chung, Chengshiu; Kelleher, Annmarie; Vazquez, Juan] Univ Pittsburgh, Dept Rehabil Sci & Technol, 5044 Forbes Tower, Pittsburgh, PA 15260 USA. [Srinivasa, Siddhartha] Intel Res Labs, Pittsburgh, PA USA. [Cooper, Rory A.; Cooper, Rosemarie; Srinivasa, Siddhartha; Xu, Jijie; Wang, Hongwu; Grindle, Garrett; Salatin, Ben; Chung, Chengshiu; Kelleher, Annmarie; Vazquez, Juan] Univ Pittsburgh, Qual Life Technol Ctr, Pittsburgh, PA 15260 USA. [Cooper, Rory A.; Cooper, Rosemarie; Srinivasa, Siddhartha; Xu, Jijie; Wang, Hongwu; Grindle, Garrett; Salatin, Ben; Chung, Chengshiu; Kelleher, Annmarie; Vazquez, Juan] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, 5044 Forbes Tower, Pittsburgh, PA 15260 USA. EM rcooper@pitt.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1383-813X BN 978-1-60750-814-4; 978-1-60750-813-7 J9 ASSIST TECHNOL RES S PY 2011 VL 29 BP 550 EP 556 DI 10.3233/978-1-60750-814-4-550 PG 7 WC Rehabilitation SC Rehabilitation GA BG9NW UT WOS:000393465400071 ER PT J AU Bikle, DD AF Bikle, Daniel D. TI Vitamin D: an ancient hormone SO EXPERIMENTAL DERMATOLOGY LA English DT Editorial Material DE animals; calcium; evolution; exoskeleton; plankton; plants; vitamin D ID CALCIUM-SENSING RECEPTOR; CRUSTACEAN ORCHESTIA-CAVIMANA; HUMAN EPIDERMAL-KERATINOCYTES; BREAM SPARUS-AURATUS; CELL-CELL ADHESION; D-BINDING PROTEIN; NF-KAPPA-B; E-CADHERIN; EXTRACELLULAR CALCIUM; 1,25-DIHYDROXYVITAMIN D-3 AB Vitamin D has been produced by plants and animals almost from the time life began. The ability to transport and metabolize vitamin D to more active forms evolved as the structures of plants and animals became more complex, and the cells within these organisms took on more specialized functions. In higher-order animals, the vitamin D receptor (VDR) is found in nearly every cell, and the ability of the cell to produce the active hormone, 1,25(OH)(2)D, is also widely distributed. Furthermore, the physiological functions with which vitamin D signalling is now associated are as diverse as the tissues in which the VDR is located. Why is this, and is there a common theme? This viewpoint article argues that there is. All cells maintain a fairly constant and submicromolar concentration of free calcium. Calcium is an important regulator of many processes within the cell. The ebb and flow of calcium within cells is controlled by calcium pumps, antiporters and channels. Animals with calcified exo- or endoskeletons have an additional need for calcium, a need that changes during the life cycle of the organism. In this article, I make the case that vitamin D signalling evolved to enable the organism to effectively regulate calcium flux, storage and signalling and that such regulation is critical for the evolutionary process. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Bikle, DD (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. EM daniel.bikle@ucsf.edu FU BLRD VA [I01 BX001066]; NIAMS NIH HHS [R01 AR050023] NR 88 TC 51 Z9 52 U1 0 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0906-6705 J9 EXP DERMATOL JI Exp. Dermatol. PD JAN PY 2011 VL 20 IS 1 BP 7 EP 13 DI 10.1111/j.1600-0625.2010.01202.x PG 7 WC Dermatology SC Dermatology GA 695QY UT WOS:000285388900002 PM 21197695 ER PT J AU McKiernan, SH Colman, RJ Lopez, M Beasley, TM Aiken, JM Anderson, RM Weindruch, R AF McKiernan, Susan H. Colman, Ricki J. Lopez, Marisol Beasley, T. Mark Aiken, Judd M. Anderson, Rozalyn M. Weindruch, Richard TI Caloric restriction delays aging-induced cellular phenotypes in rhesus monkey skeletal muscle SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Sarcopenia; Calorie restriction; Rhesus monkey ID DNA DELETION MUTATIONS; DIETARY RESTRICTION; PHYSICAL-ACTIVITY; CAUSAL ROLE; SARCOPENIA; ATROPHY; FIBERS; MASS; ABNORMALITIES; APOPTOSIS AB Sarcopenia is the age-related loss of skeletal muscle mass and function and is characterized by a reduction in muscle mass and fiber cross-sectional area, alterations in muscle fiber type and mitochondrial functional changes. In rhesus monkeys, calorie restriction (CR) without malnutrition improves survival and delays the onset of age-associated diseases and disorders including sarcopenia. We present a longitudinal study on the impact of CR on early stage sarcopenia in the upper leg of monkeys from similar to 16 years to similar to 22 years of age. Using dual-energy X-ray absorptiometry we show that CR delayed the development of maximum muscle mass and, unlike Control animals, muscle mass of the upper leg was preserved in CR animals during early phase sarcopenia. Histochemical analyses of vastus lateralis muscle biopsies revealed that CR opposed age-related changes in the proportion of Type II muscle fibers and fiber cross-sectional area. In contrast the number of muscle fibers with mitochondrial electron transport system enzyme abnormalities (ETS(ab)) was not significantly affected by CR. Laser capture microdissection of ETS(ab) fibers and subsequent PCR analysis of the mitochondria! DNA revealed large deletion mutations in fibers with abnormal mitochondrial enzyme activities. CR did not prevent stochastic mitochondrial deletion mutations in muscle fibers but CR may have contributed to the maintenance of affected fibers. (c) 2010 Elsevier Inc. All rights reserved. C1 [McKiernan, Susan H.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [McKiernan, Susan H.; Colman, Ricki J.; Lopez, Marisol] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Lopez, Marisol; Aiken, Judd M.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA. [Beasley, T. Mark] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Aiken, Judd M.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2M8, Canada. [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, William S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP McKiernan, SH (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM shmckier@wisc.edu FU NIH [P01 AG-11915, P51 RR000167]; Ellison Medical Foundation; Research Facilities Improvement Program [RR15459-01, RR020141-01] FX We acknowledge the efforts of the veterinary staff of the Wisconsin National Primate Research Center. This work was supported by NIH grants P01 AG-11915; P51 RR000167 and the Ellison Medical Foundation Senior Scholar Award (Judd Aiken). This research was conducted in part at a facility constructed with support from the Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. NR 37 TC 30 Z9 30 U1 0 U2 30 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JAN PY 2011 VL 46 IS 1 BP 23 EP 29 DI 10.1016/j.exger.2010.09.011 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 710UP UT WOS:000286542800004 PM 20883771 ER PT S AU Barnes, JL Glass, WF AF Barnes, Jeffrey L. Glass, William F., II BE Herrera, GA TI Renal Interstitial Fibrosis: A Critical Evaluation of the Origin of Myofibroblasts SO EXPERIMENTAL MODELS FOR RENAL DISEASES: PATHOGENESIS AND DIAGNOSIS SE Contributions to Nephrology LA English DT Article; Book Chapter ID TO-MESENCHYMAL TRANSITION; UNILATERAL URETERAL OBSTRUCTION; POLYCYSTIC KIDNEY-DISEASE; SPONTANEOUSLY HYPERTENSIVE-RATS; CHRONIC ALLOGRAFT-NEPHROPATHY; TUBULAR EPITHELIAL-CELLS; RENIN-ANGIOTENSIN SYSTEM; PROGRESSIVE TUBULOINTERSTITIAL FIBROSIS; MICE DEVELOP GLOMERULOSCLEROSIS; COLLAGEN-PRODUCING CELLS AB Interstitial fibrosis is a common feature of chronic kidney disease, regardless of the etiology of the primary renal syndrome. Moreover, interstitial fibrosis is the strongest morphologic predictor of clinical outcome and is most tightly linked to progression of disease, even though the primary disease may be of glomerular origin. Also, the presence of an interstitial component in chronic kidney disease often indicates an ominous outcome. The incidence of chronic kidney disease has reached epidemic proportions; thus, understanding the pathophysiology of interstitial renal disease is paramount for the development of new therapeutic approaches to slowing progression. Experimental models of renal fibrosis have been essential in determining the mechanisms and sequence of progression of fibrogenesis, including the roles of endothelium, infiltrating leukocytes and myofibroblasts; of profibrogenic cytokine and growth factor release; of tubular injury and atrophy; and of interstitial extracellular matrix accumulation. Over the last decade, considerable attention has been paid to the origin of the myofibroblast, the cell type most responsible for interstitial matrix accumulation. However, the origin(s) of myofibroblasts and how they gain access to the peritubular interstitium has become a matter of controversy and debate. Interstitial myofibroblasts have been proposed to originate from one or more of five sources: resident fibroblasts (pericytes), adventitial fibroblasts, circulating fibrocytes, tubular epithelial-mesenchymal transition (EMT) or endothelial/mesenchymal transition. To date, EMT has become the pre-eminent theory of the origin of myofibroblasts; however, a role for EMT in renal fibrosis is rigorously challenged by anecdotal and recent scientific evidence. This chapter will briefly discuss the experimental models used to explore interstitial renal disease in general and will then focus on the controversy related to the origin of myofibroblasts. Copyright (C) 2011 S. Karger AG, Basel C1 [Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.] Audie Murphy Mem Vet Adm Hosp, Med Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Glass, William F., II] Nephrocor, Glen Allen, VA USA. [Glass, William F., II] Bostwick Labs Inc, Glen Allen, VA USA. RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu FU NIDDK NIH HHS [R01 DK080106] NR 230 TC 41 Z9 48 U1 0 U2 4 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-8055-9537-7 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2011 VL 169 BP 73 EP 93 PG 21 WC Urology & Nephrology SC Urology & Nephrology GA BTP65 UT WOS:000287717700006 PM 21252512 ER PT J AU Thompson, D Cullen, KW Reed, DB Konzelmann, K Smalling, AL AF Thompson, Debbe Cullen, Karen Weber Reed, Debra B. Konzelmann, Karen Smalling, Aggie Lara TI Formative Assessment in the Development of an Obesity Prevention Component for the Expanded Food and Nutrition Education Program in Texas SO FAMILY & COMMUNITY HEALTH LA English DT Article DE curriculum development; nutrition; obesity ID PHYSICAL-ACTIVITY; CHILDHOOD OBESITY; DIETARY-INTAKE; LOW-INCOME; PARENTS; OVERWEIGHT; CHILDREN; MOTHERS; VEGETABLES; FAMILIES AB This study conducted formative research (surveys, focus groups) to assess the nutrition education needs of clients in the Texas Expanded Food and Nutrition Education Program prior to curriculum revision. Participants were current Expanded Food and Nutrition Education Program participants in 3 Texas cities (Austin, Houston, San Antonio). Data were used to tailor the curriculum to the target population. This research provides evidence that members of the target audience can provide valuable insights into a particular topic. Formative work prior to intervention development should be conducted to identify key issues regarding a particular topic and to evaluate potential educational approaches. C1 [Thompson, Debbe; Cullen, Karen Weber; Konzelmann, Karen] Baylor Coll Med, USDA, ARS, Childrens Nutr Res Ctr,Dept Pediat, Houston, TX 77030 USA. [Reed, Debra B.] Texas Tech Univ, Coll Human Nutr Sci, Dept Nutr Hospitality & Retailing, Lubbock, TX 79409 USA. [Smalling, Aggie Lara] Vet Adm Hosp, Houston, TX USA. RP Thompson, D (reprint author), Baylor Coll Med, USDA, ARS, Childrens Nutr Res Ctr,Dept Pediat, 1100 Bates St, Houston, TX 77030 USA. EM dit@bcm.tmc.edu NR 25 TC 2 Z9 2 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 BP 61 EP 71 DI 10.1097/FCH.0b013e3181fdeb3f PG 11 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 690XS UT WOS:000285044000008 PM 21135629 ER PT J AU Borrero, S Abebe, K Dehlendorf, C Schwarz, EB Creinin, MD Nikolajski, C Ibrahim, S AF Borrero, Sonya Abebe, Kaleab Dehlendorf, Christine Schwarz, Eleanor Bimla Creinin, Mitchell D. Nikolajski, Cara Ibrahim, Said TI Racial variation in tubal sterilization rates: role of patient-level factors SO FERTILITY AND STERILITY LA English DT Article DE Tubal sterilization; disparities; knowledge and attitudes; race/ethnicity ID UNITED-STATES; CONTRACEPTIVE STERILIZATION; INSURANCE STATUS; REVERSAL; REPLACEMENT; DISPARITIES; KNOWLEDGE; REGRET; WOMEN AB Objective: To assess racial differences in attitudes and knowledge about sterilization. Design: Cross-sectional survey. Setting: Questionnaires were mailed to participants' home addresses. Patient(s): One hundred ninety-three women, aged 18-45, who had undergone tubal sterilization. Intervention(s): None. Main Outcome Measure(s): Attitudes and knowledge about tubal sterilization and awareness of contraceptive alternatives. Result(s): We received 193 completed surveys (64% response rate). African American (AA) woman were more likely to have a family member who had undergone tubal sterilization, to report that their mothers influenced their sterilization decisions, and to report that prior unintended pregnancy and desire to avoid insertion of a foreign object were very important factors in their decision to choose sterilization over other methods. Compared with white women, AA women more often thought that sterilization reversal could easily restore fertility (62% vs. 36%); that a woman's sterilization would reverse itself after 5 years (60% vs. 23%); and that a man cannot ejaculate after vasectomy (38% vs. 13%). Fewer AA women had ever heard of intrauterine contraception (90% vs. 98%). Racial differences in knowledge remained statistically significant after adjusting for socioeconomic confounders. Conclusion(s): Misinformation about sterilization and limited awareness of contraceptive alternatives among AA women may contribute to racial disparities in tubal sterilization rates. (Fertil Steril (R) 2011; 95: 17-22. (C)2011 by American Society for Reproductive Medicine.) C1 [Borrero, Sonya; Abebe, Kaleab; Schwarz, Eleanor Bimla; Nikolajski, Cara; Ibrahim, Said] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Borrero, Sonya; Abebe, Kaleab; Schwarz, Eleanor Bimla; Nikolajski, Cara; Ibrahim, Said] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya; Nikolajski, Cara; Ibrahim, Said] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Schwarz, Eleanor Bimla; Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu RI Potter, Joseph/A-3122-2008 OI Abebe, Kaleab/0000-0002-3644-8419; Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU National Center for Research Resources, National Institutes of Health (NIH) [KL2 RR024154]; NIH Roadmap for Medical Research FX This publication was made possible by Grant KL2 RR024154 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 24 TC 25 Z9 25 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD JAN PY 2011 VL 95 IS 1 BP 17 EP 22 DI 10.1016/j.fertnstert.2010.05.031 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 695ZL UT WOS:000285411600010 PM 20579640 ER PT J AU Kovesdi, E Gyorgy, AB Kwon, SKC Wingo, DL Kamnaksh, A Long, JB Kasper, CE Agoston, DV AF Kovesdi, Erzsebet Gyorgy, Andrea B. Kwon, Sook-Kyung C. Wingo, Daniel L. Kamnaksh, Alaa Long, Joseph B. Kasper, Christine E. Agoston, Denes V. TI The effect of enriched environment on the outcome of traumatic brain injury; a behavioral, proteomics, and histological study SO FRONTIERS IN NEUROSCIENCE LA English DT Article DE neurogenesis; enriched environment; traumatic brain injury; memory; anxiety; hippocampus; histology; proteomics AB De novo hippocampal neurogenesis contributes to functional recovery following traumatic brain injury (TBI). Enriched environment (EEN) can improve the outcome of TBI by positively affecting neurogenesis. Blast induced traumatic brain injury (bTBI) characterized by memory impairment and increased anxiety levels, is a leading cause of chronic disability among soldiers. Using a rodent model of bTBI we asked: (a) whether long-term exposure to EEN after injury can ameliorate behavioral abnormalities and (b) what the effects of EEN are at the molecular and cellular levels and on de novo neurogenesis. We found that housing injured animals in EEN resulted in significantly improved spatial memory while animals in normal housing (NH) showed persistent memory impairment. VEGF and Tau protein but not Interleukin-6 (IL-6) levels were normalized in the dorsal hippocampus (DHC) of EEN rats while all three markers remained elevated in NH rats. Interestingly, after peaking at 6 weeks post-injury, anxiety returned to normal levels at 2 months independent of housing conditions. Housing animals in EEN had no significant effect on VEGF and Tau protein levels in the ventral hippocampus (VHC) and the amygdala (AD). We also found that EEN reduced IL-6 and IFN gamma levels in the VHC; these markers remained elevated following NH. We observed an increase in GFAP and DCX immunoreactivities in the VHC of NH animals at 2 months post-injury. Conversely, injured animals housed in EEN showed no increase in GFAP or DCX immunoreactivity in their VHC. In summary, long-term exposure of injured animals to EEN appears to play a positive role in the restoration of memory functions but not on anxiety, which returned to normal levels after a significant period of time. Cellular and molecular changes in response to EEN appear to be a part of neurogenesis-independent as well as dependent recovery processes triggered by bTBI. C1 [Kovesdi, Erzsebet; Kasper, Christine E.] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA. [Gyorgy, Andrea B.; Kwon, Sook-Kyung C.; Wingo, Daniel L.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA. [Long, Joseph B.] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD USA. RP Agoston, DV (reprint author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM vagoston@usuhs.edu FU VA grant [B5044R] FX We thank the Neurotrauma Team (WRAIR) for their technical help during the blast exposures; Dr. David Jacobowitz (USU) for his help in brain micropunch dissections; Ms. Cara Olsen (USU) for her help in statistical analysis; Drs. Neil Grunberg and John Wu (USU) for their input in designing and interpreting the behavioral experiments. The work was supported by VA grant # B5044R. NR 125 TC 45 Z9 45 U1 3 U2 7 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PY 2011 VL 5 AR 42 DI 10.3389/fnins.2011.00042 PG 12 WC Neurosciences SC Neurosciences & Neurology GA V36GI UT WOS:000209200600038 PM 21503146 ER PT J AU Laderas, TG Walter, NAR Mooney, M Vartanian, K Darakjian, P Buck, K Harrington, CA Belknap, J Hitzemann, R McWeeney, SK AF Laderas, Ted G. Walter, Nicole A. R. Mooney, Michael Vartanian, Kristina Darakjian, Priscila Buck, Kari Harrington, Christina A. Belknap, John Hitzemann, Robert McWeeney, Shannon K. TI Computational detection of alternative exon usage SO FRONTIERS IN NEUROSCIENCE LA English DT Article DE alternative splicing; exon array AB Background: With the advent of the GeneChip Exon Arrays, it is now possible to extract "exon-level" expression estimates, allowing for detection of alternative splicing events, one of the primary mechanisms of transcript diversity. In the context of (1) a complex trait use case and (2) a human cerebellum vs. heart comparison on previously validated data, we present a transcript-based statistical model and validation framework to allow detection of alternative exon usage (AEU) between different groups. To illustrate the approach, we detect and confirm differences in exon usage in the two of the most widely studied mouse genetic models (the C57BL/6J and DBA/2J inbred strains) and in a human dataset. Results: We developed a computational framework that consists of probe level annotation mapping and statistical modeling to detect putative AEU events, as well as visualization and alignment with known splice events. We show a dramatic improvement (similar to 25 fold) in the ability to detect these events using the appropriate annotation and statistical model which is actually specified at the transcript level, as compared with the transcript cluster/gene-level annotation used on the array. An additional component of this workflow is a probe index that allows ranking AEU candidates for validation and can aid in identification of false positives due to single nucleotide polymorphisms. Discussion: Our work highlights the importance of concordance between the functional unit interrogated (e.g., gene, transcripts) and the entity (e.g., exon, probeset) within the statistical model. The framework we present is broadly applicable to other platforms (including RNAseq). C1 [Laderas, Ted G.; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Oregon Clin Res & Translat Inst, Portland, OR 97239 USA. [Laderas, Ted G.; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA. [Laderas, Ted G.; Mooney, Michael; McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Walter, Nicole A. R.; Buck, Kari; Belknap, John; Hitzemann, Robert] Portland VA Med Ctr, Portland, OR USA. [Walter, Nicole A. R.; Darakjian, Priscila; Buck, Kari; Belknap, John; Hitzemann, Robert; McWeeney, Shannon K.] Portland Alcohol Res Ctr, Portland, OR USA. [Walter, Nicole A. R.; Buck, Kari; Belknap, John; Hitzemann, Robert] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Vartanian, Kristina; Harrington, Christina A.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [McWeeney, Shannon K.] Oregon Hlth & Sci Univ, Div Biostat, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP McWeeney, SK (reprint author), Oregon Hlth & Sci Univ, Knight Canc Inst, Mail Code CR145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM mcweeney@ohsu.edu OI Laderas, Ted/0000-0002-6207-7068; Mooney, Michael/0000-0003-1372-8722; McWeeney, Shannon/0000-0001-8333-6607 FU US National Institutes of Health [AA010760, AA11034, AA13484, AA011114, DA05228, MH51372]; Department of Veterans Affairs Merit Awards; Affymetrix Fellowship; National Library of Medicine Biomedical Informatics Fellowship [LM007088] FX Supported by US National Institutes of Health grants AA010760, AA11034, AA13484, AA011114, DA05228, and MH51372, Department of Veterans Affairs Merit Awards, Affymetrix, and National Library of Medicine Biomedical Informatics Fellowships to M. Mooney (LM007088) and Ted Laderas. NR 20 TC 6 Z9 6 U1 0 U2 3 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-453X J9 FRONT NEUROSCI-SWITZ JI Front. Neurosci. PY 2011 VL 5 AR 69 DI 10.3389/fnins.2011.00069 PG 11 WC Neurosciences SC Neurosciences & Neurology GA V36GI UT WOS:000209200600065 PM 21625610 ER PT J AU Wu, SV Hui, HX AF Wu, Shuping Vincent Hui, Hongxiang TI Treat your bug right SO FRONTIERS IN PHYSIOLOGY LA English DT Editorial Material C1 [Wu, Shuping Vincent] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Wu, Shuping Vincent; Hui, Hongxiang] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Excellence Pancreat Dis, Los Angeles, CA 90095 USA. [Hui, Hongxiang] Southern Med Univ, Guangzhou, Guangdong, Peoples R China. RP Wu, SV (reprint author), VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM vwu@ucla.edu NR 6 TC 4 Z9 4 U1 1 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PY 2011 VL 2 AR 9 DI 10.3389/fphys.2011.00009 PG 1 WC Physiology SC Physiology GA V35UD UT WOS:000209172600009 PM 21483729 ER PT J AU Segal, AD Orendurff, MS Czerniecki, JM Schoen, J Klute, GK AF Segal, Ava D. Orendurff, Michael S. Czerniecki, Joseph M. Schoen, Jason Klute, Glenn K. TI Comparison of transtibial amputee and non-amputee biomechanics during a common turning task SO GAIT & POSTURE LA English DT Article DE Transtibial amputee; Rotation; Torque; Transverse plane; Turning ID GROUND REACTION FORCES; PROSTHETIC FEET; WALKING; GAIT; DEGENERATION; KINETICS; PATH; PAIN AB The biomechanics of amputee turning gait has been minimally studied, in spite of its integral relationship with the more complex gait required for household or community ambulation. This study compares the biomechanics of unilateral transtibial amputees and non-amputees completing a common turning task. Full body gait analysis was completed for subjects walking at comparable self-selected speeds around a 1 m radius circular path. Peak internal and external rotation moments of the hip, knee and ankle, mediolateral ground reaction impulse (ML GRI), peak effective limb length, and stride length were compared across conditions (non-amputee, amputee prosthetic limb, amputee sound limb). Amputees showed decreased internal rotation moments at the prosthetic limb hip and knee compared to non-amputees, perhaps as a protective mechanism to minimize stress on the residual limb. There was also an increase in amputee sound limb hip external rotation moment in early stance compared to non-amputees, which may be a compensation for the decrease in prosthetic limb internal rotation moment during late stance of the prior step. ML GRI was decreased for the amputee inside limb compared to non-amputee, possibly to minimize the body's acceleration in the direction of the turn. Amputees also exhibited a shorter inside limb stride length compared to non-amputees. Both decreased ML GRI and stride length indicate a COM that is more centered over the base of support, which may minimize the risk of falling. Finally, a longer effective limb length was found for the amputee inside limb turning, possibly due to excessive trunk shift. Published by Elsevier By. C1 [Segal, Ava D.; Orendurff, Michael S.; Czerniecki, Joseph M.; Schoen, Jason; Klute, Glenn K.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. [Segal, Ava D.; Klute, Glenn K.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Klute, Glenn K.] Univ Washington, Dept Mech & Elect Engn, Seattle, WA 98195 USA. [Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Klute, GK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, 1660 S Columbian Way,MS-151, Seattle, WA USA. EM gklute@u.washington.edu FU Office of Rehabilitation R&D Service, Department of Veterans Affairs, VA Puget Sound Health Care System, Seattle, WA [A36111] FX Jane B. Shofer, MS completed the statistical analysis for the present manuscript. This material is based upon work supported by the Office of Rehabilitation R&D Service (Grant # A36111), Department of Veterans Affairs, VA Puget Sound Health Care System, Seattle, WA. NR 22 TC 17 Z9 19 U1 3 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2011 VL 33 IS 1 BP 41 EP 47 DI 10.1016/j.gaitpost.2010.09.021 PG 7 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 724FI UT WOS:000287561100008 PM 20974535 ER PT S AU Ho, L Chen, LH Wang, J Zhao, W Talcott, ST Ono, K Teplow, D Humala, N Cheng, A Percival, SS Ferruzzi, M Janle, E Dickstein, DL Pasinetti, GM AF Ho, Lap Chen, Ling Hong Wang, Jun Zhao, Wei Talcott, Stephen T. Ono, Kenjiro Teplow, David Humala, Nelson Cheng, Alice Percival, Susan S. Ferruzzi, Mario Janle, Elsa Dickstein, Dara L. Pasinetti, Giulio Maria BE Casadesus, G TI Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-Type Neuropathology and Cognitive Deterioration SO HANDBOOK OF ANIMAL MODELS IN ALZHEIMER'S DISEASE SE Advances in Alzheimers Disease LA English DT Article; Book Chapter DE Alzheimer's disease dementia; amyloid-beta protein precursor (A beta PP); high-molecular weight amyloid-beta oligomer species; polyphenols ID PHOTOINDUCED CROSS-LINKING; MOUSE MODEL; UNMODIFIED PROTEINS; TRANSGENIC MOUSE; ELLAGIC ACID; IN-VITRO; BETA; OLIGOMERS; DEFICITS; PLAQUES AB We recently found that moderate consumption of two un-related red wines generate from different grape species, a Cabernet Sauvignon and a muscadine wine that are characterized by distinct component composition of polyphenolic compounds, significantly attenuated the development of Alzheimer's disease (AD)-type brain pathology and memory deterioration in a transgenic AD mouse model. Interestingly, our evidence suggests that the two red wines attenuated AD phenotypes through independent mechanisms. In particular, we previously found that treatment with Cabernet Sauvignon reduced the generation of AD-type beta-amyloid (A beta) peptides. In contrast, evidence from our present study suggests that muscadine treatment attenuates A beta neuropathology and A beta-related cognitive deterioration in Tg2576 mice by interfering with the oligomerization of A beta molecules to soluble high-molecular-weight A beta oligomer species that are responsible for initiating a cascade of cellular events resulting in cognitive decline. Collectively, our observations suggest that distinct polyphenolic compounds from red wines may be bioavailable at the organism level and beneficially modulate AD phenotypes through multiple A beta-related mechanisms. Results from these studies suggest the possibility of developing a "combination" of dietary polyphenolic compounds for AD prevention and/or therapy by modulating multiple A beta-related mechanisms. C1 [Ho, Lap; Chen, Ling Hong; Wang, Jun; Zhao, Wei; Humala, Nelson; Cheng, Alice; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio Maria] James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. [Talcott, Stephen T.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA. [Ono, Kenjiro; Teplow, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Percival, Susan S.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. [Ferruzzi, Mario; Janle, Elsa] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. [Dickstein, Dara L.; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. RP Ho, L (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM Lap.Ho@mssm.edu NR 38 TC 0 Z9 0 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 2210-5727 BN 978-1-60750-733-8; 978-1-60750-732-1 J9 ADV ALZH DIS PY 2011 VL 1 BP 263 EP 275 DI 10.3233/978-1-60750-733-8-263 PG 13 WC Neurosciences SC Neurosciences & Neurology GA BC2XS UT WOS:000351444800020 ER PT J AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette BE Preedy, VR Watson, RR Martin, CR TI The Physiological Relationships Between the Brainstem, Vagal Stimulation, and Feeding SO HANDBOOK OF BEHAVIOR, FOOD AND NUTRITION LA English DT Article; Book Chapter ID GLUCAGON-LIKE PEPTIDE-1; IMPLANTABLE GASTRIC STIMULATION; PLASMA GHRELIN LEVELS; INHIBITS FOOD-INTAKE; INDUCED WEIGHT-LOSS; ELECTRICAL-STIMULATION; MORBID-OBESITY; LONG-TERM; SYNERGISTIC INTERACTION; INTRAVENOUS-INFUSION C1 [Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, Los Angeles, CA 90095 USA. [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Stengel, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Bldg 115,Room 117, Los Angeles, CA 90095 USA. EM astengel@mednet.ucla.edu NR 83 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-92270-6 PY 2011 BP 817 EP 828 DI 10.1007/978-0-387-92271-3_54 D2 10.1007/978-0-387-92271-3 PG 12 WC Behavioral Sciences; Nutrition & Dietetics SC Behavioral Sciences; Nutrition & Dietetics GA BDE45 UT WOS:000312946600056 ER PT S AU Canu, E McLaren, DG Fitzgerald, ME Bendlin, BB Zoccatelli, G Alessandrini, F Pizzini, FB Ricciardi, GK Beltramello, A Johnson, SC Frisoni, GB AF Canu, Elisa McLaren, Donald G. Fitzgerald, Michele E. Bendlin, Barbara B. Zoccatelli, Giada Alessandrini, Franco Pizzini, Francesca B. Ricciardi, Giuseppe K. Beltramello, Alberto Johnson, Sterling C. Frisoni, Giovanni B. BE Ashford, JW Rosen, A Adamson, M Bayley, P Sabri, O Furst, A Black, SE Weiner, M TI Mapping the Structural Brain Changes in Alzheimer's Disease: The Independent Contribution of Two Imaging Modalities SO HANDBOOK OF IMAGING THE ALZHEIMER BRAIN SE Advances in Alzheimers Disease LA English DT Article; Book Chapter DE Diffusion Tensor Imaging (DTI); Alzheimer's disease (AD); Microstructure; Fractional Anisotropy (FA); Mean Diffusivity (MD) ID MILD COGNITIVE IMPAIRMENT; WHITE-MATTER CHANGES; MOTOR CORTEX INVOLVEMENT; AGE-RELATED-CHANGES; IN-VIVO; CORPUS-CALLOSUM; NEURODEGENERATIVE DISORDERS; AMYLOID DEPOSITS; TRACT INTEGRITY; WATER DIFFUSION AB The macrostructural atrophy of Alzheimer's disease (AD) has been fully described. Current literature reports that also microstructural alterations occur in AD since the early stages. However, whether the microstructural changes offer unique information independent from macrostructural atrophy is unclear. Aim of this study is to define the independent contribution of macrostructural atrophy and microstructural alterations on AD pathology. The study involved 17 moderate to severe AD patients and 13 healthy controls. All participants underwent conventional and non conventional MRI (respectively, T1-weighted and diffusion-weighted MR scanning). We processed the images in order to obtain gray and white matter volumes to assess macrostructural atrophy, and fractional anisotropy and mean diffusivity to assess the microstructural damage. Analyses of covariance between patients and controls were performed to investigate microstructural tissue damage independent of macrostructural tissue loss, and viceversa, voxel by voxel. We observed microstructural differences, independent of macrostructural atrophy, between patients and controls in temporal and retrosplenial regions, as well as in thalamus, corticopontine tracts, striatum and precentral gyrus. Volumetric differences, independent of microstructural alterations, were observed mainly in the entorhinal cortex, posterior cingulum, and splenium. Measures of microstructural damage provide unique information not obtainable with volumetric mapping in regions known to be pivotal in AD as well as in others thought to be spared. This work expands the understanding of the topography of pathological changes in AD that can be captured with imaging techniques. C1 [Canu, Elisa; Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, LENITEM Lab Epidemiol Neuroimaging & Telemed, IRCCS Ctr San Giovanni Dio FBF, Brescia, Italy. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI USA. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Zoccatelli, Giada; Alessandrini, Franco; Pizzini, Francesca B.; Ricciardi, Giuseppe K.; Beltramello, Alberto] Osped Civile, Serv Neuroradiol, I-37126 Verona, Italy. RP Frisoni, GB (reprint author), IRCCS San Giovanni Dio FBF, LENITEM Lab Epidemiol Neuroimaging & Telemed, Via Pilastroni 4, I-25125 Brescia, Italy. EM gfrisoni@fatebenefratelli.it RI Pizzini, Francesca Bendetta/O-5291-2016; Canu, Elisa/K-1423-2016 OI Pizzini, Francesca Bendetta/0000-0002-6285-0989; Canu, Elisa/0000-0001-5804-3378 NR 68 TC 0 Z9 0 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 2210-5727 BN 978-1-60750-793-2; 978-1-60750-792-5 J9 ADV ALZH DIS PY 2011 VL 2 BP 487 EP 498 DI 10.3233/978-1-60750-793-2-487 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BC2XT UT WOS:000351445400042 ER PT J AU Puppala, S Coletta, DK Schneider, J Hu, SL Farook, VS Dyer, TD Arya, R Blangero, J Duggirala, R DeFronzo, RA Jenkinson, CP AF Puppala, Sobha Coletta, Dawn K. Schneider, Jennifer Hu, Shirley L. Farook, Vidya S. Dyer, Thomas D. Arya, Rector Blangero, John Duggirala, Ravindranath DeFronzo, Ralph A. Jenkinson, Christopher P. TI Genome-Wide Linkage Screen for Systolic Blood Pressure in the Veterans Administration Genetic Epidemiology Study (VAGES) of Mexican-Americans and Confirmation of a Major Susceptibility Locus on Chromosome 6q14.1 SO HUMAN HEREDITY LA English DT Article DE Hypertension; Linkage; Antihypertensive medication; Genetic location; Heritability ID ESSENTIAL-HYPERTENSION; UNITED-STATES; ASSOCIATION; SCAN; METAANALYSIS; SEGREGATION; PREVALENCE; PEDIGREES; COMMITTEE; DISEASE AB Objective: Hypertension or high blood pressure is a strong correlate of diseases such as obesity and type 2 diabetes. We conducted a genome-wide linkage screen to identify susceptibility genes influencing systolic blood pressure (SBP) and diastolic blood pressure (DBP) in Mexican-Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). Methods: Using data from 1,089 individuals distributed across 266 families, we performed a multipoint linkage analysis to localize susceptibility loci for SBP and DBP by applying two models. In model 1, we added a sensible constant to the observed BP values in treated subjects [Tobin et al.; Stat Med 2005;24:2911-2935] to account for antihypertensive use (i.e. 15 and 10 mm Hg to SBP and DBP values, respectively). In model 2, we fixed values of 140 mm Hg for SBP and 90 mm Hg for DBP, if the treated values were less than the standard referenced treatment thresholds of 140/90 mm Hg for hypertensive status. However, if the observed treated BP values were found to be above these standard treatment thresholds, the actual observed treated BP values were retained in order not to reduce them by substitution of the treatment threshold values. Results: The multipoint linkage analysis revealed strong linkage signals for SBP compared with DBP. The strongest evidence for linkage of SBP (model 1, LOD = 5.0; model 2, LOD = 3.6) was found on chromosome 6q14.1 near the marker D6S1031 (89 cM) in both models. In addition, some evidence for SBP linkage occurred on chromosomes 1q, 4p, and 16p. Most importantly, our major SBP linkage finding on chromosome 6q near marker D6S1031 was independently confirmed in a Caucasian population (LOD = 3.3). In summary, our study found evidence for a major locus on chromosome 6q influencing SBP levels in Mexican-Americans. Copyright (C) 2011 S. Karger AG, Basel C1 [DeFronzo, Ralph A.; Jenkinson, Christopher P.] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, Dept Med, San Antonio, TX 78229 USA. [Puppala, Sobha; Schneider, Jennifer; Farook, Vidya S.; Dyer, Thomas D.; Blangero, John; Duggirala, Ravindranath; Jenkinson, Christopher P.] Univ Texas Hlth Sci Ctr San Antonio, SW Fdn Biomed Res, San Antonio, TX 78229 USA. [Hu, Shirley L.; DeFronzo, Ralph A.; Jenkinson, Christopher P.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Arya, Rector] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Coletta, Dawn K.] Arizona State Univ, Ctr Metab Biol, Tempe, AZ USA. [Coletta, Dawn K.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Jenkinson, CP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM jenkinsonc@uthscsa.edu RI Coletta, Dawn/G-6382-2016 OI Coletta, Dawn/0000-0001-5819-5152 FU National Institutes of Health [DK42273, DK47482, DK53889, DK70746, MH59490]; American Heart Association; Veterans Administration FX We thank Marcel J. Fourcaudot and Lenore M. Rodriguez for their excellent technical assistance. We thank our nurses, James King, John Kincaid, Rose Kaminski-Graham, and Norma Diaz, for their excellent care of the patients throughout the study. This work was supported by a Veterans Administration Epidemiologic grant. This study was also supported in part by grants from the National Institutes of Health (DK42273, DK47482, DK53889, DK70746, and MH59490), and by an American Heart Association National Scientist Development Grant. We thank the Center for Inherited Disease Research (CIDR) for providing a genome scan using the VAGES data. We thank the participants of the VAGES and are grateful for their participation and cooperation. NR 55 TC 11 Z9 11 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2011 VL 71 IS 1 BP 1 EP 10 DI 10.1159/000323143 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 758IG UT WOS:000290157200001 PM 21293138 ER PT J AU Ellingson, K Muder, RR Jain, R Kleinbaum, D Feng, PJI Cunningham, C Squier, C Lloyd, J Edwards, J Gebski, V Jernigan, J AF Ellingson, Katherine Muder, Robert R. Jain, Rajiv Kleinbaum, David Feng, Pei-Jean I. Cunningham, Candace Squier, Cheryl Lloyd, Jon Edwards, Jonathan Gebski, Val Jernigan, John TI Sustained Reduction in the Clinical Incidence of Methicillin-Resistant Staphylococcus aureus Colonization or Infection Associated with a Multifaceted Infection Control Intervention SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTION; HOSPITAL ADMISSION; BACTEREMIA; STATES; SURVEILLANCE; COMMUNITY; EPIDEMIOLOGY; PREVALENCE; MORTALITY AB OBJECTIVE. To assess the impact and sustainability of a multifaceted intervention to prevent methicillin-resistant Staphylococcus aureus (MRSA) transmission implemented in 3 chronologically overlapping phases at 1 hospital. DESIGN. Interrupted time-series analyses. SETTING. A Veterans Affairs hospital in the northeastern United States. PATIENTS AND PARTICIPANTS. Individuals admitted to acute care units from October 1, 1999, through September 30, 2008. To calculate the monthly clinical incidence of MRSA colonization or infection, the number of MRSA-positive cultures obtained from a clinical site more than 48 hours after admission among patients with no MRSA-positive clinical cultures during the previous year was divided by patient-days at risk. Secondary outcomes included clinical incidence of methicillin-sensitive S. aureus colonization or infection and incidence of MRSA bloodstream infections. INTERVENTIONS. The intervention-implemented in a surgical ward beginning October 2001, in a surgical intensive care unit beginning October 2003, and in all acute care units beginning July 2005-included systems and behavior change strategies to increase adherence to infection control precautions (eg, hand hygiene and active surveillance culturing for MRSA). RESULTS. Hospital-wide, the clinical incidence of MRSA colonization or infection decreased after initiation of the intervention in 2001, compared with the period before intervention (P = .002), and decreased by 61% (P < .001) in the 7-year postintervention period. In the postintervention period, the hospital-wide incidence of MRSA bloodstream infection decreased by 50% (P = .02), and the proportion of S. aureus isolates that were methicillin resistant decreased by 30% (P < .001). CONCLUSIONS. Sustained decreases in hospital-wide clinical incidence of MRSA colonization or infection, incidence of MRSA bloodstream infection, and proportion of S. aureus isolates resistant to methicillin followed implementation of a multifaceted prevention program at one Veterans Affairs hospital. Findings suggest that interventions designed to prevent transmission can impact endemic antimicrobial resistance problems. C1 [Ellingson, Katherine] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Muder, Robert R.; Jain, Rajiv; Cunningham, Candace; Squier, Cheryl; Lloyd, Jon] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gebski, Val] Univ Sydney, Camperdown, NSW, Australia. RP Ellingson, K (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Clifton Rd NE,MS A-31, Atlanta, GA 30333 USA. EM kellingson@cdc.gov NR 31 TC 37 Z9 38 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JAN PY 2011 VL 32 IS 1 BP 1 EP 8 DI 10.1086/657665 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 694IP UT WOS:000285290200001 PM 21133794 ER PT J AU Feng, PJI Kallen, AJ Ellingson, K Muder, R Jain, R Jernigan, JA AF Feng, Pei-Jean I. Kallen, Alexander J. Ellingson, Katherine Muder, Robert Jain, Rajiv Jernigan, John A. TI Clinical Incidence of Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization or Infection as a Proxy Measure for MRSA Transmission in Acute Care Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID ADMISSION; SURVEILLANCE; BACTEREMIA; MORTALITY; OUTCOMES; IMPACT AB BACKGROUND. The incidence of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection has been used as a proxy measure for MRSA transmission, but incidence calculations vary depending on whether active surveillance culture (ASC) data are included. OBJECTIVE. To evaluate the relationship between incidences of MRSA colonization or infection calculated with and without ASCs in intensive care units and non-intensive care units. SETTING. A Veterans Affairs medical center. METHODS. From microbiology records, incidences of MRSA colonization or infection were calculated with and without ASC data. Correlation coefficients were calculated for the 2 measures, and Poisson regression was used to model temporal trends. A Poisson interaction model was used to test for differences in incidence trends modeled with and without ASCs. RESULTS. The incidence of MRSA colonization or infection calculated with ASCs was 4.9 times higher than that calculated without ASCs. Correlation coefficients for incidences with and without ASCs were 0.42 for intensive care units, 0.59 for non-intensive care units, and 0.48 hospital-wide. Trends over time for the hospital were similar with and without ASCs (incidence rate ratio with ASCs, 0.95 [95% confidence interval, 0.93-0.97]; incidence rate ratio without ASCs, 0.95 [95% confidence interval, 0.92-0.99]; P = .68). Without ASCs, 35% of prevalent cases were falsely classified as incident. CONCLUSIONS. At 1 Veterans Affairs medical center, the incidence of MRSA colonization or infection calculated solely on the basis of clinical culture results commonly misclassified incident cases and underestimated incidence, compared with measures that included ASCs; however, temporal changes were similar. These findings suggest that incidence measured without ASCs may not accurately reflect the magnitude of MRSA transmission but may be useful for monitoring transmission trends over time, a crucial element for evaluating the impact of prevention activities. C1 [Feng, Pei-Jean I.; Kallen, Alexander J.; Ellingson, Katherine; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Muder, Robert; Jain, Rajiv] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Kallen, AJ (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-35, Atlanta, GA 30333 USA. EM ffp0@cdc.gov NR 16 TC 6 Z9 7 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JAN PY 2011 VL 32 IS 1 BP 20 EP 25 DI 10.1086/657668 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 694IP UT WOS:000285290200003 PM 21133793 ER PT J AU Sonnenberg, A Melton, SD Genta, RM AF Sonnenberg, Amnon Melton, Shelby D. Genta, Robert M. TI Frequent Occurrence of Gastritis and Duodenitis in Patients with Inflammatory Bowel Disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE chronic active gastritis; Crohn's disease; duodenitis; epidemiology of gastritis; Helicobacter pylori; ulcerative colitis ID FOCALLY ENHANCED GASTRITIS; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI; CROHNS-DISEASE; ULCERATIVE-COLITIS; SYDNEY SYSTEM; BIOPSIES; PREVALENCE; ANTRUM; BODY AB Background: The purpose was to study the epidemiology of Helicobacter-negative gastritis among a large group of patients with inflammatory bowel disease (IBD) and healthy controls. Methods: From a computerized database of surgical pathology reports we selected 5493 patients who underwent colonoscopy and upper gastrointestinal endoscopy with biopsy results from both procedures. The presence of gastritis and duodenitis was compared among 550 case subjects with IBD and 4943 healthy control subjects. The results are expressed as prevalence rates, as well as age- and sex-adjusted odds ratios with 95% confidence intervals. Results: Any type gastritis was found in 13% of controls and 25% of IBD patients (Crohn's disease [CD] 33%, ulcerative colitis [UC] 19%). Duodenitis was found in 1% of controls and 13% of IBD patients (CD 26%, UC 3%). In subjects younger than 18 years the prevalence of gastritis and duodenitis were 53% and 40% in CD, respectively, and 38% and 0% in UC, respectively. Similar prevalence rates were found in men and women. The odds ratio for Helicobacter-negative chronic active gastritis associated with CD was 11.7 (7.5-18.0) and with UC 2.8 (1.4-5.0). The corresponding values for focally enhanced gastritis were 40.1 (15.5-114.9) in CD and 0 in UC. Conclusions: Helicobacter-negative gastritis and duodenitis occur significantly more often in patients with IBD than healthy controls. Such upper gastrointestinal inflammation appears to be particularly common in CD and younger patients. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Genta, Robert M.] Caris Life Sci, Irving, TX USA. [Melton, Shelby D.; Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Melton, Shelby D.; Genta, Robert M.] Dallas VA Med Ctr, Dallas, TX USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 33 TC 20 Z9 21 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2011 VL 17 IS 1 BP 39 EP 44 DI 10.1002/ibd.21356 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 693XK UT WOS:000285258500007 PM 20848539 ER PT J AU Katzman, MA Brawman-Mintzer, O Reyes, EB Olausson, B Liu, S Eriksson, H AF Katzman, Martin A. Brawman-Mintzer, Olga Reyes, Efren B. Olausson, Bengt Liu, Sherry Eriksson, Hans TI Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE generalized anxiety disorder; maintenance; quetiapine ID TREATMENT-RESISTANT DEPRESSION; SEROTONIN REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; QUALITY-OF-LIFE; DOUBLE-BLIND; OPEN-LABEL; MAJOR DEPRESSION; PRIMARY-CARE; EFFICACY; AUGMENTATION AB The objective of this study was to evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy for patients with generalized anxiety disorder (GAD). Time-to-event (anxiety symptom recurrence; maximum 52 weeks) multicenter, randomized-withdrawal, parallel-group, double-blind, placebo-controlled study of quetiapine XR (50-300 mg/day) following open-label run-in (4-8 weeks) and open-label stabilization (>= 12 weeks). Primary variable: time from randomization to anxiety event. Secondary variables included: Hamilton Anxiety Rating Scale (HAM-A) total, HAM-A psychic/somatic anxiety factors, Clinical Global Impression-Severity of Illness (CGI-S), and Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) scores; adverse events (AE) reporting. Four hundred and thirty-two patients, stabilized on quetiapine XR, were randomized to continue quetiapine XR (N=216) or switch to placebo (N=216). Risk of anxiety symptom recurrence was significantly reduced by 81% for quetiapine XR versus placebo: hazard ratio = 0.19 (95% confidence interval 0.12-0.31; P < 0.001). Fewer patients receiving quetiapine XR (N=22, 10.2%) than placebo (N=84, 38.9%) experienced anxiety symptom recurrence. Significant differences were observed between quetiapine XR and placebo in: HAM-A total, psychic/somatic, CGI-S (all P < 0.001) and Q-LES-Q (P < 0.05) scores. AEs (>10%) during open-label treatment were dry mouth, sedation, somnolence, dizziness, fatigue, and constipation. During randomized treatment, the most common AEs for quetiapine XR were headache and nasopharyngitis. Quetiapine XR monotherapy reduced the risk of anxiety symptom recurrence in patients with GAD stabilized on quetiapine XR, with tolerability results consistent with the known profile of quetiapine. Int Clin Psychopharmacol 26: 11-24 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Katzman, Martin A.] START Clin Mood & Anxiety Disorders, Toronto, ON M4W 2N4, Canada. [Katzman, Martin A.] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Katzman, Martin A.] Lakehead Univ, Dept Psychol, Thunder Bay, ON, Canada. [Katzman, Martin A.] Lakehead Univ, Master Publ Hlth Program, Thunder Bay, ON P7B 5E1, Canada. [Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Reyes, Efren B.] Natl Ctr Mental Hlth, Mandaluyong City, Philippines. [Olausson, Bengt; Eriksson, Hans] AstraZeneca R&D, Sodertalje, Sweden. [Liu, Sherry] AstraZeneca, Wilmington, DE USA. RP Katzman, MA (reprint author), START Clin Mood & Anxiety Disorders, 32 Pk Rd, Toronto, ON M4W 2N4, Canada. EM mkatzman@startclinic.ca FU AstraZeneca [D1448C00012] FX The authors thank Catherine Hoare, Ph.D., from Complete Medical Communications, who provided medical writing support funded by AstraZeneca. The following investigators were involved in this study: Lawrence Adler, Diab Almhana, Donald Anderson, Gregory Asnis, Sarah Atkinson, Roy Autry, Michael Banov, Benny Barnhart, Bruce Berg, Brian Bortnick, Olga Brawman-Mintzer, Ronald Brenner, Edward Burdick, Joel Diamond, Nizar El-Khalili, John Heussy, Miguel Flores, Michael Greenbaum, Paul Gross, David Meyer, Valentin Isacescu, William Jeter, Michael Johnson, Zerrin Kayatekin, Gustavo Kinrys, Thomas Marbury, Paul Markovitz, Jorge Porras, Craig McCarthy, Irina Mezhebovsky, Amy Mulroy, John Prater, Alfredo Rivera, Angelo Sambunaris, Veronique Sebastian, Andrew Sedillo, Eric Smith, Phebe Tucker, Amit Vijapura, Robert Buynak, Kettlie Daniels, David Grubb, Margarita Nunez, Haydn Thomas, Reinaldo Verson, Daniel Vine, Ethan Kass, Andrew Goddard, Matthew Menza, Bijan Bastani (USA); Richard Bergeron, Gilbert Dru, Carlos Galarraga-Carrero, Martin Katzman, Roumen Milev, Michael Van Ameringen, Martin Tremblay, Serge Lessard, Pratap Chokka (Canada); Thomas George, Michael Theodoros, Bruce Lawford, Phillip Morris, Peter Farnbach, Jayashri Kulkarni (Australia); Hannu Koponen, Ulla Lepola, Liisa Lahdelma, Markku Timonen, Marko Sorvaniemi, Riitta Riihikangas (Finland); Klaus-Christian Steinwachs, Eugen Schlegel, Heike Benes, Gunther Karlbauer, H.-J. Gertz (Germany); Gabor Feller, Gabor Vincze, Sandor Koffler (Hungary); Kang-Seob Oh, Jin-Pyo Hong, Jeong-Ho Chae, Bum-Hee Yu (South Korea); B Bodalia, J Langan, Christopher Strang, Barry D Silvert, John Calvert, Krishna Korlipara, James Simpson, Alun Cooper, Ravi Pawa, John Robinson (United Kingdom); Konstantin Zhukov, Boris Tsygankov, Mikhail Ivanov, Boris Karvasarskii, Vladimir Vilianov, Valeriy Krasnov, Leonid Bardenshtein, Nataliya Dobrovolskaya (Russia); Ikke Siregar, Ashwin Kandouw, Anak Kusumawardhani (Indonesia); Efren Reyes, Alma Jimenez, Agnes Padilla (The Philippines). This study (Platinum; D1448C00012) was funded by AstraZeneca. NR 63 TC 39 Z9 40 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2011 VL 26 IS 1 BP 11 EP 24 DI 10.1097/YIC.0b013e32833e34d9 PG 14 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 691MG UT WOS:000285083700002 PM 20881846 ER PT J AU Russell, R Anzueto, A Weisman, I AF Russell, Richard Anzueto, Antonio Weisman, Idelle TI Optimizing management of chronic obstructive pulmonary disease in the upcoming decade SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Review DE COPD; chronic obstructive pulmonary disease; long-acting bronchodilator; early treatment AB Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality. Caring for patients with COPD, particularly those with advanced disease who experience frequent exacerbations, places a significant burden on health care budgets, and there is a global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on the natural history and clinical course of COPD has fuelled a fundamental shift in our approach to the disease. The emergence of data highlighting the heterogeneity in rate of lung function decline has altered our perception of disease progression in COPD and our understanding of appropriate strategies for the management of stable disease. These data have demonstrated that early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in lung function and to reduce the frequency of exacerbations that contribute to functional decline. The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exacerbations, and maintaining quality of life, and slowing disease progression is now becoming an achievable aim. A challenge for the future will be to capitalize on these observations by improving the identification and diagnosis of patients with COPD early in the course of their disease, so that effective interventions can be introduced before the more advanced, disabling, and costly stages of the disease. Here we critically review emerging data that underpin the advances in our understanding of the clinical course and management of COPD, and evaluate both current and emerging pharmacologic options for effective maintenance treatment. C1 [Russell, Richard] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Weisman, Idelle] Pfizer Inc, Med Affairs, Resp, Primary Care Business Unit, New York, NY USA. RP Anzueto, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd 111E, San Antonio, TX 78229 USA. EM anzueto@uthcsa.edu OI RUSSELL, RICHARD/0000-0002-3890-7201 NR 81 TC 13 Z9 14 U1 0 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9106 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2011 VL 6 BP 47 EP 61 DI 10.2147/COPD.S13758 PG 15 WC Respiratory System SC Respiratory System GA V28WB UT WOS:000208709800006 PM 21311693 ER PT J AU Cooper, CB Anzueto, A Decramer, M Celli, B Tashkin, DP Leimer, I Kesten, S AF Cooper, Christopher B. Anzueto, Antonio Decramer, Marc Celli, Bartolome Tashkin, Donald P. Leimer, Inge Kesten, Steven TI Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE chronic obstructive pulmonary disease; clinical trials; exacerbations; inhaled anticholinergics; tiotropium AB Background: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawal in tiotropium trials. Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group tiotropium trials of at least six months' duration was performed. Trials had similar inclusion and exclusion criteria. Exacerbation definition was standardized. Patients were divided into two groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND (anticholinergics not discontinued, not previously prescribed). Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced expiratory volume in one second (FEV1)/forced vital capacity (43% versus 48%), and lower baseline FEV1 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, tiotropium reduced the risk for an exacerbation (hazard ratio [HR] = 0.83, P < 0.0001 [D] versus 0.79, P < 0.0001 [ND]) and a hospitalized exacerbation (HR = 0.85, P = 0.0467 versus 0.79, P = 0.0094). Tiotropium reduced the number of exacerbations per patient-year (rate ratio [RR] = 0.82, P < 0.0001 [D] versus RR = 0.80, P < 0.0001 [ND]) and associated hospitalizations per patient-year (RR = 0.88, P = 0.015 [D] versus RR = 0.74, P < 0.0001 [ND]). Conclusion: Tiotropium reduced exacerbations in patients who did and did not have anticholinergics discontinued upon randomization in clinical trials. C1 [Cooper, Christopher B.; Tashkin, Donald P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Decramer, Marc] Katholieke Univ Leuven, Louvain, Belgium. [Celli, Bartolome] Brigham & Womens Hosp, Boston, MA 02115 USA. [Leimer, Inge] Boehringer Ingelheim Int GmbH, Ingelheim, Germany. [Kesten, Steven] Uptake Med Corp, Tustin, CA USA. RP Cooper, CB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave,37-131 CHS, Los Angeles, CA 90095 USA. EM ccooper@mednet.ucla.edu FU Boehringer Ingelheim; Pfizer FX Preparation of this paper was funded jointly by Boehringer Ingelheim and Pfizer. The study design, collection, analysis, and interpretation of data were funded by Boehringer Ingelheim and Pfizer. NR 27 TC 5 Z9 5 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9106 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2011 VL 6 BP 269 EP 275 DI 10.2147/COPD.S17864 PG 7 WC Respiratory System SC Respiratory System GA V28WB UT WOS:000208709800030 PM 21845038 ER PT J AU Nicosia, RF Zorzi, P Ligresti, G Morishita, A Aplin, AC AF Nicosia, Roberto F. Zorzi, Penelope Ligresti, Giovanni Morishita, Ann Aplin, Alfred C. TI Paracrine regulation of angiogenesis by different cell types in the aorta ring model SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY LA English DT Article DE VEGF; bFGF; PDGF; angiopoietin; MMP; TIMP; microarray ID ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR INDUCE EXPRESSION; SMOOTH-MUSCLE CELLS; RAT AORTA; IN-VITRO; COLLAGEN GEL; INFLAMMATORY CYTOKINES; CARCINOMA-CELLS; CLOT CULTURE AB The development of blood vessels during angiogenesis is the result of paracrine interactions between tube-forming endothelial cells and angiogenic factor-producing nonendothelial cells. This process can be reproduced and studied under chemically defined culture conditions by culturing vascular explants in three-dimensional gels of extracellular matrix. Rings of rat or mouse aorta cultured in collagen, fibrin or basement membrane gels produce angiogenic outgrowths composed of a mixed population of endothelial cells and nonendothelial cells. Aortic angiogenesis is regulated by endogenous angiogenic factors, inflammatory cytokines, chemokines, extracellular matrix molecules, and proteolytic enzymes produced by cells of the vessel wall in response to the injury of the dissection procedure. In this paper, we review how macrophages, mural cells and fibroblasts regulate different stages of the angiogenic process, from the formation of immature endothelial sprouts to the reabsorption of the neovessels. We also describe how aortic cultures can be used to study interactions between angiogenic outgrowths and nonvascular cell types such as bone marrow macrophages, platelets or cancer cells. Morphologic, genetic and functional studies of this model have provided invaluable information on how vessels form, mature, interact with nonvascular cell types, and are eventually reabsorbed. Further analysis of the paracrine cross-talk between aortic endothelial and nonendothelial cells is likely to provide new insights into the angiogenic process and its key mechanisms. C1 [Nicosia, Roberto F.; Zorzi, Penelope; Ligresti, Giovanni; Morishita, Ann; Aplin, Alfred C.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol Serv, Pathol & Lab Med S113, Seattle, WA 98108 USA. [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Lab Med Serv, Seattle, WA 98108 USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol Serv, Pathol & Lab Med S113, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov FU National Heart, Lung, and Blood Institute [HL52585]; US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory FX Supported by National Heart, Lung, and Blood Institute Grant HL52585 and Merit Review Grant from US Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research Program. NR 51 TC 23 Z9 24 U1 1 U2 3 PU U B C PRESS PI BILBAO PA UNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO, SPAIN SN 0214-6282 J9 INT J DEV BIOL JI Int. J. Dev. Biol. PY 2011 VL 55 IS 4-5 SI SI BP 447 EP 453 DI 10.1387/ijdb.103222rn PG 7 WC Developmental Biology SC Developmental Biology GA 831RH UT WOS:000295748300014 PM 21858770 ER PT J AU Anderson, A Bramen, J Douglas, PK Lenartowicz, A Cho, A Culbertson, C Brody, AL Yuille, AL Cohen, MS AF Anderson, Ariana Bramen, Jennifer Douglas, Pamela K. Lenartowicz, Agatha Cho, Andrew Culbertson, Chris Brody, Arthur L. Yuille, Alan L. Cohen, Mark S. TI Large Sample Group Independent Component Analysis of Functional Magnetic Resonance Imaging Using Anatomical Atlas-Based Reduction and Bootstrapped Clustering SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE fMRI; group ICA; bagging; clustering; bootstrap ID FMRI; DEPENDENCE AB Independent component analysis (ICA) is a popular method for the analysis of functional magnetic resonance imaging (fMRI) signals that is capable of revealing connected brain systems of functional significance. To be computationally tractable, estimating the independent components (ICs) inevitably requires one or more dimension reduction steps. Whereas most algorithms perform such reductions in the time domain, the input data are much more extensive in the spatial domain, and there is broad consensus that the brain obeys rules of localization of function into regions that are smaller in number than the number of voxels in a brain image. These functional units apparently reorganize dynamically into networks under different task conditions. Here we develop a new approach to ICA, producing group results by bagging and clustering over hundreds of pooled single-subject ICA results that have been projected to a lower-dimensional subspace. Averages of anatomically based regions are used to compress the single subject-ICA results prior to clustering and resampling via bagging. The computational advantages of this approach make it possible to perform group-level analyses on datasets consisting of hundreds of scan sessions by combining the results of within-subject analysis, while retaining the theoretical advantage of mimicking what is known of the functional organization of the brain. The result is a compact set of spatial activity patterns that are common and stable across scan sessions and across individuals. Such representations may be used in the context of statistical pattern recognition supporting real-time state classification. (C) 2011 Wiley Periodicals, Inc. Int J Imaging Syst Technol, 21, 223-231, 2011; Published online in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/ima.20286 C1 [Anderson, Ariana; Bramen, Jennifer; Douglas, Pamela K.; Lenartowicz, Agatha; Cho, Andrew; Culbertson, Chris; Brody, Arthur L.; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur L.] Greater Los Angeles VA Healthcare Syst, Dept Radiol, Los Angeles, CA USA. [Yuille, Alan L.] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA. [Yuille, Alan L.] Korea Univ, Dept Brain & Cognit Engn, Seoul 136713, South Korea. [Cohen, Mark S.] Univ Calif Los Angeles, Dept Biomed Engn Neurol Psychol Biomed Phys & Rad, Los Angeles, CA USA. RP Anderson, A (reprint author), Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. EM ariana82@ucla.edu RI Cohen, Mark/C-6610-2011 OI Cohen, Mark/0000-0001-6731-4053 FU National Institute on Drug Abuse [DA026109, R01 DA20872]; Ministry of Education, Science and Technology [R31-2008-000-10008-0]; Veterans Affairs Type I Merit Review Award; Richard Metzner Chair in Clinical Neuropharmacology FX This work is supported by the National Institute on Drug Abuse under DA026109 to M. S. C and by WCU (World Class University) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (R31-2008-000-10008-0) to AY. The grant funding that supported the data collection was: the National Institute on Drug Abuse (A. L. B. [R01 DA20872]), a Veterans Affairs Type I Merit Review Award (A. L. B.), and an endowment from the Richard Metzner Chair in Clinical Neuropharmacology (A. L. B.). We thank Michael Durnhofer for maintaining the systems necessary for these data analyses. NR 32 TC 7 Z9 7 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0899-9457 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PY 2011 VL 21 IS 2 SI SI BP 223 EP 231 DI 10.1002/ima.20286 PG 9 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 771KH UT WOS:000291155100013 PM 22049263 ER PT S AU Kushniruk, AW Santos, SL Pourakis, G Nebeker, JR Boockvar, KS AF Kushniruk, Andre W. Santos, Susan L. Pourakis, George Nebeker, Jonathan R. Boockvar, Kenneth S. BE Borycki, EM BartleClar, JA Househ, MS Kuziemsky, CE Schraa, EG TI Cognitive Analysis of a Medication Reconciliation Tool: Applying Laboratory and Naturalistic Approaches to System Evaluation SO INTERNATIONAL PERSPECTIVES IN HEALTH INFORMATICS SE Studies in Health Technology and Informatics LA English DT Proceedings Paper CT Information Technology and Communications in Health (ITCH) Conference CY FEB, 2011 CL Univ Victoria, Sch Hlth Informat Sci, Victoria, CANADA HO Univ Victoria, Sch Hlth Informat Sci DE medication reconciliation; patient safety; cognitive analysis AB Adverse drug events can occur as a result of handoffs in patient care. To reduce the possibility of this occurring, the process of medication reconciliation (whereby the patient's medication history is compared to current and previous medications to ensure accuracy) is becoming recognized as becoming increasingly important. To address this, computerized medication reconciliation tools have been developed. This paper describes a combined approach to evaluating the impact of such a tool. The approach has included both an artificial laboratory-based evaluation component (involving observing subjects interacting with standardized patient cases), as well as a naturalistic condition (involving real patient cases). The results indicate that there are differences in the way that subjects interact with the medication reconciliation tool, with significant differences identified in the amount of time spent and accuracy of medication documentation between physician and pharmacist users. C1 [Kushniruk, Andre W.] Univ Victoria, Sch Hlth Informat Sci, Victoria, BC, Canada. [Santos, Susan L.] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Santos, Susan L.] Univ Med & Dent New Jersey, Dept Hlth Educ & Behav Sci, New Brunswick, NJ USA. [Pourakis, George] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nebeker, Jonathan R.] VA Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Boockvar, Kenneth S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Boockvar, Kenneth S.] Jewish Home Lifecare, New York, NY USA. RP Kushniruk, AW (reprint author), Univ Victoria, Sch Hlth Informat Sci, Victoria, BC, Canada. EM andrek@uvic.ca OI Boockvar, Kenneth/0000-0003-1165-5558 NR 3 TC 7 Z9 7 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 BN 978-1-60750-709-3 J9 STUD HEALTH TECHNOL PY 2011 VL 164 BP 203 EP 207 DI 10.3233/978-1-60750-709-3-203 PG 5 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA BG8DA UT WOS:000392222000033 PM 21335711 ER PT J AU Zhang, Y Peng, Q Kiel, JW Rosende, CA Duong, TQ AF Zhang, Yi Peng, Qi Kiel, Jeffrey W. Rosende, Carlos A. Duong, Timothy Q. TI Magnetic Resonance Imaging of Vascular Oxygenation Changes during Hyperoxia and Carbogen Challenges in the Human Retina SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID LASER-DOPPLER FLOWMETRY; CHOROIDAL BLOOD-FLOW; FUNCTIONAL MRI; OPTIC-NERVE; LAMINAR SPECIFICITY; IN-VIVO; 7 TESLA; RESOLUTION; BRAIN; CATS AB PURPOSE. To demonstrate blood oxygenation level-dependent (BOLD) magnetic resonance imaging (MRI) of vascular oxygenation changes in normal, unanesthetized human retinas associated with oxygen and carbogen challenge. METHODS. MRI was performed with a 3-T human scanner and a custom-made surface-coil detector on normal volunteers. BOLD MRI with inversion recovery was used to suppress the vitreous signal. During MRI measurements, volunteers underwent three episodes of air and 100% oxygen or carbogen (5% CO2 and 95% O-2) breathing. Eye movement was effectively managed with eye fixation, synchronized blinks, and postprocessing image coregistration. BOLD time-series images were analyzed using the cross-correlation method. Percent changes due to oxygen or carbogen inhalation versus air were tabulated for whole-retina and different regions of the retina. RESULTS. Robust BOLD responses were detected. BOLD MRI percent change from a large region of interest at the posterior pole of the retina was 5.2 +/- 1.5% (N = 9 trials from five subjects) for oxygen inhalation and 5.2 +/- 1.3% (N = 11 trials from five subjects) for carbogen inhalation. Group-averaged BOLD percent changes were not significantly different between oxygen and carbogen challenges (P > 0.05). The foveal region had greater BOLD response compared with the optic nerve head region for both challenges. CONCLUSIONS. BOLD retinal responses to oxygen and carbogen breathing in unanesthetized humans can be reliably imaged at high spatiotemporal resolution. BOLD MRI has the potential to provide a valuable tool to study retinal physiology and pathophysiology, such as how vascular oxygenation at the tissue level is regulated in the normal retina, and how retinal diseases may affect oxygen response. (Invest Ophthalmol Vis Sci. 2011; 52: 286-291) DOI: 10.1167/iovs.10-6108 C1 [Zhang, Yi; Peng, Qi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Zhang, Yi; Peng, Qi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Kiel, Jeffrey W.; Rosende, Carlos A.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU Pilot grant; Translational Technology Resource [UL1RR025767]; NIH/NEI [R01 EY014211, EY018855]; Department of Veterans Affairs FX Supported by a Pilot grant (TQD); a Translational Technology Resource grant (QP) via the Clinical Translational Science Award (CTSA, parent Grant UL1RR025767); the NIH/NEI (R01 EY014211 and EY018855 to TQD); and the VISN7 Career Development Award and MERIT from the Department of Veterans Affairs (TQD). NR 53 TC 18 Z9 18 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2011 VL 52 IS 1 BP 286 EP 291 DI 10.1167/iovs.10-6108 PG 6 WC Ophthalmology SC Ophthalmology GA 702VW UT WOS:000285925000036 PM 20847121 ER PT J AU Burjonroppa, SC Varosy, PD Rao, SV Ou, FS Roe, M Peterson, E Singh, M Shunk, KA AF Burjonroppa, Sukesh C. Varosy, Paul D. Rao, Sunil V. Ou, Fang-Shu Roe, Matthew Peterson, Eric Singh, Mandeep Shunk, Kendrick A. TI Survival of Patients Undergoing Rescue Percutaneous Coronary Intervention Development and Validation of a Predictive Tool SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE acute myocardial infarction; predictive tool; rescue percutaneous coronary intervention ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR DATA REGISTRY; MIDDLESBROUGH EARLY REVASCULARIZATION; IN-HOSPITAL MORTALITY; THROMBOLYTIC THERAPY; FAILED THROMBOLYSIS; NATIONAL REGISTRY; PRIMARY ANGIOPLASTY; RANDOMIZED-TRIALS; CARDIOGENIC-SHOCK AB Objectives This study sought to develop a tool for predicting an individual's risk of mortality following rescue percutaneous coronary intervention (PCI). Background Although fibrinolytic therapy is appropriate and improves survival for certain ST-segment elevation myocardial infarction patients, a substantial proportion suffer ongoing myocardial ischemia, a class I indication for emergent percutaneous coronary intervention (rescue PCI). Methods Using the National Cardiovascular Data Registry (NCDR), rescue PCI was defined as non-elective PCI following failed fibrinolysis in patients with continuing or recurrent myocardial ischemia. Multivariable logistic regression was used to determine mortality predictors and the C-statistic for model discrimination. The NCDR-RESCUE (Real-World Estimator of Survival in Catheterized STEMI Patients Following Unsuccessful Earlier Fibrinolysis) score was developed using a shortened list of 6 pre-angiographic variables and 70% of the cohort; performance was subsequently validated against the remaining 30%. Results Among 166,516 PCI procedures on patients with an admission diagnosis of ST-segment elevation myocardial infarction, 8,007 (4.8%) represented rescue PCI. In-hospital mortality occurred in 464 (5.8%). Factors in the final model were age, glomerular filtration rate, history of congestive heart failure, insulin-treated diabetes, cardiogenic shock, and salvage status. The NCDR-RESCUE score effectively segregated individuals into 6 clinically meaningful risk categories, with 0.4% (0.0% to 1.3%), 1.6% (0.9% to 2.4%), 7.6% (5.3% to 10.4%), 27.5% (20.7% to 35.1%), 64.2% (49.8% to 76.9%), or 100% (59.0% to 100.0%) risk, respectively, of in-hospital mortality (mean +/- 95% confidence interval, C-index = 0.88, Hosmer-Lemeshow p = 0.898). Conclusions In-hospital mortality risk among individuals undergoing rescue PCI varies from minimal to extreme and can be easily calculated using the NCDR-RESCUE score. This information can be of value in counseling patients, families, and referring caregivers. (J Am Coll Cardiol Intv 2011;4: 42-50) (C) 2011 by the American College of Cardiology Foundation C1 [Burjonroppa, Sukesh C.] Ft Worth Heart PA, Ft Worth, TX 76104 USA. [Varosy, Paul D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA. [Rao, Sunil V.; Peterson, Eric] Duke Univ, Med Ctr, Durham, NC USA. [Ou, Fang-Shu; Roe, Matthew; Peterson, Eric] Duke Clin Res Inst, Durham, NC USA. [Singh, Mandeep] Mayo Clin, Rochester, MN USA. [Shunk, Kendrick A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Burjonroppa, SC (reprint author), Ft Worth Heart PA, 1300 W Rosedale, Ft Worth, TX 76104 USA. EM sukeshbc@yahoo.com FU Portola; Cordis Corp.; Novartis; Ikaria; Abbott Vascular, and Siemens Medical Systems FX From the *Fort Worth Heart PA, Fort Worth, Texas; dagger Denver Veterans Affairs Medical Center, and University of Colorado, Denver School of Medicine, Denver, Colorado; double dagger Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina; parallel to Mayo Clinic, Rochester, Minnesota; and the University of California-San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, California. Dr. Rao is a consultant for sanofi-aventis, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo-Lilly, The Medicines Company, and Terumo USA; and has received research funding from Portola, Cordis Corp., Novartis, and Ikaria. Dr. Shunk received research support from Abbott Vascular, and Siemens Medical Systems; he is on the Advisory Board for GE Healthcare; and he has intellectual property rights from SurgiVision Options (modest) and Revascular Therapeutics. All other authors have reported that they have no relationships to disclose. NR 42 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JAN PY 2011 VL 4 IS 1 BP 42 EP 50 DI 10.1016/j.jcin.2010.09.020 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 719EA UT WOS:000287181500006 PM 21251628 ER PT J AU Guadalupe, M Pollock, BH Westbrook, S Redding, S Bullock, D Anstead, G Agan, BK Marconi, VC Barbieri, S Sankar, V Rebeles, J Flahive, Y Schoolfield, J Wang, LD Lei, XF Dow, D Yeh, CK Dang, H Infante, AJ Gao, SJ AF Guadalupe, Moraima Pollock, Brad H. Westbrook, Steven Redding, Spencer Bullock, Delia Anstead, Gregory Agan, Brian K. Marconi, Vincent C. Barbieri, Sharon Sankar, Vidya Rebeles, Jennifer Flahive, Yvette Schoolfield, John Wang, Linding Lei, Xiufen Dow, Dorothy Yeh, Chih-Ko Dang, Howard Infante, Anthony J. Gao, Shou-Jiang TI Risk Factors Influencing Antibody Responses to Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Antigens in Patients Under Antiretroviral Therapy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE KSHV; Kaposi's sarcoma; latent and lytic antibodies; risk factors; HIV/AIDS ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITORS; SEROLOGIC ASSAYS; HIV-1 INFECTION; HOMOSEXUAL-MEN; CD4 COUNT; AIDS; HUMAN-HERPESVIRUS-8; TRENDS; SEROPREVALENCE AB Background: Kaposi's sarcoma-associated herpesvirus (KSHV) seropositivity and lytic antibody titer are predictors for Kaposi's sarcoma. Methods: We examined demographic, viral, and immunologic factors that influence KSHV latent and lytic antibodies in HIV-infected patients. Results: Detection rate of KSHV latent but not lytic antibodies was lower in patients with CD4 cells/mm(3) less than 200 than greater than 200 (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.11-0.61) and CD8 cells/mm(3) less than 400 than greater than 400 (OR, 0.26; 95% CI, 0.07-0.67). Overall seropositivity rate was higher in patients with CD4 cells/mm(3) less than 200 than greater than 200 (OR, 2.34; 95% CI, 1.37-4.02) and HIV copies/mL greater than 400 than less than 400 (OR, 1.70; 95% CI, 1.09-2.65). Lytic antibody level was inversely correlated with CD4 count (P < 0.001). Lytic seropositivity (OR, 2.47; 95% CI, 1.35-4.50) and antibody level (adjusted difference mean optical density, 0.324; 95% CI, 0.16-0.46) were higher in patients with HIV infection greater than 15 than less than 15 years. Hispanics had higher lytic seropositivity rate (OR, 1.71; 95% CI, 1.07-2.73) and antibody level (adjusted difference mean optical density, 0.111; 95% CI, 0.03-0.18) than non-Hispanics. Conclusions: Lower CD4 and CD8 counts impair antibody response to KSHV latent antigens. Immune deterioration, long-term HIV infection, and Hispanic status are risk factors for Kaposi's sarcoma predictors. C1 [Guadalupe, Moraima; Rebeles, Jennifer; Flahive, Yvette; Wang, Linding; Lei, Xiufen; Gao, Shou-Jiang] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Guadalupe, Moraima; Wang, Linding; Lei, Xiufen; Dow, Dorothy; Infante, Anthony J.; Gao, Shou-Jiang] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA. [Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Westbrook, Steven; Redding, Spencer; Sankar, Vidya; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. [Bullock, Delia; Anstead, Gregory; Gao, Shou-Jiang] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Dang, Howard] Univ Texas Hlth Sci Ctr San Antonio, Dept Community Dent, San Antonio, TX 78229 USA. [Barbieri, Sharon] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Hyg, San Antonio, TX 78229 USA. [Schoolfield, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Acad Technol Serv, San Antonio, TX 78229 USA. [Agan, Brian K.; Marconi, Vincent C.] Univ Hlth Sci, Infect Dis Clin Res Program Uniformed Serv, Bethesda, MD USA. [Agan, Brian K.; Marconi, Vincent C.] San Antonio Mil Med Ctr, San Antonio, TX USA. [Westbrook, Steven; Redding, Spencer; Anstead, Gregory; Yeh, Chih-Ko] S Texas Vet Healthcare Syst, San Antonio, TX USA. RP Gao, SJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gaos@uthscsa.edu RI Gao, Shou-Jiang/B-8641-2012; Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669 FU National Institute of Health (NIH) [CA119889, CA096512, CA124332, DE017333, RR001346, DE14138]; National Institute of Allergy and Infectious Diseases, NIH [Y1-AI-5072]; Uniformed Services University of the Health Sciences FX This work is in part supported by the National Institute of Health (NIH, grants CA119889, CA096512, CA124332, DE017333, RR001346, and DE14138) and the National Institute of Allergy and Infectious Diseases, NIH, under Interagency Agreement Y1-AI-5072. Support for this work (IDCRP-014) was also provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. NR 41 TC 6 Z9 6 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2011 VL 56 IS 1 BP 83 EP 90 DI 10.1097/QAI.0b013e3181fdc928 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 692XC UT WOS:000285188200019 PM 21084997 ER PT J AU Alsanafi, S Werth, VP AF Alsanafi, Shamael Werth, Victoria P. TI Squamous Cell Carcinomas Arising in Discoid Lupus Erythematosus Scars Unusual Occurrence in an African-American and in a Sun-Protected Area SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE squamous cell carcinoma; discoid lupus erythematosus; scar; HPV infection; verrucous keratosis AB Squamous cell carcinoma is a known and rare complication of long-standing discoid lupus erythematosus. Most cases have been reported in sun-exposed skin of whites. We report 2 unusual cases of squamous cell carcinoma arising in discoid lupus erythematosus scars: one in a sun-protected area of a white patient and a second in an African-American patient. C1 [Alsanafi, Shamael; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Alsanafi, Shamael; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Alsanafi, S (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM dr_shamael@yahoo.com FU National Institutes of Health (NIH) [NIH K24-AR 02207]; Kuwaiti Government FX This study was supported in part by the National Institutes of Health (NIH K24-AR 02207) to VPW. It was also supported by a grant from the Kuwaiti Government (SA). NR 10 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JAN PY 2011 VL 17 IS 1 BP 35 EP 36 DI 10.1097/RHU.0b013e3182051928 PG 2 WC Rheumatology SC Rheumatology GA 710SV UT WOS:000286537400008 PM 21169850 ER PT J AU Vivrette, RL Rubenstein, LZ Martin, JL Josephson, KR Kramer, BJ AF Vivrette, Rebecca L. Rubenstein, Laurence Z. Martin, Jennifer L. Josephson, Karen R. Kramer, B. Josea TI Development of a Fall-Risk Self-Assessment for Community-Dwelling Seniors SO JOURNAL OF AGING AND PHYSICAL ACTIVITY LA English DT Article DE falls; qualitative research methods; preventive medicine; preventive care; preventive services ID OLDER-ADULTS; PREVENTION; INTERVENTIONS; MODEL AB Objective: To determine seniors' beliefs about falls and design a fall-risk self-assessment and educational materials to promote early identification of evidence-based fall risks and encourage prevention behaviors. Methods: Focus groups with community-dwelling seniors, conducted in two phases to identify perceptions about fall risks and risk reduction and to assess face validity of the fall-risk self-assessment and acceptability of educational materials. Results: Lay perception of fall risks was in general concordance with evidence-based research. Maintaining independence and positive tone were perceived as key motivators for fall prevention. Seniors intended to use information in the educational tool to stimulate discussions about falls with health care providers. Implications: An evidence-based, educational fall-risk self-assessment acceptable to older adults can build on existing lay knowledge about fall risks and perception that falls are a relevant problem and can educate seniors about their specific risks and how to minimize them. C1 [Vivrette, Rebecca L.; Martin, Jennifer L.; Josephson, Karen R.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Rubenstein, Laurence Z.] Univ Oklahoma, Coll Med, Donald W Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA. [Kramer, B. Josea] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. RP Vivrette, RL (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. FU Centers for Disease Control and Prevention [05FED28430]; National Institutes of Health [K23AG028452]; Archstone Foundation [01-01-10]; Archstone Foundation FX This study was funded in part by the Centers for Disease Control and Prevention (05FED28430), National Institutes of Health (K23AG028452), and the Archstone Foundation (01-01-10).; We acknowledge the contributions of the Archstone Foundation funded Fall Prevention Center of Excellence for assistance with graphic materials used in this research project. We also acknowledge Judy Stevens, PhD, and Shane Diekman, PhD, for their contributions to the focus-group discussion guides and to the development of the brochure. NR 24 TC 6 Z9 6 U1 1 U2 4 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1063-8652 J9 J AGING PHYS ACTIV JI J. Aging Phys. Act. PD JAN PY 2011 VL 19 IS 1 BP 16 EP 29 PG 14 WC Geriatrics & Gerontology; Gerontology; Sport Sciences SC Geriatrics & Gerontology; Sport Sciences GA 705QI UT WOS:000286152600002 PM 21285473 ER PT J AU Shi, M Sui, YT Peskind, ER Li, G Hwang, H Devic, I Ginghina, C Edgar, JS Pan, C Goodlett, DR Furay, AR Gonzalez-Cuyar, LF Zhang, J AF Shi, Min Sui, Yu-Ting Peskind, Elaine R. Li, Ge Hwang, HyeJin Devic, Ivana Ginghina, Carmen Edgar, John Scott Pan, Catherine Goodlett, David R. Furay, Amy R. Gonzalez-Cuyar, Luis F. Zhang, Jing TI Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; biomarkers; saliva; tau protein ID MILD COGNITIVE IMPAIRMENT; PERIPHERAL NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; ALPHA-SYNUCLEIN; CSF BIOMARKERS; DIAGNOSIS; HEALTH AB Phosphorylation of tau protein is a critical event in the pathogenesis of Alzheimer's disease (AD). Increased phosphorylated tau and total tau levels, combined with reduced concentrations of amyloid-beta 1-42 (A beta(42)) in cerebrospinal fluid (CSF), but not in plasma or serum, have been generally accepted as sensitive AD diagnostic markers. However, obtaining CSF is a relatively invasive procedure that requires participation of specially trained medical professionals, i.e., CSF is not an ideal sample source for screening or early diagnosis of AD, which is essential to current and future neuroprotective treatments for the disease. Here, we identified tau, but not A beta species, with mass spectrometry in human saliva, a body fluid that is much more accessible compared to CSF or even blood. Quantitative assessment of salivary levels of total tau, phosphorylated tau, and A beta(42) using highly sensitive Luminex assays revealed that, while A beta(42) was not detectable, the phosphorylated tau/tau ratio significantly increased in patients with AD compared to healthy controls. These results suggest that salivary tau species could be ideal biomarkers for AD diagnosis, especially at early stages of the disease or even screening asymptomatic subjects, allowing for a much larger therapeutic window for AD patients. C1 [Shi, Min; Sui, Yu-Ting; Hwang, HyeJin; Devic, Ivana; Ginghina, Carmen; Pan, Catherine; Furay, Amy R.; Gonzalez-Cuyar, Luis F.; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Peskind, Elaine R.; Li, Ge; Furay, Amy R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Edgar, John Scott; Goodlett, David R.] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98104 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU National Institutes of Health [AG033398, ES004696-5897, ES007033-6364, ES016873, NS057567, NS062684-6221, AG005136]; NINDS Institutional Center [Neuroproteomic P30 (NS055088)]; Cheng-Mei Shaw Endowment; Friends of Alzheimer's Research; Alzheimer's Association of Western and Central Washington; Department of Veterans Affairs FX This work was supported by the National Institutes of Health grants (AG033398, ES004696-5897, ES007033-6364, ES016873, NS057567, NS062684-6221 and AG005136), NINDS Institutional Center Core Grant-Neuroproteomics P30 (NS055088) as well as grants from the Cheng-Mei Shaw Endowment, Friends of Alzheimer's Research, Alzheimer's Association of Western and Central Washington and the Department of Veterans Affairs. We thank Clete Barrick for his assistance in preliminary experiments, and also deeply appreciate those who have donated their saliva for our study. NR 26 TC 24 Z9 25 U1 7 U2 20 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 27 IS 2 BP 299 EP 305 DI 10.3233/JAD-2011-110731 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 850RQ UT WOS:000297215900007 PM 21841250 ER PT J AU Canu, E McLaren, DG Fitzgerald, ME Bendlin, BB Zoccatelli, G Alessandrini, F Pizzini, FB Ricciardi, GK Beltramello, A Johnson, SC Frisoni, GB AF Canu, Elisa McLaren, Donald G. Fitzgerald, Michele E. Bendlin, Barbara B. Zoccatelli, Giada Alessandrini, Franco Pizzini, Francesca B. Ricciardi, Giuseppe K. Beltramello, Alberto Johnson, Sterling C. Frisoni, Giovanni B. TI Mapping the Structural Brain Changes in Alzheimer's Disease: The Independent Contribution of Two Imaging Modalities SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Diffusion Tensor Imaging (DTI); Alzheimer's disease (AD); Microstructure; Fractional Anisotropy (FA); Mean Diffusivity (MD) ID MILD COGNITIVE IMPAIRMENT; WHITE-MATTER CHANGES; MOTOR CORTEX INVOLVEMENT; AGE-RELATED-CHANGES; IN-VIVO; CORPUS-CALLOSUM; NEURODEGENERATIVE DISORDERS; AMYLOID DEPOSITS; TRACT INTEGRITY; WATER DIFFUSION AB The macrostructural atrophy of Alzheimer's disease (AD) has been fully described. Current literature reports that also microstructural alterations occur in AD since the early stages. However, whether the microstructural changes offer unique information independent from macrostructural atrophy is unclear. Aim of this study is to define the independent contribution of macrostructural atrophy and microstructural alterations on AD pathology. The study involved 17 moderate to severe AD patients and 13 healthy controls. All participants underwent conventional and non conventional MRI (respectively, T1-weighted and diffusion-weighted MR scanning). We processed the images in order to obtain gray and white matter volumes to assess macrostructural atrophy, and fractional anisotropy and mean diffusivity to assess the microstructural damage. Analyses of covariance between patients and controls were performed to investigate microstructural tissue damage independent of macrostructural tissue loss, and viceversa, voxel by voxel. We observed microstructural differences, independent of macrostructural atrophy, between patients and controls in temporal and retrosplenial regions, as well as in thalamus, corticopontine tracts, striatum and precentral gyrus. Volumetric differences, independent of microstructural alterations, were observed mainly in the entorhinal cortex, posterior cingulum, and splenium. Measures of microstructural damage provide unique information not obtainable with volumetric mapping in regions known to be pivotal in AD as well as in others thought to be spared. This work expands the understanding of the topography of pathological changes in AD that can be captured with imaging techniques. C1 [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Zoccatelli, Giada; Alessandrini, Franco; Pizzini, Francesca B.; Ricciardi, Giuseppe K.; Beltramello, Alberto] Osped Maggiore, Serv Neuroradiol, Verona, Italy. [Canu, Elisa; Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, LENITEM Lab Epidemiol Neuroimaging & Telemed, Brescia, Italy. RP Frisoni, GB (reprint author), IRCCS San Giovanni di Dio FBF, LENITEM Lab Epidemiol Neuroimaging & Telemed, Via Pilastroni 4, I-25125 Brescia, Italy. EM gfrisoni@fatebenefratelli.it RI Frisoni, Giovanni B/K-1360-2016; Pizzini, Francesca Bendetta/O-5291-2016; Canu, Elisa/K-1423-2016 OI Frisoni, Giovanni B/0000-0002-6419-1753; Pizzini, Francesca Bendetta/0000-0002-6285-0989; Ricciardi, Giuseppe Kenneth/0000-0001-8536-5794; Canu, Elisa/0000-0001-5804-3378; Bendlin, Barbara/0000-0002-0580-9875 FU Italian Ministry of Health; Ricerca Finalizzata "Malattie neurodegenerative legate all' invecchiamento: dalla patogenesi alle prospettive terapeutiche per un progetto traslazionale"; Lundbeck Italia SpA; National Institutes of Health [AG021155, AG000213] FX This work has been supported by research grant 125/2004 of the Italian Ministry of Health, Ricerca Finalizzata "Malattie neurodegenerative legate all' invecchiamento: dalla patogenesi alle prospettive terapeutiche per un progetto traslazionale" and by Lundbeck Italia SpA. This study was also supported by National Institutes of Health grants AG021155 and AG000213, and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital. All authors report no conflicts of interest. NR 68 TC 17 Z9 17 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 26 SU 3 BP 263 EP 274 DI 10.3233/JAD-2011-0040 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 858ZM UT WOS:000297842800019 PM 21971466 ER PT J AU Hook, G Hook, V Kindy, M AF Hook, Gregory Hook, Vivian Kindy, Mark TI The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-beta and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, beta-Secretase Activity SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer disease; amyloid-beta; BACE1; cathepsin B; guinea pig; memory deficits; oral E64d; transgenic mice ID PRECURSOR PROTEIN; TRANSGENIC MICE; IN-VIVO; A-BETA; GUINEA-PIGS; RAT-BRAIN; WILD-TYPE; PEPTIDES; VITRO; OLIGOMERIZATION AB The cysteine protease cathepsin B is a potential drug target for reducing brain amyloid-beta (A beta) and improving memory in Alzheimer's disease (AD), as reduction of cathepsin B in transgenic mice expressing human wild-type amyloid-beta protein precursor (A beta PP) results in significantly decreased brain A beta. Cathepsin B cleaves the wild-type beta-secretase site sequence in A beta PP to produce A beta, and cathepsin B inhibitors administered to animal models expressing A beta PP containing the wild-type beta-secretase site sequence reduce brain A beta in a manner consistent with beta-secretase inhibition. But such inhibitors could act either by direct inhibition of cathepsin B beta-secretase activity or by off-target inhibition of the other beta-secretase, the aspartyl protease BACE1. To evaluate that issue, we orally administered a cysteine protease inhibitor, E64d, to normal guinea pigs or transgenic mice expressing human A beta PP, both of which express the human wild-type beta-secretase site sequence. In guinea pigs, oral E64d administration caused a dose-dependent reduction of up to 92% in brain, CSF, and plasma of A beta(40) and A beta(42), a reduction of up to 50% in the C-terminal beta-secretase fragment (CTF beta), and a 91% reduction in brain cathepsin B activity, but increased brain BACE1 activity by 20%. In transgenic AD mice, oral E64d administration improved memory deficits and reduced brain A beta(40) and A beta(42), amyloid plaque, brain CTF beta, and brain cathepsin B activity, but increased brain BACE1 activity. We conclude that E64d likely reduces brain A beta by inhibiting cathepsin B and not BACE1 beta-secretase activity and that E64d therefore may have potential for treating AD patients. C1 [Hook, Gregory] Amer Life Sci Pharmaceut, San Diego, CA 92109 USA. [Hook, Vivian] Univ Calif San Diego, Dept Neurosci, Dept Med & Pharmacol, Skaggs Sch Pharm & Pharmaceut Sci,Sch Med, La Jolla, CA 92093 USA. [Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark] Appl Neurotechnol Inc, Charleston, SC USA. RP Hook, G (reprint author), Amer Life Sci Pharmaceut, 3030 Bunker Hill St,Suite 104, San Diego, CA 92109 USA. EM ghook@alspinc.com FU National Institute on Aging, National Institutes of Health, Bethesda, MD [R21AG0311963, R44AG030865, R44AG032784]; Alzheimer's Drug Discovery Foundation, New York City, NY [20100304] FX We thank Drs. M. D. Pierschbacher and Danny Levin for their review of the manuscript. This work was supported by grant Nos. R21AG0311963, R44AG030865, and R44AG032784 from the National Institute on Aging, National Institutes of Health, Bethesda, MD, and grant No. 20100304 from the Alzheimer's Drug Discovery Foundation, New York City, NY to American Life Science Pharmaceuticals (ALSP). Dr. Gregory Hook is an employee and has equity in ALSP. Professor Vivian Hook is the Chairperson of ALSP's Scientific Advisory Board and holds equity in ALSP and that relationship has been disclosed to the University of California, San Diego, which is managing that relationship. Professor Mark Kindy is affiliated with Applied Neurotechnology, Inc. and holds equity in the company and the relationship has been disclosed to the Medical University of South Carolina, which is managing the relationship. NR 89 TC 35 Z9 37 U1 1 U2 12 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 26 IS 2 BP 387 EP 408 DI 10.3233/JAD-2011-110101 PG 22 WC Neurosciences SC Neurosciences & Neurology GA 818OR UT WOS:000294763100016 PM 21613740 ER PT J AU Wharton, W Baker, LD Gleason, CE Dowling, M Barnet, JH Johnson, S Carlsson, C Craft, S Asthana, S AF Wharton, Whitney Baker, Laura D. Gleason, Carey E. Dowling, Maritza Barnet, Jodi H. Johnson, Sterling Carlsson, Cynthia Craft, Suzanne Asthana, Sanjay TI Short-term Hormone Therapy with Transdermal Estradiol Improves Cognition for Postmenopausal Women with Alzheimer's Disease: Results of a Randomized Controlled Trial SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; clinical trial; cognition; estradiol; estrogen; hormone therapy; medroxyprogesterone; memory ID ESTROGEN-REPLACEMENT THERAPY; CONJUGATED EQUINE ESTROGENS; PLACEBO-CONTROLLED TRIAL; NITRIC-OXIDE SYNTHASE; LONG-TERM; DOUBLE-BLIND; OLDER WOMEN; AGED WOMEN; MEMORY; MOOD AB We aimed to conduct a placebo-controlled, double-blind, parallel-group design intervention study to evaluate the therapeutic efficacy of hormone therapy (HT) in postmenopausal women with mild to moderate Alzheimer's disease (AD). The trial was designed to evaluate the dose-dependent effects of transdermal 17-beta estradiol, unopposed and opposed with medroxyprogesterone (MPA, Provera (c)), for 12 months in 43 postmenopausal women with AD. Participants were assessed using cognitive measures at baseline, months 1, 3, 6, and 12 of treatment and eight weeks post treatment (month 15). The dropout rate was 49% across 12 months. As a result of the Women's Health Initiative (WHI) and anticipated increased attrition, the protocol was modified to examine data only at time points where attrition was less than 30%. The results of sensitivity analyses indicated robust and reliable data collected in the first three months of the trial. Data collected in the first three months of the trial for forty-three participants were analyzed. HT had favorable cognitive effects across multiple cognitive domains, including visual memory (p-values < 0.030) and semantic memory (p-values < 0.037) in postmenopausal women with AD. Moreover, treatment-related changes in plasma estradiol were positively correlated with improvements in visual memory. Short-term HT that includes the use of estradiol has favorable effects on cognition in women with AD. C1 [Wharton, Whitney] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem VA Hosp, Madison, WI 53705 USA. [Wharton, Whitney; Gleason, Carey E.; Dowling, Maritza; Barnet, Jodi H.; Johnson, Sterling; Carlsson, Cynthia; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Baker, Laura D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Baker, Laura D.; Craft, Suzanne] Univ Washington, Sch Med, Seattle, WA USA. RP Wharton, W (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem VA Hosp, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA. EM wlwharto@medicine.wisc.edu FU NIH [AG029624, K07AG021582, K23AG024302, K23AG026752, P50AG033514, 1UL1RR025011] FX The study utilized the resources of the School of Medicine and Public Health at the University of Wisconsin, UW Department of Medicine Division of Geriatrics and Gerontology, the Geriatric Research Education and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison WI. This research was supported by NIH grants AG029624, K07AG021582, K23AG024302, K23AG026752, P50AG033514 and 1UL1RR025011. NR 74 TC 35 Z9 36 U1 3 U2 16 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 26 IS 3 BP 495 EP 505 DI 10.3233/JAD-2011-110341 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 822GU UT WOS:000295032800009 PM 21694454 ER PT J AU Fiala, M Mahanian, M Rosenthal, M Mizwicki, MT Tse, E Cho, T Sayre, J Weitzman, R Porter, V AF Fiala, Milan Mahanian, Michelle Rosenthal, Mark Mizwicki, Matthew T. Tse, Eric Cho, Tiffany Sayre, James Weitzman, Rachel Porter, Verna TI MGAT3 mRNA: A Biomarker for Prognosis and Therapy of Alzheimer's Disease by Vitamin D and Curcuminoids SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; MGAT3; surgical anesthesia; vitamin D3 ID AMYLOID-BETA; COGNITIVE DECLINE; FOLLOW-UP; PLASMA; RISK; ASSOCIATION; MACROPHAGES; PERSPECTIVE; CLEARANCE; DIAGNOSIS AB Practical biomarkers of Alzheimer's disease (AD) prognosis are lacking. Correspondingly, no drugs are known to decrease disease progression, although vitamin D3 has positive effects on cognition in vivo and 1 alpha, 25-dihydroxyvitamin D3 (1,25 D3) on amyloid-beta 1-42 (A beta) phagocytosis in vitro. We have examined in a pilot study a new biomarker in peripheral blood mononuclear cells, the transcription of mRNA of beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (MGAT3), the essential gene for A beta phagocytosis. The transcription of MGAT3 stimulated by A beta distinguishes macrophages into Type 0 (very low MGAT3 transcription), Type I (low MGAT3 transcription up regulated by bisdemethoxycurcumin), and Type II (high MGAT3 transcription down regulated by bisdemethoxycurcumin). In this pilot study of 20 AD patients and 20 control subjects, 45% patients, but only 10% control subjects, were Type 0 (p-value = 0.009). Type 0 AD patients had worse 2-year prognosis regarding loss of independence than Type I and Type II patients (p-value = 0.013). Phagocytosis of A beta in Type I and II patients was shown to be dependent on 1,25 D3 using a specific inhibitor of the 1,25 D3-VDR activated nuclear receptor transcription factor. In a Type II patient, recovery from cognitive dysfunction related to surgical anesthesia was preceded by an improvement in phagocytosis of A beta. The results of this pilot study suggest that the MGAT3 Type biomarker may characterize subgroups of AD patients with different disease progression. In vitro results suggest that vitamin D3 supplementation might be beneficial in both Type I and II patients, whereas curcuminoids only in Type I. These results must be investigated in a large prospective study. C1 [Porter, Verna] UCLA Sch Med, Dept Neurol, Los Angeles, CA USA. [Fiala, Milan; Mahanian, Michelle; Rosenthal, Mark; Tse, Eric; Cho, Tiffany; Weitzman, Rachel] Greater Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. [Mizwicki, Matthew T.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. [Sayre, James] Univ Calif Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. RP Fiala, M (reprint author), UCLA CHS 23-338,650 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM fiala@mednet.ucla.edu NR 31 TC 9 Z9 10 U1 1 U2 11 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 25 IS 1 BP 135 EP 144 DI 10.3233/JAD-2011-101950 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 800QE UT WOS:000293377700014 PM 21368380 ER PT J AU Trittschuh, EH Crane, PK Larson, EB Cholerton, B McCormick, WC McCurry, SM Bowen, JD Baker, LD Craft, S AF Trittschuh, Emily H. Crane, Paul K. Larson, Eric B. Cholerton, Brenna McCormick, Wayne C. McCurry, Susan M. Bowen, James D. Baker, Laura D. Craft, Suzanne TI Effects of Varying Diagnostic Criteria on Prevalence of Mild Cognitive Impairment in a Community Based Sample SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Age-related memory disorders; aging; Alzheimer's disease; cognition; dementia; diagnosis; epidemiology; individual differences; neuropsychological tests; normative; prevalence ID IQ-ADJUSTED NORMS; ALZHEIMERS-DISEASE; DEMENTIA; OLDER; RISK; AGE; PROGRESSION; POPULATION; SUBTYPES; MCI AB Mild cognitive impairment (MCI) is proposed to be a prodrome to dementia in some older adults. However, the presentation of MCI in the community can differ substantially from clinic-based samples. The aim of the current study is to demonstrate the effects of different operational definitions of MCI on prevalence estimates in community-dwelling older adults. A consecutive series of 200 participants aged 65 and over from the Adult Changes in Thought (ACT) community-based cohort were approached to undergo comprehensive neuropsychological and medical evaluation; 159 were included in the final analyses. Nondemented subjects were categorized using various diagnostic criteria for MCI. In a novel approach, neuropsychological test scores were evaluated using an individualized benchmark as a point of test comparison, as well as traditional methods that entail comparison to age-based normative data. Diagnostic criteria were further subdivided by severity of impairment (1.0 vs. 1.5 standard deviations [sd] below the benchmark) and extent of impairment (based on a single test or an average of tests within a cognitive domain). MCI prevalence rates in the sample were highly dependent on these diagnostic factors, and varied from 11% to 92% of the sample. Older groups tended to show higher prevalence rates, although this was not the case across all diagnostic schemes. The use of an individualized benchmark, less severe impairment cutoff, and impairment on only a single test all produced higher rates of MCI. Longitudinal follow-up will determine whether varying diagnostic criteria improves sensitivity and specificity of the MCI diagnosis as a predictor for dementia. C1 [Trittschuh, Emily H.; Cholerton, Brenna; Baker, Laura D.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Trittschuh, Emily H.; Baker, Laura D.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Crane, Paul K.; Larson, Eric B.; Cholerton, Brenna] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Bowen, James D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [McCurry, Susan M.] Univ Washington, Sch Med, Dept Psychosocial & Community Hlth, Seattle, WA USA. [Larson, Eric B.] Grp Hlth Cooperat Res Inst, Ctr Hlth Studies, Seattle, WA USA. [Bowen, James D.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA. RP Cholerton, B (reprint author), VA Puget Sound Hlth Care Syst, GRECC-A-182,9600 Vet Dr SW, Tacoma, WA 98493 USA. EM bchol@u.washington.edu RI Crane, Paul/C-8623-2014 OI Crane, Paul/0000-0003-4278-7465 FU National Institute on Aging [R01AG024180, U01AG006781]; Department of Veterans Affairs; Group Health Research Institute FX This work was supported by National Institute on Aging grants R01AG024180 and U01AG006781, the Department of Veterans Affairs, and the Group Health Research Institute. The funding sources did not provide scientific input for the study. NR 61 TC 9 Z9 9 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 25 IS 1 BP 163 EP 173 DI 10.3233/JAD-2011-101821 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 800QE UT WOS:000293377700017 PM 21368379 ER PT J AU Yu, J Gattoni-Celli, M Zhu, H Bhat, NR Sambamurti, K Gattoni-Celli, S Kindy, MS AF Yu, Jin Gattoni-Celli, Marco Zhu, Hong Bhat, Narayan R. Sambamurti, Kumar Gattoni-Celli, Sebastiano Kindy, Mark S. TI Vitamin D-3-Enriched Diet Correlates with a Decrease of Amyloid Plaques in the Brain of A beta PP Transgenic Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; animal models; transgenic mice; vitamin D ID ALZHEIMERS-DISEASE; HYPOVITAMINOSIS-D; RAT; RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3; DEFICIENCY; EXPRESSION; OLIGOMERS; BEHAVIOR; PROTEIN AB In addition to its function in calcium and bone metabolism, vitamin D is neuroprotective and important for mitigating inflammation. Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system, characterized by neuronal loss in many areas of the brain, and the formation of senile (neuritic) plaques, which increase in number and size over time. The goal of this project was to investigate whether vitamin D-3 supplementation would affect amyloid plaque formation in amyloid-beta protein precursor (A beta PP) transgenic mice that spontaneously develop amyloid plaques within 3-4 months of birth. A beta PP mice were fed control, vitamin D-3-deficient or vitamin D-3-enriched diets for five months, starting immediately after weaning. At the end of the study, the animals were subjected to behavioral studies, sacrificed, and examined for bone changes and brain amyloid load, amyloid-beta (A beta) peptide levels, inflammatory changes, and nerve growth factor (NGF) content. The results obtained indicate that a vitamin D-3-enriched diet correlates with a decrease in the number of amyloid plaques, a decrease in A beta peptides, a decrease in inflammation, and an increase in NGF in the brains of A beta PP mice. These observations suggest that a vitamin D-3-enriched diet may benefit AD patients. C1 [Yu, Jin; Gattoni-Celli, Marco; Zhu, Hong; Bhat, Narayan R.; Sambamurti, Kumar; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29403 USA. [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29403 USA. [Gattoni-Celli, Sebastiano; Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Strom Thurmond Biomed Res Bldg,Room 503,114 Dough, Charleston, SC 29403 USA. EM kindyms@musc.edu FU National Institutes of Health [ES 016774, R01 NS051575, AG023055]; Veterans Administration; National Science Foundation EPSCoR [EPS-0132573, EPS-0447660] FX We thank Drs. Srinivasan Shanmugarajan, William L. Ries, and Sakamuri V. Reddy for helping with the bone-related studies; we also thank Dr. Bruce W. Hollis for measuring the serum levels of circulating vitamin D in mice. This project was funded by grants from the National Institutes of Health (MSK, ES 016774; NRB, R01 NS051575; KS, AG023055), Veterans Administration (MSK and SG-C), and the National Science Foundation EPSCoR grants (MSK, EPS-0132573 and EPS-0447660). NR 40 TC 48 Z9 51 U1 1 U2 13 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 25 IS 2 BP 295 EP 307 DI 10.3233/JAD-2011-101986 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 800QJ UT WOS:000293378300010 PM 21422528 ER PT J AU Lu, PH Thompson, PM Leow, A Lee, GJ Lee, A Yanovsky, I Parikshak, N Khoo, T Wu, S Geschwind, D Bartzokis, G AF Lu, Po H. Thompson, Paul M. Leow, Alex Lee, Grace J. Lee, Agatha Yanovsky, Igor Parikshak, Neelroop Khoo, Theresa Wu, Stephanie Geschwind, Daniel Bartzokis, George TI Apolipoprotein E Genotype is Associated with Temporal and Hippocampal Atrophy Rates in Healthy Elderly Adults: A Tensor-Based Morphometry Study SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; Alzheimer's disease; Apolipoprotein E; asymmetry; healthy elderly; hippocampus; magnetic resonance imaging; tensor-based morphometry; temporal lobe; white matter ID E EPSILON-4 ALLELE; MILD COGNITIVE IMPAIRMENT; WHITE-MATTER INTEGRITY; ALZHEIMERS-DISEASE; BRAIN ATROPHY; APOE GENOTYPE; CHOLESTEROL TRANSPORT; IMAGE REGISTRATION; MYELIN BREAKDOWN; CEREBRAL-CORTEX AB Apolipoprotein E (ApoE) epsilon 4 genotype is a strong risk factor for developing Alzheimer's disease (AD). Conversely, the presence of the epsilon 2 allele has been shown to mitigate cognitive decline. Tensor-based morphometry (TBM), a novel computational approach for visualizing longitudinal progression of brain atrophy, was used to determine whether cognitively intact elderly participants with the epsilon 4 allele demonstrate greater volume reduction than those with the epsilon 2 allele. Healthy "younger elderly" volunteers, aged 55-75, were recruited from the community and hospital staff. They were evaluated with a baseline and follow-up MRI scan (mean scan interval = 4.72 years, s.d. = 0.55) and completed ApoE genotyping. Twenty-seven participants were included in the study of which 16 had the epsilon 4 allele (all heterozygous epsilon 3 epsilon 4 genotype) and 11 had the epsilon 2 epsilon 3 genotype. The two groups did not differ significantly on any demographic characteristics and all subjects were cognitively "normal" at both baseline and follow-up time points. TBM was used to create 3D maps of local brain tissue atrophy rates for individual participants; these spatially detailed 3D maps were compared between the two ApoE groups. Regional analyses were performed and the epsilon 4 group demonstrated significantly greater annual atrophy rates in the temporal lobes (p = 0.048) and hippocampus (p = 0.016); greater volume loss was observed in the right hippocampus than the left. TBM appears to be useful in tracking longitudinal progression of brain atrophy in cognitively asymptomatic adults. Possession of the epsilon 4 allele is associated with greater temporal and hippocampal volume reduction well before the onset of cognitive deficits. C1 [Thompson, Paul M.; Leow, Alex; Lee, Agatha; Parikshak, Neelroop; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA. [Yanovsky, Igor] Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA. [Leow, Alex; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Geschwind, Daniel] Univ Calif Los Angeles, David Geffen Sch Med, Neurogenet Program, Los Angeles, CA 90095 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Lu, PH (reprint author), Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM plu@mednet.ucla.edu RI Bartzokis, George/K-2409-2013; Leow, Alex/K-3236-2014 OI Leow, Alex/0000-0002-5660-8651 FU National Institute of Aging (NIA) [K23-AG028727]; Alzheimer's Association [NIRG-07-60424]; Alzheimer's Disease Research Center [P50 AG-16570]; Alzheimer's Disease Research Center of California; NIH [MH51928, MH6357-01A1, MH066029-01A2, AG027342-01A2, U54 RR021813]; NIBIB; National Library of Medicine; National Center for Research Resources [AG016570, EB01651, LM05639, RR019771] FX This work was supported by grant K23-AG028727 from the National Institute of Aging (NIA), a grant from the Alzheimer's Association (NIRG-07-60424), the Alzheimer's Disease Research Center grant P50 AG-16570, and Alzheimer's Disease Research Center of California grant. Further support for this study came from NIH grants (MH51928; MH6357-01A1; MH066029-01A2; AG027342-01A2; U54 RR021813 to GB). Algorithm development for this study was also funded by the NIA, NIBIB, the National Library of Medicine, and the National Center for Research Resources (AG016570, EB01651, LM05639, RR019771 to PT). NR 73 TC 36 Z9 37 U1 1 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 23 IS 3 BP 433 EP 442 DI 10.3233/JAD-2010-101398 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 721KE UT WOS:000287351200006 PM 21098974 ER PT J AU De Taboada, L Yu, J El-Amouri, S Gattoni-Celli, S Richieri, S McCarthy, T Streeter, J Kindy, MS AF De Taboada, Luis Yu, Jin El-Amouri, Salim Gattoni-Celli, Sebastiano Richieri, Steve McCarthy, Thomas Streeter, Jackson Kindy, Mark S. TI Transcranial Laser Therapy Attenuates Amyloid-beta Peptide Neuropathology in Amyloid-beta Protein Precursor Transgenic Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; animal models; laser therapy; transgenic mice ID FAMILIAL ALZHEIMERS-DISEASE; TERM NEUROLOGICAL DEFICITS; MYOCARDIAL-INFARCTION; ASPARTIC PROTEASE; SPINAL-CORD; SECRETASE CLEAVAGE; MISSENSE MUTATIONS; APOLIPOPROTEIN-E; ISCHEMIC-STROKE; IRRADIATION AB Transcranial laser therapy (TLT) was tested for efficacy in a mouse model of Alzheimer's disease (AD) using a near-infrared energy laser system. TLT is thought to stimulate ATP production, increase mitochondrial activity, and help maintain neuronal function. Studies were performed to determine the effect of TLT in an amyloid-beta protein precursor (A beta PP) transgenic mouse model. TLT was administered 3 times/week at various doses, starting at 3 months of age, and was compared to a control group (no laser treatment). Treatment was continued for a total of six months. Animals were examined for amyloid load, inflammatory markers, brain amyloid-beta (A beta) levels, plasma A beta levels, cerebrospinal fluid A beta levels, soluble A beta PP (sA beta PP) levels, and behavioral changes. The numbers of A beta plaques were significantly reduced in the brain with administration of TLT in a dose-dependent fashion. Administration of TLT was associated with a dose-dependent reduction in amyloid load. All TLT doses mitigated the behavioral effects seen with advanced amyloid deposition and reduce the expression of inflammatory markers in the A beta PP transgenic mice. All TLT doses produced an increase in sA beta PP alpha and a decrease in CTF beta levels consistent with inhibition of the beta-secretase activity. In addition, TLT showed an increase in ATP levels, mitochondrial function, and c-fos suggesting an overall improvement in neurological function. These studies suggest that TLT is a potential candidate for treatment of AD. C1 [Yu, Jin; El-Amouri, Salim; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29524 USA. [De Taboada, Luis; Richieri, Steve; McCarthy, Thomas] PhotoThera Inc, Carlsbad, CA USA. [Gattoni-Celli, Sebastiano; Kindy, Mark S.] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29524 USA. [Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Streeter, Jackson] Banyan Biomarkers Inc, Alachua, FL USA. [Kindy, Mark S.] Neurol Testing Serv Inc, Charleston, SC USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St,Room 503, Charleston, SC 29524 USA. EM kindyms@musc.edu FU PhotoThera, Inc.; Neurological Testing Service, Inc.; National Institutes of Health [ES 016774-01A1]; Veterans Administration FX This study was supported by funding from PhotoThera, Inc., Neurological Testing Service, Inc. and in part by grants from the National Institutes of Health ES 016774-01A1(M. K.), and the Veterans Administration (M. K.). Mr. De Taboada and Richieri and Drs. Streeter and McCarthy have interest in PhotoThera. Dr. Kindy has an interest in Neurological Testing Service, Inc. NR 53 TC 49 Z9 49 U1 1 U2 9 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2011 VL 23 IS 3 BP 521 EP 535 DI 10.3233/JAD-2010-100894 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 721KE UT WOS:000287351200014 PM 21116053 ER PT J AU Austin, D Hayes, TL Kaye, J Mattek, N Pavel, M AF Austin, Daniel Hayes, Tamara L. Kaye, Jeffrey Mattek, Nora Pavel, Misha TI On the disambiguation of passively measured in-home gait velocities from multi-person smart homes SO JOURNAL OF AMBIENT INTELLIGENCE AND SMART ENVIRONMENTS LA English DT Article DE Gait; passive infrared (PIR) motion detectors; smart homes; unobtrusive monitoring; walking speed ID LOWER-EXTREMITY FUNCTION; SUBSEQUENT DISABILITY; COGNITIVE IMPAIRMENT; EXECUTIVE FUNCTION; OLDER PERSONS; PREDICTOR; PERFORMANCE; DEMENTIA; INCHIANTI; SENSORS AB In-home monitoring of gait velocity with passive PIR sensors in a smart home has been shown to be an effective method of continuously and unobtrusively measuring this important predictor of cognitive function and mobility. However, passive measurements of velocity are nonspecific with regard to who generated each measurement or walking event. As a result, this method is not suitable for multi-person homes without additional information to aid in the disambiguation of gait velocities. In this paper we propose a method based on Gaussian mixture models (GMMs) combined with infrequent clinical assessments of gait velocity to model in-home walking speeds of two or more residents. Modeling the gait parameters directly allows us to avoid the more difficult problem of assigning each measured velocity individually to the correct resident. We show that if the clinically measured gait velocities of residents are separated by at least 15 cm/s a GMM can be accurately fit to the in-home gait velocity data. We demonstrate the accuracy of this method by showing that the correlation between the means of the GMMs and the clinically measured gait velocities is 0.877 (p value < 0.0001) with bootstrapped 95% confidence intervals of (0.79, 0.94) for 54 measurements of 20 subjects living in multi-person homes. Example applications of using this method to track in-home mean velocities over time are also given. C1 [Austin, Daniel; Hayes, Tamara L.; Pavel, Misha] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. [Kaye, Jeffrey; Mattek, Nora] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Kaye, Jeffrey; Mattek, Nora] Portland VA Med Ctr, Portland, OR USA. RP Austin, D (reprint author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA. EM austidan@bme.ogi.edu OI Austin, Daniel/0000-0002-3248-5503; Kaye, Jeffrey/0000-0002-9971-3478 FU National Institute of Health [P30-AG008017, P30-AG024978, R01-AG024059, K01-AG23014]; Department of Veterans Affairs [P30-AG008017, M01-RR000334]; Intel Corporation FX The authors would like to thank the volunteer subjects who participated in this research and the staff from the Oregon Center for Aging & Technology who assisted in this study. This work was supported in part by the National Institute of Health grants P30-AG008017, P30-AG024978, R01-AG024059, K01-AG23014, the Department of Veterans Affairs grants P30-AG008017 and M01-RR000334, and Intel Corporation. Dr. Hayes has a significant financial interest in Intel Corporation, a company that provided funds to purchase some of the computers used in this study. Intel Corporation may have a commercial interest in the results of this research. This potential conflict has been reviewed and managed by OHSU. NR 35 TC 11 Z9 11 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1876-1364 J9 J AMB INTEL SMART EN JI J. Ambient Intell. Smart Environ. PY 2011 VL 3 IS 2 BP 165 EP 174 DI 10.3233/AIS-2011-0107 PG 10 WC Computer Science, Artificial Intelligence; Computer Science, Information Systems; Telecommunications SC Computer Science; Telecommunications GA 778FM UT WOS:000291688100006 PM 21572911 ER PT J AU Cukrowicz, KC Schlegel, EF Smith, PN Jacobs, MP Van Orden, KA Paukert, AL Pettit, JW Joiner, TE AF Cukrowicz, Kelly C. Schlegel, Erin F. Smith, Phillip N. Jacobs, Matthew P. Van Orden, Kimberly A. Paukert, Ambert L. Pettit, Jeremy W. Joiner, Thomas E. TI Suicide Ideation Among College Students Evidencing Subclinical Depression SO JOURNAL OF AMERICAN COLLEGE HEALTH LA English DT Article DE college students; depression; subclinical depression; suicidal ideation ID QUESTIONNAIRE; INVENTORY; HOPELESSNESS; ADOLESCENCE; MODEL AB Identifying elevated suicide ideation in college students is a critical step in preventing suicide attempts and deaths by suicide on college campuses. Although suicide ideation may be most prominent in students with severe depression, this should not suggest that only students with severe depression experience significant risk factors for suicide. Objective: The purpose of these 3 studies was to explore the relation between suicide ideation and severity of depressive symptoms in college students. Participants: In each study a sample of college students were recruited for participation. Methods: Participants completed self-report assessments of depressive symptoms and suicide ideation. Results: The results of these studies suggest that although the greatest elevation in suicide ideation occurs at the highest depressive symptoms, significant suicide ideation is also experienced by college students with mild and moderate depressive symptoms. Conclusions: The implications of these findings for the assessment of suicide ideation are discussed. C1 [Cukrowicz, Kelly C.; Schlegel, Erin F.; Jacobs, Matthew P.] Texas Tech Univ, Dept Psychol, Lubbock, TX 79409 USA. [Smith, Phillip N.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA. [Van Orden, Kimberly A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Paukert, Ambert L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Pettit, Jeremy W.] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA. [Joiner, Thomas E.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. RP Cukrowicz, KC (reprint author), Texas Tech Univ, Dept Psychol, Mail Stop 42051, Lubbock, TX 79409 USA. EM kelly.cukrowicz@ttu.edu FU NIMH NIH HHS [T32 MH020061] NR 22 TC 32 Z9 35 U1 0 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0744-8481 J9 J AM COLL HEALTH JI J. Am. Coll. Health PY 2011 VL 59 IS 7 BP 575 EP 581 DI 10.1080/07448481.2010.483710 PG 7 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 881IY UT WOS:000299478100001 PM 21823951 ER PT J AU Wen, Y Feng, J Scott, DR Marcus, EA Sachs, G AF Wen, Yi Feng, Jing Scott, David R. Marcus, Elizabeth A. Sachs, George TI A cis-Encoded Antisense Small RNA Regulated by the HP0165-HP0166 Two-Component System Controls Expression of ureB in Helicobacter pylori SO JOURNAL OF BACTERIOLOGY LA English DT Article ID ESCHERICHIA-COLI; ACID RESISTANCE; UREASE EXPRESSION; ALLELIC EXCHANGE; GENE-EXPRESSION; NONCODING RNAS; PH; IDENTIFICATION; BACTERIA; COLONIZATION AB Expression of urease is essential for gastric colonization by Helicobacter pylori. The increased level of urease in gastric acidity is due, in part, to acid activation of the two-component system (TCS) consisting of the membrane sensor HP0165 and its response regulator, HP0166, which regulates transcription of the seven genes of the urease gene cluster. We now find that there are two major ureAB transcripts: a 2.7-kb full-length ureAB transcript and a 1.4-kb truncated transcript lacking 3' ureB. Acidic pH (pH 4.5) results in a significant increase in transcription of ureAB, while neutral pH (pH 7.4) increases the truncated 1.4-kb transcript. Northern blot analysis with sense RNA and strand-specific oligonucleotide probes followed by 5' rapid amplification of cDNA ends detects an antisense small RNA (sRNA) encoded by the 5' ureB noncoding strand consisting of similar to 290 nucleotides (5'ureB-sRNA). Deletion of HP0165 elevates the level of the truncated 1.4-kb transcript along with that of the 5'ureB-sRNA at both pH 7.4 and pH 4.5. Overexpression of 5'ureB-sRNA increases the 1.4-kb transcript, decreases the 2.7-kb transcript, and decreases urease activity. Electrophoretic mobility shift assay shows that unphosphorylated HP0166 binds specifically to the 5'ureB-sRNA promoter. The ability of the HP0165-HP0166 TCS to both increase and decrease ureB expression at low and high pHs, respectively, facilitates gastric habitation and colonization over the wide range of intragastric pHs experienced by the organism. C1 [Wen, Yi] Univ Calif Los Angeles, David Geffen Sch Med, Membrane Biol Lab, Dept Physiol, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wen, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Membrane Biol Lab, Dept Physiol, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM ywen@ucla.edu FU U.S. Department of Veterans Affairs; NIH [DK46917, 53462, 58333] FX This work was supported by U.S. Department of Veterans Affairs and NIH grants DK46917, 53462, and 58333. NR 77 TC 14 Z9 14 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN PY 2011 VL 193 IS 1 BP 40 EP 51 DI 10.1128/JB.00800-10 PG 12 WC Microbiology SC Microbiology GA 692GY UT WOS:000285142500003 PM 20971914 ER PT J AU Chew, RB Bryson, CL Au, DH Maciejewski, ML Bradley, KA AF Chew, Ryan B. Bryson, Chris L. Au, David H. Maciejewski, Matthew L. Bradley, Katharine A. TI Are Smoking and Alcohol Misuse Associated with Subsequent Hospitalizations for Ambulatory Care Sensitive Conditions? SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID PREVENTABLE HOSPITALIZATIONS; SOCIOECONOMIC-STATUS; CIGARETTE-SMOKING; SCREENING SCORES; HEALTH-CARE; MEDICARE BENEFICIARIES; COST-EFFECTIVENESS; DRINK ALCOHOL; MANAGED CARE; IMPACT AB Hospitalizations for ambulatory care sensitive conditions (ACSCs) are used to assess quality of care, but studies rarely adjust for health behaviors. This study evaluated whether results of smoking or alcohol screening were associated with hospitalizations for ACSCs. Participants included 33,273 male Veterans Affairs general medicine outpatients who returned mailed surveys. The main outcome was hospitalization with a primary discharge diagnosis for an ACSC in the year following screening. Analyses were adjusted for demographics, comorbidity, and other health behaviors. Current and previous smoking and abstaining from alcohol were associated with significantly increased risk of hospitalization for ACSCs, but alcohol misuse was not. However, severe alcohol misuse was associated with increased risk of hospitalizations with a primary or secondary ACSC discharge diagnosis. When ACSCs are used to evaluate the quality of care, health systems caring for populations with higher rates of smoking or nondrinking could falsely appear to have poorer quality care if alcohol and tobacco use are not considered. C1 [Chew, Ryan B.; Bryson, Chris L.; Au, David H.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, VA Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Bryson, Chris L.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98101 USA. [Au, David H.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Sch Med, Durham, NC USA. [Chew, Ryan B.] Overlake Hosp Med Ctr, Bellevue, WA USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA. RP Bradley, KA (reprint author), VA Puget Sound Hlth Care Syst, VA Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM rbchew@gmail.com; christopher.bryson@va.gov; david.au@va.gov; matthew.maciejewski@va.gov; katharine.bradley@va.gov NR 55 TC 6 Z9 6 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JAN PY 2011 VL 38 IS 1 BP 3 EP 15 DI 10.1007/s11414-010-9215-x PG 13 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 703RQ UT WOS:000285999400002 PM 20464519 ER PT J AU Wenk, JF AF Wenk, Jonathan F. TI Numerical Modeling of Stress in Stenotic Arteries With Microcalcifications: A Parameter Sensitivity Study SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE microcalcifications; sensitivity study; plaque; finite elements ID HUMAN ATHEROSCLEROTIC PLAQUES; VULNERABLE PLAQUE; FIBROUS CAP; CELLULAR MICROCALCIFICATIONS; STABILITY; THICKNESS; RUPTURE; ULTRASOUND; PATHOLOGY; IMPACT AB As a follow-up to the work presented in Wenk et al. (2010, "Numerical Modeling of Stress in Stenotic Arteries With Microcalcifications: A Micromechanical Approximation," ASME J. Biomech. Eng., 132, p. 091011), a formal sensitivity study was conducted in which several model parameters were varied. The previous work only simulated a few combinations of the parameters. In the present study, the fibrous cap thickness, longitudinal position of the region of microcalcifications, and volume fraction of microcalcifications were varied over a broader range of values. The goal of the present work is to investigate the effects of localized regions of microcalcifications on the stress field of atherosclerotic plaque caps in a section of carotid artery. More specifically, the variations in the magnitude and location of the maximum circumferential stress were assessed for a range of parameters using a global sensitivity analysis method known as Sobol' indices. The stress was calculated by performing finite element simulations of three-dimensional fluid-structure interaction models, while the sensitivity indices were computed using a Monte Carlo scheme. The results indicate that cap thickness plays a significant role in the variation in the magnitude of the maximum circumferential stress, with the sensitivity to volume fraction increasing when the region of microcalcification is located at the shoulder. However, the volume fraction played a larger role in the variation in the location of the maximum circumferential stress. This matches the finding of the previous study (Wenk et al., 2010, "Numerical Modeling of Stress in Stenotic Arteries With Microcalcifications: A Micromechanical Approximation," ASME J. Biomech. Eng., 132, p. 091011), which indicates that the maximum circumferential stress always shifts to the region of microcalcification. [DOI: 10.1115/1.4003128] C1 [Wenk, Jonathan F.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94121 USA. [Wenk, Jonathan F.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. [Wenk, Jonathan F.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Wenk, JF (reprint author), Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94121 USA. EM jwenk1@me.berkeley.edu NR 24 TC 10 Z9 10 U1 0 U2 4 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD JAN PY 2011 VL 133 IS 1 AR 014503 DI 10.1115/1.4003128 PG 6 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 700TQ UT WOS:000285767600015 PM 21186905 ER PT J AU Hou, Y Ding, V Li, K Zhou, XH AF Hou, Yan Ding, Victoria Li, Kang Zhou, Xiao-Hua TI Two New Covariate Adjustment Methods for Non-Inferiority Assessment of Binary Clinical Trials Data SO JOURNAL OF BIOPHARMACEUTICAL STATISTICS LA English DT Article DE Clinical trials; Covariate adjustment; Effect modification; Mann-Whitney test; Nonparametric ID 5 INTERVAL ESTIMATORS; STATISTICAL TESTS; ROC CURVE; EQUIVALENCE; RATIO; NONINFERIORITY; MORTALITY; DESIGN; MARGIN; RISK AB In clinical trials, examining the adjusted treatment difference has become the preferred way to establish non-inferiority (NI) in cases involving a binary endpoint. However, current methods are inadequate in the area of covariate adjustment. In this paper, we introduce two new methods, nonparametric and parametric, of using the probability and probability (P-P) curve to address the issue of unadjusted categorical covariates in the traditional assessment of NI in clinical trials. We also show that the area under the P-P curve is a valid alternative for assessing NI using the adjusted treatment difference, and we compute this area using Mann-Whitney nonparametric statistics. Our simulation studies demonstrate that our proposed methods can not only control type I error at a predefined significance level but also achieve higher statistical power than those of traditional parametric and nonparametric methods that overlook covariate adjustment, especially when covariates are unbalanced in the two treatment groups. We illustrate the effectiveness of our methodology with data from clinical trials of a therapy for coronary heart disease. C1 [Hou, Yan; Li, Kang] Harbin Med Coll, Dept Biostat, Harbin 150081, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA USA. [Ding, Victoria; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Li, K (reprint author), Harbin Med Coll, Dept Biostat, Harbin 150081, Peoples R China. EM likang@hrbmu.edu.cn; azhou@u.washington.edu FU National Natural Science Foundation of China [NSFC 30728019] FX The authors thank Harbin's Pharmaceutical Plant No. 2 for providing the data for their study. This research is partially supported by a grant from the National Natural Science Foundation of China (NSFC 30728019). Xiao-Hua Zhou, PhD, is presently a core investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 27 TC 1 Z9 2 U1 0 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1054-3406 J9 J BIOPHARM STAT JI J. Biopharm. Stat. PY 2011 VL 21 IS 1 BP 77 EP 93 AR PII 931668703 DI 10.1080/10543406.2010.494267 PG 17 WC Pharmacology & Pharmacy; Statistics & Probability SC Pharmacology & Pharmacy; Mathematics GA 700SQ UT WOS:000285765000007 PM 21191856 ER PT J AU Franco, GEL Blank, RD Akhter, MP AF Lopez Franco, Gloria E. Blank, Robert D. Akhter, Mohammed P. TI Intrinsic material properties of cortical bone SO JOURNAL OF BONE AND MINERAL METABOLISM LA English DT Article DE Intrinsic properties; Nano-indentation; Bone; LRP5; Mice ID GENETIC-DETERMINANTS; WNT/BETA-CATENIN; TOBACCO SMOKING; ELASTIC-MODULUS; BETA-CATENIN; INBRED MICE; MASS; INDENTATION; STRENGTH; HARDNESS AB The G171V mutation (high bone mass, HBM) is autosomal dominant and is responsible for high bone mass in humans. Transgenic HBM mice in which the human LRP5 G171V gene is inserted also show a similar phenotype with greater bone mass and biomechanical performance than wild-type mice, as determined by whole bone testing. Whole bone mechanics, however, depend jointly on bone mass, architecture, and intrinsic bone tissue mechanical properties. To determine whether the HBM mutation affects tissue-level biomechanical performance, we performed nano-indentation testing of unembedded cortical bone from HBM mice and their nontransgenic (NTG) littermates. Femora from 17-week-old mice (female, 8 mice/genotype) were subjected to nano-indentation using a Triboscope (Hysitron, Minneapolis, MN, USA). For each femoral specimen, approximately 10 indentations were made on the midshaft anterior surface with a target force of either 3 or 9 mN at a constant loading rate of 400 mN/s. The load-displacement data from each test were used to calculate indentation modulus and hardness for bone tissue. The intrinsic material property that reflected the bone modulus was greater (48%) in the HBM as compared to the NTG mice. Our results of intrinsic properties are consistent with the published structural and material properties of the midshaft femur in HBM and NTG mice. The greater intrinsic modulus in HBM reflects greater bone mineral content as compared to NTG (wild-type, WT) mice. This study suggests that the greater intrinsic property of cortical bone is derived from the greater bone mineral content and BMD, resulting in greater bone strength in HBM as compared to NTG (WT) mice. C1 [Akhter, Mohammed P.] Creighton Univ, ORC, Omaha, NE 68131 USA. [Lopez Franco, Gloria E.; Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, GRECC Serv, Madison, WI USA. [Lopez Franco, Gloria E.; Blank, Robert D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Endocrinol Diabet & Metab, Madison, WI USA. RP Akhter, MP (reprint author), Creighton Univ, ORC, Suite 4820,601 N,30th St, Omaha, NE 68131 USA. EM akhtermp@creighton.edu OI Blank, Robert Daniel/0000-0003-2950-1944 FU Office of Research and Development; Biomedical Laboratory RD Service; Department of Veterans Affairs; Clinical Center at the William S. Middleton Memorial Veterans Hospital FX We appreciate the valuable help of Daniel Wells, John Danforth, and Adam Stibbe. This article is based upon work supported in part by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs and performed in the Geriatrics Research, Education, and Clinical Center at the William S. Middleton Memorial Veterans Hospital. This report is Madison GRECC manuscript 2008-12. NR 26 TC 4 Z9 4 U1 0 U2 6 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0914-8779 J9 J BONE MINER METAB JI J. Bone Miner. Metab. PD JAN PY 2011 VL 29 IS 1 BP 31 EP 36 DI 10.1007/s00774-010-0194-z PG 6 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 705HH UT WOS:000286119000004 ER PT J AU Ishizuka, H Garcia-Palacios, V Lu, GW Subler, MA Zhang, HJ Boykin, CS Choi, SJ Zhao, LE Patrene, K Galson, DL Blair, HC Hadi, TM Windle, JJ Kurihara, N Roodman, GD AF Ishizuka, Hisako Garcia-Palacios, Veronica Lu, Ganwei Subler, Mark A. Zhang, Heju Boykin, Christina S. Choi, Sun Jin Zhao, Liena Patrene, Kenneth Galson, Deborah L. Blair, Harry C. Hadi, Tamer M. Windle, Jolene J. Kurihara, Noriyoshi Roodman, G. David TI ADAM8 Enhances Osteoclast Precursor Fusion and Osteoclast Formation In Vitro and In Vivo SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE ADAM8; TRANSGENIC/KNOCKOUT MICE; ADHESION MOLECULES; CELL DIFFERENTIATION; OSTEOCLAST ID STIMULATING FACTOR; DC-STAMP; BONE; CELL; MICE; DIFFERENTIATION; ALPHA(9)BETA(1); DISINTEGRIN; ACTIVATION; EXPRESSION AB ADAM8 expression is increased in the interface tissue around a loosened hip prosthesis and in the pannus and synovium of patients with rheumatoid arthritis, but its potential role in these processes is unclear. ADAM8 stimulates osteoclast (OCL) formation, but the effects of overexpression or loss of expression of ADAM8 in vivo and the mechanisms responsible for the effects of ADAM8 on osteoclastogenesis are unknown. Therefore, to determine the effects of modulating ADAM expression, we generated tartrate-resistant acid phosphatase (TRAP)-ADAM8 transgenic mice that overexpress ADAM8 in the OCL lineage and ADAM8 knockout (ADAM8 KO) mice. TRAP-ADAM8 mice developed osteopenia and had increased numbers of OCL precursors that formed hypermultinucleated OCLs with an increased bone-resorbing capacity per OCL. They also had an enhanced differentiation capacity, increased TRAF6 expression, and increased NF-kappa B, Erk, and Akt signaling compared with wild-type (WT) littermates. This increased bone-resorbing capacity per OCL was associated with increased levels of p-Pyk2 and p-Src activation. In contrast, ADAMS KO mice did not display a bone phenotype in vivo, but unlike WT littermates, they did not increase RANKL production, OCL formation, or calvarial fibrosis in response to tumor necrosis factor alpha (TNF-alpha) in vivo. Since loss of ADAM8 does not inhibit basal bone remodeling but only blocks the enhanced OCL formation in response to TNF-TNF-alpha, these results suggest that ADAM8 may be an attractive therapeutic target for preventing bone destruction associated with inflammatory disease. (C) 2011 American Society for Bone and Mineral Research. C1 [Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Ishizuka, Hisako; Garcia-Palacios, Veronica; Lu, Ganwei; Zhao, Liena; Patrene, Kenneth; Galson, Deborah L.; Kurihara, Noriyoshi; Roodman, G. David] Univ Pittsburgh, Med Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA. [Ishizuka, Hisako; Garcia-Palacios, Veronica; Lu, Ganwei; Zhao, Liena; Patrene, Kenneth; Galson, Deborah L.; Kurihara, Noriyoshi; Roodman, G. David] Univ Pittsburgh, Med Ctr, Ctr Bone Biol, Pittsburgh, PA USA. [Subler, Mark A.; Boykin, Christina S.; Hadi, Tamer M.; Windle, Jolene J.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA. [Zhang, Heju; Windle, Jolene J.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA. [Choi, Sun Jin] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA. [Blair, Harry C.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, R&D 151-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu RI Galson, Deborah/E-9370-2010 OI Galson, Deborah/0000-0002-2045-8807; Windle, Jolene/0000-0001-6690-385X FU Novartis Pharmaceuticals; NIH [RO1AR041336, P30 CA016059, R01 AR057310] FX GDR reports having served as a consultant to Amgen, Celgene, Acceleron, and Millenium and receives grant support from Novartis Pharmaceuticals. All the other authors state that they have no conflicts of interest.; This work was supported by a VA Merit Review Grant and by NIH Grants RO1AR041336 (to GDR), P30 CA016059 (to JJW), and R01 AR057310 (to DLG). The materials are the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Research and Development. NR 25 TC 17 Z9 17 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2011 VL 26 IS 1 BP 169 EP 181 DI 10.1002/jbmr.199 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 704FD UT WOS:000286035600019 PM 20683884 ER PT J AU Shlipak, MG Lash, JP Yang, W Teal, V Keane, M Cappola, T Keller, C Jamerson, K Kusek, J Delafontaine, P He, JA Miller, ER Schreiber, M Go, AS AF Shlipak, Michael G. Lash, James P. Yang, Wei Teal, Valerie Keane, Martin Cappola, Tom Keller, Chris Jamerson, Kenneth Kusek, John Delafontaine, Patrice He, Jiang Miller, Edgar R., III Schreiber, Martin Go, Alan S. CA CRIC Investigators TI Symptoms Characteristic of Heart Failure Among CKD Patients Without Diagnosed Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Hemoglobin; glomerular filtration rate ID ACUTE MYOCARDIAL-INFARCTION; RENAL-INSUFFICIENCY; HEALTH-STATUS; CYSTATIN-C; SERUM CREATININE; KIDNEY-FUNCTION; RISK-FACTOR; INDIVIDUALS; DISEASE; PREDICTORS AB Background: Epidemiological studies typically diagnose heart failure (HF) at the time of hospitalization, and have not evaluated the prevalence of HF symptoms in CKD patients without a prior HF diagnosis. Methods and Results: We modified the Kansas City Cardiomyopathy Questionnaire (KCCQ) to detect and quantify symptoms characteristic of HF (dyspnea, edema, and fatigue) among 2883 chronic kidney disease (CKD) patients without diagnosed heart failure in the Chronic Renal Insufficiency Cohort (CRIC). The KCCQ is a 23-item instrument that quantifies the impact of dyspnea, fatigue, and edema on physical, social, and emotional functions (scored 0 to 100). The median KCCQ score was 92, and 25% had KCCQ scores <75. Compared with cystatin C-based estimated glomerular filtration rate >50 mL . min . 1.73m(2) (reference), estimated glomerular filtration rate 40 to 50, 30 to 40, and <30 were independently associated with lower KCCQ scores ( <75); adjusted odds ratios and (95% CI): 1.38 (1.06-1.78), 1.39 (1.09-1.82), and 2.15 (1.54-3.00), respectively. Lower hemoglobin (Hb) levels also had independent associations with KCCQ <75: Hb >14 g/dL (reference), Mb 13 to 14 g/dL (1.03; 0.76-1.40), Hb 12 to 13 g/dL (1.41; 1.04-1.91), Mb 11 to 12 g/dL (1.56; 1.12-2.16); and Hb <1 g/dL (1.65; 1.15-2.37). Conclusion: CKD patients without diagnosed HF have a substantial burden of symptoms characteristic of HF, particularly among those with lower estimated glomerular filtration rate and hemoglobin levels. (J Cardiac Fail 2011;17:17-23) C1 [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94109 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lash, James P.] Univ Illinois, Dept Med, Chicago, IL USA. [Yang, Wei; Teal, Valerie] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Keane, Martin; Cappola, Tom] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Keller, Chris] Boise Kidney & Hypertens Inst, Boise, ID USA. [Jamerson, Kenneth] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Kusek, John] NIDDK, Bethesda, MD USA. [Delafontaine, Patrice; He, Jiang] Tulane Univ, Dept Med, New Orleans, LA 70118 USA. [Miller, Edgar R., III] Johns Hopkins Univ, Sch Publ Hlth, Dept Med, Baltimore, MD USA. [Schreiber, Martin] Cleveland Clin, Dept Hypertens & Nephrol, Stongsville, OH USA. [Go, Alan S.] Kaiser Permanente No Calif, Oakland, CA USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,111A1, San Francisco, CA 94109 USA. EM michael.shlipak@ucsf.edu RI Yang, Wei/A-9223-2009 OI Yang, Wei/0000-0001-8984-4389; Teal, Valerie/0000-0001-7116-5353; Delafontaine, Patrice/0000-0003-3744-3617 FU University of Pennsylvania [UL1 RR-024134]; Johns Hopkins University [UL1 RR-025005]; University of Maryland [M01 RR-16500]; Case Western Reserve University [UL1 RR-024989]; University of Michigan [M01 RR-000042, UL1 RR-024986]; University of Illinois at Chicago [UL1 RR-029879]; [R01 DK066488] FX Supported by M.S.'s R01 DK066488 award (principal investigator M.S.). In addition, we would like to acknowledge the CRIC GCRC and CTSA awards: University of Pennsylvania (UL1 RR-024134), Johns Hopkins University (UL1 RR-025005), University of Maryland (M01 RR-16500), Case Western Reserve University (UL1 RR-024989), University of Michigan (M01 RR-000042, UL1 RR-024986), and University of Illinois at Chicago (UL1 RR-029879). NR 19 TC 12 Z9 13 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2011 VL 17 IS 1 BP 17 EP 23 DI 10.1016/j.cardfail.2010.08.009 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 709AK UT WOS:000286407300004 PM 21187260 ER PT J AU Dougherty, CM Steele, BG Hunziker, J AF Dougherty, Cynthia M. Steele, Bonnie G. Hunziker, Jim TI Testing an Intervention to Improve Functional Capability in Advanced Cardiopulmonary Illness SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Article DE COPD; exercise; health care costs; heart failure; quality of life ID CHRONIC HEART-FAILURE; RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; OLDER-ADULTS; CARDIAC REHABILITATION; HOSPITAL UTILIZATION; EXERCISE; COPD; EFFICACY; PROGRAM AB The development of a conceptually driven exercise and self-management intervention for improving functional capability and reducing health care costs using social cognitive theory is described. The intervention has 2 components: a 1-month outpatient exercise intervention followed by a home component, lasting 5 months. The intervention is expected to have significant impact on daily function, quality of life, gait/balance, self-efficacy, and health care utilization in persons with advanced heart failure or chronic obstructive pulmonary disease. We report preliminary results related to process-related variables, including feasibility, safety, and intervention adherence. Intervention outcomes are currently under study and will be reported when available. C1 [Dougherty, Cynthia M.; Steele, Bonnie G.; Hunziker, Jim] VA Puget Sound Healthcare Syst, Seattle Div, Hlth Serv Res & Dev Dept, Seattle, WA 98109 USA. [Dougherty, Cynthia M.; Steele, Bonnie G.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. RP Dougherty, CM (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, Hlth Serv Res & Dev Dept, 1660 S Columbian Way,S-118, Seattle, WA 98109 USA. EM cynthia.dougherty@va.gov FU VA Health Services Research and Development Service, Nursing Research Initiative [NRI 04-242] FX This study is funded by the VA Health Services Research and Development Service, Nursing Research Initiative (NRI 04-242). NR 31 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-7501 J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD JAN-FEB PY 2011 VL 31 IS 1 BP 35 EP 41 DI 10.1097/HCR.0b013e3181f1fd77 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 704LA UT WOS:000286053300004 PM 20861749 ER PT J AU Huckans, M Seelye, A Woodhouse, J Parcel, T Mull, L Schwartz, D Mitchell, A Lahna, D Johnson, A Loftis, J Woods, SP Mitchell, SH Hoffman, W AF Huckans, Marilyn Seelye, Adriana Woodhouse, Jonathan Parcel, Tiffany Mull, Lisa Schwartz, Daniel Mitchell, Alex Lahna, David Johnson, Amy Loftis, Jennifer Woods, Steven Paul Mitchell, Suzanne H. Hoffman, William TI Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Hepatitis C; Neuropsychology; Impulsive behavior; Substance-related disorders; Delay discounting ID METHAMPHETAMINE-DEPENDENT INDIVIDUALS; VIRUS-INFECTION; DECISION-MAKING; CIGARETTE SMOKERS; MONETARY REWARDS; WORKING-MEMORY; HEROIN-ADDICTS; HIV-INFECTION; RISK-FACTORS; DRUG-USERS AB Objective: Determine whether adults with hepatitis C (HCV), regardless of substance use disorder, are more likely to discount delayed rewards than adults without hepatitis C, and explore the relationship between delay discounting and neuropsychological functioning. Methods: Procedures included clinical interviews, neuropsychological testing, and a delay discounting task. Results: Regardless of substance abuse history, adults with hepatitis C were significantly more likely to choose smaller immediate rewards over larger delayed rewards. Delay discounting correlated with performance on executive functioning tasks. Conclusions: Increased discounting is associated with broad executive dysfunction, suggesting that HCV-associated executive dysfunction may lead to altered decision-making style. C1 [Huckans, Marilyn; Seelye, Adriana; Woodhouse, Jonathan; Parcel, Tiffany; Mull, Lisa; Johnson, Amy; Loftis, Jennifer] Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR USA. [Huckans, Marilyn; Seelye, Adriana; Woodhouse, Jonathan; Parcel, Tiffany; Mull, Lisa; Schwartz, Daniel; Mitchell, Alex; Lahna, David; Johnson, Amy; Loftis, Jennifer; Hoffman, William] Portland VA Med Ctr, Div Res, Portland, OR USA. [Huckans, Marilyn; Schwartz, Daniel; Mitchell, Alex; Lahna, David; Loftis, Jennifer; Hoffman, William] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Huckans, Marilyn; Schwartz, Daniel; Mitchell, Alex; Lahna, David; Loftis, Jennifer; Mitchell, Suzanne H.; Hoffman, William] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Seelye, Adriana] Washington State Univ, Pullman, WA 99164 USA. [Woodhouse, Jonathan] George Fox Univ, Portland, OR USA. [Parcel, Tiffany; Mull, Lisa] Univ Pacific, Forest Grove, OR USA. [Woods, Steven Paul] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Huckans, M (reprint author), Portland VA Med Ctr P3MHN, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov OI Mitchell, Suzanne/0000-0002-0225-7200 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development; Oregon Health and Science University; Northwest Health Foundation; VA FX The first author would like to thank Diane Howieson for her initial input into the analysis plan and conceptualization of this study; Daniel Kriz, Hannah Luber, Renee Anderson, and Michael Kolessar for their many contributions as current research assistants within Marilyn Huckans' research program; Emily Kizer, Danell Bjornson, Laura Parisi, and Samantha Ruimy for administrative and recruitment support over the years; Daniel Storzbach and Arthur Vandenbark for their continued mentorship and consultation; Betsy Zucker, Anna Sasaki, Michael Chang, and the other providers of the Portland VA Medical Center Liver Clinic for their ongoing collaborative support of Marilyn Huckans' research. This material is based upon work in part supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development, as well as by the Oregon Health and Science University. This study was supported in part by a Northwest Health Foundation Grant and a VA Career Development Award to Marilyn Huckans. NR 78 TC 23 Z9 24 U1 4 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2011 VL 33 IS 2 BP 176 EP 186 AR PII 925284232 DI 10.1080/13803395.2010.499355 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 715OV UT WOS:000286894700003 PM 20694872 ER PT J AU Huckans, M Loftis, JM AF Huckans, Marilyn Loftis, Jennifer M. TI Handbook of medical neuropsychology: Applications of cognitive neuroscience, 1st edition SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Book Review ID OF-THE-LITERATURE; ALZHEIMER-DISEASE; REHABILITATION; SIGNATURE; DIAGNOSIS; TRIAL C1 [Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Mental Hlth & Clin Neurosci Div, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Huckans, M (reprint author), Portland VA Med Ctr, Res & Dev Serv, Mental Hlth & Clin Neurosci Div, Portland, OR USA. NR 19 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2011 VL 33 IS 5 BP 606 EP 608 AR PII 934036278 DI 10.1080/13803395.2011.556460 PG 3 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 773AQ UT WOS:000291279800013 ER PT J AU Lu, PH Lee, GJ Raven, EP Tingus, K Khoo, T Thompson, PM Bartzokis, G AF Lu, Po H. Lee, Grace J. Raven, Erika P. Tingus, Kathleen Khoo, Theresa Thompson, Paul M. Bartzokis, George TI Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Healthy aging; Cognition; Information processing speed; Myelin; White matter; Magnetic resonance imaging; Alzheimer's disease; Dementia ID INDUCED INTRAMYELINIC EDEMA; WHITE-MATTER INTEGRITY; PRIMARY VISUAL-CORTEX; MAGNETIC-RESONANCE; MULTIPLE-SCLEROSIS; RHESUS-MONKEY; HUMAN BRAIN; CORPUS-CALLOSUM; NERVE-FIBERS; CORTICAL DISCONNECTION AB Performance on measures of cognitive processing speed (CPS) slows with age, but the biological basis associated with this cognitive phenomenon remains incompletely understood. We assessed the hypothesis that the age-related slowing in CPS is associated with myelin breakdown in late-myelinating regions in a very healthy elderly population. An in vivo magnetic resonance imaging (MRI) biomarker of myelin integrity was obtained from the prefrontal lobe white matter and the genu of the corpus callosum for 152 healthy elderly adults. These regions myelinate later in brain development and are more vulnerable to breakdown due to the effects of normal aging. To evaluate regional specificity, we also assessed the splenium of the corpus callosum as a comparison region, which myelinates early in development and primarily contains axons involved in visual processing. The measure of myelin integrity was significantly correlated with CPS in highly vulnerable late-myelinating regions but not in the splenium. These results have implications for the neurobiology of the cognitive changes associated with brain aging. C1 [Raven, Erika P.; Thompson, Paul M.; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90095 USA. [Raven, Erika P.; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Lu, PH (reprint author), Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,Suite 200, Los Angeles, CA USA. EM plu@mednet.ucla.edu RI Bartzokis, George/K-2409-2013 FU National Institute of Aging (NIA) [K23-AG028727]; Alzheimer's Association [NIRG-07-60424]; National Institutes of Health (NIH) [MH 0266029, AG027342]; Alzheimer's Disease Research Center [P50 AG 16570]; California Alzheimer's Disease Centers; Risk Control Strategies Inc. (RCS) Alzheimer's Foundation; Department of Veterans Affairs FX This work was supported by Grant K23-AG028727 from the National Institute of Aging (NIA), a grant from the Alzheimer's Association (NIRG-07-60424), National Institutes of Health (NIH) grants (MH 0266029; AG027342), the Alzheimer's Disease Research Center Grant P50 AG 16570, and the California Alzheimer's Disease Centers. Additional support for the study came from the Risk Control Strategies Inc. (RCS) Alzheimer's Foundation and the Department of Veterans Affairs. NR 102 TC 32 Z9 33 U1 1 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2011 VL 33 IS 10 BP 1059 EP 1068 DI 10.1080/13803395.2011.595397 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 882HM UT WOS:000299554400002 PM 22133139 ER PT J AU Hershman, JM Cheng, SY Gianoukakis, AG AF Hershman, Jerome M. Cheng, Sheue-yann Gianoukakis, Andrew G. TI Update in Thyroidology 2010 SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BRAF(V600E) MUTATION ANALYSIS; UNITED-STATES; INCREASING INCIDENCE; HORMONE RECEPTORS; CANCER; NODULES; OPHTHALMOPATHY; HYPOTHYROIDISM; PREVALENCE; SPECIMENS AB This has been an exciting year in thyroid research. In this article, we summarize the new developments in selected areas of thyroid research by reporting on key papers published during the period June 2009 to June 2010. We selected those papers that, in our opinion, have significant clinical or translational impact. Selection criteria were applied for inclusion of papers for the Year in Thyroid lecture at the 92nd Annual Meeting of The Endocrine Society in San Diego, June, 2010. Papers relating to translational and clinical discovery in thyroidology were reviewed. Papers were chosen if they provided new insight into the understanding of thyroid disease and advanced clinical science, or advanced the diagnosis of disease, or proposed new therapy, or provided new data on important clinical questions in thyroidology. Here we review and discuss these papers and show how they provide new insights into clinical thyroidology. (J Clin Endocrinol Metab 96: 9-14, 2011) C1 [Hershman, Jerome M.] W Los Angeles VA Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. [Cheng, Sheue-yann] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20814 USA. [Gianoukakis, Andrew G.] Harbor Univ Calif Los Angeles UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA. [Hershman, Jerome M.; Gianoukakis, Andrew G.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Hershman, JM (reprint author), W Los Angeles VA Med Ctr, Endocrinol & Diabet Div, Endocrinolgy 111D, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 27 TC 0 Z9 0 U1 1 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2011 VL 96 IS 1 BP 9 EP 14 DI 10.1210/jc.2010-2350 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710HW UT WOS:000286502900002 PM 21209040 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Treating the Black Hypertensive in 2010: Achieve Lower Targets While Awaiting More Definitive Evidence SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID BLOOD-PRESSURE CONTROL; AMLODIPINE C1 [Bloch, Michael J.] St Marys Reg Med Ctr, Risk Reduct Ctr, Reno, NV 89503 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Div Gen Internal Med, Div Cardiol, Reno, NV 89557 USA. [Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bloch, MJ (reprint author), St Marys Reg Med Ctr, Risk Reduct Ctr, 645 N Arlington St,Suite 460, Reno, NV 89503 USA. EM mbloch@aol.com NR 10 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2011 VL 13 IS 1 BP 1 EP 4 DI 10.1111/j.1751-7176.2010.00411.x PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 703RY UT WOS:000286000200001 PM 21214713 ER PT J AU Isaacs, SN AF Isaacs, Stuart N. TI A stimulating way to improve T cell responses to poxvirus-vectored vaccines SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID VIRUS; DNA; VACCINATION; EXPRESSION; IMMUNITY; CLONING; SAFETY AB Vaccines remain one of the most cost-effective public health measures Despite ongoing efforts, protective vaccines against cancer and many infectious diseases, including malaria, tuberculosis, and HIV/AIDS, are still not in hand Most investigators believe that to succeed against these difficult targets, vaccines that generate potent T cell responses are needed In this issue of the Salek-Ardakani et al show how the relative virulence of a virus/vaccine vector affects the memory CD8(+) T cells generated and how the response may be enhanced The work has important implications for the development of future vaccines that aim to trigger CD8(+) T cell responses C1 [Isaacs, Stuart N.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Isaacs, Stuart N.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Isaacs, SN (reprint author), Univ Penn, Sch Med, Dept Med, Div Infect Dis, 502 Johnson Pavilion, Philadelphia, PA 19104 USA. FU NIAID NIH HHS [U01 AI066333, U54-AI057168, U01 AI077913, U01-AI077913, U54 AI057168, U01-AI066333] NR 16 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2011 VL 121 IS 1 BP 19 EP 21 DI 10.1172/JCI45726 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 702KF UT WOS:000285892300006 PM 21183782 ER PT J AU Bernardy, NC Hamblen, JL Friedman, MJ Kivlahan, DR AF Bernardy, Nancy C. Hamblen, Jessica L. Friedman, Matthew J. Kivlahan, Daniel R. TI Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder: Recommendations for Management and Implementation in the Department of Veterans Affairs SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE co-occurring disorders; posttraumatic stress disorder; substance use disorder; implementation ID COCAINE-DEPENDENT INDIVIDUALS; INTEGRATING TOBACCO CESSATION; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; VIETNAM COMBAT VETERANS; MENTAL-HEALTH PROBLEMS; ALCOHOL-USE DISORDERS; PRIMARY-CARE; SEEKING-SAFETY AB The recently revised Department of Veterans Affairs (VA) and Department of Defense Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder (PTSD) offers guidance to treat co-occurring PTSD and substance use disorder. The release of the guideline occurred at a time of cultural shifts in recognizing and managing substance use disorders and when major changes were made in the VA to address co-occurring PTSD and substance use disorders. The release also coincided with an increasing number of veterans returning from the wars in Afghanistan and Iraq who were coming to the VA for PTSD treatment. A key augmentation in mental health staffing has brought many new clinicians to the VA and has made it more feasible to address the two disorders in a coordinated way. In this article the authors describe the recommendations in the revised 2010 PTSD clinical practice guideline to address co-occurring PTSD and substance use disorder, review the supporting research evidence behind the recommendations, and examine methods of new VA programs to address the two disorders. A description of what is working and where obstacles still exist is provided. The new recommendations have moved the field forward by offering clinical guidance to practitioners who are working with patients with the commonly observed co-occurring PTSD and substance use disorder. (Journal of Dual Diagnosis, 7:242-261, 2011) C1 [Bernardy, Nancy C.; Hamblen, Jessica L.; Friedman, Matthew J.] White River Junction VAMC, Natl Ctr PTSD, White River Jct, VT USA. [Bernardy, Nancy C.; Hamblen, Jessica L.; Friedman, Matthew J.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA. [Friedman, Matthew J.] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Lebanon, NH USA. [Kivlahan, Daniel R.] VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. RP Bernardy, NC (reprint author), White River Junction Vet Affairs Med Ctr, Natl Ctr PTSD 116D, 215 N Main, White River Jct, VT 05009 USA. EM nancy.bernardy@va.gov NR 81 TC 4 Z9 4 U1 2 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2011 VL 7 IS 4 SI SI BP 242 EP 261 DI 10.1080/15504263.2011.620446 PG 20 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 888MK UT WOS:000300007600005 ER PT J AU Kaysen, D Atkins, DC Moore, SA Lindgren, KP Dillworth, T Simpson, T AF Kaysen, Debra Atkins, David C. Moore, Sally A. Lindgren, Kristen P. Dillworth, Tiara Simpson, Tracy TI Alcohol Use, Problems, and the Course of Posttraumatic Stress Disorder: A Prospective Study of Female Crime Victims SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE posttraumatic stress disorder; alcohol abuse; rape; crime victims; comorbidity ID NATIONAL COMORBIDITY SURVEY; RISK-FACTORS; SUBSTANCE USE; TRAUMA SURVIVORS; MENTAL-HEALTH; PTSD; SYMPTOMS; ASSAULT; WOMEN; DEPENDENCE AB Objective: In this study the authors examine whether alcohol use disorder status and consequences of drinking moderate the course of posttraumatic stress disorder (PTSD) over the first 6 months following trauma exposure in a sample of female victims of interpersonal violence. Methods: Female sexual and physical assault victims (N = 64) were recruited through police, hospital, and victim service agencies. Women completed structured clinical interviews and self-report measures within the first 5 weeks, 3 months, and 6 months post-trauma with 73% retention across all three time points (n = 47). Analyses were conducted using Hierarchical Linear Modeling using alcohol abuse/dependence, peak alcohol use, and consequences during the 30 days prior to assault as moderators of the course of PTSD over time. Results: Women with alcohol use disorder at baseline had lower initial PTSD symptoms but also less symptom recovery over time than women without alcohol use disorder. This pattern of results was also found for those with high negative drinking consequences during the month prior to the assault. Baseline alcohol use was not found to significantly moderate PTSD course over the 6 months. Conclusions: Findings suggest that negative consequences associated with alcohol use may be a risk factor for PTSD. Incorporating assessment of drinking problems for women presenting early post-trauma may be useful for identifying PTSD risk. (Journal of Dual Diagnosis, 7:262-279, 2011) C1 [Kaysen, Debra; Atkins, David C.; Moore, Sally A.; Lindgren, Kristen P.; Dillworth, Tiara; Simpson, Tracy] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Moore, Sally A.; Simpson, Tracy] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Seattle, WA USA. [Simpson, Tracy] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ CESAT, Seattle, WA USA. RP Kaysen, D (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1100 NE 45th St,Suite 300,UW Box 354944, Seattle, WA 98195 USA. EM dkaysen@uw.edu OI Lindgren, Kristen/0000-0002-0244-1016; Atkins, David/0000-0002-5781-9880 FU NIAAA NIH HHS [F32 AA014728, F32 AA014728-03] NR 58 TC 11 Z9 11 U1 7 U2 15 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2011 VL 7 IS 4 SI SI BP 262 EP 279 DI 10.1080/15504263.2011.620449 PG 18 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 888MK UT WOS:000300007600006 PM 23538605 ER PT J AU Menconi, F Hasham, A Tomer, Y AF Menconi, F. Hasham, A. Tomer, Y. TI Environmental triggers of thyroiditis: Hepatitis C and interferon-alpha SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION LA English DT Review DE Autoimmunity; hepatitis C; infection; interferon; thyroiditis ID CHRONIC VIRAL-HEPATITIS; AUTOIMMUNE ENDOCRINE DISEASE; HUMAN THYROCYTE CULTURES; HCV CHRONIC HEPATITIS; IFN-ALPHA; GENETIC SUSCEPTIBILITY; VIRUS-INFECTION; GRAVES-DISEASE; I INTERFERONS; RISK-FACTOR AB Autoimmune thyroid diseases (AITD) are postulated to develop as a result of a complex interplay between several genetic and environmental influences. The pathogenesis of AITD is still not clearly defined. However, among the implicated triggers (e.g. iodine, infections, medications), more recent data confirmed strong associations of AITD with the hepatitis C virus (HCV) infection and interferon-alpha (IFN alpha) therapy. Moreover, it is likely that HCV and IFN act in synergism to trigger AITD in patients. Indeed, approximately 40% of HCV patients develop either clinical or subclinical disease while receiving IFN alpha. Interferon induced thyroiditis (IIT) can manifest as non-autoimmune thyroiditis (presenting as destructive thyroiditis, or non-autoimmune hypothyroidism), or autoimmune thyroiditis [presenting with clinical features of Graves' disease (GD) or Hashimoto's thyroiditis (HT)]. Although not yet clearly understood, it is thought that IFN alpha can induce thyroiditis via both immune stimulatory and direct toxic effects on the thyroid. In view of the high frequency of IIT, routine screening and surveillance of HCV patients receiving IFN alpha is recommended to avoid the complications, such as cardiac arrhythmias, associated with thyrotoxicosis. In summary, IIT is a common clinical problem that can be readily diagnosed with routine thyroid function screening of HCV patients receiving IFN. The treatment of IIT consists of the standard therapy for differing clinical manifestations of IIT such as GD, HT, or destructive thyroiditis. However, anti-thyroid medications are not recommended in this setting since they can potentially be hepatotoxic. (J. Endocrinol. Invest. 34: 78-84, 2011) (C)2011, Editrice Kurtis C1 [Menconi, F.; Hasham, A.] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA. [Tomer, Y.] James J Peters VA Med Ctr, New York, NY USA. RP Menconi, F (reprint author), Mt Sinai Med Ctr, Dept Med, Div Endocrinol, Box 1118,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Francesca.Menconi@mssm.edu NR 78 TC 19 Z9 25 U1 0 U2 3 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 0391-4097 J9 J ENDOCRINOL INVEST JI J. Endocrinol. Invest. PD JAN PY 2011 VL 34 IS 1 BP 78 EP 84 DI 10.3275/7499 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 743OZ UT WOS:000289029500014 PM 21297381 ER PT J AU Akiba, Y Kaunitz, JD AF Akiba, Yasutada Kaunitz, Jonathan D. TI Duodenal chemosensing: Master control for epigastric sensation? SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID FUNCTIONAL DYSPEPSIA; CARBONIC-ANHYDRASES; NONULCER DYSPEPSIA; ACID; SENSITIVITY; GENERATION; SECRETION; STOMACH; MUCOSA C1 Univ Calif Los Angeles, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Room 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yakiba@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK054221, R01 DK54221] NR 20 TC 6 Z9 6 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD JAN PY 2011 VL 26 IS 1 BP 6 EP 7 DI 10.1111/j.1440-1746.2010.06580.x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 700SY UT WOS:000285765800004 PM 21073675 ER PT J AU Singh, H Esquivel, A Sittig, DF Murphy, D Kadiyala, H Schiesser, R Espadas, D Petersen, LA AF Singh, Hardeep Esquivel, Adol Sittig, Dean F. Murphy, Daniel Kadiyala, Himabindu Schiesser, Rachel Espadas, Donna Petersen, Laura A. TI Follow-up Actions on Electronic Referral Communication in a Multispecialty Outpatient Setting SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE referrals; primary care; sub-specialty care; electronic health records; patient safety; health information technology; communication; diagnostic errors; patient follow-up ID PRIMARY-CARE; INTERNAL-MEDICINE; CONSULTATIONS; SPECIALISTS; INTERFACE; SYSTEM; IMPACT AB OBJECTIVES: Electronic health records (EHR) enable transmission and tracking of referrals between primary-care practitioners (PCPs) and subspecialists. We used an EHR to examine follow-up actions on electronic referral communication in a large multispecialty VA facility. METHODS: We retrieved outpatient referrals to five subspecialties between October 2006 and December 2007, and queried the EHR to determine their status: completed, discontinued (returned to PCP), or unresolved (no action taken by subspecialist). All unresolved referrals, and random samples of discontinued and completed referrals were reviewed to determine whether subspecialists took follow-up actions (i.e., schedule appointments anytime in the future) within 30 days of referral-receipt. For referrals without timely follow-up, we determined whether inaction was supported by any predetermined justifiable reasons or associated with certain referral characteristics. We also reviewed if PCPs took the required action on returned information. RESULTS: Of 61,931 referrals, 22,535 were discontinued (36.4%), and 474 were unresolved (0.8%). We selected 412 discontinued referrals randomly for review. Of these, 52% lacked follow-up actions within 30 days. Appropriate justifications for inaction were documented in 69.8% (150/215) of those without action and included lack of prerequisite testing by the PCP and subspecialist opinion that no intervention was required despite referral. We estimated that at 30 days, 6.3% of all referrals were associated with an unexplained lack of follow-up actions by subspecialists. Conversely, 7.4% of discontinued referrals returned to PCPs were associated with an unexplained lack of follow-up. CONCLUSIONS: Although the EHR facilitates transmission of valuable information at the PCP-subspecialist interface, unexplained communication breakdowns in the referral process persist in a subset of cases. C1 [Singh, Hardeep; Esquivel, Adol; Murphy, Daniel; Espadas, Donna; Petersen, Laura A.] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Houston, TX USA. [Singh, Hardeep; Esquivel, Adol; Murphy, Daniel; Espadas, Donna; Petersen, Laura A.] Michael E DeBakey VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX USA. [Singh, Hardeep; Esquivel, Adol; Murphy, Daniel; Espadas, Donna; Petersen, Laura A.] Sect Hlth Serv Res, Houston, TX USA. [Singh, Hardeep; Esquivel, Adol; Murphy, Daniel; Kadiyala, Himabindu; Schiesser, Rachel; Espadas, Donna; Petersen, Laura A.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Murphy, Daniel] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu RI Murphy, Daniel/G-5017-2013 OI Murphy, Daniel/0000-0002-2329-668X FU NIH [K23CA125585]; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence [HFP90-020] FX The study was supported by an NIH K23 career development award (K23CA125585) to Dr. Singh, the VA National Center of Patient Safety, and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). NR 26 TC 22 Z9 22 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2011 VL 26 IS 1 BP 64 EP 69 DI 10.1007/s11606-010-1501-z PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 708CJ UT WOS:000286338900019 PM 20848235 ER PT J AU Gordon, AJ Kunins, HV Rastegar, DA Tetrault, JM Walley, AY AF Gordon, Adam J. Kunins, Hillary V. Rastegar, Darius A. Tetrault, Jeanette M. Walley, Alexander Y. TI Update in Addiction Medicine for the Generalist SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE review; substance-related disorders; primary health care; primary care; alcoholism and addictive behavior; drug abuse; smoking cessation ID RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE DISORDERS; IDENTIFICATION TEST AUDIT; BRIEF PHYSICIAN ADVICE; PRIMARY-CARE; BRIEF INTERVENTION; SCREENING-TEST; BEHAVIORAL-INTERVENTIONS; BUPRENORPHINE TREATMENT; PROBLEM DRINKING C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kunins, Hillary V.] Albert Einstein Coll Med, New York, NY USA. [Kunins, Hillary V.] Montefiore Med Ctr, New York, NY USA. [Rastegar, Darius A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Tetrault, Jeanette M.] Yale Univ, Sch Med, New Haven, CT USA. [Walley, Alexander Y.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151-C-H, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov OI Walley, Alexander/0000-0002-8158-4882 NR 56 TC 5 Z9 5 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2011 VL 26 IS 1 BP 77 EP 82 DI 10.1007/s11606-010-1461-3 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 708CJ UT WOS:000286338900021 PM 20697971 ER PT J AU Halvorson, SAC Cedfeldt, AS Hunter, AJ AF Halvorson, Stephanie A. C. Cedfeldt, Andrea S. Hunter, Alan J. TI Fulminant, Non-antibiotic Associated Clostridium difficile Colitis Following Salmonella Gastroenteritis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Clostridium difficile; Salmonella; community-acquired infections ID INFECTION; DISEASE; COMMUNITY; DIARRHEA; RISK; VANCOMYCIN; PATTERNS AB In the last decade there has been increasing awareness of the virulence and changing epidemiology of Clostridium difficile (C. difficile). While the vast majority of clinical cases of C. difficile are associated with antimicrobial or nosocomial exposure, this syndrome has been well described in the absence of antibiotic use. We present an unusual case of fatal, non-antibiotic associated C. difficile colitis following Salmonella serotype Saintpaul gastroenteritis in a previously healthy young person. We review the typical risk factors for C. difficile colitis and fulminant disease. We also review the epidemiology of community-acquired C. difficile-associated disease (CA-CDAD) and highlight Salmonella infection as a potential risk factor for development of CA-CDAD. C1 [Halvorson, Stephanie A. C.; Cedfeldt, Andrea S.; Hunter, Alan J.] Oregon Hlth & Sci Univ, Dept Med, Div Hosp Med, Portland, OR 97239 USA. [Cedfeldt, Andrea S.] Portland VA Med Ctr, Sect Hosp & Subspecialty Med, Portland, OR USA. RP Halvorson, SAC (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hosp Med, 3181 SW Sam Jackson Pk Rd,BTE 119, Portland, OR 97239 USA. EM halvorss@ohsu.edu NR 20 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2011 VL 26 IS 1 BP 95 EP 97 DI 10.1007/s11606-010-1466-y PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 708CJ UT WOS:000286338900025 PM 20697966 ER PT J AU Matthews, PB Jhun, CS Yaung, S Azadani, AN Guccione, JM Ge, LA Tseng, EE AF Matthews, Peter B. Jhun, Choon-Sik Yaung, Stephanie Azadani, Ali N. Guccione, Julius M. Ge, Liang Tseng, Elaine E. TI Finite Element Modeling of the Pulmonary Autograft at Systemic Pressure before Remodeling SO JOURNAL OF HEART VALVE DISEASE LA English DT Article ID ROSS PROCEDURE; AORTIC ROOT; PORCINE PULMONARY; VALVE; OPERATION; REPLACEMENT; DILATION; REOPERATIONS; DILATATION; ANEURYSM AB Background and aim of the study: Pulmonary autograft dilatation requiring reoperation is an Achilles' heel of the Ross procedure, as exposure to systemic pressure increases autograft wall stress, which may in turn lead to tissue remodeling and aneurysmal pathology. However, the magnitude of autograft wall stress with the Ross procedure is unknown. The study aim was to develop a realistic finite element (FE) model of the autograft, and to perform simulations at systemic pressure to determine wall stress distribution immediately after the Ross operation. Methods: The porcine pulmonary root geometry was generated from high-resolution microcomputed tomography (microCT) images to create a mesh composed of hexahedral elements. Previously defined constitutive equations were used to describe the regional material properties of the native porcine pulmonary root. The anterior and posterior pulmonary arteries, and each of the pulmonary sinuses, were best described by non-linear, anisotropic Fung strain energy functions, and input individually into the model. Autograft dilatation and wall stress distribution during pulmonary and systemic loading prior to remodeling were determined using explicit FE analysis in LS-DYNA. Results: The autograft was highly compliant in the low-strain region, and the majority of dilation occurred with <30 mmHg of pressurization. During pulmonic loading, a typical inflation/deflation was observed between systole and diastole, but the autograft remained almost completely dilated throughout the cardiac cycle at systemic pressure. Although the systolic blood pressure was 380% greater in the aortic than in the pulmonary position, the peak systolic diameter was increased by only 28%. The maximum principal wall stress increased approximately 10-fold during systole and 25-fold during diastole, and was greater in the sinus than the distal artery for all simulations. Conclusion: Under systemic loading conditions, the pulmonary autograft remained fully dilated and experienced large wall stresses concentrated in the sinus. The future correlation of this model with explanted autografts may lead to an improved understanding of tissue remodeling following the Ross procedure. C1 [Tseng, Elaine E.] UCSF, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), UCSF, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Suite W405,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org FU American Heart Association; Northern the California Institute for Research and Education FX These studies were supported by the American Heart Association and Northern the California Institute for Research and Education. The authors have no financial conflicts of interest to disclose. NR 34 TC 5 Z9 5 U1 2 U2 2 PU I C R PUBLISHERS PI NORTHWOOD PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET, ENGLAND SN 0966-8519 J9 J HEART VALVE DIS JI J. Heart Valve Dis. PD JAN PY 2011 VL 20 IS 1 BP 45 EP 52 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 720GC UT WOS:000287267700008 PM 21404897 ER PT J AU Dinescu, A Fernandez, H Ross, JS Karani, R AF Dinescu, Anca Fernandez, Helen Ross, Joseph S. Karani, Reena TI Audit and Feedback: An Intervention to Improve Discharge Summary Completion SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE continuity of care transition and discharge planning; geriatric patient; practice-based learning and improvement ID PRIMARY-CARE PHYSICIANS; GENERAL-PRACTITIONERS; COMMUNICATION; QUALITY; INFORMATION; CONTINUITY; ATTITUDES; HEALTH; IMPACT AB Discharge summaries (DS) communicate important clinical information from inpatient to outpatient settings. Previous studies noted increased adverse events and rehospitalization due to poor DS quality. We postulated that an audit and feedback intervention of DS completed by geriatric medicine fellows would improve the completeness of their summaries. We conducted a preintervention post intervention study. In phase 1 (AUDIT #1 and FEEDBACK) we scored all DS (n = 89) completed by first year fellows between July 2006 to December 2006 using a 21-item checklist. Individual performance scores were reviewed with each fellow in 30-minute feedback sessions. In phase 2 (AUDIT #2) we scored all DS (n = 79) completed after the first phase between February 2007 to July 2007 using the same checklist. Data were analyzed using generalized estimating equations. Fellows were more likely to complete all required DS data after feedback when compared with prior to feedback (91% vs. 71%, P < 0.001). Feedback was also associated with improved admission (93% vs. 70%, P < 0.001), duration of hospitalization (93% vs 78%, P < 0.001), discharge planning (93% vs. 18%, P < 0.02) and postdischarge care (83% vs. 57%., P < 0.001) section-specific information. In conclusion, audit and feedback sessions were associated with better DS completeness in areas of particular importance to geriatric care. Journal of Hospital Medicine 2011;6:28-32. (C) 2011 Society of Hospital Medicine. C1 [Dinescu, Anca; Fernandez, Helen; Ross, Joseph S.; Karani, Reena] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Ross, Joseph S.] James J Peters VA Med Ctr, Bronx, NY USA. [Dinescu, Anca; Fernandez, Helen; Ross, Joseph S.; Karani, Reena] Mt Sinai Sch Med, Samuel M Bronfman Dept Med, New York, NY USA. RP Dinescu, A (reprint author), 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM anca.dinescu@mssm.edu FU NIA NIH HHS [K08 AG032886, K08 AG032886-03] NR 18 TC 10 Z9 10 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2011 VL 6 IS 1 BP 28 EP 32 DI 10.1002/jhm.831 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 710AU UT WOS:000286483800007 PM 21241038 ER PT J AU Mullen, TD Spassieva, S Jenkins, RW Kitatani, K Bielawski, J Hannun, YA Obeid, LM AF Mullen, Thomas D. Spassieva, Stefka Jenkins, Russell W. Kitatani, Kazuyuki Bielawski, Jacek Hannun, Yusuf A. Obeid, Lina M. TI Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism SO JOURNAL OF LIPID RESEARCH LA English DT Article DE dihydroceramide; hexosylceramide; sphingomyelin; long-chain sphingolipids; very-long-chain sphingolipids; glucosylceramide synthase; short interfering RNA ID LONGEVITY ASSURANCE GENE-1; SQUAMOUS-CELL CARCINOMAS; (DIHYDRO)CERAMIDE SYNTHASE; SPHINGOSINE 1-PHOSPHATE; SUBSTRATE-SPECIFICITY; MASS-SPECTROMETRY; SALVAGE PATHWAY; FAMILY-MEMBERS; BREAST-CANCER; HUMAN HEAD AB Mammalian ceramide synthases 1 to 6 ( CerS1-6) generate Cer in an acyl-CoA-dependent manner, and expression of individual CerS has been shown to enhance the synthesis of ceramides with particular acyl chain lengths. However, the contribution of each CerS to steady-state levels of specific Cer species has not been evaluated. We investigated the knockdown of individual CerS in the MCF-7 human breast adenocarcinoma cell line by using small-interfering RNA ( siRNA). We found that siRNA-induced down-regulation of each CerS resulted in counter-regulation of nontargeted CerS. Additionally, each CerS knockdown produced unique effects on the levels of multiple sphingolipid species. For example, downregulation of CerS2 decreased very long-chain Cer but increased levels of CerS4, CerS5, and CerS6 expression and upregulated long-chain and medium-long-chain sphingolipids. Conversely, CerS6 knockdown decreased C16:0-Cer but increased CerS5 expression and caused non-C16:0 sphingolipids to be upregulated. Knockdown of individual CerS failed to decrease total sphingolipids or upregulate sphingoid bases. Treatment with siRNAs targeting combined CerS, CerS2, CerS5, and CerS6, did not change overall Cer or sphingomyelin mass but caused upregulation of dihydroceramide and hexosyl-ceramide and promoted endoplasmic reticulum stress. These data suggest that sphingolipid metabolism is robustly regulated by both redundancy in CerS-mediated Cer synthesis and counter-regulation of CerS expression.-Mullen, T. D., S. Spassieva, R. W. Jenkins, K. Kitatani, J. Bielawski, Y. A. Hannun, and L. M. Obeid. Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism. J. Lipid Res. 2011. 52:68-77. C1 [Mullen, Thomas D.; Spassieva, Stefka; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Jenkins, Russell W.; Kitatani, Kazuyuki; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM obeidl@musc.edu OI Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847 FU Medical University of South Carolina [5T32ES012878]; NIH/NIEHS [F30 ES016975-01]; NIH [R01 AG016583]; National Institutes of Health/National Cancer Institute [P01 CA097132]; American Heart Association [081509E]; National Institutes of Health [GM08716]; National Center for Research Resources (National Institutes of Health) [C06 RR018823]; Office of Research and Development, Department of Veterans Affairs; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC FX Support for this research was provided by Medical University of South Carolina Department of Pharmaceutical Sciences Training Program in Environmental Stress Signaling (National Institutes of Health/National Institute of Environmental Health Science) Grant 5T32ES012878 and Ruth L. Kirschstein National Research Service Award (NIH/NIEHS) Grant 1 F30 ES016975-01 (T.D.M.); NIH Grant R01 AG016583 (to L.M.O.); National Institutes of Health/National Cancer Institute Grant P01 CA097132 (Y.A.H.); American Heart Association pre-doctoral fellowship Grant 081509E (R.W.J.); and National Institutes of Health Medical Scientist Training Program Grant (GM08716) (R.W.J.). HPLC/MS analysis at the MUSC Lipidomics Core Facility was supported by the Extramural Research Facilities Program of the National Center for Research Resources (National Institutes of Health Grant C06 RR018823). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies. This work also received supportin part by a Method to Extend Research in Time (MERIT) Award (L.M.O.) from the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC. NR 43 TC 54 Z9 54 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD JAN PY 2011 VL 52 IS 1 BP 68 EP 77 DI 10.1194/jlr.M009142 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 692WA UT WOS:000285185400007 PM 20940143 ER PT J AU Li, M Balamuthusamy, S Khan, AM Maderdrut, JL Simon, EE Batuman, V AF Li, Min Balamuthusamy, Saravanan Khan, Altaf M. Maderdrut, Jerome L. Simon, Eric E. Batuman, Vecihi TI Pituitary Adenylate Cyclase-Activating Polypeptide Prevents Cisplatin-Induced Renal Failure SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Apoptosis; Cancer chemotherapy; Extracellular matrix; Inflammation; p53; Renoprotection ID VASOACTIVE-INTESTINAL-PEPTIDE; 4 SPLICE VARIANTS; MULTIPLE-MYELOMA; INDUCED NEPHROTOXICITY; PATHOLOGICAL ROLE; OXIDATIVE STRESS; CELL APOPTOSIS; IN-VITRO; KIDNEY; PACAP AB Cisplatin is widely used for cancer chemotherapy, but nephrotoxicity is a major dose-limiting side effect. Our recent studies in vitro have shown that pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorated cisplatin nephrotoxicity and that the renoprotection with PACAP38 was mediated by the PAC(1) receptor and through the p53-dependent and -independent suppression of apoptosis of human renal proximal tubular epithelial cells. In the present studies, PACAP38 prevented the rise in blood urea nitrogen and serum creatinine in mice treated with cisplatin. Cisplatin-exposed mice treated with PACAP38 had relatively well-preserved tubular integrity, even when the treatment started 24 h after cisplatin exposure. PACAP38 also reduced plasma and kidney levels of tumor necrosis factor-alpha and restored collagen IV levels. The damage to mouse kidney tubules caused by cisplatin involved p53 accumulation and was partially reversed by treatment with PACAP38. PACAP38 ameliorates cisplatin-induced acute kidney injury even when treatment started 24 h after the onset of injury and increases tubular regeneration, which further facilitates restoration of kidney function in addition to its anti-apoptotic effects. C1 [Li, Min; Balamuthusamy, Saravanan; Khan, Altaf M.; Simon, Eric E.; Batuman, Vecihi] Tulane Univ, Sch Med, Sect Nephrol & Hypertens, Dept Med, New Orleans, LA 70112 USA. [Maderdrut, Jerome L.] Peptide Res Lab, Dept Med, New Orleans, LA 70112 USA. [Simon, Eric E.; Batuman, Vecihi] US Dept Vet Affairs, SE Louisiana Vet Hlth Care Syst, New Orleans, LA 70112 USA. RP Li, M (reprint author), Tulane Univ, Sch Med, Sect Nephrol & Hypertens, Dept Med, 1430 Tulane Ave,SL 45, New Orleans, LA 70112 USA. EM minlee@tulane.edu OI Batuman, Vecihi/0000-0002-1800-9009 FU Louisiana Board of Regents [013RCEEP-07]; Dialysis Clinic, Inc.; Arimura Foundation FX This work was supported in part by the Research Commercialization and Educational Enhancement Program of the Louisiana Board of Regents (013RCEEP-07 to M. L., J.L.M. and V. B.), the Dialysis Clinic, Inc. (research endowment to V. B.), and the Arimura Foundation (research grant to M. L.). NR 36 TC 11 Z9 11 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2011 VL 43 IS 1 BP 58 EP 66 DI 10.1007/s12031-010-9394-1 PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 705CJ UT WOS:000286106100010 PM 20514524 ER PT J AU Lu, YX Germano, P Ohning, GV Vu, JP Pisegna, JR AF Lu, Yuxin Germano, Patrizia Ohning, Gordon V. Vu, John P. Pisegna, Joseph R. TI PAC1 Deficiency in a Murine Model Induces Gastric Mucosa Hypertrophy and Higher Basal Gastric Acid Output SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE PACAP; PAC1 deficient; Gastric acid secretion ID CYCLASE-ACTIVATING POLYPEPTIDE; ADENYLATE-CYCLASE; ECL CELLS; TYPE-1 RECEPTOR; SECRETION; MICE; PROLIFERATION; RAT; NEUROPEPTIDE; RELEASE AB Pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to increase the histamine release from gastric enterochromaffin-like (ECL) cells and promote gastric acid secretion in rats. In contrast, in mice, PACAP has been demonstrated to induce a decrease of gastric acid secretion, an effect presumably due to somatostatin release. To more clearly define the role of PACAP in the regulation of gastric acid output, a knockout mouse model for the PACAP-specific receptor PAC1 was applied in this study. Measurements of the basal and stimulated gastric acid secretion and morphological studies on the gastric mucosa were performed in both wild-type and PAC1-deficient mice. Compared with the wild-type mice, the PAC1-deficient mice showed a nearly threefold higher basal gastric acid output, increased gastric mucosa thickness and glands height, and proportional increases in parietal and total cell counts in the gastric mucosa. The PAC1-deficient mice also showed a trend of increased plasma gastrin levels and gastrin gene expression in the gastric mucosa. This study indicates that the expression of PAC1 is clearly important for maintaining the homeostasis of gastric acid secretion. Loss of PACAP receptor during development may lead to a compensatory mechanism regulating gastric acid secretion. C1 [Lu, Yuxin; Ohning, Gordon V.; Vu, John P.; Pisegna, Joseph R.] Vet Adm Greater Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. [Lu, Yuxin; Germano, Patrizia; Ohning, Gordon V.; Vu, John P.; Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Pisegna, JR (reprint author), Vet Adm Greater Angeles Healthcare Syst, Div Gastroenterol & Hepatol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu FU Department of Veterans Affairs; NIH [DK41301] FX This work was supported by the Department of Veterans Affairs Merit Review Grant (JRP). Antibody #S607 raised against somatostatin was provided by the CURE Digestive Diseases Research Center, Antibody/RIA Core, NIH Grant #DK41301. NR 19 TC 6 Z9 6 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2011 VL 43 IS 1 BP 76 EP 84 DI 10.1007/s12031-010-9440-z PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 705CJ UT WOS:000286106100012 PM 20821075 ER PT J AU Turner, TH Goldstein, J Hamilton, JM Jacobson, M Pirogovsky, E Peavy, G Corey-Bloom, J AF Turner, Travis H. Goldstein, Jody Hamilton, Joanne M. Jacobson, Mark Pirogovsky, Eva Peavy, Guerry Corey-Bloom, Jody TI Behavioral Measures of Saccade Latency and Inhibition in Manifest and Premanifest Huntington's Disease SO JOURNAL OF MOTOR BEHAVIOR LA English DT Article DE behavioral test; eye-tracking; Huntington's disease; oculomotor functioning; predictive testing; presymptomatic; saccade; saccadic eye movements ID MOTOR ABNORMALITIES; PREDICT-HD; RELIABILITY; PROGRESSION AB Initiation and inhibition of saccadic eye movements has been shown to be impaired in patients with Huntington's disease (HD) and premanifest gene carriers (PMGC), and may provide biomarkers useful in tracking phenotypic change. Computerized behavioral tests of prosaccade latency and disinhibition presented to 31 non-gene carriers (NGC), 25 PMGC, and 12 HD patients. These tests provided quantitative performance measures without use of eye-tracking equipment. Significant differences on saccade tests were found, with PMGC intermediate between NGC and HD patients. Saccade latency discriminated PMGC from NGC, whereas saccade disinhibition discriminated PMGC from HD patients. Results suggest utility of behavioral saccade measures as premanifest indicators of phenoconversion in HD. C1 [Turner, Travis H.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC USA. [Goldstein, Jody; Hamilton, Joanne M.; Pirogovsky, Eva; Peavy, Guerry; Corey-Bloom, Jody] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jacobson, Mark] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Turner, TH (reprint author), Charleston Mem Hosp, Movement Disorders Program Neurol, 326 Calhoun St,Suite 308,POB 250108, Charleston, SC 29401 USA. EM turnertr@musc.edu OI Pirogovsky, Eva/0000-0002-2941-9070 FU UCSD Huntington's Disease Society of America (HDSA) Center of Excellence; UCSD Alzheimer's Disease Research Center [NIH P50 AG 005131] FX This work was supported by the UCSD Huntington's Disease Society of America (HDSA) Center of Excellence and the UCSD Alzheimer's Disease Research Center (NIH P50 AG 005131). NR 22 TC 5 Z9 5 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-2895 J9 J MOTOR BEHAV JI J. Mot. Behav. PY 2011 VL 43 IS 4 BP 295 EP 302 DI 10.1080/00222895.2011.580390 PG 8 WC Neurosciences; Psychology; Psychology, Experimental; Sport Sciences SC Neurosciences & Neurology; Psychology; Sport Sciences GA 888KT UT WOS:000300003100002 PM 21774606 ER PT J AU Mercer, AJ Rabl, K Riccardi, GE Brecha, NC Stella, SL Thoreson, WB AF Mercer, A. J. Rabl, K. Riccardi, G. E. Brecha, N. C. Stella, S. L., Jr. Thoreson, W. B. TI Location of Release Sites and Calcium-Activated Chloride Channels Relative to Calcium Channels at the Photoreceptor Ribbon Synapse SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID TIGER SALAMANDER RETINA; CA2+-ACTIVATED CL-CHANNEL; CELL AFFERENT SYNAPSE; TRANSMITTER RELEASE; INTRACELLULAR CALCIUM; ROD PHOTORECEPTORS; CONE PHOTORECEPTORS; CA2+ CHANNELS; PRESYNAPTIC TERMINALS; QUANTITATIVE-ANALYSIS AB Mercer AJ, Rabl K, Riccardi GE, Brecha NC, Stells SL Jr, Thoreson WB. Location of release sites and calcium-activated chloride channels relative to calcium channels at the photoreceptor ribbon synapse. J Neurophysiol 105: 321-335, 2011. First published November 17, 2010; doi:10.1152/jn.00332.2010. Vesicle release from photoreceptor ribbon synapses is regulated by L-type Ca2+ channels, which are in turn regulated by Cl- moving through calcium-activated chloride [Cl(Ca)] channels. We assessed the proximity of Ca2+ channels to release sites and Cl(Ca) channels in synaptic terminals of salamander photoreceptors by comparing fast (BAPTA) and slow (EGTA) intracellular Ca2+ buffers. BAPTA did not fully block synaptic release, indicating some release sites are <100 nm from Ca2+ channels. Comparing Cl(Ca) currents with predicted Ca2+ diffusion profiles suggested that Cl(Ca) and Ca2+ channels average a few hundred nanometers apart, but the inability of BAPTA to block Cl(Ca) currents completely suggested some channels are much closer together. Diffuse immunolabeling of terminals with an antibody to the putative Cl(Ca) channel TMEM16A supports the idea that Cl(Ca) channels are dispersed throughout the presynaptic terminal, in contrast with clustering of Ca2+ channels near ribbons. Cl(Ca) currents evoked by intracellular calcium ion concentration ([Ca2+](i)) elevation through flash photolysis of DM-nitrophen exhibited EC50 values of 556 and 377 nM with Hill slopes of 1.8 and 2.4 in rods and cones, respectively. These relationships were used to estimate average submembrane [Ca2+](i) in photoreceptor terminals. Consistent with control of exocytosis by [Ca2+] nanodomains near Ca2+ channels, average submembrane [Ca2+](i) remained below the vesicle release threshold (similar to 400 nM) over much of the physiological voltage range for cones. Positioning Ca2+ channels near release sites may improve fidelity in converting voltage changes to synaptic release. A diffuse distribution of Cl(Ca) channels may allow Ca2+ influx at one site to influence relatively distant Ca2+ channels. C1 [Mercer, A. J.] Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Durham Res Ctr 4050, Omaha, NE 68198 USA. [Mercer, A. J.; Thoreson, W. B.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA. [Rabl, K.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Brecha, N. C.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Riccardi, G. E.; Brecha, N. C.; Stella, S. L., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Brecha, N. C.] Univ Calif Los Angeles, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Brecha, N. C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Thoreson, WB (reprint author), Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Durham Res Ctr 4050, Omaha, NE 68198 USA. EM wbthores@unmc.edu RI Mercer, Aaron/G-4163-2010; riccardi, gabriele/A-9269-2012 OI Mercer, Aaron/0000-0002-9586-6610; Stella Jr., Salvatore/0000-0003-1971-2537; Thoreson, Wallace/0000-0001-7104-042X FU Research to Prevent Blindness, National Eye Institute [EY-10542, EY-15573]; National Institutes of Health; Department of Veterans Affairs; University of Nebraska Medical Center FX This work was supported by Research to Prevent Blindness, National Eye Institute Grants EY-10542 to W. B. Thoreson and EY-15573 to N. C. Brecha, National Institutes of Health American Recovery and Reinvestment Act award to support G. E. Riccardi (to N. C. Brecha), a Senior Career Scientist Award from the Department of Veterans Affairs to N. C. Brecha, Fight for Sight grant to K. Rabl, and a University of Nebraska Medical Center Graduate Student Fellowship to A. Mercer. NR 97 TC 24 Z9 25 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2011 VL 105 IS 1 BP 321 EP 335 DI 10.1152/jn.00332.2010 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 705MU UT WOS:000286139900027 PM 21084687 ER PT J AU Kim, A Kamyab, K Zhu, JS Volpp, K AF Kim, Annice Kamyab, Kian Zhu, Jingsan Volpp, Kevin TI Why are Financial Incentives not Effective at Influencing Some Smokers to Quit? Results of a Process Evaluation of a Worksite Trial Assessing the Efficacy of Financial Incentives for Smoking Cessation SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; WEIGHT-LOSS; PROGRAM; SUCCESS AB Objective: Process evaluation of a worksite intervention in which employees were offered $750 to complete a cessation program and to quit smoking. Methods: Awareness and attitudes about financial incentives were assessed following a randomized controlled trial of 878 smokers at a US-based company. Results: Cessation program attendance was higher in incentive group versus control (20.2% vs 7.1%, P < 0.01). Most quitters (69.8%) in the incentive group who were already motivated to quit and reported that they would have quit for less money, said incentives were "not at all" or only "somewhat" important. Most nonquitters in the incentive group reported that even $1500 would not have motivated them to quit. Conclusions: Financial incentives are ineffective at motivating some smokers to quit. Internal motivation and readiness to quit need to be sufficiently high for relatively modest incentives to be effective. C1 [Kim, Annice; Kamyab, Kian] RTI Int, Publ Hlth Policy Res Program, Res Triangle Pk, NC 27709 USA. [Zhu, Jingsan; Volpp, Kevin] Univ Penn, Sch Med, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Zhu, Jingsan; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. RP Kim, A (reprint author), RTI Int, Publ Hlth Policy Res Program, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM akim@rti.org NR 22 TC 14 Z9 14 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD JAN PY 2011 VL 53 IS 1 BP 62 EP 67 DI 10.1097/JOM.0b013e31820061d7 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 704KL UT WOS:000286051800011 PM 21187795 ER PT J AU Raval, MV Dillon, PW Bruny, JL Ko, CY Hall, BL Moss, RL Oldham, KT Richards, KE Vinocur, CD Ziegler, MM AF Raval, Mehul V. Dillon, Peter W. Bruny, Jennifer L. Ko, Clifford Y. Hall, Bruce L. Moss, R. Lawrence Oldham, Keith T. Richards, Karen E. Vinocur, Charles D. Ziegler, Moritz M. CA ACS NSQIP Pediat Steering Comm TI Pediatric American College of Surgeons National Surgical Quality Improvement Program: feasibility of a novel, prospective assessment of surgical outcomes SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article DE ACS NSQIP; Pediatric surgery; Outcomes; Quality assessment ID PRIVATE-SECTOR; NSQIP; CARE AB Purpose: The American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) provides validated assessment of surgical outcomes. This study reports initiation of an ACS NSQIP Pediatric at 4 children's hospitals. Methods: From October 2008 to June 2009, 121 data variables were prospectively collected for 3315 patients, including 30-day outcomes and tailoring the ACS NSQIP methodology to children's surgical specialties. Results: Three hundred seven postoperative complications/occurrences were detected in 231 patients representing 7.0% of the study population. Of the patients with complications, 175 (75.7%) had 1, 39 (16.9%) had 2, and 17 (7.4%) had 3 or more complications. There were 13 deaths (0.39%) and 14 intraoperative occurrences (0.42%) detected. The most common complications were infection, 105 (34%) (SSI, 54; sepsis, 31; pneumonia, 13; urinary tract infection, 7); airway/respiratory events, 27 (9%); wound disruption, 18 (6%); neurologic events, 8 (3%) (nerve injury, 4; stroke/vascular event, 2; hemorrhage, 2); deep vein thrombosis, 3 (<1%); renal failure, 3 (<1%); and cardiac events, 3 (<1%). Current sampling captures 17.5% of cases across institutions with unadjusted complication rates ranging from 6.8% to 10.2%. Completeness of data collection for all variables exceeded 95% with 98% interrater reliability and 87% of patients having full 30-day follow-up. Conclusion: These data represent the first multiinstitutional prospective assessment of specialty-specific surgical outcomes in children. The ACS NSQIP Pediatric is poised for institutional expansion and future development of risk-adjusted models. (C) 2011 Elsevier Inc. All rights reserved. C1 [Raval, Mehul V.; Ko, Clifford Y.; Hall, Bruce L.; Richards, Karen E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Raval, Mehul V.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Dillon, Peter W.] Penn State Univ, Dept Surg, Sch Med, Div Pediat Surg, Hershey, PA USA. [Bruny, Jennifer L.; Ziegler, Moritz M.] Univ Colorado, Dept Pediat Surg, Childrens Hosp, Denver, CO 80202 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, Barnes Jewish Hosp, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Moss, R. Lawrence] Yale Univ, Yale New Haven Childrens Hosp, Dept Surg, New Haven, CT USA. [Oldham, Keith T.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA. [Vinocur, Charles D.] Thomas Jefferson Univ, Div Pediat Surg, AI DuPont Hosp Children, Wilmington, DE USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Vinocur, Charles/0000-0001-9650-1122; Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation FX MVR participates in the American College of Surgeons Clinical Scholars in Residence Program. MVR is supported by the John Gray Research Fellowship and the Daniel F. and Ada L. Rice Foundation. The authors would like to thank the ACS NSQIP staff and the tremendous efforts toward high-quality, accurate data collection by the ACS NSQIP SCRs. NR 10 TC 60 Z9 60 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2011 VL 46 IS 1 BP 115 EP 121 DI 10.1016/j.jpedsurg.2010.09.073 PG 7 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 706CL UT WOS:000286194200029 PM 21238651 ER PT J AU Reise, SP Horan, WP Blanchard, JJ AF Reise, Steven P. Horan, William P. Blanchard, Jack J. TI The Challenges of Fitting an Item Response Theory Model to the Social Anhedonia Scale SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID PSYCHOMETRICALLY IDENTIFIED SCHIZOTYPY; SCHIZOPHRENIA; ANXIETY; DISORDERS; SYMPTOMS; VALIDITY; BIFACTOR; LIFE AB This study explored the application of latent variable measurement models to the Social Anhedonia Scale (SAS; Eckblad, Chapman, Chapman, Mishlove, 1982), a widely used and influential measure in schizophrenia-related research. Specifically, we applied unidimensional and bifactor item response theory (IRT) models to data from a community sample of young adults (n = 2,227). Ordinal factor analyses revealed that identifying a coherent latent structure in the 40-item SAS data was challenging due to (a) the presence of multiple small content clusters (e.g., doublets); (b) modest relations between those clusters, which, in turn, implies a general factor of only modest strength; (c) items that shared little variance with the majority of items; and (d) cross-loadings in bifactor solutions. Consequently, we conclude that SAS responses cannot be modeled accurately by either unidimensional or bifactor IRT models. Although the application of a bifactor model to a reduced 17-item set met with better success, significant psychometric and substantive problems remained. Results highlight the challenges of applying latent variable models to scales that were not originally designed to fit these models. C1 [Reise, Steven P.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Blanchard, Jack J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. RP Reise, SP (reprint author), Univ Calif Los Angeles, Dept Psychol, Franz Hall, Los Angeles, CA 90095 USA. EM reise@psych.ucla.edu FU NIMH NIH HHS [K02 MH079231, R01MH51240, R01 MH051240-11, R01 MH051240, R01MH82782, R01 MH082839-03, R01 MH082782-03, K02 MH079231-05, K02MH079231, R01MH082839, R01 MH082839, R01 MH082782] NR 45 TC 12 Z9 13 U1 1 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2011 VL 93 IS 3 BP 213 EP 224 AR PII 936745431 DI 10.1080/00223891.2011.558868 PG 12 WC Psychology, Clinical; Psychology, Social SC Psychology GA 754EW UT WOS:000289837900002 PM 21516580 ER PT J AU Cooper, RA Nowak, CJ AF Cooper, Rory A. Nowak, Christopher J. TI Paralympics and veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15213 USA. [Nowak, Christopher J.] VA Paralymp Program, Washington, DC USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15213 USA. EM rcooper@pitt.edu NR 2 TC 0 Z9 0 U1 1 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 10 BP XI EP XIII DI 10.1682/JRRD.2011.11.0209 PG 3 WC Rehabilitation SC Rehabilitation GA V28XL UT WOS:000208713400002 PM 22234671 ER PT J AU Henzel, MK Bogie, KM Guihan, M Ho, CH AF Henzel, M. Kristi Bogie, Kath M. Guihan, Marylou Ho, Chester H. TI Pressure ulcer management and research priorities for patients with spinal cord injury: Consensus opinion from SCI QUERI Expert Panel on Pressure Ulcer Research Implementation SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID DEEP TISSUE-INJURY; RISK-FACTORS; SKELETAL-MUSCLE; NURSING-HOME; HETEROTOPIC OSSIFICATION; EPIDERMAL EQUIVALENTS; VETERANS; PREVENTION; INTERFACE; SYSTEM C1 [Henzel, M. Kristi; Ho, Chester H.] Louis Stokes Cleveland VA Med Ctr, Spinal Cord Injury Serv, Cleveland, OH USA. [Bogie, Kath M.] Louis Stokes Cleveland VA Med Ctr, Cleveland Adv Platform Technol Ctr, Cleveland, OH USA. [Bogie, Kath M.] Louis Stokes Cleveland VA Med Ctr, Funct Elect Stimulat Ctr, Cleveland, OH USA. [Bogie, Kath M.] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA. [Guihan, Marylou] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, SCI QUERI, Hines, IL 60141 USA. [Guihan, Marylou] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Guihan, Marylou] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. Case Western Reserve Univ, Dept Phys Med & Rehabil, Cleveland, OH 44106 USA. RP Henzel, MK (reprint author), Louis Stokes Cleveland VA Med Ctr, Spinal Cord Injury Serv, Cleveland, OH USA. EM kmb3@case.edu NR 114 TC 23 Z9 23 U1 2 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 3 BP XI EP XXXI DI 10.1682/JRRD.2011.01.0011 PG 21 WC Rehabilitation SC Rehabilitation GA 749TS UT WOS:000289493900002 PM 21480093 ER PT J AU Cameron, MH Poel, AJ Haselkorn, JK Linke, A Bourdette, D AF Cameron, Michelle H. Poel, Amy J. Haselkorn, Jodie K. Linke, Alex Bourdette, Dennis TI Falls requiring medical attention among veterans with multiple sclerosis: A cohort study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accidental falls; cohort study; disability; epidemiology; medical records; multiple sclerosis; risk; sex; veterans; wounds and injuries ID OLDER-ADULTS; ACCIDENTAL FALLS; PEOPLE; EPIDEMIOLOGY; REGISTRY; COSTS; RISK AB The purpose of this study was to estimate the relative risk of an injurious fall requiring medical attention in veterans with multiple sclerosis (MS) compared with veterans without MS after controlling for sex, age, and healthcare use. The sample included 195,417 veterans treated at Veterans Health Administration (VHA) facilities in the Northwest United States in fiscal year 2008. We obtained information regarding MS diagnosis, injurious falls (operationalized as International Classification of Diseases-9th Revision-Clinical Modification codes E880-E888), and demographic and healthcare use data from the VHA Consumer Health Information Performance Set database. Using logistic regression, we determined the adjusted odds ratio (OR) of an injurious fall to be three times higher in female veterans with MS than in female veterans without MS (OR = 3.0, 95% confidence interval [Cl] = 1.6-5.5). The adjusted OR of an injurious fall for men with MS was also higher than for men without MS, but this difference was not statistically significant (OR = 1.2, 95% CI = 0.8-2.1). We recommend further studies evaluating the medical, social, and economic consequences of injurious falls, as well as interventions to prevent injurious falls, to improve the independence and quality of life of veterans and others living with MS. C1 [Cameron, Michelle H.; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Cameron, Michelle H.; Bourdette, Dennis] Portland Dept Vet Affairs VA Med Ctr VAMC, Neurol Serv, Portland, OR USA. [Cameron, Michelle H.; Bourdette, Dennis] Portland Dept Vet Affairs VA Med Ctr VAMC, Multiple Sclerosis Ctr Excellence W, Portland, OR USA. [Poel, Amy J.; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence W, Seattle, WA USA. [Poel, Amy J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Linke, Alex] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. RP Cameron, MH (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,CR120, Portland, OR 97239 USA. EM cameromi@ohsu.edu FU National Multiple Sclerosis Society; VA Rehabilitation Research and Development Service FX This material was based on work supported by a Sylvia Lawry Physician Fellowship from the National Multiple Sclerosis Society and by a Career Development Award (Dr. Cameron) from the VA Rehabilitation Research and Development Service. NR 42 TC 22 Z9 22 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 1 BP 13 EP 20 DI 10.1682/JRRD.2009.12.0192 PG 8 WC Rehabilitation SC Rehabilitation GA 719SG UT WOS:000287228700002 PM 21328159 ER PT J AU Walter, JS Wurster, RD Zhu, QL Laghi, F AF Walter, James S. Wurster, Robert D. Zhu, Qianlong Laghi, Franco TI Respiratory muscle pacing with chronically implanted intramuscular Permaloc electrodes: A feasibility study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE animal model; electrical stimulation; feasibility study; functional electrical stimulation; intramuscular electrodes; muscle pacing; respiration; respiratory distress; spinal cord injury; tidal volume ID SPINAL-CORD-INJURY; FUNCTIONAL ELECTRICAL-STIMULATION; PROVIDE ARTIFICIAL-VENTILATION; ABDOMINAL-MUSCLES; INSPIRATORY INTERCOSTAL; DIAPHRAGM; COUGH; TETRAPLEGIA; NERVE AB We tested the feasibility of stimulating upper-intercostal and abdominal muscles plus the diaphragm by using chronically implanted intramuscular electrodes. During two survival surgeries with six dogs, intramuscular electrodes were implanted bilaterally in the three respiratory muscles. Standard stimulation of the diaphragm was conducted. The dorsolateral and ventrolateral abdominal wall areas were stimulated with a 25 mA current. The second to fourth intercostal spaces were stimulated to elicit the largest tidal volume associated with the least coactivation of the serratus and latissimus muscles. Lone diaphragm and upper-intercostal muscle pacing produced inhaled tidal volumes (mean +/- standard error of the mean) of 293 +/- 36 mL and 59 +/- 17 mL, respectively. Lone abdominal muscle pacing produced an exhaled volume of 55 +/- 17 mL. Combined pacing of diaphragm and intercostal muscles increased the inhaled volume to 389 +/- 39 mL. The addition of abdominal pacing following the combined stimulation of diaphragm and intercostals increased the exhaled volume to 472 +/- 54 mL. During autopsy, dislodgement of the electrodes overlying the ribs was a concern and probably resulted from loose animal jackets. Chronic intramuscular Permaloc electrodes can be implanted in several respiratory muscles and increase tidal volumes more than diaphragm stimulation alone. C1 [Walter, James S.; Wurster, Robert D.; Zhu, Qianlong] Edward Hines Jr Dept Vet Affairs VA Hosp, Res Serv, Hines, IL USA. [Walter, James S.] Loyola Univ, Med Ctr, Dept Urol, Maywood, IL 60153 USA. [Wurster, Robert D.] Loyola Univ, Med Ctr, Dept Neurol Surg & Physiol, Maywood, IL 60153 USA. [Laghi, Franco] Loyola Univ, Med Ctr, Div Pulm & Crit Care Med, Maywood, IL 60153 USA. [Laghi, Franco] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Pulm & Crit Care Med Sect, Hines, IL 60141 USA. RP Walter, JS (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, Roosevelt & 1st Ave, Hines, IL 60141 USA. EM James.Walter@va.gov FU VA's Office of Research and Development, Rehabilitation Research and Development Service [B3008P] FX This material was based on work supported by the VA's Office of Research and Development, Rehabilitation Research and Development Service (grant B3008P). Synapse Biomedical, Inc, provided electrodes, stimulators, and technical assistance under a Material, Cooperative, Research and Development Agreement between the company and the VA. NR 21 TC 5 Z9 6 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 2 BP 103 EP 114 DI 10.1682/JRRD.2010.05.0086 PG 12 WC Rehabilitation SC Rehabilitation GA 733BQ UT WOS:000288235800003 PM 21480085 ER PT J AU Liu, CF Collins, MP Souza, PE Yueh, B AF Liu, Chuan-Fen Collins, Margaret P. Souza, Pamela E. Yueh, Bevan TI Long-term cost-effectiveness of screening strategies for hearing loss SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE audiology; aural rehabilitation; cost-effectiveness; healthcare cost; health services; hearing aid; hearing loss; hearing loss screening; preventive care; veterans ID RANDOMIZED-TRIAL; AUDITORY IMPAIRMENT; OLDER-ADULTS; PRIMARY-CARE; HEALTH; AMPLIFICATION; HANDICAP AB Routine hearing screening can identify patients who are motivated to seek out and adhere to treatment, but little information exists on the cost-effectiveness of hearing screening in a general population of older veterans. We compared the cost-effectiveness of three screening strategies (tone-emitting otoscope, hearing handicap questionnaire, and both together) against no screening (control group) in 2,251 older veterans. The effectiveness measure for each group was the proportion of hearing aid use 1 year after screening. The audiology cost measure included costs of hearing loss screening and audiology care for 1 year after screening. Incremental cost-effectiveness was the audiology cost of additional hearing aid use for each screening group compared with the control group. The mean total audiology cost per patient was $77.04, $122.70, $121.37, and $157.08 for the control, otoscope, questionnaire, and dual screening groups, respectively. The tone-emitting otoscope appears to be the most cost-effective approach for hearing loss screening, with a significant increase in hearing aid use 1 year after screening (2.8%) and an insignificant incremental cost-effectiveness of $1,439.00 per additional hearing aid user compared with the control group. For this population of older veterans, screening for hearing loss with the tone-emitting otoscope is cost-effective. C1 [Liu, Chuan-Fen; Collins, Margaret P.; Yueh, Bevan] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. [Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Souza, Pamela E.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Washington, Dept Otolaryngol & Head & Neck Surg, Seattle, WA 98195 USA. [Yueh, Bevan] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA 98101 USA. RP Liu, CF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv 152, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM fliu@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 FU Health Services Research and Development Service of the Veterans Health Administration [I1R 99-377] FX This work was supported by the Health Services Research and Development Service of the Veterans Health Administration (grant I1R 99-377). NR 35 TC 7 Z9 7 U1 1 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 3 BP 235 EP 243 DI 10.1682/JRRD.2010.03.0041 PG 9 WC Rehabilitation SC Rehabilitation GA 749TS UT WOS:000289493900007 PM 21480098 ER PT J AU Burgar, CG Lum, PS Scremin, AME Garber, SL Van der Loos, HFM Kenney, D Shor, P AF Burgar, Charles G. Lum, Peter S. Scremin, A. M. Erika Garber, Susan L. Van der Loos, H. F. Machiel Kenney, Deborah Shor, Peggy TI Robot-assisted upper-limb therapy in acute rehabilitation setting following stroke: Department of Veterans Affairs multisite clinical trial SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE acute; arm; bilateral; dose-response; hemiparesis; intensity; rehabilitation; robotics; stroke; therapy ID CONSTRAINT-INDUCED MOVEMENT; UPPER-EXTREMITY FUNCTION; FUGL-MEYER ASSESSMENT; MOTOR FUNCTION-TEST; RECOVERY; POSTSTROKE; RELIABILITY; ARM; STIMULATION; FORELIMB AB This randomized, controlled, multisite Department of Veterans Affairs clinical trial assessed robot-assisted (RA) upper-limb therapy with the Mirror Image Movement Enabler (MIME) in the acute stroke rehabilitation setting. Hemiparetic subjects (n = 54) received RA therapy using MIME for either up to 15 hours (low-dose) or 30 hours (high-dose) or received up to 15 hours of additional conventional therapy in addition to usual care (control). The primary outcome measure was the Fugl-Meyer Assessment (FMA). The secondary outcome measures were the Functional Independence Measure (FIM), Wolf Motor Function Test, Motor Power, and Ashworth scores at intake, discharge, and 6-month follow-up. Mean duration of study treatment was 8.6, 15.8, and 9.4 hours for the low-dose, high-dose, and control groups, respectively. Gains in the primary outcome measure were not significantly different between groups at follow-up. Significant correlations were found at discharge between FMA gains and the dose and intensity of RA. Intensity also correlated with FMA gain at 6 months. The high-dose group had greater FIM gains than controls at discharge and greater tone but no difference in FIM changes compared with low-dose subjects at 6 months. As used during acute rehabilitation, motor-control changes at follow-up were no less with MIME than with additional conventional therapy. Intensity of training with MIME was positively correlated with motor-control gains. C1 [Burgar, Charles G.] Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA. [Burgar, Charles G.] Rice Univ, Dept Mech Engn & Mat Sci, Houston, TX 77251 USA. [Lum, Peter S.] Catholic Univ Amer, Washington DC Dept Vet Affairs VA Med Ctr, Washington, DC 20064 USA. [Lum, Peter S.] Catholic Univ Amer, Dept Biomed Engn, Washington, DC 20064 USA. [Scremin, A. M. Erika] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Scremin, A. M. Erika] Univ Calif Los Angeles, Los Angeles, CA USA. [Garber, Susan L.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Garber, Susan L.] Baylor Coll Med, Houston, TX 77030 USA. [Van der Loos, H. F. Machiel; Kenney, Deborah; Shor, Peggy] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Van der Loos, H. F. Machiel] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA. RP Burgar, CG (reprint author), Cent Texas Vet Hlth Care Syst, 1901 Vet Mem Dr, Temple, TX 76504 USA. EM Charles.Burgar1@va.gov RI Van der Loos, Hendrik/A-3693-2012 OI Kenney, Deborah/0000-0003-0795-1901 FU VA Rehabilitation Research and Development Service [B2695I] FX This material was based on work supported by the VA Rehabilitation Research and Development Service (grant B2695I). NR 43 TC 53 Z9 60 U1 3 U2 30 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 4 BP 445 EP 458 DI 10.1682/JRRD.2010.04.0062 PG 14 WC Rehabilitation SC Rehabilitation GA 774GB UT WOS:000291372200011 PM 21674393 ER PT J AU Folmer, RL McMillan, GP Austin, DF Henry, JA AF Folmer, Robert L. McMillan, Garnett P. Austin, Donald F. Henry, James A. TI Audiometric thresholds and prevalence of tinnitus among male veterans in the United States: Data from the National Health and Nutrition Examination Survey, 1999-2006 SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE audiometry; epidemiology; hearing loss; NHANES; noise exposure; prevalence; rehabilitation; thresholds; tinnitus; veterans ID HEARING-LOSS PREVENTION; NOISE EXPOSURE; BEAVER DAM; INTERVENTION; PROTECTION; WISCONSIN; COHORT; ADULTS; YOUTH; NEED AB Hearing loss and tinnitus are the two most prevalent service-connected disabilities among U.S. veterans. The number of veterans receiving compensation and services from the Department of Veterans Affairs (VA) for these conditions continues to increase annually. However, the majority of veterans in the United States do not use VA medical centers or clinics for healthcare and do not receive VA compensation payments. Therefore, the prevalence of hearing loss and tinnitus among U.S. veterans is unknown. This study used National Health and Nutrition Examination Survey data to estimate the prevalence of these auditory conditions among male veterans. Between 1999 and 2006, pure tone audiometric data collected from 845 male veterans were compared with pure tone thresholds collected from 2,086 male nonveterans. We used questionnaire data collected between 1999 and 2004 to calculate and compare the prevalence of tinnitus for 2,174 veterans and 4,995 nonveterans. In general, pure tone thresholds did not differ significantly between veterans and nonveterans for most frequencies tested (500-8,000 Hz). The overall prevalence of tinnitus was greater for veterans than that for nonveterans (p < 0.001), with statistically significant differences in the 50 to 59 and 60 to 69 age groups. C1 [Folmer, Robert L.; McMillan, Garnett P.; Austin, Donald F.; Henry, James A.] Portland Dept Vet Affairs Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Folmer, Robert L.; Henry, James A.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [McMillan, Garnett P.; Austin, Donald F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Robert.Folmer@va.gov FU VA Rehabilitation Research & Development Center of Excellence [C4844C] FX This material was based on work supported by a VA Rehabilitation Research & Development Center of Excellence grant C4844C to the National Center for Rehabilitative Auditory Research (located at the Portland VAMC) in Portland, Oregon. NR 27 TC 13 Z9 14 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 5 BP 503 EP 515 DI 10.1682/JRRD.2010.07.0138 PG 13 WC Rehabilitation SC Rehabilitation GA 783GJ UT WOS:000292069200006 PM 21674401 ER PT J AU Koontz, AM Lin, YS Kankipati, P Boninger, ML Cooper, RA AF Koontz, Alicia M. Lin, Yen-Sheng Kankipati, Padmaja Boninger, Michael L. Cooper, Rory A. TI Development of custom measurement system for biomechanical evaluation of independent wheelchair transfers SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE activities of daily living; assessment; forces; kinematics; kinetics; range of motion; reliability; spinal cord injury; three-dimensional motion analysis; upper limb ID SPINAL-CORD-INJURY; SITTING PIVOT TRANSFERS; SHOULDER KINEMATICS; UPPER EXTREMITY; INDIVIDUALS; MOVEMENT; MOTION; USERS; IMPINGEMENT; DISABILITY AB This study describes a new custom measurement system designed to investigate the biomechanics of sitting-pivot wheelchair transfers and assesses the reliability of selected biomechanical variables. Variables assessed include horizontal and vertical reaction forces underneath both hands and three-dimensional trunk, shoulder, and elbow range of motion. We examined the reliability of these measures between 5 consecutive transfer trials for 5 subjects with spinal cord injury and 12 non-disabled subjects while they performed a self-selected sitting pivot transfer from a wheelchair to a level bench. A majority of the biomechanical variables demonstrated moderate to excellent reliability (r > 0.6). The transfer measurement system recorded reliable and valid biomechanical data for future studies of sitting-pivot wheelchair transfers. We recommend a minimum of five transfer trials to obtain a reliable measure of transfer technique for future studies. C1 [Koontz, Alicia M.; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Koontz, Alicia M.; Lin, Yen-Sheng; Kankipati, Padmaja; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Koontz, Alicia M.; Lin, Yen-Sheng; Kankipati, Padmaja; Boninger, Michael L.; Cooper, Rory A.] Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1 H, 7180 Highland Dr,151R1-H, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU VA Rehabilitation Research and Development Service [E3589V, B3079R, A4489R]; National Institute on Disability and Rehabilitation Research (NIDRR) [H133A011107]; National Institutes of Health Center for Injury Research Control [NIH R49/CCR310285-06] FX This material was based on work supported by the VA Rehabilitation Research and Development Service (grants E3589V, B3079R, and A4489R); the National Institute on Disability and Rehabilitation Research (grant NIDRR H133A011107); and the National Institutes of Health Center for Injury Research Control (grant NIH R49/CCR310285-06). NR 28 TC 8 Z9 8 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 8 BP 1015 EP 1028 DI 10.1682/JRRD.2010.09.0169 PG 14 WC Rehabilitation SC Rehabilitation GA 847DM UT WOS:000296952100010 PM 22068376 ER PT J AU Karmarkar, AM Cooper, RA Wang, HW Kelleher, A Cooper, R AF Karmarkar, Amol M. Cooper, Rory A. Wang, Hongwu Kelleher, Annmarie Cooper, Rosemarie TI Analyzing wheelchair mobility patterns of community-dwelling older adults SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE community participation; data logger; environment; manual wheelchair use; National Veterans Wheelchair Games; older adults; physical activity; power wheelchair use; wheelchair mobility; wheelchair provision ID PHYSICAL-ACTIVITY; OBJECTIVE ASSESSMENT; PROPULSION; USERS; BIOMECHANICS AB This study determined and compared wheelchair mobility patterns for older adults during an organized sporting event and within their community. In July 2008, 39 veterans participating in the 28th National Veterans Wheelchair Games (Omaha, Nebraska) completed the study. Of these, 26 were manual wheelchair and 13 were power wheelchair users. We collected wheelchair-related mobility data using wheelchair data-logging devices. Participants were significantly more active using manual wheelchairs during the games than when using their wheelchairs in their homes in terms of distance traveled (4,466.2 vs 1,367.4 m, p < 0.001) and average speed of propulsion (0.76 vs 0.64 m/s, p < 0.001). The trend was the same for power wheelchair users, with respect to distance (7,306.2 vs 3,450.5 m, p = 0.004) and average speed (0.9 vs 0.7 m/s, p = 0.002). This study demonstrates an objective method of evaluating wheelchair use in community-dwelling older adults. C1 [Cooper, Rory A.; Wang, Hongwu; Kelleher, Annmarie; Cooper, Rosemarie] Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA USA. [Cooper, Rory A.; Wang, Hongwu; Kelleher, Annmarie; Cooper, Rosemarie] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Karmarkar, Amol M.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Fl,151R1-HD, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013; Karmarkar, Amol/E-6030-2011 OI Wang, Hongwu/0000-0002-6567-9144; Karmarkar, Amol/0000-0001-8355-1585 FU VA Center for Excellence in Wheelchairs and Associated Rehabilitation Engineering [B3142C]; Engineering Research Center on Quality of Life Technology [EEC 0540865]; PVA; Keystone PVA FX This material was based on work supported by the VA Center for Excellence in Wheelchairs and Associated Rehabilitation Engineering (grant B3142C) and Engineering Research Center on Quality of Life Technology (grant EEC 0540865). We would like to thank the PVA and Keystone PVA for their sponsorship of research conducted during the NVWG. NR 23 TC 4 Z9 4 U1 1 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 9 BP 1077 EP 1086 DI 10.1682/JRRD.2009.10.0177 PG 10 WC Rehabilitation SC Rehabilitation GA 859RC UT WOS:000297892500004 PM 22234712 ER PT J AU Rae-Grant, AD Turner, AP Sloan, A Miller, D Hunziker, J Haselkorn, JK AF Rae-Grant, Alex D. Turner, Aaron P. Sloan, Alicia Miller, Deborah Hunziker, James Haselkorn, Jodie K. TI Self-management in neurological disorders: Systematic review of the literature and potential interventions in multiple sclerosis care SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE chronic illness; headache; multiple sclerosis; neurological; Parkinson disease; self-care; self-management; stroke; systematic review; traumatic brain injury ID RANDOMIZED CONTROLLED-TRIAL; INTERNET-BASED TREATMENT; IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; DISEASE MANAGEMENT; EXERCISE PROGRAM; CLINICAL-TRIAL; PATIENT; PEOPLE; MIGRAINE AB Our objective was to review the current body of evidence supporting the efficacy of self-management programs in individuals with multiple sclerosis (MS) and other chronic neurological conditions. We reviewed published literature using standardized search terms; examined self-management interventions in a variety of chronic neurological disorders, including MS; and classified studies using the evidence classification established by the American Academy of Neurology. We reviewed 527 abstracts, of which 39 met our inclusion criteria for evaluation. Of the 39 studies, 3 provided class I evidence assessing the efficacy of self-management interventions: a randomized controlled trial of a telephone counseling program for health promotion in MS, a home-based exercise program for reducing falls in people with Parkinson disease, and the comparison of a fitness center program versus a home-based exercise program for people with traumatic brain injury. The remaining studies provided additional support for self-management interventions with a lesser degree of methodologic rigor (class II, class III, or class IV evidence). We concluded that self-management strategies are applicable to chronic neurological diseases, but a need exists for more rigorous studies in this area. We provide recommendations for future intervention study methodologies with a specific emphasis on MS care. C1 [Turner, Aaron P.; Sloan, Alicia; Hunziker, James; Haselkorn, Jodie K.] Puget Sound Hlth Care Syst, Dept Vet Affairs, Multiple Sclerosis Ctr Excellence W, Seattle, WA USA. [Rae-Grant, Alex D.; Miller, Deborah] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003 FU Department of Veterans Affairs (VA) [B4927W]; VA MS Center of Excellence West FX This material was based on work supported by a Department of Veterans Affairs (VA) Rehabilitation Research and Development Service Career Development Award (grant B4927W to Dr. Turner). Additional support was provided by the VA MS Center of Excellence West. NR 39 TC 11 Z9 11 U1 1 U2 12 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 9 BP 1087 EP 1099 DI 10.1682/JRRD.2010.08.0159 PG 13 WC Rehabilitation SC Rehabilitation GA 859RC UT WOS:000297892500005 PM 22234713 ER PT J AU Denneson, LM Corson, K Dobscha, SK AF Denneson, Lauren M. Corson, Kathryn Dobscha, Steven K. TI Complementary and alternative medicine use among veterans with chronic noncancer pain SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE acupuncture; aged; alternative therapies; chiropractic; chronic pain; complementary therapies; delivery of healthcare; herbal medicine; massage therapy; veterans ID LOW-BACK-PAIN; PRIMARY-CARE; COLLABORATIVE CARE; MILITARY VETERANS; RANDOMIZED-TRIAL; UNITED-STATES; PREVALENCE; MANAGEMENT; THERAPIES; SEVERITY AB We describe prior use and willingness to try complementary and alternative medicine (CAM) among 401 veterans experiencing chronic noncancer pain and explore differences between CAM users and nonusers. Participants in a randomized controlled trial, of a collaborative intervention for chronic pain from five Department of Veterans Affairs (VA) primary care clinics self-reported prior use and willingness to try chiropractic care, massage therapy, herbal medicines, and acupuncture. Prior CAM users were compared with nonusers on demographic characteristics, pain-related clinical characteristics, disease burden, and treatment satisfaction. A majority of veterans (n = 327, 82%) reported prior use of at least one CAM modality, and nearly all (n = 399, 99%) were willing to try CAM treatment for pain. Chiropractic care was the least preferred option, whereas massage therapy was the most preferred (75% and 96%, respectively). CAM users were less likely to have service-connection disabilities (54% vs 68%; chi square = 4.64, p = 0.03) and reported having spent a larger percentage of their lives in pain (26% vs 20%; Z = 1.40, p = 0.04) than nonusers. We detected few differences between veterans who had tried CAM and those who had not, suggesting that CAM may have broad appeal among veterans with chronic pain. Implications for VA policy and practice and for clinicians treating veterans with chronic pain are discussed. C1 [Denneson, Lauren M.] Portland Dept Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Denneson, LM (reprint author), Portland VA Med Ctr, POB 1034,P3DEP PC, Portland, OR 97207 USA. EM lauren.denneson@va.gov FU VA Veterans Health Administration and Health Services Research and Development Service [PMI 03-195, REA 06-174] FX This material is based on work supported in part by the VA Veterans Health Administration and Health Services Research and Development Service (grants PMI 03-195 and REA 06-174). NR 48 TC 22 Z9 22 U1 6 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 9 BP 1119 EP 1127 DI 10.1682/JRRD.2010.12.0243 PG 9 WC Rehabilitation SC Rehabilitation GA 859RC UT WOS:000297892500008 PM 22234716 ER PT J AU Velozo, CA Woodbury, ML AF Velozo, Craig A. Woodbury, Michelle L. TI Translating measurement findings into rehabilitation practice: An example using Fugl-Meyer Assessment-Upper Extremity with patients following stroke SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE assessment; clinical goal setting; Fugl-Meyer Assessment; item response theory; measurement; occupational therapy; Rasch analysis; rehabilitation; stroke; upper limb AB Standardized assessments are critical for advancing clinical rehabilitation, yet assessment scores often provide little information for rehabilitation treatment planning. A keyform recovery map is an innovative way for a therapist to record patient responses to standardized assessment items. The form enables a therapist to view the specific items that a patient can or cannot perform. This information can assist a therapist in tailoring treatments to a patient's individual ability level. We demonstrate how a keyform recovery map can be used to inform clinical treatment planning for individuals with stroke-related upper-limb motor impairment. A keyform map of poststroke upper-limb 'recovery defined by items of the Fugl-Meyer Assessment-Upper Extremity (FMA-UE) was generated by a previously published Rasch analysis. Three individuals with stroke enrolled in a separate research study were randomly selected from each of the three impairment strata of the FMAUE. Their performance on each item was displayed on the FMA-UE keyform. The forms directly connected qualitative descriptions of patients' motor ability to assessment measures, thereby suggesting appropriate shorter and longer term rehabilitation goals. This study demonstrates how measurement theory can be used to translate a standardized assessment into a useful, evidence-based tool for making clinical practice decisions. C1 [Velozo, Craig A.] Malcom Randall Dept Vet Affairs VA Med Ctr, Rehabil Outcomes Res Ctr, Gainesville, FL USA. [Velozo, Craig A.] Malcom Randall Dept Vet Affairs VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA. [Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA. [Woodbury, Michelle L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Woodbury, Michelle L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Velozo, CA (reprint author), Univ Florida, Dept Occupat Therapy, Coll Publ Hlth & Hlth Profess, PO 100164, Gainesville, FL 32610 USA. EM cvelozo@phhp.ufl.edu FU Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development Service; Career Development-2 Award [B6332W] FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service, Career Development-2 Award (project B6332W), principal investigator Michelle L. Woodbury. NR 34 TC 16 Z9 16 U1 0 U2 11 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2011 VL 48 IS 10 BP 1211 EP 1221 DI 10.1682/JRRD.2010.10.0203 PG 11 WC Rehabilitation SC Rehabilitation GA V28XL UT WOS:000208713400008 PM 22234665 ER PT J AU Singh, JA Beg, S Lopez-Olivo, MA AF Singh, Jasvinder A. Beg, Saba Lopez-Olivo, Maria Angeles TI Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE TOCILIZUMAB; RHEUMATOID; ARTHRITIS; BENEFIT; SAFETY ID COLLEGE-OF-RHEUMATOLOGY; INTERLEUKIN-6 RECEPTOR INHIBITION; PLACEBO-CONTROLLED TRIAL; DISEASE-ACTIVITY SCORE; DOUBLE-BLIND; RESPONSE CRITERIA; INADEQUATE RESPONSE; CLINICAL-TRIALS; METHOTREXATE; MULTICENTER AB Objective. To compare the benefit and safety of tocilizumab to placebo in patients with rheumatoid arthritis (RA). Methods. We searched multiple databases for published randomized or controlled clinical trials comparing benefit and safety of tocilizumab to placebo, disease-modifying antirheumatic drugs (DMARD), or other biologics. For dichotomous outcomes, we calculated the relative risk, and for continuous outcomes, the mean difference. Results. Eight randomized controlled trials were included in this systematic review, with 3334 participants, 2233 treated with tocilizumab and 1101 controls. The US and Canadian approved dose of tocilizumab, 8 mg/kg every 4 weeks, was given to 1561 participants. In patients taking concomitant methotrexate, compared to placebo, patients treated with approved dose of tocilizumab were substantially and statistically significantly more likely than placebo to achieve the American College of Rheumatology 50 (absolute percentage, 38.8% vs 9.6%, respectively; RR 3.2, 95% CI 2.7, 3.7); Disease Activity Score remission (30.5% vs 2.7%; RR 8.7,95% CI 6.3, 11.8); and a clinically meaningful decrease in Health Assessment Questionnaire (HAQ)/Modified HAQ scores (60.5% vs 34%; RR 1.8, 95% CI 1.6, 1.9). There were no substantive statistically significant differences in serious adverse effects (0.8% vs 0.7%; RR 1.2, 95% CI 0.8, 1.6) or withdrawals due to adverse events (4.9% vs 3.7%; RR 1.4, 95% CI 0.9, 2.1); however, tocilizumab-treated patients were significantly more likely to have any adverse event (74% vs 65%; RR 1.05, 95% CI 1.03, 1.07); elevation in the ratio of low-density lipoprotein to high-density lipoprotein cholesterol (HDL; 20% vs 12%; RR 1.7,95% CI 1.2, 2.2); and increase in the ratio of total to HDL cholesterol (12% vs 7%; RR 1.7.95% CI 1.2, 2.6); and they were less likely to withdraw from treatment for any reason (8.1% vs 14.9%; RR 0.6, 95% CI 0.5, 0.8). Conclusion. At the approved dose of 8 mg/kg every 4 weeks, tocilizumab in combination with methotrexate/DMARD is beneficial in decreasing RA disease activity and improving function. Tocilizumab treatment was associated with a significant increase in cholesterol levels and occurrence of any adverse event, but not serious adverse events. Larger safety studies are needed to address these safety concerns. (First Release Oct 15 2010; J Rheumatol 2011;38:10-20; doi:10.3899/jrheum.100717) C1 [Singh, Jasvinder A.] Univ Alabama, Med Serv, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Lopez-Olivo, Maria Angeles] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Singh, Jasvinder A.; Beg, Saba] Vet Affairs Med Ctr, Med Serv, Minneapolis, MN 55417 USA. RP Singh, JA (reprint author), Univ Alabama, Med Serv, Birmingham Vet Affairs Med Ctr, 820 Fac Off Tower,Room 805B, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health [I KL2 RR024151-01] FX Supported by the National Institutes of Health Clinical Translational Science Award I KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research). NR 45 TC 51 Z9 57 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD JAN PY 2011 VL 38 IS 1 BP 10 EP 20 DI 10.3899/jrheum.100717 PG 11 WC Rheumatology SC Rheumatology GA 709MZ UT WOS:000286446100005 PM 20952462 ER PT J AU Dichter, ME Rhodes, KV AF Dichter, Melissa E. Rhodes, Karin V. TI Intimate Partner Violence Survivors' Unmet Social Service Needs SO JOURNAL OF SOCIAL SERVICE RESEARCH LA English DT Article DE Intimate partner violence; domestic violence; service needs ID DOMESTIC VIOLENCE; WOMEN; SHELTER; HEALTH; ABUSE; RISK; POPULATION; PREGNANCY; PROGRAM; SEEKING AB Women who have experienced intimate partner violence (IPV) victimization are at risk for physical and mental health problems, as well as social and economic challenges. In this cross-sectional study, 173 adult, English-speaking women who had experienced police response to IPV completed a self-report questionnaire about their use of, interest in, and need for various social services and whether or not each type of service helped (or would help) them to feel safer. More than three quarters of the participants reported a current need for health and economic support services. There was less interest in traditional IPV resources: law enforcement and domestic violence counseling or shelter. Expanding services to meet survivors' needs for health care and economic independence may facilitate long-term safety. Recommendations for further research in this area are provided. C1 [Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Rhodes, Karin V.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Rhodes, Karin V.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Dichter, ME (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM mdichter@sp2.upenn.edu NR 40 TC 7 Z9 7 U1 4 U2 18 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0148-8376 J9 J SOC SERV RES JI J. Soc. Serv. Res. PY 2011 VL 37 IS 5 BP 481 EP 489 DI 10.1080/01488376.2011.587747 PG 9 WC Social Work SC Social Work GA 888OS UT WOS:000300013900003 ER PT J AU Rosen, D Goodkind, S Smith, ML AF Rosen, Daniel Goodkind, Sara Smith, Mary Lindsey TI Using Photovoice to Identify Service Needs of Older African American Methadone Clients SO JOURNAL OF SOCIAL SERVICE RESEARCH LA English DT Article DE Substance abuse; substance abuse treatment; aging; methadone maintenance treatment; African Americans; photovoice ID SUBSTANCE-ABUSE TREATMENT; INJECTION-DRUG USERS; 33-YEAR FOLLOW-UP; HEROIN USERS; MAINTENANCE; HEALTH; ADULTS; STRATEGY; PROGRAMS; GENDER AB This article presents findings from a photovoice project designed to identify service needs of older-adult African American methadone clients, as well as their current barriers to and supports for abstinence. The project involved 10 participants (aged 53 to 63 years old) recruited from a methadone maintenance program in a large Northeastern U.S. city. Thematic analysis techniques were used to analyze participants' narratives of their pictures. Transportation emerged as a significant challenge to accessing services, and caregiving was a motivation for remaining abstinent. Future research should use similar participatory methods and engage a broader group of aging people struggling with substance abuse. C1 [Rosen, Daniel; Goodkind, Sara] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Smith, Mary Lindsey] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Rosen, D (reprint author), Univ Pittsburgh, Sch Social Work, 2117 Cathedral Learning, Pittsburgh, PA 15260 USA. EM dar15@pitt.edu NR 36 TC 4 Z9 4 U1 2 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0148-8376 J9 J SOC SERV RES JI J. Soc. Serv. Res. PY 2011 VL 37 IS 5 BP 526 EP 538 DI 10.1080/01488376.2011.607369 PG 13 WC Social Work SC Social Work GA 888OS UT WOS:000300013900007 ER PT J AU Weaver, FM Smith, B LaVela, SL Evans, CT Ullrich, P Miskevics, S Goldstein, B Strayer, J Burns, SP AF Weaver, Frances M. Smith, Bridget LaVela, Sherri L. Evans, Charlesnika T. Ullrich, Philip Miskevics, Scott Goldstein, Barry Strayer, Jonathan Burns, Stephen P. TI Smoking behavior and delivery of evidence-based care for veterans with spinal cord injuries and disorders SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Tobacco cessation; Spinal cord injury; Evidence-based care ID NATIONAL-SURVEY; PAIN; CESSATION; SMOKERS; RISK; PREVALENCE; TOBACCO; QUIT; NONVETERANS; DEPENDENCE AB Objective: Little is known about those veterans with spinal cord injuries and disorders (SCI/D) who smoke cigarettes. This study identified the factors associated with smoking in this population, motivations for smoking, and the readiness for smoking cessation. Current practices for the delivery of evidence-based tobacco cessation were also examined. Design: Methods included surveys of veterans with SCI/D, medical record reviews of current smokers, and telephone interviews with SCI/D providers. Setting: Six Veterans Health Administration facilities with SCI centers and one SCI clinic. Participants: Survey data were analyzed for 1210 veterans, 256 medical records were reviewed, and 15 providers served as key informants. Interventions: Observational study. Outcome measures: Veterans self-reported smoking status, quit attempts, methods and care received, motivation for smoking, and health care conditions. Medical record review and informant interviews examined the tobacco cessation care provided. Results: Whereas 22% of the respondents were current smokers; 51% were past smokers. Current smokers more often reported respiratory illnesses and/or symptoms, alcohol use, pain, and depression than past or never smokers, and approximately half made quit attempts in the past year. Smokers received referral to counseling (57%) and/or prescription for medication/nicotine replacement (23%). Key informants identified difficulty of providing follow-up and patients' unwillingness to consider quitting as barriers. Conclusion: Veterans with SCI/D who smoke also had other health problems. Providers offer counseling and medication, but often have difficulty following patients to arrange/provide support. Identifying other support methods such as telehealth, considering the use of combination cessation therapies, and addressing other health concerns (e.g. depression) may affect tobacco cessation in this population. C1 [Weaver, Frances M.; Smith, Bridget; LaVela, Sherri L.; Evans, Charlesnika T.; Miskevics, Scott] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Weaver, Frances M.; Smith, Bridget; LaVela, Sherri L.; Evans, Charlesnika T.; Miskevics, Scott] Hines VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Weaver, Frances M.; Smith, Bridget] Loyola Univ, Program Hlth Serv Res, Dept Med, Maywood, IL 60153 USA. [LaVela, Sherri L.; Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Ullrich, Philip; Goldstein, Barry; Burns, Stephen P.] VA Puget Sound Healthcare Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Seattle, WA USA. [Goldstein, Barry; Burns, Stephen P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. [Goldstein, Barry; Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Strayer, Jonathan] Dayton VAMC, Dayton, OH USA. RP Weaver, FM (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. EM Frances.Weaver@va.gov NR 55 TC 13 Z9 13 U1 2 U2 3 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JAN PY 2011 VL 34 IS 1 BP 35 EP 45 DI 10.1179/107902610X12911165975061 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 734UG UT WOS:000288364400008 PM 21528625 ER PT J AU Gros, DF Veronee, K Strachan, M Ruggiero, KJ Acierno, R AF Gros, Daniel F. Veronee, Kimberly Strachan, Martha Ruggiero, Kenneth J. Acierno, Ron TI Managing suicidality in home-based telehealth SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; PTSD; VIDEOCONFERENCE; TELEPSYCHIATRY AB We describe the case of a US veteran from the war in Afghanistan with post-traumatic stress disorder (PTSD). The patient was undergoing treatment at home via telehealth as part of a research trial. In week six, he presented with severe suicidal ideation and required emergency hospitalization. Through a series of immediate enhanced communications (i.e. by videoconference) between the patient, patient's family, treatment team and local resources, the patient's symptoms were assessed to identify suicidality and an intervention was successfully carried out, involving the development of a safety plan and eventual transportation to an inpatient unit at the local Veterans Administration Medical Center, where he was hospitalized for three days. This demonstrates the value of telehealth in identifying and treating severe psychiatric symptoms in addition to supporting the safety of these procedures to address suicidality. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Veronee, Kimberly; Strachan, Martha; Ruggiero, Kenneth J.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu RI Schueter, nicos/A-3625-2014 FU Department of Defense [W81XWH-07-PTSD-IIRA]; Ralph H Johnson VAMC [REA08-261] FX The work was supported by the Department of Defense (grant W81XWH-07-PTSD-IIRA) and the Ralph H Johnson VAMC Research Enhancement Award Program (REA08-261). The views expressed in this article do not necessarily reflect those of the Department of VA or the US Government. NR 19 TC 22 Z9 22 U1 2 U2 7 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2011 VL 17 IS 6 BP 332 EP 335 DI 10.1258/jtt.2011.101207 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 824IZ UT WOS:000295196900012 PM 21844180 ER PT J AU Saifu, HN Shamouelian, A Davis, LG Santana-Rios, E Goetz, MB Asch, SM Sun, BC AF Saifu, Hemen N. Shamouelian, Albert Davis, Lisa G. Santana-Rios, Elizabeth Goetz, Matthew Bidwell Asch, Steven M. Sun, Benjamin C. TI Impact of a kiosk educational module on HIV screening rates and patient knowledge SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID EMERGENCY-DEPARTMENT; ADULTS AB We assessed the effect of a kiosk educational module on HIV screening rates and patient knowledge about HIV testing. The evaluation was performed in a walk-in clinic offering routine HIV screening. During alternating two-week periods, patients were referred either to view a kiosk-based, educational module prior to receiving usual care, or the kiosk module was turned off and no alterations to care processes were made. The primary outcome was HIV testing rate. The secondary outcome was knowledge about HIV rapid screening, as measured with a questionnaire. There were 71 patients in the kiosk periods and 79 patients in the usual-care periods. The overall HIV testing rate was 41%. The kiosk period was not associated with greater odds of HIV testing (OR 0.7; 95% CI: 0.4-1.4). In 44 patients who completed the knowledge survey, the kiosk group was strongly associated with increased knowledge (predicted increase in knowledge score: 1.3; 95% CI: 036-2.1). The brief kiosk educational module did not improve HIV screening rates, but it increased overall patient knowledge about HIV testing. C1 [Saifu, Hemen N.; Shamouelian, Albert; Davis, Lisa G.; Santana-Rios, Elizabeth; Goetz, Matthew Bidwell; Asch, Steven M.; Sun, Benjamin C.] VA Greater Los Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Goetz, Matthew Bidwell; Asch, Steven M.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Saifu, HN (reprint author), W Los Angeles Vet Affairs Med Ctr, Off 3246,Mail Stop 111G,Bldg 500,Wing 3E,11301 Wi, Los Angeles, CA 90073 USA. EM Hemen.Saifu@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU Veterans Affairs HIV/Hepatitis QUERI and a Veterans Affairs [HSRD RRP 08-255]; WLAVA FX The work was supported by the Veterans Affairs HIV/Hepatitis QUERI and a Veterans Affairs grant (HSRD RRP 08-255). We thank the WLAVA walk-in clinic nursing staff and the research assistant staff for supporting the study. NR 11 TC 4 Z9 4 U1 0 U2 1 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2011 VL 17 IS 8 BP 446 EP 450 DI 10.1258/jtt.2011.110415 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 873QZ UT WOS:000298899400009 PM 21967998 ER PT J AU Bullock, CM Beckson, M AF Bullock, Clayton M. Beckson, Mace TI Male Victims of Sexual Assault: Phenomenology, Psychology, Physiology SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID MALE RAPE VICTIMS; SPINAL-CORD; MEN; EJACULATION; ELECTROEJACULATION; ANXIETY; SERVICE; STIMULATION; MOLESTATION; DYSFUNCTION AB Myths, stereotypes, and unfounded beliefs about male sexuality, in particular male homosexuality, are widespread in legal and medical communities, as well as among agencies providing services to sexual assault victims. These include perceptions that men in noninstitutionalized settings are rarely sexually assaulted, that male victims are responsible for their assaults, that male sexual assault victims are less traumatized by the experience than their female counterparts, and that ejaculation is an indicator of a positive erotic experience. As a result of the prevalence of such beliefs, there is an underreporting of sexual assaults by male victims; a lack of appropriate services for male victims; and, effectively, no legal redress for male sexual assault victims. By comparison, male sexual assault victims have fewer resources and greater stigma than do female sexual assault victims. Many male victims, either because of physiological effects of anal rape or direct stimulation by their assailants, have an erection, ejaculate, or both during the assault. This is incorrectly understood by assailant, victim, the justice system, and the medical community as signifying consent by the victim. Studies of male sexual physiology suggest that involuntary erections or ejaculations can occur in the context of nonconsensual, receptive anal sex. Erections and ejaculations are only partially under voluntary control and are known to occur during times of extreme duress in the absence of sexual pleasure. Particularly within the criminal justice system, this misconception, in addition to other unfounded beliefs, has made the courts unwilling to provide legal remedy to male victims of sexual assault, especially when the victim experienced an erection or an ejaculation during the assault. Attorneys and forensic psychiatrists must be better informed about the physiology of these phenomena to formulate evidence-based opinions. C1 [Bullock, Clayton M.] S Market Mental Hlth Clin, Dept Publ Hlth, San Francisco, CA 94107 USA. [Beckson, Mace] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Beckson, Mace] VA Greater Los Angeles Healthcare Syst, Psychiat Intens Care Unit, Los Angeles, CA USA. RP Bullock, CM (reprint author), S Market Mental Hlth Clin, Dept Publ Hlth, 760 Harrison St, San Francisco, CA 94107 USA. EM c-bullock@sbcglobal.net NR 56 TC 16 Z9 16 U1 2 U2 29 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2011 VL 39 IS 2 BP 197 EP 205 PG 9 WC Law; Psychiatry SC Government & Law; Psychiatry GA 782NK UT WOS:000292016200010 PM 21653264 ER PT J AU Wortzel, HS Kraus, MF Filley, CM Anderson, CA Arciniegas, DB AF Wortzel, Hal S. Kraus, Marilyn F. Filley, Christopher M. Anderson, C. Alan Arciniegas, David B. TI Diffusion Tensor Imaging in Mild Traumatic Brain Injury Litigation SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID WHITE-MATTER INTEGRITY; INDUCED AXONAL INJURY; CLINICAL-PRACTICE; CORPUS-CALLOSUM; YOUNG-ADULTS; HEAD TRAUMA; ABNORMALITIES; MODERATE; DTI; ADOLESCENTS AB A growing body of literature addresses the application of diffusion tensor imaging (DTI) to traumatic brain injury (TBI). Most TBIs are of mild severity, and their diagnosis and prognosis are often challenging. These challenges may be exacerbated in medicolegal contexts, where plaintiffs seek to present objective evidence that supports a clinical diagnosis of mild (m)TBI. Because DTI permits quantification of white matter integrity and because TBI frequently involves white matter injury, DTI represents a conceptually appealing method of demonstrating white matter pathology attributable to mTBI. However, alterations in white matter integrity are not specific to TBI, and their presence does not necessarily confirm a diagnosis of mTBI. Guided by rules of evidence shaped by Daubert v. Merrell Dow Pharmaceuticals, Inc., we reviewed and analyzed the literature describing DTI findings in mTBI and related neuropsychiatric disorders. Based on this review, we suggest that expert testimony regarding DTI findings will seldom be appropriate in legal proceedings focused on mTBI. C1 [Wortzel, Hal S.] Univ Colorado, Sch Med, Denver VA Med Ctr, VISN 19,MIRECC, Denver, CO USA. [Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO USA. [Kraus, Marilyn F.] Walter Reed Natl Mil Med Ctr, Neurobehav Traumat Brain Injury Consult Serv, Bethesda, MD USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO USA. [Anderson, C. Alan] Univ Colorado, Sch Med, Neurobehavioral Disorders Program, Dept Psychiat, Denver, CO USA. [Anderson, C. Alan] Denver VA Med Ctr, Neurol Serv, Denver, CO USA. RP Wortzel, HS (reprint author), VISN 19 MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM wortzel@ucdenver.edu NR 57 TC 14 Z9 15 U1 2 U2 5 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2011 VL 39 IS 4 BP 511 EP 523 PG 13 WC Law; Psychiatry SC Government & Law; Psychiatry GA 881DV UT WOS:000299461600008 PM 22159979 ER PT J AU Patel, NK Parchman, ML AF Patel, Neela K. Parchman, Michael L. TI The Chronic Care Model and Exercise Discussions during Primary Care Diabetes Encounters SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Chronic Care Model; Diabetes; Exercise; Patient Education ID SELF-MANAGEMENT BEHAVIORS; PHYSICAL-ACTIVITY ADVICE; CHRONIC ILLNESS CARE; GLUCOSE CONTROL; QUALITY IMPROVEMENT; PREVENTIVE SERVICES; PATIENT; IMPLEMENTATION; ATTRIBUTES; CLINICS AB Background: Discussing self-care activities like exercise is challenging with the many competing demands during primary care encounters. Our objective was to study the relationship between the Chronic Care Model (CCM) score in the clinic and time spent by the physicians discussing exercise during encounters with diabetic patients. Methods: Consecutive patients with diabetes across 20 primary care clinics in South Texas were included. Time spent discussing exercise was determined using the Davis Observation Code on audio recordings of the visits. Clinicians completed the Assessment of Chronic Illness Care survey, a validated measure of the extent to which care delivered is consistent with the CCM. Data were analyzed using hierarchical linear models. Results: A total of 162 transcribed recordings were analyzed. Age, the number of problems addressed, stage of change (SOC), and overall length of the visit were associated with time spent discussing exercise. There was a significant relationship between clinic CCM score and time spent by physicians advising about exercise, independent of SOC for exercise (P < .01). Also, a discussion about exercise was more likely to occur with patients who were in the contemplation SOC for exercise. Conclusions: Discussions of exercise may be 18 to 33 seconds longer in clinics with full implementation of the CCM compared with those with basic implementation. Facilitating more complete CCM implementation in clinics with a basic level of CCM that serve a population of patients who are sedentary may realize the most benefit. (J Am Board Fam Med 2011;24:26-32.) C1 [Patel, Neela K.; Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Parchman, Michael L.] S Texas Vet Hlth Care Syst, Verdict Hlth Serv Res Program, San Antonio, TX USA. RP Patel, NK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, MC 7795,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Pateln4@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889 FU Agency for Healthcare Research and Quality (AHRQ) [K08 HS013008-03]; Bureau of Health Professions; John A Hartford Foundation Center for Excellence in Geriatrics Education; Department of Veterans Affairs; Health Resources and Services Administration Department of Health and Human Services [D01 HP08795] FX The research reported was supported by the Agency for Healthcare Research and Quality (AHRQ K08 HS013008-03) and the Bureau of Health Professions; Health Resources and Services Administration Department of Health and Human Services grant D01 HP08795; The John A Hartford Foundation Center for Excellence in Geriatrics Education; and by the Department of Veterans Affairs. NR 39 TC 6 Z9 6 U1 1 U2 3 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD JAN-FEB PY 2011 VL 24 IS 1 BP 26 EP 32 DI 10.3122/jabfm.2011.01.100137 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 702TZ UT WOS:000285920100005 PM 21209341 ER PT J AU Raval, MV Dillon, PW Bruny, JL Ko, CY Hall, BL Moss, RL Oldham, KT Richards, KE Vinocur, CD Ziegler, MM AF Raval, Mehul V. Dillon, Peter W. Bruny, Jennifer L. Ko, Clifford Y. Hall, Bruce L. Moss, R. Lawrence Oldham, Keith T. Richards, Karen E. Vinocur, Charles D. Ziegler, Moritz M. CA ACS NSQIP Pediat Steering Comm TI American College of Surgeons National Surgical Quality Improvement Program Pediatric: A Phase 1 Report SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID OUTCOMES; RISK; MORBIDITY; HOSPITALS; VARIABLES; MORTALITY AB BACKGROUND: There has been a long-standing desire to implement a multi-institutional, multispecialty program to address surgical quality improvement for children. This report documents results of the initial phase of the American College of Surgeons National Surgical Quality Improvement Program Pediatric. STUDY DESIGN: From October 2008 to December 2009, patients from 4 pediatric referral centers were sampled using American College of Surgeons National Surgical Quality Improvement Program methodology tailored to children. RESULTS: A total of 7,287 patients were sampled, representing general/thoracic surgery (n = 2,237; 30.7%), otolaryngology (n = 1,687; 23.2%), orthopaedic surgery (n = 1,367; 18.8%), urology (n = 893; 12.3%), neurosurgery (n = 697; 9.6%), and plastic surgery (n = 406; 5.6%). Overall mortality rate detected was 0.3% and 287(3.9%) patients had postoperative occurrences. After accounting for demographic, preoperative, and operative factors, occurrences were 4 times more likely in those undergoing inpatient versus outpatient procedures (odds ratio [OR] = 4.71; 95% CI, 3.01-7.35). Other factors associated with higher likelihood of postoperative occurrences included nutritional/immune history, such as preoperative weight loss/chronic steroid use (OR = 1.49; 95% CI, 1.03-2.15), as well as physiologic compromise, such as sepsis/inotrope use before surgery (OR = 1.68; 95% Cl, 1.10-1.95). Operative factors associated with occurrences included multiple procedures under the same anesthetic (OR = 1.58; 95% CI, 1.21-2.06) and American Society of Anesthesiologists classification category 4/5 versus 1 (OR = 5.74; 95% Cl, 2.94-11.24). Specialty complication rates varied from 1.5% for otolaryngology to 9.0% for neurosurgery (p < 0.001), with specific procedural groupings within each specialty accounting for the majority of complications. Although infectious complications were the predominant outcomes identified across all specialties, distribution of complications varied by specialty. CONCLUSIONS: Based on this initial phase of development, the highly anticipated American College of Surgeons National Surgical Quality Improvement Program Pediatric has the potential to identify outcomes of children's surgical care that can be targeted for quality improvement efforts. (J Am Coll Sorg 2011;212:1-11. (C) 2010 by the American College of Surgeons) C1 [Raval, Mehul V.; Ko, Clifford Y.; Hall, Bruce L.; Richards, Karen E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Raval, Mehul V.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Dillon, Peter W.] Penn State Univ, Sch Med, Dept Surg, Div Pediat Surg, Hershey, PA USA. [Bruny, Jennifer L.; Ziegler, Moritz M.] Univ Colorado, Childrens Hosp, Dept Pediat Surg, Denver, CO 80202 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Moss, R. Lawrence] Yale Univ, Yale New Haven Childrens Hosp, Dept Surg, New Haven, CT USA. [Oldham, Keith T.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA. [Vinocur, Charles D.] Thomas Jefferson Univ, Div Pediat Surg, AI DuPont Hosp Children, Wilmington, DE USA. RP Raval, MV (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Vinocur, Charles/0000-0001-9650-1122; Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F and Ada L Rice Foundation FX Dr Raval is supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. NR 16 TC 59 Z9 59 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JAN PY 2011 VL 212 IS 1 BP 1 EP 11 DI 10.1016/j.jamcollsurg.2010.08.013 PG 11 WC Surgery SC Surgery GA 705LE UT WOS:000286129100001 PM 21036076 ER PT J AU Ingraham, AM Cohen, ME Raval, MV Ko, CY Nathens, AB AF Ingraham, Angela M. Cohen, Mark E. Raval, Mehul V. Ko, Clifford Y. Nathens, Avery B. TI Comparison of Hospital Performance in Emergency Versus Elective General Surgery Operations at 198 Hospitals SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID SURGICAL CARE; ADVERSE OUTCOMES; RISK-FACTORS; QUALITY; NSQIP AB BACKGROUND: Surgical quality improvement has focused on elective general surgery (ELGS) outcomes despite the substantial risk associated with emergency general surgery (EMGS) procedures. Furthermore, any differences in the quality of care provided to EMGS versus ELGS patients are not well described. We compared risk factors and risk-adjusted outcomes associated with EMGS and ELGS procedures to assess whether hospitals have comparable outcomes across these procedures. STUDY DESIGN: Using American College of Surgeons National Surgical Quality Improvement Program data (2005 to 2008), regression models were constructed for 30-day overall morbidity, serious morbidity, and mortality among all patients, EMGS patients, and ELGS patients. Observed-to-expected (O/E) ratios were calculated from models based on EMGS or ELGS patients. Association of hospital performance after EMGS versus ELGS procedures was assessed by evaluating correlations of O/E ratios; agreement in outlier status (hospitals where O/E confidence intervals [CI] do not overlap 1.0) was evaluated with weighted kappa. RESULTS: Of 473,619 procedures, 67,445 (14.2%) patients underwent an EMGS procedure. EMGS patients were more likely to experience any morbidity (odds ratio [OR] 1.20; 95% CI 1.16 to 1.23), serious morbidity (OR 1.26; 95% CI 1.21 to 1.30), and mortality (OR 1.39; 95% CI 1.30 to 1.48). Correlation between O/E ratios for EMGS and ELGS were moderate to low (overall morbidity = 0.48, p < 0.0001; serious morbidity = 0.41, p < 0.0001, mortality = 0.18, p = 0.01). Outlier status was not consistent across EMGS and ELGS, with only slight agreement (overall morbidity = 0.18, p < 0.0001; serious morbidity = 0.16, p = 0.001, mortality = 0.19, p = 0.01). CONCLUSIONS: EMGS patients are at substantially greater risk than ELGS patients for adverse events. Hospitals do not appear to have highly consistent performance across EMGS and ELGS outcomes. Processes of care that afford improved outcomes to EMGS patients need to be identified and disseminated. (J Am Coll Surg 2011;212:20-28. (C) 2010 by the American College of Surgeons) C1 [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Ingraham, Angela M.; Cohen, Mark E.; Raval, Mehul V.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Raval, Mehul V.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Nathens, Avery B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Div Surg & Trauma, Toronto, ON M5B 1W8, Canada. RP Ingraham, AM (reprint author), Univ Cincinnati, Coll Med, Dept Surg, 231 Albert Sabin Way,Room 1586, Cincinnati, OH 45267 USA. OI Raval, Mehul/0000-0002-1527-2661 FU Clinical Scholar in Residence Program at the American College of Surgeons; John Gray Research Fellowship; Daniel F and Ada L Rice Foundation; Canada Research Chair in Systems of Trauma Care FX Drs Ingraham and Raval are supported by the Clinical Scholar in Residence Program at the American College of Surgeons. Dr Raval is also supported by the John Gray Research Fellowship and the Daniel F and Ada L Rice Foundation. Dr Nathens is supported by a Canada Research Chair in Systems of Trauma Care. NR 22 TC 38 Z9 38 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JAN PY 2011 VL 212 IS 1 BP 20 EP 28A DI 10.1016/j.jamcollsurg.2010.09.026 PG 10 WC Surgery SC Surgery GA 705LE UT WOS:000286129100003 PM 21184955 ER PT J AU Burke, LE Wang, J Sevick, MA AF Burke, Lora E. Wang, Jing Sevick, Mary Ann TI Self-Monitoring in Weight Loss: A Systematic Review of the Literature SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID LOSS PROGRAM; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; LOSS MAINTENANCE; PAPER DIARIES; EXERCISE; INTERVENTION; EXPERIENCES; PREVENTION; COMPONENT AB Self-monitoring is the centerpiece of behavioral weight loss intervention programs This article presents a systematic review of the literature on three components of self-monitoring in behavioral weight loss studies diet, exercise, and self weighing This review included articles that were published between 1993 and 2009 that reported on the relationship between weight loss and these self-monitoring strategies Of the 22 studies identified, 15 focused on dietary self-monitoring, one on self-monitoring exercise, and six on self weighing A wide array of methods was used to perform self-monitoring, the paper diary was used most often Adherence to self-monitoring was reported most frequently as the number of diaries completed or the frequency of log ins or reported weights The use of technology, which included the Internet, personal digital assistants, and electronic digital scales were reported in five studies Descriptive designs were used in the earlier studies whereas more recent reports involved prospective studies and randomized trials that examined the effect of self-monitoring on weight loss A significant association between self-monitoring and weight loss was consistently found, however, the level of evidence was weak because of methodologic limitations The most significant limitations of the reviewed studies were the homogenous samples and reliance on self-report In all but two studies, the samples were predominantly white and women This review highlights the need for studies in more diverse populations, for objective measures of adherence to self-monitoring, and for studies that establish the required dose of self-monitoring for successful outcomes J Am Diet Assoc 2011,111 92 102 C1 [Burke, Lora E.; Wang, Jing] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Burke, Lora E.; Wang, Jing] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15261 USA. RP Burke, LE (reprint author), Univ Pittsburgh, Sch Nursing, 415 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA. FU National Institutes of Health/National Institute of Nursing [K24-NR010742] FX The first and second authors are partially supported by National Institutes of Health/National Institute of Nursing Research grant no K24-NR010742 NR 42 TC 250 Z9 250 U1 7 U2 57 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD JAN PY 2011 VL 111 IS 1 BP 92 EP 102 DI 10.1016/j.jada.2010.10.008 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 703CF UT WOS:000285951000014 PM 21185970 ER PT J AU Garrido, MM Kane, RL Kaas, M Kane, RA AF Garrido, Melissa M. Kane, Robert L. Kaas, Merrie Kane, Rosalie A. TI Use of Mental Health Care by Community-Dwelling Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE perceived need; mental health care; attitudes; depression; anxiety ID ELDERLY-PATIENTS; PERCEIVED NEED; UNITED-STATES; ANXIETY DISORDER; HELP-SEEKING; LATE-LIFE; DEPRESSION; SAMPLE; DETERMINANTS; COMORBIDITY AB OBJECTIVES To examine relationships between perceived need for care, illness characteristics, attitudes toward care, and probability that older adults will use mental health care (MHC). DESIGN Secondary data analysis. SETTING The Collaborative Psychiatric Epidemiology Surveys (2001-2003). PARTICIPANTS One thousand six hundred eighty-one community-dwelling adults aged 65 and older. MEASUREMENTS Self-reported MHC use and perceived need for care in the previous 12 months, previous year and history of mental illness, history of physical illness, attitudes toward care, and sociodemographic characteristics. RESULTS Of the entire sample, 6.5% had received some type of MHC in the previous year, although 65.9% of those with major depressive disorder (MDD) and 72.5% with anxiety did not receive MHC. In respondents with previous-year depression or anxiety, use was less likely for those with low World Health Organization Disability Assessment Scale (WHO-DAS) self-care ability. Use was more likely for those with more chronic physical conditions and worse WHO-DAS cognitive capacity. Seventeen percent of those with perceived need for MHC did not receive it. In respondents with perceived need, subthreshold generalized anxiety disorder was associated with lower likelihood of use. Use was more likely for older respondents and those with more household members, at least a high school education, and better self-care ability. Forty-one percent of those who perceived a need for care but did not use it met previous-year diagnostic criteria for anxiety, and 17% met criteria for MDD. CONCLUSION Understanding the perceptions that underlie individuals' health care-seeking behavior is an important step toward reducing underuse of MHC by older adults. C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, GRECC, Bronx, NY 10468 USA. [Garrido, Melissa M.] James J Peters VA Med Ctr, Res Enhancement Award Program, Bronx, NY 10468 USA. [Garrido, Melissa M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Garrido, Melissa M.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Kane, Robert L.; Kane, Rosalie A.] Univ Minnesota Twin Cities, Div Hlth Policy & Management, Minneapolis, MN USA. [Kaas, Merrie] Univ Minnesota Twin Cities, Sch Nursing, Minneapolis, MN USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, GRECC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM melissa.garrido@mssm.edu OI Garrido, Melissa/0000-0002-8986-3536 FU National Research Service Award at University of Minnesota-Twin Cities [T32 HS-000036]; National Institute of Mental Health at Rutgers University [T32 MH16242-29] FX Robert Kane consults for United Healthgroup, SCAN Health Plan, Medtronic, Lewin and Associates, and Cleveland Clinic. Melissa Garrido was supported by a National Research Service Award predoctoral training grant at the University of Minnesota-Twin Cities (T32 HS-000036) and a National Institute of Mental Health postdoctoral training grant at Rutgers University (T32 MH16242-29). NR 40 TC 20 Z9 20 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2011 VL 59 IS 1 BP 50 EP 56 DI 10.1111/j.1532-5415.2010.03220.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 706HG UT WOS:000286208200008 PM 21198461 ER PT J AU Anderson, S Eldadah, B Halter, JB Hazzard, WR Himmelfarb, J Horne, FM Kimmel, PL Molitoris, BA Murthy, M O'Hare, AM Schmader, KE High, KP AF Anderson, Sharon Eldadah, Basil Halter, Jeffrey B. Hazzard, William R. Himmelfarb, Jonathan Horne, Frances McFarland Kimmel, Paul L. Molitoris, Bruce A. Murthy, Mahadev O'Hare, Ann M. Schmader, Kenneth E. High, Kevin P. TI Acute Kidney Injury in Older Adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE-RENAL-FAILURE; PERCUTANEOUS CORONARY INTERVENTION; CRITICALLY-ILL PATIENTS; ISCHEMIA-REPERFUSION INJURY; LONG-TERM MORTALITY; ACUTE LUNG INJURY; QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GELATINASE-ASSOCIATED LIPOCALIN; ACUTE TUBULAR-NECROSIS AB Aging kidneys undergo structural and functional changes that decrease autoregulatory capacity and increase susceptibility to acute injury. Acute kidney injury associates with duration and location of hospitalization, mortality risk, progression to chronic kidney disease, and functional status in daily living. Definition and diagnosis of acute kidney injury are based on changes in creatinine, which is an inadequate marker and might identify patients when it is too late. The incidence of acute kidney injury is rising and increases with advancing age, yet clinical studies have been slow to address geriatric issues or the heterogeneity in etiologies, outcomes, or patient preferences among the elderly. Here we examine some of the current literature, identify knowledge gaps, and suggest potential research questions regarding acute kidney injury in older adults. Answering these questions will facilitate the integration of geriatric issues into future mechanistic and clinical studies that affect management and care of acute kidney injury. C1 [High, Kevin P.] Wake Forest Univ, Bowman Gray Sch Med, Infect Dis Sect, Dept Internal Med, Winston Salem, NC 27157 USA. [Anderson, Sharon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Anderson, Sharon] Portland VA Med Ctr, Portland, OR USA. [Eldadah, Basil; Murthy, Mahadev] NIA, Bethesda, MD 20892 USA. [Halter, Jeffrey B.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Hazzard, William R.; O'Hare, Ann M.] Univ Washington, Sch Med, Seattle, WA USA. [Hazzard, William R.; Himmelfarb, Jonathan] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Horne, Frances McFarland] Assoc Specialty Prof, Washington, DC USA. [Kimmel, Paul L.] NIDDK, Bethesda, MD USA. [Molitoris, Bruce A.] Indiana Univ, Sch Med, Indianapolis, IN USA. [Schmader, Kenneth E.] Duke Univ, Durham, NC USA. [Schmader, Kenneth E.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP High, KP (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Infect Dis Sect, Dept Internal Med, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA. EM khigh@wfubmc.edu FU Association of Specialty Professors; American Society of Nephrology; American Geriatrics Society; National Institute on Aging; National Institute of Diabetes and Digestive and Kidney Diseases; John A. Hartford Foundation FX For those who attended a workshop on May 10-11, 2010 sponsored by the Association of Specialty Professors, the American Society of Nephrology, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Diabetes and Digestive and Kidney Diseases.; This workshop was supported by a generous grant from the John A. Hartford Foundation to A.S.P. We are grateful to Charles Clayton and Erika Tarver for assistance with organizing the workshop. For a full list of moderators and attendees of the conference, please visit http://www.im.org/CareerDevelopment/ GrantsandScholarships/IGP/Expanding ResearchEfforts/Pages/WorkshoponAcute KidneyInjuryinOlderAdults.aspx. NR 173 TC 55 Z9 60 U1 1 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2011 VL 22 IS 1 BP 28 EP 38 DI 10.1681/ASN.2010090934 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 730PN UT WOS:000288046500009 PM 21209252 ER PT J AU Peralta, CA Katz, R Sarnak, MJ Lx, J Fried, LF De Boer, I Palmas, W Siscovick, D Levey, AS Shlipak, MG AF Peralta, Carmen A. Katz, Ronit Sarnak, Mark J. Lx, Joachim Fried, Linda F. De Boer, Ian Palmas, Walter Siscovick, David Levey, Andrew S. Shlipak, Michael G. TI Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR EVENTS; SERUM CREATININE; ELDERLY PERSONS; POOLED ANALYSIS; RENAL-FUNCTION; HEART-FAILURE; ATHEROSCLEROSIS; MORTALITY; MARKER AB Although cystatin C is a stronger predictor of clinical outcomes associated with CKD than creatinine, the clinical role for cystatin C is unclear. We included 11,909 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS) and assessed risks for death, cardiovascular events, heart failure, and ESRD among persons categorized into mutually exclusive groups on the basis of the biomarkers that supported a diagnosis of CKD (eGFR < 60 ml/min per 1.73 m(2)): creatinine only, cystatin C only, both, or neither. We used CKD-EPI equations to estimate GFR from these biomarkers. In MESA, 9% had CKD by the creatinine-based equation only, 2% had CKD by the cystatin C-based equation only, and 4% had CKD by both equations; in CHS, these percentages were 12, 4, and 13%, respectively. Compared with those without CKD, the adjusted hazard ratios (HR) for mortality in MESA were: 0.80 (95% CI 0.50 to 1.26) for CKD by creatinine only; 3.23 (95% CI 1.84 to 5.67) for CKD by cystatin C only; and 1.93 (95% CI 1.27 to 2.92) for CKD by both; in CHS, the adjusted HR were 1.09 (95% CI 0.98 to 1.21), 1.78 (95% CI 1.53 to 2.08), and 1.74(95% CI 1.58 to 1.93), respectively. The pattern was similar for cardiovascular disease (CVD), heart failure, and kidney failure outcomes. In conclusion, among adults diagnosed with CKD using the creatinine-based CKD-EPI equation, the adverse prognosis is limited to the subset who also have CKD according to the cystatin C-based equation. Cystatin C may have a role in identifying persons with CKD who have the highest risk for complications. C1 [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Katz, Ronit; Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Katz, Ronit] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Sarnak, Mark J.; Levey, Andrew S.] Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. [Lx, Joachim] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Fried, Linda F.] Pittsburgh Vet Affairs Med Ctr, Pittsburgh, PA USA. [De Boer, Ian; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159 through N01-HC-95165, N01-HC-95169, U01 HL080295]; National Institute of Neurologic Disorders and Stroke; NIDDK [1K23DK082793-01, R01DK 066488]; [N01-HC-85079 through N01-HC-85086]; [N01-HC-35129]; [N01 HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133] FX This work was supported by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169 from the National Heart, Lung, and Blood Institute for MESA. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.; For CHS, the research reported in this article was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, and N01-HC-45133; grant number U01 HL080295 from the National Heart, Lung, and Blood Institute; with additional contributions from the National Institute of Neurologic Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm.; This work was also funded by the NIDDK (1K23DK082793-01 to C.P.) and R01DK 066488 (to M.S.). NR 31 TC 89 Z9 97 U1 0 U2 10 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2011 VL 22 IS 1 BP 147 EP 155 DI 10.1681/ASN.2010050483 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 730PN UT WOS:000288046500021 PM 21164029 ER PT J AU Luterek, JA Bittinger, JN Simpson, TL AF Luterek, Jane A. Bittinger, Joyce N. Simpson, Tracy L. TI Posttraumatic Sequelae Associated with Military Sexual Trauma in Female Veterans Enrolled in VA Outpatient Mental Health Clinics SO JOURNAL OF TRAUMA & DISSOCIATION LA English DT Article DE military sexual trauma; sexual assault; posttraumatic stress disorder; complex posttraumatic stress disorder; disorders of extreme stress not otherwise specified ID MALE VIETNAM VETERANS; STRESS-DISORDER; EXTREME STRESS; WOMEN VETERANS; STRUCTURED INTERVIEW; NATIONAL SAMPLE; PHYSICAL ABUSE; COMPLEX PTSD; ASSAULT; PREVALENCE AB The purpose of this study was to explore the relationship between military sexual assault (MSA) and posttraumatic stress disorder (PTSD) and other symptoms associated with trauma, referred to as disorders of extreme stress not otherwise specified (DESNOS) or complex PTSD within a Veterans Affairs (VA) Medical Center outpatient mental health treatment-seeking sample. The present results focus on female Veterans only because of the low rates of endorsement of MSA among male Veterans resulting in a sample too small to use in analyses. Compared with those who did not endorse MSA, those who did reported greater frequency of other potentially traumatic events; PTSD symptoms; and symptoms characteristic of DESNOS, such as difficulties with interpersonal relationships, emotion regulation, dissociation, somatization, and self-perception. When childhood and other adulthood interpersonal trauma were both taken into account, MSA continued to contribute unique variance in predicting PTSD and DESNOS symptoms. VA patients reporting MSA may represent notably heterogeneous groups that include more complex posttraumatic reactions. Treatment interventions focused on complex PTSD may be warranted for a subset of female veterans who endorse MSA. C1 [Luterek, Jane A.; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA. [Luterek, Jane A.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bittinger, Joyce N.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Luterek, JA (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, 1660 S Columbian Way,S-116 WTRC, Seattle, WA 98108 USA. EM Jane.Luterek@va.gov RI Schueter, nicos/A-3625-2014 NR 34 TC 16 Z9 16 U1 0 U2 12 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1529-9732 J9 J TRAUMA DISSOCIATIO JI J. Trauma Dissociation PY 2011 VL 12 IS 3 SI SI BP 261 EP 274 AR PII 937015763 DI 10.1080/15299732.2011.551504 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 756ZP UT WOS:000290053600005 PM 21534095 ER PT J AU Lador, R Ben-Galim, P Hipp, JA AF Lador, Ran Ben-Galim, Peleg Hipp, John A. TI Motion Within the Unstable Cervical Spine During Patient Maneuvering: The Neck Pivot-Shift Phenomenon SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article ID INTERVERTEBRAL MOTION; INJURIES; IMMOBILIZATION; STABILIZATION; INSTABILITY; INTUBATION; COLLAR AB Background: Cervical extrication collars are applied to millions of blunt trauma victims despite the lack of any evidence that a collar can protect against secondary injuries to the cervical spine. Cadaver studies support that in the presence of a dissociative injury, substantial motion can occur within the occipitocervical spine with collar application or during patient transfers. Little is known about the biomechanics of cervical stabilization; hence, it is difficult to develop and test improved immobilization strategies. Materials: Severe unstable injuries were created in seven fresh whole human cadavers. Rigid collars were applied with the body in a neutral position. Computed tomographic examinations were obtained before and after tilting the body or backboard as would be done during patient transport or to inspect the back. Relative displacements between vertebrae at the site of the injury were measured from the Computed tomographic examinations. The overall relative alignment between body and collar was assessed to understand the mechanisms that may facilitate motion at the injury site. Results: Intervertebral motion averaged 7.7 mm +/- 6.8 mm in the axial plain and 2.9 mm +/- 2.5 mm in the cranial-caudal direction. The rigid collars appeared to create pivot points where the collar contacts the head in the region under the ear and where the collar contacts the shoulders. Discussion: Rigid cervical collars appear to create pivot points that shift the center of rotation lateral to the spine and contribute to the intervertebral motions that were measured. Immobilization strategies that avoid these neck pivot-shift phenomena may help to reduce secondary injuries to the cervical spine. The whole cadaver model with simulation of patient maneuvers may provide an effective test method for cervical immobilization. C1 [Hipp, John A.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA. Michael E DeBakey Vet Adm Med Ctr, Spine Res Lab, Houston, TX USA. RP Hipp, JA (reprint author), Baylor Coll Med, Dept Orthoped Surg, 6620 Main St,11th Floor, Houston, TX 77030 USA. EM jhipp@bcm.edu NR 26 TC 11 Z9 12 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2011 VL 70 IS 1 BP 247 EP 250 DI 10.1097/TA.0b013e3181fd0ebf PG 4 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 707WD UT WOS:000286320300046 PM 21217496 ER PT J AU Bath, J Lawrence, P Chandra, A O'Connell, J Uijtdehaage, S Jimenez, JC Davis, G Hiatt, J AF Bath, Jonathan Lawrence, Peter Chandra, Ankur O'Connell, Jessica Uijtdehaage, Sebastian Jimenez, Juan Carlos Davis, Gavin Hiatt, Jonathan TI Standardization is superior to traditional methods of teaching open vascular simulation SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ORTHOPEDIC-SURGERY RESIDENTS; 80-HOUR WORK WEEK; OPERATIVE EXPERIENCE; GENERAL-SURGERY; SURGICAL TRAINEES; SKILL RETENTION; TECHNICAL SKILL; PERFORMANCE; IMPACT; IMPROVE AB Objectives: Standardizing surgical skills teaching has been proposed as a method to rapidly attain technical competence. This study compared acquisition of vascular skills by standardized vs traditional teaching methods. Methods: The study randomized 18 first-year surgical residents to a standardized or traditional group. Participants were taught technical aspects of vascular anastomosis using femoral anastomosis simulation (Limbs & Things, Savannah, Ga), supplemented with factual information. One expert instructor taught a standardized anastomosis technique using the same method each time to one group over four sessions, while, similar to current vascular training, four different expert instructors each taught one session to the other (traditional) group. Knowledge and technical skill were assessed at study completion by an independent vascular expert using Objective Structured Assessment of Technical Skill (OSATS) performance metrics. Participants also provided a written evaluation of the study experience. Results: The standardized group had significantly higher mean overall technical (95.7% vs 75.8%; P=.038) and global skill scores (83.4% vs 67%; P=.006). Tissue handling, efficiency of motion, overall technical skill, and flow of operation were rated significantly higher in the standardized group (mean range, 88%-96% vs 67.6%-77.6%; P<.05). The standardized group trended to better cognitive knowledge (mean, 68.8% vs 60.7%; P=.182), creation of a secure knot at the toe of the anastomosis, fashioning an appropriate arteriotomy, better double-ended suture placement at the heel of the anastomosis (100% vs 62.7%; P=.07), and accurate suture placement (70% vs 25%; P=.153). Seventy-two percent of participant evaluations suggested a preference for a standardized approach. Conclusions: This study demonstrates the feasibility of open vascular simulation to assess the effect of differing teaching methods on performance outcome. Findings from this report suggest that for simulation training, standardized may be more effective than traditional methods of teaching. Transferability of simulator-acquired skills to the clinical setting will be required before open simulation can be unequivocally recommended as a major component of resident technical skill training. (J Vase Surg 2011;53:229-35.) C1 [Bath, Jonathan; Lawrence, Peter; Chandra, Ankur; O'Connell, Jessica; Jimenez, Juan Carlos] Univ Calif Los Angeles, Dept Vasc Surg, Los Angeles, CA USA. [Uijtdehaage, Sebastian] Univ Calif Los Angeles, Ctr Educ Dev & Res, Los Angeles, CA USA. [Davis, Gavin; Hiatt, Jonathan] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [O'Connell, Jessica] W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA. RP Bath, J (reprint author), UCLA Surg Vasc, Box 956908,Ste 510-6,200 Med Plaza, Los Angeles, CA 90095 USA. EM jbath@mednet.ucla.edu OI Uijtdehaage, Sebastian/0000-0001-8598-4683 NR 38 TC 12 Z9 13 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2011 VL 53 IS 1 BP 229 EP 235 DI 10.1016/j.jvs.2010.07.064 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 704WB UT WOS:000286085200037 PM 21115317 ER PT J AU Meyer, C Grey, F Kreklywich, CN Andoh, TF Tirabassi, RS Orloff, SL Streblow, DN AF Meyer, Christine Grey, Finn Kreklywich, Craig N. Andoh, Takeshi F. Tirabassi, Rebecca S. Orloff, Susan L. Streblow, Daniel N. TI Cytomegalovirus MicroRNA Expression Is Tissue Specific and Is Associated with Persistence SO JOURNAL OF VIROLOGY LA English DT Article ID VIRUS-ENCODED MICRORNAS; EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; TRANSPLANT VASCULAR SCLEROSIS; RAT CYTOMEGALOVIRUS; GENE-EXPRESSION; SMALL RNAS; ALLOGRAFT ARTERIOSCLEROSIS; HEART-TRANSPLANTS; CHRONIC REJECTION AB MicroRNAs (miRNAs) are a class of small noncoding RNAs involved in posttranscriptional regulation. miRNAs are utilized in organisms ranging from plants to higher mammals, and data have shown that DNA viruses also use this method for host and viral gene regulation. Here, we report the sequencing of the small RNAs in rat cytomegalovirus (RCMV)-infected fibroblasts and persistently infected salivary glands. We identified 24 unique miRNAs that mapped to hairpin structures found within the viral genome. While most miRNAs were detected in both samples, four were detected exclusively in the infected fibroblasts and two were specific for the infected salivary glands. The RCMV miRNAs are distributed across the viral genome on both the positive and negative strands, with clusters of miRNAs at a number of locations, including near viral genes r1 and r111. The RCMV miRNAs have a genomic positional orientation similar to that of the miRNAs described for mouse cytomegalovirus, but they do not share any substantial sequence conservation. Similar to other reported miRNAs, the RCMV miRNAs had considerable variation at their 3' and 5' ends. Interestingly, we found a number of specific examples of differential isoform usage between the fibroblast and salivary gland samples. We determined by real-time PCR that expression of the RCMV miRNA miR-r111.1-2 is highly expressed in the salivary glands and that miR-R87-1 is expressed in most tissues during the acute infection phase. Our study identified the miRNAs expressed by RCMV in vitro and in vivo and demonstrated that expression is tissue specific and associated with a stage of viral infection. C1 [Meyer, Christine; Kreklywich, Craig N.; Andoh, Takeshi F.; Orloff, Susan L.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Meyer, Christine; Kreklywich, Craig N.; Andoh, Takeshi F.; Orloff, Susan L.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97239 USA. [Kreklywich, Craig N.; Andoh, Takeshi F.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA. [Kreklywich, Craig N.; Andoh, Takeshi F.; Orloff, Susan L.; Streblow, Daniel N.] Portland VA Med Ctr, Portland, OR 97239 USA. [Grey, Finn] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland. [Grey, Finn] Univ Edinburgh, Royal Sch Vet Studies, Edinburgh, Midlothian, Scotland. [Tirabassi, Rebecca S.] Univ Wisconsin, Madison, WI USA. RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 SW 185th Ave, Beaverton, OR 97006 USA. EM streblow@ohsu.edu FU National Institutes of Health [HL083194, HL085451] FX This work was supported by research grants from the National Institutes of Health to D. N. Streblow (HL083194) and S. L. Orloff (HL085451). NR 68 TC 22 Z9 22 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2011 VL 85 IS 1 BP 378 EP 389 DI 10.1128/JVI.01900-10 PG 12 WC Virology SC Virology GA 691QL UT WOS:000285095800034 PM 20980502 ER PT J AU Ellison, DH AF Ellison, David H. TI Through a glass darkly: salt transport by the distal tubule SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID NA-CL COTRANSPORTER; SODIUM-CHLORIDE COTRANSPORTER; ANGIOTENSIN-II; CONVOLUTED TUBULE; BLOOD-PRESSURE; RAT-KIDNEY; VASOPRESSIN; EXPRESSION; RECEPTOR; WNK4 AB The distal convoluted tubule (DCT) plays a central role in blood pressure and potassium homeostasis, as evidenced by diseases that occur when its function is modified. The paper by van der Lubbe and colleagues makes clear that angiotensin II itself increases the activity and abundance of the thiazide-sensitive Na-Cl cotransporter (NCC), independent of changes in circulating aldosterone. This Commentary provides additional perspective on that work. Kidney International (2011) 79, 5-8. doi: 10.1038/ki.2010.400 C1 [Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3181 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [R01 DK051496-13, R01 DK051496] NR 34 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2011 VL 79 IS 1 BP 5 EP 8 DI 10.1038/ki.2010.400 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 694XC UT WOS:000285334100001 PM 21157456 ER PT J AU Tamura, MK Yaffe, K AF Tamura, Manjula Kurella Yaffe, Kristine TI Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies SO KIDNEY INTERNATIONAL LA English DT Review DE aging; cognitive impairment; dementia; ESRD ID CHRONIC KIDNEY-DISEASE; MINI-MENTAL-STATE; CHRONIC-HEMODIALYSIS TREATMENT; SILENT CEREBRAL INFARCTION; QUALITY-OF-LIFE; DIALYSIS PATIENTS; CYSTATIN-C; ALZHEIMERS-DISEASE; OLDER-ADULTS; IMPROVES BRAIN AB Cognitive impairment, including dementia, is a common but poorly recognized problem among patients with end-stage renal disease (ESRD), affecting 16-38% of patients. Dementia is associated with high risks of death, dialysis withdrawal, hospitalization, and disability among patients with ESRD; thus, recognizing and effectively managing cognitive impairment may improve clinical care. Dementia screening strategies should take into account patient factors, the time available, the timing of assessments relative to dialysis treatments, and the implications of a positive screen for subsequent management (for example, transplantation). Additional diagnostic testing in patients with cognitive impairment, including neuroimaging, is largely based on the clinical evaluation. There is limited data on the efficacy and safety of pharmacotherapy for dementia in the setting of ESRD; therefore, decisions about the use of these medications should be individualized. Management of behavioral symptoms, evaluation of patient safety, and advance care planning are important components of dementia management. Prevention strategies targeting vascular risk factor modification, and physical and cognitive activity have shown promise in the general population and may be reasonably extrapolated to the ESRD population. Modification of ESRD-associated factors such as anemia and dialysis dose or frequency require further study before they can be recommended for treatment or prevention of cognitive impairment. Kidney International (2011) 79, 14-22; doi: 10.1038/ki.2010.336; published online 22 September 2010 C1 [Tamura, Manjula Kurella] Stanford Univ, Div Nephrol, Dept Med, Sch Med, Palo Alto, CA 94304 USA. [Tamura, Manjula Kurella] VA Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tamura, MK (reprint author), Stanford Univ, Div Nephrol, Dept Med, Sch Med, 780 Welch Rd,Suite 106, Palo Alto, CA 94304 USA. EM mktamura@stanford.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institute of Aging [K23AG028952]; Satellite Research; Amgen; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK069406] FX MKT receives support from the National Institute of Aging (K23AG028952) and from a Norman S. Coplon grant from Satellite Research. She has previously received funding support from Amgen. KY is supported by R01DK069406 from the National Institute of Diabetes and Digestive and Kidney Diseases. She serves on a data safety monitoring board for Pfizer and Medivation, and as a consultant to Novartis. NR 71 TC 40 Z9 43 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2011 VL 79 IS 1 BP 14 EP 22 DI 10.1038/ki.2010.336 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 694XC UT WOS:000285334100004 ER PT J AU Young, BA AF Young, Bessie A. TI Prevention of sudden cardiac arrest in dialysis patients: can we do more to improve outcomes? SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; HEMODIALYSIS-PATIENTS; DEATH; SURVIVAL; PREDICTORS; CHALLENGE; DESIGN; RISK AB Sudden cardiac arrest (SCA) is a leading cause of cardiac-associated mortality in dialysis patients. Risk factors unique to hemodialysis patients include abnormal electrolytes, large-volume ultrafiltration, and prior history of cardiac disease. Few randomized controlled trials of standard cardiac interventions have been completed in dialysis patients. Observational studies suggest that modification of the dialysis prescription may be one place to intervene. Prospective research is needed to determine mechanisms of SCA in hemodialysis patients. Kidney International (2011) 79, 147-149. doi:10.1038/ki.2010.433 C1 [Young, Bessie A.] Seattle VA Puget Sound Healthcare Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Young, Bessie A.] Univ Washington, Kidney Res Inst, Div Nephrol, Seattle, WA 98195 USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 1660 S Columbian Way,152-E, Seattle, WA 98108 USA. EM youngb@u.washington.edu FU NIDDK NIH HHS [R01 DK079745] NR 22 TC 2 Z9 2 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2011 VL 79 IS 2 BP 147 EP 149 DI 10.1038/ki.2010.433 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 700IV UT WOS:000285732900002 PM 21191388 ER PT J AU Sharma, T Hu, Y Stoller, M Feldman, M Ruoff, RS Ferrari, M Zhang, XJ AF Sharma, Tushar Hu, Ye Stoller, Meryl Feldman, Marc Ruoff, Rodney S. Ferrari, Mauro Zhang, Xiaojing TI Mesoporous silica as a membrane for ultra-thin implantable direct glucose fuel cells SO LAB ON A CHIP LA English DT Article ID MINIATURE BIOFUEL CELL; PRESSURE SENSOR; POWER; NANOPARTICLES; PERFORMANCE; ELECTRODES; STABILITY; BIOSENSOR; CATHETER; PROTEIN AB The design, fabrication and characterization of an inorganic catalyst based direct glucose fuel cell using mesoporous silica coating as a functional membrane is reported. The desired use of mesoporous silica based direct glucose fuel cell is for a blood vessel implantable device. Blood vessel implantable direct glucose fuel cells have access to higher continuous glucose concentrations. However, reduction in the implant thickness is required for application in the venous system as part of a stent. We report development of an implantable device with a platinum thin-film (thickness: 25 nm) deposited on silicon substrate (500 mu m) to serve as the anode, and graphene pressed on a stainless steel mesh (175 mu m) to serve as the cathode. Control experiments involved the use of a surfactant-coated polypropylene membrane (50 mu m) with activated carbon (198 mu m) electrodes. We demonstrate that a mesoporous silica thin film (270 nm) is capable of replacing the conventional polymer based membranes with an improvement in the power generated over conventional direct glucose fuel cells. C1 [Sharma, Tushar; Zhang, Xiaojing] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Hu, Ye; Ferrari, Mauro] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Stoller, Meryl; Ruoff, Rodney S.] Univ Texas Austin, Mat Sci & Engn Program, Austin, TX 78712 USA. [Feldman, Marc] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Feldman, Marc] S Texas Vet Adm Hlth Care Syst, San Antonio, TX USA. RP Zhang, XJ (reprint author), Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. EM john.zhang@engr.utexas.edu RI Ferreira, Fernanda /D-3963-2012; Sharma, Tushar/D-8320-2012; Ruoff, Rodney/K-3879-2015 FU University of Texas at Austin; NASA [NNJ06HE06A]; State of Texas Emerging Technology Fund; Veterans Administration (VA) Merit Grant FX This research was performed at the Biomedical Engineering Department, the Mechanical Engineering Department and the Microelectronics Research Center (MRC) at UT Austin, a member of the National Nanofabrication Infrastructure Network (NNIN). We are grateful to The University of Texas at Austin for a Special Research Grant (SRG) to partly support this research. The authors at the Department of Nanomedicine and Biomedical Engineering (nBME) acknowledge the grant support from the following agencies: NASA (NNJ06HE06A) and the State of Texas Emerging Technology Fund. We thank Dr Sanjay Banerjee for providing the platinum electrode materials. MS and RSR appreciate support (startup funds) from The University of Texas at Austin. We also thank Drs Porterfield and Hacker, and Danny Escobedo for the invaluable help with the in vivo porcine studies. We are also grateful to the Veterans Administration (VA) Merit Grant for the support with porcine studies. NR 53 TC 29 Z9 29 U1 2 U2 57 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2011 VL 11 IS 14 BP 2460 EP 2465 DI 10.1039/c1lc20119k PG 6 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 784PF UT WOS:000292168500022 PM 21637881 ER PT J AU Leichsenring, F Leibing, E Kruse, J New, AS Leweke, F AF Leichsenring, Falk Leibing, Eric Kruse, Johannes New, Antonia S. Leweke, Frank TI Borderline personality disorder SO LANCET LA English DT Article ID DIALECTICAL BEHAVIOR-THERAPY; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; DSM-IV CRITERIA; TRANSFERENCE-FOCUSED PSYCHOTHERAPY; SEROTONIN TRANSPORTER GENE; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED-TRIAL; CHILDHOOD SEXUAL-ABUSE; DELIBERATE SELF-HARM AB Recent research findings have contributed to an improved understanding and treatment of borderline personality disorder. This disorder is characterised by severe functional impairments, a high risk of suicide, a negative effect on the course of depressive disorders, extensive use of treatment, and high costs to society. The course of this disorder is less stable than expected for personality disorders. The causes are not yet clear, but genetic factors and adverse life events seem to interact to lead to the disorder. Neurobiological research suggests that abnormalities in the frontolimbic networks are associated with many of the symptoms. Data for the effectiveness of pharmacotherapy vary and evidence is not yet robust. Specific forms of psychotherapy seem to be beneficial for at least some of the problems frequently reported in patients with borderline personality disorder. At present, there is no evidence to suggest that one specific form of psychotherapy is more effective than another. Further research is needed on the diagnosis, neurobiology, and treatment of borderline personality disorder. C1 [Leichsenring, Falk; Kruse, Johannes; Leweke, Frank] Univ Giessen, Dept Psychosomat & Psychotherapy, D-35392 Giessen, Germany. [Leibing, Eric] Univ Goettingen, Dept Psychosomat Med & Psychotherapy, Gottingen, Germany. [New, Antonia S.] James J Peters VA Med Ctr, Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, New York, NY USA. [New, Antonia S.] Mt Sinai Sch Med, New York, NY USA. RP Leichsenring, F (reprint author), Univ Giessen, Dept Psychosomat & Psychotherapy, Ludwigstr 76, D-35392 Giessen, Germany. EM falk.leichsenring@psycho.med.uni-giessen.de RI Leweke, Frank/B-5300-2012 NR 143 TC 209 Z9 212 U1 18 U2 85 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JAN 1 PY 2011 VL 377 IS 9759 BP 74 EP 84 DI 10.1016/S0140-6736(10)61422-5 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 709MQ UT WOS:000286445200033 PM 21195251 ER PT J AU Francis, DO Maynard, C Weymuller, EA Reiber, G Merati, AL Yueh, B AF Francis, David O. Maynard, Charles Weymuller, Ernest A. Reiber, Gayle Merati, Albert L. Yueh, Bevan TI Reevaluation of Gastroesophageal Reflux Disease as a Risk Factor for Laryngeal Cancer SO LARYNGOSCOPE LA English DT Article DE Gastroesophageal reflux disease; extraesophageal reflux; laryngeal cancer; reverse causality ID LARYNGOPHARYNGEAL REFLUX; CARCINOMA; TOBACCO; PEPSIN; CARCINOGENESIS; SMOKING; INJURY; ACID; GERD AB Objectives/Hypothesis: The relationship between gastroesophageal reflux disease (GERD) and laryngeal cancer has not been fully elucidated. This case-control study investigates whether GERD increases the odds of developing these malignancies. Study Design: Case-control study. Methods: Rates of GERD among cases of laryngeal cancer identified in the Veterans Health Administration outpatient care files (year 2000-2006) were compared with controls. Cases (N = 14,449) were frequency matched 1:1 with controls. Multivariate logistic regression was used to determine the association between GERD and cancer. Results: After adjusting for tobacco and/or alcohol use, there was no association between GERD and laryngeal cancer (adjusted odds ratio, 1.01; 95% confidence interval, 0.92-1.12, P =.780). Although an association was found when time from GERD diagnosis to malignancy was less than 3 months, it disappeared when this period was extended further. Conclusions: In this population, there was no increased risk of laryngeal cancer among patients with GERD. However, in subsite analysis, a possible relationship between GERD and glottic cancer was observed. Reverse causality must be considered in future studies assessing the relationship between reflux and laryngeal cancer to limit misclassification bias. C1 [Francis, David O.; Maynard, Charles; Reiber, Gayle] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Francis, David O.; Weymuller, Ernest A.; Merati, Albert L.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. RP Francis, DO (reprint author), Med Ctr E, Vanderbilt Voice Ctr, South Tower,1215 21st Ave S,Suite 7302, Nashville, TN 37232 USA. EM david.o.francis@vanderbilt.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Yueh, Bevan/0000-0003-1380-1053 FU U.S. Department of Veterans Affairs Northwest Center of Excellence for Health Services Research and Development; American Academy of Otolaryngology-Head and Neck Surgery Resident Research C.O.R.E. FX This study was supported in part by the U.S. Department of Veterans Affairs Northwest Center of Excellence for Health Services Research and Development and by an American Academy of Otolaryngology-Head and Neck Surgery Resident Research C.O.R.E. grant. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 27 TC 11 Z9 12 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2011 VL 121 IS 1 BP 102 EP 105 DI 10.1002/lary.21165 PG 4 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 708YQ UT WOS:000286400600017 PM 21046549 ER PT J AU Trivedi, AN Matula, S Miake-Lye, I Glassman, PA Shekelle, P Asch, S AF Trivedi, Amal N. Matula, Sierra Miake-Lye, Isomi Glassman, Peter A. Shekelle, Paul Asch, Steven TI Systematic Review Comparison of the Quality of Medical Care in Veterans Affairs and Non-Veterans Affairs Settings SO MEDICAL CARE LA English DT Review DE veterans; quality of health care; hospitals, veterans; outcomes and process assessment (health care) ID ACUTE MYOCARDIAL-INFARCTION; FACTOR SURVEILLANCE SYSTEM; PRIVATE-SECTOR HOSPITALS; FEE-FOR-SERVICE; HEALTH-CARE; ADJUSTED MORTALITY; ADVANTAGE PROGRAM; DIABETES CARE; NEW-YORK; VA AB Background: The Veterans Health Administration, the nation's largest integrated delivery system, launched an organizational transformation in the mid 1990s to improve the quality of its care. Purpose: To synthesize the evidence comparing the quality of medical and other nonsurgical care in Veterans Affairs (VA) and non-VA settings. Data Sources: MEDLINE database and bibliographies of retrieved studies. Study Selection: Studies comparing the technical quality of nonsurgical care in VA and US non-VA settings published between 1990 and August 2009. Data Extraction: Two physicians independently reviewed 175 unique studies identified using the search strategy and abstracted data related to 6 domains of study quality. Data Synthesis: Thirty-six studies met the inclusion criteria. All 9 general comparative studies showed greater adherence to accepted processes of care or better health outcomes in the VA compared with care delivered outside the VA. Five studies of mortality following an acute coronary event found no clear survival differences between VA and non-VA settings. Three studies of care processes after an acute myocardial infarction found greater rates of evidence-based drug therapy in VA, and 1 found lower use of clinically-appropriate angiography in the VA. Three studies of diabetes care processes demonstrated a performance advantage for the VA. Studies of hospital mortality found similar risk-adjusted mortality rates in VA and non-VA hospitals. Limitations: Most studies used decade-old data, assessed self-reported service use, or included only a few VA or non-VA sites. Conclusions: Studies that assessed recommended processes of care almost always demonstrated that the VA performed better than non-VA comparison groups. Studies that assessed risk-adjusted mortality generally found similar rates for patients in VA and non-VA settings. C1 [Trivedi, Amal N.] Providence VA Med Ctr, Ctr Syst Outcomes & Qual Chron Dis & Rehabil SOQC, Providence, RI 02908 USA. [Trivedi, Amal N.] Brown Univ, Dept Community Hlth, Alpert Med Sch, Providence, RI 02912 USA. [Matula, Sierra; Miake-Lye, Isomi; Glassman, Peter A.; Shekelle, Paul; Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv, Los Angeles, CA 90095 USA. [Miake-Lye, Isomi; Glassman, Peter A.; Shekelle, Paul; Asch, Steven] Greater Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. [Glassman, Peter A.; Shekelle, Paul; Asch, Steven] RAND Corp, Santa Monica, CA USA. RP Trivedi, AN (reprint author), Providence VA Med Ctr, Ctr Syst Outcomes & Qual Chron Dis & Rehabil SOQC, 830 Chalkstone Ave, Providence, RI 02908 USA. EM amal.trivedi@va.gov FU Robert Wood Johnson Clinical Scholars Program; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development. Dr. Matula received funding from the Robert Wood Johnson Clinical Scholars Program. NR 53 TC 53 Z9 53 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2011 VL 49 IS 1 BP 76 EP 88 DI 10.1097/MLR.0b013e3181f53575 PG 13 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 695XW UT WOS:000285407100011 PM 20966778 ER PT J AU Min, LC Reuben, DB Keeler, E Ganz, DA Fung, CH Shekelle, P Roth, CP Wenger, NS AF Min, Lillian C. Reuben, David B. Keeler, Emmett Ganz, David A. Fung, Constance H. Shekelle, Paul Roth, Carol P. Wenger, Neil S. TI Is Patient-Perceived Severity of a Geriatric Condition Related to Better Quality of Care? SO MEDICAL CARE LA English DT Article DE quality of care; urinary incontinence; falls ID CORONARY-ARTERY-DISEASE; URINARY-INCONTINENCE; ELDERLY-PATIENTS; SEX-DIFFERENCES; BLOOD-PRESSURE; OLDER PATIENTS; DIABETES CARE; MANAGED CARE; MEDICAL-CARE; FOLLOW-UP AB Background: Care for falls and urinary incontinence (UI) among older patients is inadequate. One possible explanation is that physicians provide less recommended care to patients who are not as concerned about their falls and UI. Objective: To test whether patient-reported severity for 2 geriatric conditions, falls, and UI, is associated with quality of care. Research Design: Prospective cohort study of elders with falls and/or fear of falling (n = 384) and UI (n = 163). Subjects: Participants in the Assessing Care of Vulnerable Elders-2 Study (2002-2003), which evaluated an intervention to improve the care for falls and UI among older (age, >= 75) ambulatory care patients with falls/fear of falling or UI. Measures: Falls Efficacy Scale (FES) and the Incontinence Quality of Life surveys measured at baseline, quality of care measured by a 13-month medical record abstraction. Results: There was a small difference in falls quality scores across the range of FES, with greater patient-perceived falls severity associated with better odds of passing falls quality indicators (OR: 1.11 [95% CI: 1.02-1.21] per 10-point increment in FES). Greater patient-perceived UI severity (Incontinence Quality of Life score) was not associated with better quality of UI care. Conclusions: Although older persons with greater patient-perceived falls severity receive modestly better quality of care, those with more distressing incontinence do not. For both conditions, however, even the most symptomatic patients received less than half of recommended care. Low patient-perceived severity of condition is not the basis of poor care for falls and UI. C1 [Min, Lillian C.] Univ Michigan, Sch Med, Div Geriatr, Dept Med, Ann Arbor, MI 48109 USA. [Reuben, David B.; Fung, Constance H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Keeler, Emmett; Ganz, David A.; Shekelle, Paul; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Shekelle, Paul; Roth, Carol P.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA. [Ganz, David A.; Shekelle, Paul] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Min, LC (reprint author), Univ Michigan, Sch Med, Div Geriatr, Dept Med, 300 N Ingalls Bldg,Wing E,Room 966, Ann Arbor, MI 48109 USA. EM lmin@med.umich.edu FU AHRQ [R21 HS017621]; NIA-UCLA [K12 AG001004]; U.S. Department of Veterans Affairs, Veterans Health Administration; VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR& D Center of Excellence [VA CD2 08-012-1]; National Institute of Aging [AG028748] FX Dr. Min is supported by the AHRQ (R21 HS017621). Dr. Min was on the UCLA faculty during the writing of this manuscript, supported by NIA-UCLA (K12 AG001004). Dr. Ganz is funded by the U.S. Department of Veterans Affairs, Veterans Health Administration, VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR& D Center of Excellence (Project # VA CD2 08-012-1). This research was also supported by the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute of Aging (AG028748). NR 50 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2011 VL 49 IS 1 BP 101 EP 107 DI 10.1097/MLR.0b013e3181f53523 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 695XW UT WOS:000285407100014 PM 21079526 ER PT J AU Schenker, Y Fernandez, A Sudore, R Schillinger, D AF Schenker, Yael Fernandez, Alicia Sudore, Rebecca Schillinger, Dean TI Interventions to Improve Patient Comprehension in Informed Consent for Medical and Surgical Procedures: A Systematic Review SO MEDICAL DECISION MAKING LA English DT Review DE informed consent; intervention; comprehension; understanding; interpersonal communication ID RANDOMIZED CONTROLLED-TRIAL; INTERACTIVE VIDEO PROGRAM; ELECTROCONVULSIVE-THERAPY; PREANESTHETIC INFORMATION; WRITTEN INFORMATION; CLINICAL DECISIONS; BACK SURGERY; RECALL; FORMS; COLONOSCOPY AB Background. Patient understanding in clinical informed consent is often poor. Little is known about the effectiveness of interventions to improve comprehension or the extent to which such interventions address different elements of understanding in informed consent. Purpose. To systematically review communication interventions to improve patient comprehension in informed consent for medical and surgical procedures. Data Sources. A systematic literature search of English-language articles in MEDLINE (1949-2008) and EMBASE (1974-2008) was performed. In addition, a published bibliography of empirical research on informed consent and the reference lists of all eligible studies were reviewed. Study Selection. Randomized controlled trials and controlled trials with non-random allocation were included if they compared comprehension in informed consent for a medical or surgical procedure. Only studies that used a quantitative, objective measure of understanding were included. All studies addressed informed consent for a needed or recommended procedure in actual patients. Data Extraction. Reviewers independently extracted data using a standardized form. All results were compared, and disagreements were resolved by consensus. Data Synthesis. Forty-four studies were eligible. Intervention categories included written information, audiovisual/multimedia, extended discussions, and test/feedback techniques. The majority of studies assessed patient understanding of procedural risks; other elements included benefits, alternatives, and general knowledge about the procedure. Only 6 of 44 studies assessed all 4 elements of understanding. Interventions were generally effective in improving patient comprehension, especially regarding risks and general knowledge. Limitations. Many studies failed to include adequate description of the study population, and outcome measures varied widely. Conclusions. A wide range of communication interventions improve comprehension in clinical informed consent. Decisions to enhance informed consent should consider the importance of different elements of understanding, beyond procedural risks, as well as feasibility and acceptability of the intervention to clinicians and patients. Conceptual clarity regarding the key elements of informed consent knowledge will help to focus improvements and standardize evaluations. C1 [Schenker, Yael; Fernandez, Alicia; Sudore, Rebecca; Schillinger, Dean] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schenker, Yael] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Sudore, Rebecca] San Francisco VA Med Ctr, Hlth Serv Res & Dev, San Francisco, CA USA. [Schillinger, Dean] Univ Calif San Francisco, Ctr Vulnerable Populat, San Francisco Gen Hosp, San Francisco, CA 94143 USA. RP Schenker, Y (reprint author), Univ Calif San Francisco, Dept Med, 1001 Potrero Ave,Bldg 10,Ward 3, San Francisco, CA 94143 USA. EM yael.schenker@ucsf.edu FU Department of Health and Human Services, Health Resources and Services Administration [DHHS HRSA D55HP05165]; National Institutes of Health [K23-RR018324-01, UL1 RR02413]; NIA [K-23 AG030344-02]; Pfizer; VA Career Development Award FX Received 13 August 2009 from the Department of Medicine, University of California, San Francisco (YS, AF, RS, DS); Department of Epidemiology, University of California, San Francisco (YS); Health Services Research and Development, San Francisco Veterans Affairs Medical Center, San Francisco, California (RS); and the University of California, San Francisco, Center for Vulnerable Populations at San Francisco General Hospital (DS). Dr. Schenker was supported by the General Internal Medicine Fellowship at the University of California, San Francisco, funded by the Department of Health and Human Services, Health Resources and Services Administration (DHHS HRSA D55HP05165). Dr. Fernandez was supported by a National Institutes of Health Career Development Award (K23-RR018324-01). Dr. Sudore was supported first by an NIA Mentored Clinical Scientist Award K-23 AG030344-02 and then a VA Career Development Award and a Pfizer Fellowship in Clear Health Communication. Dr. Schillinger was supported by a grant from the National Institutes of Health (UL1 RR02413). Revision accepted for publication 16 January 2010. NR 76 TC 86 Z9 86 U1 3 U2 26 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-FEB PY 2011 VL 31 IS 1 BP 151 EP 173 DI 10.1177/0272989X10364247 PG 23 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 717CQ UT WOS:000287021000016 PM 20357225 ER PT J AU Wittenberg-Lyles, EM Shaunfield, S Goldsmith, J Sanchez-Reilly, S AF Wittenberg-Lyles, Elaine M. Shaunfield, Sara Goldsmith, Joy Sanchez-Reilly, Sandra TI How we involved bereaved family caregivers in palliative care education SO MEDICAL TEACHER LA English DT Editorial Material ID STUDENTS AB As palliative care coursework continues to proliferate within US medical education, novel curriculum approaches have included the use of cancer survivors and family caregivers. We included bereaved family caregivers in structured clinical teaching. Methods: First year students were exposed to a lecture about death and dying and then met with a bereaved caregiver in small groups of 10-15 for a presentation about the caregiving experience, bereavement, and question and answer period. Substantial pre-planning was involved to recruit caregivers and arrange for classroom space. Results: Participation evoked caregiver anxiety but was resolved with adequate arrangement of the classroom and student introductions. Conclusions: Future implementation of bereaved caregivers in palliative coursework should include an appropriate follow-up phone call as well as recruiting more caregivers than necessary for the curriculum. C1 [Wittenberg-Lyles, Elaine M.] Univ N Texas, Dept Commun Studies, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Dept Commun, Young Harris, GA USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wittenberg-Lyles, EM (reprint author), Univ N Texas, Dept Commun Studies, 1155 Union Circle 305268, Denton, TX 76203 USA. EM lyles@unt.edu NR 8 TC 2 Z9 2 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2011 VL 33 IS 5 BP 351 EP 353 DI 10.3109/0142159X.2011.530318 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 754KR UT WOS:000289854000009 PM 21517682 ER PT J AU Smith, DT Kohlwes, RJ AF Smith, Dustin T. Kohlwes, R. Jeffrey TI Teaching strategies used by internal medicine residents on the wards SO MEDICAL TEACHER LA English DT Article ID CLINICAL TEACHERS; HOUR RESTRICTIONS; STUDENTS; FACULTY; ATTITUDES; PROGRAMS; FEEDBACK; PERCEPTIONS; EDUCATION; SKILLS AB Background: Residents serve as teachers to interns and students in most internal medicine residency programs. Aim: The purpose of our study is to explore what internal medicine residents perceive as effective teaching strategies in the inpatient setting and to formulate a guideline for preparing residents to lead their ward teams. Methods: Housestaff identified as excellent teaching residents were recruited from a large internal medicine residency program. Focus groups were formed and interviews were conducted using open-ended questions. Transcripts of the interviews were reviewed, analyzed, and compared for accuracy by two investigators. The transcripts were then coded to categorize data into similar subjects from which recurrent themes in resident teaching were identified. Results: Twenty-two residents participated in four focus group interviews held in 2008. We identified five principal themes for effective teaching by residents: (T)aking advantage of teaching opportunities, (E)mpowering learners, (A)ssuming the role of leader, (C)reating a learning environment, and (H)abituating the practice of teaching. Conclusion: Strategies for effective teaching by residents exist. The TEACH mnemonic is a resident-identified method of instruction. Use of this tool could enable residency programs to create instructional curricula to prepare their residents and interns to take on the roles of team leaders and teachers. C1 [Smith, Dustin T.] Atlanta Vet Affairs Med Ctr, Med Special Dept, Div Hosp Med, Decatur, GA 30033 USA. [Smith, Dustin T.] Morehouse Sch Med, Atlanta, GA USA. [Smith, Dustin T.] Emory Univ, Sch Med, Atlanta, GA USA. [Kohlwes, R. Jeffrey] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kohlwes, R. Jeffrey] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, DT (reprint author), Atlanta Vet Affairs Med Ctr, Med Special Dept, Div Hosp Med, Decatur, GA 30033 USA. EM dustin.smith2@va.gov FU Department of Veterans Affairs FX The authors recognize Dr Miriam Kuppermann and Dr Patricia Cornett and thank them for their contributions in reviewing our manuscript. This study was supported by the Department of Veterans Affairs (Primary Medical Education Program). NR 35 TC 3 Z9 3 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2011 VL 33 IS 12 BP E697 EP E703 DI 10.3109/0142159X.2011.611838 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 873KT UT WOS:000298882900008 PM 22225453 ER PT J AU Vartanian, R Masri, J Martin, J Cloninger, C Holmes, B Artinian, N Funk, A Ruegg, T Gera, J AF Vartanian, Raffi Masri, Janine Martin, Jheralyn Cloninger, Cheri Holmes, Brent Artinian, Nicholas Funk, Alex Ruegg, Teresa Gera, Joseph TI AP-1 Regulates Cyclin D1 and c-MYC Transcription in an AKT-Dependent Manner in Response to mTOR Inhibition: Role of AIP4/Itch-Mediated JUNB Degradation SO MOLECULAR CANCER RESEARCH LA English DT Article ID ENHANCED SENSITIVITY; MAMMALIAN TARGET; BINDING-PROTEINS; RAPAMYCIN; PHOSPHORYLATION; EXPRESSION; PROMOTER; KINASE; ACTIVATION; PATHWAY AB One mechanism by which AKT kinase-dependent hypersensitivity to mammalian target of rapamycin (mTOR) inhibitors is controlled is by the differential expression of cyclin D1 and c-MYC. Regulation of posttranscriptional processes has been demonstrated to be crucial in governing expression of these determinants in response to rapamycin. Our previous data suggested that cyclin D1 and c-MYC expression might additionally be coordinately regulated in an AKT-dependent manner at the level of transcription. Under conditions of relatively quiescent AKT activity, treatment of cells with rapamycin resulted in upregulation of cyclin D1 and c-MYC nascent transcription, whereas in cells containing active AKT, exposure repressed transcription. Promoter analysis identified AKT-dependent rapamycin responsive elements containing AP-1 transactivation sites. Phosphorylated c-JUN binding to these promoters correlated with activation of transcription whereas JUNB occupancy was associated with promoter repression. Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure. AIP4/Itch-dependent JUNB protein degradation was found to be markedly reduced in active AKT-containing cells compared with cells harboring quiescent AKT. Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities. Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin. Mol Cancer Res; 9(1); 115-30. (C) 2010 AACR. C1 [Vartanian, Raffi; Masri, Janine; Martin, Jheralyn; Cloninger, Cheri; Holmes, Brent; Artinian, Nicholas; Funk, Alex; Ruegg, Teresa; Gera, Joseph] Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. [Vartanian, Raffi; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gera, Joseph] Univ Calif Los Angeles, Jonnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. RP Gera, J (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, 16111 Plummer St 151,Bldg 1,Room C111A, Los Angeles, CA 91343 USA. EM jgera@mednet.ucla.edu FU VA MERIT; NIH [R01CA109312] FX This work was supported, in whole or in part, by VA MERIT and NIH R01CA109312 grants. NR 52 TC 21 Z9 22 U1 1 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 J9 MOL CANCER RES JI Mol. Cancer Res. PD JAN PY 2011 VL 9 IS 1 BP 115 EP 130 DI 10.1158/1541-7786.MCR-10-0105 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 706LU UT WOS:000286220700010 PM 21135252 ER PT B AU Siegel, J AF Siegel, Jerome BE Baumann, CR Bassetti, CL Scammell, TE TI The Roles of Hypocretin/Orexin in Narcolepsy, Parkinson's Disease, and Normal Behavior SO NARCOLEPSY: PATHOPHYSIOLOGY, DIAGNOSIS, AND TREATMENT LA English DT Proceedings Paper CT 6th International Symposium on Narcolepsy CY SEP09, 2009 CL Ascona, SWITZERLAND SP MRC, Ctr Dev Neurobiology, Ctr Stefano Franscini Monte Verita, Swiss Federal Inst Technol Zurich Actelion, Boehringer Ingelheim, Cephalon, UCB Pharma DE Orexin; Hypocretin; Narcolepsy; Parkinson's disease; Hypothalamus; Sleep-wake regulation; Excessive daytime sleepiness ID IN-VIVO MICRODIALYSIS; SLEEP-WAKING CYCLE; MUSCLE TONE; REM-SLEEP; OREXIN NEURONS; HYPOGLOSSAL MOTONEURONS; DAYTIME SLEEPINESS; CANINE NARCOLEPSY; MEDIAL MEDULLA; INDUCED ATONIA C1 [Siegel, Jerome] Univ Calif Los Angeles, Neurobiol Res 151A3, Vet Adm Greater Los Angeles Healthcare Syst, Dept Psychiat, North Hills, CA 91343 USA. RP Siegel, J (reprint author), Univ Calif Los Angeles, Neurobiol Res 151A3, Vet Adm Greater Los Angeles Healthcare Syst, Dept Psychiat, North Hills, CA 91343 USA. EM jsiegel@ucla.edu NR 55 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-8389-3 PY 2011 BP 37 EP 45 DI 10.1007/978-1-4419-8390-9_4 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BH0LH UT WOS:000395493100004 ER PT J AU Felsenfeld, AJ Levine, BS Kleeman, CR AF Felsenfeld, A. J. Levine, B. S. Kleeman, C. R. TI Fuller Albright and our current understanding of calcium and phosphorus regulation and primary hyperparathyroidism SO NEFROLOGIA LA English DT Article DE Calcium; Hyperparathyroidism; Hypoparathyroidism; Parathyroid hormone; Phosphorus ID VITAMIN-D DEFICIENCY; OSTEITIS FIBROSA CYSTICA; AFRICAN BANTU INFANTS; PARATHYROID-HORMONE; SERUM PHOSPHORUS; PHOSPHATE; GLANDS; HYPOPARATHYROIDISM; METABOLISM; EXPRESSION AB The major contributions of Fuller Albright to our understanding of calcium and phosphorus regulation and primary hyperparathyroidism are highlighted. Albright was the first investigator to initiate a systematic study of mineral metabolism. With resources limited to the measurement of serum calcium and phosphorus and the infusion of parathyroid extract, Albright used balance studies to establish a framework for our understanding of calcium and phosphorus regulation and primary hyperparathyroidism. Albright was the first to show that the etiology of primary hyperparathyroidism could be from either an adenoma or hyperplasia of the parathyroid glands and stone disease was a separate manifestation of primary hyperparathyroidism. Albright also showed that: 1) a renal threshold for calcium excretion was present in hypoparathyroid patients; 2) correction of hypocalcemia in hypoparathyroid patients with vitamin D had a phosphaturic action; 3) renal failure reduced the intestinal absorption of calcium in primary hyperparathyroidism; 4) the "hungry bone" syndrome developed after parathyroidectomy in severe primary hyperparathyroidism; and 5) a target organ can fail to respond to a hormone. He also suggested that a malignant tumor could be responsible for ectopic hormone production. Finally, our review integrates the observations of Albright with our current knowledge of calcium regulation and disorders. C1 [Felsenfeld, A. J.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Felsenfeld, A. J.] Univ Calif Los Angeles, David Geffen Sch Med, Nephrol Sect 111L, W Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Felsenfeld, AJ (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA USA. EM Arnold.Felsenfeld@va.gov NR 71 TC 0 Z9 0 U1 0 U2 2 PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ PI MADRID PA HOSPITAL RAMON Y CAJAL CTR DE COLMENAR, KM 9,100, 28034 MADRID, SPAIN SN 0211-6995 J9 NEFROLOGIA JI Nefrologia PY 2011 VL 31 IS 3 BP 346 EP 357 DI 10.3265/Nefrologia.pre2011.Mar.10774 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 772LG UT WOS:000291234800015 PM 21629339 ER PT J AU Muldoon, LL Gahramanov, S Li, X Marshall, DJ Kraemer, DF Neuwelt, EA AF Muldoon, Leslie L. Gahramanov, Seymur Li, Xin Marshall, Deborah J. Kraemer, Dale F. Neuwelt, Edward A. TI Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models SO NEURO-ONCOLOGY LA English DT Article DE bevacizumab; blood-brain barrier; dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging; intetumumab ID RECURRENT GLIOBLASTOMA-MULTIFORME; MONOCLONAL-ANTIBODY; BRAIN-TUMORS; ANTIANGIOGENIC ACTIVITY; IN-VIVO; ANGIOGENESIS; INTEGRINS; VEGF; PERFUSION; SUSCEPTIBILITY AB We used dynamic Mill to evaluate the effects of monoclonal antibodies targeting brain tumor vasculature. Female athymic rats with intracerebral human tumor xenografts were untreated or treated with intetumumab, targeting alpha(v)-integrins, or bevacizumab, targeting vascular endothelial growth factor (n = 4-6 per group). Prior to treatment and at 1, 3, and 7 days after treatment, we performed standard MRI to assess tumor volume, dynamic susceptibility-contrast MRI with the blood-pool iron oxide nanoparticle fcrumoxytol to evaluate relative cerebral blood volume (rCBV), and dynamic contrast-enhanced MRI to assess tumor vascular permeability. Tumor rCBV increased by 27 +/- 13% over 7 days in untreated rats; intetumumab increased tumor rCBV by 65 +/- 10%, whereas bevacizumab reduced tumor rCBV by 31 +/- 10% at 7 days (P<.001 for group and day). Similarly, intetumumab increased brain tumor vascular permeability compared with controls at 3 and 7 days after treatment, whereas bevacizumab decreased tumor permeability within 24 hours (P=.0004 for group, P=.0081 for day). All tumors grew over the 7-day assessment period, but bevacizumab slowed the increase in tumor volume on Mill. We conclude that the vascular targeting agents intetumumab and bevacizumab had diametrically opposite effects on dynamic MRI of tumor vasculature in rat brain tumor models. Targeting av-integrins increased tumor vascular permeability and blood volume, whereas bevacizumab decreased both measures. These findings have implications for chemotherapy delivery and antitumor efficacy. C1 [Muldoon, Leslie L.; Gahramanov, Seymur; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Muldoon, Leslie L.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA. [Li, Xin] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Med Informat, Portland, OR 97239 USA. [Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Clin Epidemiol, Portland, OR 97239 USA. [Marshall, Deborah J.] Ortho Biotech Oncol R&D, Radnor, PA USA. [Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU Centocor Research and Development Inc.; NIH [NS053468, CA137488, NS44687] FX This study was supported by a sponsored research agreement from Centocor Research and Development Inc., and NIH grants NS053468, CA137488, and NS44687 to E.A.N. NR 42 TC 17 Z9 17 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JAN PY 2011 VL 13 IS 1 BP 51 EP 60 DI 10.1093/neuonc/noq150 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 708KQ UT WOS:000286361100005 PM 21123368 ER PT J AU Goebel, M Stengel, A Wang, LX Reeve, J Tache, Y AF Goebel, Miriam Stengel, Andreas Wang, Lixin Reeve, Joseph, Jr. Tache, Yvette TI Lipopolysaccharide Increases Plasma Levels of Corticotropin-Releasing Hormone in Rats SO NEUROENDOCRINOLOGY LA English DT Article DE Adrenocorticotropic hormone; Blood; Colon; Gastric emptying; Lipopolysaccharide; RAPID method ID PITUITARY-ADRENAL AXIS; CRF-BINDING-PROTEIN; ARGININE-VASOPRESSIN; MESSENGER-RNA; IMMUNOREACTIVE NEURONS; PERIPHERAL-BLOOD; MOLECULAR-FORMS; T-LYMPHOCYTES; ACTH; CORTICOSTERONE AB Background: Corticotropin-releasing hormone (CRH) is expressed in the brain, immune cells and the gut, where gene expression is upregulated by lipopolysaccharide (LPS) 6 h after injection. Whether these changes are reflected by increased circulating levels of CRH and adrenocorticotropic hormone (ACTH) is unknown. Methods: LPS (100 mu g/kg) was injected intraperitoneally in conscious rats, and blood processed for CRH using the new RAPID (reduced temperatures, acidification, protease inhibition, isotopic exogenous controls and dilution) method compared with EDTA blood with or without plasma methanol extraction. Hormone levels were measured by commercial radioimmunoassay. Results: The RAPID method improved blood recovery of I-125-CRH in vitro compared to EDTA only added to the blood without or with methanol extraction (90.8 +/- 2.0 vs. 66.9 +/- 2.6 and 47.5 +/- 2.0%, respectively; p < 0.001 vs. RAPID). Basal CRH levels from blood processed by the RAPID method were 28.9 +/- 2.8 pg/ml, and by other methods below the radioimmunoassay detection limit (< 10 pg/ml). At 6 h after LPS, CRH plasma levels increased significantly by 2.9 times, and in the proximal colon tended to decrease (-27.6 +/- 5.7%; p > 0.05), while circulating levels were unchanged at 3 or 4 h. ACTH levels rose compared to control rats (135.3 +/- 13.8 vs. 101.4 +/- 6.0 pg/ml; p < 0.05) 30 min after the increase in CRH, while at 3 or 6 h after LPS, the levels were not changed. Conclusion: intraperitoneal LPS induces a delayed rise in plasma CRH levels associated with an elevation in ACTH plasma levels 30 min later, suggesting that under conditions of immune challenge, CRH of peripheral origin may also contribute to pituitary activation, as detected using the RAPID method of blood processing, which improves CRH recovery. Copyright (C) 2010 S. Karger AG, Basel C1 [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med,CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [GO 1718/1-1, STE 1765/1-1]; Department of Veterans Affairs; NIHDK [57238]; [DK-41301] FX This study was supported by German Research Foundation fellowship grants GO 1718/1-1 (M.G.) and STE 1765/1-1 (A.S.), the VA Research Career Scientist Award, a Department of Veterans Affairs Merit Award (Y.T.), NIHDK 57238 (Y.T.) and Center grant DK-41301 (Animal Core, Y.T.; Peptidomic RIA Proteomic Core, J.R. Jr.). We are grateful to Mrs. Honghui Liang for her excellent technical support and Ms. Eugenia Hu for reviewing the manuscript. NR 57 TC 10 Z9 10 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2011 VL 93 IS 3 BP 165 EP 173 DI 10.1159/000322590 PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 747RU UT WOS:000289337900005 PM 21135542 ER PT J AU La Fountaine, MF Wecht, JM Cirnigliaro, CM Kirshblum, SC Spungen, AM Bauman, WA AF La Fountaine, Michael F. Wecht, Jill M. Cirnigliaro, Christopher M. Kirshblum, Steven C. Spungen, Ann M. Bauman, William A. TI QT/RR Coherence Is Associated with Testosterone Levels in Men with Chronic Spinal Cord Injury SO NEUROENDOCRINOLOGY LA English DT Article DE Spinal cord injury; Hypogonadism; Testosterone; QT interval; Autonomic nervous system ID HEART-RATE-VARIABILITY; VENTRICULAR REPOLARIZATION; QT INTERVAL; AUTONOMIC FUNCTION; SPECTRAL-ANALYSIS; FAILURE; CARDIOMYOPATHY; REFRACTORINESS; ABNORMALITIES; DYSFUNCTION AB Aim: To evaluate the effect of hypogonadism on temporal characteristics of ventricular repolarization (VR) and QT/RR coherence in men with spinal cord injury (SCI). Methods: Thirty-four men with SCI (> 1 year postinjury) were studied. After clinical evaluation, 20 subjects were diagnosed as hypogonadal and 14 as eugonadal. QT and RT time, heart rate (HR), and Bazett QTc were determined from a digital electrocardiogram during quiet rest and a cold pressor test (CPT). QT/RR coherence was calculated across three spectral frequencies including mean (Mean Coh; 0-0.2 Hz), low (LF Coh; 0.04-0.15 Hz) and high (HF Coh; 0.15-0.40 Hz). Respiration was collected via impedance pneumography. Results: No statistical differences were observed among demographics. Pairwise comparisons demonstrated a significantly reduced Mean Coh at rest in the hypogonadal group compared to the eugonadal; during the CPT, the hypogonadal group had significantly elevated Mean and HF Coh. No group main effects were observed with analysis of variance. Condition main effects were observed in QT, Mean, LF and HF Coh. Significant group-condition interactions were present in Mean and HF Coh, while trends toward significance were observed on LF Coh, HR, QT and RT. Post-hoc pairwise comparisons revealed that the change from rest to CPT in Mean, LF and HF Coh was significant in the eugonadal group, but not the hypogonadal. Conclusion: Hypogonadism in SCI appears to adversely affect temporal VR characteristics independently of QTc. QT/RR coherence suggests an autonomic synergism with testosterone. These findings may represent a pathologic sequelae that precedes the well-documented hypogonadic effects on QTc. Copyright (C) 2011 S. Karger AG, Basel C1 [La Fountaine, Michael F.; Wecht, Jill M.; Cirnigliaro, Christopher M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, VA RR & D Ctr Excellence Med Consequences Spinal, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [La Fountaine, Michael F.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP La Fountaine, MF (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov FU Veteran Affairs Rehabilitation Research and Development Service [B4162C, B3600R]; James J. Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (#B4162C, #B3600R) and the James J. Peters VA Medical Center. NR 35 TC 2 Z9 2 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2011 VL 93 IS 3 BP 174 EP 180 DI 10.1159/000323773 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 747RU UT WOS:000289337900006 PM 21252493 ER PT J AU Sung, VW Johnson, N Granstaff, US Jones, WJ Meschia, JF Williams, LS Safford, MM AF Sung, Victor W. Johnson, Natasha Granstaff, U. Shanette Jones, William J. Meschia, James F. Williams, Linda S. Safford, Monika M. TI Sensitivity and Specificity of Stroke Symptom Questions to Detect Stroke or Transient Ischemic Attack SO NEUROEPIDEMIOLOGY LA English DT Article DE Stroke assessment; Transient ischemic attack; Stroke symptoms; Screening questionnaire ID PREVALENCE; POPULATION; VALIDATION; RECORDS; WOMEN AB Background/Aims: Undiagnosed stroke is a major public health problem. The Questionnaire for Verifying Stroke-Free Status (QVSS) includes eight items and was originally designed to detect stroke-free individuals. Its six symptom-related questions could potentially be used to screen for undiagnosed stroke or transient ischemic attack (TIA), but the sensitivity and specificity of just the six symptom-related questions are unknown. Methods: A research assistant administered the QVSS to outpatients from Veterans Administration stroke and general medicine clinics. Neurologists, blinded to QVSS scores, interviewed and examined all subjects to determine stroke status. Responses to the six symptom questions of the QVSS were compared against the neurologist-determined stroke/TIA status. Results: The sensitivity of the individual symptom questions ranged from 0.22 to 0.60, and the specificity ranged from 0.79 to 0.95. The sensitivity of any of the six symptom questions was 0.82, and the specificity was 0.62. Conclusion: The six symptom-related questions of the QVSS demonstrate a high sensitivity and moderate specificity for the diagnosis of stroke or TIA compared with neurological exam. Though these findings should be validated in a more representative general population, these questions have potential for meeting the public health objective of detecting clinically unrecognized but symptomatic stroke. Copyright (C) 2011 S. Karger AG, Basel C1 [Sung, Victor W.; Johnson, Natasha; Granstaff, U. Shanette] Univ Alabama Birmingham, Birmingham Vet Adm Med Ctr, Birmingham, AL USA. [Johnson, Natasha] Univ Alabama Birmingham, Dept Neurol, Div Prevent Med, Birmingham, AL 35294 USA. [Safford, Monika M.] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Jones, William J.] Univ Colorado Denver, Dept Neurol, Aurora, CO USA. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Regenstrief Inst, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA. RP Sung, VW (reprint author), Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. EM victor.sung@va.gov OI Sung, Victor/0000-0003-1024-3404 FU Veterans Administration National Quality Scholars fellowship; [R01 HL080477-01A1A] FX This study was supported by a Veterans Administration National Quality Scholars fellowship grant (Dr. Sung). Dr. Safford was supported by R01 HL080477-01A1A. NR 16 TC 13 Z9 14 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 EI 1423-0208 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2011 VL 36 IS 2 BP 100 EP 104 DI 10.1159/000323951 PG 5 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 747RS UT WOS:000289337700006 PM 21311197 ER PT J AU Dahodwala, N Karlawish, J Siderowf, A Duda, JE Mandell, DS AF Dahodwala, Nabila Karlawish, Jason Siderowf, Andrew Duda, John E. Mandell, David S. TI Delayed Parkinson's Disease Diagnosis among African-Americans: The Role of Reporting of Disability SO NEUROEPIDEMIOLOGY LA English DT Article DE African-American; Delay; Diagnosis; Health services; Parkinsonism; Race ID OLDER-ADULTS; PREVALENCE; POPULATION; DISPARITIES; AWARENESS; DEFICITS; SECTION; CARE AB Background/Aims: Racial differences in the observed prevalence of Parkinson's disease (PD) may be due to delayed diagnosis among African-Americans. We sought to compare the stage at which African-American and white PD patients present for healthcare, and determine whether perception of disability accounts for racial differences. Methods: Using records of veterans with newly diagnosed PD at the Philadelphia Veterans Affairs Medical Center, we calculated differences in reporting of symptoms as the difference in z-scores on the Unified Parkinson Disease Rating Scale part 2 (disability) and part 3 (motor impairment). Ordinal logistic regression was used to determine predictors of stage at diagnosis. Results: African-American (n = 16) and white (n = 58) veterans with a mean age of 70.1 years were identified. African-Americans presented at a later PD stage than whites (median Hoehn + Yahr stage 2.5 vs. 2.0, p = 0.02) and were more likely to under-report disability relative to motor impairment (81 vs. 40%, p < 0.01). Multivariate analysis showed that under-reporting of disability accounted for much of the effect of race on stage of diagnosis. Conclusions: Under-reporting of disability among African-Americans may account for later stages of PD diagnosis than whites. This study begins to explain the mechanisms underlying observed racial disparities in PD. Copyright (C) 2011 S. Karger AG, Basel C1 [Dahodwala, Nabila; Siderowf, Andrew; Duda, John E.] Univ Penn, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Dahodwala, Nabila; Karlawish, Jason; Siderowf, Andrew; Mandell, David S.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Dahodwala, Nabila; Siderowf, Andrew; Duda, John E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Mandell, David S.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Dahodwala, N (reprint author), Parkinsons Dis & Movement Disorders Ctr, 330 S 9th St,2nd Floor, Philadelphia, PA 19107 USA. EM dahodwan@mail.med.upenn.edu RI Mandell, David/H-2730-2012 OI Mandell, David/0000-0001-8240-820X FU Philadelphia VAMC Parkinson's Disease Research, Education and Clinical Center; NIH [K23 AG034236] FX This study was funded by a Pilot Project Award from the Philadelphia VAMC Parkinson's Disease Research, Education and Clinical Center. N.D. is supported by NIH grant K23 AG034236. NR 21 TC 1 Z9 1 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0251-5350 J9 NEUROEPIDEMIOLOGY JI Neuroepidemiology PY 2011 VL 36 IS 3 BP 150 EP 154 DI 10.1159/000324935 PG 5 WC Public, Environmental & Occupational Health; Clinical Neurology SC Public, Environmental & Occupational Health; Neurosciences & Neurology GA 769OB UT WOS:000291024800003 PM 21508648 ER PT J AU Peskind, ER Petrie, EC Cross, DJ Pagulayan, K McCraw, K Hoff, D Hart, K Yu, CE Raskind, MA Cook, DG Minoshima, S AF Peskind, Elaine R. Petrie, Eric C. Cross, Donna J. Pagulayan, Kathleen McCraw, Kathleen Hoff, David Hart, Kim Yu, Chang-En Raskind, Murray A. Cook, David G. Minoshima, Satoshi TI Cerebrocerebellar hypometabolism associated with repetitive blast exposure mild traumatic brain injury in 12 Iraq war Veterans with persistent post-concussive symptoms SO NEUROIMAGE LA English DT Article DE Positron emission tomography; Mild traumatic brain injury; Post-concussive symptoms; Cerebellum; Blast; Veterans; Cognition ID POSTTRAUMATIC-STRESS-DISORDER; CEREBRAL GLUCOSE-METABOLISM; APOLIPOPROTEIN-E; VALIDATION; CEREBELLUM; VALIDITY; IMAGES; SCALE; PTSD; CARE AB Disagreement exists regarding the extent to which persistent post-concussive symptoms (PCS) reported by Iraq combat Veterans with repeated episodes of mild traumatic brain injury (mTBI) from explosive blasts represent structural or functional brain damage or an epiphenomenon of comorbid depression or posttraumatic stress disorder (PTSD). Objective assessment of brain function in this population may clarify the issue. To this end, twelve Iraq war Veterans (32.0 +/- 8.5 [mean +/- standard deviation (SD)] years of age) reporting one or more blast exposures meeting American Congress of Rehabilitation Medicine criteria for mTBI and persistent PCS and 12 cognitively normal community volunteers (53.0 +/- 4.6 years of age) without history of head trauma underwent brain fluorodeoxyglucose positron emission tomography (FDG-PET) and neuropsychological assessments and completed PCS and psychiatric symptom rating scales. Compared to controls, Veterans with mTBI (with or without PTSD) exhibited decreased cerebral metabolic rate of glucose in the cerebellum, vermis, pons, and medial temporal lobe. They also exhibited subtle impairments in verbal fluency, cognitive processing speed, attention, and working memory, similar to those reported in the literature for patients with cerebellar lesions. These FDG-PET imaging findings suggest that regional brain hypometabolism may constitute a neurobiological substrate for chronic PCS in Iraq combat Veterans with repetitive blast-trauma mTBI. Given the potential public health implications of these findings, further investigation of brain function in these Veterans appears warranted. Published by Elsevier Inc. C1 [Peskind, Elaine R.; Petrie, Eric C.; Pagulayan, Kathleen; McCraw, Kathleen; Hoff, David; Hart, Kim; Raskind, Murray A.] Vet Affairs Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr MIR, Seattle, WA 98108 USA. [Yu, Chang-En; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [Peskind, Elaine R.; Petrie, Eric C.; Pagulayan, Kathleen; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cross, Donna J.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Yu, Chang-En; Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Peskind, ER (reprint author), Vet Affairs Puget Sound Hlth Care Syst, NW Network Mental Illness Res Educ & Clin Ctr MIR, Mail Code S-116-MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM peskind@uw.edu RI Schueter, nicos/A-3625-2014 FU Northwest Network Mental Illness, Research, Education, and Clinical Center (MIRECC); Office of Research and Development Medical Research Service, Department of Veterans Affairs; National Institutes of Health [P50 AG05136, K08 AG023670, R01 NS045254] FX This material is based upon work supported, in part, by the Northwest Network Mental Illness, Research, Education, and Clinical Center (MIRECC) and Office of Research and Development Medical Research Service, Department of Veterans Affairs; by grants P50 AG05136, K08 AG023670, and R01 NS045254 from the National Institutes of Health; and by a grant from an anonymous foundation. NR 47 TC 100 Z9 102 U1 7 U2 21 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JAN PY 2011 VL 54 SU 1 BP S76 EP S82 DI 10.1016/j.neuroimage.2010.04.008 PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 813ZF UT WOS:000294408600011 PM 20385245 ER PT J AU Arciniegas, DB Kellermeyer, GF Bonifer, NM Anderson-Salvi, KM Anderson, CA AF Arciniegas, David B. Kellermeyer, Gregory F. Bonifer, Nancy M. Anderson-Salvi, Kristin M. Anderson, C. Alan TI Screening for cognitive decline following single known stroke using the Mini-Mental State Examination SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Article DE stroke; Mini-Mental State Examination; cognitive decline; Fugl-Meyer evaluation; motor impairment ID MODERATE VASCULAR DEMENTIA; INDUCED MOVEMENT THERAPY; ALZHEIMERS-DISEASE; CEREBROVASCULAR-DISEASE; POSTSTROKE DEMENTIA; 1ST-EVER STROKE; CLINICAL DETERMINANTS; IMPAIRMENT; RECOVERY; BRAIN AB Background: Progressive cognitive decline develops in a nontrivial minority of stroke survivors. Although commonly used to identify cognitive decline in older stroke survivors, the usefulness of the Mini-Mental State Examination (MMSE) as a screening tool for post-stroke cognitive decline across a wider range of ages is not well established. This study therefore investigated the usefulness of the MMSE for this purpose. Methods: Twenty-seven subjects, aged 18-82 years, with a single known remote stroke were assessed using the MMSE. The frequency of cognitive impairment was determined by comparison of MMSE scores with population-based norms. Relationships between cognitive performance, motor impairments, age, gender, handedness, stroke laterality, and time since stroke also were explored. Results: Age-adjusted MMSE scores identified mild cognitive impairment in 22.2% and moderate-to-severe cognitive impairment in 7.4% of subjects. Raw and age-adjusted MMSE scores were inversely correlated with time since stroke, but not with other patient or stroke characteristics. Conclusion: A relationship between time since single known stroke and MMSE performance was observed in this study. The proportion of subjects identified as cognitively impaired in this group by Z-transformation of MMSE scores using previously published normative data for this measure comports well with the rates of late post-stroke cognitive impairment reported by other investigators. These findings suggest that the MMSE, when normatively interpreted, may identify cognitive decline in the late period following single known stroke. Additionally, the lack of a relationship between MMSE and Fugl-Meyer scores suggests that the severity of post-stroke motor impairments is unlikely to serve as a clinically useful indicator of the need for cognitive assessment. A larger study of stroke survivors is needed to inform more fully on the usefulness of normatively interpreted MMSE scores as a method of screening for post-stroke cognitive decline. C1 [Arciniegas, David B.; Kellermeyer, Gregory F.; Bonifer, Nancy M.; Anderson-Salvi, Kristin M.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. [Arciniegas, David B.; Kellermeyer, Gregory F.; Anderson, C. Alan] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Neuropsychiat Serv, Denver, CO 80262 USA. [Arciniegas, David B.; Anderson, C. Alan] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Behav Neurol Sect, Denver, CO 80262 USA. [Anderson, C. Alan] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. RP Arciniegas, DB (reprint author), UCD Neurobehav Disorders Program, 13001 E 17th Pl, Aurora, CO 80045 USA. EM david.arciniegas@ucdenver.edu FU Spalding Community Foundation; HealthONE Alliance; HealthONE Spalding Rehabilitation Hospital, Aurora, CO FX The authors gratefully acknowledge the support provided for this study by the Spalding Community Foundation, the HealthONE Alliance, and HealthONE Spalding Rehabilitation Hospital, Aurora, CO. NR 61 TC 6 Z9 6 U1 3 U2 11 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6328 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2011 VL 7 BP 189 EP 196 DI 10.2147/NDT.S17886 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 821DN UT WOS:000294955100021 PM 21573080 ER PT J AU Schultz, BA Cifu, DX McNamee, S Nichols, M Carne, W AF Schultz, Billie A. Cifu, David X. McNamee, Shane Nichols, Michelle Carne, William TI Assessment and treatment of common persistent sequelae following blast induced mild traumatic brain injury SO NEUROREHABILITATION LA English DT Article DE Blast injury; polytrauma; rehabilitation ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; COGNITIVE REHABILITATION; POSTCONCUSSIVE SYMPTOMS; BEHAVIORAL TREATMENT; CLINICAL MANAGEMENT; SERVICE MEMBERS; EYE INJURIES; SLEEP; IRAQ AB The ongoing wars in Iraq and Afghanistan and terrorist activity worldwide have been associated with an increased incidence of blast injuries. While blast injuries share similarities with blunt or penetrating traumatic injuries, there are unique mechanistic elements of blast injury that create increased vulnerability to damage of specific organs. This review highlights the mechanism of blast-related injury, describes the common sequelae of blast exposure that may impact rehabilitation care, and summarizes the intervention strategies for these blast-related sequelae. C1 [Schultz, Billie A.; McNamee, Shane] Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. [Schultz, Billie A.; Cifu, David X.; McNamee, Shane; Nichols, Michelle; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. [Nichols, Michelle; Carne, William] Henry M Jackson Fdn, Hunter Holmes McGuire Vet Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA. [Cifu, David X.] US Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA. RP Schultz, BA (reprint author), Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. EM schultz.billie@mayo.edu OI Nichols, Michelle/0000-0002-2078-9649 NR 101 TC 18 Z9 18 U1 1 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2011 VL 28 IS 4 BP 309 EP 320 DI 10.3233/NRE-2011-0659 PG 12 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 795VL UT WOS:000293004900001 PM 21725164 ER PT J AU Scremin, OU Chialvo, DR Lavarello, S Berra, HH Lucero, MA AF Scremin, Oscar U. Chialvo, Dante R. Lavarello, Simona Berra, Hector H. Lucero, Miguel A. TI The environmental pollutant endosulfan disrupts cerebral cortical function at low doses SO NEUROTOXICOLOGY LA English DT Article DE Organochlorine insecticides; Epilepsy; GABA-A receptors; Electroencephalogram; Evoked potentials; Cerebral cortex; Endosulfan ID SOMATOSENSORY-EVOKED-POTENTIALS; PERSISTENT ORGANIC POLLUTANTS; ORGANOCHLORINE PESTICIDES; CHLORIDE CHANNELS; IMMUNE-RESPONSES; SEMIARID MIDWEST; EXPOSURE; CORTEX; RATS; GABA(A) AB Endosulfan can induce convulsions that could lead to brain damage. The variability and lack of specificity of neurological signs and symptoms in the pre-convulsive stages makes early diagnosis difficult. We sought to determine if electrophysiological exploration of the cerebral cortex could yield objective signs of endosulfan intoxication at levels that do not elicit convulsions. Endosulfan was administered intravenously to Sprague-Dawley adult rats under urethane anesthesia at doses from 0.5 to 4 mg/kg. EEG power and the evoked potentials (EP) to forepaw electrical stimulation were studied over the contralateral (S1CL) and homolateral (S1HL) cortical somatosensory areas and the contralateral visual area (V1CL). At each area, five EP waves were measured. Arterial blood pressure, heart rate and body temperature were also recorded. Endosulfan induced a dose-related increase in EPs at all sites. At S1CL, EP peak amplitude was greater than baseline at 1, 2 and 4 mg/kg for the first negative, second positive and third negative waves, and at 2 and 4 mg/kg for the first and third positive waves. Similar but less marked trends were observed at S1HL and V1CL. A shift of EEG power to higher frequencies (alpha and beta EEG bands) was only present at 4 mg/kg. In conclusion, endosulfan induced a large increase of cortical evoked potentials amplitudes at doses that did not elicit convulsions. These responses could be used as a non-invasive diagnostic tool to detect low-level endosulfan intoxication in humans and to help establish the NOAEL and LOAEL levels of this pollutant. Published by Elsevier Inc. C1 [Scremin, Oscar U.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Scremin, Oscar U.; Chialvo, Dante R.; Lavarello, Simona; Berra, Hector H.; Lucero, Miguel A.] UNR, Fac Ciencias Med, Inst Toxicol Agr Rosario, RA-3100 Rosario, Santa Fe, Argentina. [Scremin, Oscar U.; Chialvo, Dante R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Scremin, Oscar U.; Chialvo, Dante R.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina. RP Scremin, OU (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM oscremin@ucla.edu RI Chialvo, Dante/A-4658-2009 OI Chialvo, Dante/0000-0002-1038-3637 FU Capacitacion e Investigacion para la Medicina Argentina-Asociacion Civil FX This work was supported by funds and equipment donations from Capacitacion e Investigacion para la Medicina Argentina-Asociacion Civil, a non-profit academic organization. NR 61 TC 6 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PD JAN PY 2011 VL 32 IS 1 BP 31 EP 37 DI 10.1016/j.neuro.2010.12.001 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 716VW UT WOS:000287002600004 PM 21144862 ER PT J AU Anger, JT Nissim, HA Le, TX Smith, AL Lee, U Sarkisian, C Litwin, MS Raz, S Rodriguez, LV Maliski, SL AF Anger, Jennifer T. Nissim, Helen A. Le, Thuy X. Smith, Ariana L. Lee, Una Sarkisian, Catherine Litwin, Mark S. Raz, Shlomo Rodriguez, Larissa V. Maliski, Sally L. TI Women's Experience With Severe Overactive Bladder Symptoms and Treatment: Insight Revealed From Patient Focus Groups SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE focus groups; grounded theory; qualitative research; urinary incontinence ID QUALITY-OF-LIFE; QUESTIONNAIRE; DISEASE; BLAME; CARE AB Aims: Research has focused on treatment of overactive bladder (OAB) symptoms in women with the goal of cure. The objective of this study was to assess women's perceptions of their OAB symptoms, treatment experience, and outcomes by conducting patient focus groups. Methods: Women seen in our academic center female urology referral clinics were identified by ICD-9 codes for OAB symptoms and recruited to participate in one of five focus groups, totaling 33 patients. Non-clinician moderators conducted the focus group sessions incorporating topics related to patients' perceptions of OAB symptoms, treatments, and outcomes. Data analysis was performed using grounded theory methodology. Results: Qualitative analysis yielded several preliminary themes: impact of OAB on quality of life, strategies to control wetness, medications and side effects, and triggers. The majority of focus group participants reported only a partial response to medication and other physician-recommended treatments for OAB. Therefore, they developed self-reliant personalized strategies to improve their quality of life. These strategies included fluid restriction, preventive toileting, and, most importantly, the use of incontinence pads. Conclusions: The majority of the women who participated in the focus groups reported only a partial response to medical and other treatments for OAB. As a result, they developed personalized self-management strategies to improve their quality of life. Although most studies addressing the treatment of OAB aim at curing the condition, such a strategy may be unrealistic. Applying a chronic care model that uses a patient-centered symptom-management approach to OAB may optimize patient outcomes and improve quality of life. Neurourol. Urodynam. 30:1295-1299, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Anger, Jennifer T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Anger, Jennifer T.; Le, Thuy X.; Smith, Ariana L.; Lee, Una; Litwin, Mark S.; Raz, Shlomo; Rodriguez, Larissa V.] UCLA Dept Urol, Los Angeles, CA USA. [Le, Thuy X.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Sarkisian, Catherine] UCLA Dept Med & Geriatr, Los Angeles, CA USA. [Sarkisian, Catherine] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Litwin, Mark S.] UCLA Sch Publ Hlth, Los Angeles, CA USA. [Maliski, Sally L.] UCLA Sch Nursing, Los Angeles, CA USA. RP Anger, JT (reprint author), Cedars Sinai Med Ctr Urol Reconstruct, 99 La Cienega Blvd,Suite 307, Beverly Hills, CA 90211 USA. EM janger@mednet.ucla.edu FU NIDDK [1 K23 DK080227-01]; National Institute on Aging [1 T35 AG 026736] FX Grant sponsor: NIDDK; Grant number: 1 K23 DK080227-01 (JTA); Grant sponsor: National Institute on Aging Medical Student Training in Aging Research Program (MSTAR); Grant number: 1 T35 AG 026736. NR 17 TC 18 Z9 18 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2011 VL 30 IS 7 BP 1295 EP 1299 DI 10.1002/nau.21004 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 818CQ UT WOS:000294727800019 PM 21538495 ER PT J AU Asgari, MM White, E Warton, EM Hararah, MK Friedman, GD Chren, MM AF Asgari, Maryam M. White, Emily Warton, E. Margaret Hararah, Mohammad K. Friedman, Gary D. Chren, Mary-Margaret TI Association of Tea Consumption and Cutaneous Squamous Cell Carcinoma SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID SKIN AB Laboratory and epidemiologic studies suggest a protective effect of tea consumption on risk of cutaneous squamous cell carcinoma (SCC). We designed a case-control study to examine the association between putative protective exposures, including tea consumption, and SCC risk using a large health maintenance organization population. Cases (n = 415) were defined as Kaiser Permanente Northern California (KPNC) members with a pathology-verified SCC in 2004 and controls (n = 415) were age-, gender-, and race-matched members with no previous history of skin cancer. Tea consumption and SCC risk factors were ascertained by questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression to estimate the association of SCC with regular use, as well as dose and duration of tea consumption. Risk factor adjusted models included education, smoking, hair and eye color, skin type, family history of skin cancer, and history of freckling, sunburns, sun exposure, and tanning bed use. Adjusted analyses showed no reduction in SCC risk with regular consumption of tea (OR = 1.11, 95% CI: 0.81-1.54). Examining duration, dose, and combined duration and dose exposure variables did not alter findings. We found no evidence that tea consumption was associated with cutaneous SCC risk. C1 [Asgari, Maryam M.; Warton, E. Margaret; Hararah, Mohammad K.; Friedman, Gary D.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [White, Emily] Univ Washington, Dept Epidemiol, Med Ctr, Seattle, WA 98195 USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. [Friedman, Gary D.] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program REAP, San Francisco, CA USA. RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM maryam.m.asgari@kp.org RI Asgari, Maryam/O-4947-2016 FU National Institute of Arthritis Musculoskeletal and Skin Diseases [K23 AR 051037, K24 AR 052667]; National Cancer Institute [R01 CA 098838] FX The work was done at Kaiser Permanente Northern California, Division of Research, Oakland, California, USA. This study was supported by the National Institute of Arthritis Musculoskeletal and Skin Diseases (K23 AR 051037 to MA, K24 AR 052667 to MC) and by the National Cancer Institute (R01 CA 098838 to GF). NR 8 TC 7 Z9 7 U1 1 U2 5 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 2011 VL 63 IS 2 BP 314 EP 318 AR PII 932401769 DI 10.1080/01635581.2011.523496 PG 5 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA 723ET UT WOS:000287489900019 PM 21240832 ER PT J AU Duszak, RS Duszak, R AF Duszak, Robert S. Duszak, Richard, Jr. TI Malpractice payments by optometrists: An analysis of the national practitioner databank over 18 years SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION LA English DT Article DE National Practitioner Data Bank; Optometrist malpractice; Optometrist prescriptive authority ID MEDICAL MALPRACTICE; PHYSICIANS AB PURPOSE: The aim of this analysis was to describe characteristics and trends of malpractice payments by optometrists since the inception of the National Provider Data Bank (NPDB) as they assumed increasing prescriptive authority. METHODS: NPDB data files were analyzed for details of optometrist malpractice payments from 1991 through 2008. Payment amounts, sources, and allegations were all identified and summarized, along with geographic and demographic data. RESULTS: Between 1991 and 2008, a total of 609 optometrist malpractice payments were reported nationally, ranging from $50 to $2,050,000 (median, $57,500; mean, $156,055 +/- 246,556), with 603 (99%) less than $1,000,000. Annual inflation-adjusted mean dollars and frequency of payments increased only nominally over the 18-year interval, from $154,573 to $155,151, and 30 to 40, respectively. More than half of all cases originated in 11 states. Alleged errors in diagnosis accounted for 55% of all cases. CONCLUSION: Malpractice payments on behalf of optometrists are relatively infrequent (on average, less than 34 nationally each year) and usually relatively small (almost half less than $50,000). The frequency of payments and mean payments have increased little over the last 2 decades. Optometry 2011;82:32-37 C1 [Duszak, Robert S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Duszak, Richard, Jr.] Mid S Imaging & Therapeut, Memphis, TN USA. [Duszak, Richard, Jr.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. RP Duszak, RS (reprint author), Philadelphia Vet Affairs Med Ctr, 3800 Woodland Ave, Philadelphia, PA 19104 USA. EM bduszak@mac.com RI Duszak, Richard/L-1811-2016 OI Duszak, Richard/0000-0003-0425-3008 NR 27 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-1839 J9 OPTOMETRY JI Optometry PD JAN PY 2011 VL 82 IS 1 BP 32 EP 37 DI 10.1016/j.optm.2010.05.009 PG 6 WC Ophthalmology SC Ophthalmology GA 778MM UT WOS:000291708400007 PM 20656562 ER PT J AU Caplan, L Hines, AE Williams, E Prochazka, AV Saag, KG Cunningham, F Hutt, E AF Caplan, L. Hines, A. E. Williams, E. Prochazka, A. V. Saag, K. G. Cunningham, F. Hutt, E. TI An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Adverse effects; Glucocorticoids; Osteoporosis; Prevention ID CORTICOSTEROID-INDUCED OSTEOPOROSIS; CHRONIC KIDNEY-DISEASE; PRACTICE PATTERNS; HEALTH-CARE; ORAL CORTICOSTEROIDS; FRACTURE RISK; ELDERLY-WOMEN; BONE-DENSITY; PREVENTION; GUIDELINES AB We applied regression techniques to a large cohort of patients to understand why certain patients are prescribed medications to prevent glucocorticoid-induced osteoporosis (GIO). Rates of prescriptions to prevent osteoporosis were low. The presence of drugs and disorders associated with osteoporosis and gastrointestinal conditions actually are associated with a decreased likelihood of receiving osteoporosis-preventing medications. To understand why some patients are prescribed medications to prevent GIO while other patients are not, we examined whether there is an association among osteoporosis-inducing medical conditions or medications and prescriptions for osteoporosis prophylaxis in a large cohort of rheumatoid arthritis patients on chronic glucocorticoids. Department of Veterans' Affairs national administrative databases were used to construct a cohort (n = 9,605) and provide the data for this study. Multivariate logistic regression was performed to determine medical conditions and medications associated with dispensing of GIO-preventive medications, controlling for sociodemographic variables, comorbidities, glucocorticoid dosage, prior fractures, and rheumatoid arthritis severity. A subanalysis examined predictors of early GIO prevention. Subjects were more likely to receive GIO prophylaxis if they were older, African American, treated with multiple antirheumatic disease-modifying drugs, or received greater glucocorticoid exposure. The prescription of certain drug classes (loop diuretics and anticonvulsants) and conditions (malignancy, renal insufficiency, alcohol abuse, and hepatic disease) were associated with lower likelihood of GIO prophylaxis, despite putative links between these agents/conditions and osteoporosis. The presence of gastrointestinal disorders dramatically decreased likelihood of GIO prophylaxis. Few characteristics predicted the dispensing of GIO-preventing medications within 7 days of the initial glucocorticoid start date. Rates of prescriptions to prevent osteoporosis in a cohort of older men with rheumatoid arthritis on chronic glucocorticoids were low. Gastrointestinal disorders and drugs and disorders potentially linked to osteoporosis are associated with diminished odds of being prescribed GIO-preventing medications. C1 [Caplan, L.] Univ Colorado, Denver, CO 80045 USA. [Caplan, L.; Hines, A. E.; Williams, E.; Prochazka, A. V.; Hutt, E.] Denver VA Med Ctr, Denver, CO 80220 USA. [Caplan, L.; Prochazka, A. V.; Hutt, E.] Univ Colorado, Sch Med, Denver, CO 80045 USA. [Saag, K. G.] Univ Alabama, Ctr Educ & Res Therapeut Musculoskeletal Disorder, Birmingham, AL 35294 USA. [Saag, K. G.] Univ Alabama, Sch Med, Birmingham, AL USA. [Cunningham, F.] Vet Affairs Pharm Benefits Management, Hines, IL 60141 USA. RP Caplan, L (reprint author), Univ Colorado, POB 6511,B115, Denver, CO 80045 USA. EM liron.caplan@ucdenver.edu FU VA Health Services Research and Development service; VA HSR&D Career Development Award FX This project was supported by funding from the VA Health Services Research and Development service. Dr. Caplan is supported by a VA HSR&D Career Development Award. NR 52 TC 9 Z9 9 U1 0 U2 6 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD JAN PY 2011 VL 22 IS 1 BP 305 EP 315 DI 10.1007/s00198-010-1201-x PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 703TC UT WOS:000286003200037 PM 20358362 ER PT J AU Borckardt, JJ Reeves, ST Frohman, H Madan, A Jensen, MP Patterson, D Barth, K Smith, AR Gracely, R George, MS AF Borckardt, Jeffrey J. Reeves, Scott T. Frohman, Heather Madan, Alok Jensen, Mark P. Patterson, David Barth, Kelly Smith, A. Richard Gracely, Richard George, Mark S. TI Fast left prefrontal rTMS acutely suppresses analgesic effects of perceived controllability on the emotional component of pain experience SO PAIN LA English DT Article DE TMS; Pain; Transcranial magnetic stimulation; Control; Prefrontal cortex ID TRANSCRANIAL MAGNETIC STIMULATION; CHRONIC NEUROPATHIC PAIN; DORSAL RAPHE NUCLEUS; MOTOR CORTEX RTMS; STRESSOR CONTROLLABILITY; LEARNED HELPLESSNESS; CORTICAL STIMULATION; PLACEBO; DEPRESSION; RELIEF AB The prefrontal cortex may be a promising target for transcranial magnetic stimulation (TMS) in the management of pain. It is not clear how prefrontal TMS affects pain perception, but previous findings suggest that ventral lateral and medial prefrontal circuits may comprise an important part of a circuit of perceived controllability regarding pain, stress, and learned helplessness. Although the left dorsolateral prefrontal cortex is a common TMS target for treating clinical depression as well as modulating pain, little is known about whether TMS over this area may affect perceived controllability. The present study explored the immediate effects of fast TMS over the left dorsolateral prefrontal cortex on the analgesic effects of perceived pain controllability. Twenty-four healthy volunteers underwent a laboratory pain task designed to manipulate perception of pain controllability. Real TMS, compared with sham, suppressed the analgesic benefits of perceived control on the emotional dimension of pain, but not the sensory/discriminatory dimension. Findings suggest that, at least acutely, fast TMS over the left dorsolateral prefrontal cortex may interrupt the perceived-controllability effect on the emotional dimension of pain experience. Although it is not clear whether this cortical area is directly involved with modulating perceived controllability or whether downstream effects are responsible for the present findings, it appears possible that left dorsolateral prefrontal TMS may produce analgesic effects by acting through a cortical perceived-control circuit regulating limbic and brainstem areas of the pain circuit. (C) 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Borckardt, Jeffrey J.; Madan, Alok; Barth, Kelly; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Borckardt, Jeffrey J.; Reeves, Scott T.; Frohman, Heather; Smith, A. Richard] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29425 USA. [Jensen, Mark P.; Patterson, David] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [George, Mark S.] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. [Gracely, Richard] Univ N Carolina, Sch Dent, Dept Endodont, Ctr Neurosensory Disorders, Chapel Hill, NC USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Borckardt, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. EM borckard@musc.edu OI Frohman, Heather/0000-0001-5199-7654 FU National Institutes Health (NINDS, NINR, NIDA); South Carolina Translational Research Program; American Society for Gastrointestinal Endoscopy; Obesity Society (Covidien); National Institute for Neurological Disorders and Stroke; NIH; Glaxo-Smith Kline; Jazz Pharmaceuticals; Brainsway; Cephos; Force Protection; NIAMS; NIGMS; NIHCD; NIAMS at NIH; NINDS at NIH FX Dr. Borckardt receives funding from the National Institutes Health (NINDS, NINR, NIDA), the South Carolina Translational Research Program, The American Society for Gastrointestinal Endoscopy, and The Obesity Society (Covidien). The present study was funded by the National Institute for Neurological Disorders and Stroke. Dr. George reports research grants in the past 5 years from NIH, Glaxo-Smith Kline, Jazz Pharmaceuticals, Brainsway, Cephos, and Force Protection. He has been an unpaid advisor to Brainsonix, Brainsway, Neuronetics, Neostim and Neosync (as they make products related to TMS), and a paid advisor to Jazz, Cyberonics, Neuropace, and Puretech ventures. The full amount of his advisory income has never been more than 10% of his university salary. MUSC has 2 patent applications in Dr. George's name on combining TMS with MRI imaging. Dr. Patterson receives funding from NIAMS and NIGMS, Dr. Jensen receives funding from NIHCD, and Dr. Gracely receives funding from NIAMS and NINDS at NIH. NR 54 TC 18 Z9 18 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JAN PY 2011 VL 152 IS 1 BP 182 EP 187 DI 10.1016/j.pain.2010.10.018 PG 6 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 695ZD UT WOS:000285410800029 PM 21122992 ER PT J AU Nicolaidis, C Chianello, T Gerrity, M AF Nicolaidis, Christina Chianello, Terry Gerrity, Martha TI Development and Preliminary Psychometric Testing of the Centrality of Pain Scale SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Quality of Life; Health Function ID PATIENT HEALTH QUESTIONNAIRE; IMMPACT RECOMMENDATIONS; CLINICAL-TRIALS; PRIME-MD; VALIDATION; VALIDITY; RELIABILITY; DEPRESSION; SEVERITY; UTILITY AB Objective. The objective of the study was to develop and begin to evaluate a new measure of the centrality of pain in patients' lives. Design. The study was designed as a cross-sectional survey and cognitive interviews. Setting. The study was set in an academic general internal medicine clinic. Patients. Sixty-five adult internal medicine patients with chronic nonmalignant pain (CNMP) participated in the study. Outcome Measures. We assessed content validity and clarity of the 10-item Centrality of Pain Scale (COPS) by soliciting feedback from chronic pain experts and by conducting cognitive interviews with patients with CNMP. We assessed internal consistency reliability using Cronbach's alpha. We assessed construct validity by comparing the COPS with other measures of chronic pain morbidity including pain severity, depression, anxiety, physical and mental health function, posttraumatic stress disorder, quality of life, and provider assessment. Results. Health care providers felt the COPS had excellent face validity. Cognitive interviews revealed that patients' understanding of the items matched the intended construct, the scale measured an important concept, and items were easy to understand. The COPS had excellent internal consistency (alpha = 0.9). It was negatively associated with age (r = -0.29; P = 0.02), but not with other demographic characteristics. Higher COPS scores were associated with poorer physical (r = -0.48; P < 0.001) and mental (r = -0.39; P = 0.002) health function, quality of life (r = -0.36; P = 0.004), and provider assessment of stability (r = -0.38; P = 0.004) as well as with greater pain grade (r = 0.55; P < 0.001), and depression (r = 0.63; P < 0.001). In multivariate analyses, age, physical and mental health function, and depression were independently associated with COPS. Conclusions. The COPS has excellent internal consistency and construct validity. Additional studies are needed to further validate the scale. C1 [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Dept Med, Portland, OR 97239 USA. [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Chianello, Terry] Portland State Univ, Sch Social Work, Portland, OR 97207 USA. [Gerrity, Martha] Portland VA Med Ctr, Portland, OR USA. RP Nicolaidis, C (reprint author), Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Dept Med, L475,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM nicolaid@ohsu.edu FU Oregon Health & Science University Division of General Internal Medicine and Geriatrics; National Institute of Mental Health [K23MH073008] FX This study was funded by the Oregon Health & Science University Division of General Internal Medicine and Geriatrics. The study would not have been possible without the support of Judith L. Bowen, MD, who was serving as the Division Chief at the time the study was being conducted. We would like to thank Ruth Liebowitz, PhD, for help in conceptualizing the Centrality of Pain Scale and the members of the Society of General Internal Medicine Chronic Pain Interest Group, Erik Fromme, MD, MPH, and Ben Morasco, PhD, for reviewing early versions of the scale. We wish to thank medical assistants Cecilia Aflleje, Hope Roach, and Tony Thao for their help in incorporating the study into a busy clinical practice. We would also like to acknowledge Ana Hilde, MPH, and Angie Mejia, MSW, for administrative support. Dr Nicolaidis' time was supported, in part, via a career development award from the National Institute of Mental Health (K23MH073008). NR 20 TC 4 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 4 BP 612 EP 617 DI 10.1111/j.1526-4637.2011.01072.x PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 751OX UT WOS:000289628500008 PM 21392248 ER PT J AU Reid, MC Bennett, DA Chen, WG Eldadah, BA Farrar, JT Ferrell, B Gallagher, RM Hanlon, JT Herr, K Horn, SD Inturrisi, CE Lemtouni, S Lin, YW Michaud, K Morrison, RS Neogi, T Porter, LL Solomon, DH Von Korff, M Weiss, K Witter, J Zacharoff, KL AF Reid, M. Cary Bennett, David A. Chen, Wen G. Eldadah, Basil A. Farrar, John T. Ferrell, Bruce Gallagher, Rollin M. Hanlon, Joseph T. Herr, Keela Horn, Susan D. Inturrisi, Charles E. Lemtouni, Salma Lin, Yu Woody Michaud, Kaleb Morrison, R. Sean Neogi, Tuhina Porter, Linda L. Solomon, Daniel H. Von Korff, Michael Weiss, Karen Witter, James Zacharoff, Kevin L. TI Improving the Pharmacologic Management of Pain in Older Adults: Identifying the Research Gaps and Methods to Address Them SO PAIN MEDICINE LA English DT Review DE Analgesic Use; Chronic Noncancer Pain; Older Adults ID CHRONIC NONCANCER PAIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OBSTRUCTIVE PULMONARY-DISEASE; PERSISTENT NONMALIGNANT PAIN; NURSING-HOME RESIDENTS; NATIONAL-DATA-BANK; MUSCULOSKELETAL PAIN; UNITED-STATES; COGNITIVE IMPAIRMENT; RHEUMATIC-DISEASES AB Objective. There has been a growing recognition of the need for better pharmacologic management of chronic pain among older adults. To address this need, the National Institutes of Health Pain Consortium sponsored an "Expert Panel Discussion on the Pharmacological Management of Chronic Pain in Older Adults" conference in September 2010 to identify research gaps and strategies to address them. Specific emphasis was placed on ascertaining gaps regarding use of opioid and nonsteroidal anti-inflammatory medications because of continued uncertainties regarding their risks and benefits. Design. Eighteen panel members provided oral presentations; each was followed by a multidisciplinary panel discussion. Meeting transcripts and panelists' slide presentations were reviewed to identify the gaps and the types of studies and research methods panelists suggested could best address them. Results. Fifteen gaps were identified in the areas of treatment (e.g., uncertainty regarding the long-term safety and efficacy of commonly prescribed analgesics), epidemiology (e.g., lack of knowledge regarding the course of common pain syndromes), and implementation (e.g., limited understanding of optimal strategies to translate evidence-based pain treatments into practice). Analyses of data from electronic health care databases, observational cohort studies, and ongoing cohort studies (augmented with pain and other relevant outcomes measures) were felt to be practical methods for building an age-appropriate evidence base to improve the pharmacologic management of pain in later life. Conclusion. Addressing the gaps presented in the current report was judged by the panel to have substantial potential to improve the health and wellbeing of older adults with chronic pain. C1 [Reid, M. Cary] Weill Cornell Med Ctr, Div Geriatr & Gerontol, New York, NY 10065 USA. [Bennett, David A.] Rush Univ, Med Ctr, Dept Neurol Sci, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Chen, Wen G.] NIA, Behav & Syst Neurosci Branch, Div Neurosci, Bethesda, MD 20892 USA. [Eldadah, Basil A.] NIA, Div Geriatr & Clin Gerontol, Bethesda, MD 20892 USA. [Farrar, John T.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA. [Farrar, John T.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Ferrell, Bruce] UCLA Sch Med, Div Geriatr, Los Angeles, CA USA. Univ Penn, Sch Med, Philadelphia VA Med Ctr, Penn Pain Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA USA. [Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Herr, Keela] Univ Iowa, Coll Nursing, John A Hartford Ctr Geriatr Nursing Excellence, Iowa City, IA 52242 USA. [Horn, Susan D.] Inst Clin Outcomes Res, Salt Lake City, UT USA. [Inturrisi, Charles E.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA. [Lemtouni, Salma; Weiss, Karen] US FDA, Ctr Drug Evaluat & Res, Washington, DC 20204 USA. [Lin, Yu Woody] Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, Bethesda, MD USA. [Michaud, Kaleb] Univ Nebraska Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Neogi, Tuhina] Boston Univ, Sch Med, Sect Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA. [Neogi, Tuhina] Boston Univ, Sch Med, Rheumatol Sect, Boston, MA 02118 USA. [Porter, Linda L.] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA. [Solomon, Daniel H.] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Sch Med, Boston, MA 02115 USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA. [Von Korff, Michael] Ctr Hlth Studies Grp Hlth Cooperat, Seattle, WA USA. [Witter, James] NIAMSD, Div Skin & Rheumat Dis, Bethesda, MD 20892 USA. [Zacharoff, Kevin L.] Inflexxion Inc, Newton, MA USA. RP Reid, MC (reprint author), Weill Cornell Med Ctr, Div Geriatr & Gerontol, 525 E 68th St,Box 39, New York, NY 10065 USA. EM mcr2004@med.cornell.edu RI Inturrisi, Charles/E-7365-2013 OI Reid, Cary/0000-0001-8117-662X; Neogi, Tuhina/0000-0002-9515-1711 FU Edward R. Roybal Center for Translational Research on Aging, NIA [P30 AG22845]; NIA [P30AG10161, R01AG15819, R01AG17917, P30AG028741, K24AG022345, R01AG030141, R01AG034181]; National Center for Research Resources [UL1RR024134]; National Institute of Aging [P30AG024827, T32AG021885, K07AG033174, R01AG034056, R56AG027017, U01AG012553]; National Institute of Mental Health [R34MH082682]; National Institute of Nursing [R01NR010135]; AHRQ [R01HS017695, R01HS018721, K12HS019461]; VA Health Services [IIR-06-062]; National Cancer Institute [R01CA115363]; National Institute of Nursing Research [T32NR011147]; NIDA [RC2DA028928, R01DA022557]; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [RC1AR058601, K23AR055127, K24AR055989] FX The authors would like to acknowledge the participation of all the conference attendees, who are listed in Appendix A. Dr. Reid was supported by an Edward R. Roybal Center for Translational Research on Aging Award (P30 AG22845) provided by the NIA. Dr. Bennett was supported by NIA grants P30AG10161, R01AG15819, and R01AG17917. Dr. Farrar was supported by a grant from the National Center for Research Resources (UL1RR024134). Dr. Hanlon was supported by National Institute of Aging grants (P30AG024827, T32AG021885, K07AG033174, R01AG034056, R56AG027017, U01AG012553), a National Institute of Mental Health grant (R34MH082682), a National Institute of Nursing Research grant (R01NR010135), AHRQ grants (R01HS017695, R01HS018721, K12HS019461), and a VA Health Services Research grant (IIR-06-062). Dr. Herr was supported by grants from the National Cancer Institute (R01CA115363) and National Institute of Nursing Research (T32NR011147). Drs. Horn and Inturrisi were supported by American Recovery and Reinvestment Act (ARRA) grant RC2DA028928 from NIDA. Dr. Michaud was supported by an ARRA grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (RC1AR058601). Dr. Neogi was supported by a grant from the NIAMS (K23AR055127). Dr. Morrison was supported by grants from the NIA (P30AG028741, K24AG022345, and R01AG030141). Dr. Solomon was supported by a grant from the NIAMS (K24AR055989). Dr. Von Korff was supported by grants from the NIDA (R01DA022557) and the NIA (R01AG034181). NR 106 TC 37 Z9 38 U1 7 U2 19 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 9 BP 1336 EP 1357 DI 10.1111/j.1526-4637.2011.01211.x PG 22 WC Medicine, General & Internal SC General & Internal Medicine GA 822MJ UT WOS:000295051500009 PM 21834914 ER PT J AU Lange, G Janal, MN Maniker, A FitzGibbons, J Fobler, M Cook, D Natelson, BH AF Lange, Gudrun Janal, Malvin N. Maniker, Allen FitzGibbons, Jennifer Fobler, Malusha Cook, Dane Natelson, Benjamin H. TI Safety and Efficacy of Vagus Nerve Stimulation in Fibromyalgia: A Phase I/II Proof of Concept Trial SO PAIN MEDICINE LA English DT Article DE Fibromyalgia; Chronic Pain; Neurology ID DOUBLE-BLIND; MULTICENTER; SURGERY AB Objective. We performed an open-label Phase I/II trial to evaluate the safety and tolerability of vagus nerve stimulation (VNS) in patients with treatment-resistant fibromyalgia (FM) as well as to determine preliminary measures of efficacy in these patients. Methods. Of 14 patients implanted with the VNS stimulator, 12 patients completed the initial 3-month study of VNS; 11 patients returned for follow-up visits 5, 8, and 11 months after start of stimulation. Therapeutic efficacy was assessed with a composite measure requiring improvement in pain, overall wellness, and physical function. Loss of both pain and tenderness criteria for the diagnosis of FM was added as a secondary outcome measure because of results found at the end of 3 months of stimulation. Results. Side effects were similar to those reported in patients treated with VNS for epilepsy or depression and, in addition, dry mouth and fatigue were reported. Two patients did not tolerate stimulation. At 3 months, five patients had attained efficacy criteria; of these, two patients no longer met widespread pain or tenderness criteria for the diagnosis of FM. The therapeutic effect seemed to increase over time in that additional participants attained both criteria at 11 months. Conclusions. Side effects and tolerability were similar to those found in disorders currently treated with VNS. Preliminary outcome measures suggested that VNS may be a useful adjunct treatment for FM patients resistant to conventional therapeutic management, but further research is required to better understand its actual role in the treatment of FM. C1 [Natelson, Benjamin H.] Beth Israel Deaconess Med Ctr, Pain & Fatigue Study Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA. [Maniker, Allen] Beth Israel Deaconess Med Ctr, Dept Neurosurg, New York, NY 10003 USA. [Lange, Gudrun; FitzGibbons, Jennifer; Fobler, Malusha] UMDNJ New Jersey Med Sch, Dept Radiol, Newark, NJ USA. [Janal, Malvin N.] UMDNJ New Jersey Med Sch, Dept Psychiat, Newark, NJ USA. [Natelson, Benjamin H.] UMDNJ New Jersey Med Sch, Dept Neurosci, Newark, NJ USA. [Lange, Gudrun; FitzGibbons, Jennifer; Fobler, Malusha] New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA. [Janal, Malvin N.] NYU, Coll Dent, Dept Epidemiol & Hlth Promot, New York, NY USA. [Cook, Dane] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. [Cook, Dane] Univ Wisconsin, Dept Kinesiol, Madison, WI USA. RP Natelson, BH (reprint author), Beth Israel Deaconess Med Ctr, Pain & Fatigue Study Ctr, Dept Pain Med & Palliat Care, 10 Union Sq E, New York, NY 10003 USA. EM bnatelson@bethisraelny.org FU National Institutes of Health [AR-053732] FX This work was supported by National Institutes of Health # AR-053732. A patent application for the use of VNS in FM is pending for author Gudrun Lange under US Patent Application no. 12/322,741. We thank Dr. Daniel Clauw, a physician expert in FM and FM treatment trials and Dr. Sandra Helmers, an expert in the use of VNS in epilepsy for their help in various aspects of this study. We acknowledge the help of Dr. Adam Perlman in patient recruitment and medical decision making and the help of Ms. Kristin Thorsen, editor of the Fibromyalgia Network News, for publicizing the existence of this clinical "proof of concept" trial to the FM community at large and thus aiding in recruitment of participants. NR 19 TC 11 Z9 11 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 9 BP 1406 EP 1413 DI 10.1111/j.1526-4637.2011.01203.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 822MJ UT WOS:000295051500015 PM 21812908 ER PT J AU Corson, K Doak, MN Denneson, L Crutchfield, M Soleck, G Dickinson, KC Gerrity, MS Dobscha, SK AF Corson, Kathryn Doak, Melanie N. Denneson, Lauren Crutchfield, Megan Soleck, Geoffrey Dickinson, Kathryn C. Gerrity, Martha S. Dobscha, Steven K. TI Primary Care Clinician Adherence to Guidelines for the Management of Chronic Musculoskeletal Pain: Results from the Study of the Effectiveness of a Collaborative Approach to Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Pain Management; Quality of Healthcare; Randomized Controlled Trial ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; 5TH VITAL SIGN; MORRIS DISABILITY QUESTIONNAIRE; GENERAL-PRACTICE; IMPLEMENTATION STRATEGIES; PATIENT OUTCOMES; SCREENING-TEST; UNITED-STATES; DEPRESSION AB Objective. We assessed primary care clinician-provided guideline-concordant care as documented in patients' medical records, predictors of documented guideline-concordant care, and its association with pain-related functioning. Patients were participants in a randomized trial of collaborative care for chronic musculoskeletal pain. The intervention featured patient and primary care clinician education, symptom monitoring and feedback to clinicians by the intervention team. Methods. To assess concordance with the evidence-based treatment guidelines upon which our intervention was based, we developed an 8-item chart review tool, the Pain Process Checklist (PPC). We then reviewed electronic medical records for 365 veteran patients treated by 42 primary care clinicians over 12 months. Intervention status, demographic, and clinical variables were tested as predictors of PPC scores using generalized estimating equations (GEE). GEE was also used to test whether PPC scores predicted treatment response (>= 30% decrease in Roland-Morris Disability Questionnaire score). Results. Rates of documented guideline-concordant care varied widely among PPC items, from 94% of patients having pain addressed to 17% of patients on opioids having side effects addressed. Intervention status was unrelated to item scores, and PPC-7 totals did not differ significantly between intervention and treatment-as-usual patients (61.2%, standard error [SE] = 3.3% vs 55.2%, SE = 2.6%, P = 0.15). In a multivariate model, higher PPC-7 scores were associated with receiving a prescription for opioids (odds ratio [OR] = 1.07, P = 0.007) and lower PPC-7 scores with patient age (10-year difference OR = 0.97, P = 0.004). Finally, intervention patients who received quantitative pain and depression assessments were less likely to respond to treatment (assessed vs not: 18% vs 33%, P = 0.008, and 13% vs 28%, P = 0.001, respectively). Conclusions. As measured by medical record review, additional training and clinician feedback did not increase provision of documented guideline-concordant pain care, and adherence to guidelines by primary care clinicians did not improve clinical outcomes for patients with chronic musculoskeletal pain. C1 [Corson, Kathryn; Denneson, Lauren; Crutchfield, Megan; Soleck, Geoffrey; Dickinson, Kathryn C.; Gerrity, Martha S.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron, Portland, OR 97207 USA. [Corson, Kathryn; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Doak, Melanie N.; Gerrity, Martha S.] Portland VA Med Ctr, Primary Care Div, Portland, OR 97207 USA. RP Corson, K (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron, POB 1034,P3 DEP PC, Portland, OR 97207 USA. EM kathryn.corson@va.gov RI Duncan, Kirsty/H-1911-2011 FU Oregon Clinical and Translational Research Institute; National Center for Research Resources [UL1RR024140 01]; VA Primary Care Division; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [PMI 03-195, RCD04129] FX The authors gratefully acknowledge the assistance of Jean O'Malley MPH for consultation on statistical analyses made possible through support from the Oregon Clinical and Translational Research Institute, grant number UL1RR024140 01 from the National Center for Research Resources. We also thank Kurt Kroenke MD and Mark Sullivan MD PhD who helped to refine our intervention and measurement approaches, and the VA Primary Care Division clinicians for their participation and support.; The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects PMI 03-195 and RCD04129. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 73 TC 14 Z9 14 U1 1 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 10 BP 1490 EP 1501 DI 10.1111/j.1526-4637.2011.01231.x PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 839FA UT WOS:000296349600007 PM 21943325 ER PT J AU Macey, TA Morasco, BJ Duckart, JP Dobscha, SK AF Macey, Tara A. Morasco, Benjamin J. Duckart, Jonathan P. Dobscha, Steven K. TI Patterns and Correlates of Prescription Opioid Use in OEF/OIF Veterans with Chronic Noncancer Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Opioids; Veteran; Pain/Drug Therapy ID OPERATIONS ENDURING FREEDOM; MENTAL-HEALTH DISORDERS; MUSCULOSKELETAL PAIN; IRAQI FREEDOM; ASSOCIATION; AFGHANISTAN; MANAGEMENT; SYMPTOMS; INJURIES; EXPOSURE AB Objectives. Little is known about the treatment Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans receive for chronic noncancer pain (CNCP). We sought to describe the prevalence of prescription opioid use, types, and doses of opioids received and to identify correlates of receiving prescription opioids for CNCP among OEF/OIF veterans. Design. Retrospective review of Veterans Affairs (VA) administrative data. Setting. Ambulatory clinics within a VA regional health care network. Patients. OEF/OIF veterans who had at least three elevated pain screening scores within a 12-month period in 2008. Within this group, those prescribed opioids (N = 485) over the next 12 months were compared with those not prescribed opioids (N = 277). In addition, patients receiving opioids short term (<90 days, N = 284) were compared with patients receiving them long term (>= 90 consecutive days, N = 201). Results. Of 762 OEF/OIF veterans with CNCP, 64% were prescribed at least one opioid medication over the 12 months following their index dates. Of those prescribed an opioid, 59% were prescribed opioids short term and 41% were prescribed opioids long term. The average morphine-equivalent opioid dose for short-term users was 23.7 mg (standard deviation [SD] = 20.5) compared with 40.8 mg (SD = 36.1) for long-term users (P < 0.001). Fifty-one percent of long-term opioid users were prescribed short-acting opioids only, and one-third were also prescribed sedative hypnotics. In adjusted analyses, diagnoses of low back pain, migraine headache, posttraumatic stress disorder, and nicotine use disorder were associated with an increased likelihood of receiving an opioid prescription. Conclusion. Prescription opioid use is common among OEF/OIF veterans with CNCP and is associated with several pain diagnoses and medical conditions. C1 [Macey, Tara A.; Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Macey, Tara A.; Duckart, Jonathan P.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron, Portland, OR USA. [Macey, Tara A.; Duckart, Jonathan P.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr P3 MHADM, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM steven.dobscha@va.gov FU Portland VA Medical Center; National Institute on Drug Abuse [K23DA023467]; VA Health Services Research and Development service [REA 06-174]; Oregon Clinical and Translational Research Institute; National Institutes of Health [Ul1RR024140] FX We appreciate comments from Teresa Hudson, Pharm D., on a prior draft of this manuscript. This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center. This study was supported in part by award K23DA023467 from the National Institute on Drug Abuse to Dr. Morasco. Jonathan Duckart, MPS, was supported by a Research Enhancement Award Program grant (REA 06-174) from the VA Health Services Research and Development service. The authors appreciate the statistical support provided from the Oregon Clinical and Translational Research Institute, grant number Ul1RR024140 from the National Institutes of Health. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. No author reports having any potential conflict of interest with this study. NR 36 TC 21 Z9 21 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 10 BP 1502 EP 1509 DI 10.1111/j.1526-4637.2011.01226.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 839FA UT WOS:000296349600008 PM 21899715 ER PT J AU Marcum, ZA Perera, S Donohue, JM Boudreau, RM Newman, AB Ruby, CM Studenski, SA Kwoh, CK Simonsick, EM Bauer, DC Satterfield, S Hanlon, JT AF Marcum, Zachary A. Perera, Subashan Donohue, Julie M. Boudreau, Robert M. Newman, Anne B. Ruby, Christine M. Studenski, Stephanie A. Kwoh, C. Kent Simonsick, Eleanor M. Bauer, Doug C. Satterfield, Suzanne Hanlon, Joseph T. CA Hlth Aging & Body Composition Stud TI Analgesic Use for Knee and Hip Osteoarthritis in Community-Dwelling Elders SO PAIN MEDICINE LA English DT Article DE Aged; Analgesic; Osteoarthritis ID CARDIOVASCULAR-DISEASE INDICATORS; OLDER-ADULTS; BODY-COMPOSITION; HEALTH ABC; PAIN; CARE; RECOMMENDATIONS; MANAGEMENT; PERFORMANCE; ARTHRITIS AB Objective. To examine the prevalence and correlates of non-opioid and opioid analgesic use and descriptively evaluate potential undertreatment in a sample of community-dwelling elders with symptomatic knee and/or hip osteoarthritis (OA). Design. Cross-sectional. Setting. Health, Aging, and Body Composition Study. Patients. Six hundred and fifty-two participants attending the year 6 visit (2002-03) with symptomatic knee and/or hip OA. Outcome Measures. Analgesic use was defined as taking >= 1 non-opioid and/or >= 1 opioid receptor agonist. Non-opioid and opioid doses were standardized across all agents by dividing the daily dose used by the minimum effective analgesic daily dose. Inadequate pain control was defined as severe/extreme OA pain in the past 30 days from a modified Western Ontario and McMaster Universities Osteoarthritis Index. Results. Just over half (51.4%) reported taking at least one non-opioid analgesic and approximately 10% was taking an opioid, most (88.5%) of whom also took a non-opioid. One in five participants (19.3%) had inadequate pain control, 39% of whom were using <1 standardized daily dose of either a non-opioid or opioid analgesic. In adjusted analyses, severe/extreme OA pain was significantly associated with both non-opioid (adjusted odds ratio [AOR] = 2.44; 95% confidence interval [95% CI] = 1.49-3.99) and opioid (AOR = 2.64; 95% CI = 1.26-5.53) use. Conclusions. Although older adults with severe/extreme knee and/or hip OA pain are more likely to take analgesics than those with less severe pain, a sizable proportion takes less than therapeutic doses and thus may be undertreated. Further research is needed to examine barriers to optimal analgesic use. C1 [Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Med Geriatr, Pittsburgh, PA 15213 USA. [Kwoh, C. Kent] Univ Pittsburgh, Sch Med, Dept Med Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA. [Perera, Subashan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Boudreau, Robert M.; Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Studenski, Stephanie A.; Kwoh, C. Kent; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Studenski, Stephanie A.; Kwoh, C. Kent; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Bauer, Doug C.] Univ Calif San Francisco, Sch Med, Dept Med Gen Internal Med, San Francisco, CA USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu RI ; Perera, Subashan/D-7603-2014; Newman, Anne/C-6408-2013 OI Boudreau, Robert/0000-0003-0162-5187; Donohue, Julie/0000-0003-2418-6017; Newman, Anne/0000-0002-0106-1150 FU National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695]; VA Health Services [IIR-06-062]; NIH, National Institute on Aging FX This study was primarily supported by National Institute on Aging grants and contracts (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056, N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), an Agency for Healthcare Research and Quality grant (R01 HS017695), and a VA Health Services Research grant (IIR-06-062). This research was also supported in part by the Intramural Research program of the NIH, National Institute on Aging. The authors would like to thank Yihuang Kang and Yan Zheng for their assistance with data programming. NR 35 TC 12 Z9 12 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2011 VL 12 IS 11 BP 1628 EP 1636 DI 10.1111/j.1526-4637.2011.01249.x PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 854PO UT WOS:000297506900009 PM 21992521 ER PT J AU Alexandre, M Pandol, SJ Gorelick, FS Thrower, EC AF Alexandre, Martine Pandol, Stephen J. Gorelick, Fred S. Thrower, Edwin C. TI The Emerging Role of Smoking in the Development of Pancreatitis SO PANCREATOLOGY LA English DT Review DE Acute and chronic pancreatitis; Zymogen activation; Cellular injury; Nicotine; NNK; Tobacco smoking ID CIGARETTE-SMOKING; RISK-FACTOR; NICOTINE EXPOSURE; TOBACCO; ADENOCARCINOMA; LUNG; RATS; CELL; INHALATION; ALCOHOL AB Background/Aims: Cigarette smoking has been linked to many diseases, including pancreatic cancer and more recently, pancreatitis. Methods: Electronic searches of primarily PubMed from 1990 to August 2011 were conducted and only articles published in English were reviewed. Original articles and reviews were selected based on screening of article abstracts and their relevance to tobacco smoking, its components, nicotine and its metabolites, and their effects particularly on the pancreas. Results: Smoking may affect the risk of developing chronic pancreatitis or its progression. Smoking may also affect the risk for developing acute pancreatitis. Its effects in pancreatitis appear to be dose dependent and its effects may be alcohol independent but synergize with alcohol. Conclusion: Specific constituents of cigarette smoke, including nicotine and its metabolites, could mediate effects on the pancreas. Copyright (C) 2011 S. Karger AG, Basel and IAP C1 [Alexandre, Martine; Gorelick, Fred S.; Thrower, Edwin C.] Yale Univ, Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA. [Gorelick, Fred S.] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA. [Alexandre, Martine; Gorelick, Fred S.; Thrower, Edwin C.] Vet Adm Connecticut Healthcare, West Haven, CT USA. [Pandol, Stephen J.] Vet Affairs Greater Los Angeles Hlth Care Syst, So Calif Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. [Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Thrower, EC (reprint author), VA Healthcare Syst Connecticut, GI Res Lab, Bldg 4,950 Campbell Ave, West Haven, CT 06516 USA. EM edwin.thrower@yale.edu FU National Institutes of Health [RO1 DK54021]; Veterans Administration Merit; Senior Career Development Award; Department of Veterans Affairs; National Institutes of Health/NIAAA Southern California Research Center for Alcoholic Liver and Pancreatic Diseases [P60 AA11999]; National Institutes of Health/NCCAM UCLA Center for Excellence in Pancreatic Diseases [P01AT003960-01] FX The authors would like to acknowledge the following funding sources: National Institutes of Health Grant RO1 (DK54021 to F.S.G.), Veterans Administration Merit and Senior Career Development Award (to F.S.G.), National Institutes of Health Grant R21 (DK69702 to E.C.T.) and National Institutes of Health Grant RO1 supplement (DK54021 supplement to M.A.), Department of Veterans Affairs (to S.J.P.), National Institutes of Health/NIAAA Southern California Research Center for Alcoholic Liver and Pancreatic Diseases (P60 AA11999 to S.J.P.), National Institutes of Health/NCCAM UCLA Center for Excellence in Pancreatic Diseases (P01AT003960-01 to S.J.P.). The authors would like to thank Asad Khan for useful suggestions concerning the manuscript. NR 36 TC 30 Z9 30 U1 2 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2011 VL 11 IS 5 BP 469 EP 474 DI 10.1159/000332196 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 872ZU UT WOS:000298850900003 PM 21986098 ER PT J AU Khalid, A Dewitt, J Ohori, NP Chen, JH Fasanella, KE Sanders, M McGrath, KM Nikiforova, M AF Khalid, Asif Dewitt, John Ohori, N. Paul Chen, Jey-Hsin Fasanella, Kenneth E. Sanders, Michael McGrath, Kevin M. Nikiforova, Marina TI EUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer SO PANCREATOLOGY LA English DT Article DE Pancreatic cancer; Autoimmune pancreatitis; Endoscopic ultrasound; K-ras ID FINE-NEEDLE-ASPIRATION; GUIDED TRUCUT BIOPSY; DIAGNOSIS AB Background/Aims: Autoimmune pancreatitis (AIP) may mimic pancreatic cancer (PC). The detection of DNA mutations in endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) material may improve discrimination between AIP and PC and is the context for this study. Methods: In a retrospective study, archived EUS-FNA material from patients with AIP and PC at two centers was analyzed for KRAS mutations and loss-of-heterozygosity analysis involving 18 microsatellite markers. KRAS status and the fractional allelic loss (number of affected microsatellites divided by informative ones) were compared for AIP and PC. Results: Thirty-two patients with 33 samples were studied. There were 16 patients with AIP (17 samples) and 16 patients with PC. DNA amplification failed in 7 samples. Of 25 patients (26 samples), 14 had AIP (7 male, age 57 +/- 17 years; mean +/- SD) and 11 had PC (7 male, age 65 +/- 14 years; mean +/- SD). Cytology results for AIP were inflammatory = 3, inconclusive = 10, suspicious for malignancy = 2 and for PC were malignant = 5, suspicious for malignancy = 4 and inconclusive = 2, respectively. KRAS mutation was detected in none of the AIP cases and 10/11 PC cases (91%, Pearson chi(2) = 22.16, p < 0.001) or 10/16 PC cases (63%) accounting for PC cases with failed DNA amplification. Mean (+/- SD) fractional allelic loss for the AIP cases (0.16 +/- 0.15) was not significantly different from the PC cases (0.26 +/- 0.19). Conclusions: A KRAS mutation in EUS/FNA material from a pancreatic mass is associated with malignancy and may help discriminate from benign conditions such as AIP. Copyright (C) 2011 S. Karger AG, Basel and IAP C1 [Khalid, Asif; Ohori, N. Paul; Fasanella, Kenneth E.; Sanders, Michael; McGrath, Kevin M.; Nikiforova, Marina] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Khalid, Asif] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Dewitt, John; Chen, Jey-Hsin] Indiana Univ, Med Ctr, Indianapolis, IN USA. RP Khalid, A (reprint author), Div Gastroenterol, M2,PUH 200 Lothrop St, Pittsburgh, PA 15213 USA. EM khalida@upmc.edu RI Fasanella, Kenneth/I-2781-2012 NR 17 TC 10 Z9 12 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PY 2011 VL 11 IS 5 BP 482 EP 486 DI 10.1159/000331505 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 872ZU UT WOS:000298850900005 PM 21997479 ER PT B AU Weintraub, D Hoops, S AF Weintraub, Daniel Hoops, Staci BE Olanow, CW Stocchi, F Lang, AE TI Anxiety Syndromes and Panic Attacks SO PARKINSON'S DISEASE: NON-MOTOR AND NON-DOPAMINERGIC FEATURES LA English DT Article; Book Chapter ID DEEP BRAIN-STIMULATION; OBSESSIVE-COMPULSIVE SYMPTOMS; PARKINSONS-DISEASE PATIENTS; PSYCHIATRIC-SYMPTOMS; SUBTHALAMIC NUCLEUS; PERSONALITY-TRAITS; SOCIAL PHOBIA; RATING-SCALES; DOUBLE-BLIND; DEPRESSION C1 [Weintraub, Daniel; Hoops, Staci] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. NR 62 TC 1 Z9 1 U1 1 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-4443-9795-6; 978-1-4051-9185-2 PY 2011 BP 193 EP 201 D2 10.1002/9781444397970 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA BA6JM UT WOS:000337162400018 ER PT B AU Duda, JE Stern, MB AF Duda, John E. Stern, Matthew B. BE Olanow, CW Stocchi, F Lang, AE TI Olfactory Dysfunction SO PARKINSON'S DISEASE: NON-MOTOR AND NON-DOPAMINERGIC FEATURES LA English DT Article; Book Chapter ID IDIOPATHIC PARKINSONS-DISEASE; SMELL IDENTIFICATION TEST; SNIFF MAGNITUDE TEST; ODOR IDENTIFICATION; LEWY BODIES; NEURODEGENERATIVE DISEASE; BODY PATHOLOGY; DE-NOVO; DIAGNOSIS; BULB C1 [Duda, John E.; Stern, Matthew B.] Univ Penn, Sch Med, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA. [Duda, John E.; Stern, Matthew B.] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Duda, John E.; Stern, Matthew B.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. RP Duda, JE (reprint author), Univ Penn, Sch Med, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA. NR 84 TC 1 Z9 1 U1 0 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-4443-9795-6; 978-1-4051-9185-2 PY 2011 BP 304 EP 314 D2 10.1002/9781444397970 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA BA6JM UT WOS:000337162400028 ER PT J AU Thompson, AW Liu, HH Hays, RD Katon, WJ Rausch, R Diaz, N Jacob, EL Vassar, SD Vickrey, BG AF Thompson, Alexander W. Liu, Honghu Hays, Ron D. Katon, Wayne J. Rausch, Rebecca Diaz, Natalie Jacob, Erin L. Vassar, Stefanie D. Vickrey, Barbara G. TI Diagnostic accuracy and agreement across three depression assessment measures for Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE SCID; PHQ-9; GDS; Geriatric Depression Scale; Patient Health Questionnaire-9 ID SCALE; VALIDITY; SYMPTOMS AB Purpose: To assess diagnostic accuracy of two self-administered depression measures compared to an interviewer-administered measure in subjects with Parkinson's disease (PD), and to analyze clinical and sociodemographic factors associated with disagreement among the three depression assessment tools. Methods: We assessed 214 PD subjects using the Patient Health Questionnaire-9 (PHQ-9), the Geriatric Depression Scale-15 (GDS-15), and the Structured Clinical Interview for the DSM-IV depression module (SCID). Diagnostic accuracy of the PHQ-9 and GDS-15 compared to the SCID was evaluated. Multivariate logistic regression was conducted to analyze factors associated with measure disagreement. We compared item agreement between the PHQ-9 and SCID to test the hypothesis that there would be less agreement between items assessing depression symptoms overlapping with common PD symptoms, compared to items having minimal overlap with PD manifestations. Results: Compared to SCID diagnosis of major depression, PHQ-9 sensitivity is 50% and specificity is 93%; GDS-15 sensitivity is 43% and specificity is 96%. The GDS-15 has 85% sensitivity and 79% specificity and the PHQ-9 has 54% sensitivity and 85% specificity compared to SCID diagnosis of minor or major depression. The PHQ-9 and SCID show more agreement on items unrelated to PD manifestations. Pain was the only factor associated with disagreement between the SCID and PHQ-9. Conclusion: Compared to the PHQ-9, the GDS-15 had higher sensitivity and similar positive predictive value, suggesting it is a superior screening tool in clinical applications for PD. On future depression screening or diagnostic instruments, consideration should be given to excluding depression items overlapping with PD manifestations. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Thompson, Alexander W.] Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, Dept Psychiat, Temple, TX 76508 USA. [Liu, Honghu] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Liu, Honghu; Hays, Ron D.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. [Liu, Honghu; Hays, Ron D.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Hays, Ron D.] RAND Corp, Santa Monica, CA USA. [Katon, Wayne J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rausch, Rebecca; Vassar, Stefanie D.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Diaz, Natalie] Harbor UCLA Dept Neurol, Los Angeles, CA USA. [Jacob, Erin L.] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. RP Thompson, AW (reprint author), Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, Dept Psychiat, Temple, TX 76508 USA. EM awt@alumni.rice.edu RI Hays, Ronald/D-5629-2013 FU NIEHS [ES10544]; NIH/NINDS [NS038367]; Veteran's Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC); UCLA Resource Center for Minority Aging Research/Center for Health Improvement in Minority Elderly (RCMAR/CHIME); NIH/NIA [P30AG021684]; UCLA/Drew Project EXPORT; NCMHD; UCLA Older Americans Independence Center, NIH/NIA [P30-AG028748]; [2P20MD000182] FX We appreciate the work of research assistants Michelle Ornelas, Cristina Ruiz, and Nadia Ruiz who collected the bulk of these study data. We would also like to acknowledge Jeff Bronstein and Yvette Bordelon for UPDRS and Hoehn and Yahr data collection, Jurgen Unutzer for depression measure selection, and Beate Ritz for planning and execution of data collection. The PEG study originally identifying the subjects was supported by NIEHS ES10544 (PI: Ritz). The research presented here was supported by NIH/NINDS NS038367 for the UCLA UDALL Parkinson's Disease Center of Excellence and by the Veteran's Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC). Ron Hays was supported in part by the UCLA Resource Center for Minority Aging Research/Center for Health Improvement in Minority Elderly (RCMAR/CHIME), NIH/NIA Grant Award Number P30AG021684, the UCLA/Drew Project EXPORT, NCMHD, 2P20MD000182, and the UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748. NR 29 TC 15 Z9 16 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JAN PY 2011 VL 17 IS 1 BP 40 EP 45 DI 10.1016/j.parkreldis.2010.10.007 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 722XD UT WOS:000287467700008 PM 21084211 ER PT J AU Bordelon, YM Hays, RD Vassar, SD Diaz, N Bronstein, J Vickrey, BG AF Bordelon, Yvette M. Hays, Ron D. Vassar, Stefanie D. Diaz, Natalie Bronstein, Jeff Vickrey, Barbara G. TI Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease SO PARKINSONS DISEASE LA English DT Article AB We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies. C1 [Bordelon, Yvette M.; Vassar, Stefanie D.; Bronstein, Jeff; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Hays, Ron D.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Hays, Ron D.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hays, Ron D.] RAND Corp, Santa Monica, CA 90407 USA. [Vassar, Stefanie D.; Bronstein, Jeff; Vickrey, Barbara G.] Parkinsons Dis Res, VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Diaz, Natalie] Harbor UCLA Med Ctr, Dept Neurol, Torrance, CA 90502 USA. RP Bordelon, YM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM ybordelon@mednet.ucla.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS038367]; Veterans Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC); NIA [P30AG021684, P30-AG028748]; NCMHD [2P20MD000182] FX The research presented here was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke for the University of California Los Angeles UDALL Parkinson's Disease Center of Excellence (NS038367) and by the Veterans Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC). R. D. Hays was also supported in part by NIA (nos. P30AG021684 and P30-AG028748) and NCMHD (no. 2P20MD000182) grants. We thank Cherry Mao, MS, and Aaron Cook, MPH, for technical assistance in paper preparation. NR 12 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-8083 J9 PARKINSONS DIS-US JI Parkinsons Dis. PY 2011 AR UNSP 967839 DI 10.4061/2011/967839 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA V29RN UT WOS:000208765600087 ER PT J AU Kleiner-Fisman, G Martine, R Lang, AE Stern, MB AF Kleiner-Fisman, Galit Martine, Rebecca Lang, Anthony E. Stern, Matthew B. TI Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease SO PARKINSONS DISEASE LA English DT Article AB Patients with Parkinson disease are increasingly recognized to suffer from non-motor symptoms in addition to motor symptoms. Many non-motor symptoms fluctuate in parallel with motor symptoms and in relationship to plasma levodopa levels. Though these symptoms are troublesome and result in reduced quality of life to patients and their caregivers, there has not been an objective method of recognizing and quantifying non-motor fluctuations (NMFs). This study sought to develop a patient-based instrument that would accurately capture the experience of patients with NMFs. Patient-based nominal group technique sessions, focus groups, and expert opinion were utilized in developing this questionnaire. C1 [Kleiner-Fisman, Galit] Univ Toronto, Baycrest Hosp, Toronto, ON M6A 2E1, Canada. [Martine, Rebecca; Stern, Matthew B.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19107 USA. [Lang, Anthony E.] Univ Toronto, Toronto Western Hosp, Toronto, ON M51 2S8, Canada. [Stern, Matthew B.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Kleiner-Fisman, G (reprint author), Univ Toronto, Baycrest Hosp, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada. EM gkleinerfisman@yahoo.com FU Philadelphia VA Medical Center FX The authors thank Dr. A. Siderowf for facilitation of data acquisition at Pennsylvania Hospital. They also wish to thank the clinician expert panel members: Drs. Anderson, Miyasaki, Samuel, Siderowf, Shulman, Stacy, Voon, and Weiner. This study was supported by a competitive pilot project grant from the Philadelphia VA Medical Center. NR 12 TC 2 Z9 2 U1 1 U2 2 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-8083 J9 PARKINSONS DIS-US JI Parkinsons Dis. PY 2011 AR UNSP 292719 DI 10.4061/2011/292719 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA V29RN UT WOS:000208765600021 ER PT S AU Kim, J Bordiuk, OL Ferrante, RJ AF Kim, Jinho Bordiuk, Olivia L. Ferrante, Robert J. BE Brotchie, J Bezard, E Jenner, P TI EXPERIMENTAL MODELS OF HD AND REFLECTION ON THERAPEUTIC STRATEGIES SO PATHOPHYSIOLOGY, PHARMACOLOGY, AND BIOCHEMISTRY OF DYSKINESIA SE International Review of Neurobiology LA English DT Review; Book Chapter ID TRANSGENIC MOUSE MODEL; HUNTINGTONS-DISEASE MICE; NEURONAL INTRANUCLEAR INCLUSIONS; AMYOTROPHIC-LATERAL-SCLEROSIS; TOXIN 3-NITROPROPIONIC ACID; STRIATAL PROJECTION NEURONS; INCREASED OXIDATIVE DAMAGE; PLACEBO-CONTROLLED TRIAL; CYTOCHROME-C RELEASE; KNOCK-IN MOUSE AB Huntington's disease (HD) is an autosomal dominant, progressive, and fatal neurodegenerative disorder caused by an expanded polyglutamine cytosine adenine-guanine repeat in the gene coding for the protein huntingtin. Despite great progress over the past two decades since the identification of the gene mutation, a direct causative pathway from the HD gene mutation to neuronal dysfunction and death has not yet been established. One important advance in understanding the pathogenic mechanisms of this disease has been the development of experimental mouse models that replicate many of the clinical, neuropathological, and molecular events in HD patients. These murine models have played a critical role in providing accurate and experimentally accessible systems to study multiple features of disease pathogenesis and to test potential therapeutic strategies. A better understanding of the pathophysiological mechanisms of disease and how they interrelate has become important in identifying a treatment for HD and in the design of human clinical trials. In this chapter, we review the current state of HD mouse models and their successes in elucidating disease pathogenesis and in developing pharmacotherapies. There is no clinically proven treatment for HD that can halt or ameliorate the inexorable disease progression. As such, a guide to assessing studies in mouse models and salient issues related to translation from mice to humans are included. C1 [Kim, Jinho; Ferrante, Robert J.] Presbyterian Univ Hosp, Dept Neurol Surg, Pittsburgh, PA 15213 USA. [Bordiuk, Olivia L.] New England Vet Adm VISN 1, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA. [Ferrante, Robert J.] Univ Pittsburgh, Pittsburgh, PA 15213 USA. [Ferrante, Robert J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA. [Ferrante, Robert J.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA. [Kim, Jinho] Lab Med & Pathol, Boston, MA 02118 USA. [Bordiuk, Olivia L.] New England Vet Adm VISN 1, Geriatr Res Educ Clin Ctr, Bedford, MA 01730 USA. RP Kim, J (reprint author), Presbyterian Univ Hosp, Dept Neurol Surg, Pittsburgh, PA 15213 USA. RI Hartman, Jessica/N-3210-2016 FU NINDS NIH HHS [NS045806, NS058793, NS066912] NR 324 TC 10 Z9 10 U1 3 U2 13 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-381328-2 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2011 VL 98 BP 419 EP 481 DI 10.1016/B978-0-12-381328-2.00016-X PG 63 WC Neurosciences SC Neurosciences & Neurology GA BXA93 UT WOS:000295559600016 PM 21907096 ER PT J AU Tillquist, MN Maddox, TM AF Tillquist, Maggie N. Maddox, Thomas M. TI Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement SO PATIENT PREFERENCE AND ADHERENCE LA English DT Review DE prosthetic heart valves; patient preference; valve type; anticoagulant; structural valve deterioration ID ORAL ANTICOAGULANT TREATMENT; BLEEDING COMPLICATIONS; INCEPTION-COHORT; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; DECISION-MAKING; RISK; OUTCOMES; THERAPY; MANAGEMENT AB Nearly 15 million people in the United States suffer from either aortic or mitral valvular disease. For patients with severe and symptomatic valvular heart disease, valve replacement surgery improves morbidity and mortality outcomes. In 2009, 90,000 valve replacement surgeries were performed in the United States. This review evaluates the advantages and disadvantages of mechanical and bioprosthetic prosthetic heart valves as well as the factors for consideration in deciding the appropriate valve type for an individual patient. Although many caveats exist, the general recommendation is for patients younger than 60 to 65 years to receive mechanical valves due to the valve's longer durability and for patients older than 60 to 65 years to receive a bioprosthetic valve to avoid complications with anticoagulants. Situations that warrant special consideration include patient co-morbidities, the need for anticoagulation, and the potential for pregnancy. Once these characteristics have been considered, patients' values, anxieties, and expectations for their lifestyle and quality of life should be incorporated into final valve selection. Decision aids can be useful in integrating preferences in the valve decision. Finally, future directions in valve technology, anticoagulation, and medical decision-making are discussed. C1 [Maddox, Thomas M.] Univ Colorado, VA Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, Denver, CO 80220 USA. [Maddox, Thomas M.] Univ Colorado, Dept Med Cardiol, Denver, CO 80220 USA. [Tillquist, Maggie N.] Univ Colorado, Sch Med, Denver, CO 80220 USA. RP Maddox, TM (reprint author), Univ Colorado, VA Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.maddox@va.gov NR 40 TC 19 Z9 22 U1 1 U2 10 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2011 VL 5 BP 91 EP 99 DI 10.2147/PPA.S16420 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 888QJ UT WOS:000300018300001 PM 21448466 ER PT J AU West, PL McKeown, NJ Hendrickson, RG AF West, Patrick Leight McKeown, Nathanael J. Hendrickson, Robert G. TI Massive Hymenoptera Envenomation in a 3-Year-Old SO PEDIATRIC EMERGENCY CARE LA English DT Article DE Hymenoptera; yellow jacket; massive envenomation; rhabdomyolysis ID AFRICANIZED HONEYBEE STINGS; ACUTE-RENAL-FAILURE; YELLOW JACKET; BEE STINGS; INSECT STINGS; CHILD; HORNET; VENOM AB Background: Envenomation by a large number of hymenopterans can cause significant morbidity and mortality due to venom load. We present the first case of massive Hymenoptera envenomation by native US Hymenoptera. Case: A 3-year-old boy and his family were hiking in Oregon and were attacked by yellow jackets. On emergency department arrival, the child was uncomfortable and vomiting. Vital signs were normal; physical examination showed more than 90 punctate lesions on the head and neck, and 30 below the neck without urticaria. Initial laboratory values were normal except for a white blood cell count of 37,500/mu L and mild hypokalemia, including a normal creatinine kinase. Intravenously administered fluids, ondansetron, midazolam, and morphine were given for symptom control. Generalized edema developed 12 hours later and was treated with intravenously administered dexamethasone and diphenhydramine. His creatinine kinase peaked at 2085 U/L after 32 hours. Forty-eight hours after the incident, the child began to take oral fluids with laboratory values returning to normal. Discussion: Delayed toxic effects of mass envenomation are due to direct toxic effects from the large venom load, with several cases of death reported. All prior cases of mass Hymenoptera envenomation in the United States have involved Africanized "killer" honeybees. Guidelines recommend admitting all pediatric patients sustaining more than 50 stings for 24 hours for laboratory evaluations. Conclusions: Delayed toxic reaction may be caused by native US species of Hymenoptera. Physicians should be aware that endemic US species can cause this reaction and should have a low threshold to admit pediatric patients with more than 50 stings for 24 hours. C1 [West, Patrick Leight; McKeown, Nathanael J.; Hendrickson, Robert G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [West, Patrick Leight; McKeown, Nathanael J.; Hendrickson, Robert G.] Oregon Poison Ctr, Portland, OR USA. [McKeown, Nathanael J.] Portland VA Med Ctr, Portland, OR USA. RP West, PL (reprint author), 3181 SW Sam Jackson Pk Rd,CB 550, Portland, OR 97239 USA. EM westp@ohsu.edu NR 20 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-5161 J9 PEDIATR EMERG CARE JI Pediatr. Emerg. Care PD JAN PY 2011 VL 27 IS 1 BP 46 EP 48 DI 10.1097/PEC.0b013e3182045f47 PG 3 WC Emergency Medicine; Pediatrics SC Emergency Medicine; Pediatrics GA 702SO UT WOS:000285916000014 PM 21206257 ER PT J AU Goebel, M Stengel, A Wang, LX Tache, Y AF Goebel, Miriam Stengel, Andreas Wang, Lixin Tache, Yvette TI Central nesfatin-1 reduces the nocturnal food intake in mice by reducing meal size and increasing inter-meal intervals SO PEPTIDES LA English DT Article DE Food intake; Hypothalamus; Meal pattern; Mouse; Nesfatin-1; Satiation; Satiety ID REGULATED TRANSCRIPT PEPTIDE; SATIETY MOLECULE NESFATIN-1; EDINGER-WESTPHAL NUCLEUS; BLOOD-BRAIN-BARRIER; RAT-BRAIN; HYPOTHALAMUS; IMMUNOREACTIVITY; NEURONS; SYSTEM; IDENTIFICATION AB Nesfatin-1 is well established to reduce food intake upon brain injection in rats, while in mice its anorexigenic action and brain expression are largely unexplored. We characterized the influence of intracerebroventricular (icy) and peripheral (intraperitoneal, ip, subcutaneous, sc) injection of nesfatin-1 on dark phase ingestive behavior using an automated feeding monitoring system and co-localized NUCB2/nesfatin-1 immunoreactivity in the associated brain areas. Nesfatin-1 (0.3, 1 or 3 mu g/mouse, icy) caused a dose-related reduction of 4-h dark phase food intake by 13%, 27%, and 46% respectively. Nesfatin-1 (3 mu g/mouse, icy) action had a 2-h delayed onset, 82% peak inhibition occurring at 3-4 h post-injection and was long lasting (30% reduction for 12 h period post-injection). Nesfatin-1 (3 mu g/mouse, icv)-treated mice had a 46% lower meal frequency associated with 2-times longer inter-meal intervals and a 35% reduction in meal size compared to vehicle during the 1-4 h post-injection (p<0.05). NUCB2/nesfatin-1-immunopositive neurons were found in hypothalamic (supraoptic, paraventricular, arcuate, dorsomedial, lateral) and brainstem (dorsal vagal complex) feeding regulatory nuclei. When injected peripherally, neither food intake nor feeding microstructure parameters were altered. These results demonstrate that NUCB2/nesfatin-1 is prominently expressed in mouse hypothalamus and medulla and acts in the brain to curtail the dark phase feeding by inducing satiation and satiety indicated by reduced meal size and prolonged inter-meal intervals respectively. The lack of nesfatin-1 effect when injected peripherally at a 23-times higher dose indicates a primarily central site of the anorexigenic action for nesfatin-1 in mice. (C) 2010 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU Veterans Administration [R01 NIH DK-33061, DK-41301] FX This work was supported by Veterans Administration Research Career Scientist Award, R01 NIH DK-33061, Center Grant DK-41301 (Animal Core and Supplement Grant, Y.T. and Peptide Biochemistry Core, Joseph R. Reeve, Jr.). We are grateful to Dr. Kym Faull for performing the mass spectral analysis, to Mrs. Honghui Liang for the excellent technical support and thank Ms. Eugenia Hu for reviewing the manuscript. NR 38 TC 53 Z9 56 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JAN PY 2011 VL 32 IS 1 BP 36 EP 43 DI 10.1016/j.peptides.2010.09.027 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 711CC UT WOS:000286562300006 PM 20933030 ER PT J AU Wang, LX Stengel, A Goebel, M Martinez, V Gourcerol, G Rivier, J Tache, Y AF Wang, Lixin Stengel, Andreas Goebel, Miriam Martinez, Vicente Gourcerol, Guillaume Rivier, Jean Tache, Yvette TI Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice SO PEPTIDES LA English DT Article DE Urocortin; Corticotropin-releasing factor receptor; Food intake; Astressin(2)-B; Meal pattern; Mouse ID UROCORTIN-III; FACTOR CRF; MOTOR-ACTIVITY; COLONIC TRANSIT; OBESE MICE; RAT; BRAIN; HORMONE; EXPRESSION; AGONIST AB The orexigenic effect of urocortins (Ucns), namely Ucn 1, Ucn 2 and Ucn 3 through activation of corticotropin-releasing factor (CRF) receptors, has been well characterized after injection into the brain but not in the periphery. We examined the role of CRF receptor subtype 2 (CRF(2)) in the regulation of food intake using intraperitoneal (ip) injection of Ucns and the selective CRF(2) antagonist, astressin(2)-B, and CRF(2) knockout (-/-) mice. Meal structures were monitored using an automated episodic solid food intake monitoring system. Ucn 2 (3, 10 or 30 mu g/kg, ip) induced a rapid in onset, long lasting and dose-dependent decrease (38%, 66% and 86%, respectively at 4 h) of cumulative food intake after an overnight fast in mice. Ucn 3 anorexic effect was 10-times less potent. Astressin(2)-B (30 or 100 mu g/kg) injected ip, but not intracerebroventricularly, blocked the inhibitory effect of ip Ucn 1 and Ucn 2 (10 mu g/kg). Fasted CRF(2-/-) mice did not respond to ip Ucn 1 (10 mu g/kg). Meal microstructure analysis of the 4-h re-feeding response to an overnight fast showed that Ucn 2 (10 mu g/kg, ip) decreased meal size and duration, but increased meal frequency. In mice fed ad libitum, Ucn 2 (30 mu g/kg) injected ip before the dark phase decreased the 4-h nocturnal meal size and duration without influencing meal frequency while the 10 mu g/kg dose had no effect. These data indicate that Ucns, through peripheral CRF(2) receptor-mediated induction of satiation, inhibit the eating response to a fast more potently than the physiological nocturnal feeding in mice. (C) 2010 Elsevier Inc. All rights reserved. C1 [Wang, Lixin; Stengel, Andreas; Goebel, Miriam; Martinez, Vicente; Gourcerol, Guillaume; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Dept Med,Digest Dis Div, Los Angeles, CA 90095 USA. [Wang, Lixin; Stengel, Andreas; Goebel, Miriam; Martinez, Vicente; Gourcerol, Guillaume; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA. RP Wang, LX (reprint author), Bldg 115,Rm 117B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lixinw@ucla.edu RI Martinez, Vicente/N-1189-2014 FU Digestive Diseases Research Center [DK 41301]; Veterans Administration; NIHDDK [PO1 26741]; German Research Foundation [STE 1765/1-1, GO 1718/1-1]; [R01 NIH DK-33061]; [R01 NIH DDK 57238] FX This work was supported by R01 NIH DK-33061, R01 NIH DDK 57238, Digestive Diseases Research Center DK 41301 (Animal Core and Administrative Supplement Grant) and Veterans Administration Research Career Scientist Award (Y.T), NIHDDK PO1 26741 (J.R.) and German Research Foundation Grants STE 1765/1-1 (A.S.), GO 1718/1-1 (M.G.). J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor and Founder of Sentia Medical Sciences Inc. We are grateful to Mrs. Honghui Liang for her excellent technical support and we thank Ms. Eugenia Hu for reviewing the manuscript. NR 42 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JAN PY 2011 VL 32 IS 1 BP 51 EP 59 DI 10.1016/j.peptides.2010.10.017 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 711CC UT WOS:000286562300008 PM 20969907 ER PT J AU Lembke, V Goebel, M Frommelt, L Inhoff, T Lommel, R Stengel, A Tache, Y Grotzinger, C Bannert, N Wiedenmann, B Klapp, BF Kobelt, P AF Lembke, Vanessa Goebel, Miriam Frommelt, Lisa Inhoff, Tobias Lommel, Reinhardt Stengel, Andreas Tache, Yvette Groetzinger, Carsten Bannert, Norbert Wiedenmann, Bertram Klapp, Burghard F. Kobelt, Peter TI Sulfated cholecystokinin-8 activates phospho-mTOR immunoreactive neurons of the paraventricular nucleus in rats SO PEPTIDES LA English DT Article DE CCK; c-Fos oxytocin; Phospho-mTOR; PVN ID C-FOS EXPRESSION; DORSAL VAGAL COMPLEX; FOOD-INTAKE; PERIPHERAL INJECTION; SOLITARY TRACT; BRAIN-STEM; LEAN MICE; OXYTOCIN; HYPOTHALAMUS; SATIETY AB The serin/threonin-kinase, mammalian target of rapamycin (mTOR) was detected in the arcuate nucleus (ARC) and paraventricular nucleus of the hypothalamus (PVN) and suggested to play a role in the integration of satiety signals. Since cholecystokinin (CCK) plays a role in the short-term inhibition of food intake and induces c-Fos in PVN neurons, the aim was to determine whether intraperitoneally injected CCK-8S affects the neuronal activity in cells immunoreactive for phospho-mTOR in the PVN. Ad libitum fed male Sprague-Dawley rats received 6 or 10 mu g/kg CCK-8S or 0.15 M NaCl ip (n = 4/group). The number of c-Fos-immunoreactive (ir) neurons was assessed in the PVN, ARC and in the nucleus of the solitary tract (NTS). CCK-8S increased the number of c-Fos-ir neurons in the PVN (6 mu g: 103 +/- 13 vs. 10 mu g: 165 +/- 14 neurons/section; p<0.05) compared to vehicle treated rats (4 +/- 1, p<0.05), but not in the ARC. CCK-8S also dose-dependently increased the number of c-Fos neurons in the NTS. Staining for phospho-mTOR and c-Fos in the PVN showed a dose-dependent increase of activated phospho-mTOR neurons (17 +/- 3 vs. 38 +/- 2 neurons/section; p < 0.05), while no activated phospho-mTOR neurons were observed in the vehicle group. Triple staining in the PVN showed activation of phospho-mTOR neurons co-localized with oxytocin, corresponding to 9.8 +/- 3.6% and 19.5 +/- 3.3% of oxytocin neurons respectively. Our observations indicate that peripheral CCK-8S activates phospho-mTOR neurons in the PVN and suggest that phospho-mTOR plays a role in the mediation of CCK-8S's anorexigenic effects. (C) 2010 Elsevier Inc. All rights reserved. C1 [Lembke, Vanessa; Frommelt, Lisa; Lommel, Reinhardt; Stengel, Andreas; Klapp, Burghard F.; Kobelt, Peter] Univ Med Berlin, Dept Med, Div Psychosomat Med & Psychotherapy, Charite, Berlin, Germany. [Goebel, Miriam; Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Goebel, Miriam; Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Goebel, Miriam; Stengel, Andreas; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Inhoff, Tobias; Groetzinger, Carsten; Wiedenmann, Bertram; Kobelt, Peter] Univ Med Berlin, Dept Med, Div Hepatol Gastroenterol & Endocrinol, Charite, Berlin, Germany. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. RP Kobelt, P (reprint author), Charite Univ Med Berlin, Dept Med, Div Psychosomat Med & Psychotherapy, Campus Mitte,Luisenstr 13 A, D-10117 Berlin, Germany. EM peter.kobelt@charite.de OI Grotzinger, Carsten/0000-0001-9872-3087 FU German Research Foundation [DFG KO 3864/2-1]; Charite-Universitatsmedizin Berlin [UFF 10/45004, 10/45018]; Veterans Administration; [DK-41301] FX This work was supported by grants from the German Research Foundation to P.K. (DFG KO 3864/2-1) and from Charite-Universitatsmedizin Berlin to P.K. (UFF 10/45004 and 10/45018) as well as Veterans Administration Research Career Scientist Award (Y.T.), and Center Grant DK-41301 (Animal Core, Y.T.). NR 37 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JAN PY 2011 VL 32 IS 1 BP 65 EP 70 DI 10.1016/j.peptides.2010.09.025 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 711CC UT WOS:000286562300010 PM 20933028 ER PT J AU Glick, HA AF Glick, Henry A. TI Sample Size and Power for Cost-Effectiveness Analysis (Part 1) SO PHARMACOECONOMICS LA English DT Article ID EFFECTIVENESS RATIOS; CLINICAL-TRIALS AB Basic sample size and power formulae for cost-effectiveness analysis have been established in the literature. These formulae are reviewed and the similarities and differences between sample size and power for cost-effectiveness analysis and for the analysis of other continuous variables such as changes in blood pressure or weight are described. The types of sample size and power tables that are commonly calculated for cost-effectiveness analysis are also described and the impact of varying the assumed parameter values on the resulting sample size and power estimates is discussed. Finally, the way in which the data for these calculations may be derived are discussed. C1 [Glick, Henry A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Glick, Henry A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Glick, HA (reprint author), Univ Penn, Div Gen Internal Med, Room 1211 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM hlthsvrs@mail.med.upenn.edu FU Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center FX This article was funded in part by the Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center. NR 22 TC 12 Z9 12 U1 0 U2 7 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2011 VL 29 IS 3 BP 189 EP 198 DI 10.2165/11585080-000000000-00000 PG 10 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 730RD UT WOS:000288050900003 PM 21309615 ER PT J AU Glick, HA AF Glick, Henry A. TI Sample Size and Power for Cost-Effectiveness Analysis (Part 2) The Effect of Maximum Willingness to Pay SO PHARMACOECONOMICS LA English DT Article ID LIFE AB Sample size and power for cost-effectiveness analysis depend on assumptions about the difference in cost and effect, the standard deviations of cost and effect, the correlation of the difference in cost and effect, the alpha and beta errors and maximum willingness to pay (W). The first seven of these parameters share much in common in their effect on sample size and power for cost-effectiveness analysis, including that each is associated with a single pattern of power. W, on the other hand, is unique in that, when plotted for positive values, we can potentially observe any of six patterns of power associated with positive values of W. In addition, as W approaches infinity, power need be neither monotonically increasing nor decreasing and it can be multi-modal. In this article, the relationship between W and sample size and power is explained. C1 [Glick, Henry A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Glick, Henry A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Glick, HA (reprint author), Univ Penn, Div Gen Internal Med, Room 1211 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM hlthsvrs@mail.med.upenn.edu FU Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center FX This work was funded in part by the Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center. The author has no conflicts of interest that are directly relevant to the content of this article. NR 7 TC 5 Z9 5 U1 0 U2 1 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1170-7690 EI 1179-2027 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2011 VL 29 IS 4 BP 287 EP 296 PG 10 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 746TV UT WOS:000289271500002 PM 21395349 ER PT J AU Rao, NL Ziran, BH Lipsky, BA AF Rao, Nalini Ziran, Bruce H. Lipsky, Benjamin A. TI Treating Osteomyelitis: Antibiotics and Surgery SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID INTRAVENOUS ANTIMICROBIAL THERAPY; RNAIII-INHIBITING PEPTIDE; DIABETIC FOOT INFECTIONS; NEEDLE BONE-BIOPSY; STAPHYLOCOCCUS-AUREUS; ORTHOPEDIC INFECTIONS; PRESSURE ULCERS; SOFT-TISSUE; BEADS; DISEASES AB Background: Osteomyelitis is an inflammatory disorder of bone caused by infection leading to necrosis and destruction. It can affect all ages and involve any bone. Osteomyelitis may become chronic and cause persistent morbidity. Despite new imaging techniques, diagnosis can be difficult and often delayed. Because infection can recur years after apparent "cure," "remission" is a more appropriate term. Methods: The study is a nonsystematic review of literature. Results: Osteomyelitis usually requires some antibiotic treatment, usually administered systemically but sometimes supplemented by antibiotic-containing beads or cement. Acute hematogenous osteomyelitis can be treated with antibiotics alone. Chronic osteomyelitis, often accompanied by necrotic bone, usually requires surgical therapy. Unfortunately, evidence for optimal treatment regimens or therapy durations largely based upon expert opinion, case series, and animal models. Antimicrobial therapy is now complicated by the increasing prevalence of antibiotic-resistant organisms, especially methicillin-resistant Staphylococcus aureus. Without surgical resection of infected bone, antibiotic treatment must be prolonged to 6 weeks). Advances in surgical technique have increased the potential for bone (and often limb) salvage and infection remission. Conclusions: Osteomyelitis is best managed by a multidisciplinary team. It requires accurate diagnosis and optimization of host defenses, appropriate anti-infective therapy, and often bone debridement and reconstructive surgery. The antibiotic regimen must target the likely (or optimally proven) causative pathogen, with few adverse effects and reasonable costs. The authors offer practical guidance to the medical and surgical aspects of treating osteomyelitis. (Mast. Reconstr. Surg. 127 (Suppl.): 177S, 2011.) C1 Univ Pittsburgh, Sch Med, Atlanta Med Ctr, Pittsburgh, PA USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Rao, NL (reprint author), 5750 Ctr Ave,Suite 510, Pittsburgh, PA 15206 USA. EM raon@upmc.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 FU Pfizer; Ortho-McNeil/Johnson Johnson; Cubist; Merck FX Dr. Lipsky has been a consultant to and received research funding from Pfizer, Ortho-McNeil/Johnson & Johnson, Cubist, and Merck. The other authors have no financial interest to disclose. NR 58 TC 44 Z9 49 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JAN PY 2011 VL 127 IS 1 SU S BP 177S EP 187S DI 10.1097/PRS.0b013e3182001f0f PG 11 WC Surgery SC Surgery GA 705IP UT WOS:000286122400025 PM 21200289 ER PT J AU Hoerster, KD Mayer, JA Sallis, JF Pizzi, N Talley, S Pichon, LC Butler, DA AF Hoerster, Katherine D. Mayer, Joni A. Sallis, James F. Pizzi, Nicole Talley, Sandra Pichon, Latrice C. Butler, Dalila A. TI Dog walking: Its association with physical activity guideline adherence and its correlates SO PREVENTIVE MEDICINE LA English DT Article DE Dog walking; Physical activity; Health promotion ID NEIGHBORHOOD ENVIRONMENT; UNITED-STATES; HEALTH; OWNERSHIP; ADULTS; INTERVENTIONS; PROMOTE; BEHAVIOR; SCALE; PETS AB Objective. We examined the prevalence and correlates of dog walking among dog owners, and whether dog walking is associated with meeting the American College of Sports Medicine/American Heart Association physical activity guidelines. Methods. In March 2008, we mailed a survey to dog-owning clients from two San Diego County veterinary clinics. Useable data were obtained from 984 respondents, and 75 of these completed retest surveys. We assessed associations between potential correlates and dog walking (i.e., yes/no dog walking for at least 10 min in past week). Results. Test-retest reliability of measures was generally high. Approximately one-third of the sample (31.5%) were not dog walkers. Proportions of dog walkers versus non-dog walkers meeting United States guidelines were 64.3% and 55.0%, respectively. Dog walking was independently associated with meeting guidelines in a multivariate model (odds ratio = 1.59, p = 0.004). Three variables were independently associated with dog walking in a multivariate model: dog encouragement of dog walking, dog-walking obligation, and dog-walking self-efficacy. Conclusion. Dog walking was associated with meeting physical activity guidelines, making it a viable method for promoting physical activity. Dog-walking obligation and self-efficacy may be important mediators of dog walking and may need to be targeted if interventions are to be successful. Published by Elsevier Inc. C1 [Hoerster, Katherine D.; Mayer, Joni A.; Sallis, James F.; Pizzi, Nicole; Talley, Sandra; Pichon, Latrice C.; Butler, Dalila A.] San Diego State Univ, Sch Publ Hlth, San Diego, CA 92123 USA. [Hoerster, Katherine D.; Sallis, James F.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, 1660 S Columbian Way,S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov FU San Diego State University Research Foundation FX We thank Debra Rubio, Beth Gordon, Elva Arredondo, Simon Marshall, Thomas McKenzie, Donald Slymen, and the San Diego Veterinary Medical Association. We thank the veterinarian owners and staff of the two participating clinics for their assistance with recruitment and other study procedures. This research was supported by a San Diego State University Research Foundation Research Support Fund awarded to Dr. Mayer. This funding source had no involvement in study design; in the collection, analysis, and interpretation of data; or in the decision to submit this article for publication. NR 39 TC 26 Z9 26 U1 3 U2 22 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JAN PY 2011 VL 52 IS 1 BP 33 EP 38 DI 10.1016/j.ypmed.2010.10.011 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 707OQ UT WOS:000286296300008 PM 21047528 ER PT J AU Whitley, BM Moreira, DM Thomas, JA Aronson, WJ Terris, MK Presti, JC Kane, CJ Amling, CL Freedland, SJ AF Whitley, B. M. Moreira, D. M. Thomas, J-A Aronson, W. J. Terris, M. K. Presti, J. C., Jr. Kane, C. J. Amling, C. L. Freedland, S. J. CA SEARCH Database Study Grp TI Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE biochemical recurrence; obesity; radical prostatectomy; weight change ID BODY-MASS INDEX; OBESITY; GROWTH; MEN; MORTALITY; INSULIN; RECURRENCE; CARBOHYDRATE; RESTRICTION; SURVIVAL AB BACKGROUND: We examined the relationship between weight change in the year before radical prostatectomy (RP) and biochemical recurrence (BCR) and adverse pathology. METHODS: We abstracted data from 359 men undergoing RP in the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 2001-2007. Logistic regression and Cox proportional hazards models were used to test the association between weight change in the year before surgery and adverse pathology and BCR, respectively. RESULTS: In all, 152 (42%) men gained weight, 193 (54%) lost weight and 14 (4%) had the same weight. Among weight gainers, median gain was 2.4 kg and among weight losers, median loss was 2.7 kg. As a continuous variable, weight change was not associated with adverse pathology or BCR (all P>0.05). In secondary analysis, on multivariate analysis, men gaining >= 2.5 kg were at higher BCR risk (hazards ratio = 1.65, 95% confidence interval (Cl): 1.03-2.64, P = 0.04) while weight loss >= 2.5 kg was not associated with BCR (hazards ratio = 0.83, 95% CI: 0.54-1.29, P = 0.41). CONCLUSIONS: As a continuous variable, weight change was not associated with outcome. In secondary hypothesis-generating analyses, weight gain >= 2.5 kg in the year before surgery, regardless of final body mass index, was associated with increased BCR following RP. If validated, these data suggest weight gain >= 2.5 kg may promote prostate cancer progression. C1 [Freedland, S. J.] Duke Univ, Sch Med, Div Urol, Duke Prostate Ctr,Dept Pathol, Durham, NC 27710 USA. [Whitley, B. M.; Moreira, D. M.; Thomas, J-A; Freedland, S. J.] Duke Univ, Sch Med, Dept Surg, Duke Prostate Ctr,Div Urol Surg, Durham, NC 27710 USA. [Whitley, B. M.; Moreira, D. M.; Thomas, J-A; Freedland, S. J.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Durham, NC USA. [Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, M. K.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Augusta, GA USA. [Terris, M. K.] Med Coll Georgia, Dept Surg, Div Urol Surg, Augusta, GA 30912 USA. [Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, J. C., Jr.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. [Kane, C. J.] Univ Calif San Diego, Med Ctr, Dept Surg, Div Urol, San Diego, CA 92103 USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Duke Prostate Ctr,Dept Pathol, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270; Moreira, Daniel/0000-0003-4517-244X NR 24 TC 8 Z9 8 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PY 2011 VL 14 IS 4 BP 361 EP 366 DI 10.1038/pcan.2011.42 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 843FN UT WOS:000296657800013 PM 21894174 ER PT S AU Hook, V Kindy, M Hook, G AF Hook, Vivian Kindy, Mark Hook, Gregory BE Dunn, B TI Discovery of the Cysteine Protease Cathepsin B as a Drug Target for Alzheimer's Disease SO PROTEINASES AS DRUG TARGETS SE RSC Drug Discovery Series LA English DT Article; Book Chapter ID AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; TRANSGENIC MICE; WILD-TYPE; IN-VIVO; ACTIVE-SITE; PEPTIDE NEUROTRANSMITTERS; CHROMAFFIN CELLS; BACE1; INHIBITORS C1 [Hook, Vivian] Univ Calif San Diego, Dept Neurosci, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Pharmacol, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Med, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Hook, Gregory] Amer Life Sci Pharmaceut Inc, San Diego, CA 92109 USA. RP Hook, V (reprint author), Univ Calif San Diego, Dept Neurosci, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. NR 61 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, CAMBRIDGE CB4 4WF, CAMBS, ENGLAND SN 2041-3203 BN 978-1-84973-049-5 J9 RSC DRUG DISCOV JI RSC Drug Discov. PY 2011 IS 18 BP 145 EP 168 D2 10.1039/9781849733151 PG 24 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA BA5JG UT WOS:000336722600007 ER PT J AU Adler, DA Possemato, K Mavandadi, S Lerner, D Chang, H Klaus, J Tew, JD Barrett, D Ingram, E Oslin, DW AF Adler, David A. Possemato, Kyle Mavandadi, Shahrzad Lerner, Debra Chang, Hong Klaus, Johanna Tew, James D. Barrett, David Ingram, Erin Oslin, David W. TI Psychiatric Status and Work Performance of Veterans of Operations Enduring Freedom and Iraqi Freedom SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; PRODUCTIVITY LOSS; JOB-PERFORMANCE; CARE MANAGEMENT; DEPRESSION; ASSOCIATION; OUTCOMES; WAR; US AB Objective: This cross-sectional study investigated the relationship between psychiatric diagnosis and impaired work functioning among American service members returning from Operation Iraqi Freedom-Operation Enduring Freedom (OEF-OIF). Methods: Participants were 797 OEF-OIF veterans, of whom 473 were employed. They were referred for further psychiatric assessment by primary care providers at six Veterans Affairs medical centers and underwent a behavioral health interview that assessed psychiatric and health status and work impairment as measured by the Work Limitations Questionnaire (WLQ). The four WLQ subscales (mental-interpersonal demands, time management, output, and physical demands) and an aggregated measure of productivity loss were considered in the analysis. Associations between patient characteristics, psychiatric status, and work impairments were investigated with regression models. Results: Major depressive disorder, posttraumatic stress disorder, and generalized anxiety or panic disorder were significantly associated with impairments in mental-interpersonal demands, time management, and output. Alcohol dependence and illicit drug use were associated with impairments in output and physical demands. On average these productivity losses were four times those found in a previous study of nonveteran employees with no psychiatric disorders. Conclusions: Veterans' ability to maintain gainful employment is a major component of successful reintegration into civilian life, and psychiatric disorders have a negative impact on work performance. This study demonstrated that multiple dimensions of job performance are impaired by psychiatric illness among OEF-OIF veterans. Delivery of empirically supported interventions to treat psychiatric disorders and development of care models that focus on work-specific interventions are needed to help veterans return to civilian life. (Psychiatric Services 62:39-46, 2011) C1 [Tew, James D.] Univ Penn, Philadelphia VA Med Ctr, Sch Med, Philadelphia, PA 19104 USA. [Tew, James D.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. [Adler, David A.; Lerner, Debra; Chang, Hong] Tufts Med Ctr, Dept Med, Boston, MA USA. [Adler, David A.; Lerner, Debra; Chang, Hong] Tufts Med Ctr, Dept Psychiat, Boston, MA USA. [Possemato, Kyle] Syracuse Univ, Ctr Integrated Healthcare, Syracuse Dept Vet Affairs VA Med Ctr, Syracuse, NY USA. [Possemato, Kyle] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Barrett, David] Univ Maryland, Dept Psychiat, Baltimore, MD 21201 USA. [Barrett, David] VA Maryland Hlth Care Syst, Baltimore, MD USA. RP Oslin, DW (reprint author), Univ Penn, Philadelphia VA Med Ctr, Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM oslin@upenn.edu RI Schueter, nicos/A-3625-2014 FU Mental Illness Research, Education, and Clinical Center (MIRECC); Department of Veterans Affairs Veterans Integrated Service Network 4 (VISN-4); VISN-5 MIRECC; VISN-2 Center for Integrated Healthcare; Tufts Medical Center FX This project was supported by the Mental Illness Research, Education, and Clinical Center (MIRECC), Department of Veterans Affairs Veterans Integrated Service Network 4 (VISN-4), the VISN-5 MIRECC, the VISN-2 Center for Integrated Healthcare, and the Fisher Fund of the Tufts Medical Center. The authors thank the primary care providers who facilitated care for the veterans in this project. NR 35 TC 33 Z9 33 U1 1 U2 16 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2011 VL 62 IS 1 BP 39 EP 46 DI 10.1176/appi.ps.62.1.39 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 702SX UT WOS:000285917200009 PM 21209298 ER PT J AU Dassori, AM Copeland, LA Zeber, JE Miller, AL AF Dassori, Albana M. Copeland, Laurel A. Zeber, John E. Miller, Alexander L. TI Factors in Second-Generation Antipsychotic Switching Patterns in a National Sample of Older Veterans With Schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID WEIGHT-GAIN; METABOLIC SYNDROME; DIABETES-MELLITUS; PREVALENCE; CLOZAPINE; DRUGS; INTERVENTION; MEDICATIONS; OLANZAPINE; AFFAIRS AB Objective: A 2004 consensus statement by the American Psychiatric Association and other groups noted that metabolic side effects of second-generation antipsychotics require monitoring. To reduce risk, prescribers may consider factors differentially associated with development of metabolic abnormalities, such as age, gender, and race-ethnicity. As part of a study of older patients with schizophrenia (50-102 years), this study evaluated factors associated with antipsychotic switches and switches that incurred a greater or lesser metabolic risk. Methods: Administrative data were analyzed for a national cohort of 16,103 Veterans Health Administration patients with schizophrenia receiving second-generation antipsychotics. Multinomial logistic regression predicted the likelihood of switches from 2002 to 2003 and again from 2004 to 2005. Results: At baseline nearly half the patients (45%) had a diagnosis of hypertension, a third (34%) had dyslipidemia, and 15% had a diagnosis of obesity. In both periods diabetes was associated with switches to lower-risk antipsychotics, and older patients were likely to experience neutral or no switches. Women were more likely to experience switches to higher-risk antipsychotics in 2004-2005. Conclusions: General medical conditions potentially associated with antipsychotic-related metabolic concerns were common; however, half of these patients were prescribed medication that made them liable to developing metabolic problems. Modest evidence suggests that metabolic considerations became a higher priority during the study. Future research should investigate the differential impact of antipsychotics on metabolic dysregulation for women and elderly patients. Findings underscore the need to monitor metabolic parameters of older patients taking antipsychotics. (Psychiatric Services 62:47-53, 2011) C1 [Dassori, Albana M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Dassori, Albana M.] S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX USA. [Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.] Scott & White Healthcare, Temple, TX USA. [Copeland, Laurel A.; Zeber, John E.; Miller, Alexander L.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX 76502 USA. RP Copeland, LA (reprint author), Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM laurel.copeland@va.gov OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service (HSRD) [IIR-05-YYY]; PhRMA Foundation; AstraZeneca; Pfizer; Pfizer Organon; Sanofi Aventis FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSRD) and HSRD grant IIR-05-YYY. The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.; Dr. Zeber has received grant funding from the PhRMA Foundation. Dr. Miller has received grant funding from AstraZeneca, Pfizer, Pfizer Organon, and Sanofi Aventis. The other authors report no competing interests. NR 25 TC 7 Z9 7 U1 1 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2011 VL 62 IS 1 BP 47 EP 53 DI 10.1176/appi.ps.62.1.47 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 702SX UT WOS:000285917200010 PM 21209299 ER PT J AU Boeka, AG Solomon, AC Lokken, K McGuire, BM Bynon, JS AF Boeka, Abbe G. Solomon, Andrea C. Lokken, Kristine McGuire, Brendan M. Bynon, J. Steve TI A biopsychosocial approach to liver transplant evaluation in two patients with Wilson's disease SO PSYCHOLOGY HEALTH & MEDICINE LA English DT Article DE Wilson's disease; cognitive; neuropsychiatric; transplant ID DIAGNOSIS; THERAPY AB Wilson's disease (WD) is characterized by hepatic, neurological, and/or psychiatric disturbances. In some cases, liver transplantation is indicated. Because psychologists and other health care workers play an increasing role in the evaluation of individuals presenting for transplant, an understanding of the heterogeneous phenotype of WD is important for mental health professionals working in medical settings. This article reviews two cases of patients with WD (one probable, one confirmed) presenting for liver transplantation and a biopsychosocial assessment approach is demonstrated. Patients are presented in terms of medical, psychiatric, and psychosocial history, neuropsychological examination results, and the subsequent indications for liver transplantation. Both patients exhibited neurocognitive and psychiatric symptoms. One patient was determined to be a marginally suitable candidate for transplantation, whereas the other was considered at high risk for negative outcome post-transplant. This article demonstrates the importance of considering phenotypic presentation, neurocognitive function, psychiatric status, and psychosocial circumstances in assessing transplant readiness in patients with WD. A comprehensive and integrative biopsychosocial assessment approach is appropriate for evaluating patients with WD presenting for liver transplantation. C1 [Boeka, Abbe G.; Lokken, Kristine] Univ Alabama, Dept Psychiat & Behav Neurobiol, Div Consultat Liason, Birmingham, AL 35294 USA. [Solomon, Andrea C.] Univ Alabama, Dept Neurol, Div Neuropsychol, Birmingham, AL 35294 USA. [Lokken, Kristine] Birmingham VA Med Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA. [McGuire, Brendan M.] Univ Alabama, Dept Med, Div Gastroenterol, Birmingham, AL 35294 USA. [Bynon, J. Steve] Univ Alabama, Dept Surg, Div Transplantat, Birmingham, AL 35294 USA. RP Boeka, AG (reprint author), Univ Alabama, Dept Psychiat & Behav Neurobiol, Div Consultat Liason, Birmingham, AL 35294 USA. EM abbe.boeka@vanderbilt.edu NR 17 TC 0 Z9 0 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1354-8506 J9 PSYCHOL HEALTH MED JI Psychol. Health Med. PY 2011 VL 16 IS 3 BP 268 EP 275 AR PII 936276882 DI 10.1080/13548506.2010.532561 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 750WY UT WOS:000289580000002 PM 21491335 ER PT J AU Osatuke, K Reid, M Stiles, WB Kasckow, JW Zisook, S Mohamed, S AF Osatuke, Katerine Reid, Mary Stiles, William B. Kasckow, John W. Zisook, Sidney Mohamed, Somaia TI Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia SO PSYCHOTHERAPY RESEARCH LA English DT Article DE process research; qualitative research methods; narrative; assimilation ID DEPRESSION RATING-SCALE; CLIENTS ASSIMILATION; INNOVATIVE MOMENTS; MENTAL-ILLNESS; PSYCHOTHERAPY; RECOVERY; DISORDER; VOICES; MODEL; THERAPY AB This case study applied the assimilation model to examine the changing narrative of an outpatient with schizophrenia and symptoms of depression across a successful pharmacotherapy. The assimilation model describes how clients assimilate painful, problematic experiences. Therapeutic progress is understood to reflect increasing assimilation, measured by the Assimilation of Problematic Experiences Scale (APES). The authors used a 15-min semistructured interview (Problematic Experiences Questionnaire) to elicit narrative descriptions of the patient's problems and coping across five interviews throughout his 12-week treatment. They describe how the patient's narrative and APES ratings of his main problems by two clinicians changed in concert through treatment, explain these developments using assimilation concepts, and interpret the results in relation to assimilation and insight in schizophrenia. C1 [Osatuke, Katerine] Vet Hlth Adm, Natl Ctr Org Dev, Cincinnati, OH 45249 USA. [Reid, Mary] Univ Edinburgh, Coll Med, Edinburgh EH8 9YL, Midlothian, Scotland. [Stiles, William B.] Miami Univ, Dept Psychol, Oxford, OH USA. [Kasckow, John W.] Vet Affairs Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Kasckow, John W.] Vet Affairs Pittsburgh Healthcare Syst, Behav Hlth, Pittsburgh, PA USA. [Kasckow, John W.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Mohamed, Somaia] Vet Affairs NE Program Evaluat Ctr, VISN MIRECC 1, West Haven, CT USA. [Mohamed, Somaia] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. RP Osatuke, K (reprint author), Vet Hlth Adm, Natl Ctr Org Dev, 11500 Northlake Dr,Suite 230, Cincinnati, OH 45249 USA. EM Katerine.Osatuke@va.gov FU NIMH NIH HHS [MH6398] NR 68 TC 5 Z9 7 U1 2 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1050-3307 J9 PSYCHOTHER RES JI Psychother. Res. PY 2011 VL 21 IS 1 BP 41 EP 53 AR PII 926982196 DI 10.1080/10503307.2010.508760 PG 13 WC Psychology, Clinical SC Psychology GA 722BA UT WOS:000287403000005 PM 20845225 ER PT J AU Fan, VS Bridevaux, PO McDonell, MB Fihn, SD Besser, LM Au, DH AF Fan, Vincent S. Bridevaux, Pierre-Olivier McDonell, Mary B. Fihn, Stephan D. Besser, Lilah M. Au, David H. TI Regional Variation in Health Status among Chronic Obstructive Pulmonary Disease Patients SO RESPIRATION LA English DT Article DE Chronic obstructive pulmonary disease; Lung disease, obstructive; Health-related quality of life; Regional variation; Geographic differences ID QUALITY-OF-LIFE; VETERANS-AFFAIRS; AIR-POLLUTION; GEOGRAPHIC-VARIATION; COMORBIDITY INDEX; RANDOMIZED-TRIAL; CARE UTILIZATION; ELDERLY PATIENTS; LUNG-DISEASE; COPD AB Background: Little is known about geographic differences in health status among patients with chronic obstructive pulmonary disease (COPD). Objectives: The aim of this study was to examine regional variations in self-reported health status of COPD patients at 7 Veterans Affairs clinics. Methods: The Ambulatory Care Quality Improvement Project was a multicenter, randomized trial conducted from 1997 to 2000 that evaluated a quality improvement intervention in the primary care setting. Four thousand and nine participants with COPD (age 6 45 years) completed the Seattle Obstructive Lung Disease Questionnaire (SOLDQ) and 2,991 also completed the Medical Outcomes Study 36-item short form (SF-36). The unadjusted maximal difference in health status scores is reported as the ratio of the highest and lowest site prevalence. We report the maximal site difference in mean health status scores after adjusting for demographics, comorbidities, utilization, medication use and clinic factors. Results: Subjects were predominantly older (66.5 +/- 9.2 years) Caucasian (83.2%) men (97.9%). After adjustment, the maximal site difference for each health status score was significant (p < 0.01) but larger for the SOLDQ (physical 11.2, emotional 9.7, coping skills 7.6) than for the SF-36 (physical component summary 4.7, mental component summary 2.6). Most of the health status variation was explained by individual or clinic level factors, not clinic site. Conclusions: Our models explained < 30% of variation in health status measures; therefore, future studies should consider additional predictors of health status such as physical performance, social determinants of health, COPD treatment and environmental factors. Despite its limitations, this study suggests a need to consider regional differences in health status when comparing COPD health outcomes in diverse geographic areas. Copyright (C) 2010 S. Karger AG, Basel C1 [Fan, Vincent S.; Bridevaux, Pierre-Olivier; McDonell, Mary B.; Fihn, Stephan D.; Besser, Lilah M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. [Fan, Vincent S.; Fihn, Stephan D.; Au, David H.] Univ Washington, Dept Med, Seattle, WA USA. [Bridevaux, Pierre-Olivier] Univ Hosp Geneva, Div Pulm Med, Geneva, Switzerland. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM vincent.fan@va.gov FU VA Health Services Research and Development [SDR96-002, IIR99-376]; Department of Veterans Affairs Health Services Research and Development; Swiss National Fund; Societe Academique Vaudoise; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland FX The Veterans Affairs ACQUIP was funded by VA Health Services Research and Development grants No. SDR96-002 and IIR99-376. Researcher funding: Department of Veterans Affairs Health Services Research and Development Career Development Awards (Drs. D.H. Au and V.S. Fan); grants from the Swiss National Fund, the Societe Academique Vaudoise and the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (Dr. P.-O. Bridevaux). NR 45 TC 8 Z9 8 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0025-7931 J9 RESPIRATION JI Respiration PY 2011 VL 81 IS 1 BP 9 EP 17 DI 10.1159/000320115 PG 9 WC Respiratory System SC Respiratory System GA 732RU UT WOS:000288207800005 PM 20720400 ER PT J AU Rasmussen, A Sevier, S Kelly, JA Glenn, SB Aberle, T Cooney, CM Grether, A James, E Ning, J Tesiram, J Morrisey, J Powe, T Drexel, M Daniel, W Namjou, B Ojwang, JO Nguyen, KL Cavett, JW Te, JL James, JA Scofield, RH Moser, K Gilkeson, GS Kamen, DL Carson, CW Quintero-del-Rio, AI Ballesteros, MD Punaro, MG Karp, DR Wallace, DJ Weisman, M Merrill, JT Rivera, R Petri, MA Albert, DA Espinoza, LR Utset, TO Shaver, TS Arthur, E Anaya, JM Bruner, GR Harley, JB AF Rasmussen, Astrid Sevier, Sydney Kelly, Jennifer A. Glenn, Stuart B. Aberle, Teresa Cooney, Carisa M. Grether, Anya James, Ellen Ning, Jared Tesiram, Joanne Morrisey, Jean Powe, Tiny Drexel, Mark Daniel, Wes Namjou, Bahram Ojwang, Joshua O. Nguyen, Kim L. Cavett, Joshua W. Te, Jeannie L. James, Judith A. Scofield, R. Hal Moser, Kathy Gilkeson, Gary S. Kamen, Diane L. Carson, Craig W. Quintero-del-Rio, Ana I. Ballesteros, Maria del Carmen Punaro, Marilynn G. Karp, David R. Wallace, Daniel J. Weisman, Michael Merrill, Joan T. Rivera, Roberto Petri, Michelle A. Albert, Daniel A. Espinoza, Luis R. Utset, Tammy O. Shaver, Timothy S. Arthur, Eugene Anaya, Juan-Manuel Bruner, Gail R. Harley, John B. TI The Lupus Family Registry and Repository SO RHEUMATOLOGY LA English DT Review DE Systemic lupus erythematosus; Registry; Repository; Autoimmune diseases; Genetics; Heritability; Genome-wide association studies; Linkage analysis; Minorities; Women ID HONG-KONG CHINESE; GENOME-WIDE ASSOCIATION; COPY-NUMBER VARIATION; DISEASE SUSCEPTIBILITY; RHEUMATOID-ARTHRITIS; ERYTHEMATOSUS SLE; FUNCTIONAL VARIANTS; AMERICAN FAMILIES; REVISED CRITERIA; GENETIC-VARIANTS AB The Lupus Family Registry and Repository (LFRR) was established with the goal of assembling and distributing materials and data from families with one or more living members diagnosed with SLE, in order to address SLE genetics. In the present article, we describe the problems and solutions of the registry design and biometric data gathering; the protocols implemented to guarantee data quality and protection of participant privacy and consent; and the establishment of a local and international network of collaborators. At the same time, we illustrate how the LFRR has enabled progress in lupus genetics research, answering old scientific questions while laying out new challenges in the elucidation of the biologic mechanisms that underlie disease pathogenesis. Trained staff ascertain SLE cases, unaffected family members and population-based controls, proceeding in compliance with the relevant laws and standards; participant consent and privacy are central to the LFRR's effort. Data, DNA, serum, plasma, peripheral blood and transformed B-cell lines are collected and stored, and subject to strict quality control and safety measures. Coded data and materials derived from the registry are available for approved scientific users. The LFRR has contributed to the discovery of most of the 37 genetic associations now known to contribute to lupus through 104 publications. The LFRR contains 2618 lupus cases from 1954 pedigrees that are being studied by 76 approved users and their collaborators. The registry includes difficult to obtain populations, such as multiplex pedigrees, minority patients and affected males, and constitutes the largest collection of lupus pedigrees in the world. The LFRR is a useful resource for the discovery and characterization of genetic associations in SLE. C1 [Rasmussen, Astrid; Sevier, Sydney; Kelly, Jennifer A.; Glenn, Stuart B.; Aberle, Teresa; Grether, Anya; James, Ellen; Ning, Jared; Tesiram, Joanne; Morrisey, Jean; Powe, Tiny; Drexel, Mark; Daniel, Wes; Namjou, Bahram; Ojwang, Joshua O.; Nguyen, Kim L.; Cavett, Joshua W.; Te, Jeannie L.; Scofield, R. Hal; Moser, Kathy; Bruner, Gail R.; Harley, John B.] Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, Oklahoma City, OK 73104 USA. [Sevier, Sydney; James, Judith A.; Scofield, R. Hal; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Cooney, Carisa M.] So Illinois Univ, Sch Med, Div Plast & Reconstruct Surg, Springfield, IL USA. [James, Judith A.] Oklahoma Med Res Fdn, Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Scofield, R. Hal; Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Carson, Craig W.] Oklahoma Arthrit Ctr, Edmond, OK USA. [Quintero-del-Rio, Ana I.; Ballesteros, Maria del Carmen] Ponce Sch Med, Div Genet, Dept Biochem, Ponce, PR USA. [Quintero-del-Rio, Ana I.; Ballesteros, Maria del Carmen] Univ Cent Caribe, Dept Pediat, Bayamon, PR USA. [Punaro, Marilynn G.] Texas Scottish Rite Hosp Children, Pediat Rheumatol Serv, Dallas, TX 75219 USA. [Punaro, Marilynn G.; Karp, David R.] Univ Texas SW Med Ctr Dallas, Div Rheumat Dis, Dallas, TX 75390 USA. [Weisman, Michael] Cedars Sinai Med Ctr, Div Rheumatol, W Hollywood, CA USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA. [Rivera, Roberto] Hosp Dr Susoni, Arecibo, PR USA. [Petri, Michelle A.] Johns Hopkins Univ, Dept Med, Div Rheumatol, Baltimore, MD USA. [Albert, Daniel A.] Dartmouth Hitchcock Med Ctr, Div Rheumatol, Lebanon, NH 03766 USA. [Espinoza, Luis R.] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Rheumatol Sect, New Orleans, LA USA. [Utset, Tammy O.] Univ Chicago, Pritzker Sch Med, Rheumatol Sect, Chicago, IL 60637 USA. [Shaver, Timothy S.] Arthrit & Rheumatol Clin Kansas, Wichita, KS USA. [Arthur, Eugene] McBride Clin, Oklahoma City, OK USA. [Anaya, Juan-Manuel] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res, Bogota, Colombia. RP Harley, JB (reprint author), Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, MLC 4010,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM john.harley@cchmc.org RI ; Anaya, Juan-Manuel/J-1960-2016 OI Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Anaya, Juan-Manuel/0000-0002-6444-1249 FU National Institutes of Health [R37AI24717, R01AR42460, P20RR020743, R01AR053734, P01AR049084, P20AR04 6669, RC1AR058554, R01AR043274]; National Institute of Arthritis, Musculoskeletal and Skin Diseases [N01AR62277]; South Carolina Clinical & Translational Research Institute; Medical University of South Carolina's Clinical and Translational Science Award (CTSA); National Institutes of Health/National Center for Research Resources [UL1RR029882]; Board of Regents of the State of Louisiana FX This work was supported by the National Institutes of Health, mainly from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (N01AR62277) with important contributions from additional grants from the National Institutes of Health (R37AI24717, R01AR42460, P20RR020743, R01AR053734, P01AR049084, P20AR04 6669, RC1AR058554 and R01AR043274). G. S. G. and D. L. K. were supported by the South Carolina Clinical & Translational Research Institute, Medical University of South Carolina's Clinical and Translational Science Award (CTSA) and National Institutes of Health/National Center for Research Resources (UL1RR029882). L. R. E. was funded by the Board of Regents of the State of Louisiana. NR 65 TC 30 Z9 31 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD JAN PY 2011 VL 50 IS 1 BP 47 EP 59 DI 10.1093/rheumatology/keq302 PG 13 WC Rheumatology SC Rheumatology GA 692ZD UT WOS:000285193500008 PM 20864496 ER PT J AU Mikuls, TR Fay, BT Michaud, K Sayles, H Thiele, GM Caplan, L Johnson, D Richards, JS Kerr, GS Cannon, GW Reimold, A AF Mikuls, Ted R. Fay, Brian T. Michaud, Kaleb Sayles, Harlan Thiele, Geoffrey M. Caplan, Liron Johnson, Dannette Richards, John S. Kerr, Gail S. Cannon, Grant W. Reimold, Andreas TI Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry SO RHEUMATOLOGY LA English DT Article DE Rheumatoid arthritis; Mortality; US veterans; Men; MTX; Glucocorticoids ID CARDIOVASCULAR-DISEASE; VIETNAM VETERANS; EXCESS MORTALITY; COHORT; METHOTREXATE; OUTCOMES; MANIFESTATIONS; POPULATION; PREDICTORS; MORBIDITY AB Methods. Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. Results. A total of 138 deaths were observed during 2314 patient-years of follow-up (n = 1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with similar to 40% lower mortality risk. Conclusion. Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population. C1 [Mikuls, Ted R.; Fay, Brian T.; Michaud, Kaleb; Sayles, Harlan; Thiele, Geoffrey M.] Univ Nebraska, Med Ctr, Omaha Vet Affairs Med Ctr, Dept Med, Omaha, NE 68198 USA. [Mikuls, Ted R.; Fay, Brian T.; Michaud, Kaleb; Sayles, Harlan; Thiele, Geoffrey M.] Univ Nebraska, Med Ctr, Nebraska Arthrit Outcomes Res Ctr, Omaha, NE 68198 USA. [Caplan, Liron] Univ Colorado, Denver, CO 80202 USA. [Caplan, Liron] Denver VAMC, Dept Res, Denver, CO USA. [Johnson, Dannette] Jackson VAMC, Dept Med, Jackson, MS USA. [Johnson, Dannette] Univ Mississippi, Jackson, MS 39216 USA. [Richards, John S.; Kerr, Gail S.] DC VAMC, Dept Med, Washington, DC USA. [Richards, John S.; Kerr, Gail S.] Georgetown Univ, Washington, DC USA. [Cannon, Grant W.] George E Wahlin VAMC, Dept Med, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Reimold, Andreas] Dallas VAMC, Dept Med, Dallas, TX USA. [Reimold, Andreas] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Mikuls, TR (reprint author), Univ Nebraska, Med Ctr, Omaha Vet Affairs Med Ctr, Dept Med, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu OI Thiele, Geoffrey/0000-0001-5688-8596 FU Veterans Health Administration (VHA); Abbott Laboratories; Bristol-Myers Squibb; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR050004, R03 AR054539]; VHA (VA Merit); VA HSR&D Career Development Award [CDP 09-388] FX The VARA Registry has received research support from the Health Services Research & Development (HSR&D) Program of the Veterans Health Administration (VHA) in addition to unrestricted research funds from Abbott Laboratories and Bristol-Myers Squibb. T. R. M. receives research support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR050004, R03 AR054539) and the VHA (VA Merit). L. C. is supported by a VA HSR&D Career Development Award.; L.C. is supported by VA HSR&D Career Development Award (CDP 09-388). All other authors have declared no conflicts of interest. NR 41 TC 38 Z9 40 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD JAN PY 2011 VL 50 IS 1 BP 101 EP 109 DI 10.1093/rheumatology/keq232 PG 9 WC Rheumatology SC Rheumatology GA 692ZD UT WOS:000285193500014 PM 20659916 ER PT J AU Avidan, AY Hays, RD Diaz, N Bordelon, Y Vassar, S Vickrey, B AF Avidan, A. Y. Hays, R. D. Diaz, N. Bordelon, Y. Vassar, S. Vickrey, B. TI HEALTH-RELATED QUALITY OF LIFE ASSOCIATIONS VARY BY TYPE OF SLEEP DISTURBANCES IN PARKINSON'S DISEASE SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Hays, R. D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Hays, R. D.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. [Diaz, N.] Harbor UCLA, Dept Neurol, Los Angeles, CA USA. [Vassar, S.; Vickrey, B.] VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. RI Hays, Ronald/D-5629-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0624 BP A216 EP A216 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400625 ER PT J AU Chase, MH Zhang, J Fung, SJ Xi, M Sampogna, S AF Chase, M. H. Zhang, J. Fung, S. J. Xi, M. Sampogna, S. TI ASHWAGANDHA PROVIDES NEUROPROTECTION AGAINST APNEA-INDUCED NEURONAL DEGENERATION IN THE HIPPOCAMPUS OF ADULT GUINEA PIGS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Chase, M. H.; Zhang, J.; Fung, S. J.; Xi, M.; Sampogna, S.] Websci Int, Los Angeles, CA USA. [Chase, M. H.; Zhang, J.; Fung, S. J.; Xi, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0148 BP A54 EP A54 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400149 ER PT J AU Fenik, VB Lim, V Fung, SJ Chase, MH AF Fenik, V. B. Lim, V Fung, S. J. Chase, M. H. TI EXCITATORY INPUTS TO HYPOGLOSSAL MOTONEURONS ARE DIFFERENTIALLY DEPRESSED DURING REM SLEEP IN RATS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Fenik, V. B.; Lim, V; Fung, S. J.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fenik, V. B.; Lim, V; Fung, S. J.; Chase, M. H.] WebSci Int, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0081 BP A31 EP A31 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400083 ER PT J AU Fung, CH Martin, JL Josephson, KR Jouldjian, S Alessi, CA AF Fung, C. H. Martin, J. L. Josephson, K. R. Jouldjian, S. Alessi, C. A. TI PREDICTORS OF BRIGHT LIGHT EXPOSURE IN OLDER POST-ACUTE REHABILITATION PATIENTS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Fung, C. H.] Cedars Sinai Med Ctr, Cedars Sinai Sleep Med Fellowship Program, Los Angeles, CA 90048 USA. [Martin, J. L.; Josephson, K. R.; Jouldjian, S.; Alessi, C. A.] VA Greater Los Angeles Healthcare, GRECC, North Hills, CA USA. [Martin, J. L.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0891 BP A304 EP A305 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834401139 ER PT J AU Fung, SJ Xi, M Chase, MH AF Fung, S. J. Xi, M. Chase, M. H. TI ASHWAGANDHA ANTAGONIZES APNEA-INDUCED EXCITOTOXIC PROCESSES IN THE HIPPOCAMPAL CA3-CA1 PATHWAY SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Fung, S. J.; Xi, M.; Chase, M. H.] VA Greater LA Healthcare Syst, Los Angeles, CA USA. [Fung, S. J.; Xi, M.; Chase, M. H.] Websci Int, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0145 BP A53 EP A53 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400146 ER PT J AU Gajewski, ND Laitman, BM Mann, GL Kubin, L Ross, RJ Morrison, AR AF Gajewski, N. D. Laitman, B. M. Mann, G. L. Kubin, L. Ross, R. J. Morrison, A. R. TI alpha-1 ADRENOCEPTOR ANTAGONIST PRAZOSIN REDUCES NON-REM SLEEP (NREMS) AROUSALS IN FEAR-CONDITIONED WISTAR-KYOTO RATS (WKY) SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Gajewski, N. D.; Laitman, B. M.; Mann, G. L.; Kubin, L.; Ross, R. J.; Morrison, A. R.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA. [Ross, R. J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Ross, R. J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0209 BP A74 EP A75 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400210 ER PT J AU Khawaja, IS Kunisaki, K Hurwitz, TD Thuras, P Schumacher, M Germain, A Amborn, B Sebesta, G Dieperink, ME AF Khawaja, I. S. Kunisaki, K. Hurwitz, T. D. Thuras, P. Schumacher, M. Germain, A. Amborn, B. Sebesta, G. Dieperink, M. E. TI IMPROVEMENT IN SLEEP QUALITY OF PATIENTS COMPLETING A PSYCHIATRY PARTIAL HOSPITALIZATION PROGRAM (PHP) SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Khawaja, I. S.; Kunisaki, K.; Hurwitz, T. D.; Thuras, P.; Schumacher, M.; Amborn, B.; Sebesta, G.; Dieperink, M. E.] VA Med Ctr, Dept Psychiat, Minneapolis, MN USA. [Khawaja, I. S.; Kunisaki, K.; Hurwitz, T. D.; Thuras, P.; Dieperink, M. E.] Univ Minnesota, Minneapolis, MN USA. [Germain, A.] VA Pittsburgh Healthcare Syst, Psychiat, Pittsburgh, PA USA. [Germain, A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0715 BP A246 EP A246 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400716 ER PT J AU Kozak, PJ Paer, A Jackson, NJ Chakravorty, S Grandner, MA AF Kozak, P. J. Paer, A. Jackson, N. J. Chakravorty, S. Grandner, M. A. TI ALCOHOL, SMOKING, CAFFEINE AND DRUG USE ASSOCIATED WITH SLEEP DURATION AND SLEEP QUALITY SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Kozak, P. J.; Paer, A.; Jackson, N. J.; Grandner, M. A.] Univ Penn, Div Sleep Med, Philadelphia, PA 19104 USA. [Chakravorty, S.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 2 U2 9 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0017 BP A9 EP A9 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400019 ER PT J AU Laitman, BM Gajewski, ND Mann, GL Kubin, L Ross, RJ Morrison, AR AF Laitman, B. M. Gajewski, N. D. Mann, G. L. Kubin, L. Ross, R. J. Morrison, A. R. TI alpha-1 ADRENOCEPTOR ANTAGONIST PRAZOSIN REDUCES REM SLEEP (REMS) FRAGMENTATION AND NON-REM SLEEP (NREMS) LATENCY IN FEAR-CONDITIONED WISTAR-KYOTO RATS (WKY) SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Laitman, B. M.; Gajewski, N. D.; Mann, G. L.; Kubin, L.; Ross, R. J.; Morrison, A. R.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA. [Ross, R. J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0186 BP A67 EP A67 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400187 ER PT J AU Levine, CG Sher, AE Weaver, EM AF Levine, C. G. Sher, A. E. Weaver, E. M. TI SURGICAL TREATMENT FOR ADULT OBSTRUCTIVE SLEEP APNEA: A SYSTEMATIC REVIEW OF HIGH-LEVEL EVIDENCE SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Weaver, E. M.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Weaver, E. M.] VA Puget Sound Hlth Care Syst, Otolaryngol Head & Neck Surg, Seattle, WA USA. [Sher, A. E.] Capital Reg Otolaryngol Head Neck Grp, Albany, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0429 BP A148 EP A148 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400430 ER PT J AU Martin, JL Hughes, J Jouldjian, S Washington, D Yosef, J Alessi, CA AF Martin, J. L. Hughes, J. Jouldjian, S. Washington, D. Yosef, J. Alessi, C. A. TI INSOMNIA AMONG WOMEN VETERANS: RESULTS OF A POSTAL SURVEY SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Martin, J. L.; Washington, D.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, J. L.; Hughes, J.; Jouldjian, S.; Washington, D.; Yosef, J.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0919 BP A314 EP A314 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834401167 ER PT J AU Pavlova, I Lyamin, O Kosenko, P Mukhametov, L Siegel, J AF Pavlova, I Lyamin, O. Kosenko, P. Mukhametov, L. Siegel, J. TI REGIONAL DIFFERENCES IN THE CORTICAL EEG ASYMMETRY DURING SLOW WAVE SLEEP IN THE FUR SEAL SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Pavlova, I; Lyamin, O.; Mukhametov, L.] Utrish Dolphinarium Ltd, Moscow, Russia. [Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, North Hills, CA USA. [Lyamin, O.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Mukhametov, L.] Severtsov Inst Ecol & Evolut, Moscow, Russia. [Kosenko, P.] S Fed Univ, Rostov Na Donu, Russia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0101 BP A38 EP A38 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400103 ER PT J AU Peterson, VL Cameron, MH Lovera, J Boudreau, EA Kim, E McMillan, GP Turner, AP Haselkorn, JK Bourdette, D AF Peterson, V. L. Cameron, M. H. Lovera, J. Boudreau, E. A. Kim, E. McMillan, G. P. Turner, A. P. Haselkorn, J. K. Bourdette, D. TI POOR SLEEP QUALITY IS ASSOCIATED WITH REDUCED PARTICIPATION IN PEOPLE WITH MULTIPLE SCLEROSIS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Peterson, V. L.; Cameron, M. H.; Kim, E.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cameron, M. H.; Boudreau, E. A.; Kim, E.; Turner, A. P.; Haselkorn, J. K.; Bourdette, D.] Vet Hlth Adm, MS Ctr Excellence W, Seattle, WA USA. [Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [McMillan, G. P.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Turner, A. P.; Haselkorn, J. K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Haselkorn, J. K.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0621 BP A215 EP A215 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400622 ER PT J AU Richards, A Neylan, TC St-Hilaire, M Metzler, T Marmar, C AF Richards, A. Neylan, T. C. St-Hilaire, M. Metzler, T. Marmar, C. TI SLEEP QUALITY PREDICTS FUTURE POSITIVE AFFECT IN A PROSPECTIVE STUDY OF POLICE ACADEMY RECRUITS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Richards, A.; Neylan, T. C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Richards, A.; Neylan, T. C.; Metzler, T.] San Francisco VA Med Ctr, San Francisco, CA USA. [St-Hilaire, M.] Montreal Univ Hosp Ctr, Montreal, PQ, Canada. [Marmar, C.] NYU, Med Ctr, Dept Psychiat, New York, NY 10016 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0720 BP A248 EP A248 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400721 ER PT J AU Rumble, M Guo, M Phelan, CH Peppard, PE Benca, R AF Rumble, M. Guo, M. Phelan, C. H. Peppard, P. E. Benca, R. TI A PILOT RANDOMIZED CLINICAL EFFECTIVENESS TRIAL OF GROUP COGNITIVE-BEHAVIORAL THERAPY FOR INDIVIDUALS WITH PERSISTENT INSOMNIA FROM THE WISCONSIN SLEEP COHORT STUDY SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Rumble, M.; Guo, M.; Phelan, C. H.; Peppard, P. E.; Benca, R.] Univ Wisconsin, Madison, WI USA. [Phelan, C. H.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0528 BP A181 EP A181 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400529 ER PT J AU Wu, F Nienhuis, R Lam, H Maidment, N Siegel, J AF Wu, F. Nienhuis, R. Lam, H. Maidment, N. Siegel, J. TI ROLE OF THE HYPOCRETIN (OREXIN) 2 RECEPTOR: NO EFFECT OF CATAPLEXY ALTERING DRUGS ON HYPOCRETIN (HCRT) LEVELS IN HCRT-R2 MUTANT NARCOLEPTIC DOGS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Wu, F.; Nienhuis, R.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Wu, F.; Nienhuis, R.; Lam, H.; Maidment, N.; Siegel, J.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0003 BP A4 EP A4 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400005 ER PT J AU Xi, M Fung, SJ Chase, MH AF Xi, M. Fung, S. J. Chase, M. H. TI INTERACTIONS BETWEEN PROJECTIONS FROM THE AMYGDALA AND THE PEDUNCULOPONTINE TEGMENTAL NUCLEUS IN THE CONTROL OF ACTIVITY OF NEURONS IN THE NUCLEUS PONTIS ORALIS SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Xi, M.; Fung, S. J.; Chase, M. H.] WebSci Int, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0091 BP A34 EP A35 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400093 ER PT J AU Zhang, J Xi, M Fung, SJ Sampogna, S Chase, MH AF Zhang, J. Xi, M. Fung, S. J. Sampogna, S. Chase, M. H. TI THE EPITHELIUM OF THE CHOROID PLEXUS IS INVOLVED IN THE HYPOCRETIN TRANSPORTATION FROM THE CSF TO THE CIRCULATORY SYSTEM SO SLEEP LA English DT Meeting Abstract CT 25th Anniversary Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 11-15, 2011 CL Minneapolis, MN SP Associated Profess Sleep Soc (APSS) C1 [Zhang, J.; Xi, M.; Fung, S. J.; Sampogna, S.; Chase, M. H.] Websci Int, Los Angeles, CA USA. [Zhang, J.; Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2011 VL 34 SU S MA 0138 BP A51 EP A51 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886EG UT WOS:000299834400139 ER PT J AU Mendez, MF Manes, F AF Mendez, Mario F. Manes, Facundo TI The emerging impact of social neuroscience on neuropsychiatry and clinical neuroscience SO SOCIAL NEUROSCIENCE LA English DT Article C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Sch Med, Los Angeles, CA 90095 USA. [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Manes, Facundo] Favaloro Univ, Inst Neurosci, Buenos Aires, DF, Argentina. [Manes, Facundo] Inst Cognit Neurol INECO, Buenos Aires, DF, Argentina. RP Mendez, MF (reprint author), VAGLA, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA NIH HHS [R01 AG034499] NR 6 TC 3 Z9 3 U1 0 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 1747-0919 J9 SOC NEUROSCI-UK JI Soc. Neurosci. PY 2011 VL 6 IS 5-6 SI SI BP 415 EP 419 DI 10.1080/17470919.2011.624806 PG 5 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 882NL UT WOS:000299570500001 PM 21970720 ER PT J AU Lee, J Quintana, J Nori, P Green, MF AF Lee, Junghee Quintana, Javier Nori, Poorang Green, Michael F. TI Theory of mind in schizophrenia: Exploring neural mechanisms of belief attribution SO SOCIAL NEUROSCIENCE LA English DT Article DE Theory of mind; Belief attribution; Schizophrenia; fMRI; Social cognition ID TEMPORO-PARIETAL JUNCTION; SOCIAL COGNITION; NEUROCOGNITIVE DEFICITS; TEMPOROPARIETAL JUNCTION; BRAIN-REGIONS; FMRI; PEOPLE; PERCEPTION; ROBUST; OPTIMIZATION AB Background: Although previous behavioral studies have shown that schizophrenia patients have impaired theory of mind (ToM), the neural mechanisms associated with this impairment are poorly understood. This study aimed to identify the neural mechanisms of ToM in schizophrenia, using functional magnetic resonance imaging (fMRI) with a belief attribution task. Methods: In the scanner, 12 schizophrenia patients and 13 healthy control subjects performed the belief attribution task with three conditions: a false belief condition, a false photograph condition, and a simple reading condition. Results: For the false belief versus simple reading conditions, schizophrenia patients showed reduced neural activation in areas including the temporoparietal junction (TPJ) and medial prefrontal cortex (MPFC) compared with controls. Further, during the false belief versus false photograph conditions, we observed increased activations in the TPJ and the MPFC in healthy controls, but not in schizophrenia patients. For the false photograph versus simple reading condition, both groups showed comparable neural activations. Conclusions: Schizophrenia patients showed reduced task-related activation in the TPJ and the MPFC during the false belief condition compared with controls, but not for the false photograph condition. This pattern suggests that reduced activation in these regions is associated with, and specific to, impaired ToM in schizophrenia. C1 [Lee, Junghee; Quintana, Javier; Nori, Poorang; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Lee, Junghee; Quintana, Javier; Nori, Poorang; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lee, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 300 Med Plaza,Room 2261, Los Angeles, CA 90095 USA. EM jungheelee@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU Veterans Integrated Service Network 22 Mental Illness Research, Education and Clinical Center; Veterans Administration Medical Research Service; NIMH [MH043292, MH065707] FX Support for this study came from the Veterans Integrated Service Network 22 Mental Illness Research, Education and Clinical Center (to Lee); a Merit Review Award from the Veterans Administration Medical Research Service (to Quintana); and NIMH grants MH043292 and MH065707 (to Green). We wish to thank Dr. Rebecca Saxe for providing the vignettes for the task. For generous support of the UCLA Brain Mapping Center, we also thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. Financial disclosure: The authors have nothing to disclose. NR 60 TC 22 Z9 23 U1 3 U2 10 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 1747-0919 J9 SOC NEUROSCI-UK JI Soc. Neurosci. PY 2011 VL 6 IS 5-6 SI SI BP 569 EP 581 DI 10.1080/17470919.2011.620774 PG 13 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 882NL UT WOS:000299570500012 PM 22050432 ER PT S AU Radu, A Hristescu, G Katsel, P Haroutunian, V Davis, KL AF Radu, Aurelian Hristescu, Gabriela Katsel, Pavel Haroutunian, Vahram Davis, Kenneth L. BE Arabnia, HR Tran, QN TI Microarray Database Mining and Cell Differentiation Defects in Schizophrenia SO SOFTWARE TOOLS AND ALGORITHMS FOR BIOLOGICAL SYSTEMS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter ID ANTERIOR CINGULATE CORTEX; MYELINATION-RELATED GENES; PROGENITOR CELLS; OLIGODENDROCYTE DYSFUNCTION; MESSENGER-RNA; ADULT BRAIN; EXPRESSION; NEUROPATHOLOGY; POSTMORTEM; MATTER AB The causes of schizophrenia remain unknown, but a key role of oligodendrocytes and of the myelination process carried out by them has gained increasing support. The adult human brain parenchyma contains a relatively large population of progenitor cells that can generate oligodendrocytes. Defects in these adult oligodendrocyte progenitor cells (OPCs) or in their proliferation/differentiation have received little attention as potential causes of schizophrenia yet. We compared the set of genes whose expression is modified in schizophrenia, as revealed by our microarray studies, with genes specifically expressed in stem cells, as revealed by studies on human embryonic stem cells. We also evaluated the genes that are upregulated when stem cells engage in differentiation programs. These genes can be viewed as fingerprints or signatures for differentiation processes. The comparisons revealed that a substantial fraction of the genes downregulated in the brains of persons with schizophrenia belong to the differentiation signature. A plausible interpretation of our observations is that a cell differentiation process, possibly of adult OPCs to oligodendrocytes, is perturbed in schizophrenia. These observations constitute an incentive for a new direction of study, aimed at investigating the potential role of OPCs in schizophrenia. C1 [Radu, Aurelian] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA. [Hristescu, Gabriela] Rowan Univ, Dept Comp Sci, Glassboro, NJ 08028 USA. [Katsel, Pavel; Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, Mental Illness Res Ctr, Bronx, NY 10468 USA. [Katsel, Pavel; Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, Educ Ctr, Bronx, NY 10468 USA. [Katsel, Pavel; Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, Ctr Clin, Bronx, NY 10468 USA. [Katsel, Pavel; Haroutunian, Vahram; Davis, Kenneth L.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Radu, A (reprint author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM aurelian.radu@mssm.edu; hristescu@rowan.edu; pavel.katsel@mssm.edu; vahram.haroutunian@mssm.edu; kenneth.davis@mssm.edu FU NIMH NIH HHS [MH064673, MH45212] NR 31 TC 5 Z9 5 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4419-7045-9 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2011 VL 696 BP 67 EP 74 DI 10.1007/978-1-4419-7046-6_7 D2 10.1007/978-1-4419-7046-6 PG 8 WC Biology; Mathematical & Computational Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Research & Experimental Medicine GA BUK92 UT WOS:000289694000007 PM 21431547 ER PT S AU Brice, SE Cowart, LA AF Brice, Sarah E. Cowart, L. Ashley BE Cowart, LA TI SPHINGOLIPID METABOLISM AND ANALYSIS IN METABOLIC DISEASE SO SPHINGOLIPIDS AND METABOLIC DISEASE SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter ID INDUCED INSULIN-RESISTANCE; PROTEIN-KINASE-C; MAMMALIAN SERINE-PALMITOYLTRANSFERASE; NECROSIS-FACTOR-ALPHA; INDUCED MITOCHONDRIAL APOPTOSIS; ENDOPLASMIC-RETICULUM MEMBRANE; THIN-LAYER CHROMATOGRAPHY; SKELETAL-MUSCLE CELLS; SATURATED FATTY-ACIDS; CHAIN BASE SYNTHESIS AB Sphingolipids are an important class of structural and signaling molecules within the cell. As sphingolipids have been implicated in the development and pathogenesis of insulin resistance and the metabolic syndrome, it is important to understand their regulation and metabolism. Although these lipids are initially produced through a common pathway, there is no "generic" sphingolipid. Indeed, the biophysical and signaling properties of lipids may be manipulated by the subunit composition or isoform of their synthetic enzymes, via regulation of substrate integration. Functionally distinct pools of chemically-equivalent lipids may also be generated by de novo synthesis and recycling of existing complex sphingolipids. The highly integrated metabolism of the many bioactive sphingolipids means that manipulation of one enzyme or metabolite can result in a ripple effect, causing unforeseen changes in metabolite levels, enzyme activities, and cellular programmes. Fortunately, a suite of techniques, ranging from thin-layer chromatography to liquid chromatography-mass spectrometry approaches, allows investigators to undertake a functional characterization of all or part of the sphingolipidome in their systems of interest. C1 [Brice, Sarah E.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Adm, Charleston, SC USA. RP Brice, SE (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM brices@musc.edu NR 172 TC 14 Z9 14 U1 0 U2 5 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4614-0649-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2011 VL 721 BP 1 EP 17 D2 10.1007/978-1-4614-0650-1 PG 17 WC Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine GA BWF42 UT WOS:000293800300001 PM 21910079 ER PT J AU Sowa, GA Coelho, JP Bell, KM Zorn, AS Vo, NV Smolinski, P Niyonkuru, C Hartman, R Studer, RK Kang, JD AF Sowa, Gwendolyn A. Coelho, J. Paulo Bell, Kevin M. Zorn, Andrew S. Vo, Nam V. Smolinski, Patrick Niyonkuru, Christian Hartman, Robert Studer, Rebecca K. Kang, James D. TI Alterations in gene expression in response to compression of nucleus pulposus cells SO SPINE JOURNAL LA English DT Article DE Intervertebral disc; Gene expression; Compression ID LUMBAR INTERVERTEBRAL DISC; IN-VIVO; DYNAMIC COMPRESSION; PRESSURE MEASUREMENTS; FINITE-ELEMENT; SPINE; MODEL; DEGENERATION; FREQUENCY AB BACKGROUND CONTEXT: It is clear that mechanical forces are involved in initiating disc degeneration but also have the potential to exert beneficial effects. However, the signaling pathways initiated by mechanical stress and thresholds for these responses have not been elucidated. We have developed a metabolically active compression system with the advantages of having the ability to test cells in vitro as well as within their native matrix and control exposure to environmental factors. We hypothesized that nucleus pulposus cells would respond to compressive stress with different thresholds for alterations in catabolic and anabolic gene expression. PURPOSE: The purpose of the study was to establish the utility of a novel compression chamber and examine the effects of various magnitudes and durations of compression on nucleus pulposus inflammatory, catabolic, and anabolic gene expression. STUDY DESIGN: In vitro controlled examination of intervertebral disc cell responses to compression. METHODS: A chamber capable of imparting 0 to 20 MPa of hydrostatic compression onto nucleus pulposus cells was fabricated. Healthy rabbit nucleus pulposus cells were cultured in alginate beads and exposed to static compression at 0.7, 2, and 4 MPa for 4 or 24 hours. Gene expression analysis (real-time polymerase chain reaction) was performed to compare markers of inflammation (inducible nitric oxide synthase, cyclooxygenase-2), matrix catabolism (matrix metalloproteinase-3), and anticatabolic/anabolic metabolism (tissue inhibitor of metalloproteinase-1, aggrecan) in control and compressed cells. RESULTS: Compression resulted in magnitude-and duration-dependent changes in gene expression. Increasing magnitudes showed more anticatabolic gene expression changes, whereas increasing duration resulted in increases in procatabolic gene expression. CONCLUSION: These data demonstrate favorable effects of compression in relation to genes involved in matrix homeostasis and procatabolic gene expression in response to sustained loading levels, consistent with traumatic effects. These data provide an improved understanding of how compression affects cell signaling, which has the potential to be exploited to initiate repair and prevent matrix breakdown. (C) 2011 Elsevier Inc. All rights reserved. C1 [Sowa, Gwendolyn A.; Coelho, J. Paulo; Bell, Kevin M.; Zorn, Andrew S.; Vo, Nam V.; Hartman, Robert; Kang, James D.] Univ Pittsburgh, Dept Orthopaed Surg, Ferguson Lab Orthopaed Res, Pittsburgh, PA 15213 USA. [Sowa, Gwendolyn A.; Coelho, J. Paulo; Niyonkuru, Christian] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Smolinski, Patrick] Univ Pittsburgh, Dept Mech Engn, Pittsburgh, PA 15216 USA. [Studer, Rebecca K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Sowa, GA (reprint author), Univ Pittsburgh, Dept Orthopaed Surg, Ferguson Lab Orthopaed Res, 3471 5th Ave, Pittsburgh, PA 15213 USA. EM sowaga@upmc.edu FU DePuy Spine; CSRS FX Author disclosures: JDK (endowments, Pittsburgh Foundation; research support: staff/materials, J&J (ATRM Biologic), DePuy Spine; grants, CSRS). NR 31 TC 15 Z9 18 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD JAN PY 2011 VL 11 IS 1 BP 36 EP 43 DI 10.1016/j.spinee.2010.09.019 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 696AP UT WOS:000285414600010 PM 21056011 ER PT J AU Ronald, J Rajagopalan, R Cerrato, F Nord, AS Hatsukami, T Kohler, T Marcovina, S Heagerty, P Jarvik, GP AF Ronald, James Rajagopalan, Ramakrishnan Cerrato, Felecia Nord, Alex S. Hatsukami, Thomas Kohler, Ted Marcovina, Santica Heagerty, Patrick Jarvik, Gail P. TI Genetic Variation in LPAL2, LPA, and PLG Predicts Plasma Lipoprotein(a) Level and Carotid Artery Disease Risk SO STROKE LA English DT Article DE atherosclerosis; carotid stenosis; genomics; lipoprotein(a); risk factors ID CORONARY-HEART-DISEASE; INTIMA-MEDIA THICKNESS; APOLIPOPROTEIN(A) GENE; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK; VASCULAR-DISEASE; ISCHEMIC-STROKE; GENOTYPE DATA; COPY NUMBER; POLYMORPHISM AB Background and Purpose-Lipoprotein(a) [Lp(a)] level is an established risk factor for coronary artery disease and has been implicated in carotid artery disease (CAAD). The relationship between genetic variation in the LPA gene region and CAAD risk remains unknown. Methods-We genotyped single nucleotide polymorphisms (SNPs) in the LPAL2, LPA, and PLG regions in 530 individuals with severe CAAD and 770 controls and kringle IV type 2 (KIV2) repeat length in a subset of 90 individuals. Results-Nine SNPs collectively accounted for 30% of the variance in Lp(a) level. Six SNPs were associated with Lp(a) level after accounting for KIV2 copy number, and the dominant KIV2 allele combined with these markers explained 60% of the variance in Lp(a) level. Five SNPs, including rs10455872, which had an odds ratio of 2.1 per minor allele and haplotypes formed by rs10455872, rs6919346, and rs3123629, were significant predictors of CAAD. After accounting for Lp(a) level, all evidence of CAAD-genotype association in the LPA region was eliminated. Conclusions-LPA region SNPs capture some but not all of the effect of KIV2 repeat length on Lp(a) level. There are associations between LPA region SNPs and CAAD that appear to be attributable to effects on Lp(a) level. (Stroke. 2011; 42: 2-9.) C1 [Jarvik, Gail P.] Univ Washington, Med Ctr, Div Med Genet, Dept Med, Seattle, WA 98195 USA. [Marcovina, Santica] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA. [Nord, Alex S.] Univ Washington, Div Genome Sci, Dept Med, Seattle, WA 98195 USA. [Hatsukami, Thomas; Jarvik, Gail P.] Univ Washington, Div Vasc Surg, Dept Med, Seattle, WA 98195 USA. [Heagerty, Patrick] Univ Washington, Div Biostat, Dept Med, Seattle, WA 98195 USA. [Kohler, Ted] Vet Affairs Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA USA. RP Jarvik, GP (reprint author), Univ Washington, Med Ctr, Div Med Genet, Dept Med, Box 357720, Seattle, WA 98195 USA. EM pair@u.washington.edu RI Jarvik, Gail/N-6476-2014 OI Jarvik, Gail/0000-0002-6710-8708 FU National Institutes of Health (NIH) [PO1 HL 30086, RO1 HL67406]; VA Puget Sound Health Care System, Seattle, Washington including the Veteran Affairs Epidemiology Research and Information Center [CSP 701S] FX This work was funded by the National Institutes of Health (NIH) PO1 HL 30086 and RO1 HL67406. This work was supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington, including the Veteran Affairs Epidemiology Research and Information Center Program (award CSP 701S). NR 51 TC 19 Z9 20 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 2011 VL 42 IS 1 BP 2 EP 9 DI 10.1161/STROKEAHA.110.591230 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 699AN UT WOS:000285636400008 PM 21127300 ER PT B AU Ran, QT Liang, HY AF Ran, Qitao Liang, Hanyu BE Basu, S Wiklund, L TI The Use of Gpx4 Knockout Mice and Transgenic Mice to Study the Roles of Lipid Peroxidation in Diseases and Aging SO STUDIES ON EXPERIMENTAL MODELS SE Oxidative Stress in Applied Basic Research and Clinical Practice LA English DT Article; Book Chapter DE Aging; Glutathione peroxidase 4; Gpx4 isoforms; Lipid peroxidation ID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; MILD COGNITIVE IMPAIRMENT; RAT-LIVER MITOCHONDRIA; IN-VIVO FORMATION; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; CYTOCHROME-C; DNA-DAMAGE; SUPEROXIDE-DISMUTASE; SELENOPROTEIN PHGPX AB Lipid peroxidation, a primary event of oxidative stress, is considered to be important in disease pathogenesis and aging. Glutathione peroxidase 4 (Gpx4) is an antioxidant defense enzyme that can directly reduce lipid hyproperoxides in membrane lipids. Several Gpx4 knockout mouse models and Gpx4 transgenic mouse models have been generated over the past 7 years, and data collected from those models indicate that Gpx4 plays an essential role in protecting against lipid peroxidation. Because Gpx4 knockout mice and Gpx4 transgenic mice show increased lipid peroxidation and decreased lipid peroxidation, respectively, those models were used to investigate the roles of lipid peroxidation in aging and disease. For example, lifespan studies showed that Gpx4 heterozygous knockout mice and Gpx4 transgenic mice altered lifespans, indicating that mild change in lipid peroxidation does not affect aging. However, studies using Gpx4 transgenic and knockout models showed that overexpression of Gpx4 protected against A beta toxicity and that deficiency of Gpx4 resulted in increased amyloidogenesis in brain, indicating that lipid peroxidation is important in the pathogenesis of Alzheimer's disease. Studies using Gpx4 transgenic mice also showed that overexpression of Gpx4 reduced atherosclerosis and attenuated cardiac ischemia/reperfusion injury, suggesting that lipid peroxidation is important in cardiovascular disease. Therefore, Gpx4 knockout and transgenic mouse models are useful in dissecting the in vivo roles of lipid peroxidation in diseases and aging. C1 [Ran, Qitao; Liang, Hanyu] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Ran, Qitao] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM RAN@uthscsa.edu NR 86 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-60761-955-0 J9 OXID STRESS APPL BAS JI Oxid. Stress Appl. Basic Res. Clin. Pract. PY 2011 BP 265 EP 278 DI 10.1007/978-1-60761-956-7_12 D2 10.1007/978-1-60761-956-7 PG 14 WC Biochemistry & Molecular Biology; Medicine, General & Internal SC Biochemistry & Molecular Biology; General & Internal Medicine GA BVJ58 UT WOS:000291666700012 ER PT J AU Broyles, LM Gordon, AJ Sereika, SM Ryan, CM Erlen, JA AF Broyles, Lauren Matukaitis Gordon, Adam J. Sereika, Susan M. Ryan, Christopher M. Erlen, Judith A. TI Do Words Matter? Incongruent Responses to Inconsistently Worded AUDIT-C Alcohol Screening Instruments SO SUBSTANCE ABUSE LA English DT Article DE Alcohol consumption; alcohol-related disorders; mass screening; psychometrics ID IDENTIFICATION TEST AUDIT; CONSUMPTION QUESTIONS; PROBLEM DRINKING; USE DISORDERS; PRIMARY-CARE; POPULATION; VALIDATION AB The first 3 questions of the Alcohol Use Disorders Identification Test (AUDIT-C) are often used as a brief alcohol screening instrument. However, the implications of common modifications made to the original AUDIT questions and response options have not been considered. The authors examined existing data from a randomized controlled trial of 310 persons with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) that was testing the efficacy of 2 antiretroviral medication adherence interventions. Logistic regression was used to model the probability of participants having inconsistent AUDIT-C item responses. Three patterns of conflicting responses to the AUDIT-C items were identified. Common item modifications resulted in 14% (n = 48) of the parent study sample reporting conflicting responses across related AUDIT-C items. The odds of having conflicting data were 3 times greater in opioid users (odds ratio [OR] = 3.139, 95% confidence interval [CI] = 1.267-7.777, P = .01) and greater in persons with higher levels of conscientiousness (OR = 1.053, 95% CI = 1.006-1.103, P = .03). Inconsistent question format and response options may impede proper scoring and interpretation of the AUDIT-C. Further discussion and consensus building are needed on the psychometrically ideal version of the AUDIT-C. C1 [Broyles, Lauren Matukaitis; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Pittsburgh, PA 15206 USA. [Broyles, Lauren Matukaitis] VISN4 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Pittsburgh, PA USA. [Broyles, Lauren Matukaitis; Gordon, Adam J.; Ryan, Christopher M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Broyles, Lauren Matukaitis; Sereika, Susan M.; Erlen, Judith A.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov FU Ruth L. Kirschstein National Research Service Award (NRSA) from the National Institute of Nursing Research (NINR) [F31NR008822]; NINR [R01NR004749] FX This study was financially supported by a Ruth L. Kirschstein National Research Service Award (NRSA) to Dr. Broyles from the National Institute of Nursing Research (NINR, F31NR008822) and by NINR grant R01NR004749 to Dr. Erlen. The material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 15 TC 3 Z9 3 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 4 BP 202 EP 209 DI 10.1080/08897077.2011.600673 PG 8 WC Substance Abuse SC Substance Abuse GA 888PO UT WOS:000300016200004 PM 22014250 ER PT J AU Broyles, LM Gordon, AJ Sereika, SM Ryan, CM Erlen, JA AF Broyles, Lauren Matukaitis Gordon, Adam J. Sereika, Susan M. Ryan, Christopher M. Erlen, Judith A. TI Predictive Utility of Brief Alcohol Use Disorders Identification Test (AUDIT) for Human Immunodeficiency Virus Antiretroviral Medication Nonadherence SO SUBSTANCE ABUSE LA English DT Article DE Acquired immunodeficiency syndrome; alcohol consumption; HIV infection; mass screening; patient adherence ID HIV-INFECTION; SCREENING SCORES; PRIMARY-CARE; DISEASE PROGRESSION; PROBLEM DRINKING; SUBSTANCE-ABUSE; MALE VETERANS; ADHERENCE; THERAPY; CONSUMPTION AB Alcohol use negatively affects adherence to antiretroviral therapy (ART), thus human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care providers need accurate, efficient assessments of alcohol use. Using existing data from an efficacy trial of 2 cognitive-behavioral ART adherence interventions, the authors sought to determine if results on 2 common alcohol screening tests (Alcohol Use Disorders Identification Test-Consumption [AUDIT-C] and its binge-related question [AUDIT-3]) predict ART nonadherence. Twenty-seven percent of the sample (n = 308) were positive on the AUDIT-C and 34% were positive on the AUDIT-3. In multivariate analyses, AUDIT-C-positive status predicted ART nonadherence after controlling for race, age, conscientiousness, and self-efficacy (P = .036). Although AUDIT-3-positive status was associated with ART nonadherence in unadjusted analyses, this relationship was not maintained in the final multivariate model. The AUDIT-C shows potential as an indirect screening tool for both at-risk drinking and ART nonadherence, underscoring the relationship between alcohol and chronic disease management. C1 [Broyles, Lauren Matukaitis; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Pittsburgh, PA 15206 USA. [Broyles, Lauren Matukaitis; Gordon, Adam J.; Ryan, Christopher M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Broyles, Lauren Matukaitis; Sereika, Susan M.; Erlen, Judith A.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Broyles, Lauren Matukaitis] VA Pittsburgh Healthcare Syst, VISN4 Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov FU National Institute of Nursing Research (NINR) [F31NR008822]; NINR [R01NR004749]; Health Services Research & Development Service of the US Department of Veterans Affairs; VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania FX This study was financially supported by a Ruth L. Kirschstein National Research Service Award (NRSA) to Dr. Broyles from the National Institute of Nursing Research (NINR, F31NR008822) and by NINR grant no. R01NR004749 to Dr. Erlen. Dr. Broyles is currently supported by a Career Development Award (CDA) from the Health Services Research & Development Service of the US Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 35 TC 9 Z9 9 U1 1 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2011 VL 32 IS 4 BP 252 EP 261 DI 10.1080/08897077.2011.599255 PG 10 WC Substance Abuse SC Substance Abuse GA 888PO UT WOS:000300016200010 PM 22014256 ER PT J AU Alexander, SC Pollak, KI Morgan, PA Strand, J Abernethy, AP Jeffreys, AS Arnold, RM Olsen, M Rodriguez, KL Garrigues, SK Manusov, JRE Tulsky, JA AF Alexander, Stewart C. Pollak, Kathryn I. Morgan, Perri A. Strand, Justine Abernethy, Amy P. Jeffreys, Amy S. Arnold, Robert M. Olsen, Maren Rodriguez, Keri L. Garrigues, Sarah K. Manusov, Justin R. E. Tulsky, James A. TI How do non-physician clinicians respond to advanced cancer patients' negative expressions of emotions? SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Communication; Emotions; Empathy; Nurse practitioners; Medical oncology; Physician assistants; Professional-patient relations ID PHYSICIAN COMMUNICATION; ONCOLOGISTS; EFFICACY; ANXIETY; SKILLS; TRIAL; MODEL AB Patients with advanced cancer often experience negative emotion; clinicians' empathic responses can alleviate patient distress. Much is known about how physicians respond to patient emotion; less is known about non-physician clinicians. Given that oncology care is increasingly provided by an interdisciplinary team, it is important to know more about how patients with advanced cancer express emotions to non-physician clinicians (NPCs) and how NPCs respond to those empathic opportunities. We audio recorded conversations between non-physician clinicians and patients with advanced cancer. We analyzed 45 conversations between patients and oncology physician assistants, nurse practitioners, and nurse clinicians in which patients or their loved ones expressed at least one negative emotion to the NPC (i.e., an empathic opportunity). Empathic opportunities were coded three ways: type of emotion (anger, sadness, or fear), severity of emotion (least, moderate, or most severe), and NPC response to emotion (not empathic, on-topic medical response, and empathic response). We identified 103 empathic opportunities presented to 25 different NPCs during 45 visits. Approximately half of the empathic opportunities contained anger (53%), followed by sadness (25%) and fear (21%). The majority of emotions expressed were moderately severe (73%), followed by most severe (16%), and least severe (12%). The severity of emotions presented was not found to be statistically different between types of NPCs. NPCs responded to empathic opportunities with empathic statements 30% of the time. Additionally, 40% of the time, NPCs responded to empathic opportunities with on-topic, medical explanations and 30% of the responses were not empathic. Patients expressed emotional concerns to NPCs typically in the form of anger; most emotions were moderately severe, with no statistical differences among types of NPC. On average, NPCs responded to patient emotion with empathic language only 30% of the time. A better understanding of NPC-patient interactions can contribute to improved communication training for NPCs and, ultimately, to higher quality patient care in cancer. C1 [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Olsen, Maren] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Inst Enhance Palliat Care, Pittsburgh, PA USA. [Arnold, Robert M.; Rodriguez, Keri L.] Univ Pittsburgh, Sch Med, Inst Doctor Patient Commun, Pittsburgh, PA USA. [Arnold, Robert M.; Rodriguez, Keri L.] Univ Pittsburgh, Dept Med, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Morgan, Perri A.; Strand, Justine; Tulsky, James A.] Duke Univ, Phys Assistant Program, Durham, NC USA. [Pollak, Kathryn I.; Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA. [Pollak, Kathryn I.; Morgan, Perri A.; Strand, Justine; Abernethy, Amy P.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren; Tulsky, James A.] Durham VA Med Ctr, Ctr Hlth Serv Res, Durham, NC USA. [Alexander, Stewart C.; Garrigues, Sarah K.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA. [Alexander, Stewart C.; Abernethy, Amy P.; Garrigues, Sarah K.; Manusov, Justin R. E.; Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Alexander, SC (reprint author), 2424 Erwin Rd,Suite 602, Durham, NC 27705 USA. EM alexa045@mc.duke.edu OI Abernethy, Amy/0000-0001-6930-8722 FU Department of Veterans Affairs [RCD 07-006, MRP 04-410] FX Dr. Alexander and Rodriguez are supported by Health Services Research Career Development Awards (RCD 07-006 & MRP 04-410) from the Department of Veterans Affairs. All authors have made substantial contributions to the manuscript and have seen and approved the final version of the manuscript, and all subsequent versions. The authors have no conflicts of interest or financial disclosures to declare. NR 26 TC 8 Z9 8 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD JAN PY 2011 VL 19 IS 1 BP 155 EP 159 DI 10.1007/s00520-010-0996-5 PG 5 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 706EF UT WOS:000286199800016 PM 20820814 ER PT J AU Mashmoushi, AK Gilkeson, GS Oates, JC AF Mashmoushi, Ahmad K. Gilkeson, Gary S. Oates, Jim C. BE Lahita, RG TI The Role of Reactive Nitrogen and Oxygen Intermediates in Systemic Lupus Erythematosus SO SYSTEMIC LUPUS ERYTHEMATOSUS, 5TH EDITION LA English DT Article; Book Chapter ID NITRIC-OXIDE SYNTHASE; MRL-LPR/LPR MICE; HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; MRL/LPR MICE; FREE-RADICALS; NADPH OXIDASE; MITOCHONDRIAL HYPERPOLARIZATION; ENDOTHELIAL DYSFUNCTION C1 [Mashmoushi, Ahmad K.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Gilkeson, Gary S.; Oates, Jim C.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. RP Mashmoushi, AK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. NR 126 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-096171-2 PY 2011 BP 199 EP 211 PG 13 WC Rheumatology SC Rheumatology GA BEG25 UT WOS:000316462800015 ER PT J AU Anzueto, A Frutos-Vivar, F Esteban, A Bensalami, N Marks, D Raymondos, K Apezteguia, C Arabi, Y Hurtado, J Gonzalez, M Tomicic, V Abroug, F Elizalde, J Cakar, N Pelosi, P Ferguson, ND AF Anzueto, A. Frutos-Vivar, F. Esteban, A. Bensalami, N. Marks, D. Raymondos, K. Apezteguia, C. Arabi, Y. Hurtado, J. Gonzalez, M. Tomicic, V. Abroug, F. Elizalde, J. Cakar, N. Pelosi, P. Ferguson, N. D. CA Ventila Grp TI Influence of body mass index on outcome of the mechanically ventilated patients SO THORAX LA English DT Article ID BLUNT TRAUMA PATIENTS; INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; RISK-FACTOR; OBESITY; MORTALITY; METAANALYSIS; ADULTS; IMPACT AB Background There are limited data on the impact of body mass index on outcomes in mechanically ventilated patients. Methods Secondary analysis of a cohort including 4698 patients mechanically ventilated. Patients were screened daily for management of mechanical ventilation, complications (acute respiratory distress syndrome, sepsis, ventilator associated pneumonia, barotrauma), organ failure (cardiovascular, respiratory, renal, hepatic, haematological) and mortality in the intensive care unit. To estimate the impact of body mass index on acute respiratory distress syndrome and mortality, the authors constructed models using generalised estimating equations (GEE). Results Patients were evaluated based on their body mass index: 184 patients (3.7%) were underweight, 1995 patients (40%) normal weight, 1781 patients (35.8%) overweight, 792 patients (15.9%) obese and 216 patients (4.3%) severely obese. Severely obese patients were more likely to receive low tidal volume based on actual body weight but high volumes based on predicted body weight. In obese patients, the authors observed a higher incidence of acute respiratory distress syndrome and acute renal failure. After adjustment, the body mass index was signif